id	compound_id	toxicity_adm_other_routes	toxicity_age_group	toxicity_dose_other_types	toxicity_dose_other_units	toxicity_dose_type	toxicity_dose_units	toxicity_dose_value	toxicity_exp_other_types	toxicity_experiment_type	toxicity_food_status	toxicity_frequency_other_period	toxicity_frequency_period	toxicity_frequency_times	toxicity_health_status	toxicity_routes	toxicity_sex	toxicity_source_type	toxicity_source_uri	toxicity_species	tox_application_smiles	toxicity_do_id	tox_application_pt_3	tox_application_cid	tox_application_unii	toxicity_age_group_median	toxicity_diff_dose_type	tox_application_dosing_comment_2	tox_application_pt_2	toxicity_dose_comment	toxicityappcombo	toxicity_age_group_to	toxicity_population_size	toxicity_do	tox_application_dosing_comment	tox_application_mw	tox_application_query_3	tox_application_query	toxicity_age_group_from	tox_application_pt	tox_application_dosing_comment_3	toxicity_duration	toxicity_duration_units	tox_application_query_2	toxicity_source_page
1	3		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00248651	Homo sapiens							max			25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks.			97	Dyspepsia								12	week		
2	3		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03591458	Homo sapiens										Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.			1	Type1 Diabetes								12	week		
3	3		child				mg/kg	0.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01581281	Homo sapiens							max						144	Migraine								24	week		
4	3					Highest studied dose	%	10		single			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/21676162/	Homo sapiens						57				10 % cream			1	pain					57			1	day		
5	3					Recommended	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8494126/	Homo sapiens						55							27	chronic pain								3	week		
6	3					Studied dose	mg	100		single			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17512256/	Homo sapiens												70	5						21			1	day		
7	3					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24259978/	Homo sapiens						43.2							16	globus pharyngeus								4	week		
8	3					Studied dose	mg	520.3		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20923818/	Homo sapiens						22.1	mean						96									1	day		
9	3					Studied dose	mg	520.3		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20923818/	Homo sapiens							mean						96									1	day		
10	3					Studied dose	mg	59		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10493324/	Homo sapiens						60.4	mean						25	diabetic peripheral neuropathy pain								6	week		
11	4					Highest studied dose	mg/kg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31229401	Homo sapiens						23.1						51	30	thalassemia major					10			1	year		
12	4					Highest studied dose	mg/kg	40		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203560Orig1s000lbl.pdf	Homo sapiens																									
13	4					Overdose	mg/kg	60		steady			day	1	unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203560Orig1s000lbl.pdf	Homo sapiens										2 to 3 times the prescribed dose for several weeks			1									2	week		
14	4					Overdose	mg/kg	80		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203560Orig1s000lbl.pdf	Homo sapiens													1	iron overloaded beta-thalassemia											
15	4					Overdose	mg/kg	90		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28556939/	Homo sapiens						20				dispensing error			1						20						
16	4					Recommended	mg/kg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203560Orig1s000lbl.pdf	Homo sapiens																			2						
17	4					Recommended	mg/kg	20		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203560Orig1s000lbl.pdf	Homo sapiens						17.1						53	296						2			12	month		
18	4						mg	130		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/18508948	Homo sapiens						30.5						45	17						18						
19	5		adult			Highest studied dose	mg	400		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27805571/	Homo sapiens																						8	day		
20	5		adult			Highest studied dose	mg	400		multiple			day	2	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27317305/	Homo sapiens																						6	day		
21	5		adult			Highest studied dose	mg	600		multiple			day	1	healthy	intramuscular	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000ClinPharmR.pdf	Homo sapiens																									60
22	5		adult			Highest studied dose	mg	800		multiple			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27805571/	Homo sapiens																						8	day		
23	5		adult			Highest studied dose	mg	800		multiple			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27317305/	Homo sapiens																						6	day		
24	5		adult			Minumum effective dose	mg	300		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000ClinPharmR.pdf	Homo sapiens													363	acute uncomplicated influenza											98
25	5		adult			Recommended	mg	600		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf	Homo sapiens													654	H1N1											4
26	5		adult			Recommended	mg	600		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf	Homo sapiens													660	H1N1											4
27	5		adult			Recommended	mg	600		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000ClinPharmR.pdf	Homo sapiens													365	acute uncomplicated influenza											98
28	5		adult				mg	600		single					unhealthy	intramuscular	M+F		https://clinicaltrials.gov/ct2/show/NCT00705406	Homo sapiens													200	Influenza											
29	5					Studied dose	mg/kg	11.4		steady			day	1	unhealthy	intravenous	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836703/	Homo sapiens							median					9.8	7	H1N1					2.4			11	day		500
30	6					Highest studied dose	mg	1000		steady			day	3	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20457817	Homo sapiens						33				infused over 1 h every 8 h			6						33			10	day		
31	6					Highest studied dose	mg	1500		steady			day	2	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20457817	Homo sapiens						33				received 1,500 mg infused over 1 h every 12 h			6						33			10	day		
32	6					Highest studied dose	mg	2000		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20457817	Homo sapiens						29.5				CXA-101 was given as a 1-hour intravenous infusion at dose of 2,000 mg			6						29.5			1	hour		
33	7		adult			Highest studied dose	mg	1600		multiple			day	2	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/28258380	Homo sapiens																						7	day		
34	7		adult			Highest studied dose	mg	2000		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/28258380	Homo sapiens																									
35	7		adult				mg	600		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/28258380	Homo sapiens														hepatitis C virus								2	day		
36	8					Highest studied dose	mg	600		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf	Homo sapiens													52	advanced solid tumors								14	day		p. 8
37	8					Recommended	mg	300		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf	Homo sapiens													195	gBRCAm ovarian cancer								19.4	month		
38	8					Recommended	mg	300		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208558Orig1s000MultidisciplineR.pdf	Homo sapiens													195	gBRCAm ovarian cancer								19.4	month		p. 99
39	8					Recommended	mg	300		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208558Orig1s000MultidisciplineR.pdf	Homo sapiens													195	gBRCAm ovarian cancer								19.4	month		p. 99
40	8					Recommended|MTD	mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf	Homo sapiens										400 mg BID was the MTD for the capsule formulation			223	gBRCA-mutated advanced ovarian cancer								158	day		
41	8					Recommended|MTD	mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf	Homo sapiens										400 mg BID was the MTD for the capsule formulation			2618	gBRCA-mutated advanced ovarian cancer								158	day		
42	8					Recommended|MTD	mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf	Homo sapiens										400 mg BID was the MTD for the capsule formulation				gBRCA-mutated advanced ovarian cancer								158	day		
43	8					Recommended|MTD	mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206162lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208558Orig1s000MultidisciplineR.pdf	Homo sapiens										400 mg BID was the MTD for the capsule formulation			223	gBRCA-mutated advanced ovarian cancer								158	day		p. 101
44	9					Highest studied dose	mg	1000		multiple			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28784673	Homo sapiens													8									7	day		p.4
45	9					Highest studied dose	mg	800		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21709093	Homo sapiens													6									7	day		p.4390
46	9					Recommended	%	0.3		multiple			day	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206307Orig1s000CrossR.pdf	Homo sapiens										4 drops in the affected ear			618	Acute otitis externa								7	day		p.18, p.21
47	9					Recommended	%	0.3		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206307s000lbl.pdf	Homo sapiens										4 drops in the affected ear. Prolonged use				Acute otitis externa								7	day		p.1
48	10		adult				mg	800		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03099187	Homo sapiens										Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.			127	Interstitial Lung Disease								24	week		
49	10		adult				mg	801		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00001596	Homo sapiens													23	Pulmonary Fibrosis of Hermansky-Pudlak Syndrome								36	month		
50	10		adult				mg	801		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01366209	Homo sapiens													278	Idiopathic Pulmonary Fibrosis								52	week		
51	10					Recommended	mg	2403		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022535s000lbl.pdf	Homo sapiens						67						80	623	idiopathic pulmonary fibrosis					40			62	week		
52	10					Recommended	mg	2403		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000CrossR.pdf	Homo sapiens						67						80	623	idiopathic pulmonary fibrosis					40			62	week		p. 23
53	11		adult			MTD	mg	250		steady			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/25795637	Homo sapiens													11	advanced solid tumors								28	day		
54	11		adult			Overdose	mg	600		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf	Homo sapiens													1	idiopathic pulmonary fibrosis								21	day		
55	11		adult			Overdose	mg	600		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf	Homo sapiens													2	cancer								8	day		
56	11		adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01979952	Homo sapiens													56	Idiopathic Pulmonary Fibrosis								6	month		
57	11		adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02597933	Homo sapiens							max			Patients were administered orally 150 milligram (mg) soft gelatin capsules, twice daily with a possibility to interrupt treatment or to reduce to 100mg to manage adverse events.			288	Systemic Sclerosis								52	week		
58	11		adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02999178	Homo sapiens													332	Interstitial Lung Disease								52	week		
59	11					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf	Homo sapiens						67				equivalent to 180.60 mg nintedanib ethanesulfonate		89	723	idiopathic pulmonary fibrosis					42			10	month		
60	11					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000CrossR.pdf	Homo sapiens						67				equivalent to 180.60 mg nintedanib ethanesulfonate		89	723	idiopathic pulmonary fibrosis					42			10	month		p. 15
61	11					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf	Homo sapiens						67				equivalent to 180.60 mg nintedanib ethanesulfonate		89	723	idiopathic pulmonary fibrosis					42			10	month		p. 87
62	11					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000MedR.pdf	Homo sapiens						67				equivalent to 180.60 mg nintedanib ethanesulfonate		89	723	idiopathic pulmonary fibrosis					42			10	month		p. 88
63	11						mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19846979	Homo sapiens						61							6						61			28	day		
64	11						mg	250		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19846979	Homo sapiens						61							4						61			28	day		
65	13					Highest studied dose	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22314425	Homo sapiens						49							10	genotype 1 hepatitis C					49			3	day		
66	14		adult			Recommended	mg	25		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000MedR.pdf	Homo sapiens													446									12	week		p. 83
67	14		adult				mg	12.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204760Orig1s000MedR.pdf	Homo sapiens													441									12	week		p. 83
68	14		adult				mg	25		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02839889	Homo sapiens													3	Opioid-Induced Constipation								2	week		
69	14					Highest studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27137715	Homo sapiens												45	6						18						
70	14					Highest studied dose	mg	250		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27137716	Homo sapiens						59						65	6						18			7	day		
71	15					Highest studied dose	mg/kg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20864621/	Homo sapiens						26							74									1	day		
72	15					MTD	mg	200		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20864621/	Homo sapiens						28							24									21	day		
73	15					MTD	mg/kg	20		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20864621/	Homo sapiens						26							74									1	day		
74	15					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000MedR.pdf	Homo sapiens						37.1	mean			Among these 393 patients, 349/393 patients (89%) received eliglustat for at least 6 months, 204/393 patients (52%) received eliglustat for at least 12 months 62/393 patients (16%) have received eliglustat for at least 24 months, and 19/393 (5%) have received eliglustat for at least 60 months.			393	Gaucher disease type 1								6	month		nda/2014/205494Orig1s000MedR.pdf - p.135
75	15					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205494Orig1s000MedR.pdf	Homo sapiens						37.1	mean			Among these 393 patients, 349/393 patients (89%) received eliglustat for at least 6 months, 204/393 patients (52%) received eliglustat for at least 12 months 62/393 patients (16%) have received eliglustat for at least 24 months, and 19/393 (5%) have received eliglustat for at least 60 months.			393	Gaucher disease type 1								6	month		nda/2014/205494Orig1s000MedR.pdf - p.140
76	15					Studied dose	mg	350		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20864621/	Homo sapiens						28							24									21	day		
77	16		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01097616	Homo sapiens										After a 2-week single-blind placebo Run-in, participants received suvorexant LD (20 mg for participants aged 18 to <65 years; and 15 mg for participants aged ≥65 years) daily before bedtime during the 3-month DB TRT Phase, and could continue on same dose during the optional 3-month DB EXT Phase.			254	Insomnia								3	month		
78	16		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01097629	Homo sapiens										After a 2-week single-blind placebo Run-in, participants received suvorexant LD (20 mg for participants aged 18 to <65 years; and 15 mg for participants aged ≥65 years) daily before bedtime during the 3-month DB TRT Phase, and could continue on same dose during the optional 3-month DB EXT Phase.			239	Insomnia								3	month		
79	16		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02750306	Homo sapiens							max						142	Insomnia								4	week		
80	16		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01097616	Homo sapiens										After a 2-week single-blind placebo Run-in, participants received suvorexant HD (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime during the 3-month DB TRT Phase, and could continue on same dose during the optional 3-month DB EXT Phase.			383	Insomnia								3	month		
81	16		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01097629	Homo sapiens										After a 2-week single-blind placebo Run-in, participants received suvorexant HD (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime during the 3-month DB TRT Phase, and could continue on same dose during the optional 3-month DB EXT Phase.			387	Insomnia								3	month		
82	16					Highest studied dose	mg	100		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29705869	Homo sapiens						34.3				The dosing period (19 days in total) consisted of the following 3 parts: administration of a single suvorexant dose, a 120 h (5 day) washout period, and administration of a once nightly suvorexant dose for 14 consecutive days			6						34.3			14	day		
83	19		adult			Recommended	mg	150		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf	Homo sapiens																						5	month		
84	19					Highest studied dose	mg	350		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24615776	Homo sapiens						64						91	4	non-Hodgkin lymphoma					32			28	day		
85	19					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205858lbl.pdf	Homo sapiens						71						92	110	Relapsed Chronic Lymphocytic Leukemia					47			5	month		
86	20					Highest studied dose	%	7.5		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/24894552/ | https://pubmed.ncbi.nlm.nih.gov/25226015/ | https://pubmed.ncbi.nlm.nih.gov/27224843/	Homo sapiens										Study 200/200A had 6 months duration and 60 participants		65	15	onychomycosis					18			28	day		
87	20					Recommended	%	5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf	Homo sapiens						55							194	onychomycosis								336	day		nda/2014/204427Orig1s000MedR.pdf - p.79
88	20					Recommended	%	5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf	Homo sapiens						55							194	onychomycosis								52	week		nda/2014/204427Orig1s000MedR.pdf - p.78
89	20					Recommended	%	5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf	Homo sapiens						55							205	onychomycosis								336	day		nda/2014/204427Orig1s000MedR.pdf - p.79
90	20					Recommended	%	5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf	Homo sapiens						55							791	onychomycosis								336	day		nda/2014/204427Orig1s000MedR.pdf - p.83
91	20					Recommended	%	5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf	Homo sapiens						55							791	onychomycosis								336	day		nda/2014/204427Orig1s000MedR.pdf - p.85
92	21					Highest studied dose	mg/m2	1200		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18245542	Homo sapiens						58.5				Belinostat was administered i.v. as a 30-min nfusion daily on days 1 to 5 of a 21-day cycle.		74	5	advanced malignancy refractory					25			5	day		
93	21					Recommended|MTD	mg/m2	1000		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18245542	Homo sapiens						58.5				Belinostat was administered i.v. as a 30-min nfusion daily on days 1 to 5 of a 21-day cycle.		74	18	advanced malignancy refractory					25			5	day		
94	21					Recommended|MTD	mg/m2	1000		steady			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf	Homo sapiens						64				1,000 mg/m2 administered over 30 minutes by IV infusion once daily on Days 1-5 of a 21-day cycle.		81	129	relapsed or refractory peripheral T-cell lymphoma					29			5	day		
95	21						mg/m2	600		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18245542	Homo sapiens						58.5				Belinostat was administered i.v. as a 30-min nfusion daily on days 1 to 5 of a 21-day cycle.		74	6	advanced malignancy refractory					25			5	day		
96	22		ADULT			Highest studied dose	mg	1200		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf	Homo sapiens													46									1	day		229
97	22		ADULT			Highest studied dose	mg	400		multiple			day	1	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf	Homo sapiens							total daily dose						8									21	day		229
98	22		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32064090/	Homo sapiens						34	total daily dose						1	bacterial infectious disease	25mg per day		paroxetine	enalapril			40mg per day	4	day	amitriptyline	52-4
99	22		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33884276/	Homo sapiens						64				median duration			14	bacterial infectious disease								48	day		ofab093
100	23		adult			Recommended	%	10		multiple			day	1	healthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf	Homo sapiens													239									8	week		/nda/2014/203567Orig1s000MedR.pdf - p.108
101	23					Recommended	%	10		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf	Homo sapiens						51							1227	onychomycosis								52	week		/nda/2014/203567Orig1s000MedR.pdf - p.103
102	23					Recommended	%	10		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf	Homo sapiens						51							1227	onychomycosis								52	week		/nda/2014/203567Orig1s000MedR.pdf - p.104
103	23					Recommended	%	10		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203567Orig1s000MedR.pdf	Homo sapiens						51							1227	onychomycosiss								52	week		/nda/2014/203567Orig1s000MedR.pdf - p.103
104	24		adult			Recommended	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s000MedR.pdf	Homo sapiens										2.08 mg of vorapaxar, which is equivalent to 2.5 mg of vorapaxar sulfate			13186									30	day		p. 142
105	24		adult			Recommended	mg	2.5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204886s000lbl.pdf	Homo sapiens										2.08 mg of vorapaxar, which is equivalent to 2.5 mg of vorapaxar sulfate				intracranial hemorrhage | transient ischemic attack								30	day		
106	24					Highest studied dose	mg	40		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19286091	Homo sapiens						63.5	starting						173	coronary artery disease					63.5						
107	25					MTD	mg	750		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26020125 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Homo sapiens						54						81	189	ALK-positive NSCLC patients					22			18	month		
108	25					MTD	mg	750		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Homo sapiens						53							255	ALK-positive NSCLC patients					53			18	month		
109	25					Recommended	mg	450		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26020125	Homo sapiens						37							6	ALK-positive NSCLC patients					37						
110	25					Recommended	mg	450		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26020125 |https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Homo sapiens						37							6	ALK-positive NSCLC patients					37			32.1	week		
111	25					Recommended	mg	450		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26020125 |https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf	Homo sapiens						37							6	ALK-positive NSCLC patients					37						
112	25						mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26020125/	Homo sapiens						39							4	ALK-positive NSCLC patients					39						
113	27		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01170949	Homo sapiens							max|total daily dose			50 or 100 or 150mg per day			50	Chronic Urticaria								28	day		
114	27					MTD	mg	300		multiple			week	1	unhealthy	oral	M+F		https://www.karger.com/Article/Abstract/217014	Homo sapiens													15	cancer								8	week		
115	27					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1325463/	Homo sapiens							mean			The median duration of treatment was 6 weeks (range 2-8 + weeks). Treatment consisted of miltefosine 50 mg orally twice daily after meals in the first week. In the absence of side-effects this dose was increased to three times daily in the second week.			54	cancer								6	week		
116	27					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf	Homo sapiens													89	leishmaniasis								28	day		applications/Miltefosine_application.pdf - p.13
117	27					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf	Homo sapiens													89	leishmaniasis								28	day		applications/Miltefosine_application.pdf - p.14
118	27					Studied dose	mg	100		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000MedR.pdf	Homo sapiens							mean			Miltefosine was administered to four groups at 50 mg/day for 6 weeks, 50 mg per day for one week followed by 100 mg/d for 3 weeks, 100 mg/d for 4 weeks and 100 mg/d for one week followed by 150 mg/day for 3 weeks.			120	leishmaniasis								6	week		nda/2014/204684Orig1s000MedR.pdf - p.159
119	27					Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204684Orig1s000MedR.pdf	Homo sapiens										50 mg twice a day if weight ≥ 25 kg or once a day if weight < 25 kg			299	leishmaniasis								28	day		
120	29					Highest studied dose	ug/kg/min	0.6		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31490245/	Homo sapiens						65.5							85	cardiogenic shock											
121	30					Highest studied dose	mg	300		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens												44	11						18			3	day		nda/2014/205677Orig1s000MedR.pdf - p.20
122	30					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
123	30					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens												92	151	24-Hour Sleep-Wake Disorder					18			4	week		nda/2014/205677Orig1s000MedR.pdf - p.84
124	30					Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
125	30					Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
126	30					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
127	30					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
128	30					Studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens							max					92	114	24-Hour Sleep-Wake Disorder					18			4	week		nda/2014/205677Orig1s000MedR.pdf - p.84
129	30					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens							mean					92	429	24-Hour Sleep-Wake Disorder					18			4	week		nda/2014/205677Orig1s000MedR.pdf - p.84
130	30					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens										multiple and single dose studies; duration from 1 day to 24 months		92	1346	24-Hour Sleep-Wake Disorder					18			360	day		nda/2014/205677Orig1s000MedR.pdf - p.81
131	30					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205677Orig1s000MedR.pdf	Homo sapiens												92	164	24-Hour Sleep-Wake Disorder					18			4	week		nda/2014/205677Orig1s000MedR.pdf - p.84
132	31					Highest studied dose	ug	250		steady			day	1	unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/27026339/	Homo sapiens														Asthma								14	day		
133	31						ug	125		steady			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/23949963	Homo sapiens						64.6							69	COPD					64.6			12	week		
134	32					Recommended	mg	400		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30900816	Homo sapiens						35.56						45	12						18						
135	33					Highest studied dose	mg	200		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19852962	Homo sapiens						38						54	9						25			5	day		
136	33					Highest studied dose	mg	400		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19852962	Homo sapiens						24						44	9						20			5	day		
137	33					Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19852962	Homo sapiens						38						55	9						23						
138	33					Recommended	mg	150		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf	Homo sapiens						49						73	781						18			12	week		p. 57
139	33						mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22326470	Homo sapiens													37	HCV genotypes 2–6 infection								7	day		
140	34					Highest studied dose	mg/kg	12.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23045577	Homo sapiens						65				12.5 mg/kg per day on a 28 days on, 7 days off, schedule (35-day cycle)		82	7	relapsed/refractory B-cell malignancies					41			28	day		
141	34					Recommended	mg	560		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552s000lbl.pdf	Homo sapiens						68						84	111	mantle cell lymphoma					40			8.3	month		
142	34						mg	420		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26588924	Homo sapiens						67								chronic lymphocytic leukemia | small lymphocytic lymphoma					67			9.01	month		
143	34						mg/kg	2.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23045579	Homo sapiens						67						82	9	relapsed/refractory B-cell malignancies					41			28	day		
144	34						mg/kg	8.3		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23045578	Homo sapiens						66						82	8	relapsed/refractory B-cell malignancies					41			28	day		
145	35					Overdose	mg	5600		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/28920564	Homo sapiens						18							1						18						
146	35					Recommended	mg	1200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	410	epilepsy					32			6	month		
147	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					18			6	month		
148	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					19			6	month		
149	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					20			6	month		
150	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					21			6	month		
151	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					22			6	month		
152	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					23			6	month		
153	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					24			6	month		
154	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					25			6	month		
155	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					26			6	month		
156	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					27			6	month		
157	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					28			6	month		
158	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					29			6	month		
159	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					30			6	month		
160	35					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf	Homo sapiens										patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.		60	415	epilepsy					31			6	month		
161	36					Recommended	MBq	185		single			day	1	unknown	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf	Homo sapiens													761												
162	36					Recommended	MBq	355.9		single			day	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf	Homo sapiens						72							1	Parkinson's disease											
163	37		adult			Recommended	mg	10		steady			day	1	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf	Homo sapiens																									
164	37		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00903331	Homo sapiens													119	Idiopathic Pulmonary Fibrosis								12	month		
165	37		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02021292	Homo sapiens													40	Chronic Thromboembolic Pulmonary Hypertension								24	week		
166	37		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02070991	Homo sapiens													31	Pulmonary Hypertension								12	week		
167	37		child|adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01743001	Homo sapiens													114	Eisenmenger Syndrome								16	week		
168	37					Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21541781	Homo sapiens													6												
169	37					MTD	mg	300		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204410Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/21541781	Homo sapiens													6												p. 83
170	38		adult			Recommended	mg	1		steady			day	3	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204819s000lbl.pdf	Homo sapiens																									
171	38					Highest studied dose	mg	2.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27096084	Homo sapiens												36	24						33						
172	38					Highest studied dose	mg	2.5		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32299845	Homo sapiens						51.9							60	early diffuse cutaneous systemic sclerosis					51.9			10	week		
173	38						mg	1		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27096084	Homo sapiens												36	22						33						
174	39					Highest studied dose	mg	120		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/28756067	Homo sapiens												65	84						35						
175	39					Highest studied dose	mg	80		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27128831	Homo sapiens												70	11						45			30	day		
176	40		adult			Recommended	mg	20		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf	Homo sapiens										pooled data				major depressive disorder								6	week		
177	40		adult			Recommended	mg	20		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204447Orig1s000MedR.pdf	Homo sapiens										pooled data phase I				major depressive disorder											p. 97
178	40		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00735709	Homo sapiens													140	Major Depressive Disorder								8	week		
179	40		adult				mg	10		steady			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02932904	Homo sapiens													91									5	week		
180	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00731120	Homo sapiens													152	Generalized Anxiety Disorder								8	week		
181	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00735709	Homo sapiens													139	Major Depressive Disorder								8	week		
182	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01163266	Homo sapiens							max						155	Major Depressive Disorder								8	week		
183	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01179516	Homo sapiens													154	Major Depressive Disorder								8	week		
184	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01355081	Homo sapiens													122	Major Depressive Disorder								8	week		
185	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01422213	Homo sapiens													195	Major Depressive Disorder								8	week		
186	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02371980	Homo sapiens													1106	Major Depressive Disorder								16	week		
187	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02371980	Homo sapiens													145	Major Depressive Disorder								28	week		
188	40		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02389816	Homo sapiens													165	Major Depressive Disorder								8	week		
189	40		adult				mg	15		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01153009	Homo sapiens										Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.			147	Major Depressive Disorder								8	week		
190	40		adult				mg	15		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01179516	Homo sapiens										Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.			151	Major Depressive Disorder								8	week		
191	40		adult				mg	2.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00672620	Homo sapiens													149	Major Depressive Disorder								8	week		
192	40		adult				mg	2.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00731120	Homo sapiens													151	Generalized Anxiety Disorder								8	week		
193	40		adult				mg	20		multiple			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01299805	Homo sapiens													12									14	day		
194	40		adult				mg	20		steady			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02932904	Homo sapiens										Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.			91									5	week		
195	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01153009	Homo sapiens										Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.			154	Major Depressive Disorder								8	week		
196	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01163266	Homo sapiens							max			Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.			150	Major Depressive Disorder								8	week		
197	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01422213	Homo sapiens													207	Major Depressive Disorder								8	week		
198	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02371980	Homo sapiens													144	Major Depressive Disorder								28	week		
199	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02389816	Homo sapiens													163	Major Depressive Disorder								8	week		
200	40		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02528409	Homo sapiens										10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.			40	Binge Eating Disorder								12	week		
201	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00672620	Homo sapiens													153	Major Depressive Disorder								8	week		
202	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00672958	Homo sapiens													299	Major Depressive Disorder								6	week		
203	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00734071	Homo sapiens													148	Generalized Anxiety Disorder								8	week		
204	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00735709	Homo sapiens													140	Major Depressive Disorder								8	week		
205	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00744627	Homo sapiens													150	Generalized Anxiety Disorder								8	week		
206	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01355081	Homo sapiens													119	Major Depressive Disorder								8	week		
207	40		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02371980	Homo sapiens													140	Major Depressive Disorder								28	week		
208	40		elderly				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00811252	Homo sapiens													156	Major Depressive Disorder								8	week		
209	40					Highest studied dose	mg	60		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22448783	Homo sapiens						24							5						24			12	day		
210	40					Highest studied dose	mg	75		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22448783	Homo sapiens						24							6						24						
211	40					Overdose	mg	250		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29923970	Homo sapiens						50				50 tablets of 5mg			1	major depressive disorder	10 mg			clonazepam	50						
212	40						mg	9		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22448783	Homo sapiens						24							22						24			6	hour		
213	41					Recommended	mg	50		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30272231	Homo sapiens						33.5							11						33.5			14	day		
214	41					Studied dose	mg	250		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22422361	Homo sapiens						34.5							41												
215	42		adolescents				mg	360		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf	Homo sapiens													2									1	day		
216	42		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01345669	Homo sapiens							max			Patient received Afatinib film-coated tablets with starting dose 40 mg (milligram)/day and escalation to 50 mg/day and/or reduction to 40, 30 or 20 mg/day according to absence or presence of drug-related adverse events (AEs), orally, once daily for up to 80 weeks or until recurrence / occurrence of second primary tumour, unacceptable side effects, or other reason necessitating withdrawal.			411	Head and Neck Neoplasms								80	week		
217	42		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02131155	Homo sapiens							max						25	Head and Neck Squamous Cell Carcinoma								80	week		
218	42					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18026190/	Homo sapiens						58							2	solid tumours								14	day		
219	42					MTD	mg	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18026190/	Homo sapiens						58							18	solid tumours								14	day		
220	42					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000MedR.pdf	Homo sapiens						61.5				median duration			229	adenocarcinoma of the lung								336	day		201292Orig1s000MedR.pdf - p.66
221	42					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/23816960/	Homo sapiens						61.5				median duration			229	adenocarcinoma of the lung								336	day		201292Orig1s000MedR.pdf - p.65
222	42					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/23816960/	Homo sapiens						61.5				median duration			229	adenocarcinoma of the lung								336	day		201292Orig1s000MedR.pdf - p.66
223	42					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/201292Orig1s000MedR.pdf | https://www.boehringer-ingelheim.ca/sites/ca/files/documents/giotrifpmen.pdf	Homo sapiens						61.5				median duration			229	adenocarcinoma of the lung								336	day		201292Orig1s000MedR.pdf - p.66 | documents/giotrifpmen.pdf - p.13
224	42						mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/22452896/	Homo sapiens										median duration		82	390	non-small cell lung cancer					32			5.1	month		giotrif-epar-public-assessment-report_en.pdf - p.102
225	42						mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/giotrif-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/22452896/	Homo sapiens										median duration		82	390	non-small cell lung cancer					32			5.1	month		giotrif-epar-public-assessment-report_en.pdf - p.110
226	42						mg	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18026190/	Homo sapiens						58							18	solid tumours								14	day		
227	42						mg	85		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18026190/	Homo sapiens						58							6	solid tumours								14	day		
228	43					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5				10 mg administered orally once daily on two consecutive days followed by 3 mg once daily			4	advanced solid tumour								2	day		
229	43					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5				10 mg administered orally once daily on two consecutive days followed by 3 mg once daily			4	advanced solid tumour								2	day		204114s000lbl.pdf - p.10
230	43					Highest studied dose	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5							3	advanced solid tumour								28	day		
231	43					Highest studied dose	mg	4		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5							3	advanced solid tumour								28	day		204114s000lbl.pdf - p.10
232	43					MTD	mg	3		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/mekinist-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5							12	advanced solid tumour								28	day		mekinist-epar-public-assessment-report_en.pdf - p.46
233	43					Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22663011/	Homo sapiens						55							211	melanoma								3	week		204114Orig1s000SumR.pdf - p.21
234	43					Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5							70	advanced solid tumour								28	day		
235	43					Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114Orig1s000SumR.pdf	Homo sapiens						55							211	melanoma								3	week		204114Orig1s000SumR.pdf - p.21
236	43					Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114Orig1s000SumR.pdf | https://pubmed.ncbi.nlm.nih.gov/22663011/	Homo sapiens						55							211	melanoma								3	week		204114Orig1s000SumR.pdf - p.21
237	43						mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22805291/	Homo sapiens						58.5							3	advanced solid tumour								21	day		
238	43						mg	2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000MedR.pdf	Homo sapiens						54.5							211	melanoma								4.3	month		204114Orig1s000MedR.pdf - p.92
239	43						mg	2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000MedR.pdf	Homo sapiens						54.5							211	melanoma								4.3	month		204114Orig1s000MedR.pdf - p.99
240	44					Highest studied dose	mg	100		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/24958809	Homo sapiens													20									21	day		
241	44					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109288/	Homo sapiens													10									21	day		
242	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf	Homo sapiens						53							187	unresectable or metastatic melanoma with BRAF V600E mutation-positive melanoma					53			4.9	month		
243	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53							187	unresectable or metastatic melanoma with BRAF V600E mutation-positive melanoma					53			4.9	month		p. 97
244	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53							187	unresectable or metastatic melanoma with BRAF V600E mutation-positive melanoma					53			4.9	month		p. 98
245	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53							187	unresectable or metastatic melanoma with BRAF V600E mutation-positive melanoma					53			4.9	month		p. 99
246	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53						93	187						22			4.9	month		p. 94
247	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53						93	187						22			4.9	month		p. 96
248	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53						93	187						22			4.9	month		p. 97
249	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53						93	187						22			4.9	month		p. 98
250	44					Recommended	mg	150		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens						53						93	187						22			4.9	month		p. 99
251	44					Recommended	mg	150		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202806Orig1s000MedR.pdf	Homo sapiens													187									4.9	month		p. 95
252	44						mg	200		multiple			day	2	unhealthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109288/	Homo sapiens													20									21	day		
253	46					Highest studied dose	ug	100		multiple			day	1	healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/23232038	Homo sapiens						29.1						53	9						21			14	day		
254	46					Highest studied dose	ug	100		multiple					unhealthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/23232038	Homo sapiens						36.9						60	22	asthma					21						
255	46					Highest studied dose	ug	500		multiple					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23043183	Homo sapiens						33.1							9						33.1						
256	47		adult			Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf	Homo sapiens													833	type 2 diabetes								24	week		129
257	47		adult			Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf	Homo sapiens													834	type 2 diabetes								24	week		129
258	47					Recommended	mg	100		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							425	type 2 diabetes								24	week		9
259	47					Recommended	mg	100		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							430	type 2 diabetes								24	week		9
260	47					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							834	type 2 diabetes								24	week		9
261	47					Recommended	mg	300		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							425	type 2 diabetes								24	week		9
262	47					Recommended	mg	300		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							842	type 2 diabetes								24	week		9
263	47					Recommended	mg	300		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							430	type 2 diabetes								24	week		9
264	47					Recommended	mg	300		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							825	type 2 diabetes								24	week		9
265	47					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							1667	type 2 diabetes								24	week		9
266	47					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204042s027lbl.pdf	Homo sapiens						56							834	type 2 diabetes								24	week		9
267	47						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01939496	Homo sapiens													56	Type 2 Diabetes Mellitus								6	week		
268	47						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02065791	Homo sapiens													2200	Type 2 Diabetes Mellitus								6	week		
269	47						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02360774	Homo sapiens													13	Type 2 Diabetes Mellitus								18	week		
270	51		adult				mg	60		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02638337	Homo sapiens													317	Vaginal Dryness								12	week		
271	51		adult (Postmenopausal)			Recommended	mg	60		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203505s000lbl.pdf	Homo sapiens																									
272	51		adult (Postmenopausal)			Recommended	mg	60		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203505Orig1s000MedR.pdf	Homo sapiens													301	Vulvar and Vaginal Atrophy								52	week		p. 114
273	51					Highest studied dose	mg	200		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12443837	Homo sapiens						62						75	8						55			12	week		
274	53					Highest studied dose	mg	10		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22875080	Homo sapiens						56				maximum dose of 10 mg for 21 days on a 28 day schedule			2	advanced solid tumors					56			21	day		
275	53					Highest studied dose	mg	50		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204026Orig1s000ClinPharmR.pdf	Homo sapiens													30												
276	53					Highest studied dose	mg/m2	3.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33025730	Homo sapiens						12.3						20.8	29	recurrent, progressive, or refractory CNS tumor					5.8			21	day		
277	53					MTD	mg	4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23243282	Homo sapiens						64.7				oral pomalidomide on days 1 to 21 of each 28-day cycle		72	14	relapsed and refractory multiple myeloma					55			21	day		
278	53					MTD	mg/m2	2.6		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33025730	Homo sapiens						12.3						20.8	29	recurrent, progressive, or refractory CNS tumor					5.8			21	day		
279	53					Recommended|MTD	mg	4		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204026lbl.pdf	Homo sapiens						61				4 mg, once daily for 21 of 28 days		88	107	relapsed multiple myeloma					37			21	day		
280	53						mg	2		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23243282	Homo sapiens						64.7				oral pomalidomide on days 1 to 21 of each 28-day cycle		72	6	relapsed and refractory multiple myeloma					55			21	day		
281	53						mg	3		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23243282	Homo sapiens						64.7				oral pomalidomide on days 1 to 21 of each 28-day cycle		72	8	relapsed and refractory multiple myeloma					55			21	day		
282	53						mg	5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23243282	Homo sapiens						64.7				oral pomalidomide on days 1 to 21 of each 28-day cycle		72	10	relapsed and refractory multiple myeloma					55			21	day		
283	54		adult			Recommended	mg	25		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt2.pdf	Homo sapiens										resubmission 2012			6626												p. 48
284	54		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00755846	Homo sapiens													44	Type 2 Diabetes								12	week		
285	54		adult				mg	12.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00286455	Homo sapiens													133	Type 2 Diabetes								26	week		
286	54		adult				mg	12.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00755846	Homo sapiens													44	Type 2 Diabetes								12	week		
287	54		adult				mg	12.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01263470	Homo sapiens													84	Type 2 Diabetes								12	week		
288	54		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00286455	Homo sapiens													132	Type 2 Diabetes								26	week		
289	54		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00755846	Homo sapiens													45	Type 2 Diabetes								12	week		
290	54		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00968708	Homo sapiens							max			Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min).			2701	Type 2 Diabetes and Acute Coronary Syndrome								41	month		
291	54		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01263470	Homo sapiens													80	Type 2 Diabetes								12	week		
292	54		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01289119	Homo sapiens													92	Type 2 Diabetes								16	week		
293	54		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00755846	Homo sapiens													43	Type 2 Diabetes								12	week		
294	54		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01263470	Homo sapiens													79	Type 2 Diabetes								12	week		
295	54		adult				mg	6.25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00755846	Homo sapiens													42	Type 2 Diabetes								12	week		
296	54		adult				mg	6.25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01263470	Homo sapiens													79	Type 2 Diabetes								12	week		
297	54					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18405788/	Homo sapiens						55.6						75	16	type 2 diabetes					18			14	day		
298	54					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18405789	Homo sapiens						26.6						55	5						18						
299	56					Overdose	mg	400		multiple			week	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30951878	Homo sapiens						21							1						21						
300	56					Recommended	mg|mg	400 | 200		multiple			day|week	1|3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/204384s000lbl.pdf	Homo sapiens						34	complex			400 mg once daily for the first 2 weeks and as 200 mg 3 times per week for the following 22 weeks			79	y multi-drug resistant tuberculosis					34			2 | 22	week|week		
301	57		adult				mg	2.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02179177	Homo sapiens													8	Sickle Cell Disease								6	month		
302	57		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03590743	Homo sapiens										Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.			2	Calf Vein Thrombosis								3	month		
303	57					Highest studied dose	mg	25		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23451769	Homo sapiens						27						41	8						20			7	day		
304	57					Highest studied dose	mg	50		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30498375	Homo sapiens												39	23						20						
305	57					Overdose	mg	210		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/28964584	Homo sapiens						48		2.5 mg, single		apixaban (210 mg; 2.8 mg/kg), levothyroxine (1.5 mg) and amitriptyline (unknown amount, at most 2.5 g).			1		1.5 mg single			levothyroxine	48					amitriptyline	
306	57					Overdose	mg	25		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf	Homo sapiens																						7	day		
307	57					Overdose	mg	40		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/33278889	Homo sapiens										8 pills of apixaban 5 mg (40 mg) and 3 pills of digoxin 0.25 mg (0.75 mg).			1		single 0.75 mg			digoxin							
308	57					Recommended	mg	5		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf	Homo sapiens														nonvalvular atrial fibrillation								12	week		
309	57						mg	2.5		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30569731	Homo sapiens						85							1	Auricular fibrillation	oral; 2.5 mg/12h			apixaban	85			3	month		
310	57						mg	2.5		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23451769	Homo sapiens						27						39	6						19			7	day		
311	58					Highest studied dose	mg	100		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000MedR.pdf	Homo sapiens													6									8	day		p. 41
312	58					Highest studied dose	mg	200		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000MedR.pdf	Homo sapiens													6												p. 41
313	58					Recommended	mg	5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203858s000lbl.pdf	Homo sapiens						30.7	starting			5 mg daily and titrated to daily doses of 10 mg, 20 mg, 40 mg, and 60 mg at weeks 2, 6, 10, and 14, respectively		55	29	homozygous familial hypercholesterolemia					18			14	week		
314	58					Studied dose	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000MedR.pdf	Homo sapiens						30.7						55	29	homozygous familial hypercholesterolemia					18			56	week		p. 168
315	58						mg	100		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000MedR.pdf	Homo sapiens													7												p. 41, 166
316	60					Recommended	mg	45		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdf	Homo sapiens													31									3	month		
317	60					Recommended	mg	45		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	Homo sapiens										The median dose intensity was 37 mg or, 83% of the expected 45 mg dose.			449									80	day		
318	60						mg	60		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf	Homo sapiens													19									3	month		
319	60						mg	60		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469Orig1s000MedR.pdf |https://pubmed.ncbi.nlm.nih.gov/23190221	Homo sapiens													19									3	month		
320	62		adult			Recommended	mg	5		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203214s000lbl.pdf	Homo sapiens																									
321	62		adult			Recommended	mg	5		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000MedR.pdf	Homo sapiens										pooled study			1216									12	month		p. 122
322	62		adult				mg	10		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000MedR.pdf	Homo sapiens										pooled study			1214									12	month		p. 122
323	62		adult				mg	100		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01743677	Homo sapiens													60												
324	62					Highest studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27128212	Homo sapiens													8												
325	62					Highest studied dose	mg	30		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18557720	Homo sapiens						54.2							10						54.2			28	day		
326	63					Highest studied dose	mg/m2	8		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6478448	Homo sapiens														refractory malignancies								5	day		
327	63					MTD	mg/m2	5		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/16847470	Homo sapiens						57							12	Chronic Myeloid Leukemia					57			9	day		
328	63					Overdose	mg/m2	2.5		multiple			day	2	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Homo sapiens													1	Chronic Myeloid Leukemia								5	day		
329	63					Overdose	mg/m2	2.5		multiple			day	2	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf	Homo sapiens													1	CML								5	day		p. 67
330	63					Recommended	mg/m2	1.25		multiple			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Homo sapiens						59				the median total dose delivered during the trials was 131 mg/m2 (range 1.2 to 678).			108	chronic phase chronic myeloid leukemia					59			7.4	month		
331	63					Recommended	mg/m2	1.25		multiple			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf	Homo sapiens						59							158	chronic phase, Accelerated Phase chronic myeloid leukemia					59			7.4	month		p. 57
332	63					Recommended	mg/m2	1.25		multiple			day	2	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Homo sapiens						59				the median total dose delivered during the trials was 70 mg/m2.			55	Chronic Myeloid Leukemia – Accelerated Phase					59			1.9	month		
333	63					Recommended	mg/m2	1.25		steady			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Homo sapiens						59				the median total dose delivered during the trials was 131 mg/m2 (range 1.2 to 678).			108	chronic phase chronic myeloid leukemia					59			7.4	month		
334	63					Recommended	mg/m2	1.25		steady			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf	Homo sapiens						59							108	chronic phase CML					59			7.4	month		
335	63					Recommended	mg/m2	1.25		steady			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203585Orig1s000MedR.pdf	Homo sapiens						59							108	chronic phase CML					59			7.4	month		p. 57
336	63						mg/m2	3		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/16847470	Homo sapiens						57							12	Chronic Myeloid Leukemia					57			9	day		
337	64		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00505284	Homo sapiens													71	Diabetic Neuropathy								15	week		
338	64		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00505284	Homo sapiens							max			Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).			68	Diabetic Neuropathy								15	week		
339	64		adult				mg	6		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00505284	Homo sapiens							max			Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).			67	Diabetic Neuropathy								15	week		
340	64		adult				mg	8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00505284	Homo sapiens							max			Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).			68	Diabetic Neuropathy								15	week		
341	64		child				mg	12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01161524	Homo sapiens							max			During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.			114	Epilepsy								52	week		
342	64		child				mg	12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01161524	Homo sapiens							max			Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.			85	Epilepsy								31	week		
343	64					Overdose	mg	10		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32349889	Homo sapiens						2				10 mg perampanel tablet (0.77 mg/kg)			1						2						
344	64					Overdose	mg	2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32349889	Homo sapiens						2				2 mg perampanel tablets (0.25 mg/kg)			1						2						
345	64					Overdose	mg	264		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf	Homo sapiens													1												
346	64					Overdose	mg	300		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29299938	Homo sapiens						54				10 tablets			1	refractory seizures					54						
347	64					Recommended	mg	12		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf	Homo sapiens						35							255	epilepsy					35			6	week		
348	64					Recommended	mg	12		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf	Homo sapiens														epilepsy								6	week		
349	65					Highest studied dose	mg	220		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/22421192/	Homo sapiens						60				median duration			12	solid tumors								92.5	day		
350	65					MTD|Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22421192/	Homo sapiens						60				median duration			12	solid tumors								119	day		
351	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.47
352	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.48
353	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.49
354	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.53
355	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.54
356	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.57
357	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.59
358	65					Recommended	mg	160		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203085Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf	Homo sapiens												82	500	colorectal cancer					22			21	day		203085Orig1s000MedR.pdf - p.47
359	65					Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22421192/	Homo sapiens						60							8	solid tumors								21	day		
360	65					Studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22421192/	Homo sapiens						60							12	solid tumors								21	day		
361	65					Studied dose	mg	220		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/22421192/	Homo sapiens						60							12	solid tumors								21	day		
362	66		adult				mg	14		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00134563	Homo sapiens													358	Multiple Sclerosis								108	week		
363	66		adult				mg	7		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00134563	Homo sapiens													368	Multiple Sclerosis								108	week		
364	66					Overdose	mg	672		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/33421160	Homo sapiens																									
365	66					Recommended	mg	14		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26865517	Homo sapiens						36							250	Multiple sclerosis								9	year		p.923
366	66					Recommended	mg	14		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30511679	Homo sapiens						37.8							43	Multiple sclerosis								458	day		p.2781
367	66					Recommended	mg	14		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202992s006lbl.pdf	Homo sapiens						37								Multiple sclerosis											p.8,9
368	66					Recommended	mg	14		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202992s006lbl.pdf	Homo sapiens														Multiple sclerosis											p.1
369	66					Recommended	mg	14		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202992s006lbl.pdf	Homo sapiens														Multiple sclerosis											p.7
370	67		adult				mg	800		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens													5												
371	67					Recommended	mg	500		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000MedR.pdf	Homo sapiens												91	571						18			24	week		
372	67						mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203341Orig1s000ClinPharmR.pdf	Homo sapiens													2	advanced malignant solid tumors								24	week		
373	68		adult				mg	160		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01212991	Homo sapiens										until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.			871	Prostate Cancer								3	year		
374	68		adult				mg	160		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02294461	Homo sapiens										Median treatment emergent period length (months) for Enzalutamide 7.10			198	Prostate Cancer								7	month		
375	68		adult				mg	160		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02528643	Homo sapiens										treatment duration was 71.0 (6, 574) days [median (minimum, maximum)] for enzalutamide			107	Hepatocellular Carcinoma								71	day		
376	68					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925	Homo sapiens						68				All patients treated at 480 and 600 mg per day levels were postchemotherapy and received the drug in two divided doses of 240 and 300 mg each.			3	castration-resistant prostate cancer					68			28	day		
377	68					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						68				All patients treated at 480 and 600 mg per day levels were postchemotherapy and received the drug in two divided doses of 240 and 300 mg each.			3	castration-resistant prostate cancer					68			28	day		p. 106
378	68					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925 |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						68				All patients treated at 480 and 600 mg per day levels were postchemotherapy and received the drug in two divided doses of 240 and 300 mg each.			3	castration-resistant prostate cancer					68			28	day		p. 106
379	68					MTD	mg	240		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						68							29	castration-resistant prostate cancer					68			28	day		p. 53
380	68					Recommended	mg	160		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf	Homo sapiens						69						92	800	metastatic castration-resistant prostate cancer					41			8.3	month		
381	68					Recommended	mg	160		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						69						92	800	metastatic castration-resistant prostate cancer					41			8.3	month		p. 79
382	68						mg	240		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925 |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						68				All patients treated at 480 and 600 mg per day levels were postchemotherapy and received the drug in two divided doses of 240 and 300 mg each.			22	castration-resistant prostate cancer					68			28	day		p. 106
383	68						mg	360		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20398925 |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203415Orig1s000MedR.pdf	Homo sapiens						68							28	castration-resistant prostate cancer					68			28	day		p. 106
384	70		adult				ug	200		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00358436	Homo sapiens													600	Chronic Obstructive Pulmonary Disease								52	week		
385	70		adult				ug	200		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00363896	Homo sapiens													627	Chronic Obstructive Pulmonary Disease								52	week		
386	70		adult				ug	200		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00500318	Homo sapiens													86	Chronic obstructive pulmonary disease								6	week		
387	70		adult				ug	400		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02038829	Homo sapiens													94	Chronic Obstructive Pulmonary Disease								7	day		
388	70		adult				ug	400		steady			day	2	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01966107	Homo sapiens													1791	Chronic Obstructive Pulmonary Disease								36	month		
389	70					Highest studied dose	ug	6000		single					healthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/19640353/	Homo sapiens													16												
390	70					Highest studied dose	ug	800		steady			day	2	healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/22366196	Homo sapiens						39.3						45	8						18			7	day		
391	70					Recommended	ug	200		steady			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf	Homo sapiens													891	COPD								40	week		p. 101
392	70						ug	200		steady			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000MedR.pdf	Homo sapiens													448	COPD								52	week		p. 101
393	70						ug	400		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21628603	Homo sapiens						30						43	6						24			5	min		
394	71		adult			Highest studied dose	mg/m2	70		multiple			week	2	unhealthy	intravenous			https://doi.org/10.1182/blood.V118.21.2930.2930	Homo sapiens										Carfilzomib was given as a 30-minute IV infusion on days (D) 1, 2, 8, 9, 15, and 16 of a 28-day cycle (C). C1 D1–2 doses were 20 mg/m2, followed by escalation to a higher dose of either 36, 45, 56, or 70 mg/m2.			2	multiple myeloma								2	week		
395	71					MTD	mg/m2	56		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27460677	Homo sapiens						58				Carfilzomib was intravenously administered over 30 min on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. The dosage on days 1 and 2 of cycle 1 was 20 mg/m2 , and if tolerated, it was escalated to 45 or 56 mg/m2 on day 8 of cycle 1 and thereafter.			4	relapsed or refractory multiple myeloma					58			2	week		
396	71					Recommended	mg/m2	20		steady			week	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf	Homo sapiens						63						87	526	relapsed and/or refractory multiple myeloma					37			3	week		
397	71					Recommended	mg/m2	20		steady			week	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202714Orig1s000MedR.pdf	Homo sapiens						63						87	526	relapsed and/or refractory multiple myeloma					37			3	week		p. 51
398	72		adult			Recommended	mg	25		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf	Homo sapiens										combined data for doses: 25, 50 and 100 mg			2736									12	week		p. 300
399	72		adult				mg	100		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00410514	Homo sapiens													65	Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)								12	week		
400	72		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00662909	Homo sapiens													433	Overactive Bladder								12	week		
401	72		adult				mg	25		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00912964	Homo sapiens													432	Overactive Bladder								12	week		
402	72		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01340027	Homo sapiens													77	Overactive Bladder								12	week		
403	72		adult				mg	50		multiple			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02787083	Homo sapiens													4	Interstitial Cystitis								12	week		
404	72		adult				mg	50		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00912964	Homo sapiens													440	Overactive Bladder								12	week		
405	72		adult				mg	50		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00410514	Homo sapiens													70	Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)								12	week		
406	72		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00662909	Homo sapiens													442	Overactive Bladder								12	week		
407	72		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01340027	Homo sapiens													78	Overactive Bladder								12	week		
408	72		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02216214	Homo sapiens							max			Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.			445	Overactive Bladder								12	week		
409	72					Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24178236	Homo sapiens						23.8							6						23.8						
410	72					Studied dose	mg	200		multiple			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000MedR.pdf |https://pubmed.ncbi.nlm.nih.gov/24178236	Homo sapiens						23.6							8						23.6			7	day		p. 19
411	72					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23471546/	Homo sapiens						58							167	overactive bladder								80	day		
412	73		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00603291	Homo sapiens													95	Obesity								52	week		
413	73		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00603902	Homo sapiens													801	Obesity								52	week		
414	73		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02044874	Homo sapiens													202	Tobacco Use Disorder								12	week		
415	73		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00603291	Homo sapiens													256	Obesity								52	week		
416	73		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00603902	Homo sapiens													1602	Obesity								52	week		
417	73		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02044874	Homo sapiens													201	Tobacco Use Disorder								12	week		
418	73		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03007394	Homo sapiens													118	Cocaine Use Disorder								13	week		
419	73					MTD	mg	40		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000MedR.pdf	Homo sapiens													45												p. 26, p. 197
420	73					Recommended	mg	10		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000MedR.pdf	Homo sapiens												66	3195						18			1	year		p. 63
421	73					Recommended	mg	10		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000MedR.pdf	Homo sapiens												66	3195						18			1	year		p. 63
422	74		adult				mg	100		multiple					unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00895011	Homo sapiens										One dose 30 minutes prior to initiation of sexual activity			99	Erectile Dysfunction											
423	74		adult				mg	200		multiple					unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00895011	Homo sapiens										One dose 30 minutes prior to initiation of sexual activity			99	Erectile Dysfunction											
424	74					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202276Orig1s000MedR.pdf	Homo sapiens																						35.3	week		p. 99
425	74					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202276Orig1s000MedR.pdf	Homo sapiens																						35.3	week		p. 99
426	74						mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202276Orig1s000MedR.pdf	Homo sapiens																						35.3	week		p. 99
427	77					Recommended	%	0.0015		multiple			day	1	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202514Orig1s000MedR.pdf	Homo sapiens										combined studies 74457, 74458, 15-003		72	18	open-angle glaucoma | ocular hypertension					27			6	week		p.66
428	77						%	0.0003		multiple			day	1	unhealthy	ophthalmic	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202514Orig1s000MedR.pdf	Homo sapiens						60							1						60			8	day		p.66
429	78		adult			Overdose	mg	450		multiple			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207925s000lbl.pdf	Homo sapiens																						4.5	day		
430	78		adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02135432	Homo sapiens													8	Chronic Obstructive Pulmonary Disease											
431	78		adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02971839	Homo sapiens													3	Cystic Fibrosis								28	day		
432	78		child				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00909727	Homo sapiens													26	Cystic Fibrosis								48	week		
433	78		child|adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00909532	Homo sapiens													83	Cystic Fibrosis								48	week		
434	78		child|adult				mg	150		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01614457	Homo sapiens													34	Cystic Fibrosis								24	week		
435	78					Recommended	mg	50		steady			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207925Orig1s000MedR.pdf	Homo sapiens						2							1						2						p. 27
436	78					Recommended	mg	50		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207925Orig1s000MedR.pdf	Homo sapiens												6	34						2						p. 27
437	78					Recommended	mg	75		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207925Orig1s000MedR.pdf	Homo sapiens												6	34						2						p. 27
438	79		adult			Highest studied dose	mg	540		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/21300760 | https://pubmed.ncbi.nlm.nih.gov/21300762	Homo sapiens													4	locally advanced or metastatic basal cell carcinoma											
439	79		adult				mg	150		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00739661	Homo sapiens										until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study			52	Ovarian Cancer											
440	79		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01898598	Homo sapiens													11	Basal Cell Carcinoma								12	week		
441	79		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02067104	Homo sapiens										Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.			5	Basal Cell Carcinoma								2	month		
442	79					Recommended	mg	150		multiple			day	1	pregnant	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf	Homo sapiens																									
443	79					Recommended	mg	150		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf	Homo sapiens													10									10	month		
444	79					Recommended	mg	150		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf	Homo sapiens						61						101	138	Advanced Basal Cell Carcinoma					21			10	month		
445	79					Recommended	mg	150		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203388Orig1s000MedRpdf.pdf	Homo sapiens													104	Advanced Basal Cell Carcinoma								10	month		p. 91
446	79						mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24077351	Homo sapiens						14.5							10	Medulloblastoma					14.5			28	day		
447	79						mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24077351	Homo sapiens						14.5							10	Medulloblastoma					14.5			28	day		
448	79						mg/m2	170		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24077351	Homo sapiens						11.6							7	Medulloblastoma					11.6			28	day		
449	80		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01599754	Homo sapiens													360	Renal Cell Cancer								3	year		
450	80					Highest studied dose	mg	30		steady			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens													2	advanced solid malignancies								28	day		
451	80					MTD	mg	5		steady			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens										The MTD and recommended phase II dose is 5 mg BID in the fasted state			8	advanced solid malignancies								28	day		
452	80						mg	15		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens													6	advanced solid malignancies								28	day		
453	80						mg	20		steady			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16027439	Homo sapiens													4	advanced solid malignancies								28	day		
454	80						mg	5		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000MedR.pdf	Homo sapiens						62	starting					82	359						20			4	week		
455	81					Highest studied dose	%	0.25		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000MedR.pdf	Homo sapiens										9 additional trials			1	superficial basal cell carcinoma								2	day		p. 53
456	81					Recommended	%	0.015		multiple			day	1	unhealthy	topical	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000MedR.pdf	Homo sapiens						61							1						61						p. 52
457	81					Recommended	%	0.05		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202833Orig1s000MedR.pdf	Homo sapiens										9 additional trials			1	nodular basal cell carcinoma								2	day		p. 53
458	83		adult			Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf	Homo sapiens										Patients with baseline platelet count > 200,000/µL started at 20 mg b.i.d. Patients with baseline platelet count > 100,000/µL to ≤ 200,000/µL started at 15 mg b.i.d.			155	myelofibrosis								24	week		202192Orig1s000MedR.pdf - p.67-70
459	83		adult			Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf | https://www.ema.europa.eu/en/documents/assessment-report/jakavi-epar-public-assessment-report_en.pdf	Homo sapiens										Patients with baseline platelet count > 200,000/µL started at 20 mg b.i.d. Patients with baseline platelet count > 100,000/µL to ≤ 200,000/µL started at 15 mg b.i.d.			155	myelofibrosis								24	week		202192Orig1s000MedR.pdf - p.67-70
460	83		adult				mg	15		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00550043	Homo sapiens													12	Rheumatoid Arthritis								4	week		
461	83		adult				mg	25		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00550043	Homo sapiens													10	Rheumatoid Arthritis								4	week		
462	83		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00550043	Homo sapiens													9	Rheumatoid Arthritis								4	week		
463	83		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00550043	Homo sapiens													10	Rheumatoid Arthritis								4	week		
464	83					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf	Homo sapiens						75							3	myelofibrosis								14.7	month		202192Orig1s000MedR.pdf - p.24
465	83					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/20843246/	Homo sapiens						71							6	myelofibrosis								14.7	month		202192Orig1s000MedR.pdf - p.24
466	83					MTD	mg	25		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf	Homo sapiens						67							47	myelofibrosis								14.7	month		202192Orig1s000MedR.pdf - p.24
467	83					MTD	mg	25		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/20843246/	Homo sapiens						67							47	myelofibrosis								14.7	month		202192Orig1s000MedR.pdf - p.24
468	83						mg	50		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000MedR.pdf	Homo sapiens						62							5	myelofibrosis								14.7	month		202192Orig1s000MedR.pdf - p.24
469	83						mg	72		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20843246/	Homo sapiens						65	mean						153	myelofibrosis								14.7	month		
470	84					Highest studied dose	mg	80		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													70									28	day		p. 69-70
471	84						mg	10		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													24									44	day		p. 69
472	84						mg	15		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													24									44	day		p. 69
473	84						mg	20		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													70									28	day		p. 70
474	84						mg	60		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													24									44	day		p. 69
475	84						mg	70		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202067Orig1s000MedR.pdf	Homo sapiens													24									44	day		p. 69
476	85		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01539837	Homo sapiens													7	Parkinson's disease								6	month		
477	85		adult				mg	15		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01539837	Homo sapiens													7	Parkinson's disease								6	month		
478	85					Recommended	mg/kg	100		multiple			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32470438	Homo sapiens							max|total daily dose			Deferiprone was administered orally, daily at 75–100 mg/kg per day			193	Transfusion-dependent haemoglobinopathies											e475
479	85					Recommended	mg/kg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31620867	Homo sapiens													10	Infratentorial superficial siderosis								2.3	year		p.3
480	85					Recommended	mg/kg	33		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf	Homo sapiens							max						642	Transfusional iron overload due to thalassemia syndromes											p.3
481	85					Recommended	mg/kg	33		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf	Homo sapiens							max						642	Transfusional iron overload due to thalassemia syndromes											p.4
482	85					Recommended	mg/kg	33		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf	Homo sapiens							max							Transfusional iron overload due to thalassemia syndromes											p.1
483	85						mg/kg	15		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01741532	Homo sapiens													58	Pantothenate Kinase-associated Neurodegeneration								18	month		
484	86					Recommended|MTD	mg	250		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000MedR.pdf	Homo sapiens						51						79	119	Adenocarcinoma | Squamous Cell Carcinoma |Non-small Cell Lung Cancer					21			7.8	month		
485	86					Recommended|MTD	mg	250		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000MedR.pdf	Homo sapiens						52						82	136	Adenocarcinoma | Adenosquamous Carcinoma|Non-small Cell Lung Cancer					29			5.1	month		
486	86						mg	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31778074	Homo sapiens						49				28-day cycles			6						49			3	cycle		
487	87					Highest studied dose	mg	90		single					healthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/27128215	Homo sapiens													72												p.109
488	87					Highest studied dose	mg/kg	0.15		multiple					healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150Orig1s000ClinPharmR.pdf	Homo sapiens										0.15 mg/kg over 24 hours for 3 days			6									3	day		p.61
489	87					Highest studied dose	mg/kg	3.2		single					healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022150Orig1s000ClinPharmR.pdf	Homo sapiens										i.v infusion during 1 hour			4												p.61
490	87					Recommended	mg	30		multiple			day	2	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022150s000lbl.pdf	Homo sapiens										The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area. Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur. No more than 3 doses may be administered in any 24 hour period.				Acute attacks of hereditary angioedema											p.1
491	88					Highest studied dose	mg	1600		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.9000	Homo sapiens													3	cancer								8	week		
492	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20818844/	Homo sapiens										median progression-free survival			32	metastatic melanoma								7	month		
493	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000SumR.pdf - p.11 | 202429Orig1s000MedR.pdf - p.13
494	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000MedR.pdf - p.75
495	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000MedR.pdf - p.80
496	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000MedR.pdf - p.82
497	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000MedR.pdf - p.86
498	88					Recommended|MTD	mg	960		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202429Orig1s000MedR.pdf	Homo sapiens										median duration			336	melanoma								4.2	month		202429Orig1s000MedR.pdf - p.87
499	88						mg	1120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20818844/	Homo sapiens										median progression-free survival			6	metastatic melanoma								7	month		
500	88						mg	1120		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.9000	Homo sapiens													5	cancer								8	week		
501	88						mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20818844/	Homo sapiens										median progression-free survival			4	metastatic melanoma								7	month		
502	88						mg	360		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20818844/	Homo sapiens										median progression-free survival			8	metastatic melanoma								7	month		
503	88						mg	360		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.9000	Homo sapiens														cancer								8	week		
504	88						mg	720		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.9000	Homo sapiens													6	cancer								8	week		
505	89		adult				mg	90		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01347580	Homo sapiens										Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.			908	Myocardial Infarction								30	day		
506	89		adult				mg	90		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01998399	Homo sapiens													12	Pneumonia								90	day		
507	89					Highest studied dose	mg	1260		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/24040849|https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwji45rs27fuAhVmiYsKHW3hA2MQFjAGegQICBAC&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F797%2Fdownload&usg=AOvVaw3STEHV1bh8A3ZobpKVV1Gj	Homo sapiens													6												
508	89					MTD	mg	900		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/24040849|https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwji45rs27fuAhVmiYsKHW3hA2MQFjAGegQICBAC&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F797%2Fdownload&usg=AOvVaw3STEHV1bh8A3ZobpKVV1Gj	Homo sapiens													6												
509	89					Recommended	mg	90		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf	Homo sapiens										In the management of ACS, initiate BRILINTA treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily.			9333	acute coronary syndrome				aspirin, p.o				277	day		p.3
510	89					Recommended	mg	90		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022433s020lbl.pdf	Homo sapiens										In the management of ACS, initiate BRILINTA treatment with a 180 mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily.				acute coronary syndrome											p.1
511	90					Highest studied dose	mg	80		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16198660	Homo sapiens												45	6						19						p.419
512	90					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf	Homo sapiens							max						7111	Atrial Fibrillation								19	month		p.1, p.12
513	90					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf	Homo sapiens														Deep Vein Thrombosis|Pulmonary Embolism											p.1, p.14
514	90					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf	Homo sapiens							max							Atrial Fibrillation|Deep Vein Thrombosis|											p.1
515	90					Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf	Homo sapiens							max			15 mg orally twice daily for three weeks followed by 20 mg orally once daily to treat DVT or PE			4130	Deep Vein Thrombosis|Pulmonary Embolism								208	day		p.1, p.14
516	90					Studied dose	mg	50		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18715524	Homo sapiens												76	12						60						p.2759, p.2760
517	91		adult			Recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf	Homo sapiens										combined data: 600 mg/day, 900 mg/day and 1200 mg/day. each administered in 3 equally divided doses			813									28	day		
518	91		adult				mg	900		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03043560	Homo sapiens							max						21	Major Depressive Disorder								5	week		
519	91					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21451152	Homo sapiens						37.7							153	drug-resistant partial epilepsy					37.7			18	week		
520	91					Overdose	mg	2500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022345s000lbl.pdf	Homo sapiens														epilepsy											
521	91					Recommended	mg	350		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25006968	Homo sapiens						30							2	epilepsy					30			6	year		
522	91					Recommended	mg	50		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/26909536	Homo sapiens						48	starting			started at 50 mg orally 3 times per day and then progressively advanced to 250 mg 3 times			1	epilepsy					48			6	month		
523	92		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01691248	Homo sapiens													300	Clostridium Difficile-Associated Diarrhea								40	day		
524	92					Recommended	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf	Homo sapiens													564	C. difficile-associated diarrhea								10	day		p.4
525	92					Recommended	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213138lbl.pdf	Homo sapiens														C. difficile-associated diarrhea											p.1
526	93		adult			Highest studied dose	mg	1875		multiple			day	3	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf	Homo sapiens																						4	day		
527	93		adult			Recommended	mg	750		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000MedR.pdf	Homo sapiens										Overall 14% (249/1797) of subjects discontinued telaprevir due to adverse events compared to 7/493 (1%) subjects who discontinued in Pbo/PR groups.			1797					peginterferon alfa				12	week	ribavirin	p. 68
528	93					Recommended	mg	750		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30566559	Homo sapiens						58				Overall 14% (249/1797) of subjects discontinued telaprevir due to adverse events compared to 7/493 (1%) subjects who discontinued in Pbo/PR groups.			1	chronic hepatitis C virus				peginterferon alfa	58			2	month	ribavirin	
529	94					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19926964	Homo sapiens													91	HIV-1 infection								96	week		p.62
530	94					Recommended	mg	25		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf	Homo sapiens													686	HIV-1 infection											p.1
531	94					Recommended	mg	25		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf	Homo sapiens													686	HIV-1 infection											p.3
532	94					Recommended	mg	25		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202022s000lbl.pdf	Homo sapiens														HIV-1 infection											p.1
533	95					Recommended	mg	800		steady			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25693997	Homo sapiens												60	13						18			6	day		
534	95						mg	400		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22799589	Homo sapiens													6	Severe hepatic impairment											
535	95						mg	400		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23454058	Homo sapiens						40.7							6	hepatitis C genotype 2/3 infection					40.7			14	day		
536	96		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00740051	Homo sapiens													151	Type 2 Diabetes								52	week		
537	96		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01897532	Homo sapiens										Adverse events with an onset after the first dose of trial medication up to a period of 7 days after the last permanent study drug stop; up to 4.3 years			3494	Type 2 Diabetes								4	year		
538	96		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02350478	Homo sapiens													20	Type 2 Diabetes								12	week		
539	96					Highest studied dose	mg	600		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201280lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/18812608	Homo sapiens						38.3						63	6						23						
540	97					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18645193	Homo sapiens												85	3	metastatic castration-resistant prostate cancer					52			28	day		p.4566
541	97					Highest studied dose	mg	2000		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000MedR.pdf	Homo sapiens														metastatic castrationresistant prostate cancer								28	day		p. 27
542	97					Recommended	mg	1000		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf	Homo sapiens														metastatic castration-resistant prostate cancer	5 mg, b.i.d			prednisone, p.o							p.1
543	97					Recommended	mg	1000		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202379lbl.pdf	Homo sapiens														metastatic castration-resistant prostate cancer	5 mg, b.i.d			prednisone, p.o							p.5
544	97					Recommended	mg	500		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210308s000lbl.pdf	Homo sapiens						70							542	metastatic castrationresistant prostate cancer				Corticosteroid	70			13.8	month		
545	97					Recommended	mg	500		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210308s000lbl.pdf	Homo sapiens						70							546	metastatic castrationresistant prostate cancer				Corticosteroid	70			13.8	month		
546	98		adult				mg	300		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00777179	Homo sapiens													75	Non-Small Cell Lung Cancer								12	week		
547	98		adult				mg	300		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01876784	Homo sapiens													117	Thyroid Cancer								22	month		
548	98					Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/22206795/	Homo sapiens						34.4							5									1	day		caprelsa-epar-public-assessment-report_en.pdf - p.24
549	98					Recommended	mg/day	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21282542/	Homo sapiens						61				median duration			623	non-small-cell lung cancer								9.1	week		
550	98					Recommended	mg/day	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/21282542/	Homo sapiens						61				median duration			623	non-small-cell lung cancer								9.1	week		
551	98					Recommended|MTD	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15905307/ | https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf	Homo sapiens						45.6				mean duration			8	cancer								81	day		caprelsa-epar-public-assessment-report_en.pdf - p.28
552	98					Recommended|MTD	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17409986/	Homo sapiens						52.5							6	solid tumors								191.5	day		
553	98					Recommended|MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15905307/ | https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf	Homo sapiens						57.7				mean duration			25	cancer								76	day		caprelsa-epar-public-assessment-report_en.pdf - p.28
554	98					Recommended|MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17409986/	Homo sapiens						55.5							6	solid tumors								76.5	day		
555	98					Recommended|MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf	Homo sapiens						50.7				Median Duration of Exposure			231	medullary thyroid cancer								607	day		022405Orig1s000MedR.pdf - p.71
556	98						mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17409986/	Homo sapiens						50							3	solid tumors								43	day		
557	98						mg	300		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15905307/ | https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf	Homo sapiens						34.4							6									1	day		caprelsa-epar-public-assessment-report_en.pdf - p.28
558	98						mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17409986/	Homo sapiens						53							3	solid tumors								37	day		
559	98						mg	400		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22206795/	Homo sapiens						34.4							6									1	day		
560	98						mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15905307/	Homo sapiens						51.6				mean duration			8	cancer								88	day		
561	98						mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15905307/	Homo sapiens						50.6				mean duration			8	cancer								24	day		
562	98						mg	800		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22206795/	Homo sapiens						34.4							6									1	day		
563	99		adult			Highest studied dose	mg	1800		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/31278761/	Homo sapiens													50	alcohol dependence								7	day		
564	99		adult			Recommended	mg	120		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/28597471/	Homo sapiens													5914	neuropathic pain								12	week		
565	99		children				mg/kg	6.67		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01506453	Homo sapiens													25	Acute Lymphoblastic Leukemia								21	day		
566	99		children|adults				mg/kg	15		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01954927	Homo sapiens													42	Sickle Cell Disease											
567	99					Highest studied dose	mg	1200		steady			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf	Homo sapiens													2074	epilepsy					12			7	day		
568	99					MTD	mg	2433		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19796802/	Homo sapiens							mean					73	46	neuropathic pain	50.1 mg			NORTRIPTYLINE	53			7	day		
569	99					MTD	mg	2433		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19796802/	Homo sapiens							mean					73	46	neuropathic pain					53			7	day		
570	99					Overdose	mg	45000		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21554310/	Homo sapiens						62							1	depression					62						
571	99					Recommended	mg	600		steady			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf	Homo sapiens													2074	epilepsy					12			7	day		
572	99					Recommended	mg	600		steady			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf	Homo sapiens													2203	epilepsy					12			7	day		
573	99						mg	1200		steady					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00395044	Homo sapiens							total daily dose						25	Cannabis dependence								12	week		
574	99						mg	1800		steady					unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00755417	Homo sapiens							total daily dose						181	hot flashes|Post menopausal								4	week		
575	99						mg	1800		steady					unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00777023	Homo sapiens							total daily dose						190	hot flashes|Post menopausal								4	week		
576	99						mg	300		multiple			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02926573	Homo sapiens													55	Head And Neck Mucosal Surgery											
577	99						mg	400		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00420771	Homo sapiens													6	benzodiazepine abuse								8	week		
578	99						mg	400		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01141049	Homo sapiens													19	Alcohol Dependence								6	week		
579	99						mg	400		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01893632	Homo sapiens													1	Benzodiazepine Dependence								12	week		
580	99						mg	600		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02725710	Homo sapiens													47	Uterine Aspiration											
581	99						mg	600		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00755417	Homo sapiens													174	hot flashes|Post menopausal								4	week		
582	99						mg	600		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00777023	Homo sapiens													186	hot flashes|Post menopausal								4	week		
583	101		adult			Highest studied dose	ug	5000		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022522s000lbl.pdf	Homo sapiens													1												
584	101		adult				mg	500		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00297102	Homo sapiens													769	Chronic Obstructive Pulmonary Disease								52	week		
585	101		adult				mg	500		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00297115	Homo sapiens													778	Chronic Obstructive Pulmonary Disease								52	week		
586	101		adult				ug	500		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01630200	Homo sapiens													40	Chronic Obstructive Pulmonary Disease								6	month		
587	101		adult				ug	500		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01973998	Homo sapiens													31	Chronic Obstructive Pulmonary Disease								180	day		
588	101					Recommended	ug	450		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022522s000lbl.pdf	Homo sapiens						64						91	4438	COPD					40			1	year		
589	103		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01629966	Homo sapiens													227	Generalized Anxiety Disorder								8	week		
590	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01473394	Homo sapiens							max			Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.			255	Major Depressive Disorder								9	week		
591	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01574183	Homo sapiens							max			Flexible dose up to 40 mg capsule daily			41	Marijuana Dependence								8	week		
592	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01629966	Homo sapiens													225	Generalized Anxiety Disorder								8	week		
593	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01844115	Homo sapiens							max						202	Generalized Anxiety Disorder								8	week		
594	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01844115	Homo sapiens							max						75	Generalized Anxiety Disorder								8	week		
595	103		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01999920	Homo sapiens							max|total daily dose			10mg to 40mg per day for 12 weeks			13	Adult Separation Anxiety Disorder								12	week		
596	103		child				mg	15		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01878292	Homo sapiens													175	Major Depressive Disorder								8	week		
597	103		child				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01878292	Homo sapiens													180	Major Depressive Disorder								8	week		
598	103		child				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02372799	Homo sapiens							max						187	Major Depressive Disorder								8	week		
599	103					Overdose	mg	840		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31777303	Homo sapiens						3							1												p.3
600	103					Overdose	mg	920		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33158691	Homo sapiens						1.8							1												p.2
601	103					Recommended	mg	40		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000OtherR.pdf	Homo sapiens													56												p.10, p.11
602	103					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27738360	Homo sapiens										patients were treated with vilazodone accordingto a fixed-titration schedule of 10 mg qd for 7 days, followed by 20 mg qd for the next 7 days, and then at the targeted dose of 40 mg qd, and were instructed to take study drug in the morning with food.		65	436	Major depressive disorder					18			8	week		p.25
603	103					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27738360	Homo sapiens										patients were treated with vilazodone accordingto a fixed-titration schedule of 10 mg qd for 7 days, followed by 20 mg qd for the next 7 days, and then at the targeted dose of 40 mg qd, and were instructed to take study drug in the morning with food.		65	599	Major depressive disorder					18			52	week		p.25
604	103					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27738360	Homo sapiens										patients were treated with vilazodone accordingto a fixed-titration schedule of 10 mg qd for 7 days, followed by 20 mg qd for the next 7 days, and then at the targeted dose of 40 mg qd, and were instructed to take study drug in the morning with food.		65	599	Major depressive disorder					18			52	week		
605	103					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022567s000lbl.pdf	Homo sapiens														Major depressive disorder											p.1
606	103					Studied dose	mg	80		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022567Orig1s000OtherR.pdf	Homo sapiens							max						56												p.10, p.11
607	105					Recommended	g	5		multiple			day	7	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/11689755	Homo sapiens										2% clindamycin phosphate vaginal cream (Cleocin VaginalCream), 5 g intravaginally at bedtime for 7 days		51	79	Bacterial Vaginosis					16						p.571
608	105					Recommended	mg	1200		multiple			day	4	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Homo sapiens										In life-threatening situations due to either aerobes or anaerobes these doses may be increased. Doses of as much as 4,800 mg daily have been given intravenously to adults.				Infections due to susceptible strains of streptococci, pneumococci, and staphylococci											
609	105					Recommended	mg	300		multiple			day	4	unhealthy	intramuscular			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Homo sapiens										600 mg to 1,200 mg per day in 2, 3 or 4 equal doses				Infections due to susceptible strains of streptococci, pneumococci, and staphylococci											
610	105					Recommended	mg	300		multiple			day	4	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7a6967b3-5563-4bed-9eee-d400f800e799&type=display	Homo sapiens										600 mg to 1,200 mg per day in 2, 3 or 4 equal doses				Infections due to susceptible strains of streptococci, pneumococci, and staphylococci											
611	105					Recommended	mg	450		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdf	Homo sapiens										Serious infections – 150 to 300 mg every 6 hours. More severe infections – 300 to 450 mg every 6 hours.				Infections due to susceptible strains of streptococci, pneumococci, and staphylococci											p.1
612	107		adult			Recommended	mg/kg	5		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf	Homo sapiens										Induction Treatment: The recommended initial dosage for patients with normal renal function is 5 mg/kg (given intravenously at a constant rate over 1 hour) every 12 hours for 14 to 21 days. Maintenance Treatment: Following induction treatment, the recommended maintenance dosage of CYTOVENE-IV solution is 5 mg/kg given as a constant-rate intravenous infusion over 1 hour once daily, 7 days per week, or 6 mg/kg once daily, 5 days per week.			179	CMV retinitis in HIV infection											
613	107					Highest studied dose	mg	1000		multiple			day	6	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7769276/	Homo sapiens						37.4				Persons were enrolled into group A once they met entry criteria and were assigned to one of three dosages of oral ganciclovir: 500 or 1000 mg every 12 h or 1000 mg every 3 h (six doses/day). Enrollment at the next higher level occurred only after 6 subjects had been enrolled at the lower dosage. Participants received 28 days of oral ganciclovir.			19	AIDS								28	day		
614	107					Highest studied dose	mg	2000		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7769276/	Homo sapiens						38.6				Group B participants were enrolled concurrently with group A participants and were assigned sequentially the following maintenance doses of oral ganciclovir: 1000 mg every 8 h: 500, 750, or 1000 mg every 3 h (six doses/day); or 2000 mg every 8 h. The regimens were selected to optimize information regarding the pharmacokinetics and tolerability oforal ganciclovir administered at different doses and intervals.			50	CMV retinitis in HIV infection								28	day		
615	107					Highest studied dose	mg/kg	50		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11069232/	Homo sapiens						7.4				Initially, all patients received an intravenous infusion of 5 mg/kg of Gcv (study day 1). After 2 days, they received an oral dose of 10, 20, 30, 40, or 50 mg/kg of Gcv suspension (maximum, 2000 mg) with food (study day 3). This dose was continued every 8 h, except in children who could swallow capsules and opted to take the 250-mg Gcv capsules (Cytovene; Roche). In those who opted for capsules, the initial dose of oral suspension was given in 250 mg increments to match the Gcv capsule dose. The first capsule dose was given on study day 5.		16.9	36	CMV retinitis in HIV infection					0.5						
616	108					Highest studied dose	mg/kg	400		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13121040/	Homo sapiens						58	max			Administration of EDTA initiated March 25, 25 mg given. Subsequently increasing amounts to 6 g in 45 minutes injected without change in calcium level. 400 mg/kg body weight was given finally.			1	Hypercalcemia|Breast cancer								15	day		p.360
617	108					Highest studied dose	mg/kg	400		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13121040/	Homo sapiens						58	max			Administration of EDTA initiated March 25, 25 mg given. Subsequently increasing amounts to 6 g in 45 minutes injected without change in calcium level. April 10: 400 mg/kg body weight was given finally.			1	Hypercalcemia|Breast cancer								15	day		p.360
618	108					Recommended	mg/kg	25		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7099793	Homo sapiens										recommended dose in indicated in: https://www.medsafe.govt.nz/profs/Datasheet/e/EdetateDisodiumUSPinj.pdf		8	130	Plumbism	3 mg/kg; 6/day; 5 days			2,3-dimercapto-1-propanol, i.v	1			5	day		
619	108					Studied dose	mg/kg	160		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13121040/	Homo sapiens						49							1	Hypercalcemia|Multiple myeloma											p.361
620	108					Studied dose	mg/kg	175		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13121040/	Homo sapiens						49							1	Hypercalcemia|multiple myeloma											p.361
621	110					Highest studied dose	mg/m2	40		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10656432	Homo sapiens										Melphalan was administered overa 24-h period			7	Advanced cancer								13	course		p.60
622	110					MTD	mg/m2	200		multiple			70 days	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9720737	Homo sapiens													55	Multiple myeloma								2	course		p.248, 250
623	110					MTD	mg/m2	30		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10656432	Homo sapiens										Melphalan was administered overa 24-h period			9	Advanced cancer								23	course		p.60
624	110					Recommended	mg/m2	100		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf	Homo sapiens										For Conditioning Treatment, the recommended dose of Evomela is 100 mg/m2/day administered over 30 minutes by intravenous infusion for 2 consecutive days (Day -3 and Day -2) prior to autologous stem cell transplantation (ASCT, Day 0).				Multiple myeloma								2	day		p.1
625	114					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19117344	Homo sapiens										50 mg/mq daily orally on Days 1-7 in 3-week cycles. 6 cycles		78	6	Urothelial bladder cancer	175 mg/m(2) (Day 1), 6 cycles			paclitaxel, i.v	47			7	day		p.519
626	114					Highest studied dose	mg/m2	3300		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8558227	Homo sapiens										cycle 1		64	6	Breast cancer	160 mg/m2			paclitaxel, i.v	26						p.98
627	114					MTD	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19117344	Homo sapiens										50 mg/mq daily orally on Days 1-7 in 3-week cycles. 12 cycles		78	6	Urothelial bladder cancer	175 mg/m(2) (Day 1), 12 cycles			paclitaxel, i.v	47			7	day		p.519
628	114					MTD	mg/m2	200		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24440659	Homo sapiens												72	5	Acute lymphoblastic leukemia	40 mg/m(2) daily × 3 days			Clofarabine, i.v	21			3	day		p.5, 16
629	114					MTD	mg/m2	2000		multiple			3 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9296218	Homo sapiens										The median number of cycles administered to all patients was 5		70	6	Breast cancer	200 mg/m2, once in 3 weeks, 5 cycles			paclitaxel, i.v	27			5	cycle		p.658
630	114					MTD	mg/m2	2700		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8558227	Homo sapiens										cycle 1		64	6	Breast cancer	160 mg/m2			paclitaxel, i.v	26						p.98
631	114					Recommended	mg/kg	5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s112lbl.pdf	Homo sapiens							max			Oral: Usually 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing.				Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma											p.1
632	114					Recommended	mg/kg	50		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s112lbl.pdf	Homo sapiens							total|max			Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly.				Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma								5	day		p.1
633	114					Studied dose	mg/m2	300		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24440659	Homo sapiens												72	25	Acute lymphoblastic leukemia	40 mg/m(2) daily × 3 days			Clofarabine, i.v	21			3	day		p.5, 16
634	116		adult			Recommended	mg	3		multiple			day	3	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050555s037lbl.pdf	Homo sapiens																									
635	116		adult				mg/kg	1.5		multiple			day	3	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/820195	Homo sapiens													28	gram-negative bacilli infection											
636	116		adult				mg/kg	2		single					unhealthy	intraperitoneal			https://pubmed.ncbi.nlm.nih.gov/3950451	Homo sapiens													5	end stage renal disease											
637	116					Highest studied dose	mg/kg	12		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6440126	Homo sapiens							mean							cystic fibrosis											
638	116					Recommended	mg	300		multiple			day	2	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201820s000lbl.pdf	Homo sapiens													190						6			28	day		
639	118					Highest studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9052519	Homo sapiens						45.5							23	Ulcerative colitis								15	month		p.356
640	118					Recommended	g	4		multiple			day	3	unhealthy	oral	M+F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display	Homo sapiens													7492	Tuberculosis											
641	120						mL	20		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/182003	Homo sapiens										20 mL of 52%. The 20 ml dose was given intravenously over a 10 min interval.		83	45						19			10	min		
642	120						mL	60		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/4406624 |https://pubmed.ncbi.nlm.nih.gov/463851	Homo sapiens						66				60 mL of 52%			1						66			30	min		
643	121		adult			Highest studied dose	mg/kg	15		multiple			day	1	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/11409580	Homo sapiens													15	pulmonary tuberculosis											
644	121		adult			Recommended	mg	590		multiple			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207356s000lbl.pdf	Homo sapiens																									
645	121					Highest studied dose	mg/kg	15		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/18046534	Homo sapiens												30	6						21						
646	121					Highest studied dose	mg/kg	60		single					healthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/18046534	Homo sapiens												30	6						21						
647	121					Recommended	mg	590		multiple			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/27748623	Homo sapiens						58						61	44						16			84	day		
648	122		adult			Highest studied dose	mg	1		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021797s018,021798s019lbl.pdf	Homo sapiens													183	hepatitis B								52	week		6.1
649	123		adult			Recommended	mg/kg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4204592	Homo sapiens										25 mg/kg daily for a period of 60 days, followed by a maintenance dose of 15 mg/kg per day, were followed for two years			304	tuberculosis								60	day		
650	123					Recommended	mg/kg	25		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25861347	Homo sapiens						79							1	pulmonary tuberculosis					79						
651	124		old			Studied dose	mg/kg	2.5		steady			day	3	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/907325	Homo sapiens																						7	day		
652	124					Highest studied dose	mg/kg	3.6		steady			day	3	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/6937967	Homo sapiens										200 mg (2.2-3.6 mg/kg) netilmicin intramuscularly every 8 hours for 7-10 days (mean 8.8 days).			16	chronic or recurrent urinary tract infections								10	day		
653	124					Studied dose	mg/kg	1.5		steady			day	3	unhealthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2668247	Homo sapiens						36.8						79	55	appendicitis | other intra-abdominal infections					14			16	day		
654	124					Studied dose	mg/kg	4.5		steady			day	1	unhealthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2668247	Homo sapiens						40.3						80	57	appendicitis | other intra-abdominal infections					18			13	day		
655	124					Studied dose	mg/kg	6		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8889724	Homo sapiens													21									7	day		
656	126		adult			Recommended	%	0.15		steady			day	2	unhealthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/12113643/	Homo sapiens													659	glaucoma or ocular hypertension								12	month		
657	126		adult			Recommended	%	0.15		steady			day	2	unhealthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/12470755/	Homo sapiens													77	intraocular pressure								8	week		
658	131					Recommended	mg/kg	2.5		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf	Homo sapiens						52.9							263	Infection	5 mg/kg, IV, Q8H15			DALFOPRISTIN				5	day		Study 301
659	132		unknown			Highest studied dose	%	1		multiple			day	4	unknown	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20191slr018_alomide_lbl.pdf	Homo sapiens														conjunctivitis								4	week		
660	133					Overdose	g	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1257824	Homo sapiens						16							1												p.294
661	133					Overdose	g	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1257824	Homo sapiens						16							1												p.295
662	133					Overdose	g	25		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25779481	Homo sapiens						20							1		2.5 mg, single			pyridoxine, p.o							p.2
663	133					Overdose	mg	3000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3337420	Homo sapiens						7				125 mg/kg			1												73/127
664	133					Overdose	mg/kg	112		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9490997	Homo sapiens						17	max						1	Tuberculosis											
665	133					Recommended	mg	900		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22150035	Homo sapiens										dose of 15 to 25 mg per kilogram of body weight, rounded up to the nearest 50 mg, with a maximum dose of 900 mg			3986	Tuberculosis	900 mg; 1/week			rifapentine, p.o				3	month		p.2160
666	133					Recommended	mg	900		multiple			week	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf	Homo sapiens										15 mg/kg up to 900 mg/day, two or three times/week				Tuberculosis											p.1
667	134		adult			MTD	mg/m2	630		multiple			day	1	unhealthy	parenteral			https://pubmed.ncbi.nlm.nih.gov/2104537	Homo sapiens																						5	day		
668	134		adult			MTD	mg/m2	850		single					unhealthy	parenteral			https://pubmed.ncbi.nlm.nih.gov/2104537	Homo sapiens																									
669	134					Recommended	mg/m2	260		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11531286	Homo sapiens						62				altretamine 260 mg/m2/day po divided into four doses taken after meals and at bedtime for 14 of 28 days for six cycles			97	Epithelial Ovarian Cancer					62			14	day		
670	135					Overdose	mg	50		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8329789	Homo sapiens						2	total			50 mg (4.6 mg/kg); accidental Overdose			1						2						
671	135					Overdose	mg	52.5		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8329789	Homo sapiens							total			52.5 mg (25 mg/kg) and patient 3 received 53.1 mg (40.8 mg/kg). accidental Overdose			2												
672	135					Overdose	mg	65		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8329789	Homo sapiens						3.5	total			65 mg (approximately 3.8 mg/kg), accidental Overdose			1						3.5						
673	135					Overdose	mg/kg	14.5		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1841836	Homo sapiens							total						1												
674	135					Overdose	mg/kg	20.5		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1841836	Homo sapiens							total						1												
675	135					Recommended	mg/kg	0.7		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/50-740s2_AmBisome_medr.pdf	Homo sapiens						39						68	87						21						p. 27
676	135						mg/kg	5		steady			week	2	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT01259713	Homo sapiens													237	Acute Lymphoblastic Leukemia											
677	136					Recommended	mg	80		multiple			day	3	unhealthy	oral			https://extranet.who.int/pqweb/sites/default/files/MA111part4.pdf	Homo sapiens														Plasmodium falciparum malaria	480 mg, b.i.d			lumefantrine, p.o				3	day		p.3
678	136					Recommended	mg	80		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022268lbl.pdf	Homo sapiens										Coartem Tablets should be administered over 3-days for a total of 6 doses: an initial dose, second dose after 8 hours and then twice daily (morning and evening) for the following two days				Plasmodium falciparum malaria	480 mg, b.i.d			lumefantrine, p.o				3	day		p.1
679	137					Highest studied dose	%	10		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/2948929	Homo sapiens						20							25	acne vulgaris					20			8	week		
680	139					MTD	mg/m2	40		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11025470	Homo sapiens								120 mg/kg over 1h on days 3, and 2		40 mg/m2/dose every 6 h on days 8 through 5 (total of 16 doses). This corresponded to a mean total busulfan dose of 22.1 mg/kg with a range of 16–27.5 mg/kg.			6	Acute Myelogenous Leukemia|Myelodysplastic syndrome	60 mg/kg; over 4 h on day4			etoposide. i.v.				4	day	cyclophosphamide. i.v.	p.407
681	139					Overdose	mg/kg	18		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15568037	Homo sapiens						48							1	Myelodysplastic syndrome											p.126
682	139					Overdose	mg/kg	4		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15568037	Homo sapiens						14				9 doses			1	Myelodysplastic syndrome								2	day		p.127
683	139					Recommended	mg/kg	0.8		multiple			day	4	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf	Homo sapiens										two-hour infusion every six hours for four consecutive days for a total of 16 doses				Chronic myelogenous leukemia								4	day		p.1
684	140		adult			Highest studied dose	mg	2100		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1998178	Homo sapiens													9									9	month		
685	140					Recommended	mg	250		steady			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf	Homo sapiens						41							548	acute, mechanical, lower back pain					41			7	day		6
686	140					Recommended	mg	350		steady			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/011792Orig1s041.pdf	Homo sapiens						41							279	acute, mechanical, lower back pain					41			7	day		6
687	141					Overdose	mg	250		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6655776	Homo sapiens						38							1		600 mg; single			cimetidine, p.o						aspirin	
688	141					Overdose	mg/kg	3.2		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3065402	Homo sapiens						1.8							1												
689	141					Overdose	mg/kg	5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13462782	Homo sapiens						2.5							1												p.239
690	141					Recommended	mg/kg	0.2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf	Homo sapiens							max			The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient.				Chronic lymphatic leukemia|Malignant lymphomas								4.5	week		p.1
691	141					Recommended	mg/kg	0.2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf	Homo sapiens							max			The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient.				Chronic lymphatic leukemia|Malignant lymphomas								4.5	week		p.2
692	141					Recommended	mg/kg	0.2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf	Homo sapiens							max			The usual oral dosage is 0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks as required. This usually amounts to 4 to 10 mg per day for the average patient.				Chronic lymphatic leukemia|Malignant lymphomas								4.5	week		p.3
693	142		child			Studied dose	oz	1.5		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf	Homo sapiens							mean						1									1	day		
694	142					Recommended	%	2		single			day	1	healthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf	Homo sapiens												64	36						18			1	day		nda/2005/21669s000_MedR.pdf - p.83
695	142					Recommended	%	3		multiple			day	1	healthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf	Homo sapiens							mean			2% or 4%		60	23						22			21	day		nda/2005/21669s000_MedR.pdf - p.83
696	142					Recommended	%	3		multiple			day	1	healthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21669s000_MedR.pdf	Homo sapiens							mean			2% or 4%; 3 weeks - induction and 72 hours - challenge		79	204						18			3	week		nda/2005/21669s000_MedR.pdf - p.83
697	142					Recommended	mg	2.5		multiple			month	3	unhealthy	subgingival	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20774lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20774-ltr-lab-mr.pdf | https://pubmed.ncbi.nlm.nih.gov/9776027/	Homo sapiens						47							225	periodontitis								9	month		nda/98/20774-ltr-lab-mr.pdf - p.41
698	145		ADULT			Highest studied dose	mg/kg	5.25		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24502830	Homo sapiens						31.9	total			5.25 mg/kg (total cumulative dose) received cladribine  0.875 mg/kg  per  course for four courses during the first 48 weeks, then two courses \nduring the second 48 weeks. Treatment courses were scheduled on day 1 and weeks 5, 9, and 13 during year 1, and weeks 48 and 52 at \nthe start of year 2. Every course was given over 4 or 5 consecutive days.			204	multiple sclerosis								2	year		p.262
699	145		ADULT			MTD	mg/m2	8		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7911736	Homo sapiens						57				1-hour intermittent infusion, repeated daily for 5 days, with a cycle length of 28 days.		75	4	cancer					22			5	day		p.170
700	145		ADULT			Studied dose	mg/kg	0.07		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/10720289	Homo sapiens						43.8				Patients received six courses of cladribine 0.07 mg/kg/day SC for 5 consecutive days (total dose, 2.1 mg/kg)			52	multiple sclerosis								30	day		p.1152
701	146		adult			Recommended	%	6		steady			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/157250/	Homo sapiens										cream			1756	eczema								3	month		
702	146					Studied dose	g	4		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2950208/	Homo sapiens						32							1	acute episode of abdominal pain and nausea					32						
703	146					Studied dose	g	5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2950208/	Homo sapiens						43				1 to 5 g			1	intestinal infection					43						
704	147					Highest studied dose	g/m2	4.5		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6223674	Homo sapiens												76	6	Acute leukemia					16			6	day		p.363, 366
705	147					Highest studied dose	g/m2	4.5		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7306918	Homo sapiens												76	6	Acute leukemia					16			6	day		p.2578
706	147					MTD	g/m2	3		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6223674	Homo sapiens										The maximal tolerated dose (MTD) of ARA-C was 3,000 mg per square meter administered as a one-hour infusion every 12 hours for 6 days		76	27	Acute leukemia					16			6	day		p.366
707	147					Recommended	mg/m2	100		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/071868s032lbl.pdf	Homo sapiens										In the induction therapy of acute non-lymphocytic leukemia, the usual cytarabine dose in combination with other anti-cancer drugs is 100 mg/m2/day by continuous intravenous infusion (Days 1-7) or 100 mg/m2 intravenous every 12 hours (Days 1-7).				Acute non-lymphocytic leukemia								7	day		p.1
708	148		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8478309/	Homo sapiens													2825	infectious diseases								7	day		
709	148					Recommended	mg	500		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8478316/	Homo sapiens												65	193	infectious diseases					16			4	day		
710	149					Highest studied dose	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27298719	Homo sapiens						24							16	cystic fibrosis					24			3	year		
711	149					Recommended	mg	500		steady			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022106lbl.pdf	Homo sapiens						54						90	853	intra-abdominal infections					18						
712	149						mg/kg	5		single					unknown	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26014957	Homo sapiens													26									1	hour		
713	149						mg/kg	8		single					unknown	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26014957	Homo sapiens													26									1	hour		
714	150		adult			Studied dose	ug/kg	135		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_INTEGRILIN_medr_P4.pdf	Homo sapiens										followed by 0.75 ug/kg*min for 24 hours			1286	Coronary artery disease								1	day		nda/98/20718_INTEGRILIN_medr_P4.pdf - p.9
715	150					Recommended	ug/kg	180		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_INTEGRILIN_medr_P2.pdf	Homo sapiens						59				2 hours infusion			42	Coronary artery disease								1	day		nda/98/20718_INTEGRILIN_medr_P2.pdf - p.26
716	150					Studied dose	ug/kg	250		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_INTEGRILIN_medr_P2.pdf	Homo sapiens						57				3 hours infusion			39	Coronary artery disease								1	day		nda/98/20718_INTEGRILIN_medr_P2.pdf - p.26
717	150					Studied dose	ug/kg	90		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20718_INTEGRILIN_medr_P2.pdf	Homo sapiens						59.8				4 and 12 hours duration			98	Coronary artery disease								1	day		nda/98/20718_INTEGRILIN_medr_P2.pdf - p.50
718	150						ug/kg	11700		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00089895	Homo sapiens							total						4686	Non-ST-segment Elevation Acute Coronary Syndrome											
719	151					MTD	g	0.1		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4924649/	Homo sapiens								15 mg/kg; oral; 2/week					27	pulmonary tuberculosis	6 g; oral; 2/week			AMINOSALICYLATE SODIUM				2	week	ISONIAZID	
720	151					MTD	g	0.5		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4924649/	Homo sapiens								15 mg/kg; oral; 2/week					27	pulmonary tuberculosis	6 g; oral; 2/week			AMINOSALICYLATE SODIUM				2	week	ISONIAZID	
721	151					MTD	g	0.75		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4924649/	Homo sapiens								15 mg/kg; oral; 2/week					27	pulmonary tuberculosis	6 g; oral; 2/week			AMINOSALICYLATE SODIUM				2	week	ISONIAZID	
722	151					MTD	g	1.25		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4924649/	Homo sapiens								15 mg/kg; oral; 2/week					27	pulmonary tuberculosis	6 g; oral; 2/week			AMINOSALICYLATE SODIUM				2	week	ISONIAZID	
723	151					MTD	g	1.5		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4924649/	Homo sapiens								15 mg/kg; oral; 2/week					27	pulmonary tuberculosis	6 g; oral; 2/week			AMINOSALICYLATE SODIUM				2	week	ISONIAZID	
724	152					Recommended	mg/kg	150		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7803641	Homo sapiens						34	total daily dose						32	Cryptococcal meningitis	400 mg/d			fluconazole, p.o				10	week		p.743
725	152					Recommended	mg/kg	150		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf	Homo sapiens							total daily dose|max							Infections caused by susceptible strains of Candida and/or Cryptococcus											
726	153		adult			Recommended	mg	500		single			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20250s7s8lbl.pdf	Homo sapiens													933	malaria											7
727	155					Highest studied dose	mg/kg	1078.52		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3993426/	Homo sapiens										iodine content 46.36% (500*100/46.36)		76	20	renal failure					24			1	day		
728	155					Highest studied dose	mg/kg	1510		single			day	1	unhealthy	intraarterial			https://pubmed.ncbi.nlm.nih.gov/3993426/ | https://pubmed.ncbi.nlm.nih.gov/6382927/	Homo sapiens										iodine content 46.36% (700*100/46.36)				coronary artery disease								1	day		
729	156		adult and children			Studied dose	mg	54250		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			2074	computed tomography											
730	156		adult and children			Studied dose	mg	62775		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			1851	computed tomography											
731	156		adult and children			Studied dose	mg	68544		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10064	computed tomography											
732	156		adult and children			Studied dose	mg	69768		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10831	computed tomography											
733	156		adult and children			Studied dose	mg	83700		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			1851	computed tomography											
734	156		adult and children			Studied dose	mg	87516		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10064	computed tomography											
735	156		adult and children			Studied dose	mg	88740		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10831	computed tomography											
736	156		adult and children			Studied dose	mg/mL	612		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10064	computed tomography											
737	156		adult and children			Studied dose	mg/mL	612		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										300 mg I/mL; total dose administered approx 100-200 mL			10831	computed tomography											
738	156		adult and children			Studied dose	mg/mL	61225		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			2074	computed tomography											
739	156		adult and children			Studied dose	mg/mL	775		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			1851	computed tomography											
740	156		adult and children			Studied dose	mg/mL	775		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/22106356/	Homo sapiens										370 mg I/mL; total dose administered approx 100-200 mL			2074	computed tomography											
741	156					Studied dose	%	61		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28483940/	Homo sapiens						21							1	disseminated lupus erythematosus manifested mainly by lupus nephritis, computed tomography					21						
742	156					Studied dose	mg/mL	612		single					unknown	intrathecal	M		https://pubmed.ncbi.nlm.nih.gov/16369390/	Homo sapiens						45							1	cervical myelography					45						
743	157					Recommended	mg	124709.092		single			day	1	unknown	intravenous	M+F		https://clinicaltrials.gov/ct2/show/results/NCT00244140	Homo sapiens						51.9	max			Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml,			412												
744	158					Recommended	mg/kg	1.6		single			day	1	unknown	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2687200/	Homo sapiens							mean						1186												
745	159					Highest studied dose	mg/kg	10		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7751691/	Homo sapiens						37						63	14	HIV infection					23			24	week		
746	159					Highest studied dose	mg/kg	4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10681323/	Homo sapiens						7.6				Lamivudine oral solution			11	Chronic hepatitis B								4	week		
747	159					Recommended	mg	150		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf	Homo sapiens													251	HIV-1 infection	200 mg; 3/day			zidovudine				24	week		
748	159						mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10681323/	Homo sapiens						14.6				Lamivudine tablet			12	Chronic hepatitis B								4	week		
749	161					Highest studied dose	mg/m2	400		single					unhealthy	oral			https://www.tctjournal.org/action/showPdf?pii=S1083-8791%2813%2900730-1|https://pubmed.ncbi.nlm.nih.gov/24887380	Homo sapiens						36		4g/m2					2	Lymphoma	1 g/m2		melphalan	etoposide, i.v			140 mg/m2			ara-C, i.v	
750	161					MTD	mg/m2	300		single					unhealthy	oral			https://www.tctjournal.org/action/showPdf?pii=S1083-8791%2813%2900730-1|https://pubmed.ncbi.nlm.nih.gov/24887380	Homo sapiens						36		4g/m2					6	Lymphoma	1 g/m2		melphalan	etoposide, i.v			140 mg/m2			ara-C, i.v	
751	161					Recommended	mg/m2	130		multiple			6 weeks	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017588s042lbl.pdf	Homo sapiens														Brain tumors|Hodgkin’s lymphoma											p.1
752	163					Recommended	%	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1675534	Homo sapiens												37	33	Acne vulgaris					12			10	week		p.177
753	163					Recommended	%	1		multiple			day	2	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/6452987	Homo sapiens														Acne vulgaris											
754	164					Highest studied dose	mg	1200		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf	Homo sapiens													16												
755	164					Highest studied dose	mg	2400		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Medr_P2.pdf	Homo sapiens													12												
756	165						mg	800		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/013217s057lbl.pdf	Homo sapiens										3-4 times/day								Serotonergic drugs							
757	166					MTD	mg/m2	3.2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16142489	Homo sapiens										patients were treated with 70 Gy (2 Gy/day) and simultaneous chemotherapy (5-FU 600 mg/m2/day and MMC, both as continuous infusion on days 1-5 and 36-40.		68	6	Head and neck cancer	600 mg/m2/day			5-FU, i.v	36.2			5	day		p.816
758	166					MTD	mg/m2	6		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10678557	Homo sapiens								80 mg/m2				71	3	Non-small cell lung cancer	60 mg/m2			docetaxel , i.v	53					cisplatin, i.v	p.548
759	166					Recommended	mg/m2	15		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50763_Mitozytrex_lbl.pdf	Homo sapiens														Disseminated adenocarcinoma of the stomach|Disseminated adenocarcinoma of the pancreas											p.1
760	166					Studied dose	mg/m2	4		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16142489	Homo sapiens										patients were treated with 70 Gy (2 Gy/day) and simultaneous chemotherapy (5-FU 600 mg/m2/day and MMC, both as continuous infusion on days 1-5 and 36-40.		68	6	Head and neck cancer	600 mg/m2/day			5-FU, i.v	36.2			5	day		p.816
761	168		adult			Highest studied dose	mg/m2	2900		multiple			3 weeks	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf	Homo sapiens													2									28	day		
762	168		adult			Recommended	mg/m2	1500		multiple			3 weeks	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021877lbl.pdf	Homo sapiens										1,500 mg/m² administered intravenously over 2 hours on days 1, 3, and 5 repeated every 21 days.												28	day		
763	168		adult				mg/m2	1200		multiple			3 weeks	3	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15908649	Homo sapiens													31									28	day		
764	168		adult				mg/m2	1800		multiple			3 weeks	3	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15908649	Homo sapiens													4									28	day		
765	168		child			Highest studied dose	mg/m2	2250		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15908649	Homo sapiens													1									5	day		
766	170					Highest studied dose	mg	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11176767	Homo sapiens													11	human immunodeficiency virus disease								6	week		
767	170					Recommended	mg	37.5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/016832s022_017703s018lbl.pdf	Homo sapiens							starting			The recommended starting dose is 37.5 mg/day. This daily dose should be gradually increased by 18.75 mg at one week intervals until the desired clinical response is obtained. The effective daily dose for most patients will range from 56.25 to 75 mg.				Attention Deficit Hyperactivity Disorder											
768	170						mg	96		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11176767	Homo sapiens							mean			with dosages ranging from 37.5 to 150 mg/day			45	human immunodeficiency virus disease								6	week		
769	171					Highest studied dose	mg	600		multiple			month	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/8750367	Homo sapiens						37.9							76	Pneumonia due to Pneumocystis carinii											p.1167
770	171					Overdose	mg	1600		single					unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc2b635e-4840-4dc3-a177-5484371680e8&type=display	Homo sapiens						17							1	Pneumonia due to Pneumocystis carinii											
771	171					Recommended	mg	300		multiple			month	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019887s014lbl.pdf	Homo sapiens														Pneumonia due to Pneumocystis carinii											p.6
772	171					Recommended	mg/kg	4		multiple			day	1	unhealthy	intramuscular			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc2b635e-4840-4dc3-a177-5484371680e8&type=display	Homo sapiens										duration 14-21 days				Pneumonia due to Pneumocystis carinii								21	day		
773	171					Recommended	mg/kg	4		multiple			day	1	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=cc2b635e-4840-4dc3-a177-5484371680e8&type=display	Homo sapiens										duration 14-21 days				Pneumonia due to Pneumocystis carinii								21	day		
774	172					MTD	ug/kg	25		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28735378	Homo sapiens										The initial starting dose for the phase II portion of the trial was the previously recommended dose of 25 ug/kg/day over 6-h iv infusion daily for 7 days.		35	2	Ewing sarcoma					24			7	day		p.5-6
775	172					Studied dose	ug/kg	17.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28735378	Homo sapiens										Because of the hepatotoxicity seen in the initial two patients (25 ug/kg/day), the starting dose for the adult phase II component of the trial was decreased to 17.5 ug/kg/day for 7 days		22	4	Ewing sarcoma					19			7	day		p.5-6
776	173					Highest studied dose	mg/kg	100		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/2209679	Homo sapiens						32							13	Neurocysticercosis								10	day		p.229
777	173					Studied dose	mg	1800		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/10991886	Homo sapiens												47	9						26						
778	174					Recommended	mg	1500		multiple			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/8139647	Homo sapiens													16		800 mg/day; 6 months			ofloxacin, p.o				6	month		
779	174					Recommended	mg/kg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12379063	Homo sapiens													207	Tuberculosis	600 mg/d; 2 months			rifampin, p.o				2	month		p.643
780	174					Recommended	mg/kg	30		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=257bd8cf-74d7-45db-bf25-354a8d26634e&type=display#LINK_5b1b9b20-2ad0-4c1c-b6cb-e086db370aff	Homo sapiens							max							Tuberculosis											
781	175					MTD	mg/kg	20		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22472995	Homo sapiens										1650 mg orally, once per day			6									14	day		p.2, p.4
782	175					Recommended	mg	600		multiple			week	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf	Homo sapiens								q.d.		Initial Phase (2 Months): 600 mg twice weekly for two months			361	Pulmonary tuberculosis caused by Mycobacterium tuberculosis	q.d.		ethambutol, po	isoniazid, po			q.d.	6	month	pyrazinamide, po	p.6
783	175					Recommended	mg	600		multiple			week	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf	Homo sapiens										Initial Phase (2 Months): 600 mg twice weekly for two months by direct observation of therapy, with an interval of no less than 3 consecutive days (72 hours) between doses. Continuation Phase (4 Months): 600 mg once weekly for 4 months				Pulmonary tuberculosis caused by Mycobacterium tuberculosis								6	month		p.1
784	176					MTD	g/m2	2		multiple			6 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1531148	Homo sapiens										Patients received a 20-minute infusion of the MTD of STZ (2g/m2) followed 1 hour later with a 60-minute infusion of BCNU (125 mg/m2).		79	24	Cancer	125 mg/m2; 1/6wk			carmustine, i.v	31						p.258
785	176					Recommended	mg/m2	500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/142579	Homo sapiens										If at 6 weeks the patient had shown an objective response or had remained objectively stable, cycles of treatment were continued every 6 weeks until progressive disease was ascertained.			51	Adenocarcinoma of the pancreas	1000 mg/m2 given on day 1 and 21			Cyclophosphamide, i.v.				5	day		p.608
786	177		adult			Highest studied dose	mg	1800		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022154lbl.pdf	Homo sapiens																						4	day		
787	177		adult			Recommended	mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022154lbl.pdf	Homo sapiens													847	chronic hepatitis B								104	week		
788	177		adult			Recommended	mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022154lbl.pdf	Homo sapiens														chronic hepatitis B											
789	177		adult			Recommended	mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022154s000_MedR_P2.pdf	Homo sapiens													849	chronic hepatitis B								104	week		p. 158
790	178					Highest studied dose	mg	1600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11120961	Homo sapiens												45	18						18			7	day		p.173
791	178					Highest studied dose	mg	2400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12621389	Homo sapiens												35	16						18						p.250
792	178					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12749505	Homo sapiens												72	232	Group A beta-hemolytic streptococcal tonsillitis/pharyngitis					13			5	day		p.436
793	178					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14996517	Homo sapiens												83	224	Community-acquired pneumonia					18			10	day		p.57
794	178					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16611950	Homo sapiens													140	asthma								10	day		p.1598
795	178					Recommended	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021144s013lbl.pdf	Homo sapiens														Community-acquired pneumonia								10	day		p.12
796	179		adult			Highest studied dose	mg/m2	1000		multiple			4 weeks	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14740784/	Homo sapiens										Temozolomide 500 mg/m2 was administered as a single oral dose every 28 days. Doses were escalated to 750 or 1000 mg/m2.			6	solid tumors											
797	179		adult			Highest studied dose	mg/m2	250		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/10576660/	Homo sapiens										Temozolomide 100–250 mg/m2 was administered once daily for 5 days every 28 days. Temozolomide capsules (Schering-Plough Research Institute, Kenilworth, NJ, USA) were administered orally to cohorts of three patients at an initial dosage of 100 mg/m2/day for 5 days, followed by sequential escalation to 150, 200 or 250 mg/m2/day for 5 days to additional three-patient cohorts, until a DLT was observed. The capsules contained 20 and 100 mg of temozolomide, and daily doses were rounded up to the nearest 20 mg to achieve 5-day dosages of 500, 750, 1000 and 1250 mg/m2 as closely as possible. No intrasubject dose escalation was allowed. Patients were instructed to fast after midnight before each dose and to continue fasting 2 h after each dose.			3	malignancies, refractory or relapsing								5	day		
798	179		adult			MTD	mg/m2	200		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/10576660/	Homo sapiens										Temozolomide 100–250 mg/m2 was administered once daily for 5 days every 28 days. Temozolomide capsules (Schering-Plough Research Institute, Kenilworth, NJ, USA) were administered orally to cohorts of three patients at an initial dosage of 100 mg/m2/day for 5 days, followed by sequential escalation to 150, 200 or 250 mg/m2/day for 5 days to additional three-patient cohorts, until a DLT was observed. The capsules contained 20 and 100 mg of temozolomide, and daily doses were rounded up to the nearest 20 mg to achieve 5-day dosages of 500, 750, 1000 and 1250 mg/m2 as closely as possible. No intrasubject dose escalation was allowed. Patients were instructed to fast after midnight before each dose and to continue fasting 2 h after each dose.			6	malignancies, refractory or relapsing								5	day		
799	179		adult			MTD	mg/m2	750		multiple			4 weeks	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14740784/	Homo sapiens										Temozolomide 500 mg/m2 was administered as a single oral dose every 28 days. Doses were escalated to 750 or 1000 mg/m2.			6	solid tumors											
800	179		adult			Recommended	mg/m2	150		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf	Homo sapiens										75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of TEMODAR for 6 cycles.			224	glioblastoma multiforme, newly diagnosed								5	day		
801	179		adult			Recommended	mg/m2	150		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf	Homo sapiens										Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle.			158	anaplastic astrocytoma								5	day		
802	179		adult			Recommended	mg/m2	75		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021029s029lbl.pdf	Homo sapiens										75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of TEMODAR for 6 cycles.			288	glioblastoma multiforme, newly diagnosed								42	day		
803	180					MTD	mg/m2	60		multiple			month	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9816047	Homo sapiens										1600 mg of oral sustained release pentoxifylline every 8 h for 4 doses in combination with i.v. bolus thioTEPA 60 mg/m2 administered 3 h after the second dose of pentoxifylline. Treatment cycles were repeated every 21-35 days.		76	25	Breast cancer	1600 mg; t.i.d; 4 doses			pentoxifylline, p.o	30			2	cycle		p.793
804	180					MTD	mg/m2	65		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1710167	Homo sapiens										Courses were repeated every 3-4 weeks. Median number of courses administered is 2 (range 1-8)		74	8	Cancer					25			2	cycle		p.3172
805	180					MTD	mg/m2	750		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10531568	Homo sapiens							total	800 mg/m(2); q.d; 3 days		iv over 2 hr, in two doses, the first one starting 12 h after completion of the etoposide infusion (day −2).			6	Disseminated solid tumors	30 mg/m(2); 4 times/day; 4 days			Busulfan, p.o				1	day	Etoposide. i.v.	p.453
806	180					Recommended	mg/kg	5		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208264s000lbl.pdf	Homo sapiens								40 mg/kg/day		two administrations of 5 mg/kg given intravenously approximately 12 hours apart on Day -6 before allogeneic HSCT in conjunction with high-dose busulfan and cyclophosphamide				Class 3 Beta-Thalassemia	weight-based dose			Busulfan, I.V				1	day	Cyclophosphamide, I.V	p.1
807	180					Studied dose	mg/m2	75		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1710167	Homo sapiens										Courses were repeated every 3-4 weeks. Median number of courses administered is 2 (range 1-8)		74	7	Cancer					25			2	cycle		p.3172
808	181					Highest studied dose	mg	100		multiple			day	2	healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15616299	Homo sapiens										Fed subjects			6									9	day		p.223
809	181					Highest studied dose	mg	300		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15616299	Homo sapiens										Fed subjects			6												p.223
810	181					MTD	mg	100		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15616299	Homo sapiens										Fasted subjects			6												p.223
811	181					MTD	mg	200		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15616299	Homo sapiens										Fed subjects. Food increased the maximum tolerated single-dose from 100 to 200 mg,but the duration of infusion did not affect tolerability.			6												p.223
812	181					Recommended	mg	50		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf	Homo sapiens										The recommended dosage regimen for TYGACIL is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of TYGACIL should be administered over approximately 30 to 60 minutes every 12 hours.			3788	Complicated skin and skin structure infections											p.10
813	181					Recommended	mg	50		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021821s021lbl.pdf	Homo sapiens										The recommended dosage regimen for TYGACIL is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of TYGACIL should be administered over approximately 30 to 60 minutes every 12 hours.				Complicated skin and skin structure infections|Complicated intra-abdominal infections|Community-acquired bacterial pneumonia								14	day		p.1
814	182					Recommended	g	1		multiple			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/results/NCT02648698	Homo sapiens						31.93							60	Chronic Endometritis								14	day		
815	182					Recommended	g	2		single			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00322465	Homo sapiens						27.8							73	Urethritis	100mg, PO, Q2D7			Doxycycline							
816	182					Recommended	mg/kg	500		multiple			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00334633	Homo sapiens						28.5							196	Bacterial Vaginosis								7	day		
817	183					Highest studied dose	g	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7115451/	Homo sapiens						56.7				Tiopronin (250 mg/day) was administered in identically sized tablets. Every 20 days the dose was increased by the same amount, up to a maximum daily dose of 1 gm/day for tiopronin.			28	rheumatoid arthritis								1	year		
818	183					Highest studied dose	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20559104/	Homo sapiens										The study design was based on a conventional “3 + 3” dose-escalation model, with the initial 3 patients receiving 1 g/d of oral tiopronin divided three times daily beginning on the day of enrollment until Day 14 after the aSAH ictus. A maximum dose of 3 g/d was preselected during the design of the study, because this is the highest FDA-approved dose of tiopronin.		74	9	aneurysmal subarachnoid hemorrhage					43			14	day		
819	183					Recommended	g	0.267		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211843s000lbl.pdf	Homo sapiens										The recommended initial dosage in adult patients is 800 mg/day. Administer THIOLA EC in 3 divided doses at the same times each day, with or without food.			17	cystinuria											
820	183					Recommended	g	0.267		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211843s000lbl.pdf	Homo sapiens										The recommended initial dosage in adult patients is 800 mg/day. Administer THIOLA EC in 3 divided doses at the same times each day, with or without food.			49	cystinuria											
821	184					Highest studied dose	mg/m2	80		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18798063	Homo sapiens						60	total daily dose			TAS-102 was taken orally three times a day for 5 consecutive days, followed by 2 days of rest each week for 2 weeks. This treatment cycle was repeated every 4 weeks			6	Cancer				thymidine phosphorylase, p.o				5	day		p.797
822	184					MTD	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22735906	Homo sapiens						59				Days 1–5 and Days 8–12. α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI) are combined at a molar ratio of 1 : 0.5			3	Cancer				thymidine phosphorylase, p.o				5	day		p.431, 432
823	184					MTD	mg/m2	70		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18798063	Homo sapiens						60	total daily dose			TAS-102 was taken orally three times a day for 5 consecutive days, followed by 2 days of rest each week for 2 weeks. This treatment cycle was repeated every 4 weeks			6	Cancer				thymidine phosphorylase, p.o				5	day		p.797
824	185		child|adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00997035	Homo sapiens										1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment. 400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment.			119	Mycotic Ulcer								3	month		
825	185					Overdose	mg	400		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30306637/	Homo sapiens													31	Acute myeloid leukemia, Acute lymphoid leukemia, Lymphoma, Others											
826	185					Recommended	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32171012/	Homo sapiens													327	Acute myeloid leukemia, lymphocytic leukemia, Myelodysplastic syndrome, Multiple myeloma Lymphoma and Other								14	day		
827	185					Recommended	mg/kg	16		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27313918/	Homo sapiens						17				12 to 16 mg/kg			1	cystic fibrosis and allergic bronchopulmonary aspergillosis					17						
828	185					Recommended	mg/kg	16		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27313918/	Homo sapiens						9				12 to 16 mg/kg			1	cystic fibrosis and invasive aspergillosis					9						
829	186					Recommended	%	2		single			day	1	unknown	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021501s000_MedR_P2.pdf	Homo sapiens													2539	UNK											
830	188					Highest studied dose	mmol/kg	0.3		single			day	1	unhealthy	intravenous	M+F		https://link.springer.com/article/10.1007/s002560050343	Homo sapiens													14	unilateral recurrent anterior dislocation											
831	191		adult			Recommended	mg	14		multiple			day	2	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/9132982/	Homo sapiens								140 mg; 2/day		Vaginal suppositories containing 1.05 g of sulfanilamide, 14 mg of aminacrine hydrochloride, and 140 mg of allantoin (AVC suppositories) twice a day for 7 days.			51	trichomoniasis	1.05 g; 2/day			sulfanilamide				7	day	allantoin	
832	193					Overdose	mg/kg	234		multiple					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7133084	Homo sapiens													10	gasping syndrome											
833	196		CHILD|ADULT			Recommended	%	10		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/24898622/	Homo sapiens						36.85							170	scabies								5	day		p.3
834	198					Highest studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16127567	Homo sapiens						42		500 mg, q.i.d.					52	Helicobacter pylori infections	30 mg, q.d.			lansoprazole, p.o				7	day	tetracycline, p.o	p.113
835	198					Highest studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26157713	Homo sapiens													124	Helicobacter pylori infections	1000 mg, b.i.d			amoxicillin, p.o				10	day		p.5
836	198					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23376004	Homo sapiens												79	104	Helicobacter pylori infections	1000 mg, t.i.d			amoxicillin, p.o	21			2	week		p.2, p.7
837	198					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23376004	Homo sapiens												79	108	Helicobacter pylori infections	1000 mg, t.i.d			amoxicillin, p.o	18			2	week		p.2, p.7
838	200		adult				mg	400		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01062256	Homo sapiens													107	Cough											
839	200					Highest studied dose	mg	400		steady			day	6	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27121557	Homo sapiens										2 * 200 mg tablets every 4 hours			24									6	day		
840	200					Highest studied dose|Recommended	mg	1200		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27121557	Homo sapiens													24									6	day		
841	200						mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30946892	Homo sapiens						63.7							12	filamentary keratitis					63.7			4	week		
842	202					Highest studied dose	g	45.2		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13545726 | https://pubmed.ncbi.nlm.nih.gov/13171792	Homo sapiens													1	BLASTOMYCOSIS								13	month		
843	202						mg	225		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13545726	Homo sapiens						7							1	BLASTOMYCOSIS					7			30	day		
844	203					MTD	g/m2	18		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10572607	Homo sapiens						45	total						6	Sarcoma								5	day		p.1090
845	203					MTD	g/m2	2.25		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/11840607	Homo sapiens						45							3	Breast cancer	45 mg/m2			doxorubicin, i.v				3	day		p.6
846	203					Recommended	g/m2	1.2		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019763s017lbl.pdf	Homo sapiens										Treatment is repeated every 3 weeks or after recovery from hematologic toxicity.				Testicular cancer								5	day		p.1
847	204		adult			Highest studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/152180	Homo sapiens										Cholebrin was given in two foil packs of six tablets each pack containing 3 g			48									1	day		
848	204		adult			Highest studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/152180	Homo sapiens										Cholebrin was given in two foil packs of six tablets each pack containing 3 g			49									1	day		
849	204					Highest studied dose	g	4.5		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/129790	Homo sapiens													1												
850	204						g	3		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/129790	Homo sapiens													2												
851	210					Overdose	g	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017681s018lbl.pdf	Homo sapiens														Urinary tract infections								4	week		
852	210					Recommended	g	1		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7076604	Homo sapiens												65	10						24			7	day		
853	210					Recommended	g	1		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7076604	Homo sapiens												65	10						24						
854	211					Highest studied dose	g/kg	1.0351966873706		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/433646	Homo sapiens										350 mg I/ml in a dose of 0.5 g I per kg body weight; iodine content 48.3%		71	11						32						
855	212		adult			Recommended	g	1		steady			day	4	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/21879777/	Homo sapiens														acute bacillary dysentery								7	day		
856	212					Overdose	g	28		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/500943/	Homo sapiens						19							1	suicide attempt					19						
857	212					Overdose	mg/kg	150		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1972527/	Homo sapiens										100 or 150 mg/kg			12	acute bacillary dysentery											
858	215					Recommended	g	1.6		multiple			day	1.1	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						35.44	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 1.6 (0.16-35.5). Daily application (number/day) median(range): 1.1 (0.95-3.01). Treatment duration (days) median(range): 356 (1-376).		83.43	248				titanium dioxide	ecamsule	12.04			356	day	avobenzone	
859	215					Recommended	g	3.1		multiple			day	1.2	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						6.69	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 3.1 (0.07-26.85). Daily application (number/day) median(range): 1.2 (1-7.78). Treatment duration (days) median(range): 44.5 (1-363).		67.95	246				titanium dioxide	ecamsule	0.5			44.5	day	avobenzone	
860	215					Recommended	g	3.7		multiple			day	1.3	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						3.69	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 3.7 (0.86-29.6). Daily application (number/day) median(range): 1.3 (1-2.8). Treatment duration (days) median(range): 31 (1-225).		48.15	79				titanium dioxide	ecamsule	0.64			31	day	avobenzone	
861	216					Accidental dose	%	10		single					unknown	topical	F		https://pubmed.ncbi.nlm.nih.gov/1935041/	Homo sapiens						31							1									1	day		126
862	216					Recommended	%	6		multiple			day	4	unknown	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31058986/	Homo sapiens							max			Maximum allowed on US market dose		58	6		2.35%			CC(C)(C)C1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)OC	27			4	day	Octocrylene	2085
863	217					Overdose	g	4		multiple			day	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021749s008lbl.pdf	Homo sapiens																						14	day		
864	217						g	0.5		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/2923478	Homo sapiens							starting			initially from 0-5 g (cases 4 and 5) to 1 g (cases 1, 2,and 3) given subcutaneously on alternate days. This was increased after two months in all cases to 1 g five nights each week. Ca-DTPA was given subcutaneously by the infusion pump over a period of 10-12 hours.		20	5	homozygous beta thalassaemia	200 mg two to five times daily			Zinc sulphate	5			7	month		
865	220					Studied dose	g	2.68		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14022105	Homo sapiens													119	Tuberculosis								11	month		p.381
866	221					Recommended	g/m2	5.5		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020645lbl.pdf	Homo sapiens								200-600 mg/kg		AMMONUL (sodium phenylacetate and sodium benzoate, Injection 10% / 10% ) is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours		53	316	Hyperammonemia	5.5 g/m2			Sodium Benzoate, i.v	0					Arginine HCl, i.v	p.11
867	221					Recommended	mg/kg	300		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020645lbl.pdf	Homo sapiens							max	200-600 mg/kg						Cancer	5.5 g/m2			Sodium Benzoate, i.v				14	day	Arginine HCl, i.v	p.8
868	223					Recommended	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14617017/	Homo sapiens						61.8							140	polycythemia vera								4	week		
869	227					Highest studied dose	g	4		multiple			day	3	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/28052852	Homo sapiens								2g, t.i.d					13	Ventilator-associated pneumonia, caused by colistin-resistant A. baumannii infection	8 g, t.i.d		polymyxin B, i.v	ampicillin, i.v			1.43 mg/kg, b.i.d			meropenem, i.v	p.5
870	227					Recommended	g	2		multiple			day	2	unhealthy	intravenous			https://www.mims.com/malaysia/drug/info/sulperazon?type=full	Homo sapiens														Bacterial infections				cefoperazone, i.v							
871	228		adult			Higher than recommended	g	2		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/468450/	Homo sapiens													6												
872	228		adult			Recommended	mg/kg	250		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4246303/	Homo sapiens													20	chronic urinary-tract infection								9	month		
873	228		adult			Recommended	mg/kg	500		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4246303/	Homo sapiens													43	pustular acne vulgaris								4	week		
874	229						%	0.5		multiple					unhealthy	oromucosal	M		https://pubmed.ncbi.nlm.nih.gov/2721319	Homo sapiens						75				several times with approximately 4 ml of 0.5% solution of tetracaine			1						75			1	day		
875	231		adult			Highest studied dose	mg	400		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7236507	Homo sapiens													1												
876	232					Highest studied dose	mg/kg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19935406	Homo sapiens							total daily dose			50 mg/kg of body weight per day. The drug was administered orally in 3 equal doses a day.		65	7	Amyotrophic lateral sclerosis					37			4	week		p.18
877	232					Recommended	mg	500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020675s013lbl.pdf	Homo sapiens													60	Primary biliary cirrhosis											p.4
878	235					Highest studied dose	mmol/kg	0.3		single			day	1	unknown	intravenous	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027821/	Homo sapiens													6163												
879	237					Studied dose	mL	3		single					unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	Homo sapiens							max			one-half (1/2) ml into three interdigital spaces of each extremity per study. A maximum dose of 3 ml (30 mg) isosulfan blue is, therefore, injected.				lymphedema of the extremities											
880	243					Highest studied dose	g	25		single					unhealthy	intravenous			https://www.pediatriconcall.com/drugs/dextrose/480	Homo sapiens														Hypoglycaemia											
881	243					Highest studied dose	mg/kg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27780197	Homo sapiens										40% oral dextrose gel, gel was massaged into the buccal mucosa			73	Neonatal Hypoglycaemia Prophylaxis											
882	243					Recommended	%	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15983093	Homo sapiens										10% dextrose administered in 5 g (50 ml) aliquots			25	Adult hypoglycaemia											
883	243					Recommended	%	10		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017521s068lbl.pdf	Homo sapiens														Source of water and calories											p.2
884	245					Highest studied dose	mg/kg	364		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/32894932/	Homo sapiens													1												
885	246					Recommended	mg	70		multiple			week	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/09048slr037_methoxsalen_lbl.pdf	Homo sapiens							max			The methoxsalen capsules should be taken 2 hours before UVA exposure with some food or milk. The number of doses per week of methoxsalen capsules will be determined by the patient’s schedule of UVA exposures. In no case should treatments be given more often than once every other day.				Psoriasis				UVA							p.5
886	246					Recommended	mg/kg	0.6		multiple			week	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19292787	Homo sapiens						49.7				8-MOP was given as a liquid preparation in soft gelatine capsules at a dose of 0.6 mg/kg 1 h before UVA irradiation. The initial irradiation dose was 1.5 J/cm2 for the palms and soles and 1.0 J/cm2 for the back of the hands and feet in patients with skin type III/IV. The respective doses for patients with skin typeI/II were 1.2 and 0.8 J/cm2.			14	Palmoplantar eczema								20	week		p.103
887	247		adult				%	25		multiple			day	1	pregnant	topical	F		https://pubmed.ncbi.nlm.nih.gov/17439567	Homo sapiens										There were 444 women treated with 559 BBL applications (79.5%, 15.5%, 4.5% and 0.5% received one, two, three and four treatments, respectively)			444	scabies											
888	247						%	10		multiple			day	1	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/12174005	Homo sapiens						4.7							37	Scabies					4.7			3	week		
889	248					Recommended	%	4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-112_TRI-Luma_medr_P3.pdf	Homo sapiens						41.4							320	Melasma								56	day		Study 29
890	251		adult			MTD	mg/m2	1360		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15868379/	Homo sapiens										Menadiol sodium diphosphate at doses ranged from 40 mg/m2 to 1360 mg/m2 administered as a short intravenous infusion every 3 weeks. Each dosing cohort consisted of at least 3 patients who completed at least two cycles of treatment and 3 weeks of follow-up, and were evaluable for toxicity. Entry of patients into subsequent cohorts required that at least 3 patients receive at least 2 cycles of therapy without dose-limiting toxicity, defined as one or more grade 3 or higher toxicity or 2 or more grade 2 events. The doses of menadiol were escalated using a modified Fibonacci scheme until this threshold was exceeded, and then an additional 3 patients were planned to be accrued to the previous dose level to confirm the maximum tolerated dose (MTD), defined as the highest dose below that which was associated with at least 2/6 patients experiencing grade 3 or higher toxicity.			13	advanced malignancy								2	cycle		
891	251						mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11121919/	Homo sapiens						67.5							12	coagulopathies associated with cholestasis								3	day		
892	252		adult			RP2D	mg	2		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000SumR.pdf	Homo sapiens													44	onchocerciasis											13
893	252		adult			RP2D	mg	4		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000SumR.pdf	Homo sapiens													45	onchocerciasis											13
894	252		adult			RP2D	mg	8		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210867Orig1s000SumR.pdf	Homo sapiens													38	onchocerciasis											13
895	252		adult				mg	16		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens													10												
896	252		adult				mg	36		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens													10												
897	252		adult				mg	4		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens													10												
898	252		adult				mg	8		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT03012828	Homo sapiens													10												
899	252					Recommended	mg	18		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14517193/	Homo sapiens												45	5						18						1111
900	252					Recommended	mg	36		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14517193/	Homo sapiens												45	10						18						1111
901	252					Recommended	mg	8		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf	Homo sapiens												60	978	onchocerciasis					18						3
902	252					Recommended	mg	8		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf	Homo sapiens												60	978	onchocerciasis					18						4
903	252					Recommended	mg	8		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210867lbl.pdf	Homo sapiens												60	978	onchocerciasis					18						5
904	254					Highest studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17554116/	Homo sapiens						50	max			dose range 800-2400 mg/day (depends on creatinine clearance rates)			89	Amyloid amyloidosis								24	month		
905	256		ADULT			Studied dose	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32991606/	Homo sapiens						62.1						77	95	osteoarthritis					43			4	week		p.13
906	257					Highest studied dose	mg/m2	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens						62						74	7	cancer					43			3	day		
907	257					Highest studied dose	mg/m2	2000		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/11272282/	Homo sapiens						63						74	4	cancer					40						
908	259		ADULT			MTD	mg/m2	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9491790	Homo sapiens						47				five consecutive days every week for 4 weeks			10	cancer								5	day		p.40
909	259		ADULT			Studied dose	mg/m2	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9491790	Homo sapiens						47				five consecutive days every week for 4 weeks			26	cancer								5	day		p.40
910	260					Highest studied dose	mg/m2	1600		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12706360/	Homo sapiens						55						81	6	advanced solid tumours					39			4	cycle		
911	263					Highest studied dose	mg/m2	1040		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9508200/	Homo sapiens												80	1	cancer					18			5	day		
912	263					Highest studied dose	mg/m2	768		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11139306/	Homo sapiens												16	16	cancer					4			28	day		
913	263					MTD	mg/m2	1000		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9918208/	Homo sapiens												71	7	cancer					41			5	day		
914	263					MTD	mg/m2	640		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11139306/	Homo sapiens												16	16	cancer					4			28	day		
915	263					MTD	mg/m2	904		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9508200/	Homo sapiens												80	3	cancer					18			5	day		
916	263					RP2D	mg/m2	800		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9508200/	Homo sapiens												80	13	cancer					18			5	day		
917	263					RP2D	mg/m2	800		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9918208/	Homo sapiens												71	75	cancer					41			5	day		
918	265		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://www.researchgate.net/publication/288652229_Clinical_efficacy_of_T-593_Osutidine_on_gastric_ulcer_resistant_to_H2-receptor_antagonist_andor_proton_pump_inhibitor	Homo sapiens							max			T-593 was administered to the patients in a dose of 400mg daily (given in 2 doses of 200mg each) for 8 weeks. If the ulcer did not heal, in some cases, the dose was increased to 800mg per day (2 doses of 400mg each) for another 8 weeks.			29	gastric ulcer								16	week		
919	265		ADULT			Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://www.researchgate.net/publication/288387050_Clinical_effects_of_T-593_Osutidine_on_endocrine_function_and_healing_in_patients_with_peptic_ulcer	Homo sapiens													40	peptic ulcer disease								8	week		
920	270					Overdose	g	2.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/913071	Homo sapiens						19													19						
921	270						mg	25		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7471621	Homo sapiens												35							20						
922	270						mg	50		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7471621	Homo sapiens												35							20						
923	276		ADULT			Studied dose	%	5		single					healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/31879957/	Homo sapiens						39				patch test			1									1	day		307-309
924	285		ADULT			Highest studied dose	ug	40		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17209669/	Homo sapiens														thromboangiitis obliterans											
925	285					Recommended	ug	10		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27068583| https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34982	Homo sapiens						88							1	thromboangiitis obliterans								2	month		
926	286					Recommended	mg	50		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18303135/	Homo sapiens						71				7 to 21 days duration			4	cough	mean dose 26 mg; 1 week			Warfarin				12	day		
927	286					Studied dose	mg	4		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21342238/	Homo sapiens						57							1	common cold					57			1	day		
928	289					Studied dose	%	10		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/17300246	Homo sapiens						29.6	unknown					48	20	acne vulgaris					20			12	week		
929	291		adult			Studied dose	mL	5		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29826957/	Homo sapiens										2 teaspoonful during 10 min			1									1	day		
930	291					Studied dose	g	0.26		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20783236/	Homo sapiens						55		0.13 g; oral; 3/day					1	headache	0.26 g; oral; 3/day			phenazone	55			1	year	caffeine	
931	291					Studied dose	mL	10		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29006854/	Homo sapiens						45				2 teaspoonful			1						45			1	day		
932	297		ADULT			Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16476941	Homo sapiens							unknown						16	Parkinson disease								2	week		
933	297		ADULT			MTD	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16476941	Homo sapiens							unknown						16	Parkinson disease								2	week		
934	297		ADULT			Studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16476941	Homo sapiens							unknown						16	Parkinson disease								2	week		
935	303					Overdose	mg	5000		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8363125	Homo sapiens						19				100 50-mg tablets of dimenhydrinate			1						19						
936	303					Overdose	mg/kg	13		single					unhealthy	rectal			https://pubmed.ncbi.nlm.nih.gov/12532948/	Homo sapiens										40 mg (13 mg/kg) suppository of dimenhydrinate			2	vomiting											
937	303					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26813018	Homo sapiens										four doses of 1 mg/kg every six hours (maximum 200 mg)			100	Acute Gastroenteritis								7	day		
938	303						mg	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24276103	Homo sapiens						43							47	vertigo					43			15	min		
939	309					Studied dose	%	5		multiple					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/7758311/	Homo sapiens						68							1	cutaneous mycosis					68			2	day		
940	310					Recommended	mg	25		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2594597/	Homo sapiens						18							1	constipation	200 mg; oral; 1/day			poloxalkol	18			5	year		
941	310					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5371464/	Homo sapiens												88	20	constipation	200 mg; oral; 1/day			poloxalkol	65			28	day		
942	310					Recommended	mg	50		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1451505/	Homo sapiens													2	constipation	60 mg; oral; 1/day			docusate sodium				2	week		
943	310					Studied dose	mg	25		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/638688/	Homo sapiens						51				large quantities of Dorbanex			1	psychiatric ailments	200 mg; oral; 1/day			poloxalkol	51			1	day		
944	311						mg	250		multiple			day	3	unhealthy	oral	M+F		https://www.hpbonline.org/article/S1365-182X(19)30434-4/fulltext	Homo sapiens										Eleven patients treated for at least one year were included in this analysis. DHC was initiated at 250mg three times per day and the subsequent daily dose was titrated to avoid watery diarrhea, a known side-effect of this cathartic drug.		75	11	recurrent acute cholangitis					36			1	year		
945	314					Studied dose	%	1		single			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/18714544/	Homo sapiens						29				patch test			1	itching lesions					29			1	day		
946	314					Studied dose	g	360		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9168328/	Homo sapiens						59				possibly 360 g			1						59			1	day		
947	314					Studied dose	g	72		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23473463/	Homo sapiens						74							1	depression, chronic alcoholism, cardiac insufficiency and breast cancer					74			1	day		
948	318						%	1		multiple					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/7418402/	Homo sapiens						30				a case roprt. dosage regimen unknown			1	psoriasis											
949	320		ADULT			Studied dose	%	10		single					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/30891767/	Homo sapiens						79							1												p.151
950	324		CHILD			Highest studied dose	g	1.5		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/779682/	Homo sapiens												18	17	trichuris trichiura infection					7			1	day		205-11
951	326		ADULT			Recommended	%	3		multiple			2 hours	1	healthy	topical	unknown		https://www.drugs.com/pro/sun-defense-cream.html	Homo sapiens										Apply evenly 30 minutes before sun exposure and reapply every 2-3 hours.															
952	326		ADULT			Studied dose	g/m2	20		multiple			day	4	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31961417/	Homo sapiens						36.5				Sunscreen product was applied at 2 mg/cm2 to 75% of body surface area during 4 days of the study, with a total of 13 applications. The study product was applied 1 time on day 1 (0 hours) and 4 times per day for the remaining 3 days: 24, 26, 28, and 30 hours on day 2; 48, 50, 52, and 54 hours on day 3; and 72, 74, 76, and 78 hours on day 4			35									4	day		
953	331					Abused dose	mg	250		single					unknown	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						17				dose taken as contents of Benzedrex inhaler			1						17						
954	331					Abused dose	mg	250		single					unknown	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						19				dose taken as contents of Benzedrex inhaler			1						19						
955	331					Abused dose	mg	250		single					unknown	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						34				dose taken as contents of Benzedrex inhaler			1						34						
956	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						19				dose taken as contents of Benzedrex inhaler			1						19						
957	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						22				dose taken as contents of Benzedrex inhaler			1						22						
958	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						23				dose taken as contents of Benzedrex inhaler			1						23						
959	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						24				dose taken as contents of Benzedrex inhaler			1						24						
960	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						25				dose taken as contents of Benzedrex inhaler			1						25						
961	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						26				dose taken as contents of Benzedrex inhaler			1						26						
962	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						27				dose taken as contents of Benzedrex inhaler			1						27						
963	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						28				dose taken as contents of Benzedrex inhaler			1						28						
964	331					Abused dose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/37732/	Homo sapiens						29				dose taken as contents of Benzedrex inhaler			1						29						
965	331					Studied dose	mg	180		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3709618/	Homo sapiens												37	7						25			14	day		
966	332						%	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31190944/	Homo sapiens								1%; 2/day		The complete formulation of the cream tested was composed by: benzoylperoxide 4%, mandelic acid 1%, lactobionic acid 1%, pure retinol 0.05%, palmitate retinol 0.5%, sulfate zinc 1%, glycyrrhetinic acid, undecylenic acid and phytosphingosines (Kurac, from Braderm®). Each patient was instructed to apply a thin film of the topical medical device cream as a monotherapy twice a day for 12 weeks.			20	facial acne	4%; 2/day		sulfate zinc	benzoylperoxide			1%; 2/day	12	week	lactobionic acid	
967	332						%	45		multiple			2 weeks	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31553119/	Homo sapiens						19.4				45% mandelic acid peel was done in group II at an interval of 2 weeks for a total of 12‐week duration (total six peeling sessions were done).			25	acne vulgaris								12	week		
968	335					Recommended	uCi	10000		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2984362/	Homo sapiens						60							1	carcinoma											
969	335						mg	16.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/34039871/	Homo sapiens						52							59	rheumatoid arthritis								7	day		
970	339		ADULT			Highest studied dose	%	10		single					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9249286/	Homo sapiens						31				patch test			1									1	day		165-6
971	340					Recommended	%	5		multiple			day	2	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/14641355	Homo sapiens													21	skin irritation								26	day		
972	340					Recommended	%	5		multiple					unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/22320671	Homo sapiens													1	radiotherapy effects											
973	340					Recommended	%	5		multiple					unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/22320671	Homo sapiens													1	stasis dermatitis											
974	341					Studied dose	%	5		multiple			week	3	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/18892064/	Homo sapiens						34							1						34			12	day		
975	342		infant			Overdose	mg	30		multiple			day	3	healthy	oral (mother), breasteeding (infant)			https://pubmed.ncbi.nlm.nih.gov/3371222	Homo sapiens										mother received oral drops 3 times/day, and breasfed the infant.			1									14	day		
976	342					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/32164969	Homo sapiens														productive cough											
977	344					Recommended	mg	60		single					unhealthy	dental	M+F		https://pubmed.ncbi.nlm.nih.gov/15402120/	Homo sapiens										3 c.c. of piperocaine 2% with epinephrine 1:60,000 solution was used as a local anesthetic in dental surgery. The five patients of 57 requiring supplemental injections, received 1.5 cc. in the area of the initial injection and 1.5 cc. infiltrated about the area to be operated on.		90	57	dental surgery	1:60,000; single			epinephrine	10						
978	346		ADULT			Highest studied dose	%	15		multiple			day	1	unknown	topical	unknown		https://journals.sagepub.com/doi/10.3109/10915818409021274	Homo sapiens													50									5	day		147-209
979	347		ADULT			Studied dose	%	2		single					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9455642/	Homo sapiens						38	max						1									1	day		304-5
980	347		ADULT			Studied dose	%	2		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/15725287/	Homo sapiens						58							1	Atopic dermatitis								1	day		93-5
981	354					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5325539	Homo sapiens													24	Urinary tract infections| Pyuria| Pyelonephritis| Cystitis								13	day		p.230
982	354					Studied dose	mg	500		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4228868	Homo sapiens						20							1	Acne											p.344, 345
983	359		adult			Studied dose	%	50		single					healthy	topical			https://hpvchemicals.oecd.org/ui/handler.axd?id=3E210D3A-7F37-4DBD-8C2A-44416EF6BBE9	Homo sapiens													20									24	hour		
984	360		adult				%	0.5		single			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/5350404/	Homo sapiens										photopatch test			10									1	day		
985	360					Studied dose	%	1		single			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/5552349/	Homo sapiens						60				patch test - 1%; patient used Lifebuoy soap, which contains tribromsalan			1	atopic dermatitis					60			1	day		
986	360					Studied dose	%	1		single			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/7082027/	Homo sapiens						47				patch test - 1%; patient used deodorant soap, which contains tribromsalan			1	Photoallergic contact dermatitis					47			1	day		
987	361					Highest studied dose	%	9		multiple			day	1	healthy	topical	M		https://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_016.pdf | https://pubmed.ncbi.nlm.nih.gov/743875/	Homo sapiens												65	10						21			21	day		
988	361					Recommended	%	1.5		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11109156/	Homo sapiens										patients who needed a topical corticosteroid cream were provided with a low-potency cream containing 0.025% triamcinolone acetonide		74	50	atopic dermatitis					12			42	day		
989	363					Studied dose	mg	5.38		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/19681344|https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/083060326.pdf	Homo sapiens										Dose was calculated using the following information: Brolafin emulsion contains 0.670 g trolamine per 100 g emulsion. Patients received 45g tube of emulsion.			15	Wound								4	week		p.330
990	371						%	2		multiple					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/88168/	Homo sapiens						59				From the first postoperative day merbromin in a 2% aqueous solution was applied to the surgical wounds and decubitus areas.			1	surgical wounds											
991	371						%	2		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/9404570/	Homo sapiens										Topical application of mercurochrome, a 2% solution of merbromin.		38	8	skin wounds					4						
992	377		ADULT			Highest studied dose	g	1		multiple			day	2	healthy	intramuscular	unknown		https://pubmed.ncbi.nlm.nih.gov/1601759/	Homo sapiens							total daily dose					23	10						16			5	day		
993	377		ADULT			Highest studied dose	g	2		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10965103/	Homo sapiens						49.6	total daily dose						32	bacterial infection								3	day		
994	377		CHILD			Highest studied dose	mg/kg	50		single			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/8619595/	Homo sapiens												17.8	6	systemic infection					1.3						
995	380		ADULT			Studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33247483/	Homo sapiens						33.67							28	major depressive disorder	up to 40 mg/day			citalopram				6	week		p.12, 25
996	380		CHILD			Overdose	mg	100		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/21955016/	Homo sapiens						5							1												p.780
997	380		UNKNOWN			Overdose	mg/kg	11		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/21955016/	Homo sapiens													1												p.780
998	388		babies				mg	0.1		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/21032188	Homo sapiens							starting						15												
999	388					Highest studied dose	mg	16		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6807409	Homo sapiens							total			Depending on how hard and how many times the teat is squeezed, each full dropper contains 10 to 30 drops-that is, 2 to 6 mg atropine methonitrate. For the purpose of estimating the administered dose, a full dropper is considered as 20 drops here. The total dose of atropine methonitrate given varied between 0.8 mg and 16 mg (0-39 mg/kg and 3-55 mg/kg).			1												
1000	388						mg	0.4		multiple			day	6	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5909489	Homo sapiens										Eumydrin drops (atropine methyl nitrate in 0.6% alcoholic solution), two drops (0.4 mg.) with each feed for a week.			1									1	week		
1001	388						mg	0.8		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6807409	Homo sapiens							total			Depending on how hard and how many times the teat is squeezed, each full dropper contains 10 to 30 drops-that is, 2 to 6 mg atropine methonitrate. For the purpose of estimating the administered dose, a full dropper is considered as 20 drops here. The total dose of atropine methonitrate given varied between 0.8 mg and 16 mg (0-39 mg/kg and 3-55 mg/kg).			1												
1002	388						mL	2.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21032188	Homo sapiens													1									2	week		
1003	390		ADULT			Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23581533/	Homo sapiens						52.5						65	297	osteoarthritis					40			6	week		p.853
1004	390		ADULT			Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8829889/	Homo sapiens						50.5							162	rheumatoid arthritis								6	month		p.313
1005	391		ADULT			Recommended	mg	60		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2004546/	Homo sapiens						54.4	max						87	rheumatoid arthritis								6	week		p.340
1006	393		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24383899/	Homo sapiens						73.3						83	20	rheumatoid arthritis					70			48	week		p.120
1007	393		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=39738	Homo sapiens														rheumatoid arthritis											
1008	395		ADULT			Recommended	mg	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9272401/	Homo sapiens						45.9						63	10	Manic Depressive disorder					27			5	day		p.340
1009	399		ADULT			Highest studied dose	mg	24		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23512719/	Homo sapiens						64.8							23	hypertension								16	week		
1010	399		ADULT			Recommended	mg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21029001/	Homo sapiens						52.87	max						110	essential hypertension								8	week		p.375
1011	402		ADULT			Highest studied dose	mg	1200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens						26							10												p.1104, 1105
1012	402		ADULT			Studied dose	mg	600		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33727798/	Homo sapiens						25.3						32	12						20			7	day		p.1104, 1105
1013	403					Studied dose	mg	6		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7701049/	Homo sapiens												39	13	schizophrenia					23						
1014	403					Studied dose	mg	6		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7701049/	Homo sapiens												39	13	schi					23						
1015	404		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18636784/	Homo sapiens														gout								6	month		
1016	405		ADULT			Recommended	mg	300		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24725621/	Homo sapiens						78.5							25	pneumonia								11.4	day		p.3
1017	405		ADULT			Studied dose	mg	500		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8953683/	Homo sapiens						52.3							58	bacterial infectious disease								5	day		p.510
1018	406		ADULT			Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7100263/|https://pubmed.ncbi.nlm.nih.gov/3048975/	Homo sapiens							max|total daily dose						23	schizophrenia								8	week		95-6|670-84
1019	407		ADULT			Highest studied dose	mg	1		multiple			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6661373/	Homo sapiens													4									7	day		279S-283S
1020	407		ADULT			Overdose	g	17.5		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29095168/	Homo sapiens							min			max dose - 50 g			3									1	day		82-84
1021	407					Highest studied dose	mg	3		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6661373/	Homo sapiens													4									1	day		279S-283S
1022	408		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9194208/	Homo sapiens							max						24	rheumatoid arthritis								16	week		p.8
1023	408		ADULT			Studied dose	ug/kg/day	20000		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12847560/	Homo sapiens													12												p.86
1024	410					Highest studied dose	mg	30		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6840161	Homo sapiens						54						60	12	hypertensive disease					40						
1025	415		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15587753/	Homo sapiens												30	85	bacterial infectious disease					2						p.603
1026	417		ADULT			Highest studied dose	mg	80		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3693585/	Homo sapiens													14	ventricular arrhythmias								4	month		
1027	417					Highest studied dose	mg	81.25		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3680596/	Homo sapiens						79							15	ventricular premature complexes					43			7	day		
1028	417					Recommended	mg	300		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19069153/	Homo sapiens						60							1	atrial fibrillation								3	day		
1029	417					Studied dose	mg	32.5		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3680596/	Homo sapiens												79	15	ventricular premature complexes					43			6	day		
1030	417					Studied dose	mg	65		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3680596/	Homo sapiens												79	15	ventricular premature complexes					43			14	day		
1031	417					Studied dose	mg	70		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20631453/	Homo sapiens						71.7							60	atrial fibrillation											
1032	418		ADULT			Highest studied dose	mg	600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23319135/	Homo sapiens												40	12						27						p.156
1033	418		ADULT			Recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8301936/	Homo sapiens						54						73	12	hyperlipid					40			16	week		p.1355
1034	419		ADULT			Highest studied dose	mg	80		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5293942/	Homo sapiens													2									1	day		193-6
1035	419		ADULT			Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6375710/	Homo sapiens						51							160	hypertension	10 mg			Pindolol				4	month		547-52
1036	420		ADULT			Highest studied dose	ug	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3044503/	Homo sapiens						55						72	13	hypertension					45			8	week		p.97
1037	421		ADULT			Highest studied dose	mg	90		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2009145/	Homo sapiens													12	hypertension											
1038	423		ADULT			Highest studied dose	ug/kg/min	4		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8850384/	Homo sapiens						59.2	max			Intravenous dopexamine was introduced in a single-blind, uncontrolled fashion at a rate of 0.5 ug/kg/min for 15 minutes in all patients. The dosage was increased by 0.5 ug/kg/min and then 1.0 ug/kg/min every 15 minutes up to 4.0 ug/kg/min if necessary.			18	congestive heart failure								90	min		p.793
1039	423		ADULT			Studied dose	ug/kg/min	1.2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7915979/	Homo sapiens						62						76	5	coronary artery disease					51						p.839
1040	425		ADULT			Highest studied dose	mg	40		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7907873/	Homo sapiens													6												
1041	425		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/19032340/	Homo sapiens													3000	allergic rhinitis								3	month		
1042	425					Overdose	mg	60		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28396756/	Homo sapiens						3							1												
1043	426					Recommended	mg	60		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209176Orig1s000MedR.pdf	Homo sapiens						58.8				60 mg administered intravenously over 60 minutes daily for 14 consecutive days followed by a 2-week drug free period (Cycle 1), and then administration of 60 mg administered intravenously over 60 minutes daily for 10 days within a 14 day period followed by a 2-week drug free period (Cycle 2 and thereafter).		75	184						29			14	day		p. 77
1044	427		ADULT			Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24944418/	Homo sapiens												80	12	hypertension					48			12	week		
1045	428						mg	50		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18447661/	Homo sapiens														diabetic neuropathy											
1046	429		ADULT			Higher than recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19458926/	Homo sapiens						49.8							40	spastic cerebral palsy											p.569
1047	430		ADULT			Recommended	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26116425/	Homo sapiens						71.8							8	COPD								28	day		p.50
1048	431		ADULT			Recommended	mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1981698/	Homo sapiens						44							12	anxiety disorder								5	week		215-23
1049	431		ADULT			Recommended	mg	1		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11952667/	Homo sapiens						78				Maximum daily dosage			1	anxiety								3	month		34-6
1050	431		CHILD			Accidental dose	mg	0.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17666930/	Homo sapiens						1.5							1									1	day		472-3
1051	434					Highest studied dose	mg	600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16408815/	Homo sapiens													12												
1052	434					Studied dose	mg	400		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16898073/	Homo sapiens												34	10						21			5	day		
1053	435		ADULT			Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1284163/	Homo sapiens							total daily dose			slow-release formulation			118	ischemia								7	day		S88-94
1054	435		ADULT			Studied dose	mg	150		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6367415/	Homo sapiens							total daily dose					75	20	ischemia					49			4	week		684-8
1055	436						mg	1		multiple			day	1	unhealthy	intratumoral injection	M		https://pubmed.ncbi.nlm.nih.gov/12679162/	Homo sapiens												60	9	glioma, malignant					5			7	day		
1056	437		ADULT			Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12821477/	Homo sapiens						34						45	6						18			14	day		2256-63
1057	437		ADULT			Highest studied dose	mg	800		multiple			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17692724/	Homo sapiens												45	12						18			14	day		1098-106
1058	437		ADULT			Highest studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17692724/	Homo sapiens												45	6						18			1	day		1098-106
1059	437		ADULT			Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17919545/	Homo sapiens						41	total daily dose					80	266	maxillary sinusitis					18			10	day		1632-44
1060	438					Studied dose	mg	5		multiple			week	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2694740/	Homo sapiens													300	myoma								6	month		
1061	440		ADULT			Recommended	mg	1		multiple			day	3	unhealthy	oral	M+F		https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic	Homo sapiens														Bronchospasm											
1062	440		ADULT			Recommended	mg	1		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/195789/	Homo sapiens													55	asthma								7	day		p.14
1063	440		ADULT			Recommended	ug	500		multiple			day	6	unhealthy	respiratory	M+F		https://www.mims.com/malaysia/drug/info/hexoprenaline?mtype=generic	Homo sapiens										As sulfate: 100-200 mcg up to 6 times/day by aerosol inhalation. As HCl: 250-500 mcg every 4-6 hr by nebulisation; max: 3 mg/day for nebulisation.				Bronchospasm											
1064	442		ADULT			Highest studied dose	mg	75		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29051989/	Homo sapiens						22							6									1	day		69-77
1065	442		ADULT			Recommended	mg	25		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30143001/	Homo sapiens						60							1	autoimmune disease								15	day		130
1066	442		ADULT			Recommended	mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/34150809/	Homo sapiens						31.38							50	pondyloarthropathy								24	week		5-6
1067	443		ADULT			Highest studied dose	mg	0.25		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23372610/	Homo sapiens																						5	day		46
1068	443		ADULT			Highest studied dose	mg	0.25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23390360/	Homo sapiens													101	Urinary Incontinence								12	week		113
1069	443		ADULT			Highest studied dose	mg	0.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23372610/ | https://pubmed.ncbi.nlm.nih.gov/23390360/	Homo sapiens																						1	day		46 | 111-20
1070	444		ADULT			Recommended|Highest studied dose	mL	50		single					unhealthy	intravascular	F		https://pubmed.ncbi.nlm.nih.gov/23347254/	Homo sapiens						34				Imeron 350 and Imeron 400 MCT			1	stomach disease								1	day		2141-4
1071	447		ADULT			Recommended	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25532503/	Homo sapiens						55						73	165	reflux esophagitis					21						p.6,7
1072	448		ADULT			Higher than recommended	ug/kg/min	40		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31813897/	Homo sapiens						63.9				40µg/kg/min (maximum total administration time 210min)			10	atrial fibrillation											p.37
1073	448		ADULT			Studied dose	ug/kg/min	11.8		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31118364/	Homo sapiens						67.4	mean|max			Landiolol was administered at an initial dosage of 1μg/kg/\nmin. The dosage was increased from 1μg/kg/min to 2.5, 5,\nand 10μg/kg/min, in a stepwise manner within the first\nhour (titration period). . At\nrecurrence of hemodynamically unstable VT or recurrence\nof VF, the dosage could be increased to a maximum of\n40μg/kg/min. The mean±SD maximum dosage was\n11.8±6.7μg/kg/min.			27	heart conduction disease											p.1461
1074	451		ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18340570/	Homo sapiens						40						62	33	migraine disorder					18						p.47
1075	452					Overdose	mg	6000		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/34488903/	Homo sapiens						33	total						1												
1076	452					Recommended	mg	60		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30839430/	Homo sapiens						34.8							117	pain disorder								7	day		
1077	452					Studied dose	mg	100		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/30839430/	Homo sapiens						36.7							121	pain disorder								7	day		
1078	453					Recommended	%	1		multiple			day	1	unhealthy	topical	M+F		https://clinicaltrials.gov/ct2/show/NCT02394340	Homo sapiens						45.05				1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.			20	tinea pedis	40 mg; PO; day 1 and 8			Omeprazole				6	day		
1079	454		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21155616/	Homo sapiens						58.3							30	essential hypertension								14	week		p.208
1080	455					Highest studied dose	mg	90		multiple			day	1	unhealthy	oral	M+F		https://www.readcube.com/articles/10.1007%2Fs007740050034	Homo sapiens						72							39	osteoporosis								24	week		
1081	457		ADULT			Highest studied dose	mg	75		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1354949/ | https://pubmed.ncbi.nlm.nih.gov/11510627/	Homo sapiens													5									1	day		135-9 | 503
1082	457		ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8836336/	Homo sapiens						37							28	rticaria								28	day		320-5
1083	457		ADULT			Recommended	mg	10		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16937762/	Homo sapiens												55	2						30			1	day		262-3
1084	458		ADULT			Highest studied dose	mg/kg	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17096684/|https://pubmed.ncbi.nlm.nih.gov/17142982/|https://pubmed.ncbi.nlm.nih.gov/20052390/	Homo sapiens						27						45	6						18			1	day		459-68|2460-4|681482
1085	458		ADULT			Highest studied dose	mg/kg	6		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17096684/|https://pubmed.ncbi.nlm.nih.gov/17142982/|https://pubmed.ncbi.nlm.nih.gov/20052390/	Homo sapiens						25						44	6						18			7	day		459-68|2460-4|681482
1086	458		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20832593/	Homo sapiens						29	total daily dose			https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1912			1	lomerulonephritis								4.5	month		2804-7
1087	458		ADULT			Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18084697/	Homo sapiens						59						68	59	jogren's syndrome					47			16	week		464-9
1088	460		ADULT			Highest studied dose	mg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16644612/	Homo sapiens						57.1	max						533	coronary artery disease											p.114
1089	460		ADULT			Highest studied dose	mg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16644612/	Homo sapiens						72	max						133	coronary artery disease											p.114,124
1090	463		ADULT			Recommended	%	1		multiple			day	2	unhealthy	topical	M+F		https://www.tandfonline.com/doi/abs/10.3109/09546639709160277 | https://pubmed.ncbi.nlm.nih.gov/17020421/	Homo sapiens												65	101	skin disease					18			14	day		91 | 1963
1091	464		ADULT			Studied dose	mg	75		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19462821/	Homo sapiens													85	benign prostatic hyperplasia								12	week		
1092	465		ADULT			Highest studied dose	ug/kg/min	0.4		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21326107/	Homo sapiens						62				olprinone was administered at 0.4 μg·kg(-1)·min(-1) after establishment of hypothermic CPB; continuous infusion			8	cardiovascular system disease											p.580
1093	465		ADULT			Studied dose	ug/kg/min	0.1		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28028637/	Homo sapiens						68	max			OLP was administered continuously at\n0.1 μg/kg/min for 24 h from the start of surgery in the first\n6 patients and at 0.05 μg/kg/min from the start of surgery\nuntil liver parenchymal transection in the next 17 patients		79	23	liver and biliary tract disease					52						p.5
1094	466		ADULT			Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11199949/	Homo sapiens												65	101	generalized anxiety disorder					18			4	week		p.61
1095	467		ADULT			Recommended	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6151914/	Homo sapiens						78						89	19	skin disease					65						p.349
1096	467		ADULT			Recommended	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6119170/	Homo sapiens						23							32	hay fever								7	week		p.494
1097	467		ADULT			Recommended	mg/kg	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6986007/	Homo sapiens						31	max			patients received 0.5 mg/kg oxatomide b.i.d., if necessary this dose was doubled.		45	44	hay fever					6						p.148
1098	468		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9792572/	Homo sapiens						31						43	6	asthma					19			7	day		p.1030
1099	469		ADULT			Highest studied dose	mg	1000		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22809012/	Homo sapiens						24.3				as Pazufloxacin mesilate		33	8						20			1	day		
1100	469		ADULT			Highest studied dose	mg	2000		single					healthy	intravenous	M		https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456000_A100_1.pdf#page=27 | https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456_K102_1.pdf#page=21	Homo sapiens						23						31	8						21			1	day		
1101	469		ADULT			Recommended|Studied dose	mg	1000		multiple			day	2	healthy	intravenous	M		https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456000_A100_1.pdf#page=27 | https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456_K102_1.pdf#page=21	Homo sapiens						22						29	8						20			5	day		
1102	469		ADULT			Recommended|Studied dose	mg	1000		multiple			day	2	unhealthy	intravenous	M+F		https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456000_A100_1.pdf#page=30 | https://www.pmda.go.jp/drugs/2010/P201000035/480297000_21400AMZ00456_K102_1.pdf#page=130	Homo sapiens						72						94	140	bacterial pneumonia					25			14	day		
1103	473		ADULT			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19067472/	Homo sapiens						63.1							8	prostatic hyperplasia								3	day		
1104	473		ADULT			Studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15456336/	Homo sapiens													117	chronic bronchitis or urinary tract infections								10	day		
1105	474						mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24122181	Homo sapiens						60.5							23	sporadic Creutzfeldt-Jakob disease					60.5			2	month		
1106	475		ADULT			Highest studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9357394/	Homo sapiens												72	64	sthma					18			8	week		426-35
1107	475		ADULT			Highest studied dose	mg	120		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8162671/	Homo sapiens										first dosing day			10									1	day		441-50
1108	476		ADULT			Highest studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17586104/	Homo sapiens												45	10						18			1	day		351
1109	476		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15786539/	Homo sapiens						47.2						71	54	eptic ulcer	200 mg b.d.		CC1(C(N2C(S1)C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)C(=O)O)C	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC	27		750 mg b.d.	7	day	CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	1631
1110	477					Recommended	mg/kg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf	Homo sapiens						9.2							33	Dravet syndrome				clobazam				8	week	valproate	6
1111	477					Recommended	mg/kg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf	Homo sapiens						9.2							33	Dravet syndrome				clobazam				8	week	valproate	7
1112	479		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21980828/	Homo sapiens						56						75	15	atopic asthma					39			2	year		p.140
1113	480		ADULT			Recommended	mg	1.2		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=981	Homo sapiens							max			Usually, for adults, start with 1/2 to one tablet (0.2-0.4mg of talipexole hydrochloride) once daily, then increase the daily dose by an increment of one tablet (0.4mg) at weekly intervals by checking your condition, and your maintenance dose is determined [standard daily dose: 3-9 tablets (1.2-3.6mg)]. If the daily dose is two tablets (0.8mg), divide it into two doses and take each dose after each meal. If the daily dose is three tablets (1.2mg) or more, divide it into three doses and take each dose after each meal.				Parkinson's disease											
1114	480		ADULT			Studied dose	mg	2.4		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7913738/	Homo sapiens						39.2	max					63	13	Gilles de la Tourette syndrome					19			12	week		p.316
1115	482		ADULT			Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8794786/	Homo sapiens						56							10	cirrhosis of liver								4	week		p.1729
1116	482		ADULT			Studied dose	mg	50		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25100080/	Homo sapiens						69.3							151	gastric ulcer								24	week		p.790
1117	483		ADULT			Overdose	g	2.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29135905/	Homo sapiens						18							1												p.581
1118	483		ADULT			Studied dose	g	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6241563/	Homo sapiens						41.37	total daily dose			A 300 mg tablet was specially produced for this study and patients were administered 4 tablets (1.2 g) in the morning, 3 tablets (0.9 g) at midday and another 3 tablets (0.9g) in the evening.			8	Huntington's chorea								3	week		p.332
1119	483		ADULT			Studied dose	g	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6241563/	Homo sapiens						47.57	total daily dose			A 300 mg tablet was specially produced for this study and patients were administered 4 tablets (1.2 g) in the morning, 3 tablets (0.9 g) at midday and another 3 tablets (0.9g) in the evening.			7	Huntington's chorea								3	week		p.332
1120	484		ADULT			Higher than recommended	mg	2.5		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6992927/	Homo sapiens						49.6	starting						25									3	month		1207-9
1121	484		ADULT			Highest studied dose	mg	5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12387462/	Homo sapiens						52.5						60	151						43			12	week		1109-14
1122	484		ADULT			Recommended	mg	2.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17607296/	Homo sapiens						54							1	Gilbert syndrome	200 mg, 3/day			flavoxate				6	month		403-8
1123	486					Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8904615/	Homo sapiens												56	10	cirrhosis of liver					35			4	day		
1124	489		ADULT			Recommended|Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://journaljammr.com/index.php/JAMMR/article/view/13470/24697	Homo sapiens												85	1486	stomach disorder					16			28	day		1881-1892
1125	489		ADULT			Recommended|Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21127703/	Homo sapiens						36.8							71	gastritis								4	week		758397
1126	490		ADULT			Highest studied dose	mg	120		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3519043/	Homo sapiens						45.5						53	11	hypertension					33						p.694, 695
1127	490		ADULT			Recommended	mg	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11239257/	Homo sapiens						71	max			11 patients were treated with 25 mg of urapidil, 4 patients received 50 mg and only 1,100 mg.			16	hypertension											p.132
1128	490		ADULT			Recommended	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3886400/	Homo sapiens												58	11	hypertension					31			6	week		p.38
1129	490		ADULT			Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3042355/	Homo sapiens						55.5	max			twice daily urapidil (total of 30-120 mg/day)			107	essential hypertension								12	week		p.159
1130	492		ADULT			Highest studied dose	mg	40		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7006620/	Homo sapiens													6									15	day		
1131	492		ADULT			Studied dose	mg	20		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1832291/	Homo sapiens													6									16	week		
1132	492		ADULT			Studied dose	mg	40		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6987114/	Homo sapiens													9	hypertension								3	week		
1133	493		ADULT			Highest studied dose	mg	100		multiple			day	3	healthy	oral	M		https://link.springer.com/article/10.1007%2FBF03259533	Homo sapiens						31.2							6									5	day		1-7
1134	493		ADULT			Highest studied dose	mg	300		single					healthy	oral	M		https://link.springer.com/article/10.1007%2FBF03259533	Homo sapiens						31.2							6									1	day		1-7
1135	495		ADULT			Highest studied dose	mg	150		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens						33.3							6									1	day		436-43
1136	495		ADULT			Highest studied dose	mg/kg	0.16		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6478731/	Homo sapiens						33.3							6									1	day		436-43
1137	496						%	1		multiple			day	1	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/2906845/	Homo sapiens														glaucoma								2	month		
1138	498		ADULT			Studied dose	mg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4085521/	Homo sapiens						26.5							2												p.190
1139	499		CHILD			Studied dose	mg/kg	40		multiple			day	4	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7334585	Homo sapiens													59	respiratory tract infections								7	day		
1140	499					Studied dose	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6436182/	Homo sapiens						64.5						84	22	urinary tract infection					25			10	day		
1141	500		ADULT			Recommended	%	1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/8720204/	Homo sapiens						47.7							132	tinea pedis											p.506
1142	501					Higher than recommended	mg/kg	1.2		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf	Homo sapiens												15		Duchenne muscular dystrophy					5			52	week		6.1
1143	501					Recommended	mg/kg	0.9		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf	Homo sapiens												15	51	Duchenne muscular dystrophy					5			12	week		Table 1
1144	501					Recommended	mg/kg	0.9		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf	Homo sapiens												15	51	Duchenne muscular dystrophy					5			52	week		Table 1
1145	502		ADULT			Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1971575/	Homo sapiens																						1	day		212-7
1146	502		ADULT			Highest studied dose	mg	750		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14503971/	Homo sapiens						30.7							27	ovarian hyperstimulation syndrome								1	day		281-6
1147	503		ADULT			Highest studied dose	g	1.2		multiple			day	1	healthy	oral	M		https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext	Homo sapiens													10									2	week		AB272-AB273
1148	504		ADULT			Highest studied dose	mg	90		single					unhealthy	caudal epidural	M+F		https://pubmed.ncbi.nlm.nih.gov/8874908/	Homo sapiens						48				for 48 hr			168	pain disorder								2	day		914-8
1149	505		ADULT			Highest studied dose	mg	8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4042078/	Homo sapiens						21.8						24	10						20						p.279
1150	505		ADULT			Studied dose	mg	6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2881572/	Homo sapiens												41	11						20						p.186
1151	506					Studied dose	ug	0.3		multiple			day	1	unhealthy	oral	M+F		https://www.proquest.com/docview/1114466213	Homo sapiens						52.7							58	secondary hyperparathyroidism								8	week		
1152	506					Studied dose	ug	2		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8155746/	Homo sapiens													12												
1153	510					Studied dose	mg	0.2		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/43806/	Homo sapiens												30	5						23						
1154	510					Studied dose	mg	2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/43806/	Homo sapiens							total					30	5						23						
1155	511						mg	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26000220/	Homo sapiens														anxiety disorder											
1156	512		ADULT			Recommended	%	0.25		multiple			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/17220049/	Homo sapiens													68	glaucoma								52	week		p.729
1157	512		ADULT			Studied dose	mg	6		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8565030/	Homo sapiens						61.6	max			Nipradilol therapy was started at a dose of 3 mg twice a day. If a satisfactory anti-hypertensive effect was not obtained and\npatients tolerated the treatment, the daily dose was increased to 12 mg.			70	hypertension								9.8	month		p.673
1158	514					Studied dose	%	1		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/3393168/	Homo sapiens						23							18												
1159	515		ADULT			Highest studied dose	ug	1600		single					healthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/8477178/	Homo sapiens												21	11						20			1	day		31-5
1160	516		ADULT			Studied dose	mg	2.5		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1792811/	Homo sapiens													67	chronic heart failure								6	month		
1161	516		ADULT			Studied dose	mg	5		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1792811/	Homo sapiens													67	chronic heart failure											
1162	517		ADULT			Highest studied dose	mg	320		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7594329/	Homo sapiens						48.9							32	duodenal ulcer	30 mg q.d. (6 weeks)			amoxicillin				6	week	lansoprazole	S.130
1163	517		ADULT			Studied dose	mg	160		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7594330/	Homo sapiens						36							13	gastric ulcer	30 mg q.d.			lansoprazole				8	week		S.133
1164	521		ADULT			Recommended	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25433006/	Homo sapiens						65							14	bacterial infectious disease											p.4
1165	521		ADULT			Recommended	mg	6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25433006/	Homo sapiens						65				continuous infusion			14	bacterial infectious disease											p.4
1166	526		ADULT			Highest studied dose	mg	140		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/17067318	Homo sapiens						35							5												p.454
1167	526		ADULT			Highest studied dose	mg	300		multiple			day	1	healthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/17876866	Homo sapiens						36							6									7	day		p.478
1168	526		ADULT			Highest studied dose	mg/kg	30		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/16240703	Homo sapiens																									
1169	526		ADULT			Studied dose	mg	70		multiple			day	2	healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/17067318	Homo sapiens						38							6									7	day		p.455
1170	527		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2344862/	Homo sapiens						76							6	atherosclerosis					61			2.5	month		
1171	527					Studied dose	mg	320		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32664877/	Homo sapiens						60.3				cinepazide maleate			466	ischemic stroke								14	day		
1172	528		adult			Studied dose	%	0.1		steady			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/32668038/	Homo sapiens							max						10	transit melanoma								45	month		
1173	530		ADULT			Highest studied dose	mg	200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4577839/	Homo sapiens						54							12	gastric ulcer											p.85
1174	530		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/949902/	Homo sapiens													32	gastric ulcer								1	year		p.221
1175	531		ADULT			Studied dose	ug	75		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8521763/	Homo sapiens										6 to 36 cycle, 21 day			100000		30 ug			ethinylestradiol				36	cycle		
1176	533					Highest studied dose	mg/m2	188		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11304785/	Homo sapiens										daily 3-5 schedule repeated every 3 week		76	6	solid tumors					37			6	cycle		
1177	533					Highest studied dose	mg/m2	760		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12114420/	Homo sapiens												81	3	advanced malignancies					29			12	cycle		
1178	533					Highest studied dose	mg/m2	760		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12847318/	Homo sapiens										every 21 days		17	6	refractory solid tumors					1			2	cycle		
1179	533					MTD	mg/m2	141		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11304785/	Homo sapiens										daily 3-5 schedule repeated every 3 week		76	6	solid tumors					37			6	cycle		
1180	533					MTD	mg/m2	165		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11304785/	Homo sapiens										daily 3-5 schedule repeated every 3 week		76	6	solid tumors					37			6	cycle		
1181	533					MTD	mg/m2	572		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12114420/	Homo sapiens												81	12	advanced malignancies					29			34	cycle		
1182	533					MTD	mg/m2	572		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12114420/	Homo sapiens												81	43	advanced malignancies					29			2	cycle		
1183	533					RP2D	mg/m2	585		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12847318/	Homo sapiens										every 21 days		17	6	refractory solid tumors					1			2	cycle		
1184	540		ADULT			Recommended	mg	220		steady			day	2	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/13374373/	Homo sapiens						23							1	vaginal discharge								4	week		
1185	540		ADULT			Recommended	mg	250		multiple			day	1	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/13199327/	Homo sapiens						47				21 day every month			1	vaginal discharge								2	cycle		
1186	540		ADULT			Recommended	mg	500		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2301196/	Homo sapiens						55							1	gastrointestinal disorder								3	day		
1187	540		ADULT			Studied dose	mg	250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2518869/	Homo sapiens						50						67	10	proctitis					26			4	week		
1188	555					Recommended	mg	25		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3291100/	Homo sapiens						55.1				one to 54 weeks (mean 7.2 weeks)			15	xerostomia								7.2	week		
1189	555					Recommended	mg	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6358997/	Homo sapiens						58				In four subjects, the dose was increased from 75 mg to 100 mg daily			27	xerostomia								4	week		
1190	555					Studied dose	%	2		single			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/17034478/	Homo sapiens						63				patch test			1						63			1	day		
1191	555					Studied dose	%	5		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9687050/	Homo sapiens						64				patch test			1						64			1	day		
1192	555					Studied dose	%	5		single			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9255488/	Homo sapiens										patch test			2	anise oil allergy								1	day		
1193	555					Studied dose	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10487404/	Homo sapiens						69.1							49	xerostomia								4	week		
1194	557		ADULT			Highest studied dose	g	4		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7706179/	Homo sapiens						58							52	infectious disease								10	day		813-7
1195	557		ADULT			Studied dose	g	4		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3925036/	Homo sapiens							total daily dose						131	pneumonia								14	day		164-200
1196	559		ADULT			Highest studied dose	ug/kg	67		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1675577/	Homo sapiens							max			Each volunteer received in four sessions in a randomized and single-blind manner three different doses (6.7 micrograms kg-1, 27 micrograms kg-1 and 67 micrograms kg-1) of atipamezole or saline placebo as 5 min i.v. infusions preceded by a fixed i.v. dose of dexmedetomidine (0.67 micrograms kg-1).		28	6						22						
1197	560		ADULT			Studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9124849/	Homo sapiens												79	16						64						p.2825
1198	563					Studied dose	mg	500		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2889942/	Homo sapiens												76	2	cataract					67			2	month		
1199	567		ADULT				g	0.5		multiple			8 hours	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18203711/	Homo sapiens						51.4				panipenem/betamipron (Carbenin) 0.5/0.5 g intravenously every 8 h			55	cancer	0.5 g intravenously every 8 h			panipenem							p.52,53
1200	571		ADULT			MTD	mg/kg/day	35		multiple			day	1	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/8174116/	Homo sapiens						49				hepatic arterial (HA) infusion		74	5	cancer					40			14	day		p.2122, 2123
1201	571		ADULT			Studied dose	mg/kg/day	25		multiple			day	1	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/7641176/	Homo sapiens						62				7-day hepatic arterial infusion of BrdUrd at 25 mg/kg/day		71	13	hepatic cancer					37			7	day		p.3689
1202	571		ADULT			Studied dose	mg/kg/day	25		multiple			day	1	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/8174116/	Homo sapiens						49				49		74	3	cancer					40			14	day		p.2122, 2123
1203	574		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15450070/	Homo sapiens						66							1	diabetes mellitus											p.1785
1204	574		ADULT			Recommended	mg	100		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7202882/	Homo sapiens						84							1	diabetes mellitus											p.45
1205	574		ADULT			Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.mims.com/malaysia/drug/info/buformin?mtype=generic	Homo sapiens							max							type 2 diabetes mellitus											
1206	576		CHILD|ADULT			Studied dose	%	0.5		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1778089/	Homo sapiens						8						38	23	Lice infestation					5						p.468
1207	577					Highest studied dose	mg	10		single					healthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/5041932	Homo sapiens																									
1208	578		ADULT			Studied dose	mg	0.25		multiple			day	2	unhealthy	oral	M+F		https://dlisv03.media.osaka-cu.ac.jp/contents/osakacu/journal/00306096-49-2-77.pdf	Homo sapiens						52.2				carboquone was given in a daily dose of 0.5 mg divided twice			50	breast cancer								28	day		p.81
1209	578		ADULT			Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://www.jstage.jst.go.jp/article/tjem1920/138/2/138_2_151/_pdf	Homo sapiens							max|total daily dose			Twelve patients with multiple myeloma were administered intravenously or orally with 0.5 to 1 mg Carboquone every day. The\ntotal dose of Carboquone ranged from 11.5 to 123.5 mg with a mean of 51.9 mg. The duration of treatment ranged from 14 to 192 days with a mean of 72.5 days		75	12	multiple myeloma					52			72.5	day		p.155
1210	579					MTD	mg/m2	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11528249/	Homo sapiens						60							3	colorectal cancer	2.0 mg/m2 IV; on day 1 of a 21-day cycle			raltitrexed				12	day		
1211	579					MTD	mg/m2	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11528249/	Homo sapiens						60							6	colorectal cancer	2.5 mg/m2 IV; on day 1 of a 21-day cycle			raltitrexed				12	day		
1212	579					MTD	mg/m2	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11528249/	Homo sapiens						60							9	colorectal cancer	3.0 mg/m2 IV; on day 1 of a 21-day cycle			raltitrexed				12	day		
1213	579					MTD	mg/m2	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11528249/	Homo sapiens						60							9	colorectal cancer	3.0 mg/m2 IV; on day 1 of a 21-day cycle			raltitrexed				12	day		
1214	579					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16823593/	Homo sapiens								250 mg IV; daily for 7 days				74	587	colon cancer	6 mg/m2 IV; on the day of surgery, 1 week after surgery, and every month for 6 months after surgery			mitomycin C	49			1	year	5-fluorouracil	
1215	579					Studied dose	mg	400		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2667512/	Homo sapiens						53							1	ovary cancer					53			8	week		
1216	579					Studied dose	mg/m2	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2239802/	Homo sapiens												70	115	gastrointestinal cancer					17			6	week		
1217	580		ADULT			Accidental dose	mg	4500		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/34030906/	Homo sapiens						81							1									1	day		e1-811.e2
1218	583		ADULT			Recommended	g	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7389424/	Homo sapiens										2-hour intravenous drip infusion		80	15	bacterial infectious disease					19						p.243
1219	583		ADULT			Recommended	g	4		multiple			day	3	unhealthy	intramuscular	M+F		https://www.mims.com/singapore/drug/info/ceftezole?mtype=generic	Homo sapiens							max|total daily dose			2-4 g daily in 2-3 divided doses.				bacterial infectious disease											
1220	589		ADULT			Highest studied dose	mg	675		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4966194/	Homo sapiens						63	total daily dose						41	arteriosclerotic cardiovascular disease								12	week		40-4
1221	589		ADULT			Highest studied dose	mg	80		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/4956317/	Homo sapiens												26	5						22			1	day		535-41
1222	590		ADULT			Studied dose	g	2.25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3520204/	Homo sapiens							typical			for 14 weeks			174	hepatitis								16	week		35-44
1223	590		ADULT			Studied dose	mg	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3896964/	Homo sapiens						59.8							16	epatitis								6	month		975-9
1224	591		ADULT			Highest studied dose	mg	30		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11549099/	Homo sapiens												50	8						18			3	day		950-8
1225	591		ADULT			Studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19105585/	Homo sapiens						61.4							65	chronic obstructive pulmonary disease								24	week		3-57
1226	591		ADULT			Studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19105585/	Homo sapiens						61.8						80	29	chronic obstructive pulmonary disease					40			24	week		3-57
1227	592		ADULT			Highest studied dose	%	0.5		multiple			day	2	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/7152079/	Homo sapiens												73	15	psoriasis					20			21	day		414-8
1228	592		ADULT			Recommended	%	0.05		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/10789866/	Homo sapiens						36							1	atopic dermatitis								1	day		305
1229	592		CHILD			Recommended	%	0.05		multiple					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/26840685/	Homo sapiens						0.7							1	Rash				CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC				3	month	C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl	76-7
1230	593		ADULT			Highest studied dose	mg	240		multiple			day	3	healthy	oral	M+F		https://www.ema.europa.eu/en/documents/referral/clobutinol-article-107-procedures-annex-ii_en.pdf	Homo sapiens													12									7	day		p.2
1231	593		ADULT			Studied dose	mg/mL	4		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2095610/	Homo sapiens						55				1 tablespoon 3 times daily		79	30	whooping cough					24			5	day		p.279
1232	596		ADULT			Recommended	mg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30439816/	Homo sapiens						61							1	sleep disorder								7	day		415-7
1233	596		CHILD			Accidental dose	mg	200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27567425/	Homo sapiens						1.5							1									1	day		2469.e1-2469.e2
1234	600					Studied dose	%	5		steady			day	3	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/14424470/	Homo sapiens										cream			1	ringworm								1	week		
1235	606		ADULT			Highest studied dose	mg/m2	400		single					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/898185/	Homo sapiens													5									1	day		1-6
1236	607		ADULT			Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	unknown		http://www.ncbi.nlm.nih.gov/pubmed/13816307	Homo sapiens													18	Angina								3	month		
1237	610		ADULT			Highest studied dose	mg	600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4556166/	Homo sapiens							total daily dose						9	Inflammation								8	day		111-21
1238	611		ADULT			Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	F		https://academic.oup.com/jjco/article-abstract/4/1/65/859994	Homo sapiens							total daily dose						6	breast cancer								1	course		65-8
1239	613		ADULT			Highest studied dose	mg	160		single					healthy	oral	M		http://www3.uah.es/farmamol/Public/PDF_files/IDrugs.pdf | https://pubmed.ncbi.nlm.nih.gov/18465521/	Homo sapiens							total daily dose						7									1	day		155 | 152-7
1240	613		ADULT			Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M		http://www3.uah.es/farmamol/Public/PDF_files/IDrugs.pdf | https://pubmed.ncbi.nlm.nih.gov/18465521/	Homo sapiens														prostatic hypertrophy								8	week		155 | 152-7
1241	615					Studied dose	mg	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8807239/	Homo sapiens						21				4 tablets contain 1000 mg			1	menstrual pain			allylisopropylacetylurea	acetaminophen						caffeine	
1242	618					Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29339723/	Homo sapiens						14.5							6	attention deficit hyperactivity disorder								6	week		
1243	621		ADULT			Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3325316/	Homo sapiens						59.1							19	periarthritis								3	week		p.333
1244	621		ADULT			Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6340972/	Homo sapiens						50.9						66	20	rheumatoid arthritis					33			3	month		p.312
1245	621		ADULT			Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6340972/	Homo sapiens												66	33	rheumatoid arthritis					23			9	month		p.313
1246	622					Studied dose	%	5		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/8458203/	Homo sapiens												45	3	rhemautic					41			2	week		
1247	622					Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/338255	Homo sapiens												86	19	osteoarthritis					53			4	week		
1248	624		ADULT			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2110437/	Homo sapiens												81	20	urinary tract infection					20			10	day		
1249	624		ADULT			Studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2110437/	Homo sapiens												79	19	urinary tract infection					41			10	day		
1250	624		ADULT			Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2110437/	Homo sapiens							median			200 - 600 mg		82	62	urinary tract infection					20			10	day		
1251	624		ADULT			Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2110437/	Homo sapiens												82	21	urinary tract infection					23			10	day		
1252	624		ADULT			Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8452177/	Homo sapiens										2 - 12 weeks			90	bone infection								6	week		
1253	625		ADULT			Recommended	mg	80		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25869815/	Homo sapiens						51.7							44	Stone - kidney/ureter											p.4
1254	626		ADULT			Recommended	%	0.1		single					unhealthy	topical	M+F		https://www.mims.com/singapore/drug/info/fluprednidene?mtype=generic	Homo sapiens														dermatitis											
1255	627						mg	160		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3158563/	Homo sapiens						65.4						79	60	obstructive lung disease					48			2	week		
1256	633		ADULT			Highest studied dose	mg	1500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5811101/	Homo sapiens										maximum duration		66	8	diabetes mellitus					14			25	month		155-69
1257	635						%	0.1		multiple			day	1	unhealthy	oromucosal	M+F		https://pubmed.ncbi.nlm.nih.gov/12834495	Homo sapiens						38.2				rinsing with 15 ml for 30 s			46	supragingival plaque | gingivitis					38.2			2	week		
1258	635						mg	10		multiple			day	1	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/1773929	Homo sapiens													100									5	day		
1259	637					Highest studied dose	mg	1067.58		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8427942/	Homo sapiens												35	6						21						13-39
1260	637					Highest studied dose	mg	711.72		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8427942/	Homo sapiens												35	8						21						13-39
1261	637					Recommended	mg	400		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/8837673/	Homo sapiens						63							1												442-3
1262	641		ADULT			Studied dose	g	5		single					unknown	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6896837/	Homo sapiens																									p.610
1263	647		adult			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral			DOI:10.1111/j.1527-3466.1996.tb00316.x	Homo sapiens																						8	week		
1264	649		ADULT			Highest studied dose	mg	250		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5731790/	Homo sapiens							complex			with 3 uC [14C]lynestrenol			1									1	day		337-43
1265	649		ADULT			Studied dose	mg	5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5332557/	Homo sapiens						32	max			two-thirds (218) of the women completed 15 or more cycles		40	332		150 ug			mestranol	18			15	cycle		1024-30
1266	651		ADULT			Highest studied dose	mg	400		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3743616	Homo sapiens													6	liver disease								4	month		
1267	652		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7582391/	Homo sapiens												41	12	allergic rhinitis					19						p.376
1268	655		ADULT			Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5135250/	Homo sapiens												72	15	hypertensive disease					32			7	day		p.788
1269	655		ADULT			Recommended	mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=33877	Homo sapiens										In general, for adults, take 1 to 2 tablets (25 to 50mg of the active ingredient) at a time, once a day in the morning, or take 12.5 to 25mg at a time, 2 times a day in the morning and noon.				hypertension											
1270	656		ADULT			Highest studied dose	mg	80		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1100303/	Homo sapiens												38	8						22						p.339
1271	658		ADULT			Recommended	mg	10		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31571834/	Homo sapiens						29.8							24		0.5mg			Flupentixol							p.3336
1272	670		ADULT			Highest studied dose	mg	1200		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6456646/	Homo sapiens							total daily dose						5									2	week		143-8
1273	671		ADULT			Highest studied dose	mg/kg	0.5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33037726/	Homo sapiens						64							110	atrial fibrillation											p.19
1274	673		ADULT			Abused dose	mg	50		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2595393/	Homo sapiens						27							1												p.72
1275	678		ADULT			Studied dose	mg	30		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3287737/	Homo sapiens						47	max			15-30 mg t.i.d.		68	23	Stress incontinence - female					23			6	week		p.12
1276	678		ADULT			Studied dose	mg	90		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2053226/	Homo sapiens						52						61	3	Stress incontinence - female					46						p.177
1277	679					Overdose	mg	120		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/4823333	Homo sapiens						14				60 to 120 mg of nylidrin			1		1 g			chlorothiazide	14						
1278	679						mg	6		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/663705	Homo sapiens						32							1	unstable angina pectoris					32			1	week		
1279	679						mg/min	50		multiple					pregnant	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1945214	Homo sapiens							starting			initiated with the dose of 50 micrograms/minute and continued at the dose of 100-150 micrograms/minute for a maximum of 3 days.			30									3	day		
1280	685		ADULT			Studied dose	mg	400		multiple			week	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/6207714/	Homo sapiens													43	prostatic cancer								12	week		
1281	689						mg/kg	200		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/11785507	Homo sapiens										Initially, 200 mg/kg of paraldehyde are used, but up to 400 mg/kg can be administered. This is usually a single infusion ; however, if seizures continue, it may be repeated at 12 hourly intervals			20												
1282	689						mL	10		multiple			30 min	1	unhealthy	rectal			https://pubmed.ncbi.nlm.nih.gov/1090222	Homo sapiens										The treatment of delirium tremens was divided into two phases. Induction of a calm state was accomplished by rapid drug administration under constant observation by a physician until the patient was quiet but awake. Half of the patients were treated with paraldehyde, 10 ml rectally in 20 ml cottonseed oil, given every 30 minutes. Maintenance of a calm state after its induction was accomplished in paraldehyde-treated patients with rectal doses of 5 or 10 ml every 2 to 4 hours as needed.			17	Severe Delirium Tremens											
1283	689						mL	120		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13487613	Homo sapiens						43							3						43			2	day		
1284	689						mL	120		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/7105866	Homo sapiens													1												
1285	689						mL	360		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13487613	Homo sapiens						38													38			5	day		
1286	689						mL	5 |5 | 3| 5| 5		multiple			15 min	1	unhealthy	intramuscular|intramuscular|intravenous|intravenous|intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7105866	Homo sapiens						65	complex			Time of Day Dose of Paraldehyde Route: 0845: 5ml IM; 0900: 5ml IM; 1000: 3 ml IV; 1300: 5ml IV; 1800: 5ml IV			1						65						
1287	692		ADULT			Studied dose	mL/kg	0.05		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9609895/	Homo sapiens						56.3						80	149	liver disease					22						p.721
1288	694		ADULT			Highest studied dose	mg	20		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4359662/	Homo sapiens													2									3	week		p.2
1289	695		ADULT			Highest studied dose	mg	200		multiple			day	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6083365/	Homo sapiens						28	max			Initial dosage was 200 mg daily. This was subsequently increased by 200 mg every four days until a dosage of 200 mg three times daily was reached. Later this was increased to 200 mg four or five times\ndaily, according to each patient’s response.		64	44	epilepsy					10			15	month		p.582
1290	695		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6819339/	Homo sapiens												65	48	epilepsy					16			6	month		p.1116
1291	699		ADULT			Recommended	mg	150		single					unhealthy	oral	M+F		https://www.mims.com/hongkong/drug/info/pilsicainide%20hydrochloride?mtype=generic	Homo sapiens														heart rhythm disease											
1292	699		ADULT			Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10966544/	Homo sapiens						60.5							49	atrial fibrillation											p.5
1293	699		ADULT			Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16723783/	Homo sapiens						58							58	atrial fibrillation								2	week		p.659
1294	704		ADULT			Recommended	mg	225		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34239	Homo sapiens														gout											
1295	704		ADULT			Studied dose	%	0.1		multiple			day	4	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/23023407/	Homo sapiens													75	allergic conjunctivitis								4	week		p.581
1296	704		ADULT			Studied dose	%	0.1		multiple			day	4	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/8172273/	Homo sapiens						51.2							74	conjunctivitis								15	day		p.655
1297	706		ADULT			Studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7972348/	Homo sapiens						68.1							96	dementia								12	week		p.164
1298	707		ADULT			Recommended	g	16		steady			6 hours	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/065386lbl.pdf	Homo sapiens							total daily dose			Initial presumptive treatment of patients with nosocomial pneumonia should start with Piperacillin and Tazobactam for Injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18 g (16 g piperacillin/ 2 g tazobactam).				pneumonia	Initial presumptive treatment of patients with nosocomial pneumonia should start with Piperacillin and Tazobactam for Injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18 g (16 g piperacillin/ 2 g tazobactam).			TAZOBACTAM							
1299	707		CHILD			Studied dose	mg/kg	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7695268/	Homo sapiens						3.4						12	24	bacterial infectious disease	drug was infused intravenously over 30 min, 100 and 12.5 mg of piperacillin and\ntazobactam (high dose) per kg of body weight			Tazobactam	0.1						p.2819
1300	708		ADULT			Recommended	mg	15		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10213329/	Homo sapiens						30.3							60	hypertonic bladder								14	day		p.198
1301	708		ADULT			Recommended	mg	20		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8578271/	Homo sapiens						50						77	43	Urinary Bladder Disease					27			21	day		p.290
1302	709					Highest studied dose	mg	300		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3492378/	Homo sapiens												47	50	pain disorder					22						
1303	710					Studied dose	mg	250		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21195892/	Homo sapiens												53	3	multidrug-resistant tuberculosis					37			5	day		
1304	712		UNKNOWN			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34095	Homo sapiens							max							asthma											
1305	713		ADULT			Highest studied dose	mg	2250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5304316/	Homo sapiens												60	15	ischemic heart disease					30			2	week		
1306	717					Studied dose	mg	350		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/5687044	Homo sapiens												56	45	Urethritis					19			4	day		p.229
1307	717					Studied dose	mg	350		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/4192321	Homo sapiens												41	48	Gonorrhoea	500 mg, single			Tetracycline phosphate, p.o.	19						p.154
1308	723					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33534617/	Homo sapiens						42.4							114	community-acquired pneumonia								10	day		
1309	723					Studied dose	mg	400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11020265/	Homo sapiens												68	19	methicillin-resistant Staphylococcus aureus					21			14	day		
1310	724		ADULT			Highest studied dose	mg	1400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8384067/	Homo sapiens						55	max			four patients received 2000-2800 mg/day as an initial dose.		76	4	ATLL					41			7	day		p.2219
1311	724		ADULT			RP2D	mg/m2	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2369134/	Homo sapiens														cancer								5	day		
1312	724		ADULT			Studied dose	mg/m2	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2369134/	Homo sapiens													2	cancer								15	day		
1313	728		ADULT			Studied dose	g	5		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6252159/	Homo sapiens						62.2						88	133	urinary tract infection					18			5	day		p.217
1314	730		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28755683/	Homo sapiens						37.2						57	26	multiple sclerosis					18			2	month		p.5
1315	731						g	4		multiple			day	6	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20248057/	Homo sapiens						32				6 g. immediately and 4 g. four-hourly.			1	diarrhea								3	day		
1316	731						g/kg	0.05		multiple			day	6	unhealthy	oral	F		https://jamanetwork.com/journals/jama/article-abstract/257467	Homo sapiens						45				The first dose was calculated at the rate of 0.1 g per kilogram of body weight; succeeding doses on the basis of 0.05 g per kilogram of body weight were given every four hours.			1	diarrhea								9	day		
1317	732					Highest studied dose	g	3		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5939973	Homo sapiens												15	6	Rheumatic fever					5			2	week		p.507
1318	732					Studied dose	g	0.5		multiple			day	1	unhealthy	oral	F		https://www.nejm.org/doi/full/10.1056/NEJM196101052640111	Homo sapiens						89							1	Urinary-tract infection								19	day		p.40
1319	732					Studied dose	g	1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13526923	Homo sapiens						68							1	Urinary-tract infection								37	day		p.688
1320	734		ADULT			Recommended	g	1		multiple			day	1	unhealthy	oral	M+F		http://www.rusmedserv.com/lekarstva/komponent/sulfamonomethoxine.html	Homo sapiens							starting							Streptococcus pneumonia											
1321	738		ADULT			Studied dose	mg	426		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7097505/	Homo sapiens												35	6						27						p.566
1322	740					Highest studied dose	mg	1		multiple			day	4	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13640910	Homo sapiens													6	Essential hypertension								3	month		p.152/1612
1323	743					Highest studied dose	mg/m2	139.5		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 450 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. Uracil and tegafur in a 4:1 molar concentration ratio. The total dose was divided by three and administered three times daily at 8-hour intervals.			6		310.5 mg/m2			uracil				28	day		
1324	743					Highest studied dose	mg/m2	279		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 900 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. A 5-day schedule repeated every 21 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			5		621 mg/m2			uracil				5	day		
1325	743					RP2D	mg/m2	111.6		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9348565 | https://pubmed.ncbi.nlm.nih.gov/8949982	Homo sapiens						54				tegafur and uracil (UFT): 360 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			6	carcinoma	248.4 mg/m2			uracil	54			28	day		
1326	743					RP2D	mg/m2	248		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9348565 | https://pubmed.ncbi.nlm.nih.gov/8949982	Homo sapiens						59				tegafur and uracil (UFT): 800 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. A 5-day schedule repeated every 21 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			8	carcinoma	552 mg/m2			uracil	59			5	day		
1327	743						mg/m2	124		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 400 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			8		276 mg/m2			uracil				28	day		
1328	744		ADULT			Highest studied dose	mg	90		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20015104/	Homo sapiens						22.9							31									5	day		648-57
1329	745		ADULT			Highest studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16001233/	Homo sapiens						51							65	insulin resistance								86	day		p.1722
1330	749		ADULT			Studied dose	mg	18		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10215017/	Homo sapiens							max			9 to 18 mg		49	10	schizophrenia					15			14	day		
1331	750		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		http://www.obatinfo.com/2010/01/nonflamin.html	Homo sapiens							max							pain disorder											
1332	751		ADULT			Highest studied dose	ug/kg/min	15		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8163718/	Homo sapiens						27.4				1-hour infusion		38	5	congestive heart failure					20						p.181
1333	753		ADULT			Overdose	mg	25		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16436902/	Homo sapiens						21				3 weeks with a 7-day pause			1									2	cycle		
1334	754		UNKNOWN			Recommended	mg	40		multiple			day	3	unhealthy	oral	M+F		https://www.ohara-ch.co.jp/appendix/pdf/inc03/supacal40T-SIE.pdf	Homo sapiens														pancreatitis											
1335	756		ADULT			Recommended	mg	200		multiple			day	3	pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/21182931/	Homo sapiens										the estimated daily dose was 700 mg			283									3	month		
1336	756					Recommended	mg	200		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10515105/	Homo sapiens						57							1	hemorrhoids								10	day		
1337	756					Recommended	mg	271.2		multiple			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/19489977/	Homo sapiens						25				Borraza-G Ointment: Tribenoside271.2mg, Lidocaine54.2mg			1	haemorrhoids	54.2 mg			Lidocaine				2	week		
1338	757		adult			Highest studied dose	mg/m2	5.4		multiple			month	5	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/17325846/	Homo sapiens													16	lymphoproliferative disorders or multiple myeloma								1	cycle		
1339	757		adult			MTD	mg/m2	1.88		multiple			month	4	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/18245131/	Homo sapiens													4	advanced solid malignancies								3	cycle		
1340	757		adult			Studied dose	mg/m2	2.25		multiple			month	4	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/18245131/	Homo sapiens													5	advanced solid malignancies								2	cycle		
1341	757		adult			Studied dose	mg/m2	3		multiple			month	4	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/18245131/	Homo sapiens													5	advanced solid malignancies								2	cycle		
1342	757		adult			Studied dose	mg/m2	4.3		multiple			month	5	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/17325846/	Homo sapiens													18	lymphoproliferative disorders or multiple myeloma								1	cycle		
1343	757					Highest studied dose	mg/m2	14		steady			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/17146106/	Homo sapiens													2	refractory acute myeloid leukemia								5	day		
1344	757					MTD	mg/m2	12		steady			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/17146106/	Homo sapiens													15	refractory acute myeloid leukemia								5	day		
1345	757					MTD	mg/m2	12.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12011137/	Homo sapiens										30-Minute Infusion Every 21 Days			3	cancer								3	cycle		
1346	762		ADULT			Studied dose	mg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1794835/	Homo sapiens						24.1							12												p.806
1347	763					Recommended	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8573683/	Homo sapiens						39						65	45	knee effusion					18			4	day		
1348	765					Highest studied dose	g	14		multiple			4 min	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13510792	Homo sapiens						58	total			Within four days the total dose of bemegride was 14g. and of amiphenazole 4.2g. Cycles of 50 mg bemegride and 15 mg amiphenazole every 3-5 min were repeated every day (total 1.1g bemegride on day 1, 5g on day 2, 7.9g on day 3)			1	Barbiturate poisoning	4.2 g, total for 4 days			amiphenazole, i.v				3	day		p.758
1349	767		ADULT			Highest studied dose	mg	225		multiple			month	2	unhealthy	intramuscular	M+F		https://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/205735/1/ngh033004_831.pdf	Homo sapiens							total			Intramuscular administration dosage of the SC-7525 was 2 cc (50 mg) during a week before and 7 cc (175 mg) during 3 weeks after the operation; 225 mg for 4 weeks in total.		74	8	gastrointestinal disease					34			4	week		831-839
1350	770		ADULT			Recommended	mg	90		multiple			day	2	unhealthy	oral	unknown		https://books.google.ru/books?id=PghVgVDfF7UC&pg=PA316&lpg=PA316&dq=Buterazine+use&source=bl&ots=ecek3NMJTc&sig=PL9iCBDDaQG9C7pFXOO17hdGoZY&hl=en&sa=X&ved=0ahUKEwjt3dXMwonPAhXNOSwKHQUIBr0Q6AEIKTAD#v=onepage&q=Buterazine%20use&f=false Retrieved from Antihypertensive Drugs Today edited by Hideya Saito, Masaru Minami, p.316	Homo sapiens							max							essential hypertension											p.316
1351	772					Studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2497487/	Homo sapiens												32	8						19						
1352	772					Studied dose	mg	400		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7604145/	Homo sapiens												14	20	mental retardation					8			6	month		
1353	773		ADULT			Recommended	mg	10		multiple			day	3	unhealthy	oral	unknown		https://quest3plus.bpfk.gov.my/front-end/attachment/815/pharma/210295/V_36481_20191101_110605_D4.pdf	Homo sapiens														pain disorder											
1354	773		ADULT			Studied dose	mg	4		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3478945/	Homo sapiens													143	aural fullness											
1355	777		ADULT			Studied dose	g	1		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27394175/	Homo sapiens												24	12						19			5	day		
1356	778		ADULT			Highest studied dose	mg	2000		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7876395/	Homo sapiens						33.2				A multiple-dose study was performed with an intravenous infusion of 2,000 mg at a constant rate for 60 minutes every 12 hours		47	6						25			5	day		p.1058
1357	781		ADULT			Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5934250/	Homo sapiens												68	15	diabetes mellitus					28			6	week		p.105
1358	782		ADULT			Studied dose	mg/kg	0.26		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21093730/	Homo sapiens							mean						23	epilepsy								2	year		
1359	782		ADULT			Studied dose	mg/kg	0.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21093730/	Homo sapiens							mean						23	epilepsy								1	month		
1360	785		ADULT			Recommended	%	0.3		multiple			day	1	unhealthy	topical	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=32407	Homo sapiens										In general, apply an adequate amount of the medicine to the affected area, once to several times a day.				skin inflammation											
1361	789					Highest studied dose	mg	400		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1545477/	Homo sapiens													9	pain disorder								2	day		
1362	793					Recommended|Highest studied dose	mg	1200		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6120671	Homo sapiens						53							1	Cirrhosis											
1363	795					Studied dose	mg	2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2633923	Homo sapiens						24							8												
1364	797		ADULT			Recommended	mg	1		multiple			day	5	pregnant	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/17320086/	Homo sapiens						34.3							439									1	day		35-9
1365	798		ADULT			Highest studied dose	mg	900		multiple			week	3	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/4097364/	Homo sapiens							total weekly dose					84	25	prostatic hypertrophy					56			12	month		523-30
1366	798		ADULT			Studied dose	mg	300		multiple			week	1	unhealthy	intramuscular	M		https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/121731	Homo sapiens							total weekly dose						50	prostatic hypertrophy								10	week		799-802
1367	799		ADULT			MTD	mg/m2	2.4		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens						61				It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks			11	cancer								3	week		p.377
1368	799		ADULT			Studied dose	mg/m2	3.2		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19118068	Homo sapiens						61				It was taken orally in the morning, either 1 h before or after eating, once every 7 days for 3 consecutive weeks			7	cancer								3	week		p.377
1369	800		adult			Recommended	mg/m2	25		multiple			day	2	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/teysuno-epar-public-assessment-report_en.pdf	Homo sapiens										Teysuno is an oral, fixed dose combination drug of tegafur, gimeracil and oteracil			11	advanced gastric cancer				tegafur						oteracil	p.53
1370	800		adult			Recommended	mg/m2	25		multiple			day	2	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/teysuno-epar-public-assessment-report_en.pdf	Homo sapiens										Teysuno is an oral, fixed dose combination drug of tegafur, gimeracil and oteracil			700	advanced gastric cancer				tegafur						oteracil	p.53
1371	800		adult				mg/m2	40		steady			day	2	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/teysuno-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/22162925	Homo sapiens														advanced gastric cancer				tegafur				6	week	oteracil	p. 61
1372	800					Studied dose	mg	80		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/30830659	Homo sapiens						65	typical						358	cell lung cancer				tegafur	65			6	week	oteracil	
1373	801		ADULT			Studied dose	mg	10		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12519461/	Homo sapiens												25	6						20			7	day		p.98
1374	803		ADULT			Recommended	mg	500		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14236022/	Homo sapiens													135												
1375	804		ADULT			Recommended	mL	102.5		single					unknown	intravascular	M+F		https://pubmed.ncbi.nlm.nih.gov/12942302/	Homo sapiens						57.4	mean			patients with adverse events			61754									1	day		2006-11
1376	805		ADULT			Studied dose	mg	40		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6749701/	Homo sapiens													60	cough								7	day		
1377	805					Overdose	mg	750		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/518294/	Homo sapiens						17							1												
1378	808		ADULT			Highest studied dose	mg	1000		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3932547/	Homo sapiens							total daily dose					80	97	bacterial pneumonia					19			14	day		605-38
1379	808		ADULT			Highest studied dose	mg	3000		single					unhealthy	oral	M		https://www.jstage.jst.go.jp/article/chemotherapy1953/32/Supplement8/32_Supplement8_542/_article/-char/ja/	Homo sapiens												32	2	gonorrhea					24			1	day		542-568
1380	809		ADULT			Highest studied dose	mg	1000		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens						36.5				30 min iv infusion		45	6						25						p.997, 991
1381	809		ADULT			Studied dose	mg	500		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8089072/	Homo sapiens						36.5						45	6						25			4.5	day		p.997, 991
1382	811		ADULT			Recommended	mg	1		multiple			day	7	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6147285/	Homo sapiens						60.5						91	48	sleep disorder					25						p.236
1383	811		ADULT			Recommended	mg	2		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6132929/	Homo sapiens						39	max					60	60	sleep disorder					21						p.35
1384	812		ADULT			Studied dose	mg	8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1589555/	Homo sapiens													6									1	day		238-62
1385	813		ADULT			Accidental dose	mg/kg	37.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8462375/	Homo sapiens						30				The calculated dose of T61 ingested by the patient was 0.75 ml/kg body wt			1					embutramide				1	day	tetracaine hydrochloride	752-6
1386	816		ADULT			Studied dose	mg	150		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1900485/	Homo sapiens													52	infertility								12	month		
1387	816		ADULT			Studied dose	mg	450		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6431212/	Homo sapiens							max			300 - 450 mg/day		53	52	depression					26			6	week		
1388	817		ADULT			Highest studied dose	%	100		single					healthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/7105702/	Homo sapiens										patch test			22									1	day		285-6
1389	822		CHILD			Overdose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6481543/	Homo sapiens						1							1												p.645
1390	822		CHILD|ADOLESCENT|ADULT			Recommended	drop	15		multiple			day	2	unhealthy	oral	M+F		https://pdf.hres.ca/dpd_pm/00045654.PDF	Homo sapiens										Drops of normethadone HCl 10 mg/mL (1%) and p-hydroxyephedrine HCl 20 mg/mL				respiratory system disease	20 mg/mL			p-hydroxyephedrine							p.4,5
1391	824		ADULT			Highest studied dose	mg	6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9147023/	Homo sapiens						34.7						47	6						24						p.546
1392	826		ADULT			Studied dose	ug	5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1940194/	Homo sapiens						23.7							7												S32
1393	827		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2899329/	Homo sapiens						57.9							20	endogenous depression											p.88, 89
1394	828		ADULT			Recommended	g	0.5		multiple			day	2	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9695479/	Homo sapiens						84							1	non-hod	0.5 g, i.v, b.i.d			Betamipron				1	day		p.651, 652
1395	828		ADULT			Recommended	g	1		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12111568/	Homo sapiens						76	max						43	pneumonia	1g, i.v., b.i.d			Betamipron							p.153
1396	832		ADULT			Studied dose	mg	19.65		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17154678/	Homo sapiens						45.7				Pholcodine (15mL at 0.131% corresponding to 19.65mg; Biocalyptol® 1) three times daily for 72 hours.			62	respiratory airway obstruction								72	hour		p.2
1397	832		ADULT			Studied dose	mg	20		multiple			8 hours	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3190994/	Homo sapiens						29.3							6									10	day		p.451
1398	832		ADULT			Studied dose	mL	10		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17983379/	Homo sapiens						45.6							11									7	day		p.1446
1399	835		CHILD			Highest studied dose	mg/kg	600		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/2574565/	Homo sapiens						11							1	non-Hodgkin lymphoma								1	day		3809-11
1400	836		ADULT			Highest studied dose	mg	450		single					healthy	oral	M+F		https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?format=pdf&lang=en	Homo sapiens						23						27	10						21						p.5
1401	836		ADULT			Studied dose	mg	150		multiple			day	2	healthy	oral	M+F		https://www.scielo.br/j/bjps/a/73GTSDjmy8PCtSrgBjhmQVk/?format=pdf&lang=en	Homo sapiens						26						28	10						22			5	day		p.5
1402	836		ADULT			Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1331217/	Homo sapiens													14	asthma								6	day		p.4
1403	838		ADULT			Highest studied dose	mg/m2	500		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24045182	Homo sapiens						53				30-minute intravenous infusion; 500 mg/m(2) twice weekly for 2 weeks on/1 week off. Patients were on study for a median of 53 days.			6	sarcoma								2	week		p.6
1404	838		ADULT			MTD	mg/m2	400		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21762967	Homo sapiens						66				IPI-504 was administered intravenously at 400 mg/m2 on days 1, 4, 8, and 11 of a 21-day cycle. The median number of study drug cycles started was 2 (range: 1 to 34) with a median number of 5 study drug doses received (range: 1 to 129)			19	prostate cancer								2	cycle		p.4
1405	838		ADULT			MTD	mg/m2	400		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24045182	Homo sapiens						53				30-minute intravenous infusion; 400 mg/m(2) twice weekly for 2 weeks on/1 week off. Patients were on study for a median of 53 days.			6	sarcoma								2	week		p.6, 7
1406	839		ADULT			Studied dose	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8031062/	Homo sapiens													15	chronic obstructive pulmonary disease					40			10	day		p.873
1407	841		ADULT			Recommended	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7824756/	Homo sapiens						43.8	max|total daily dose						19	schizophrenia								12	week		p.341
1408	841		ADULT			Recommended	mg	6		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=36605	Homo sapiens							total daily dose							depressive neurosis											
1409	843		ADULT			Studied dose	g	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6417824/	Homo sapiens													16	ischemic heart disease											
1410	846					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16622748/	Homo sapiens						31.5							19	familial adenomatous polyposis								26	week		
1411	849		ADULT			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3527514/ | https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.1988.tb00515.x	Homo sapiens												71	6	hypertension					21			4	day		352-8
1412	850		ADULT			Recommended	%	5		multiple					unhealthy	topical	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=39561	Homo sapiens										In general, apply an appropriate amount several times a day to the affected area.				dermatitis											
1413	852					Studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7526678/	Homo sapiens							unknown			average daily dose		73	22	dilated cardiomyopathy					32			31	day		
1414	852					Studied dose	mg	60		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8739027/	Homo sapiens														congestive heart failure								16	week		
1415	859		CHILD			Recommended	%	0.7		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/22897595/	Homo sapiens						6.7							13	molluscum contagiosum								8	week		p.6
1416	861		ADULT			Highest studied dose	mg	120		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15159319/	Homo sapiens						30.2							5												p.854
1417	861		ADULT			Studied dose	mg	30		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18689558/	Homo sapiens						51.2							21									8	week		p.4
1418	862					Highest studied dose	mg/kg	200		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8641905/	Homo sapiens												64	20	cerebral glioma					21			4	week		
1419	862					Highest studied dose	mg/kg	63		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228990/	Homo sapiens						61				2 is the median number of 4-week cycles every other week schedule			6	solid tumors	30 mg/m(2); IV: for 3 of every 4			docetaxel				7	day		
1420	862					Highest studied dose	mg/kg	88		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228990/	Homo sapiens						61				2 of 4-week cycles every other week schedule			1	solid tumors	30 mg/m(2); IV: for 3 of every 4			docetaxel				7	day		
1421	862					Highest studied dose	mg/kg	88		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228990/	Homo sapiens						61				5 is the Median number of 4-week cycles every other week schedule			6	solid tumors	30 mg/m(2); IV: for 3 of every 4			docetaxel				7	day		
1422	862					Studied dose	mg/kg	63		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228990/	Homo sapiens						61							6	solid tumors	30 mg/m(2); IV: for 3 of every 4			docetaxel				21	day		
1423	870					Studied dose	%	0.1		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/1839725/	Homo sapiens						45				patch test; patient used the pesticides over the last year			1						45			1	day		
1424	870					Studied dose	%	0.1		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9923784/	Homo sapiens						45				patch test			1						45			1	day		
1425	870					Studied dose	%	0.5		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/7924295/	Homo sapiens						26				patch test			1						26			1	day		
1426	870					Studied dose	%	0.5		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/8365173/	Homo sapiens						21				patch test			1						21			1	day		
1427	870					Studied dose	g	3.75		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14514005/	Homo sapiens						17							1						17			1	day		
1428	881					Studied dose	%	10		single			day	1	healthy	topical	M		https://link.springer.com/article/10.2165/00128415-199505760-00023	Homo sapiens						47				patch test 0.1-10%; exact ammount of Glycol salicylate in applied Dolo-Arthrosenex Gel is unknown			1						47			1	day		
1429	881					Studied dose	%	5		multiple					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/21569750/	Homo sapiens						64				patch test 1-5%;			1	cervical pain					64			2	week		
1430	881					Studied dose	mg	12.5		multiple			day	5	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/22110924/	Homo sapiens						30.8							228	ankle joint distortion	41.5 mg; 5/day; during 10 days			arnica tincture				10	day		
1431	881					Studied dose	mg	12.5		multiple			day	5	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/22110924/	Homo sapiens						30.8							228	ankle joint distortion								10	day		
1432	884		ADULT			Highest studied dose	ug/m2	600		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11422263/	Homo sapiens													86									1	day		21-5
1433	884		ADULT			Studied dose	%	2		single					healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/3743050/	Homo sapiens						48				patch test			1									1	day		322-4
1434	885					Studied dose	g	0.03		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14424128/	Homo sapiens						33							1	Asthma					33			3	year		
1435	885					Studied dose	g	0.03		multiple			day	6	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14424128/	Homo sapiens						48				up to 6 per day during 14 years before goitre appearance			1	Asthma					48			14	year		
1436	891					Recommended	mg	2326		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20791420/	Homo sapiens							mean			The mean of the average dose used in the three-month period of assessment was 2,326 mg in a three- or four-times-daily schedule. (S.E. 308.2 mg.). Over the three months there was an average increase of 244.8 mg. (S.E. 192.3 mg.) in the dose of methyldopa required to control the blood pressure.		68	30	hypertension					36			3	month		
1437	891					Recommended	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14269222/	Homo sapiens										Treatment was begun with alpha methyl dopa in doses of 250 mg every 6 hr. If, after 48 hr., there was no response, the dose was stepped up (every day in the in-patients and every 4th day in the out-patients). The average daily dose was 3.0 gm per day, but doses as high as 6.0 gm daily were given to two patients.			39	hypertension											
1438	891						g	2.5		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7175995/	Homo sapiens						19				overdose, a case report			1												
1439	892		ADULT			Recommended	%	0.5		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/8335734/	Homo sapiens													41									1	day		179
1440	893		ADULT			Highest studied dose	g	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28641925	Homo sapiens						42.7							6	myopathy											p.6, 20
1441	894		ADULT			Higher than recommended	mg	700		multiple			day	3	unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/15187789/	Homo sapiens						51							1									1	day		95-100
1442	895		ADOLESCENT|ADULT			Studied dose	%	1		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/3233958/|https://pubmed.ncbi.nlm.nih.gov/5075717/	Homo sapiens													140	dermatitis								1	day		372-5|12-6
1443	902					Overdose	mg/kg	30		multiple			day	1	unhealthy	topical			https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_015.pdf	Homo sapiens							min			treatment of ulcers with large amounts of Resorcinol for a long period of time				Skin ulcers											p.27
1444	902					Recommended	%	3		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/4380436	Homo sapiens												29	32	Acne vulgaris				Bithionol topical, 0.4%	14			1	year	Salicylic acid topical, 4.5%	p.241
1445	911									multiple					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/233882 | https://pubmed.ncbi.nlm.nih.gov/33759209	Homo sapiens						24	unknown			Dosage unknown				chronic psoriasis					24						
1446	936		ADULT			Higher than recommended	mg	100		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/32949255/	Homo sapiens						49	total daily dose						62	pain disorder	150 mg		tamsulosin	paracetamol			0.4 mg	1	day	diclofenac	2747-2752
1447	936		ADULT			Recommended	mg	20		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/16413812/	Homo sapiens						40							1	asthma								1	day		194-7
1448	936		ADULT			Recommended	mg	20		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1859001/	Homo sapiens						70							1	adenocarcinoma	150 mg		succinylcholine	fentanyl			100 mg	1	day	thiopental	97-8
1449	937		ADULT			Recommended	%	0.55		multiple			day	1	healthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/25780032/	Homo sapiens						55							1									3	week		381
1450	937		ADULT			Recommended	%	0.55		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/18811577/	Homo sapiens										instruments sterilized with ortho-phthalaldehyde		71	2	bladder carcinoma					60			1	day		2181-4
1451	946		CHILD			Highest studied dose	%	5		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/3219832/	Homo sapiens						8							1	asthma								1	day		254-9
1452	952		ADULT			Highest studied dose	mg	800		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/5462432/	Homo sapiens													5									1	day		1-25
1453	954		ADULT			Highest studied dose	%	8		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/18037214/|https://pubmed.ncbi.nlm.nih.gov/6378513/	Homo sapiens										patch test			182									48	hour		S40-8|1-10
1454	954		ADULT			Highest studied dose	mL	1		multiple			day	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/14889282/	Homo sapiens						29				Jacobson's solution		46	50	salpingitis					18			18	day		379-81
1455	960		CHILD			Studied dose	mg/kg	1		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27596055/	Homo sapiens							mean			0.12-2 mg/kg		16	46	Immune thrombocytopenia								12	month		
1456	967		ADULT			Recommended	mg	1.2		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21332976/	Homo sapiens						30.3				AMC/DCBA Cool lozenge, containing the active\ningredients AMC (0.6 mg) and DCBA (1.2 mg)			77	Throat infection - tonsillitis	AMC/DCBA Cool lozenge, containing the active\ningredients AMC (0.6 mg) and DCBA (1.2 mg)			amylmetacresol							p.4, 8
1457	971		ADULT			Studied dose	%	1		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/7398276/	Homo sapiens						38							1	hemorrhoid								1	day		150-1
1458	971		ADULT			Studied dose	mg	65		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/3699401/	Homo sapiens						37				Venoplant, extracts of Aesculus Hippocastanum			1	bone disease								1	day		62-5
1459	974		ADULT			Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34560	Homo sapiens							max			1 to 8 tablets (100 to 800 mg of the active ingredient) a day, in 1 to 4 divided doses.				gastritis											
1460	982		ADULT			Recommended	mg	2		multiple			day	3	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=2387	Homo sapiens										For adults, take 0.5 g (2 mg of the active ingredient) at a time, three times daily, before meals.				gastritis											
1461	987		ADULT			Highest studied dose	%	2		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/8879928/	Homo sapiens										0.8 mg/cm2		69	19	eczema					18			2	day		414-8
1462	988		ADULT			Highest studied dose	g/m2	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens										21-day cycles		82	3	advanced cancer					40			2	cycle		
1463	988		ADULT			MTD	g/m2	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9654110/	Homo sapiens										21-day cycles		82	10	advanced cancer					40			2	cycle		
1464	990		ADULT			Highest studied dose	ppm	1000		single					healthy	topical	unknown		https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0536.1986.tb01166.x	Homo sapiens													40		1000 ppm			2-methyl-4-isothiazolin-3-one				2	day		85-90
1465	1003		ADULT			Studied dose	mg/kg	1		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/5911153/	Homo sapiens													109	renal failure											
1466	1010					Studied dose	mg	174.4		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/692943/	Homo sapiens												27	10						19						p.210
1467	1015		ADULT			Recommended	mg	50		single					unknown	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28225167/	Homo sapiens						26							1		1000 ug			Pyridoxine Hydrochloride				1	day	hydroxocobalamin acetate	e115-e116
1468	1016		ADULT			Highest studied dose	g	2		single					unhealthy	intraperineal	M		https://pubmed.ncbi.nlm.nih.gov/7394975/	Homo sapiens						52.5						74	29	prostatitis					27			1	day		542-7
1469	1016		ADULT			Studied dose	mg	631		multiple			day	2	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/12120883/	Homo sapiens						62.8	total daily dose						88	bronchitis								8	day		279-84
1470	1018					Studied dose	mg	300		multiple			day	1	unhealthy	intravenous	M+F		https://www.jstage.jst.go.jp/article/kjm1952/20/4/20_4_177/_pdf	Homo sapiens							total daily dose						42	Leukemia											p.191
1471	1021		ADULT			Highest studied dose	%	5		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/6653119/	Homo sapiens										patch test		71	2	ulcer of lower limbs					54			1	day		525-6
1472	1032		ADULT			Higher than recommended	mg	1		multiple			day	1	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/8746880/	Homo sapiens						53.2							37									4	week		p.230, 231
1473	1032		ADULT			Recommended	ug	500		multiple			day	1	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/26786399/	Homo sapiens						57.8				Ovestinon vaginal cream 0.1% (500 ug/0.5 g)			12									21	day		p.5
1474	1032		ADULT			Studied dose	mg	2		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10783346/	Homo sapiens						53.6							27									12	month		p.1030
1475	1040		ADULT			Studied dose	ug	50		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/20451215/	Homo sapiens						24.7						31							19						p.1149
1476	1040		ADULT			Studied dose	ug	50		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1911739/	Homo sapiens						26.7							15												p.93,94
1477	1042		adult			Recommended	mg	300		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022577lbl.pdf	Homo sapiens													368	HIV-1								24	week		15
1478	1042		adult			Recommended	mg	300		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022577lbl.pdf	Homo sapiens													368	HIV-1								48	week		15
1479	1042		children			Recommended	mg	300		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/14693529/	Homo sapiens													18	HIV-1								4	week		128
1480	1043		adult			Recommended	mg/m2	135		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020262s048lbl.pdf	Homo sapiens																						3	hour		
1481	1044		adult				%	2.5		multiple			day	4	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/40310_Hydrocortisone_Prntlbl.pdf	Homo sapiens										each gram contains 25 mg															
1482	1044		children				mg/kg	1		multiple			day	4	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT02044159	Homo sapiens													23	vasoactive infusion											
1483	1044					Highest studied dose	mg	200		multiple			day	4	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/32170323	Homo sapiens						56				50 mg at 09:00h, 15:00h, 21:00h, and 03:00h		64	10	primary adrenal insufficiency					40						
1484	1044					Highest studied dose	mg	200		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32170323	Homo sapiens						56				50 mg at 09:00h, 15:00h, 21:00h, and 03:00h		64	10	primary adrenal insufficiency					40						
1485	1044					Highest studied dose	mg	200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32170323	Homo sapiens						56				50mg at 09:00h, 15:00h, 21:00h, and 03:00h		64	10	primary adrenal insufficiency					40						
1486	1044					Highest studied dose	mg	200		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32170323	Homo sapiens						56				continuous intravenous infusion (CIV) of 200 mg hydrocortisone over 24 hours (diluted in 50 ml glucose 5% and administered via perfusor at a rate of 4 ml/h)		64	10	primary adrenal insufficiency					40						
1487	1045		adult			MTD	mg	40		multiple			2 weeks	1	unhealthy	intramuscular	M		https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.4726	Homo sapiens										durations varied between 6 and 8 weeks			3	prostate cancer	0.0–0.4U/ml			low-molecular-weight heparin				8	week		
1488	1045					Recommended	ug	10		multiple			day	1	unhealthy	vaginal	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208564Orig1s000MedR.pdf	Homo sapiens												75	215	dyspareunia					40			12	week		
1489	1045					Recommended	ug	4		multiple			day	1	unhealthy	vaginal	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208564Orig1s000MedR.pdf	Homo sapiens												75	191	dyspareunia					40			12	week		
1490	1045					Studied dose	mg	100		multiple			2 years	4	unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/2338934/	Homo sapiens						83							1	hysterectomy	100 mg; 4/2 years			testosterone	83			2	year		
1491	1045					Studied dose	mg	100		multiple			2 years	8	unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/2338934/	Homo sapiens						56							1	hysterectomy	100 mg; 6/2 years			testosterone	56			2	year		
1492	1045						ug	100		steady			day	1	healthy	transdermal	F		https://clinicaltrials.gov/ct2/show/NCT01308814	Homo sapiens													86									12	day		
1493	1047		adult			Recommended	mg	75		steady			day	1	unhealthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/30296416/	Homo sapiens							median						150	hypogonadism								52	week		
1494	1047		adult				mg	10.4		steady			day	1	unhealthy	topical	F		https://clinicaltrials.gov/ct2/show/NCT01573442	Homo sapiens													100	Arthralgia								6	month		
1495	1047		adult				mg	125		multiple			week	1	unhealthy	intramuscular	M		https://clinicaltrials.gov/ct2/show/NCT00475501	Homo sapiens													14	Muscle Atrophy								52	week		
1496	1047		adult				ug	300		steady			day	1	unhealthy	transdermal	F		https://clinicaltrials.gov/ct2/show/NCT00957034	Homo sapiens													4	Heart Failure								180	day		
1497	1047		adult				ug	300		steady			day	1	unhealthy	transdermal	F		https://clinicaltrials.gov/ct2/show/NCT01121211	Homo sapiens													43	Anorexia Nervosa								24	week		
1498	1047		adult				ug	450		steady			day	1	unhealthy	transdermal	F		https://clinicaltrials.gov/ct2/show/NCT00957034	Homo sapiens													7	Heart Failure								180	day		
1499	1047					Recommended	mg	100		steady			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/20592293/	Homo sapiens						74							106	with limitations in mobility								6	month		
1500	1049					Highest studied dose	mg	250		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/11760	Homo sapiens						44							25	Schizophrenia								6	month		p.1438
1501	1049					Recommended	mg	100		single					unhealthy	intramuscular|subcutaneous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1967dc24-f2a5-4095-baa9-a9d1c5410311&type=display	Homo sapiens										For most patients, a dose of 12.5 to 25 mg (0.5 to 1 mL) may be given to initiate therapy. The onset of action generally appears between 24 and 72 hours after injection and the effects of the drug on psychotic symptoms becomes significant within 48 to 96 hours. Subsequent injections and the dosage interval are determined in accordance with the patient’s response. When administered as maintenance therapy, a single injection may be effective in controlling schizophrenic symptoms up to four weeks or longer. The response to a single dose has been found to last as long as six weeks in a few patients on maintenance therapy. Dosage should not exceed 100 mg. If doses greater than 50 mg are deemed necessary, the next dose and succeeding doses should be increased cautiously in increments of 12.5 mg.				Schizophrenia											
1502	1049					Recommended	mg	21		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/14751428	Homo sapiens							max						30	Schizophrenia								22	week		p.315
1503	1050		adult			Highest studied dose	mg	120		multiple			week	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/011757s119lbl.pdf	Homo sapiens																						4	week		
1504	1050					Highest studied dose	mg	1250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30351511	Homo sapiens													24	multiple sclerosis relapse								3	day		
1505	1050					Highest studied dose	mg/kg	1000		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8107739	Homo sapiens												15	26	sickle cell disease					0			30	min		
1506	1051		adult			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	Homo sapiens																									
1507	1051		adult			Recommended	mg	2		multiple			day	4	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/015923s093s098,018701s071s076lbl.pdf	Homo sapiens														dementia-related psychosis								10	week		
1508	1051		adult			Recommended	mg	5		multiple			day	3	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c559b0b0-4087-d12a-e718-c18ccb6811e6	Homo sapiens														dementia-related psychosis								10	week		
1509	1051		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00129220	Homo sapiens							max			2.5 to 10 mg per day for 6 weeks			20	Bipolar I Disorder								6	week		
1510	1051					Overdose	mg	0.9		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/28128816	Homo sapiens						11				0.7-0.9 mg of haloperidol (0.35-0.45 ml / 7-9 drops)			1						11						
1511	1051					Overdose	mg	300		single					pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/11770584	Homo sapiens						34				30 10-mg haloperidol pills			1						34						
1512	1051						mg	10		steady			day	2	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT01211522	Homo sapiens													192	Delirium								14	day		
1513	1051						mg	5		multiple			day	2	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/7891421	Homo sapiens						56		5 mg i.m, twice daily for one week.					1		150 mg p.o per day			amoxapine	56			1	week	biperiden	
1514	1052		adult				mg	20		steady			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02932904	Homo sapiens													84									5	week		
1515	1052		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01354314	Homo sapiens													11	HIV Associated Neurocognitive Disorder								24	week		
1516	1052		adult				mg	60		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00246441	Homo sapiens							max|total daily dose			dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day			20	Comorbid Social Anxiety Disorder and Alcoholism								16	week		
1517	1053					Highest studied dose	mg	960		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2529964	Homo sapiens												67	11	Huntington's disease					19			8	week		
1518	1053					Overdose	mg	270		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/2018593	Homo sapiens						3							1						3						
1519	1053					Overdose	mg	900		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/31033494	Homo sapiens						27				4 bottles (150 mL each) of DXM			1						27						
1520	1053					Recommended	mg	120		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26294136	Homo sapiens						26.5							40						26.5						
1521	1053						mg	50		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8741125	Homo sapiens												52	16	chronic intractable partial onset seizures					19			8	week		
1522	1055		adult			Overdose	g	2		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/008762s065lbl.pdf	Homo sapiens										lethal dose in adults is estimated to be 2 to 5 grams.															
1523	1055		adult				mg/kg	10		single					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010151s047s048lbl.pdf	Homo sapiens							starting			loading dose is 10 to 15 mg/kg at a rate not exceeding 50 mg/min															
1524	1055		adult				mg/kg	10		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010151s047s048lbl.pdf	Homo sapiens							starting			loading dose is 10 to 15 mg/kg at a rate not exceeding 50 mg/min															
1525	1055					Highest studied dose	mg	600		single					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/040759lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/22454904	Homo sapiens						31				six 100 mg tablets of phenytoin			15	epilepsy					31						
1526	1055					Overdose	g	20		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/26312007/	Homo sapiens						41				200 tablets of phenytoin 100 mg (20 g)			1		500 mg			glibenclamide	41						
1527	1055					Overdose	g	28.6		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30461233	Homo sapiens						42							1		2,000 mg daily			levetiracetam	42						
1528	1055					Overdose	g	5		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24307853/	Homo sapiens						49				50 phenytoin pills			1						49						
1529	1055					Overdose	mg/kg	60		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27756964/	Homo sapiens						7	total			injectable dose twice with a cumulative dose of 60 mg/kg over a short span of 12 h			1						7						
1530	1056		adult			Overdose	mg	1565		single					unknown	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/7258388/	Homo sapiens							mean			inhalation powder			10												
1531	1056		adult			Recommended	mg	10		multiple			day	1	unhealthy	respiratory	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022549s000lbl.pdf	Homo sapiens										inhalation powder			259	agitation associated with schizophrenia or bipolar I disorder								4	week		
1532	1056		adult				mg	1.25		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00489476	Homo sapiens													43	Migraine											
1533	1056		adult				mg	10		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00628589	Homo sapiens										Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours			113	Schizophrenia											
1534	1056		adult				mg	2.5		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00489476	Homo sapiens													43	Migraine											
1535	1056		adult				mg	5		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00489476	Homo sapiens													43	Migraine											
1536	1056		adult				mg	5		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00628589	Homo sapiens										Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours			116	Schizophrenia											
1537	1057					Studied dose	mg	15		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22154396	Homo sapiens												41.9		Endometriosis					10.2			12	month		
1538	1057						uCi	20		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/484634	Homo sapiens												35	6						25						
1539	1058		adult				ug	1		single					healthy	subcutaneous	M+F		https://clinicaltrials.gov/ct2/show/NCT02770521	Homo sapiens													8												
1540	1058		adult				ug	18		multiple			day	3	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02769624	Homo sapiens										A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.			14	Congenital Heart Disease								1	day		
1541	1058					Highest studied dose	ug	150		single					healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/33282202/	Homo sapiens						30.3							43						30.3						
1542	1058					Overdose	mg	100		single					unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/23662045/	Homo sapiens						58	min						1	CREST syndrome, Raynaud's syndrome, esophageal motility impairment, and severe pulmonary hypertension					58						
1543	1058					Overdose	mg	20		steady			day	3	unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/19285625/	Homo sapiens						10		40 mg					1	pulmonary hypertension	500 mg		coumadin	chlorothiazide	10		4 mg	1	day	lasix	
1544	1058					Overdose	mg	7.5		single					unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/29674328/	Homo sapiens						29							1	group 1 pulmonary arterial hypertension					29						
1545	1058					Recommended	ug	36		steady			day	4	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/22917554/	Homo sapiens							max			18 to 36 mcg		19.2	29	pulmonary hypertension					7.1			6	week		
1546	1060		ADULT			MTD	mg	6		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/921062/	Homo sapiens										After 110 min, the patients were given on both days 2 inhalations of salbutamol (0.2 mg; 30 min later, 0.4 mg)		64	7	asthma					28			2	day		861-9
1547	1060		ADULT			Studied dose	ug	180		multiple			day	4	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205636Orig1s000MedR.pdf	Homo sapiens						37							168	asthma								40	week		87
1548	1060		CHILD			Overdose	mg/kg	1.9		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15232249/	Homo sapiens						3							1									1	day		464-5
1549	1061					Highest studied dose	mg/m2	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8021737	Homo sapiens										Median: 2 cycles		17	8	Cancer					1.1			21	day		p.1455
1550	1061					MTD	mg/m2	175		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7799021	Homo sapiens										Administered daily for 5 consecutive days. The treatment was repeated every 3 weeks. 23 cycles. 50 mg/m2 of etoposide equivalent, corresponds to 57 mg/m2 of etoposide phosphate. MTD is in etoposide equivalents.		72	7	Cancer					39			5	day		p.203
1551	1061					MTD	mg/m2	175		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7799021	Homo sapiens										Administered daily for 5 consecutive days. The treatment was repeated every 3 weeks. 23 cycles. MTD is in etoposide equivalents.		72	7	Cancer					39			5	day		p.203
1552	1061					MTD	mg/m2	20		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8021737	Homo sapiens										Median: 2 cycles		17	7	Cancer					1.1			21	day		p.1455
1553	1061					MTD	mg/m2	220		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7799021	Homo sapiens										Administered daily for 5 consecutive days. The treatment was repeated every 3 weeks. 26 cycles. MTD is in etoposide equivalents.		72	8	Cancer					39			5	day		p.203
1554	1061					Recommended	mg/m2	100		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020457s013lbl.pdf	Homo sapiens							max			The usual dose ranges from 50 to 100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5.				Testicular cancer											p.1
1555	1061					Recommended	mg/m2	60		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9469322	Homo sapiens							max			The starting dose was 50 mg/m2/d (30 mg/m2/d for prior radiotherapy) for 21 days, every 28 days. A dose escalation to a maximum dose of 60 mg/m2/d was prescribed.		83	97	Ovarian carcinoma					39			21	day		p.407
1556	1062		adult			Highest studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6329583/	Homo sapiens										20 to 100 mg			136												
1557	1062		children			Overdose	mg	1500		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/28425352/	Homo sapiens													517												
1558	1063					Highest studied dose	mg	120		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/9392980	Homo sapiens												70	12	Chronic asthma					37			3	day		p.323
1559	1063					Overdose	mg	200		single					unhealthy	intrabursal	F		https://pubmed.ncbi.nlm.nih.gov/10667036	Homo sapiens						46				accidental; Triamcinolone Acetonide was injected as a depot preparation in the swollen bursa and around the hip joint, but pertinently not in the joint.			1	Bursitis of the hip											p.13
1560	1064		adult			Recommended	mg	145		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021656s029lbl.pdf	Homo sapiens													439	dyslipidemia											
1561	1064					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7225166/	Homo sapiens										Fenofibrate was given in increasing doses (200 X 1, 150 X 2 and 200 X 2 mg/day). Each such treatment period lasted for 2 months.			46	hyperlipoproteinaemia								2	month		
1562	1064						mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12028504/	Homo sapiens						49.5				micronized fenoﬁbrate 200 mg/day for 12 weeks			87	dyslipidemia								12	week		
1563	1065					Recommended	%	0.25		steady			day	3	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019216s025lbl.pdf	Homo sapiens										Instill one drop into the conjunctival sac two to four times daily.				orticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva								10	day		
1564	1065						%	0.1		steady			day	4	healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/30267699	Homo sapiens						41.7							76						41.7			4	week		
1565	1066					Overdose	mg	180		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24580061	Homo sapiens						12							1	Developmental delay											p.210
1566	1066					Overdose	mg	252		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31308582	Homo sapiens						16							1	Conduct disorder											p.47
1567	1066					Recommended	mg	12		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021999s036lbl.pdf	Homo sapiens														Schizophrenia											p.1
1568	1066					Recommended	mg	234		multiple			month	2	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/25938474	Homo sapiens						37.7				Subjects assigned to the paliperidone palmitate group were initiated with 2 injections in the deltoid muscle that were given approximately 1 week apart: 234 mg on day 1 and 156 mg on day 8 (± 4 days). Flexible monthly maintenance doses of paliperidone palmitate within a range of 78–234 mg (50–150 mg equivalents; recommended target maintenance dose was 156 mg) were started on day 38.			226	Schizophrenia											p.565
1569	1066					Recommended	mg	234		multiple			month	2	unhealthy	intramuscular			https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf	Homo sapiens										The recommended initiation of INVEGA SUSTENNA® is with a dose of 234 mg on treatment day 1 and 156 mg one week later, both administered in the deltoid muscle.				Schizophrenia|Schizoaffective disorder											p.1
1570	1066					Recommended	mg	9		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24580061	Homo sapiens						38							1	Schizophrenia											p.210
1571	1066					Studied dose	mg	15		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24556260	Homo sapiens						30							1	Schizophrenia											
1572	1067					Overdose	mg	400		single			day	1	healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1506835/	Homo sapiens						29							1						29			1	day		
1573	1067					Overdose	mg	60		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22144931/	Homo sapiens													1	bilateral inguinal hernia								1	day		
1574	1067					Studied dose	%	1		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019627_S035_DIPRIVAN_MEDR.pdf	Homo sapiens													109	pain								1	day		
1575	1067					Studied dose	%	2		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/019627_S035_DIPRIVAN_MEDR.pdf	Homo sapiens													113	pain								1	day		
1576	1068					MTD	mg	103		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9175963/	Homo sapiens						28							12									1	day		
1577	1068					Studied dose	mg	40		single			day	1	healthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/24945125/	Homo sapiens										8 ml of 0.5% bupivacaine			1									1	day		
1578	1068					Studied dose	mg	750		single			day	1	healthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/6797328/	Homo sapiens						23				150 ml of 0.5%			1						23			1	day		
1579	1069		adult			Recommended	mg	22.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3028633/	Homo sapiens							mean			single daily dosage regimen ranging between 5 and 40 mg			276	hypertension								8	week		
1580	1069					Recommended	mg	10		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204308Orig1s000MedR.pdf	Homo sapiens						32.4							51									1	day		nda/2013/204308Orig1s000MedR.pdf - p.40
1581	1070		adult			Highest studied dose	mg/m2	1000		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/348320/	Homo sapiens										500 - 1000 mg/m2			32	advanced carcinoma of the colon or rectum								7	day		
1582	1070		adult			Highest studied dose	mg/m2	5.3		multiple			week	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6849198/	Homo sapiens							mean						28	malignant brain tumors				radiotherapy				3	week		
1583	1070		preterm newborn			Overdose	mg	1350		steady			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9195118/	Homo sapiens													1	bloody stools and apnoea								1	day		
1584	1070					Overdose	g	12.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7717611/	Homo sapiens						58							1	chronic depressive illness					58						
1585	1070					Overdose	g	8.5		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15956228/	Homo sapiens						62							1	extensive past medical history, including end-stage renal disease					62						
1586	1072						g	2		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/5035788	Homo sapiens												45	7						29						
1587	1072						g	2		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/5035788	Homo sapiens												45	7						29						
1588	1072						g	2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5035788	Homo sapiens												45	7						29						
1589	1072						g	4		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14880425	Homo sapiens						74				4 gm. per day in divided doses			1						74			24	day		
1590	1075					Higher than recommended	mg	120		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2021388	Homo sapiens												57	12	Asthma					28			3	day		p.588
1591	1075					Highest studied dose	mg	360		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/7582277	Homo sapiens						37.5							6	Asthma											p.1465
1592	1075					Overdose	mg	200		single					unhealthy	intrabursal	F		https://pubmed.ncbi.nlm.nih.gov/10667036	Homo sapiens						46							1	Bursitis											p.13
1593	1076		adult			Studied dose	mg	0.2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5273245/	Homo sapiens							mean			93 patients (52%) received a daily maintenance dose of one tablet, 78 (44 %) received two tablets, and 8 received three tablets per day.			179	heart failure	0.05 mg; 2 tablets per day			digoxin				10	week		
1594	1076					Studied dose	mg	0.1		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7816418/	Homo sapiens												29	10						23			14	day		
1595	1077		adult			Overdose	mg	3000		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23795312/	Homo sapiens													1	HIV infection								1	day		
1596	1077		adult				mg	1000		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00852969	Homo sapiens													15	Chronic Kidney Disease								14	week		
1597	1077					Highest studied dose	g	2		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020381s054lbl.pdf	Homo sapiens										median duration		75	95	Hyperlipidemia | Dyslipidemia					21			16	week		
1598	1077					Overdose	g	11		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16496499/	Homo sapiens						56							1	schizophrenia					56			1	day		
1599	1077					Overdose	g	22.5		single			2 days	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20138459/	Homo sapiens						23							1						23			2	day		
1600	1077					Studied dose	mg	1250		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020381s054lbl.pdf	Homo sapiens							mean			median duration		75	402	Hyperlipidemia | Dyslipidemia					21			16	week		
1601	1080		adult				ug	2000		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/5382073	Homo sapiens													8	pernicious anaemia								14	day		
1602	1080					Highest studied dose	g	20		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17543660	Homo sapiens						26.9							1						26.9						
1603	1080					Overdose	g	5		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/31000316	Homo sapiens						3				5 g (373 mg/kg)			1	cyanide toxicity					3						
1604	1080						g	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/28994688	Homo sapiens						62							1	Vasoplegic Syndrome					62						
1605	1080						mg	20		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/19821145	Homo sapiens						13							1						13						
1606	1081		adult				mg/mL	50		multiple			week	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01354964	Homo sapiens										Participants received weekly oral vitamin D drops using a weight-based calculated dosage to reach a target level of ≥30 ng/ml at second visit and a goal level of ≥50 ng/ml at third visit.			11	Insulin Resistance								6	month		
1607	1081					Highest studied dose	ug	200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18326608	Homo sapiens						33.4				monthly increasing doses of 2,000 I.U. (50μg, week 1 to 4), 4,000 I. U. (100μg, week 5 to 8) and 8,000 I.U. (200μg, week 9 to 12) of cholecalciferol per day			25									3	week		
1608	1081					Highest studied dose	unit	100000		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18326608	Homo sapiens										2 capsules each labeled to contain 50 000 IU (1.25 mg) cholecalciferol		84	30						27						
1609	1081					Overdose	unit	2000000		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25269374	Homo sapiens												95	2						90						
1610	1081						unit	100000		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/18326608	Homo sapiens						34.9							12												
1611	1083					Highest studied dose	ug	25		multiple			day	2	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/20214460	Homo sapiens						63.8							147	Chronic obstructive pulmonary disease											p.21
1612	1083					Recommended	ug	30		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf	Homo sapiens							total			A total daily dose of greater than 30 mcg is not recommended. One 15 mcg/2 mL vial every 12 hours				Chronic obstructive pulmonary disease											p.1
1613	1083						ug	15		steady			day	2	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT00909779	Homo sapiens													420	COPD								1	year		
1614	1085					Higher than recommended	mg	90		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	6	metastatic solid tumors					32			28	day		Table 3
1615	1085					Highest studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	13	metastatic solid tumors					32			28	day		Table 4
1616	1085					Highest studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	17	metastatic solid tumors					32			28	day		Table 4
1617	1085					Highest studied dose	mg	120		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	4	metastatic solid tumors					32			28	day		Table 4
1618	1085					Highest studied dose	mg	120		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	5	metastatic solid tumors					32			28	day		Table 4
1619	1085					Highest studied dose	mg	160		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	4	metastatic solid tumors					32			28	day		Table 3
1620	1085					Highest studied dose	mg	90		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	7	metastatic solid tumors					32			28	day		Table 4
1621	1085					MTD	mg	120		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	9	metastatic solid tumors					32			28	day		Table 3
1622	1085					MTD	mg	70		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	5	metastatic solid tumors					32			28	day		Table 4
1623	1085					Recommended	mg	50		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	3	metastatic solid tumors					32			28	day		Table 3
1624	1085					Recommended	mg	70		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	4	metastatic solid tumors					32			28	day		Table 3
1625	1085					Studied dose	mg	35		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19789325/	Homo sapiens												81	7	metastatic solid tumors					32			28	day		Table 3
1626	1086		adult			Overdose	mg/m2	150		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf	Homo sapiens										1-hour infusions			1									1	hour		
1627	1086		adult			Overdose	mg/m2	200		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf	Homo sapiens										1-hour infusions			1									1	hour		
1628	1086		adult			Recommended	mg/m2	60		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf	Homo sapiens																									
1629	1086		adult				mg/m2	100		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022534s000lbl.pdf	Homo sapiens																									
1630	1086					MTD	mg/m2	43		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9626217	Homo sapiens						58						81	10	Advanced Refractory Cancer					41			6	week		
1631	1086						mg/m2	52		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9626217	Homo sapiens						58						81	3	Advanced Refractory Cancer					41			6	week		
1632	1086						mg/m2	75		multiple			3 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8761385	Homo sapiens						51						65	39	advanced breast cancer:					36			31.1	month		
1633	1087		adult			Recommended	%	0.01		multiple			day	1	unhealthy	topical	M+F		https://pdf.hres.ca/dpd_pm/00056991.PDF	Homo sapiens										Thin layer DUOBRII (Halobetasol Propionate and Tazarotene Lotion 0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) applied topically, once daily to the affected area to cover approximately 3%-12% BSA for 8 weeks.			270	plaque psoriasis	0.045%; 1/day			tazarotene				8	week		
1634	1087					Recommended	g	2		multiple			day	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208183Orig1s000MedR.pdf	Homo sapiens						51	median			Ultravate (halobetasol propionate) lotion, 0.05% twice daily. Average daily amount used 4 g (median) for 15 days (median).		86	277	plaque psoriasis					18			15	day		
1635	1088					Recommended	mg	0.451		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203593Orig1s000lbl.pdf	Homo sapiens								0.02 mg, q.d		24 white tablets, each containing 3 mg drospirenone (DRSP), 0.02 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefolate calcium • 4 light orange tablets, each containing 0.451 mg levomefolate calcium			1056	Pregnancy prevention	3 mg, q.d			drospirenone, p.o						ethinyl estradiol (betadex clathrate), p.o	p.19
1636	1088					Recommended	mg	0.451		multiple			day	1	healthy|unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203593Orig1s000lbl.pdf	Homo sapiens								0.02 mg, q.d		24 white tablets, each containing 3 mg drospirenone (DRSP), 0.02 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefolate calcium • 4 light orange tablets, each containing 0.451 mg levomefolate calcium				Pregnancy prevention|premenstrual dysphoric disorder|acne	3 mg, q.d			drospirenone, p.o						ethinyl estradiol (betadex clathrate), p.o	p.2
1637	1088					Recommended	mg	0.451		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203593Orig1s000lbl.pdf	Homo sapiens								0.02 mg, q.d		24 white tablets, each containing 3 mg drospirenone (DRSP), 0.02 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefolate calcium • 4 light orange tablets, each containing 0.451 mg levomefolate calcium			285	Premenstrual dysphoric disorder	3 mg, q.d			drospirenone, p.o						ethinyl estradiol (betadex clathrate), p.o	p.19
1638	1088					Recommended	mg	0.451		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203593Orig1s000lbl.pdf	Homo sapiens								0.02 mg, q.d		24 white tablets, each containing 3 mg drospirenone (DRSP), 0.02 mg ethinyl estradiol (EE) as betadex clathrate and 0.451 mg levomefolate calcium • 4 light orange tablets, each containing 0.451 mg levomefolate calcium			536	Acne	3 mg, q.d			drospirenone, p.o						ethinyl estradiol (betadex clathrate), p.o	p.19
1639	1089		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00790205	Homo sapiens							max			Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.			7266	Type 2 Diabetes								5	year		
1640	1089		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01099618	Homo sapiens													16	Type 2 Diabetes								3	year		
1641	1089		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01186562	Homo sapiens													54	Pancreatitis								1	year		
1642	1089		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01549964	Homo sapiens													260	Type 2 Diabetes								24	week		
1643	1089		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02513771	Homo sapiens													45	HIV-1 Infection								16	week		
1644	1089					Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30346099	Homo sapiens						14.8							8	type 2 diabetes mellitus					14.8						
1645	1089					Overdose	mg	1700		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/22277726/	Homo sapiens						86													86						
1646	1089					Studied dose	mg	800		single					healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021995lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/19602719	Homo sapiens												45	77						18						
1647	1091					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11028256	Homo sapiens													14	Hypertension								4	week		p.1169
1648	1091					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1678920	Homo sapiens													37	Hypertension								1	month		p.903
1649	1091					MTD	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf	Homo sapiens														Benign Prostatic Hyperplasia|Hypertension											p.9
1650	1091					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf	Homo sapiens							max							Benign Prostatic Hyperplasia|Hypertension											p.6
1651	1091					Studied dose	mg	20		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7533452	Homo sapiens							max						494	Benign Prostatic Hyperplasia								2	year		p.409
1652	1091					Studied dose	mg	20		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf	Homo sapiens							max						636	Benign Prostatic Hyperplasia											p.12
1653	1091					Studied dose	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19057Orig1s021,%2020347Orig1s009%20lbl.pdf	Homo sapiens							max						859	Hypertension											p.16
1654	1094		adult			Recommended	mg	400		multiple			day	4	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022348lbl.pdf	Homo sapiens														Pain											
1655	1094		adult			Recommended	mg	400		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017463s105lbl.pdf	Homo sapiens														pain											
1656	1094					Overdose	g	90		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/20419362	Homo sapiens						19				450 tablets of 200 mg ibuprofen (90,000 mg total; 1,200 mg/kg).									19						
1657	1094					Overdose	mg	199800		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/18072160	Homo sapiens						17				999 tablets of 200 mg ibuprofen each.									17						
1658	1094					Overdose	mg	240000		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/18072160	Homo sapiens						49				2 bottles: 600 tablets of 200 mg ibuprofen each								divalproex sodium	49						
1659	1094					Overdose	mg	240000		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/18072160	Homo sapiens						49				2 bottles: 600 tablets of 200 mg ibuprofen each									49						
1660	1094					Recommended	mg	400		multiple			day	4	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf	Homo sapiens						42						73	195						17						p.87
1661	1094					Recommended	mg	800		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21127424	Homo sapiens						33				3200 mg (800 mg every 6 hours)			40						33			5	day		
1662	1094					Recommended	mg	800		multiple			day	4	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022348s000MedR.pdf	Homo sapiens						44						69	304						20						p.87
1663	1094						mg	200		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01842633	Homo sapiens													62	Episodic Tension Type Headache											
1664	1094						mg	97.5		multiple			day	4	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01420653	Homo sapiens													112	Dental Pain								2	day		
1665	1094						mg/kg	10		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02241512	Homo sapiens													29	Post-ERCP Pancreatitis											
1666	1095					Highest studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209905Orig1s000MedR.pdf	Homo sapiens						9.6	max			Mean length of exposure			97	Attention Deficit Hyperactivity Disorder								53.9	day		
1667	1095					Studied dose	mg	150		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12187149/	Homo sapiens						13				20 Adderall 5 mg and 10 mg tablets (AMPHETAMINE and DEXTROAMPHETAMINE salts)			1	Attention Deficit Hyperactivity Disorder					13			1	day		
1668	1095					Studied dose	mg	30		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000MedR.pdf	Homo sapiens						35.8							30									1	day		
1669	1095					Studied dose	mg	30		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000MedR.pdf	Homo sapiens						42.5							44									1	day		
1670	1096					Recommended	mg	12.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10483843/	Homo sapiens						35.5							24	attention deficit hyperactivity disorder								6	week		
1671	1096					Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5540117/	Homo sapiens						8.43				Duration: 3 to 5 weeks			26	hyperactivity								4	week		
1672	1096					Studied dose	mg	375		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6830477/	Homo sapiens						25				50 DEXTROAMPHETAMINE SULFATE 5 mg and 10 mg tablets			1	amphetamine abuse					25			1	day		
1673	1096						mg	30		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01215929	Homo sapiens													18	Methamphetamine dependence								2	week		
1674	1097		adult				mg	200		multiple			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02727322	Homo sapiens										Patients will receive nitrofurantoin 100mg once daily during catheter use.			75	Pelvic Organ Prolapse											
1675	1097					Recommended	mg	100		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16718946/	Homo sapiens						50							1						50			8	day		
1676	1097					Recommended	mg	125		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5700010/	Homo sapiens							mean					75	5	urinary infections					62						
1677	1097					Studied dose	mg	50		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7019458/	Homo sapiens						31.3							48	urinary infections								1	year		
1678	1098					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3890282	Homo sapiens														severe shigellosis								5	day		
1679	1098					Overdose	g	1		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018679s044lbl.pdf	Homo sapiens																									
1680	1099		adult			Recommended	mg	50		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf	Homo sapiens													93	alcohol dependence								12	week		
1681	1099		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01052831	Homo sapiens										For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.			24	Impulse Control Disorders								8	week		
1682	1099		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00142818	Homo sapiens										150 mg daily for males; 100 mg daily for females			40	Cocaine and Alcohol Dependence								13	week		
1683	1099		adult				mg	50		multiple			day	2	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01999114	Homo sapiens													66									7	day		
1684	1099		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00938886	Homo sapiens													75	Hazardous Drinking								10	week		
1685	1099		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01053078	Homo sapiens										1 month treatment; Naltrexone 25mg once daily for 5 days, then 50 mg once daily for 23 days			10	Hypoglycemia								1	month		
1686	1099		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01721330	Homo sapiens							max						1	Attention Deficit Hyperactivity Disorder								6	week		
1687	1099					Overdose	mg	1500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22778191/	Homo sapiens						26							1	polydrug					26						
1688	1100					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13640851/	Homo sapiens						36							90	chronic allergic rhinitis								1	week		
1689	1100					Studied dose	mg	100		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13039563/	Homo sapiens						2							1						2			1	day		
1690	1100					Studied dose	mg	25		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13526305/	Homo sapiens						49							1	chronic allergic rhinitis	50 mg; 11 days			antistin	49			11	day		
1691	1101		adult			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Homo sapiens													67												
1692	1101		adult			Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Homo sapiens													200	schizophrenia |schizoaffective disorder								8	week		
1693	1101		adult			Overdose	g	2		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Homo sapiens													1												
1694	1101		adult			Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Homo sapiens																						6	week		
1695	1101		adult				mg	10		single					unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02755116	Homo sapiens													71	Postoperative Nausea and Vomiting											
1696	1101		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00396565	Homo sapiens													47	Schizophrenia								6	week		
1697	1101		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01170117	Homo sapiens							max			Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. T			75	Anorexia Nervosa								16	week		
1698	1101		adult				mg	15		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00686998	Homo sapiens										8mg/ day oral capsule increased to 16mg/day then to 24 mg per day			22	Schizophrenia								28	day		
1699	1101		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00129220	Homo sapiens							max			5 to 20 mg per day for 6 weeks			105	Bipolar I Disorder								6	week		
1700	1101		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00510146	Homo sapiens							max			During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.			343	Bipolar I Disorder								24	week		
1701	1101		old			Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf	Homo sapiens														DEMENTIA-RELATED PSYCHOSIS								6	week		
1702	1101					Recommended	mg	5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21086lbl.pdf	Homo sapiens						83						97	65	psychiatric symptoms					61			6	week		
1703	1101						mg	10		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33564555	Homo sapiens						20							1	paranoid schizophrenia					20						
1704	1102					Highest studied dose	g	45		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens						57							4						57						
1705	1102					Highest studied dose	g	45		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens						57				used only 500-mg tablets			4						57			28	day		
1706	1102					MTD	g	15		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17702032	Homo sapiens												61	4	Huntington’s Disease					38			28	day		
1707	1102					MTD	g	27		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15831235	Homo sapiens						51.4							7	recurrent malignant gliomas					51.4			28	day		
1708	1102					MTD	mg/kg	150		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17053987	Homo sapiens						57							3						57			28	day		
1709	1102						g	18		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17702032	Homo sapiens												73	11	Huntington’s Disease					31			28	day		
1710	1102						g	36		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11489804	Homo sapiens						57				used only 500-mg tablets			7						57			28	day		
1711	1102						g	36		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15831235	Homo sapiens						51.4							4	recurrent malignant gliomas					51.4			28	day		
1712	1103					MTD	mg/kg	100		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14288454/	Homo sapiens										4 to 16 months duration			3	hydrocephalu								10.3	month		
1713	1103					Recommended	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9881560/	Homo sapiens													52	elevated intraocular pressure								12	week		
1714	1103					Studied dose	mg	500		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32082641/	Homo sapiens						70				next: 250 mg 4 times a day for 15 days			1	Diabetes | Chronic Renal Failure					70			5	day		
1715	1104					Overdose	mg	7500		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4588639	Homo sapiens						44							1	Renal Homotransplantation	1 g			prednisone, p.o							p.134
1716	1104					Recommended	mg/kg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15362028	Homo sapiens													71	Crohn's disease								24	month		p.735
1717	1104					Recommended	mg/kg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19109574	Homo sapiens													63	Wegener's granulomatosis |microscopic polyangiitis								12	month		p.2797
1718	1104					Recommended	mg/kg	5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf	Homo sapiens										The initial dose is usually 3 to 5 mg/kg daily, beginning at the time of transplant. IMURAN is usually given as a single daily dose on the day of, and in a minority of cases 1 to 3 days before, transplantation. Dose reduction to maintenance levels of 1 to 3 mg/kg daily is usually possible.				Renal Homotransplantation											p.1
1719	1105		adult			Highest studied dose	ug	320		steady			day	2	unhealthy	respiratory	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020911s029s030lbl.pdf	Homo sapiens										day			56	asthma								7	day		
1720	1105		adults and children			Studied dose	ug	320		steady			day	1	unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/26653155/	Homo sapiens													219	allergic rhinitis								6	week		
1721	1105		child				ug	80		steady			day	1	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT01697956	Homo sapiens													67	Perennial Allergic Rhinitis								6	week		
1722	1105		child				ug	80		steady			day	1	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT01783548	Homo sapiens													362	Perennial Allergic Rhinitis								6	week		
1723	1105					Highest studied dose	ug	320		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/28937845/	Homo sapiens												45	66						18						
1724	1105					Recommended	ug	40		steady			day	2	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/21324520/	Homo sapiens												18	71	asthma	360 ug			albuterol	5			44	week		
1725	1105					Recommended	ug	40		steady			day	2	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/21324520/	Homo sapiens												18	72	asthma					5			44	week		
1726	1106					Highest studied dose	mg	4		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8570773/	Homo sapiens													9	depression								6	week		
1727	1106					Overdose	mg	600		single			day	1	unhealthy	oral	F		https://link.springer.com/article/10.2165/00128415-201013120-00042	Homo sapiens						35		20mg, PO, single					1	bipolar disorder	15g, PO, single			valpromide						alprazolam	
1728	1107					Highest studied dose	g	12		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/318219	Homo sapiens						22				was given iv in four divided doses			1	bacterial endocarditis					22			12	day		
1729	1107						g	1		multiple			day	4	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6641504	Homo sapiens						77							1	peritonitis					77			4	day		
1730	1107						g	2		multiple			day	3	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/21042010	Homo sapiens						45							1						45			3	day		
1731	1107						g	2		single					unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/3578148	Homo sapiens						17							1						17						
1732	1108					Recommended	mg	1000		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/011870s040lbl.pdf	Homo sapiens										For Edema: The usual adult dosage is 500 mg to 1000 mg (10 mL to 20 mL) once or twice a day. For Control of Hypertension: The usual adult starting dosage is 500 mg or 1000 mg (10 mL to 20 mL) a day as a single or divided dose. Dosage is increased or decreased according to blood pressure response. Rarely some patients may require up to 2000 mg (40 mL) a day in divided doses.				Edema|Hypertension											p.4
1733	1109		adult			Overdose	g	20		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/92705	Homo sapiens													3												
1734	1109		adult			Overdose	g	3		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/74598	Homo sapiens										fifteen tablets four times daily (about 12 g per day)			1	duodenal ulcer								5	day		
1735	1109		adult			Recommended	mg	300		multiple			day	4	unhealthy	respiratory			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aa4ee5b-b5be-4a98-5b8c-6f75e2b59e51	Homo sapiens																									
1736	1109					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3520794	Homo sapiens						50						85	17						22			12	week		
1737	1110						mg	50		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/16092s042,16093s044lbl.pdf	Homo sapiens														edema											
1738	1111		adult			MTD	mg	40		steady			day	1	unhealthy	oral	unknown		https://www.rxlist.com/monopril-drug.htm#description	Homo sapiens														hypertension								3	week		
1739	1111					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1534664/	Homo sapiens													12	essential hypertension								8	week		
1740	1111					Recommended	mg	20		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19915se5-037_monopril_lbl.pdf	Homo sapiens													688	hypertension					65			12	month		16
1741	1113					Highest studied dose	mg	15		single					unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/25834466/	Homo sapiens						64.3				Doses were given by SC injection in the abdominal area 30 minutes before the start of chemotherapy. A local anesthetic, usually a lidocaine preparation or ethyl chloride spray, was applied to the area of the injection site prior to study drug administration.			13	nausea and vomiting, chemotherapy-Induced											
1742	1113					Highest studied dose	mg	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7758060/	Homo sapiens						50.6				The first dose was given 1 hour before the start of chemotherapy and the same dose was repeated every 12 hours for 7 days		76	233	nausea and vomiting, chemotherapy-Induced					23			7	day		
1743	1113					Highest studied dose	ug/kg	160		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8032704/	Homo sapiens						54				A solution of granisetron was prepared in 0.9% sodium chloride to a total volume of 50 ml. It was adminstered as a 30-min intravenous infusion, and completed 5 min before cisplatin therapy. All patients were treated with cisplatin, either alone or in combination with other cytostatic agents. If a combination of agents was used, patients received cisplatin first. Cisplatin, at a dose of 50 mg/m^2 or more, was administered as an intravenous infusion over a period not exceeding 6 h.			165	nausea and vomiting, chemotherapy-Induced	>50 mg/m^2			cisplatin							
1744	1113					Recommended	mg	1		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	Homo sapiens													267	nausea and vomiting, postoperative											
1745	1113					Recommended	ug/kg	40		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020239s021,020305s014,021238s007lbl.pdf	Homo sapiens										patients receiving KYTRIL Injection, in single-day chemotherapy trials. These patients received chemotherapy, primarily cisplatin, and intravenous fluids during the 24-hour period following KYTRIL Injection administration.			1268	nausea and vomiting, chemotherapy-Induced											
1746	1114					Highest studied dose	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/365920	Homo sapiens													19	seasonal allergic rhinitis								2	week		
1747	1115					Recommended	mg/day	75		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017090s078lbl.pdf	Homo sapiens							starting							depression											
1748	1115						mg/day	200		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9023787	Homo sapiens										The dose of imipramine was rapidly increased from 50 to 200 mg/day during the first five days and maintained at this level throughout the study.		70	82	major depression | melancholia					18			42	day		
1749	1115						mg/day	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19653341	Homo sapiens						42.6							59	irritable bowel syndrome								12	week		
1750	1116		adult			Recommended	%	0.1		steady			day	1	unhealthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf	Homo sapiens										ointment			812	dermatoses								3	week		
1751	1116		adult				mL	2.5		multiple			day	1	unhealthy	topical	F		https://clinicaltrials.gov/ct2/show/NCT00438659	Homo sapiens										Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.			84	Radiation Dermatitis											
1752	1116		child|adult				ug	220		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02061202	Homo sapiens													35	Sickle Cell Disease								16	week		
1753	1116					Recommended	%	0.1		steady			day	1	unhealthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019543s024lbl.pdf	Homo sapiens										ointment			63	dermatoses								3	week		
1754	1117		adult			Recommended	mg	15		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017577s034,018211s017,020897s018lbl.pdf	Homo sapiens							mean						429	neurological diseases								4.5	month		
1755	1117		elderly				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01126424	Homo sapiens													25	Cognitive Impairment								21	day		
1756	1117					Overdose	mg	100		single					unknown	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017577s034,018211s017,020897s018lbl.pdf	Homo sapiens						34							1					alcohol	34						
1757	1117					Overdose	mg	100		single					unknown	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017577s034,018211s017,020897s018lbl.pdf	Homo sapiens						13							1					alcohol	13						
1758	1117					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32981151/	Homo sapiens							mean					70	30	Hyperhidrosis					12			2.4	year		
1759	1117					Recommended	mg/kg	0.2		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/31821098/	Homo sapiens													24	had undergone primary endoscopic valve ablation for posterior urethral valves								44.2	month		
1760	1118		adult			Recommended	ug	250		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203826s000lbl.pdf	Homo sapiens										50 mcg to 250 mcg by intravenous bolus administration. The most frequently reported initial bolus dose is 50 mcg or 100 mcg.															
1761	1118					Highest studied dose	mg	40		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26143019	Homo sapiens						37.5						77	112	Seasonal Allergic Rhinitis					19						
1762	1118					Recommended	%	10		multiple			day	3	healthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203510s000lbl.pdf	Homo sapiens										10% at 3 to 5 minute intervals up to a maximum of 3 drops per eye									1						
1763	1118						mg	10		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33062792	Homo sapiens						34				used multiple OTC DayQuil LiquiCaps (containing phenylephrine 10 mg per LiquiCaps) over 2 days			1						34			2	day		
1764	1119					Overdose	mg	864		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/3702350	Homo sapiens						83							1						83						
1765	1119						mg/kg	6		single					unhealthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/22272683	Homo sapiens						6							1						6						
1766	1121					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000MedR.pdf	Homo sapiens						51.9							295	obesity	92 mg; 1/day			topiramate				52	week		nda/2012/022580Orig1s000MedR.pdf - p.105
1767	1121					Recommended	mg	37.5		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf	Homo sapiens										fasting condition		45	17						18			1	day		nda/2012/202088Orig2s000MedR.pdf - p.12
1768	1121					Recommended	mg	37.5		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202088Orig2s000MedR.pdf	Homo sapiens										fed		45	17						18			1	day		nda/2012/202088Orig2s000MedR.pdf - p.12
1769	1121					Studied dose	mg	390		single			day	1	healthy	oral	M+F		https://www.koreascience.or.kr/article/JAKO201429638663634.pdf	Homo sapiens						30				A 36-year-old man and a 24-year-old woman			2									1	day		
1770	1123		adult			Highest studied dose	mg	1200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1617910/	Homo sapiens														rheumatoid arthritis											
1771	1123		adult			Highest studied dose	mg	1200		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/9884815/	Homo sapiens													10									7	day		
1772	1123		children			Highest studied dose	mg/kg	20		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1617910/	Homo sapiens														rheumatoid arthritis											
1773	1124					Highest studied dose	mg	800		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31585944	Homo sapiens													212	Pharyngotonsillitis caused by group A streptococci								5	day		
1774	1124					Recommended	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31585944	Homo sapiens													210	Pharyngotonsillitis caused by group A streptococci								10	day		
1775	1124					Recommended	g	3		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Homo sapiens										2 gram of penicillin V 1 hour before the procedure, and then, 1 gram 6 hours later				Prophylaxis against bacterial endocarditis											p.2
1776	1124					Recommended	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1428189	Homo sapiens										Penicillin was given either as a suspension of 20 mg/kg/day in four divided doses up to a maximum daily dose of 500 mg or as 250 mg capsules four times daily for ten days			175	Streptococcal pharyngitis|Streptococcal tonsillitis								10	day		p.70/306
1777	1124					Recommended	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1656738	Homo sapiens													117	Streptococcal Pharyngitis								10	day		p.3A-25S
1778	1124					Recommended	mg	500		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf	Homo sapiens							max							Infections due to penicillin G­ sensitive microorganisms											p.2
1779	1124					Recommended	mg	590		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11815577	Homo sapiens													113	Streptococcal Pharyngitis								10	day		p.341
1780	1124					Recommended	mg/kg	10		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9006528	Homo sapiens										10-mg/kg penicillin V potassium, every 6 hours (maximum, 250 mg every 6 hours), for 10 days.		12	216	Streptococcal Pharyngitis					1			10	day		p.48
1781	1125					Recommended	mg	10		multiple			day	2	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021876Orig1s000MedR.pdf	Homo sapiens						26				maximum dosage is 4 tablets per day (if indicated)			133		10 mg; 2 per day (up to 4)			doxylamine succinate				14	day		nda/2013/021876Orig1s000MedR.pdf - p.82
1782	1125					Studied dose	mg	117		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3630649/	Homo sapiens						41.5	mean						172	premenstrual syndrome								2.9	year		
1783	1125					Studied dose	mg	175		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2860378/	Homo sapiens						42				50-300 mg daily			58	premenstrual syndrome											
1784	1126					Recommended	g	1		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25411350	Homo sapiens						29.81				PYR-SULF consisted of PYR 200 mg on 1st day followed by 50 mg (<60 kg) or 75 mg (>60 kg) daily and SULF 4 g daily in four divided doses on all days. Curative therapy was given for 4–6 weeks according to the response; 25 mg of PYR once daily and 500 mg of SULF four times daily was continued as maintenance therapy			16	Cerebral toxoplasmosis	50-75 mg oral; 1/day			pyrimethamine				5	week		p.4
1785	1126					Recommended	g	4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12095805	Homo sapiens								15 mg oral; 1/day				80	22	Ocular toxoplasmosis	50 mg oral; 1/day			pyrimethamine	16			4	week	folinic acid	p.36, 38
1786	1126					Recommended	g	6		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1428784	Homo sapiens						33.8	max						29	Central nervous system toxoplasmosis	50-75 mg oral; 1/day			pyrimethamine				7	week		p.476
1787	1127					Highest studied dose	mg	25		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6386025	Homo sapiens												44	5						25			7	day		p.372
1788	1127					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3371085	Homo sapiens						58	max						18	Hypertension	40 mg; q.d			furosemide, p.o				10	week		p.696
1789	1127					Recommended	mg	5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5639627	Homo sapiens													12	Hypertension	50 mg; q.d			hydrochlorothiazide, p.o				6	week		p.423
1790	1128		adult			Studied dose	mg	150		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens													448	Vaginal Candidiasis											
1791	1128		adult			Studied dose	mg	150		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30782643/	Homo sapiens							max						345	fungal infections, pregnancies								7	day		
1792	1128		adult			Studied dose	mg	150		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30782643/	Homo sapiens							min						249	fungal infections, pregnancies								7	day		
1793	1128					Recommended	mg/kg	5.3		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10394841/	Homo sapiens							mean						40	systemic candidosis and candidaemia								26	day		
1794	1128					Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30535104/	Homo sapiens						46.1							124	coccidioidomycosis					46.1			147	day		
1795	1128					Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30541454/	Homo sapiens												73	31	HIV-uninfected cryptococcal meningitis					16			137	day		
1796	1128					Studied dose	mg/kg	15		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019949s051lbl.pdf	Homo sapiens												17	577	candidosis					0			1616	day		
1797	1128					Studied dose	mg/kg	6		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10394841/	Homo sapiens							typical			2 to 50 mg/kg			726	systemic candidosis and candidaemia								162	day		
1798	1128						mg	100		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01354314	Homo sapiens													11	HIV Associated Neurocognitive Disorder								24	week		
1799	1130		adult			Studied dose	g	7		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6325736	Homo sapiens													26	chronic sinusitis | otitis media								10	day		
1800	1130		children			Studied dose	mg/kg	200		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6270413	Homo sapiens													26												
1801	1130					Studied dose	g	2		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6287388	Homo sapiens												76	30	urinary tract infections					23			28	day		
1802	1132					Highest studied dose	mg	500		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6311007	Homo sapiens												43	12						25						p.83
1803	1132					Studied dose	mg/kg	10		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6310997	Homo sapiens												94	38	gram-negative baciliary infections					25						p.110
1804	1133					Highest studied dose	mg/m2	3000		multiple			week	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/11844837	Homo sapiens						66							4	Prostate cancer								2	cycle		p.1118
1805	1133					MTD	mg/m2	2500		multiple			week	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/11844837	Homo sapiens						66							6	Prostate cancer								2	cycle		p.1119, 1124
1806	1134					Recommended	mg	2		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs				phenothiazines							
1807	1134					Recommended	mg	2		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs				tricyclic antidepressants							
1808	1134					Recommended	mg	2		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs											
1809	1134					Recommended	mg	2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/791573	Homo sapiens										For benztropine mesylate, the dose was 2 mg; Dosage schedule was one capsule in the morning and one in the late afternoon. If substantial improvement was not present within 48 hr, dosage was increased to three times daily, with the third capsule given at midday. On the last day of the study, the number on a particular dosage and the dose of benztropine mesylate were: 1 on 2 mg, 15 on 4 mg, and 3 on 6 mg.		66	19	neuroleptic-induced extrapyramidal symptoms					20			7	day		
1810	1134					Recommended	mg	2		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5066	Homo sapiens										16 patients receive two 2 mg capsules per day, 5 additional patients were raised to four capsules per day during the second week			21	Schizophrenia|Drug-Induced Extrapyramidal Disorders								28	day		
1811	1134					Recommended	mg	6		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs				phenothiazines							
1812	1134					Recommended	mg	6		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs				tricyclic antidepressants							
1813	1134					Recommended	mg	6		multiple			day	1	unhealthy	parenteral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012015s027lbl.pdf	Homo sapiens							max			The usual daily dose is 1 to 2 mg, with a range of 0.5 to 6 mg parenterally.				Parkinsonism|Extrapyramidal disorders due to neuroleptic drugs											
1814	1134					Studied dose	mg	2.25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9109903	Homo sapiens							max			Adverse effects of benztropine at maximum tolerated doses, which didn`t exceed 4.5 mg per day		80	19	Parkinson's disease					21			6	week		
1815	1134					Studied dose	mg	2.25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9109903	Homo sapiens							max			Benztropine was begun at 0.75 mg/day and increased each week by 0.75 mg on a twice daily (bid) regimen. The maximum doses given were 4.5 mg/day (2.25 mg b.i.d). Adverse effects of benztropine at maximum tolerated doses, which didn`t exceed 4.5 mg per day.		80	19	Parkinson's disease					21			6	week		
1816	1135					Highest studied dose	mg	4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8930778	Homo sapiens										oral solution syrop			24												
1817	1135						mg	0.5		single					healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-082_Tavist_medr_P2.pdf	Homo sapiens													32												page 58
1818	1135						mg	1		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-082_Tavist_medr_P2.pdf	Homo sapiens										two 0.5 mg clemastine tablets			32												page 58
1819	1136					Overdose	mg	240		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/26479786	Homo sapiens																						2	day		
1820	1136					Recommended	mg	32		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/011483s033lbl.pdf	Homo sapiens								30 mg		two capsules orally every 4 hours. Capsule: 356.4 mg aspirin, 30 mg caffeine, and 16 mg dihydrocodeine bitartrate.					356.4 mg			aspirin	18			3	day	caffeine	
1821	1138					Overdose	mg/m2	150		multiple			day	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf	Homo sapiens						17				intended dose was 50 mg per day for 3 days			1						17			2	day		
1822	1138					Overdose	mg/m2	300		single					unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf	Homo sapiens						58							1	acute lymphoblastic leukemia					58						
1823	1138					Recommended	mg/m2	60		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf	Homo sapiens																									
1824	1138						mg/m2	300		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050467s078,050629s030lbl.pdf	Homo sapiens							total																		
1825	1139					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9597557	Homo sapiens												43	23						20						p.38
1826	1139					Overdose	mg	12000		single					unknown	oral			https://www.medicines.org.uk/emc/product/712/smpc#gref	Homo sapiens													1												
1827	1140		adult			Recommended	ug/kg	500		single					unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205703s000lbl.pdf	Homo sapiens							mean						369	supraventricular tachycardia											
1828	1140					Recommended	ug/kg	500		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27523955/	Homo sapiens						58							16	out-of-hospital cardiac arrest											
1829	1140					Recommended	ug/kg	500		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/1358003/	Homo sapiens						44	mean						20	ASA physical status I-III											
1830	1140					Studied dose	ug/kg/min	400		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/24687543/	Homo sapiens						15							1	hypertrophic cardiomyopathy					15						
1831	1141		adult			Recommended	%	0.5		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20985lbl.pdf	Homo sapiens													257	actinic keratoses								4	week		
1832	1141		adult				mg	1250		multiple			2 days	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7302355	Homo sapiens													7	hepatoma								2	week		
1833	1141		adult				mg	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7463330	Homo sapiens													6	breast cancer											
1834	1141					Highest studied dose	mg/m2	3400		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3373260	Homo sapiens						54				24-hour infusion, repeated weekly		78	8	Advanced Pancreatic Cancer| Colorectal Cancer					24			16	week		
1835	1141					MTD	mg/m2	2600		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3373260	Homo sapiens						54				24-hour infusion, repeated weekly		78	8	Advanced Pancreatic Cancer| Colorectal Cancer					24			16	week		
1836	1141						%	5		steady			day	2	unhealthy	topical			https://clinicaltrials.gov/ct2/show/NCT00847912	Homo sapiens										thin layer of cream is applied to face and ears			468	Keratinocyte carcinoma								2	week		
1837	1141						mg/m2	2800		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8262730	Homo sapiens						59				24-hour infusion, repeated weekly			3						59						
1838	1141						mg/m2	3000		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8262730	Homo sapiens						59				24-hour infusion, repeated weekly			14						59						
1839	1141						mg/m2	3250		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8262730	Homo sapiens						59				24-hour infusion, repeated weekly			9						59						
1840	1142					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24991839/	Homo sapiens						64							8	advanced solid malignancies	150 mg/m2; daily for 7/14 d			temozolomide				6	week		
1841	1142					Studied dose	g	12		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						27							1						27			1	day		
1842	1142					Studied dose	g	12		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						16							1						16			1	day		
1843	1142					Studied dose	g	12		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						2.5							1						2.5			1	day		
1844	1142					Studied dose	g	20		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						18							1						18			1	day		
1845	1142					Studied dose	g	4		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						29							1						29			1	day		
1846	1142					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24991839/	Homo sapiens						64							15	advanced solid malignancies	150 mg/m2; daily for 7/14 d			temozolomide				6	week		
1847	1142					Studied dose	mg	200		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11555803/	Homo sapiens						16							1				ibuprofen	levothyroxine	16			1	day	aspirin	
1848	1142					Studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24991839/	Homo sapiens						64							7	advanced solid malignancies	150 mg/m2; daily for 7/14 d			temozolomide				6	week		
1849	1142						mg	200		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01537315	Homo sapiens													7	cardiovascular disease								6	month		
1850	1143					Highest studied dose	ug	20		multiple			day	24	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/21962419	Homo sapiens													7	Pulmonary hypertension								1	day		p.816
1851	1143					Highest studied dose	ug	300		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9349930	Homo sapiens													12	Thromboangiitis obliterans								3	week		
1852	1143					MTD	ng/kg/min	4.4		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7524508	Homo sapiens							mean			Continuous intravenous infusion. Hemodynamic parameters were measured, and iloprost infusion was started at an initial rate of 1 ng/kg/minute, increasing by 1 ng/kg/minute every 10 minutes until adverse hemodynamic effects or other toxic effects were observed. This was considered the maximum-tolerated dose.		55	5	Pulmonary hypertension					14			14	day		p.1531
1853	1143					MTD	ug	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7538285	Homo sapiens												57	32	Raynaud's syndrome					47			10	day		p.197
1854	1143					Recommended	ug	5		multiple			day	9	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021779s014lbl.pdf	Homo sapiens										Patients should receive 6 to 9 doses (inhalations) per day (minimum of 2 hours between doses during waking hours)				Pulmonary arterial hypertension											p.1
1855	1144					Recommended	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6346848	Homo sapiens												73	311	Hypertension					21			40	week		p.261
1856	1145		adult			Overdose	mg	2400		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020685s073lbl.pdf	Homo sapiens													23	HIV-1											20
1857	1145					Higher than recommended	mg	1200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10513637/	Homo sapiens						42							5	HIV-1											97
1858	1146					Studied dose	mg	13		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2050969/	Homo sapiens												3	2						2.5			1	day		
1859	1146					Studied dose	mg	18		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4046139/	Homo sapiens													1									1	day		
1860	1146					Studied dose	mg	5.7		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4051281/	Homo sapiens													1									1	day		
1861	1146					Studied dose	ug	600		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206977Orig1s000MedR.pdf	Homo sapiens						35							36									1	day		
1862	1146						ug	50		steady					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01950260	Homo sapiens							total daily dose						30	Graves Disease								8	week		
1863	1147		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/010721s058lbl.pdf	Homo sapiens							max|total daily dose			For the control of vertigo associated with diseases affecting the vestibular system, the\nrecommended dose is 25 to 100 mg daily, in divided dosage				Vertigo, vestibular disorder											p.4
1864	1147		ADULT			Recommended	mg	50		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10674593/	Homo sapiens												45	108						18						p.276
1865	1148					Highest studied dose	mg/kg	0.1		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/1859751/	Homo sapiens						4.2							6	surgical procedures	20 ug/kg; 1/d			atropine				1	day		
1866	1148					Studied dose	mg	225		single			day	1	unhealthy	oral	M		https://link.springer.com/article/10.2165/00128415-201214130-00129	Homo sapiens						9							1	infection					9			1	day		
1867	1148					Studied dose	mg	5		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15896593/	Homo sapiens						51							1	polycystic kidney disease	1 mg; 1/d			glycopyrrolate	51			1	day		
1868	1149		adult			Overdose	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020636s050,020933s040lbl.pdf	Homo sapiens										overdose at doses ranging from 800 to 1800 mg per day for up to 15 days												15	day		
1869	1149		adult			Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020636s050,020933s040lbl.pdf	Homo sapiens																						14	day		
1870	1149		child				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00074412	Homo sapiens													758	HIV Infections								6	month		
1871	1149					Overdose	mg	200		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17605042	Homo sapiens										40 times the recommended dose of 2 mg/kg/day			1												
1872	1149					Recommended	mg	200		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201152Orig1s000MedR.pdf	Homo sapiens													506						18			14	day		p. 56
1873	1149					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201152Orig1s000MedR.pdf	Homo sapiens													505						18			14	day		p. 56
1874	1150					Overdose	mg	225		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6391305	Homo sapiens						26							1	Depression											p.1137/99
1875	1150					Overdose	mg	2760		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17823790	Homo sapiens						23							1	Depression	50 mg; single			olanzapine, p.o							p.1007
1876	1150					Overdose	mg	750		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14489944	Homo sapiens						20							1	Depression											
1877	1150					Recommended	mg	90		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf	Homo sapiens										Initial dose: The usual starting dose of NARDIL is one tablet (15 mg) three times a day. Early phase treatment: Dosage should be increased to at least 60 mg per day at a fairly rapid pace consistent with patient tolerance. It may be necessary to increase dosage up to 90 mg per day to obtain sufficient MAO inhibition. Maintenance dose: After maximum benefit from NARDIL is achieved, dosage should be reduced slowly over several weeks. Maintenance dose may be as low as one tablet, 15 mg, a day or every other day, and should be continued for as long as is required.				Depression											p.1
1878	1150					Recommended	mg	90		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011909s038lbl.pdf	Homo sapiens										Initial dose: The usual starting dose of NARDIL is one tablet (15 mg) three times a day. Early phase treatment: Dosage should be increased to at least 60 mg per day at a fairly rapid pace consistent with patient tolerance. It may be necessary to increase dosage up to 90 mg per day to obtain sufficient MAO inhibition. Maintenance dose: After maximum benefit from NARDIL is achieved, dosage should be reduced slowly over several weeks. Maintenance dose may be as low as one tablet, 15 mg, a day or every other day, and should be continued for as long as is required.				Depression											p.6
1879	1151					Highest studied dose	mg	40		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2932357	Homo sapiens										Patients were given a single daily loading dose of 40 mg of piroxicam intramuscularly on Days 1 and 2, followed by a daily injection of 20 mg of piroxicam on Days3 through 7. For the remainder of the trial, patients took on pepiroxicam capsule (20 mg) daily. If necessary, however, one 20 mg piroxicam capsule could be substituted for each daily injection starting on Day 4.		74	135	Acute sprains|Tendinitis| Low back pain					19			8	day		p.260
1880	1151					Overdose	mg	1800		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6496192	Homo sapiens						54							1	Arthralgia											
1881	1151					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2202544	Homo sapiens													40	Osteoarthritis								12	week		p.233
1882	1151					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9093797	Homo sapiens													117	Osteoarthritis								2	month		p.158
1883	1151					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018147s044lbl.pdf	Homo sapiens														Osteoarthritis|Rheumatoid arthritis											p.1
1884	1152		adult				mg	0.75		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00472199	Homo sapiens							max			4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.			166	Restless Legs Syndrome								26	week		
1885	1152		adult				mg	0.75		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00654498	Homo sapiens										4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily			202	Restless Legs Syndrome								6	week		
1886	1152		adult				mg	2.25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02397837	Homo sapiens													33	Bipolar Disorder								12	week		
1887	1152					Highest studied dose	mg	2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9214527	Homo sapiens						62.8							55	Parkinson's disease								10	week		p.128
1888	1152					Recommended	mg	1.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24834511	Homo sapiens						61.6	max			range 0.375–4.5 mg q.d.			391	Parkinson's disease								33	week		p.740
1889	1152					Recommended	mg	1.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24834511	Homo sapiens						63	max			range 0.375–4.5 mg q.d.			511	Parkinson's disease								33	week		p.740
1890	1152					Recommended	mg	1.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9305331	Homo sapiens						62.7	max			The dose was titrated over a period up to 7 weeks from 0.375 mg to a maximum of 4.5 mg daily in three divided doses. Patients entered the maintenance phase of the study once they achieved a dose of 4.5 mg daily or once dose-limiting toxicity developed			163	Parkinson's disease								31	week		p.727
1891	1153					Highest studied dose	mg	10		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2806513	Homo sapiens						56						68	12	bronchial asthma					44			1	week		
1892	1153					Overdose	mg	2		single					unhealthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/8400938	Homo sapiens						15							1						15						
1893	1153					Overdose	mg	2.5		single					pregnant	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/6102210	Homo sapiens						35							1						35						
1894	1153					Overdose	mg	50		single					pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/7793711	Homo sapiens						21							1						21						
1895	1153					Overdose	mg	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3692499	Homo sapiens						22													22						
1896	1153						ug/kg	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10891825	Homo sapiens						9.1	starting			a loading dose of 10 µg/kg over a 10-minute period followed by a maintenance infusion of 0.4 µg/kg/min.			29	severe asthma					9.1			10	min		
1897	1155		adult			Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9758292/	Homo sapiens							max			100 or 200 mg			881	chronic bronchitis or pneumonia								10	day		
1898	1155					Highest studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8522468/	Homo sapiens						27							4						27						
1899	1156		adult			Highest studied dose	mg	120		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/200179lbl.pdf	Homo sapiens													8												
1900	1156		adult			Highest studied dose	mg	2.4		single					healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/33325799	Homo sapiens													6												
1901	1156		adult			Recommended	mg	10		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-400_Levitra_Medr_P1.pdf	Homo sapiens													2203												p. 34
1902	1156					Highest studied dose	mg	2.4		multiple			day	12	healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/33325799	Homo sapiens						27.5	starting			at 2.4 mg doses administered two times every 4 hours (q4h) (Day 1), three times q4h (Day 2), and four times q4h (Days 3 through 9).		31	8						24						
1903	1157					Highest studied dose	mg/m2	2.8		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10080616	Homo sapiens										Vincristine sulfate liposome injection was administered on day 1 of each 21-day cycle as a 1-hour infusion.		83	3	Cancer					32			2	cycle		p.701
1904	1157					MTD	mg/m2	2.25		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19708032	Homo sapiens										VSLI was administered on a weekly basis as an intravenous infusion (either peripherally or through a central venous catheter) over 60 minutes at a dose of 2.25 mg/m2 concurrently with dexamethasone 40 mg intravenously or orally on Days 1 through 4 and Days 11 through 14 of each 4-week cycle.		62	18	Acute lymphoblastic leukemia	40 mg			dexamethasone, i.v.	19						p.1,6
1905	1157					MTD	mg/m2	2.4		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10080616	Homo sapiens										Vincristine sulfate liposome injection was administered on day 1 of each 21-day cycle as a 1-hour infusion.		83	6	Cancer					32			2	cycle		p.704
1906	1157					Recommended	mg/m2	2.25		multiple			week	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202497s011lbl.pdf	Homo sapiens										2.25 mg/m2 intravenously over 1 hour once every 7 days			83	Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)											p.8
1907	1157					Studied dose	mg/m2	2.4		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19708032	Homo sapiens										VSLI was administered on a weekly basis as an intravenous infusion (either peripherally or through a central venous catheter) over 60 minutes at a dose of 2.4 mg/m2 concurrently with dexamethasone 40 mg intravenously or orally on Days 1 through 4 and Days 11 through 14 of each 4-week cycle.		62	7	Acute lymphoblastic leukemia	40 mg			dexamethasone, i.v.	19						p.1,6
1908	1158		adult				mg	100		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00128102	Homo sapiens										Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.			329	Mesothelioma								3	day		
1909	1158					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021991lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/16960145	Homo sapiens						69	starting			300 mg twice daily for 3 days per week, and the frequency was escalated to 5 days per week if tolerated		80	12	cutaneous Tcell lymphoma					26			3	day		
1910	1158						mg	250		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/18297527	Homo sapiens						63				twice daily for 5 days each week of a 4-week cycle		74	5	advanced multiple myeloma					38			5	day		
1911	1162					Studied dose	mg	20		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012462s048lbl.pdf	Homo sapiens										The initial adult dosage is 2 Lomotil tablets four times daily. Each Lomotil tablet contains: 2.5 mg of diphenoxylate hydrochloride and 0.025 mg of atropine sulfate.					0.025 mg			atropine sulfate				2	day		
1912	1162						mg	300		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012462s048lbl.pdf	Homo sapiens							max			A dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tablets. Duration was 40-70 days												40	day		
1913	1163					Recommended	mg	0.5		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3297483/	Homo sapiens										Ethynodiol diacetate (Femulen), an oral contraceptive, was provided in a 28-tablet blister pack. The tablets were taken continuously from day one of the menstrual cycle or from the 15th day following delivery. Women were advised to take one tablet at the same time each day.		47	425						16			1	year		
1914	1163					Recommended	mg	0.5		steady					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4870629/	Homo sapiens										The formulation consisted of 10 tablets containing 0·1 mg of mestranol, followed by 10 tablets containing 0·1 mg of mestranol combined with 0·5 mg of ethynodiol diacetate (SC11800). In the first cycle, medication was commenced on the fifth day, but in subsequent cycles only five days of freedom from treatment were allowed, in the hope of avoiding pituitary rebound. Therefore, medication was recommenced usually about the second or third day of the cycle.			178		0.1 mg; oral; 1/day			mestranol							
1915	1164		adult			Recommended	mg	20		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020632s034s035lbl.pdf	Homo sapiens							max			5 to 20 mg			2068	obesity								52	week		14
1916	1164					Higher than recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						42.9							146	obesity								24	week		
1917	1164					Higher than recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23444896/	Homo sapiens						32							7	vasovagal syncope								137	day		
1918	1164					Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						43.4							151	obesity								24	week		
1919	1164					Minumum effective dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						44.5							149	obesity								24	week		
1920	1164					Minumum effective dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						43.4							169	obesity								24	week		
1921	1164					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						43.3							203	obesity								24	week		
1922	1164					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10102256/	Homo sapiens						44.2							196	obesity								24	week		
1923	1164					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23444896/	Homo sapiens						32							7	vasovagal syncope								98	day		
1924	1165					Recommended	mg/kg	5		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/50747_Synercid_medr_P1.pdf	Homo sapiens						52.9							263	Infection	2.5 mg/kg, IV, Q8H15			QUINUPRISTIN				5	day		Study 301
1925	1167					Highest studied dose	mg	0.3		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/12372940	Homo sapiens													5	anuric patients with symptomatic hypotension											
1926	1168		adult				mg	100		multiple			day	1	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/16078335/	Homo sapiens													172	tendinitis											
1927	1168					Overdose	mg	2400		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf	Homo sapiens						45				twelve 200 mg Oruvail									45						
1928	1168						mg	12.5		single					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf	Homo sapiens						36.8						65	90						18						p. 34
1929	1168						mg/kg	1		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10456820	Homo sapiens							starting			1 mg/kg ketoprofen injected over 10 min i.v. as a loading dose, followed by an infusion of 4 mg kgª1 ketoprofen over 24 h up to 72 h.			29									72	hour		
1930	1168						ug	100		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02257970	Homo sapiens							max			Ketoprofen 225-300 mgs daily, taken orally			50	Lymphedema								6	month		
1931	1168						ug	75		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02257970	Homo sapiens													19	Lymphedema								4	month		
1932	1168						ug	75		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02257970	Homo sapiens													21	Lymphedema								4	month		
1933	1168						ug	75		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02257970	Homo sapiens													23	Lymphedema								4	month		
1934	1169		adult			Recommended	mg	420		multiple			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	Homo sapiens																									
1935	1169		adult			Recommended	mg	84		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf	Homo sapiens										two 42 mg capsules			114	Parkinson’s disease											
1936	1169		adult			Recommended	mg	84		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209184Orig1s000MedR.pdf	Homo sapiens										two 42 mg capsules			114	Parkinson’s disease											p. 77
1937	1169		child|adult				mg/kg	0.51		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01176435	Homo sapiens													15	Vision Impairment								20	week		
1938	1169		child|adult				mg/kg	0.76		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01176435	Homo sapiens													15	Vision Impairment								20	week		
1939	1169						g	3		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5550880	Homo sapiens						54							1	idiopathic Parkinson's disease					54			3	week		
1940	1169						mg	3500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4856355	Homo sapiens						60							1	Parkinson’s disease					60			1	month		
1941	1169						mg	4000		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4856355	Homo sapiens						70							1	Parkinson’s disease					70			1	year		
1942	1170		adolescent				mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00102063	Homo sapiens													100	schizophrenia								42	day		
1943	1170		adolescent				mg	30		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00102063	Homo sapiens													102	schizophrenia								42	day		
1944	1170		adult			Overdose	mg	1080		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf	Homo sapiens													1												
1945	1170		adult			Recommended	mg	10		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf	Homo sapiens														Dementia-Related Psychosis								2	week		
1946	1170		children				mg	15		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00198107	Homo sapiens							max			10 mg for < 50 kg, 15 mg for pts with weight > 50 kg			40	autism											
1947	1170					Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18626272	Homo sapiens												17	6	Psychiatric Disorders					10			14	day		
1948	1170					Highest studied dose	mg	45		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/18563956/	Homo sapiens						39				in three equal-dose in jections over a 4-hour period only on day 1.		65	4	schizophrenia					18						
1949	1170					Overdose	mg	195		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021729lbl.pdf	Homo sapiens													10												
1950	1170						mg	15		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01338298	Homo sapiens													20	schizophrenia											
1951	1170						mg	2		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18563956/	Homo sapiens						35						45	16						18						
1952	1170						mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00489866	Homo sapiens							max			Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks			7	posttraumatic stress disorder								2	week		
1953	1170						mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00497055	Homo sapiens													45	Methamphetamine Dependence								9	week		
1954	1170						mg	400		steady			4 weeks	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00705783	Homo sapiens										Aripiprazole depot			269	schizophrenia								52	week		
1955	1171		children			Recommended	g	1		steady			day	3	unhealthy	intramuscular	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf	Homo sapiens							median						343	infections								5	day		
1956	1171		children			Recommended	g	1		steady			day	3	unhealthy	intramuscular	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050580s042lbl.pdf	Homo sapiens							median						612	infections								5	day		
1957	1171					Recommended	g	1		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/3102347/	Homo sapiens												75	102	urogenital gonorrhoea					18						
1958	1171					Recommended	mg/kg	30		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/3774385/	Homo sapiens												18	10	cystic fibrosis					10						
1959	1172		adult			Recommended	mg	7.5		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33070009/	Homo sapiens							mean						17	Parkinson's disease, anxiety								12	week		
1960	1172					Highest studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28846022/	Homo sapiens							median						334	generalized anxiety disorder								6	week		
1961	1172					Overdose	mg	2250		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/15386505/	Homo sapiens						36							1						36						
1962	1172						mg	15		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02458469	Homo sapiens													10	Spinal Cord Injury								2	week		
1963	1172						mg	20		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02132832	Homo sapiens													19	Marijuana Dependence								9	day		
1964	1172						mg	30		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00875836	Homo sapiens													88	Marijuana Dependence								12	week		
1965	1172						mg	30		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02803749	Homo sapiens													17	Parkinson's disease								12	week		
1966	1173		adult				mg	160		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00878969	Homo sapiens										80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months			25	Endothelial Dysfunction								18	month		
1967	1173		adult				mg	320		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00208767	Homo sapiens							max|total daily dose			Valsartan was titrated to a target dose of 320 mg orally daily			80	Carotid Artery Disease								2	year		
1968	1173		adult				mg	320		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00696436	Homo sapiens										Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks. Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.			277	Hypertension								6	week		
1969	1173		adult				mg	320		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01281306	Homo sapiens										Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.			143	Hypertension								8	week		
1970	1173					Highest studied dose	mg	640		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17762658	Homo sapiens						57.5							131						57.5			24	week		
1971	1173					Overdose	mg	2.24		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/15222725	Homo sapiens						25				28 Diovan 80 mg tablets (2.24 g)			1						25						
1972	1173					Recommended	mg	320		steady			day	1	pregnant	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/15329835	Homo sapiens																									
1973	1173					Recommended	mg	320		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	Homo sapiens													2316	hypertension								6	month		
1974	1173					Recommended	mg	320		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf	Homo sapiens													2506	Heart Failure								6	month		
1975	1174					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30420123/	Homo sapiens								300 mg				42	717	HIV-1	50 mg			dolutegravir	26			48	week	tenofovir disoproxil fumarate	
1976	1175		adult			Recommended	mg	15		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020415s034s036,021208s024s026lbl.pdf	Homo sapiens													453									6	week		
1977	1175		adult				mg	60		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00249444	Homo sapiens							max|total daily dose			Mirtazapine will be administered on a fixed-flexible schedule, with dose titrated up to 60 mg per day or the maximum tolerated dose.			42	Comorbid Cocaine Dependence and Depression								8	week		
1978	1175		child				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01302964	Homo sapiens							max|total daily dose			The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.			20	Anxiety								10	week		
1979	1175		children			Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020415s034s036,021208s024s026lbl.pdf	Homo sapiens														major depressive disorde											
1980	1175					Highest studied dose	mg	75		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18370465	Homo sapiens												35							18						
1981	1175					Recommended	mg	15		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32676274	Homo sapiens						55							1						55			6	week		
1982	1176		adult			Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208232Orig1s000MedR.pdf	Homo sapiens							max			median duration			28	acromegaly								252	day		
1983	1176		adult				mg	40		multiple			4 weeks	1	unhealthy	intramuscular	M+F		https://clinicaltrials.gov/ct2/show/NCT00426153	Homo sapiens							max						28	Polycystic Liver Disease								1	year		
1984	1176					Studied dose	mg	20		multiple			4 weeks	1	unhealthy	intramuscular	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/021008a_medr_P1.pdf	Homo sapiens						49.4	mean						151	acromegaly								24	week		
1985	1176					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/208232Orig1s000MedR.pdf	Homo sapiens						54.2	max			median duration			155	acromegaly								42.4	week		
1986	1176					Studied dose	mg	40		multiple			month	1	unhealthy	intramuscular	M+F		https://www.fda.gov/media/115272/download	Homo sapiens						12.9							30	hypothalamic obesity								6	month		
1987	1177					Recommended	mg	5		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf	Homo sapiens							starting							Hypertension								12	week		
1988	1178					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18276803/	Homo sapiens												17	15	chronic hepatitis B					12						
1989	1178					Recommended	mg/kg	0.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18276803/	Homo sapiens										0.14 than 0.3 mg/kg		11	19	chronic hepatitis B					7						
1990	1178					Recommended	mg/kg	0.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18276803/	Homo sapiens												6	13	chronic hepatitis B					2						
1991	1179					Highest studied dose	mg	32		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/12502672	Homo sapiens						59							6	Type 2 Diabetes					59			2	month		
1992	1179					Recommended	mg	16		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11141435	Homo sapiens						41							1		10 mg/day			amlodipine	41			5	month		
1993	1179					Recommended	mg	16		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020838s036lbl.pdf	Homo sapiens																									
1994	1179					Recommended	mg	23		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020838s036lbl.pdf	Homo sapiens						67	mean			The mean daily dose was approximately 23 mg and 59% of subjects on treatment received 32 mg once daily.			207	heart failure					67			34	month		
1995	1179						mg	2		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020838s036lbl.pdf	Homo sapiens										14 placebo-controlled trials. primarily at daily doses of 2 to 32 mg per day			2350									4	week		
1996	1180					Recommended	%	0.05		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/7152080	Homo sapiens						36							25	Psoriasis								3	week		p.420
1997	1182		adult			Recommended	mg/m2	25		steady			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022137lbl.pdf	Homo sapiens										Each 5-day course of treatment should commence every 28 days.				B-cell chronic lymphocytic leukemia								5	day		
1998	1182		adult			Recommended	mg/m2	40		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022273lbl.pdf	Homo sapiens										Begin each 5-day course of treatment every 28 days.				B-cell chronic lymphocytic leukemia								5	day		
1999	1182					Highest studied dose	mg/m2	100		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2428488	Homo sapiens						32				as a continuous infusion		59	2	Acute Leukemia					19			5	day		
2000	1182					MTD	mg/m2	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2452888	Homo sapiens						55				a loading dose of 20 mg/m2 followed by a CIV infusion of 45mg/m2/24 hours for 48 hours		78							26			2	day		
2001	1182					MTD	mg/m2	40		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2428488	Homo sapiens						32				as a continuous infusion		59	11	Acute Leukemia					19			5	day		
2002	1182					Recommended	mg/m2	40		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022273s000_MedR.pdf	Homo sapiens						64						75	81						30			5	day		p. 61
2003	1182						mg/m2	45		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2452888	Homo sapiens						55				every 24 hours for 48 hours		78	1						26			2	day		
2004	1183					Higher than recommended	mg	500		multiple			week	1	healthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/3140580	Homo sapiens						31.6							16	Preterm birth								16	week		p.179
2005	1184					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9839093/	Homo sapiens						57.2	max			Forced titration from 25-50 mg t.i.d. and a titration of 50-100 mg tid that was based on glucose control.			84	diabetes mellitus								24	week		
2006	1184					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11323089/	Homo sapiens						63	max			This 5-year surveillance study assessed the tolerability and safety of acarbose in patients with diabetes. The mean starting daily dose of acarbose was 152 mg (range 50–300 mg, median 150 mg). At the end of the 5-year surveillance period themean daily dose was 201 mg (range 50–300 mg,median 200 mg). One-third of the patients received acarbose as monotherapy and two-thirds in combination with other glucose-lowering treatment.			1954	diabetes mellitus, type 2								5	year		
2007	1184					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17532710/	Homo sapiens						63	max			Acarbose was dosed as recommended in the medical data sheet, i.e. starting with low doses in order to avoid intestinal symptoms like flatulence or diarrhoea and increasing the dose slowly. The initial dose per day was <100mg for 27.7% of patients, 66.6% received 100–250mg, and 5.7% received 250–300mg. After 12 weeks of acarbose treatment, 4.1% of patients with type 2 diabetes received <100mg, 64.1% received 100–250mg, and 31.7% received 250–300mg. Only 0.1% of patients received doses >300 mg/day. The fact that 68.2% of patients were treated with an acarbose dose <250 mg/day even at the end of the 12-week observation period is important for the interpretation of the results.			27803	diabetes mellitus								12	week		
2008	1185		adult			Recommended	mg	1000		multiple			day	4	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000MedR.pdf	Homo sapiens													92	Acute pain								5	day		
2009	1185		adult			Recommended	mg	650		multiple			day	6	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000MedR.pdf	Homo sapiens													91	Acute pain								5	day		
2010	1185					Recommended	g	1		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32620339/	Homo sapiens						31							202									28	day		
2011	1185					Studied dose	g	10		single			day	1	unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/8296799/	Homo sapiens						37	max			plus 10 g 2 days earlier			1						37			1	day		
2012	1185					Studied dose	g	5.75		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12426016/	Homo sapiens						54	mean			6 to 8 weeks			1	pain					54			7	week		
2013	1185					Studied dose	g	9		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18338302/	Homo sapiens						47							1	pain					47			2	day		
2014	1185						mg	1000		single					healthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02418182	Homo sapiens													33	pain											
2015	1185						mg	650		multiple			day	4	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01420653	Homo sapiens													111	Dental Pain								48	hour		
2016	1186					Highest studied dose	g	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14127093/	Homo sapiens							max						100	diabetes mellitus								7	month		
2017	1186					Recommended	g	0.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2013345/	Homo sapiens						74							1	diabetes mellitus								20	year		
2018	1187					Highest studied dose	mg	100		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3400079/ | https://pubmed.ncbi.nlm.nih.gov/9703120/	Homo sapiens						34							12									1	day		
2019	1187					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12423433/	Homo sapiens						54.4							23	renal transplant								1	year		
2020	1187					Recommended	mg/kg	0.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10233316/	Homo sapiens						52							16	renal transplant								5	year		
2021	1187					Studied dose	mg	20		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25775629/	Homo sapiens						69							1	bullous lichen sclerosus	30 mg; 1/d			prednisone	69			2	day		
2022	1187					Studied dose	mg	525		single			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/019821_S002&S006_SORIATANE_AP.pdf	Homo sapiens						32							1	Darier's disease					32			1	day		
2023	1187						mg	30		steady					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01078168	Homo sapiens							total daily dose						11	Alzheimer's Disease								28	day		
2024	1188					Highest studied dose	mg	24		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7867679/	Homo sapiens												45	18						21						
2025	1189					Recommended	%	0.3		multiple			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/22007702	Homo sapiens												65	40	Cutaneous photoaging					45			6	month		p.59
2026	1189					Recommended	%	0.3		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021753s004lbl.pdf	Homo sapiens														Acne											p.1
2027	1189					Studied dose	%	0.1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/20415678	Homo sapiens													87	Acne								12	week		p.1364
2028	1191					Highest studied dose	mg	3200		multiple			day	1	unhealthy	oral	F		https://books.google.ru/books?id=0imPNTTuyysC&pg=PA57&lpg=PA57&dq=albendazole+3200+mg/day&source=bl&ots=puJwTcRNB9&sig=ACfU3U0fo-4zPrZjg81VYFlMRRe9brtv2w&hl=ru&sa=X&ved=2ahUKEwiV7_Dagd_tAhVL-yoKHfNGCfwQ6AEwCHoECAUQAg#v=onepage&q=albendazole%203200%20mg%2Fday&f=false	Homo sapiens						38							1	Neurocysticercosis								4	day		p.57-58
2029	1191					MTD	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19904538	Homo sapiens										Cycle: treatment - 14 days; break - 7 days; at least 7 cycles			9	Advanced cancer								14	day		p.600
2030	1191					Overdose	g	16		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf	Homo sapiens							total daily dose			a patient took at least 16 grams over 12 hours			1	Hydatid Disease								12	hour		p.10
2031	1191					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf	Homo sapiens														Hydatid Disease											p.9
2032	1191					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf	Homo sapiens														Hydatid Disease|Neurocysticercosis											p.6
2033	1191					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020666s005s006lbl.pdf	Homo sapiens														Hydatid Disease|Neurocysticercosis											p.9
2034	1193		adult			Highest studied dose	mg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018276s052lbl.pdf	Homo sapiens													641	panic disorder								10	week		
2035	1193					Overdose	mg/kg	0.23		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/10643652/	Homo sapiens						30		1.29 g/kg					1		38.3 mg/l			tramadol	30					alcohol	
2036	1193						mg	1		multiple			week	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT03012334	Homo sapiens													85	Migraine								28	week		
2037	1194					Highest studied dose	mg	420		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25650051	Homo sapiens						66.4							20	Levodopa-Induced Dyskinesia in Parkinson Disease								8	week		p.793
2038	1194					Overdose	g	0.8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19135627	Homo sapiens						2				accidental			1												p.120
2039	1194					Overdose	g	10		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18821491	Homo sapiens						47				suicide attempt			1	Schizophrenia	250 mg, single			diphenhydramine, p.o							p.174
2040	1194					Overdose	mg	3000		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3791133	Homo sapiens						23				suicide			1	Schizophrenia											p.757
2041	1194					Recommended	mg	274		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28604926	Homo sapiens						63.9							63	Levodopa-Induced Dyskinesia in Parkinson Disease								25	week		
2042	1194					Recommended	mg	274		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29368539	Homo sapiens						53.3							27	Multiple sclerosis								4	week		p.605
2043	1194						mg	100		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02486211	Homo sapiens													7	Cardiac Arrest								1	week		
2044	1194						mg	100		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01071395	Homo sapiens													36	Parkinson's disease											
2045	1195		adult			Highest studied dose	mg	100		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Homo sapiens																									
2046	1195		adult			Recommended	mg	5		multiple			day	1	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Homo sapiens														pulmonary arterial hypertension											
2047	1195		adult			Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Homo sapiens														pulmonary arterial hypertension											
2048	1195		children				mg	5		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02080637	Homo sapiens							max						13	heart defects								3	day		
2049	1195					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf | https://pubmed.ncbi.nlm.nih.gov/22506623	Homo sapiens						45.6							17	pulmonary arterial hypertension					45.6			114	week		
2050	1195						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00768300	Homo sapiens							max						329	Early Idiopathic Pulmonary Fibrosis								4	year		
2051	1195						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02290613	Homo sapiens							max						19	Arterial Hypertension								6	month		
2052	1196						mg	1		steady			day	3	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/18498s8lbl.pdf	Homo sapiens										Topical Lotion or cream contain 1 mg of the active steroid amcinonide. Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.				corticosteroidresponsive dermatoses											
2053	1196						mg	1		steady			day	3	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/19729_Cyclocort.pdf	Homo sapiens													78	corticosteroidresponsive dermatoses											
2054	1197		adult			Recommended	mg/m2	200		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020221s033lbl.pdf	Homo sapiens													150	Head and Neck Cancer				radiation treatment				19.8	month		9
2055	1197		adult			Recommended	mg/m2	910		multiple			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020221s033lbl.pdf	Homo sapiens													122	Ovarian Cancer	100 mg/m2			cisplatin				19.8	month		9
2056	1198					Highest studied dose	g	10		multiple			hour	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7580360	Homo sapiens										10 g IV at induction of anesthesia, followed by infusion of 2 g/h for 5 hours		74	15	Fibrinolytic Bleeding					50			5	hour		
2057	1198					Recommended	g	5		multiple			hour	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/015230s037lbl.pdf	Homo sapiens										For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR 1000 mg Tablets or 10 AMICAR 500 mg Tablets (5 g) or 20 milliliter of AMICAR Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR 1000 mg Tablet or 2 AMICAR 500 mg Tablets (1 g) or 5 milliliter of AMICAR Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.				Fibrinolytic Bleeding								8	hour		p.6
2058	1198					Studied dose	g	2		multiple			hour	6	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/015230s037lbl.pdf	Homo sapiens													1	Fibrinolytic Bleeding											p.6
2059	1199					Recommended	mg	250		steady			day	4	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf	Homo sapiens							starting															2	week		
2060	1199					Recommended	mg	250		steady			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6691645	Homo sapiens							starting						163	hormonally responsive breast cancer								3	week		
2061	1200						mg	50		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01975935	Homo sapiens													21	Type 2 Diabetes								10	week		
2062	1201						mg	300		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072691s036lbl.pdf	Homo sapiens										Amoxapine may be given in a single daily dose, not to exceed 300 mg, preferably at bedtime. If the total daily dosage exceeds 300 mg, it should be given in divided doses.				depression								3	week		
2063	1202		adult			Highest studied dose	mg	60		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9797018/ | https://pubmed.ncbi.nlm.nih.gov/7626450/	Homo sapiens													4									1	day		
2064	1202					Highest studied dose	mg	30		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21316048/	Homo sapiens						28.6				for the unhealthy woman			38	ovulatory dysfunctio								1	day		
2065	1202					Recommended	mg	1		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022214s000MedR.pdf	Homo sapiens						13							36	gynecomastia								6	month		nda/2008/022214s000MedR.pdf - p.53
2066	1202					Recommended	mg	1		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022214s000MedR.pdf	Homo sapiens						14.6							39	gynecomastia								6	month		nda/2008/022214s000MedR.pdf - p.53
2067	1202						mg	1		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01545336	Homo sapiens													12	Pulmonary Arterial Hypertension								3	month		
2068	1203		adult			Recommended	mg	10		steady			day	1	unhealthy	subcutaneous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf	Homo sapiens							max			2 to 10 mg			522	Parkinson's disease				trimethobenzamide				2	month		4
2069	1203		adult			Recommended	mg	10		steady			day	1	unhealthy	subcutaneous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021264s010lbl.pdf	Homo sapiens							max			2 to 10 mg			522	Parkinson's disease								2	month		5
2070	1203		adult				mg	144		steady			day	1	unhealthy	subcutaneous	M+F		https://clinicaltrials.gov/ct2/show/NCT02006121	Homo sapiens							max			Hourly flow rate adjusted in increments of 0.5-1.0 mg/hour/day during titration to reach the patient's individualized required dose in a range of 3-8 mg/hour for 14-18 hours per day.			98	Parkinson's Disease								12	week		
2071	1203					Highest studied dose	mg	4		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/18978491/	Homo sapiens						65.21	mean						546	Parkinson's disease					65.21			12	month		
2072	1203					Highest studied dose	mg	4		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/23527823/	Homo sapiens												90	5	Parkinson's disease					30						Table 2
2073	1203					Recommended	mg	1.5		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/23527823/	Homo sapiens												90	32	Parkinson's disease					30						Table 2
2074	1203					Recommended	mg	10		steady			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/31111272/	Homo sapiens												87	114	Parkinson's disease					44			6	month		Fig. 1
2075	1203					Recommended	mg	2.3		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/23527823/	Homo sapiens												90	18	Parkinson's disease					30						Table 2
2076	1203					Recommended	mg	3		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/23527823/	Homo sapiens												90	12	Parkinson's disease					30						Table 2
2077	1203					Recommended	mg	35		steady			day	1	unhealthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/31818699/	Homo sapiens						62.9	max			10 to 35 mg			54	Parkinson's disease								12	week		
2078	1204		adult			Recommended	mg	130		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209296Orig1s000MedR.pdf	Homo sapiens													50									30	min		p. 27
2079	1204						mg	125		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31958446	Homo sapiens						53				125 mg was administered orally on day 1 followed by 80 mg orally daily on days 2 to 7		73	64	Cough					23						
2080	1204						mg	125		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00896038	Homo sapiens													30	Post traumatic stress disorder								21	day		
2081	1204						mg	125		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01149369	Homo sapiens													63	Chronic Nausea and Vomiting								4	week		
2082	1204						mg	40		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00888329	Homo sapiens													34	Gynecologic Surgery Population											
2083	1205		adult			Studied dose	g	10		single			day	1	unknown	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s032lbl.pdf	Homo sapiens													1									1	day		
2084	1205					Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/776487/	Homo sapiens						42							1	hypertension					42			2	week		
2085	1205					Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3802701/	Homo sapiens						62							32	ventricular ectopy								2	week		
2086	1205					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3802701/	Homo sapiens						62							32	ventricular ectopy								2	week		
2087	1205					Recommended	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3802701/	Homo sapiens						62							32	ventricular ectopy								2	week		
2088	1205					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6111212/	Homo sapiens						53	mean						9	angina pectoris								1	month		
2089	1205					Studied dose	mg	540		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/776487/	Homo sapiens							mean					65	16	hypertension					42			10	week		
2090	1205						mg	50		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01522950	Homo sapiens													18	Hypertension								8	month		
2091	1206					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/8851570	Homo sapiens													6	HIV inection								14	day		p.559
2092	1206					Overdose	mg	31500		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens														Pneumocystis carinii pneumonia				dapsone							p.16
2093	1206					Recommended	mg	1500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens													175	Pneumocystis carinii pneumonia											p.12
2094	1206					Recommended	mg	1500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens													203	Pneumocystis carinii pneumonia											p.12
2095	1206					Recommended	mg	1500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens													203	Pneumocystis carinii pneumonia											p.13
2096	1206					Recommended	mg	1500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020500s010lbl.pdf	Homo sapiens													73	Pneumocystis carinii pneumonia											p.15
2097	1207					Overdose	mg	27		multiple			day	1	unhealthy	oral	F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display	Homo sapiens						50	total daily dose						1	Rheumatoid arthritis								10	day		
2098	1207					Recommended	mg	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1536666	Homo sapiens						51							115	Rheumatoid arthritis								48	week		p.266
2099	1207					Recommended	mg	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6416259	Homo sapiens												76	72	Rheumatoid arthritis					22			21	week		p.1310
2100	1207					Recommended	mg	3		multiple			day	3	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display	Homo sapiens														Rheumatoid arthritis											
2101	1207					Recommended	mg	6		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27821451	Homo sapiens							total daily dose						15									7	day		p.2
2102	1207					Recommended	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2688083	Homo sapiens							total daily dose					63	67	Rheumatoid arthritis					45			24	month		p.254
2103	1208		adult			Highest studied dose	mg/m2	45		multiple			2 weeks	5	unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/33636454	Homo sapiens										daily on days 1-5 and 15-19 of 28-day cycle			8	advanced non-small cell lung cancer								28	day		
2104	1208		adult			Overdose	mg/m2	290		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208216s000lbl.pdf	Homo sapiens													1												
2105	1208		adult			Recommended	mg/m2	75		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208216s000lbl.pdf	Homo sapiens							starting			starting dose for the first treatment cycle is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.												7	day		
2106	1208		adult			Recommended	mg/m2	75		multiple			day	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208216s000lbl.pdf	Homo sapiens							starting			starting dose for the first treatment cycle is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.												7	day		
2107	1208					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21576646	Homo sapiens						70				1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle1, followed by oral azacitidine daily (120 to 600 mg) on the first 7 days of each additional 28-day cycle.		91	3	myelodysplastic syndromes | chronic myelomonocytic leukemia | acute myeloid leukemia					31			7	day		
2108	1208					MTD	mg	480		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21576646	Homo sapiens						70				1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle1, followed by oral azacitidine daily (120 to 600 mg) on the first 7 days of each additional 28-day cycle.		91	14	myelodysplastic syndromes | chronic myelomonocytic leukemia | acute myeloid leukemia					31			7	day		
2109	1208					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214120s000lbl.pdf	Homo sapiens						68				once daily on Days 1 through 14 of each 28-day cycle		86	236	Acute Myeloid Leukemia					55			14	day		
2110	1209					Highest studied dose	mg	8		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/37045	Homo sapiens												25	32						18						
2111	1211					Recommended	mg	10		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3912190/	Homo sapiens												81	12	stroke					69			18	day		
2112	1211					Recommended	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15597084/	Homo sapiens						42							12	alcohol dependence								12	week		
2113	1211					Studied dose	mg	240		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8007036/	Homo sapiens						21							1	cerebral palsy					21			1	day		
2114	1211					Studied dose	mg	500		single			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021589s000_Kemstro_MedR.pdf	Homo sapiens						25							1						25			1	day		nda/2003/021589s000_Kemstro_MedR.pdf - p.36
2115	1211					Studied dose	mg	800		single			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021589s000_Kemstro_MedR.pdf	Homo sapiens						42							1	spasticity					42			1	day		nda/2003/021589s000_Kemstro_MedR.pdf - p.36
2116	1211					Studied dose	mg	800		single			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021589s000_Kemstro_MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/9711203/	Homo sapiens						42							1	spasticity					42			1	day		nda/2003/021589s000_Kemstro_MedR.pdf - p.36
2117	1211						mg	10		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01008280	Homo sapiens													88	Hepatitis C											
2118	1211						mg	10		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01751386	Homo sapiens													20	Alcoholism											
2119	1211						mg	10		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01980706	Homo sapiens													43	Alcohol Dependence								16	week		
2120	1211						mg	30		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01980706	Homo sapiens													37	Alcohol Dependence								16	week		
2121	1213					Highest studied dose	mg/m2	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10430065	Homo sapiens													6	Cancer											p.1660
2122	1213					MTD	mg/m2	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11352954	Homo sapiens						59		100 mg/m2; once in 6 weeks					28	Non-small-cell lung cancer	15-30 mg/m2; once in 2 weeks			Vinorelbine, i.v						cisplatin, i.v	p.2629, 2632
2123	1213					Recommended	mg/m2	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021055s010lbl.pdf	Homo sapiens										Recommended initial dose is 300 mg/m2/day.				Cutaneous T-cell lymphoma											p.1
2124	1213					Studied dose	mg/m2	500		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12637463	Homo sapiens						56							45	Breast Cancer											p.1003
2125	1213					Studied dose	mg/m2	500		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12637463	Homo sapiens						56							45	Breast Cancer											p.1004
2126	1214		adult			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9471040/	Homo sapiens													29	prostate cancer								12	week		
2127	1214		adult			Recommended	mg	50		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf	Homo sapiens										The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that CASODEX be taken at the same time each day.			401	prostate cancer				LHRH analog							
2128	1214					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16771791/	Homo sapiens						72.1				Patients were initially recruited into a nonrandomized phase to assess the tolerability of oral bicalutamide 300 mg (two 150 mg tablets) given once daily. Tolerance was assessed in these patients after 6 weeks of treatment and, if acceptable, future patients were randomized on 1 : 1 to either bicalutamide 450 mg (three 150 mg tablets) or castration (bilateral orchidectomy or goserelin acetate 3.6 mg depot every 28 days). If, after 6 weeks, tolerance at the 450 mg dose was acceptable, further patients were to be randomized at 1 : 1 : 1 to bicalutamide 450 mg, bicalutamide 600 mg (four 150 mg tablets) or castration. However, if tolerance at the 450 mg dose was unacceptable, future patients were to be randomized to bicalutamide 300 mg or castration. If the 600 mg dose was acceptable (after 6 weeks of follow-up), recruitment to the bicalutamide 450 mg dose was ended and all future patients entering the study were to be randomized at 1 : 1 : 1 to bicalutamide 600 mg, bicalutamide 750 mg (five 150 mg tablets) or castration.		84	42	prostate cancer					56			29.2	month		
2129	1215		adult			Recommended	mg/mL	0.3		multiple			day	1	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022369s000_MedR.pdf	Homo sapiens										0.03%; 1 drop into the eye			137												p. 52
2130	1215		adult				%	0.01		multiple			day	1	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022184Orig1s000MedR.pdf	Homo sapiens										1 drop into the eye			186												p. 28
2131	1215		adult				%	0.0125		multiple			day	1	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022184Orig1s000MedR.pdf	Homo sapiens										1 drop into the eye			188												p. 28
2132	1217					Highest studied dose	mg/m2	1.9		steady			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20213332	Homo sapiens						52							33	recurrent malignant glioma					52			6	week		
2133	1217					MTD	mg/m2	1.7		steady			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20213332	Homo sapiens						52				The duration of a cycle was defined as 6 weeks, with bortezomib given twice a week for four consecutive weeks, followed by 2 weeks without treatment.			33	recurrent malignant glioma					52			6	week		
2134	1217					Recommended	mg/m2	1.3		steady			week	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205004s000lbl.pdf	Homo sapiens						71		60 mg/m2		Bortezomib for Injection (1.3 mg/m2/dose) is administered twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 to 21).		91	340	multiple myeloma	9 mg/m2			melphalan	48			54	week	prednisone	
2135	1217					Recommended	mg/m2	1.3		steady			week	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205004s000lbl.pdf	Homo sapiens										Bortezomib was administered intravenously at doses of 1.3 mg/m2 twice weekly for 2 out of 3 weeks (21-day cycle). After eight 21-day cycles patients continued therapy for three 35-day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (9 months) with a median duration of 6 cycles (4.1 months).			331	multiple myeloma |mantle cell lymphoma								4.1	month		
2136	1217					Recommended	mg/m2	1.3		steady			week	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205004s000lbl.pdf	Homo sapiens										Bortezomib was administered intravenously at doses of 1.3 mg/m2 twice weekly for 2 out of 3 weeks (21-day cycle). After eight 21-day cycles patients continued therapy for three 35-day cycles on a weekly schedule. Duration of treatment was up to 11 cycles (9 months) with a median duration of 6 cycles (4.1 months).			331	relapsed multiple myeloma								4.1	month		
2137	1218		adult			Recommended	%	0.33		steady			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204708Orig1s000MedR.pdf	Homo sapiens										The product contains 0.5% brimonidine tartrate (salt) which is equivalent to 0.33% brimonidine (active moiety). In			330									29	day		p. 66
2138	1218		adult				%	0.07		single					unhealthy	topical	M+F		https://clinicaltrials.gov/ct2/show/NCT00989014	Homo sapiens													28	Erythematotelangiectatic Rosacea											
2139	1218		adult				%	0.5		single					unhealthy	topical	M+F		https://clinicaltrials.gov/ct2/show/NCT00989014	Homo sapiens													31	Erythematotelangiectatic Rosacea											
2140	1218						%	0.33		single					unhealthy	oromucosal	M		https://pubmed.ncbi.nlm.nih.gov/28297016	Homo sapiens						4							1						4						
2141	1218						%	0.5		single					unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-490S007_Brimonidine%20Tartrate%20Ophthalmic_medr.pdf	Homo sapiens						4.8						7	38						2						p. 19
2142	1221					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7040493	Homo sapiens										The doses used was 1 mg; graded increases were administered to daily maxima of 10 mg bumetanide		72	18	Renal edema					22						p.597
2143	1221					Recommended	mg	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28291262	Homo sapiens													21	Autism spectrum disorders								3	month		p.4
2144	1222					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16367894	Homo sapiens													34	Parkinson’s disease	370.6 mg			L-dopa, po				10	week		p.18, p.19, p.22
2145	1222					Overdose	mg	2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf	Homo sapiens							min			high doses of DOSTINEX (>2mg/day) for the treatment of Parkinson’s disease (the recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg)				Parkinson’s disease											p.4
2146	1222					Recommended	mg	0.5		multiple			week	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf	Homo sapiens													221	Hyperprolactinemic disorders											p.9
2147	1222					Recommended	mg	1		multiple			week	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020664s011lbl.pdf	Homo sapiens							max			the recommended dosage of DOSTINEX Tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg)				Hyperprolactinemic disorders											p.4
2148	1223		adult			MTD	ug	10		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10389917/	Homo sapiens													3	colon and prostate cancer								28	day		
2149	1223		adult			Recommended	ug	2		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10389917/	Homo sapiens													6	colon and prostate cancer								28	day		
2150	1223		adult			Recommended	ug	4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10389917/	Homo sapiens													3	colon and prostate cancer								28	day		
2151	1223		adult			Recommended	ug	5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10389917/	Homo sapiens													7	colon and prostate cancer								28	day		
2152	1223					Recommended	ug	1.5		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21224117/	Homo sapiens												93	14	Prostate Cancer					61			10.6	week		
2153	1224					Highest studied dose	mg	2500		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18398145	Homo sapiens										7/7 schedule. Patients self-administered capecitabine for 7 days followed by a 7-day rest.		68	7	Breast cancer					34			7	day		p.1799
2154	1224					MTD	mg	2000		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18398145	Homo sapiens										7/7 schedule. Patients self-administered capecitabine for 7 days followed by a 7-day rest.		53	7	Breast cancer					41			7	day		p.1799
2155	1224					Recommended	mg/m2	1250		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020896s037lbl.pdf	Homo sapiens										Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one week rest period in 3-week cycles (2.1) •Adjuvant treatment is recommended for a total of 6 months (8 cycles)				Adjuv ant Colon Cancer|Metastatic Colorectal Cancer|Metastatic Breast Cancer											p.1
2156	1225		ADULT			Studied dose	mg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9655566/	Homo sapiens													110	hypertension	50 mg			captopril				12	month		
2157	1226		adult				%	8		single					unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01533428	Homo sapiens													186	Painful Diabetic Peripheral Neuropathy											
2158	1226					Recommended	%	8		multiple			3 months	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf	Homo sapiens										Qutenza patch contains 8% capsaicin (640 mcg/cm2). Each patch contains a total of 179 mg of capsaicin. Apply Qutenza for 60 minutes and repeat every 3 months or as warranted by the return of pain (not more frequently than every three months)				Neuropathic pain associated with postherpetic neuralgia											p.1
2159	1226					Recommended	%	8		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/20655809	Homo sapiens													222	Neuropathic pain associated with postherpetic neuralgia											p.975
2160	1227					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17561956	Homo sapiens						73.1							91	Epilepsy								40	week		p.1297
2161	1227					Recommended	mg	1200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31755090	Homo sapiens						41.8	max|total daily dose						442	Epilepsy								2	year		p.2440
2162	1227					Recommended	mg	1600		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf	Homo sapiens							max|total daily dose			Maximum daily dose: 1200 mg/24 hr (>15 yr); 1600 mg/24 hr (adults, in rare instances)				Epilepsy											p.1
2163	1228					MTD	mg/m2	125		multiple			6 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1531148	Homo sapiens												79	24	Advanced cancer	2 g/m2, single			streptozocin, i.v	31						p.258
2164	1228					MTD	mg/m2	150		multiple			7 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9457812	Homo sapiens												66	11	Glioma	12 x 10(6) units/m2; Days 1-3 each week of a 7-week cycle.			IFN-a, s.c	26						p.299, 300
2165	1228					Recommended	mg/m2	200		multiple			6 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017422s055lbl.pdf	Homo sapiens							max			As a single agent, 150 to 200 mg/m2 BiCNU intravenously every 6 weeks as a single dose or divided into daily injections such as 75 to 100 mg/m2 on 2 successive days.				Brain tumors| Multiple myeloma| Hodgkin's lymphoma| Non-Hodgkin's lymphomas											p.1
2166	1229		adult			Recommended	mg	200		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/11817976/	Homo sapiens													2150	chronic bronchitis								10	day		
2167	1229		adult			Recommended	mg	400		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/11817976/	Homo sapiens													2149	chronic bronchitis								10	day		
2168	1229					Higher than recommended	mg	400		steady			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17530036/	Homo sapiens												30	8						18			10	day		
2169	1230					Highest studied dose|Recommended	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31549737	Homo sapiens						53.2							10	Renal Replacement Therapy					53.2						
2170	1230						g	1		multiple			day	2	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Homo sapiens										Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E.coli												10	day		
2171	1230						g	2		multiple			day	2	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Homo sapiens										Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E.coli												10	day		
2172	1230						mg	500		multiple			day	2	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Homo sapiens										Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E.coli												10	day		
2173	1233		adult			Recommended	g	3		steady			day	2	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50588slr027_cefotan_lbl.pdf	Homo sapiens													1	Infections								1	day		18
2174	1234					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7726498/	Homo sapiens												38	18						19						
2175	1234					Recommended	mg	400		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7830237/	Homo sapiens												26	12						18			7	day		
2176	1234					Recommended	mg/kg	9		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7567313/	Homo sapiens						4.9							1152	Infectious Disease								7	day		
2177	1235		children				mg/kg	8		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00585312	Homo sapiens													53	Familial Adenomatous Polyposis								5	year		
2178	1235					MTD	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21246519/	Homo sapiens						66				plus radiotherapy since day 15; orally or by percutaneous endo-scopic gastrostomy			8	head and neck cancer	150 mg; 1/d			erlotinib							
2179	1235					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212157Orig1s000MedR.pdf	Homo sapiens						40							283	migraine											nda/2020/212157Orig1s000MedR.pdf - p.80
2180	1235					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212157Orig1s000MedR.pdf	Homo sapiens						41							287	migraine											nda/2020/212157Orig1s000MedR.pdf - p.80
2181	1235					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17053988/	Homo sapiens						59				Chemoradiotherapy 5 weeks			4	oesophageal cancer								5	week		
2182	1235					Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21246519/	Homo sapiens						43				plus radiotherapy since day 15; orally or by percutaneous endo-scopic gastrostomy			3	head and neck cancer	150 mg; 1/d			erlotinib							
2183	1235						mg	100		steady			day	2	healthy	oral			https://clinicaltrials.gov/ct2/show/NCT00994461	Homo sapiens													76									2	week		
2184	1235						mg	400		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02429427	Homo sapiens													1755	Breast Cancer								2	year		
2185	1236					Highest studied dose	mg	1800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1314010	Homo sapiens							max			doses ranging from 500 mg/d to 1800 mg/d gradually during 3 to more than 24 months.		49	7						25			3	month		
2186	1237					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13888859/	Homo sapiens						47				mean duration; range 3 to 15 days			10	hypertension								8	day		
2187	1237					Highest studied dose	mg	600		single			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/14435310/ | https://pubmed.ncbi.nlm.nih.gov/4852369/	Homo sapiens													1									1	day		
2188	1237					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR.pdf	Homo sapiens						57.2							156	hypertension	40 mg; 1/day			azilsartan medoxomil				8	week		/nda/2011/202331Orig1s000MedR.pdf - p.95
2189	1237					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR.pdf	Homo sapiens						57.2							156	hypertension	40 mg; 1/day			azilsartan medoxomil				8	week		/nda/2011/202331Orig1s000MedR.pdf - p.99
2190	1237					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR.pdf	Homo sapiens						57.2							160	hypertension								8	week		nda/2011/202331Orig1s000MedR.pdf - p.99
2191	1237					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR.pdf	Homo sapiens													181	hypertension								6	week		nda/2011/202331Orig1s000MedR.pdf - p.95
2192	1237					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202331Orig1s000MedR.pdf	Homo sapiens													184	hypertension	40 mg; 1/day			azilsartan medoxomil				6	week		/nda/2011/202331Orig1s000MedR.pdf - p.95
2193	1237					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/334436/ | https://pubmed.ncbi.nlm.nih.gov/354839/	Homo sapiens						53.6							37	hypertension								8	week		
2194	1237					Studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/354839/	Homo sapiens						55.3							19	hypertension								12	week		
2195	1237						mg	25		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02236520	Homo sapiens													13	Hypertension								8	week		
2196	1238		adult			Highest studied dose	mg	10		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021658lbl.pdf	Homo sapiens																									
2197	1238		adult			Highest studied dose	ug	282		multiple			day	1	unhealthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202129Orig1s000MedR.pdf	Homo sapiens										141 µg each nostril daily				allergic rhinitis								14	day		p.42
2198	1238		adult			Highest studied dose	ug	2880		single					healthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021658lbl.pdf	Homo sapiens																									
2199	1238		children				ug	100		steady			day	1	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT00163293	Homo sapiens													79	Asthma								12	month		
2200	1238		children				ug	200		steady			day	1	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT00163293	Homo sapiens													76	Asthma								12	month		
2201	1238					Highest studied dose	ug	640		multiple			day	2	unhealthy	respiratory	M+F		accessdata.fda.gov/drugsatfda_docs/nda/2008/021658s000_MedR_P6.pdf	Homo sapiens						48.3						70							17			12	week		p. 133
2202	1238						mg	0.64		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15139796	Homo sapiens						27.3						40	6						19						
2203	1238						mg	6.9		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15139796	Homo sapiens						27.3						40	6						19						
2204	1238						ug	200		steady			day	1	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT02155881	Homo sapiens													40	Seasonal Allergic Rhinitis								2	week		
2205	1239					Recommended	%	8		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21022s004lbl.pdf	Homo sapiens													281	Onychomycosis								48	week		p.11
2206	1240		adult			Highest studied dose	mg	300		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4074430/	Homo sapiens																						1	day		
2207	1240		adult				mg	100		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01409564	Homo sapiens													18	Alzheimer's Disease								24	week		
2208	1240					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12370857/	Homo sapiens						64							17	type 2 diabetes mellitus								12	week		
2209	1240					Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10510990/	Homo sapiens						64.3							137	intermittent claudication								24	week		
2210	1240					Recommended	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10510990/	Homo sapiens						64.5							135	intermittent claudication								24	week		
2211	1241					Highest studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22503212	Homo sapiens												35	6						20						
2212	1241					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21688_sensipar_lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/15558528	Homo sapiens						49				dose was escalated weekly in 25-mg increments from 25 to 300 mg/d.		71	7						31			7	day		
2213	1241						mg	180		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00345839	Homo sapiens							max						1938	Secondary Hyperparathyroidism								2	year		
2214	1241						mg	180		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00975000	Homo sapiens							max						57	Hyperparathyroidism								2	year		
2215	1243		adult			Highest studied dose	mg	2000		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050662s042,050698s024,050775s013lbl.pdf	Homo sapiens							max			500 or 1000 or 2000 mg			53	HIV disease								12	week		
2216	1243					Recommended	mg	500		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17355733/	Homo sapiens												51	41	rheumatoid arthritis					33			6	month		
2217	1245		child			Highest studied dose	mg/m2	70		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021673lbl.pdf	Homo sapiens													2	ALL								5	day		
2218	1245					Highest studied dose	mg	6		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/24415560	Homo sapiens										6 mg X 21 days of a 28 day cycle)		76	1	Acute Myeloid Leukemia					60			21	day		
2219	1245					Highest studied dose	mg/m2	55		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12637486	Homo sapiens						42				over 1 hour daily for 5 days. Courses were repeated every 3 to 6 weeks depending on toxicity and response.			4	acute leukemia					42			5	day		
2220	1245					MTD	mg/m2	2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12637486	Homo sapiens						51				over 1 hour daily for 5 days. Courses were repeated every 3 to 6 weeks depending on toxicity and response.			6	solid tumors					51			5	day		
2221	1245					MTD	mg/m2	40		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12637486	Homo sapiens						42				over 1 hour daily for 5 days. Courses were repeated every 3 to 6 weeks depending on toxicity and response.			31	acute leukemia					42			5	day		
2222	1246		adult			Recommended	mg	250		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019906s043lbl.pdf	Homo sapiens							max			Initial Treatment/Dose Adjustment. Treatment with Anafranil should be initiated at a dosage of 25 mg daily and gradually increased, as tolerated, to approximately 100 mg during the first 2 weeks. During initial titration, Anafranil should be given in divided doses with meals to reduce gastrointestinal side effects. Thereafter, the dosage may be increased gradually over the next several weeks, up to a maximum of 250 mg daily. After titration, the total daily dose may be given once daily at bedtime to minimize daytime sedation.			322	obsessive-compulsive disorder											
2223	1246		Children and Adolescents			Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019906s043lbl.pdf	Homo sapiens							max			Initial Treatment/Dose Adjustment (Children and Adolescents). As with adults, the starting dose is 25 mg daily and should be gradually increased (also given in divided doses with meals to reduce gastrointestinal side effects) during the first 2 weeks, as tolerated, up to a daily maximum of 3 mg/kg or 100 mg, whichever is smaller. Thereafter, the dosage may be increased gradually over the next several weeks up to a daily maximum of 3 mg/kg or 200 mg, whichever is smaller (see PRECAUTIONS, Pediatric Use). As with adults, after titration, the total daily dose may be given once daily at bedtime to minimize daytime sedation.			46	obsessive-compulsive disorder											
2224	1246					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12404554/	Homo sapiens						35				Treatment was started at a dosage of 50 mg/day on days 1 to 4 followed by up-titration to 100 mg/day on days 5 to 8 and 150 mg/day on days 9 to 14. From day 15 dosage was adjusted tp between 150 and 300 mg/day according to efficacy and safety.			112	obsessive-compulsive disorder								10	week		
2225	1247		adult			Highest studied dose	mg	500		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/4025444 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Homo sapiens													89					lactic acid							p. 5
2226	1247		adult			Highest studied dose	mg	500		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/4025444 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Homo sapiens																		lactic acid							p. 5
2227	1247		adult				mg	50		multiple			day	1	unhealthy	vaginal	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21143_Trivagizole%203_medr.pdf	Homo sapiens													323									3	day		p. 5
2228	1247					Recommended	mg	10		multiple			day	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2073120	Homo sapiens						33				five clotrimazole troches (10 mg each) daily for 14 days		43	20	Oral Candidiasis					22			14	day		
2229	1248		adult			Studied dose	g	9.8		multiple			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/10090118/	Homo sapiens							mean						54	infective endocarditis								27	day		
2230	1248					Studied dose	g	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29665445/	Homo sapiens							median					80	23	endocarditis or osteoarticular infections					66			7	day		
2231	1248					Studied dose	g	12		steady			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28786715/	Homo sapiens						21							1	infective endocarditis caused by methicillin-susceptible Staphylococcus aureus					21			24	day		
2232	1250					Recommended	mg	1000		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25869627	Homo sapiens						4.2				1 g is max recommended dose (https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=10727aa8-a03e-4b61-9a80-a024cb4a2d28&type=display)			12												p.7
2233	1250					Recommended	mg	250		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25869627	Homo sapiens						4.2							12									5	day		p.7
2234	1250						mg	100		multiple			week	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00842309	Homo sapiens													14	Body Dysmorphic Disorder								8	week		
2235	1250						mg	50		multiple			week	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01399866	Homo sapiens													30	Nicotine dependence								2	week		
2236	1250						mg	50		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01086475	Homo sapiens													34	Autism Spectrum Disorders											
2237	1252		children			Highest studied dose	mg/m2	1.5		single					unknown	intravenous			https://pubmed.ncbi.nlm.nih.gov/14522028	Homo sapiens													1												
2238	1252					Highest studied dose	ug/kg	0.15		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1139861	Homo sapiens							total					77	2	malignant melanoma					40						
2239	1252					Overdose	mg/kg	0.15		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/10531579	Homo sapiens													1									3	day		
2240	1254		adult				mg/kg	1.25		steady			day	4	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01024972	Homo sapiens													16	Cerebral Vasospasm								7	day		
2241	1254						mg	25		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017443s043s046s048s049lbl.pdf	Homo sapiens							starting			25 mg once daily for seven days, then 25 mg t.i.d. for seven days, 50 mg t.i.d. for seven days, 100 mg t.i.d. Therapy with a dose four times daily may be necessary for some individuals. Doses higher than 100 mg four times daily should not be used.												7	day		
2242	1256					Highest studied dose	mg	300		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7979291	Homo sapiens						38							9	Pneumocystis pneumonia								10	week		p.1582
2243	1256					MTD	mg	200		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7979291	Homo sapiens						38							7	Pneumocystis pneumonia								10	week		p.1582
2244	1256					Overdose	g	10		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6660028	Homo sapiens						45							1	Dermatitis herpatiformis											p.216
2245	1257					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	Homo sapiens						57.6							337	overactive bladder								50	day		1041
2246	1257					Recommended	mg	7.5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex_biopharmr.pdf	Homo sapiens						57.6							561	overactive bladder								50	day		1041
2247	1258					Highest studied dose	mg/m2	100		steady			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9324279	Homo sapiens						52				100 mg/m2 over 6 h every 12 h × 10 doses (1000 mg/m2)		78	13	chronic myelogenous leukemia (CML)					23			5	day		
2248	1258					Highest studied dose	mg/m2	660		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/9180389	Homo sapiens													7	chronic myelogenous leukemia								28	day		
2249	1258					Recommended	mg/m2	15		steady			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021790lbl.pdf	Homo sapiens						70				The recommended dose is 15 mg/m2 administered by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days. Cycle should be repeated every 6 weeks		76	81	myelodysplastic syndromes					65			3	day		
2250	1258					Recommended	mg/m2	15		steady			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021790s000_Dacogen_MedR.pdf	Homo sapiens													83									3	day		p. 82
2251	1258					Recommended|MTD	mg/m2	20		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30962963	Homo sapiens						59				20 mg decitabine/m2/day by a 1-hour hepatic arterial infusion on five consecutive days every 4 weeks.			6	unresectable liver-predominant metastases					59			5	day		
2252	1258						mg/m2	15		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20456354	Homo sapiens						61				dose level of 15 mg/m2/day of decitabine administered intravenously over 1 hour on days 1–10			16	CLL					61			10	day		
2253	1258						mg/m2	15		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20456354	Homo sapiens						72							4	NHL					72			5	day		
2254	1258						mg/m2	20		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/16882708	Homo sapiens						65							14	myelodysplastic syndrome					65			5	day		
2255	1259		adult			Highest studied dose	mg	45		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	Homo sapiens																						10	day		
2256	1259		child|adult				mg	10		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01916967	Homo sapiens													79	Urticaria								2	week		
2257	1259						mg	1.25		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf	Homo sapiens												11	48						2			36	day		p. 25
2258	1260					Recommended	ug	150		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16542051/	Homo sapiens						24.6							221		20 mug			ethinylestradiol				13	month		
2259	1261					Recommended	%	0.05		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	Homo sapiens													425	Atopic dermatitis											p.3
2260	1261					Recommended	%	0.05		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021844s008lbl.pdf	Homo sapiens														Atopic dermatitis											p.1
2261	1262					MTD	mg/kg	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29896269/	Homo sapiens						8.5							22	tonsillectomy								4	week		
2262	1262					Recommended	ug/kg	0.55		single			day	1	unhealthy	intravenous	M+F		https://www.fda.gov/media/86341/download	Homo sapiens							mean			high dose: 0.5-0.6 ug/kg			86	cardiac surgery								1	day		
2263	1262					Recommended	ug/kg	0.68		single			day	1	unhealthy	intravenous	M+F		https://www.fda.gov/media/86341/download	Homo sapiens							mean						38	cardiac surgery								1	day		
2264	1262					Studied dose	mg/kg	15		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29896269/	Homo sapiens						8.5							22	tonsillectomy								4	week		
2265	1262					Studied dose	ug	100		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/23983290/	Homo sapiens						3							1	pyogenic meningitis					3			1	day		
2266	1263		adult			Highest studied dose	mg/m2	900		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1433357/	Homo sapiens										Twenty-five patients were treated with doxorubicin (60 mg/m2) preceded by administration of ADR-529 in escalating dosages (i.e., 60, 300, 600, 750, and 900 mg/m2) to groups of three to nine patients. ADR-529 was administered over a 15-minute period beginning 30 minutes before doxorubicin treatment; the protocol was repeated every 3 weeks.			6	advanced malignancies	60 mg/m^2; 1/3 week			doxorubicin							
2267	1263		adult			Recommended	mg/m2	500		multiple			day	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf	Homo sapiens										The recommended dosage ratio of ZINECARD to doxorubicin is 10:1 (e.g., 500 mg/m2 ZINECARD to 50 mg/m2 doxorubicin). The adverse reaction profile described in this section was identified from randomized, placebo-controlled, double-blind studies in patients with metastatic breast cancer who received the combination of the FAC (fluorouracil, doxorubicin, and cyclophosphamide) chemotherapy regimen with or without ZINECARD. The dose of doxorubicin was 50 mg/m2 in each of these trials.			102	breast cancer	50 mg/m^2		cyclophosphamide	doxorubicin						fluorouracil	
2268	1263		adult			Recommended	mg/m2	500		multiple			day	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf	Homo sapiens										The recommended dosage ratio of ZINECARD to doxorubicin is 10:1 (e.g., 500 mg/m2 ZINECARD to 50 mg/m2 doxorubicin). The adverse reaction profile described in this section was identified from randomized, placebo-controlled, double-blind studies in patients with metastatic breast cancer who received the combination of the FAC (fluorouracil, doxorubicin, and cyclophosphamide) chemotherapy regimen with or without ZINECARD. The dose of doxorubicin was 50 mg/m2 in each of these trials.			413	breast cancer	50 mg/m^2		cyclophosphamide	doxorubicin						fluorouracil	
2269	1263		adult			RP2D	mg/m2	600		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1433357/	Homo sapiens										Twenty-five patients were treated with doxorubicin (60 mg/m2) preceded by administration of ADR-529 in escalating dosages (i.e., 60, 300, 600, 750, and 900 mg/m2) to groups of three to nine patients. ADR-529 was administered over a 15-minute period beginning 30 minutes before doxorubicin treatment; the protocol was repeated every 3 weeks.			9	advanced malignancies	60 mg/m^2; 1/3 week			doxorubicin							
2270	1263					MTD	mg/m2	250		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11410492/	Homo sapiens						57	total			Dexrazoxane was administered as a 96-h continuous i.v. infusion repeated every 28 days. The initial dose of dexrazoxane was 125 mg/m2/day. The dose was escalated in cohorts of patients following a modified Fibonacci scheme to 166.25 and 250 mg/m2 /day and then deescalated to 221 mg/m2 /day when toxicity was encountered. Dexrazoxane doses were escalated in cohorts of 3 to 6 patients per dose level.		76	22	advanced malignancies					46						
2271	1264		adult			Recommended	mg	10		multiple			day	2	unhealthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211635s000lbl.pdf	Homo sapiens										10 mg doses are administered as a single spray intranasally into one nostril. A second dose, when required, may be administered at least 4 hours after the initial dose								benzodiazepines							
2272	1264		adult			Recommended	mg	10		multiple			day	4	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020124s033lbl.pdf	Homo sapiens														anxiety disorders				benzodiazepines							
2273	1264		adult			Recommended	mg	10		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/013263s094lbl.pdf	Homo sapiens														Anxiety Disorders				OPIOIDS							
2274	1264					Overdose	mg	2000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/357765	Homo sapiens						28													28						
2275	1264					Overdose	mg	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/357765	Homo sapiens						61													61						
2276	1264					Recommended	mg/kg	0.2		multiple			day	2	unhealthy	rectal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020648s022lbl.pdf	Homo sapiens										recommended dose of diazepam rectal gel is 0.2-0.5 mg/kg depending on age.			573	seizure activity					12						
2277	1264					Recommended	mg/kg	0.2		multiple			day	2	unhealthy	rectal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020648s022lbl.pdf	Homo sapiens										recommended dose of diazepam rectal gel is 0.2-0.5 mg/kg depending on age.				seizure activity					12						
2278	1265		adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02049385	Homo sapiens							max			Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.			6	Major Depressive Disorder								3	week		
2279	1265		adult				mg/kg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens																									
2280	1265		adult + children				mg/kg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens																									
2281	1265		children				mg/kg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens														hypoglycemia hyperinsulinism								4	year		
2282	1265		children				mg/kg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens																									
2283	1265		infant + neonates				mg/kg	15		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017453s020lbl.pdf	Homo sapiens																									
2284	1266					Highest studied dose	mg	400		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29762909	Homo sapiens						38.1							6									7	day		
2285	1266					Recommended	mg	200		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2d4d6a8e-3122-4b91-b46a-5708e60ea5c1&type=display	Homo sapiens							total daily dose			Initiate dosing at 50 mg by mouth once or twice daily. Titrate up or down dose based on individual response. The minimum recommended dosage is 50 mg daily, and the maximum recommended dosage is 200 mg daily				Primary hyperkalemic periodic paralysis|Primary hypokalemic periodic paralysis											
2286	1267		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8381032/	Homo sapiens							median						32	acquired immune deficiency syndrome	10 mg/kg			ganciclovir				70	day		
2287	1267					Highest studied dose	mg/kg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1379914/	Homo sapiens												18.9	28	acquired immune deficiency syndrome					0.7			4	month		
2288	1267					Recommended	mg/kg	12.8		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1379914/	Homo sapiens												18.9	73	acquired immune deficiency syndrome					0.7			3	month		
2289	1267					Recommended	mg/kg	13		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1379914/	Homo sapiens												18.9	10000	acquired immune deficiency syndrome					0.7			3	month		
2290	1267					Recommended	mg/kg	20.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1379914/	Homo sapiens							mean					18.9	32	acquired immune deficiency syndrome					0.7			7	month		
2291	1268					Studied dose	mg	300		multiple					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/6103299/	Homo sapiens						40				On the first day of therapy all patients received a 5O mg tablet containing DEC or placebo and also a single application of about 15 ml of lotion (300 mg DEC citrate or placebo). For the next 7 days, tablets were given three times daily and lotion once daily after a bath. From the second week patients were given tablets and lotion on only 1 day a week. During the first 2 months they took three tablets, in three divided doses, once weekly; thereafter they took four tablets, in two divided doses per week.			10	onchocerciasis					40			6	month		
2292	1268					Studied dose	mg	50		multiple					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6103299/	Homo sapiens						37				On the first day of therapy all patients received a 5O mg tablet containing DEC or placebo and also a single application of about 15 ml of lotion (300 mg DEC citrate or placebo). For the next 7 days, tablets were given three times daily and lotion once daily after a bath. From the second week patients were given tablets and lotion on only 1 day a week. During the first 2 months they took three tablets, in three divided doses, once weekly; thereafter they took four tablets, in two divided doses per week.			10	onchocerciasis					37			6	month		
2293	1268					Studied dose	mg/kg	2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7001687/	Homo sapiens												46	11	filariasis					13			21	day		
2294	1268					Studied dose	mg/kg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7001687/	Homo sapiens												69	11	filariasis					12			6	day		
2295	1268					Studied dose	mg/kg	6		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31641754/	Homo sapiens						35		400 mg; single					43	Filariasis	200 ug/kg; single			ivermectin				1	day	albendazole	
2296	1268					Studied dose	mg/kg	8		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1463361/	Homo sapiens							mean			In a long-course schedule, each carrier was given 6, 7, 8, 9 or 10 mg kg -1 body weight DEC in three divided doses daily for seven consecutive days. In a short-course schedule, each carrier was given 15 mg kg- 1 body weight (b.w.) DEC for one, two or three consecutive days.			972	filariasis								7	day		
2297	1269					Studied dose	mg	120		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/19564877	Homo sapiens										According to the Latin America consensus on obesity, the daily recommended dose of diethylpropion is 40–120 mg per day															
2298	1270					Highest studied dose	drop	1		multiple			day	9	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31712024	Homo sapiens						56.7				High-dose difluprednate (every 1-3 hours while awake). In eyes where rejection resolved completely, the mean duration of difluprednate treatment was 13.8 ± 13.4 weeks			33	Corneal graft rejection								13.8	day		p.2
2299	1270					Recommended	drop	1		multiple			day	4	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022212lbl.pdf	Homo sapiens										difluprednate ophthalmic emulsion 0.05% one drop into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.				Inflammation and pain associated with ocular surgery											p.2
2300	1271					Overdose	mg	18		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/490791	Homo sapiens						41							1												p.2100
2301	1271					Overdose	mg	22.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2592582	Homo sapiens						2				accidental			1												p.901, 902
2302	1271					Overdose	mg	25		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6409318	Homo sapiens						26							1												p.393
2303	1272					Recommended	mg	10		single					healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/19034471	Homo sapiens													56	Labor induction											p.22
2304	1273					Overdose	g	5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1567532	Homo sapiens						62				suicide attempt			1	Angina pectoris											p.62
2305	1273					Overdose	g	8		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23960064	Homo sapiens						58				suicide attempt			1		8 g, single			paracetamol, p.o							e15
2306	1273					Overdose	mg	1750		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7960280	Homo sapiens						23				suicide attempt			1												p.75
2307	1273					Recommended	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11549300	Homo sapiens						61							198	Angina pectoris								28	week		p.1786
2308	1274						mg	432		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15837258	Homo sapiens							median			Highest dose was 432 ± 181 mg/day (range 150 to 900 mg/day)			118	obstructive hypertrophic cardiomyopathy								2	week		
2309	1275		adult				mg	250		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00350870	Homo sapiens													28	Cocaine dependence											
2310	1275					Highest studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26966095	Homo sapiens						57							5	Glioblastoma	150–200 mg/m2 daily on days 1–5 of every 28 day cycle			temozolomide				15	day		p.4,5
2311	1275					MTD	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26966095	Homo sapiens						57							7	Glioblastoma	150–200 mg/m2 daily on days 1–5 of every 28 day cycle			temozolomide				55	day		p.4,5
2312	1275					Overdose	g	37.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1431956	Homo sapiens						42				suicide attempt			1	Alcoholism	50 mg, single			diazepam, p.o							p.925
2313	1275					Overdose	g	7		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7421263	Homo sapiens						24				suicide attempt			1	Alcoholism				Alcohol							p.741
2314	1275					Overdose	mg	1500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8341040	Homo sapiens						45	max						1	Alcoholism											p.390
2315	1276					Recommended	%	10		steady			day	5	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11464183/	Homo sapiens										cream		77	370	Recurrent herpes simplex labialis					18			4.1	day		1
2316	1277		adult			Studied dose	mg	22.5		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27565970/	Homo sapiens													1	atrial dysrhythmia								1	day		
2317	1277		adult				ug	250		multiple			day	2	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02308748	Homo sapiens													20									1	day		
2318	1277		adult				ug	500		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01873950	Homo sapiens													22												
2319	1277					Highest studied dose	ug	830		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10971309/	Homo sapiens						25							9									5	day		
2320	1277					Recommended	ug	500		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn_medr_P2.pdf	Homo sapiens						61							181	Atrial fibrillation								24	week		nda/99/20-931_Tikosyn_medr_P2.pdf - p.28
2321	1277					Studied dose	mg	5		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17316157/	Homo sapiens						33							1					cocaine	33			1	day		
2322	1278		infants			Studied dose	mg/kg	3		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/3371147	Homo sapiens													3	idiopathic apnea											
2323	1279					Studied dose	ug	15		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12231522/	Homo sapiens						72							12	prostate cancer								4	week		
2324	1279						ug	2.5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00601107	Homo sapiens													31	Psoriasis								24	week		
2325	1279						ug	5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00601107	Homo sapiens													28	Psoriasis								24	week		
2326	1279						ug	7.5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00601107	Homo sapiens													25	Psoriasis								24	week		
2327	1280					Highest studied dose	mg	12.7		single					unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/29671128	Homo sapiens										Highest studied dose for intranasal route			24	Chronic intermittent sleep impairment											p.133
2328	1280					Overdose	mg	150		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/25661472	Homo sapiens						2				a 2-year-old male who ingested up to 150 mg (13.2 mg/kg).			1												p.179
2329	1280					Overdose	mg/kg	13		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/29196111	Homo sapiens																									p.1
2330	1280					Recommended	mg	20		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens														Nausea and vomiting of pregnancy	20 mg oral; 1-2/day			pyridoxine hydrochloride						CNS depressants	p.3
2331	1280					Recommended	mg	20		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209661lbl.pdf	Homo sapiens														Nausea and vomiting of pregnancy	20 mg oral; 1-2/day			pyridoxine hydrochloride							p.1
2332	1280					Recommended	mg	20		single					healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf	Homo sapiens													48		20 mg oral single dose			pyridoxine hydrochloride							p.48
2333	1280					Recommended	mg	20		steady			day	2	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209661Orig1s000MedR.pdf	Homo sapiens													37		20 mg oral single dose			pyridoxine hydrochloride				11	day		p.63
2334	1280					Studied dose	mg	25		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23633146	Homo sapiens										A single oral dose of doxylamine hydrogen succinate of 25 mg (equivalent to 17.4 mg of doxylamine base)		58	12						28						p.133
2335	1281					Highest studied dose	mg	8.25		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/25416184 | https://pubmed.ncbi.nlm.nih.gov/12552051	Homo sapiens						42							61	acute migraine headache											
2336	1281						mg	2.5		multiple					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/15320756 |https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x	Homo sapiens							starting																		
2337	1281						mg/kg	0.4		multiple					unhealthy	oral			https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2044.2009.06124.x |https://pubmed.ncbi.nlm.nih.gov/337985	Homo sapiens												9							2						
2338	1282		adult				mg	4		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00734656	Homo sapiens													83												
2339	1282		children|adolescents				mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00849901	Homo sapiens							max						117	Major Depressive Disorder								38	week		
2340	1282		elderly				mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00811252	Homo sapiens													151	Major Depressive Disorder											
2341	1282		elderly				mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00811252	Homo sapiens													51	Major Depressive Disorder											
2342	1282					Overdose	mg	2820		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22306002	Homo sapiens						25							1	Major Depressive Disorder											
2343	1282					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19152958	Homo sapiens						49.9							82	Fibromyalgia											p.459
2344	1282					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19152958	Homo sapiens						51.5							72	Fibromyalgia											p.458
2345	1282					Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81a06b90-50d3-40c1-98ca-0e344c76b2c4&type=display	Homo sapiens							max					89	2327	Major Depressive Disorder					17						
2346	1282					Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81a06b90-50d3-40c1-98ca-0e344c76b2c4&type=display	Homo sapiens							max					89	568	Diabetic Peripheral Neuropathic Pain					17						
2347	1282					Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81a06b90-50d3-40c1-98ca-0e344c76b2c4&type=display	Homo sapiens							max					89	668	Generalized Anxiety Disorder					17						
2348	1282					Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81a06b90-50d3-40c1-98ca-0e344c76b2c4&type=display	Homo sapiens							max					89	876	Fibromyalgia					17						
2349	1282					Recommended	mg	60		multiple			day	2	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=81a06b90-50d3-40c1-98ca-0e344c76b2c4&type=display	Homo sapiens														Major Depressive Disorder|Generalized Anxiety Disorder											
2350	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00408876	Homo sapiens							max						112	Chronic Low Back Pain								11	week		
2351	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00424593	Homo sapiens							max			30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase			115	Chronic Low Back Pain								41	week		
2352	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00607789	Homo sapiens							max			Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.			20	Depression											
2353	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00673452	Homo sapiens							max						263	Fibromyalgia								12	week		
2354	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00767806	Homo sapiens							max						198	Generalized Anxiety Disorder								15	week		
2355	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00803361	Homo sapiens							max						108	Generalized Anxiety Disorder								15	week		
2356	1282						mg	120		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01018680	Homo sapiens													264	Osteoarthritis								9	week		
2357	1282						mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00408876	Homo sapiens													59	Chronic Low Back Pain								13	week		
2358	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00406848	Homo sapiens													249	Depression								11	week		
2359	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00408876	Homo sapiens							max						116	Chronic Low Back Pain								12	week		
2360	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00672620	Homo sapiens													150	Major Depressive Disorder								8	week		
2361	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00730691	Homo sapiens													154	Generalized Anxiety Disorder								8	week		
2362	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01000805	Homo sapiens													262	Major Depressive Disorder								7	week		
2363	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01070329	Homo sapiens													261	Depression								7	week		
2364	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01145755	Homo sapiens													47	Major Depressive Disorder								6	week		
2365	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01153009	Homo sapiens													150	Major Depressive Disorder								7	week		
2366	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01552057	Homo sapiens													159	Fibromyalgia								15	week		
2367	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01552057	Homo sapiens													194	Fibromyalgia								15	week		
2368	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01564862	Homo sapiens													207	Major Depressive Disorder								8	week		
2369	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01855919	Homo sapiens													116	Chronic Low Back Pain								12	week		
2370	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01855919	Homo sapiens													118	Chronic Low Back Pain								12	week		
2371	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01855919	Homo sapiens													234	Chronic Low Back Pain								12	week		
2372	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02005601	Homo sapiens													53	Sub-Acute Pain								2	week		
2373	1282						mg	60		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02248480	Homo sapiens													178	Chronic Osteoarthritis								12	week		
2374	1283					Highest studied dose	mg	40		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9871428/	Homo sapiens						39.3							3									1	day		
2375	1283					Recommended	mg	0.5		multiple			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_medr_P2.pdf	Homo sapiens						35							33									52	week		nda/2001/21319_Duagen_medr_P2.pdf - p.25
2376	1283					Recommended	mg	0.5		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21319_Duagen_medr_P1.pdf	Homo sapiens						66.4							720	Benign prostatic hyperplasia								2	year		nda/2001/21319_Duagen_medr_P1.pdf - p.37
2377	1283						mg	0.5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00303446	Homo sapiens													25	Spinal and Bulbar Muscular Atrophy								24	month		
2378	1283						mg	0.5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00368979	Homo sapiens													193	Benign Prostatic Hyperplasia								52	week		
2379	1284		adult			Highest studied dose	mg	20		multiple			day	3	pregnant	oral	F		https://www.tandfonline.com/doi/full/10.3109/09513590.2015.1121982	Homo sapiens													72									7	day		
2380	1285					Highest studied dose	mg	800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30792988	Homo sapiens						37.3							67	tuberculosis					37.3			180	day		
2381	1285					Highest studied dose	mg/kg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28483965	Homo sapiens													52	HIV infection											
2382	1285					Overdose	g	3		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23077707	Homo sapiens						12							1	HIV infection					12						
2383	1285					Recommended	mg	600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11418896	Homo sapiens						33		1250 mg q12h					1	HIV infection	300 mg q12h			abacavir	33			2	day	nelfinavir	
2384	1287					Highest studied dose	mg	2400		steady			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Homo sapiens										800 mg tid			8									7	day		
2385	1287					Highest studied dose	mg	2400		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Homo sapiens										400 mg six times daily			15	Parkinson’s Disease	14 days			levodopa/carbidopa				14	day		
2386	1287					Highest studied dose	mg	800		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Homo sapiens														Parkinson’s Disease											
2387	1287					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20796LBL.PDF	Homo sapiens													603	Parkinson’s Disease								6	month		
2388	1287						mg	25		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8039535	Homo sapiens						24						28	12						22						
2389	1288					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12160194	Homo sapiens												80	48	hypertension					21			8	week		
2390	1288					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12160194	Homo sapiens												80	56	hypertension					21			8	week		
2391	1288						mg	50		multiple			day	1	healthy	oral			https://clinicaltrials.gov/ct2/show/NCT01237899	Homo sapiens													15									7	day		
2392	1289					Highest studied dose	mg	0.5		multiple			week	1	unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33478397	Homo sapiens						80.1				20,000 IU (1 capsule) per week			70												
2393	1289					Highest studied dose	mg	15		multiple					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/30805225	Homo sapiens							total			100,000 international units given orally every 2 hours for a total of 600,000 international units over 12 hours.			1												
2394	1290		adult			Highest studied dose	mg	200		multiple			day	2	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021743lbl.pdf | https://www.ema.europa.eu/en/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf	Homo sapiens													6									5	day		tarceva-epar-scientific-discussion_en.pdf - p.15 | scientific-discussion/tarceva-epar-scientific-discussion_en.pdf - p.33
2395	1290		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00402779	Homo sapiens													75	Oral Cancer								1	year		
2396	1290		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00674973	Homo sapiens										Time Frame: From the time of randomization until progression of disease or death (up to 30 months)			104	Pancreatic Carcinoma								30	month		
2397	1290					Highest studied dose	mg	100		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19956953/	Homo sapiens						54							6	solid tumors								1	day		
2398	1290					Highest studied dose	mg	1000		single			day	1	healthy	oral			https://www.ema.europa.eu/en/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf | https://pubmed.ncbi.nlm.nih.gov/11432895/	Homo sapiens													4									1	day		tarceva-epar-scientific-discussion_en.pdf - p.14
2399	1290					Highest studied dose	mg	200		multiple			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021743lbl.pdf | https://www.ema.europa.eu/en/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf	Homo sapiens													5												tarceva-epar-scientific-discussion_en.pdf - p.15
2400	1290					Highest studied dose	mg	2000		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16878326/	Homo sapiens						63							19	nonsmall cell lung cance								4	week		
2401	1290					Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26214085/	Homo sapiens						62							3	nonsmall cell lung cance	30 mg/m2; Days 1-3			Amrubicin				21	day		
2402	1290					Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26214085/	Homo sapiens						62							3	nonsmall cell lung cance	35 mg/m2; Days 1-3			Amrubicin				21	day		
2403	1290					Recommended	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26214085/	Homo sapiens						62							3	nonsmall cell lung cance	30 mg/m2; Days 1-3			Amrubicin				21	day		
2404	1290					Recommended	mg	150		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_medr.PDF | https://www.ema.europa.eu/en/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf	Homo sapiens						62				median duration			485	nonsmall cell lung cance								8.1	week		21-743_Tarceva_medr.PDF - p.59-61 | tarceva-epar-scientific-discussion_en.pdf - p.32
2405	1290					Recommended	mg	150		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-743_Tarceva_medr.PDF | https://www.ema.europa.eu/en/documents/scientific-discussion/tarceva-epar-scientific-discussion_en.pdf	Homo sapiens						62				median duration			485	nonsmall cell lung cance								8.1	week		tarceva-epar-scientific-discussion_en.pdf - p.37
2406	1290					Recommended|MTD	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11432895/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021743lbl.pdf	Homo sapiens						57							7	solid tumors								3	week		
2407	1290					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11432895/	Homo sapiens						57							6	solid tumors								3	week		
2408	1291		unknown			Overdose	mg	40		single			day	1	unknown	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/anda/97/74826ap.pdf	Homo sapiens																									
2409	1291					Highest studied dose	mg	6		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1972381/	Homo sapiens												47	60						21						
2410	1291					Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1968713/	Homo sapiens													685	insomnia								7	day		
2411	1292					Highest studied dose	mg	6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23038043	Homo sapiens													12												p.564
2412	1292					Overdose	mg	270		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	Homo sapiens																									p.13
2413	1292					Overdose	mg	90		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17606111	Homo sapiens						86							1												
2414	1292					Recommended	mg	3		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23038043	Homo sapiens													8									7	day		p.564
2415	1292					Recommended	mg	3		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf	Homo sapiens														Insomnia											p.1
2416	1292						mg	2		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00856973	Homo sapiens							max			1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years			163	Attention-deficit/Hyperactivity Disorder - Associated Insomnia								12	week		
2417	1292						mg	3		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00374556	Homo sapiens													14	Osteoarthritis								12	week		
2418	1292						mg	3		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00645944	Homo sapiens													19	Schizophrenia								8	week		
2419	1292						mg	3		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00856973	Homo sapiens							max			2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years			159	Attention-deficit/Hyperactivity Disorder - Associated Insomnia								12	week		
2420	1293					Highest studied dose	mg	5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3881294/	Homo sapiens												54	172	Pregnancy prevention					14			5	day		p.209
2421	1293					Highest studied dose	mg	5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3881294/	Homo sapiens												54	222	Pregnancy prevention					14			5	day		p.209
2422	1293					Highest studied dose	mg	5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3881294/	Homo sapiens												54	222	Pregnancy prevention					14			5	day		p.211
2423	1293					Overdose	mg	0.595		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29037581	Homo sapiens						29							1		34 mg, single			cyproterone acetate, p.o							
2424	1293					Recommended	mg	0.02		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf	Homo sapiens										Take one tablet by mouth at the same time every day. The dosage of LoSeasonique is one orange tablet containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by one yellow ethinyl estradiol tablet for 7 days. 84 orange tablets, each containing 0.1 mg of levonorgestrel and 0.02 mg ethinyl estradiol, and 7 yellow tablets each containing 0.01 mg of ethinyl estradiol.		41	2185	Pregnancy prevention	0.1 mg; q.d			levonorgestrel, p.o	18			84	day		p.4
2425	1293					Recommended	mg	0.02		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022262lbl.pdf	Homo sapiens										Take one tablet by mouth at the same time every day. The dosage of LoSeasonique is one orange tablet containing levonorgestrel and ethinyl estradiol daily for 84 consecutive days, followed by one yellow ethinyl estradiol tablet for 7 days. 84 orange tablets, each containing 0.1 mg of levonorgestrel and 0.02 mg ethinyl estradiol, and 7 yellow tablets each containing 0.01 mg of ethinyl estradiol.				Pregnancy prevention	0.1 mg; q.d			levonorgestrel, p.o				84	day		p.1
2426	1294					Highest studied dose	mg/kg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23167925	Homo sapiens										The maximal target dose was ethosuximide 60 mg/kg/day or 2000 mg/day (whichever was lower)		13	154	Absence epilepsy					4			12	month		p.24
2427	1294					Recommended	g	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6818076	Homo sapiens												14	6	Absence epilepsy					4						p.833
2428	1294					Recommended	g	1.5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012380s032lbl.pdf	Homo sapiens														Absence epilepsy											p.1
2429	1296					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-584S003_Lodine_medr.pdf	Homo sapiens													493	osteoarthritis								4	week		0654D-357-US, -358-US, -370-US, and -371-US.
2430	1296					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-584S003_Lodine_medr.pdf	Homo sapiens													493	osteoarthritis								4	week		
2431	1297		adult			Recommended	ug	70		steady			day	1	healthy	subdermal	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf	Homo sapiens										25 - 70 mcg/day			942									3	year		
2432	1297		adult			Recommended	ug	70		steady			day	1	healthy	subdermal	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021529s018lbl.pdf	Homo sapiens										approximately 25 - 70 mcg/day			942									3	year		
2433	1298		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00414440	Homo sapiens							max			Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).			214	Autosomal Dominant Polycystic Kidney Disease											
2434	1298		adult				mg	7.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01379521	Homo sapiens							total daily dose			in combination with transcatheter arterial chemoembolization (TACE)			33	Hepatocellular Carcinoma								24	month		
2435	1298		child|adult				mg/m2	4.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01289912	Homo sapiens													32	Tuberous Sclerosis Complex								6	month		
2436	1298					Highest studied dose	mg	4		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_MedR_P2.pdf	Homo sapiens										transplant tablet			4									1	day		022334s000_MedR_P2.pdf - p.19
2437	1298					Highest studied dose	mg	50		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_MedR_P2.pdf	Homo sapiens										oncology tablet			61									1	day		022334s000_MedR_P2.pdf - p.19
2438	1298					MTD	mg	50		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						55.5				in combination with thoracic radiotherapy			3	non-small-cell lung cancer								11	week		
2439	1298					MTD|Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.386 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_MedR_P2.pdf	Homo sapiens						51							5	neuroendocrine tumors								18.9	month		022334s000_MedR_P2.pdf - p.19
2440	1298					MTD|Highest studied dose	mg	70		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						60							16	advanced cancer	250 mg/m2 IV: 4 weeks			cetuximab				4	week		022334s000_MedR_P2.pdf - p.19
2441	1298					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_MedR_P1.pdf | https://www.ema.europa.eu/en/documents/assessment-report/afinitor-epar-public-assessment-report_en.pdf	Homo sapiens						61				median exposure			269	kidney cancer								95	day		022334s000_MedR_P2.pdf - p.61
2442	1298					Recommended	mg	20		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24368401/	Homo sapiens						56		100 mg/m2 IV; 2 per 3 weeks					5	small-cell lung cancer	75 mg/m2 IV; 1 per 3 weeks			cisplatin				3	week	etoposide	
2443	1298					Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24368401/	Homo sapiens						62.5		100 mg/m2 IV; 2 per 3 weeks					6	small-cell lung cancer	75 mg/m2 IV; 1 per 3 weeks			cisplatin				21	day	etoposide	
2444	1298						mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24368401/	Homo sapiens						51		100 mg/m2 IV; 2 per 3 weeks					4	small-cell lung cancer	75 mg/m2 IV; 1 per 3 weeks			cisplatin				21	day	etoposide	
2445	1298						mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						62				in combination with thoracic radiotherapy			6	non-small-cell lung cancer								11	week		
2446	1298						mg	20		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						55.5				in combination with thoracic radiotherapy			7	non-small-cell lung cancer								11	week		
2447	1298						mg	30		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24368401/	Homo sapiens						56		100 mg/m2 IV; 2 per 3 weeks					13	small-cell lung cancer	75 mg/m2 IV; 1 per 3 weeks			cisplatin				3	week	etoposide	
2448	1298						mg	30		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						60							6	advanced cancer	250 mg/m2 IV: 4 weeks							4	week		
2449	1298						mg	35		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						55.5	mean			in combination with thoracic radiotherapy			10	non-small-cell lung cancer								11	week		
2450	1298						mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						62				in combination with thoracic radiotherapy			5	non-small-cell lung cancer								11	week		
2451	1298						mg	50		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25701455/	Homo sapiens						60							7	advanced cancer	250 mg/m2 IV: 4 weeks							4	week		
2452	1299					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9823425/	Homo sapiens												77	4	Breast cancer					37			12	week		p.678
2453	1299					Highest studied dose	mg	800		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1394219	Homo sapiens												75	3						48						p.5935
2454	1299					Recommended	mg	25		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020753s020lbl.pdf	Homo sapiens													2252	Breast cancer											p.4
2455	1299					Recommended	mg	25		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020753s020lbl.pdf	Homo sapiens														Breast cancer											p.1
2456	1300		children				mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00867165	Homo sapiens													92	Primary hypercholesterolemia								12	week		
2457	1300					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf	Homo sapiens													15									14	day		
2458	1300					Recommended	mg	10		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33644733	Homo sapiens						57							1						57			8	week		
2459	1300						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01611883	Homo sapiens													75	Type 2 Diabetes								24	week		
2460	1302		adult			Highest studied dose	mg	300		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021856lbl.pdf	Homo sapiens																						7	day		
2461	1302		adult			Recommended	mg	40		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021856lbl.pdf	Homo sapiens													757	hyperuricemia | gout								1	year		
2462	1302		adult			Recommended	mg	80		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021856lbl.pdf	Homo sapiens													1279	hyperuricemia | gout								1	year		
2463	1302		adult				mg	120		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174915	Homo sapiens													269	Gout								28	week		
2464	1302		adult				mg	120		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174967	Homo sapiens													38	Gout								4	week		
2465	1302		adult				mg	240		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174915	Homo sapiens													134	Gout								28	week		
2466	1302		adult				mg	30		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01082640	Homo sapiens													32	Renal Impairment								12	month		
2467	1302		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174967	Homo sapiens													37	Gout								4	week		
2468	1302		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174915	Homo sapiens													267	Gout								28	week		
2469	1302		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00174967	Homo sapiens													40	Gout								4	week		
2470	1302		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01077284	Homo sapiens													33	Hyperuricosuria								6	month		
2471	1302		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01078389	Homo sapiens							max			Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.			157	Joint Damage								24	month		
2472	1302		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01350388	Homo sapiens													40	Chronic Kidney Disease								24	week		
2473	1303		adult			Recommended	mg	1200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020189s027lbl.pdf	Homo sapiens										adult patients who received Felbatol® monotherapy at dosages of 3600 mg/day in double-blind controlled trials			58	epilepsy											
2474	1303					Highest studied dose	mg	1200		steady			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9579889/	Homo sapiens						30				newly diagnosed subjects with epilepsy receiving FBM monotherapy at a starting dose of 1,200 mg/day (400 mg/three times daily, t.i.d.) and increased 1,200 mg/day, if tolerated, at 14-day intervals to 3,600 mg/day were investigated.		45	5	epilepsy					18			14	day		
2475	1304					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2475701/	Homo sapiens													50	hypertension								4	week		
2476	1305					Recommended	mg	400		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017604s046lbl.pdf	Homo sapiens													6786	rheumatoid arthritis| osteoarthritis								52	week		
2477	1306		adult			Studied dose	mg	0.2		multiple			day	1	healthy	topical	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20788_PROPECIA%20TABLETS,%201MG_MEDR_P1.PDF	Homo sapiens													115									12	month		
2478	1306		adult			Studied dose	mg	1		multiple			day	1	healthy	topical	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20788_PROPECIA%20TABLETS,%201MG_MEDR_P1.PDF	Homo sapiens													117									12	month		
2479	1306					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1371291/	Homo sapiens												77	69	benign prostatic hyperplasia					47			7	day		
2480	1306					Highest studied dose	mg	100		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2550402/	Homo sapiens												71	12						50			1	day		
2481	1306					Recommended	mg	1		multiple			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20788_PROPECIA%20TABLETS,%201MG_MEDR_P2.PDF	Homo sapiens												41	471						19			12	month		
2482	1306						mg	1		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02781311	Homo sapiens													12	Androgenetic Alopecia								24	week		
2483	1306						mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00475501	Homo sapiens													13	low blood concentration of testosterone								52	week		
2484	1306						mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01296672	Homo sapiens													306	Prostate Cancer								3	month		
2485	1306						mg	5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01585441	Homo sapiens													3	Chronic Central Serous Chorioretinopathy								3	month		
2486	1307					Overdose	g	1		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27884575	Homo sapiens						62							1	Atrial fibrillation				lamotrigine, p.o						quetiapine, p.o	p.1
2487	1307					Overdose	g	10		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9825278	Homo sapiens						36							1												p.423
2488	1307					Overdose	mg	1200		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20562156	Homo sapiens						18							1												p.487
2489	1307					Overdose	mg	3800		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3107447	Homo sapiens						28		20 mg					1		50 mg			diazepam, p.o						loperamide, p.o	
2490	1307					Recommended	mg	200		multiple			day	2	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display	Homo sapiens										The maximum recommended dose for patients with paroxysmal supraventricular arrhythmias is 300 mg/day. For sustained VT the recommended starting dose is 100 mg every 12 hours. This dose may be increased in increments of 50 mg bid every four days until efficacy is achieved. Most patients with sustained VT do not require more than 150 mg every 12 hours (300 mg/day), and the maximum dose recommended is 400 mg/day.				Paroxysmal supraventricular tachycardias|paroxysmal atrial fibrillation/flutter|Sustained ventricular tachycardia											
2491	1308					Highest studied dose	mg/m2	1750		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8004761	Homo sapiens												79	3	Carcinoma	500 mg/m2 by 2-h infusion; weekly x 6			leucovorin, i.v	30			6	week		p.263
2492	1308					MTD	mg/m2	1650		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8004761	Homo sapiens												79	6	Carcinoma	500 mg/m2 by 2-h infusion; weekly x 6			leucovorin, i.v	30			6	week		p.263
2493	1308					MTD	mg/m2	544		multiple			day	5	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/10378673	Homo sapiens							mean			5-days continuous infusion, followed by 16-day treatment free interval; chronomodulated rate		75	29	Gastrointestinal adenocarcinoma metastatic to the liver	6025 mg/m2/cycle (5 days)			5-FU, i.v	44			321	course		p.390
2494	1308					Recommended	mg/kg	0.6		multiple			day	1	unhealthy	intraarterial			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c8edabc1-67cd-421b-a147-7c1f19f05b8e&type=display	Homo sapiens							max			The recommended therapeutic dosage schedule of floxuridine by continuous arterial infusion is 0.1 to 0.6 mg/kg/day. The higher dosage ranges (0.4 to 0.6 mg) are usually employed for hepatic artery infusion				Gastrointestinal adenocarcinoma metastatic to the liver											
2495	1309		adult			Recommended	mg	1		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9695999/	Homo sapiens										After a 2-hour stabilization period, patients were randomly assigned to receive flumazenil (1 mg in 20 mL saline solution) or an identical volume of placebo solution (NaCl 0.9%) by intravenous infusion for 3 to 5 minutes.			265	hepatic encephalopathy											
2496	1309					Highest studied dose	mg	3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1647443/	Homo sapiens												62	10	epilepsy					32						
2497	1309					Recommended	mg	7.13		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8239101/	Homo sapiens						35.2	mean			After baseline vital signs and neurologic assessment, patients received the study drug, which contained either flumazenil 1 mg/10 mL or placebo. Ten milliliters of the study drug was administered over 20 seconds each minute for up to ten minutes' duration for a maximum dose of 100 mL (10 mg flumazenil). Drug administration was discontinued if the patient's overall clinical condition was """"""""""""""""much improved"""""""""""""""" or """"""""""""""""very much improved"""""""""""""""" (CGIS score of 1 or 2) or if there was an adverse event. If patients did not respond to the double-blind study drug, investigators had the option of administering up to 30 mL (3 g) open-label flumazenil. The mean+/-SD dose of drug given during the double-blind phase was 71.3+/-34.2 mL in the flumazenil group (7.13 mg flumazenil). The dose range of study drug was 10 to 100 mL for flumazenil (1 to 10 mg) and 20 to 100 mL for placebo. The maximum allowed dose of 100 mL was administered to 49 of 87 patients (56%) in the flumazenil group.		75	87	benzodiazepine overdose					17						
2498	1310					Recommended	ug	160		steady			day	2	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021247LBL.pdf	Homo sapiens							starting			Adults (age 12 and older): The recommended starting dose is 160 mcg twice daily. The maximum dose should not exceed 320 mcg twice daily. Children (age 6 to 11): The recommended starting dose is 80 mcg twice daily. The maximum dose should not exceed 160 mcg twice daily.		78	217	asthma					4			12	week		
2499	1310					Recommended	ug	320		steady			day	2	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021247LBL.pdf	Homo sapiens							starting			Adults (age 12 and older): The recommended starting dose is 160 mcg twice daily. The maximum dose should not exceed 320 mcg twice daily. Children (age 6 to 11): The recommended starting dose is 80 mcg twice daily. The maximum dose should not exceed 160 mcg twice daily.		78	113	asthma					4			12	week		
2500	1310					Recommended	ug	80		steady			day	2	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021247LBL.pdf	Homo sapiens							starting			Adults (age 12 and older): The recommended starting dose is 160 mcg twice daily. The maximum dose should not exceed 320 mcg twice daily. Children (age 6 to 11): The recommended starting dose is 80 mcg twice daily. The maximum dose should not exceed 160 mcg twice daily.		78	189	asthma					4			12	week		
2501	1310						ug	85		steady			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021247s000_ClinPharmR.pdf	Homo sapiens												11	510	asthma					6						
2502	1313		adult			Recommended	mg	250		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8977067/	Homo sapiens										Patients were followed for a mean period of 16.5 months.			75	prostate cancer								16.5	month		
2503	1313					Recommended	mg	250		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18339379/	Homo sapiens						26.3		0.15 mg		Women received flutamide 250 mg/day alone (n = 27) or combined with a fixed dose of an oral contraceptive containing 0.020 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (n = 56).			83	hirsutism	0.020 mg			ethinyl estradiol				84	month	desogestrel	
2504	1314		adult			Highest studied dose	mg	16		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Homo sapiens																									
2505	1314		adult			Highest studied dose	mg	2		multiple			day	2	healthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Homo sapiens																						7	day		
2506	1314		adult			Highest studied dose	mg	80		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020121s045lbl.pdf	Homo sapiens																						10	day		
2507	1314		adult			Highest studied dose	ug	1320		multiple			day	1	healthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Homo sapiens																						15	day		
2508	1314		adult			Highest studied dose	ug	3520		single					healthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20548slr020,20121slr030_flovent_lbl.pdf	Homo sapiens																									
2509	1314		children				ug	25		steady			day	2	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT02980133	Homo sapiens													211	Asthma								12	week		
2510	1314		children				ug	50		steady			day	2	unhealthy	respiratory			https://clinicaltrials.gov/ct2/show/NCT02980133	Homo sapiens													208	Asthma								12	week		
2511	1314						ug	200		steady			day	1	unhealthy	intranasal			https://clinicaltrials.gov/ct2/show/NCT01817790	Homo sapiens													314	Seasonal Allergic Rhinitis								14	day		
2512	1314						ug	880		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00275561	Homo sapiens													19	Eosinophilic Esophagitis								6	week		
2513	1314						ug	880		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00426283	Homo sapiens													28	Eosinophilic Esophagitis								3	month		
2514	1315		ADULT			Overdose	g	5.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7804678/	Homo sapiens						58							1	bipolar disorder											
2515	1315		ADULT			Overdose	g	9		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7906658/	Homo sapiens													1												p.200
2516	1315		ADULT			Overdose	g	9.6		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17952747/	Homo sapiens						25							1	depressive neurosis											p.793
2517	1315		ADULT			Overdose	mg	4800		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7906658/	Homo sapiens													1												p.203
2518	1315		ADULT			Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16160624/	Homo sapiens						67.8							39	major depressive disorder								7	week		p.472
2519	1315		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							max			Recommended starting dose is 50 mg at bedtime, with increases of\n50 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 300 mg/day. Daily doses over 100mg should be divided				obsessive compulsive disorder											p.1
2520	1316					Highest studied dose	mg	500		multiple			month	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/29901634	Homo sapiens						54							1	breast cancer					54						
2521	1316						mg	500		multiple			month	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/33261799	Homo sapiens						56							1	ductal carcinoma of the breast					56						
2522	1317					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28477508/	Homo sapiens						67	mean			60 to 1160			43	malignancy								10	day		
2523	1317					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28477508/	Homo sapiens						67	mean						43	malignancy								10	day		
2524	1318		adult				mg	250		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00770588	Homo sapiens										Duration: until to objective PD			147	Non-Small Cell Lung Cancer											
2525	1318					Recommended	mg	250		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	Homo sapiens													102									28	day		
2526	1318						mg	1000		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25784657	Homo sapiens						51							4	NSCLC					51			2	week		
2527	1318						mg	1250		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25784657/	Homo sapiens						51							3	NSCLC					51			2	week		
2528	1318						mg	500		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-399_IRESSA_Medr_P2.pdf	Homo sapiens													114									28	day		
2529	1319		adult				mg/m2	800		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf	Homo sapiens													979	malignancies								6	month		
2530	1319					MTD	mg/m2	2200		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8996158	Homo sapiens						58				wk for 3 weeks every 4 weeks		77	6	Non-Small-Cell Lung Cancer					40						
2531	1319					MTD	mg/m2	5700		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020509s082lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/17434832	Homo sapiens						55						71	4						34						
2532	1319					Recommended	mg/m2	1000		multiple			4 weeks	3	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/30397477	Homo sapiens						74				on days 1, 8, and 15 of a 28-day cycle			1						74			6	cycle		
2533	1319						mg/m2	2800		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8996158	Homo sapiens						58				wk for 3 weeks every 4 weeks		77	5	Non-Small-Cell Lung Cancer					40						
2534	1320					Overdose	g	9		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018422s048lbl.pdf	Homo sapiens						7							1												p.13
2535	1320					Recommended	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7614520	Homo sapiens						59							87	Non-insulin-dependent diabetes mellitus								24	week		p.198
2536	1321		adult			Highest studied dose	mg	32		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/8911975/	Homo sapiens													18	diabetes mellitus								2	week		
2537	1321					Studied dose	mg	4.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19125777/	Homo sapiens						57.5	mean			dose up to 6 mg/day			1393	diabetes mellitus								52	week		
2538	1321					Studied dose	mg	42		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26521901/	Homo sapiens						40							1	diabetes mellitus	50 mg; 1/d			zolpidem	40			1	day		
2539	1321					Studied dose	mg	5.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25205142/	Homo sapiens							mean			titrated up to 6 or 8 mg/day		80	482	diabetes mellitus					18			104	week		
2540	1321					Studied dose	mg	6.5		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21485125/	Homo sapiens						79							1	diabetes mellitus					79			1	day		
2541	1321						mg	4		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00620282	Homo sapiens													17	Type 2 Diabetes Mellitus								12	week		
2542	1322					Overdose	g	1		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16909651	Homo sapiens						55							1	Type 2 diabetes mellitus	1600 u; single			insulin, i.v							p.265
2543	1322					Overdose	mg	375		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16794105	Homo sapiens						15							1		14.5 g; single			melformin, p.o							p.565
2544	1322					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17300595	Homo sapiens										After the starting dose of 5 mg/day, glipizide was uptitrated to a potential maximum dose of 20 mg/day.			584	Type 2 diabetes mellitus	>/=1500 mg/day; 52 wk			melformin, p.o				52	week		p.199
2545	1322					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21816980	Homo sapiens													408	Type 2 diabetes mellitus	1500–2500mg/day			melformin, p.o				52	week		p.2020
2546	1322					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017783s021lbl.pdf	Homo sapiens							total daily dose			Titration: The recommended starting dose is 5 mg, dosage adjustments should ordinarily be in increments of 2.5–5 mg, the maximum recommended total daily dose is 40 mg. The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content. Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided. Total daily doses above 30 mg have been safely given on a b.i.d. basis to long-term patients.				Type 2 diabetes mellitus											p.3
2547	1323		children			Highest studied dose	g/kg	0.7		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11533313/	Homo sapiens							total						6	Cystic fibrosis								4	week		2557S
2548	1323					Highest studied dose	g/kg	0.86		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/14722645/	Homo sapiens							total			TPN supplemented with glutamine at a dose of 0.86 g of glutamine/kg bw/day, corresponding to 60 g of glutamine per day for a 70 kg man, given as a continuous infusion over 24 h.		88		Multiple organ failure					22			5	day		p.267
2549	1324		adult			Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4927607/	Homo sapiens										treatment periods ranging from 8 to 29 months. The mean glyburide dose used during the chronic study was 16 mg with a range from 2.5 to 40 mg			23	diabetes								18.5	month		
2550	1324					Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16021069/	Homo sapiens						32.8	median						236	gestational diabetes mellitus								62.6	day		
2551	1324						mg	2.5		steady			day	1	unhealthy|pregnant	oral	F		https://clinicaltrials.gov/ct2/show/NCT00744965	Homo sapiens							starting						189	Mild Gestational Diabetes											
2552	1325		adult			Recommended	mg	10.8		steady			day	1	unhealthy	subcutaneous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020578s034,020578s035lbl.pdf	Homo sapiens													231	Prostatic Carcinoma				flutamide				12	week	after 90 days of radiation therapy	
2553	1325		adult			Recommended	mg	10.8		steady			day	1	unhealthy	subcutaneous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020578s034,020578s035lbl.pdf	Homo sapiens													231	Prostatic Carcinoma				flutamide				12	week	radiation therapy	
2554	1325					Recommended	mg	3.6		steady			day	1	unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/25738668/	Homo sapiens												49	103	breast cancer				Chemotherapy	18			3	month		
2555	1326					Highest studied dose	mg	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4571980	Homo sapiens						41				The average daily dosage of guanadrel was 70 mg (25 to 150)		68	21	hypertension					17			6	week		
2556	1326						mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4031111	Homo sapiens						54						64		hypertension					43			12	week		
2557	1327		children			Recommended	ug	65		steady			day	1	unhealthy	subdermal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022058s006lbl.pdf	Homo sapiens													47	central precocious puberty								12	month		14
2558	1328					Overdose	mg	2000		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1536497	Homo sapiens						27							1	Hypertension				ethanol							
2559	1328					Overdose	mg	750		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30821162	Homo sapiens						38							1	Hypertension	10 mg, single			clonazepam, p.o							p.53, 54
2560	1328					Recommended	mg	200		multiple			day	1	unhealthy	oral			https://www.medicines.org.uk/emc/product/4527	Homo sapiens							max			Initially 50mg once daily. This can be increased gradually to a dose not exceeding 200mg daily.				Hypertension											
2561	1328					Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	Homo sapiens														Hypertension											p.2
2562	1328					Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1996/008303s068lbl.pdf	Homo sapiens														Hypertension											p.3
2563	1328					Recommended	mg	40		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf	Homo sapiens										The usual dose is 20-40mg, repeated as necessary.				Hypertension											p.1
2564	1329					Highest studied dose	g	0.8		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13706413	Homo sapiens												80	16	Edema					32						p.56
2565	1330		adult			Highest studied dose	mg	1		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/18035195/	Homo sapiens										10-minute infusion of ibutilide under fasting conditions			8												
2566	1330		adult			Recommended	mg	1		multiple			10 min	1	unhealthy	intravenous			https://www.pfizer.ca/sites/default/files/201904/Corvert_PM_222103_29Mar2019_E.pdf	Homo sapiens										two 10-minute infusions of ibutilide 1 mg at a 10-minute interval			776	atrial flutter or atrial fibrillation								2	times		
2567	1331					Highest studied dose	mg	24		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28817490	Homo sapiens													31	Bipolar Disorder								6.5	week		p.3
2568	1331					MTD	mg	32		multiple			day	1	unhealthy	oral			https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1527-3458.1997.tb00320.x|https://pubmed.ncbi.nlm.nih.gov/20368905	Homo sapiens												55	24	Schizophrenia					18			4	day		p.141
2569	1331					Overdose	mg	438		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							total			438 mg over a four-day period			1	Schizophrenia								4	day		p.17
2570	1331					Overdose	mg	576		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens													1	Schizophrenia											p.17
2571	1331					Recommended	mg	10		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens										doses of 10 mg/day or greater			874	Schizophrenia											p.9
2572	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			20-24 mg/day (presumed on a b.i.d basis)				Schizophrenia								5	week		p.7
2573	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			20-24 mg/day (presumed on a b.i.d basis)				Schizophrenia											p.7
2574	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			double-blind placebo-controlled short-term studies, where the dose was increased slowly, as recommended (target dose range of 6-12 mg twice daily from the label dosage indicated)			1344	Schizophrenia											p.7
2575	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			target dose range of 6-12 mg twice daily from the label dosage indicated			1344	Schizophrenia								5	week		p.7
2576	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			target dose range of 6-12 mg twice daily from the label dosage indicated				Schizophrenia											p.7
2577	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			target dose range of 6-12 mg twice daily from the label dosage indicated				Schizophrenia											p.8
2578	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens							max			target dose range of 6-12 mg twice daily from the label dosage indicated				Schizophrenia											p.9
2579	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens										24 mg/day (presumed on a b.i.d basis)			3210	Schizophrenia											p.8
2580	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens										24 mg/day (presumed on a b.i.d basis)				Schizophrenia								4	week		p.8
2581	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens													160	Schizophrenia											p.4
2582	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens														Schizophrenia											p.5
2583	1331					Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf	Homo sapiens														Schizophrenia											p.6
2584	1332					Recommended	%	5		multiple			week	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf	Homo sapiens													215	Actinic keratosis								16	week		p.8
2585	1332					Recommended	%	5		multiple			week	3	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/10597781	Homo sapiens						35							65	Anogenital warts								16	week		p.2400
2586	1333					Highest studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3886191/	Homo sapiens						53							32	congestive heart failure								12	week		
2587	1333					Overdose	ug/kg/min	198		single			day	1	unhealthy	intravenous	F		https://link.springer.com/article/10.2165/00128415-199505560-00017	Homo sapiens						0.208333333333333	max			10 times the prescribed dose			1	heart failure											
2588	1333					Overdose	ug/kg/min	198		single			day	1	unhealthy	intravenous	F		https://link.springer.com/article/10.2165/00128415-199505560-00017	Homo sapiens						0.208333333333333	max						1	heart failure											
2589	1333					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6683463/	Homo sapiens						49							13	congestive heart failure								1	month		
2590	1333					Recommended	mg/kg	3		single			day	1	unhealthy	intravenous	M+F		https://www.nature.com/articles/pr1984440	Homo sapiens							max						6	pulmonary hypertension											
2591	1333					Recommended	mg/kg/day	5.8		multiple			day	1	unhealthy	intravenous	M+F		https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/604456	Homo sapiens							mean						43	congestive heart failure								64	day		
2592	1334					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6222098	Homo sapiens												65	3	depression					18			6	week		
2593	1335					Recommended|MTD	mg	75		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020727lbl.pdf	Homo sapiens						57				A total of 317 of patients received BiDil for at least 6 months, and 220 received BiDil for at least 12 months.			517	heart failure	40 mg; 3/day			isosorbide dinitrate				9	month		label/2005/020727lbl.pdf - p.13
2594	1335					Recommended|MTD	mg	75		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020727_S000_Bidil_MedR.pdf	Homo sapiens						57				A total of 317 of patients received BiDil for at least 6 months, and 220 received BiDil for at least 12 months.			517	heart failure	40 mg; 3/day			isosorbide dinitrate				9	month		nda/2005/020727_S000_Bidil_MedR.pdf - p.56
2595	1335					Recommended|MTD	mg	75		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020727_S000_Bidil_MedR.pdf	Homo sapiens						57				A total of 317 of patients received BiDil for at least 6 months, and 220 received BiDil for at least 12 months.			517	heart failure	40 mg; 3/day			isosorbide dinitrate				9	month		nda/2005/020727_S000_Bidil_MedR.pdf - p.57
2596	1335					Recommended|MTD	mg	75		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/020727_S000_Bidil_MedR.pdf	Homo sapiens						57				A total of 317 of patients received BiDil for at least 6 months, and 220 received BiDil for at least 12 months.			517	heart failure	40 mg; 3/day			isosorbide dinitrate				9	month		nda/2005/020727_S000_Bidil_MedR.pdf - p.59
2597	1336		adult			Highest studied dose	mg	240		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10188765/	Homo sapiens										sustained-release (Imdur)			312	chronic stable angina pectoris								6	week		
2598	1336		adult			Recommended	mg	60		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10188765/	Homo sapiens										sustained-release (Imdur)			267	chronic stable angina pectoris								2	week		
2599	1336		adult			Studied dose	mg	20		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf	Homo sapiens													159	myocardial infarction or congestive heart failure								1	week		
2600	1336		adult			Studied dose	mg	5		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020215s024lbl.pdf	Homo sapiens													54	myocardial infarction or congestive heart failure								1	week		
2601	1337		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01895270	Homo sapiens							total daily dose						11	Opioid Dependence								8	week		
2602	1337		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02168842	Homo sapiens							max						170	Parkinson's Disease								36	month		
2603	1337					Highest studied dose	mg	30		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15610940	Homo sapiens										sustained-release		44	8						27						
2604	1337					Highest studied dose	mg/kg	0.015		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/2966552	Homo sapiens													8	Chest pain| stable angina											p.1103
2605	1337					MTD	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24123224	Homo sapiens						58.5							26	Parkinson's disease								12	month		p.1823, 1826, 1827
2606	1337					Overdose	mg	100		single					healthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a&type=display	Homo sapiens							max																		
2607	1337					Overdose	mg	200		single					healthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bf3425e0-428d-4bdb-ac9a-3b9d483df83a&type=display	Homo sapiens																		ethanol							
2608	1338		adult			Recommended	mg	100		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	Homo sapiens													350	HIV and oropharyngeal or esophageal candidiasis	0.1 g/kg			hydroxypropyl-beta-cyclodextrin				15	day		
2609	1338		adult			Recommended	mg	100		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020657s027lbl.pdf	Homo sapiens													350	HIV and oropharyngeal or esophageal candidiasis								15	day		
2610	1338		adult			Recommended	mg	400		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/11249550/	Homo sapiens														tinea								1	week		
2611	1338		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00791219	Homo sapiens													75	Onychomycosis								12	week		
2612	1338					Studied dose	mg/kg	2.5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17517842/	Homo sapiens												16	33	risk for fungal infection					0.5						
2613	1339		adult			Highest studied dose	mg	14		single			day	8	healthy	intranasal	M		https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000OtherR.pdf	Homo sapiens													34									1	day		
2614	1339					Recommended	mg	56		multiple			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000MedR.pdf	Homo sapiens						48							115	treatment-resistant depression				oral antidepressant				28	week		nda/2019/211243Orig1s000MedR.pdf - p.207
2615	1339					Recommended	mg	56		multiple			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000MedR.pdf	Homo sapiens						70	mean			dosed flexibly from 28 to 84 mg			72	treatment-resistant depression				oral antidepressant				28	week		nda/2019/211243Orig1s000MedR.pdf - p.207
2616	1339					Recommended	mg	70		multiple			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000MedR.pdf	Homo sapiens						45	mean			dosed flexibly from 56 to 84 mg			115	treatment-resistant depression				oral antidepressant				28	week		nda/2019/211243Orig1s000MedR.pdf - p.207
2617	1339					Recommended	mg	84		multiple			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000MedR.pdf	Homo sapiens						47							116	treatment-resistant depression				oral antidepressant				28	week		nda/2019/211243Orig1s000MedR.pdf - p.207
2618	1339					Studied dose	mg/kg	0.5		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29501990/	Homo sapiens												65	126	major depressive disorder | bipolar disorder					18			1	day		
2619	1339						mg	10		single					healthy	intravenous	M		https://clinicaltrials.gov/ct2/show/NCT00486902	Homo sapiens													85	Cesarean Section											
2620	1339						mg	50		single					unhealthy	intranasal			https://clinicaltrials.gov/ct2/show/NCT01304147	Homo sapiens													19	Treatment-Resistant Depression											
2621	1339						mg/kg	0.5		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01680172	Homo sapiens													3	Depression and Anxiety|Cancer											
2622	1339						mg/kg	1		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT01920555	Homo sapiens													20	Treatment-Resistant Depression											
2623	1339						mg/kg	2.55		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT01089361	Homo sapiens							total daily dose						10	Sepsis											
2624	1340		adult			Highest studied dose	mg	2		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/25031584	Homo sapiens													1									3	week		
2625	1340					Overdose	mg	1.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23279031	Homo sapiens													1	atopic dermatitis								5	day		
2626	1340					Overdose	mg	120		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6113023	Homo sapiens						21							1						21						
2627	1340						mg/mL	0.05		multiple			day	1	unhealthy	ophthalmic	F		https://pubmed.ncbi.nlm.nih.gov/32064627	Homo sapiens						69				Eye drops containing ketotifen fumarate (0.05 mg/mL)			1	seasonal allergic conjunctivitis					69			1	month		
2628	1341					Highest studied dose	mg	3000		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7433343	Homo sapiens							max			Labetalol was used in a mean daily dose of 1356 mg (range 400-3000 mg)		81	32	Hypertension					18						
2629	1341					Overdose	g	14		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29147632	Homo sapiens						38	max						1					alcohol, p.o							
2630	1341					Recommended	mg	1200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s026lbl.pdf|https://www.ebmconsult.com/articles/monograph-labetalol-normodyne-trandate|https://www.pdr.net/drug-summary/Labetalol-Hydrochloride-Injection-labetalol-hydrochloride-1568	Homo sapiens							total daily dose							Hypertension											p.10
2631	1341					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018716s026lbl.pdf	Homo sapiens							max			The usual maintenance dosage of labetalol HCl is between 200 and 400 mg twice daily.				Hypertension											p.5
2632	1341					Studied dose	mg	300		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019425s021lbl.pdf	Homo sapiens							total							Hypertension											p.14
2633	1342					Studied dose	g	4.5		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11185974/	Homo sapiens						32							1	epilepsy	2 mg; 1/d			clonazepam	32			1	day		
2634	1342					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022115s000_MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022509Orig1s000MedR.pdf	Homo sapiens							typical			dose range: 12.5-600 mg			118	partial seizures								52	week		
2635	1342					Studied dose	mg	800		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9806147/	Homo sapiens						2							1						2			1	day		
2636	1342						mg	200		steady					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01015586	Homo sapiens							total daily dose						21	Alcohol Dependence|Bipolar Disorder								6	week		
2637	1342						mg	400		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01142310	Homo sapiens													26	Memory Impairment								38	week		
2638	1344		adult			Highest studied dose	mg	90		single			day	1	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021566s000_Prevacid_medr.pdf	Homo sapiens													9									1	day		
2639	1344		adult			Recommended	mg	30		multiple			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021566s000_Prevacid_medr.pdf	Homo sapiens													67									7	day		nda/2004/021566s000_Prevacid_medr.pdf - p.66
2640	1344		adult			Recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8490080/	Homo sapiens										mean duration (2-12 weeks range)			40	peptic ulcer								7	week		
2641	1344		adult			Studied dose	mg	600		single			day	1	unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020406s092,021428s039lbl.pdf	Homo sapiens													1									1	day		
2642	1344					Highest studied dose	mg	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9854205/	Homo sapiens													14	Zollinger-Ellison syndrome								6	month		
2643	1344					Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15735486/	Homo sapiens						14.1							64	non-erosive gastroesophageal reflux disease								8	week		
2644	1344						mg	30		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02873702	Homo sapiens													20	Erosive Esophagitis								8	week		
2645	1345		ADULT			Highest studied dose	ug	10		multiple			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1755739/|https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf	Homo sapiens												39	18						22			7	day		1564-8|020597Orig1s000rev
2646	1345		ADULT			Highest studied dose	ug	10		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1755739/|https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf	Homo sapiens												39	16						22			1	day		1564-8|020597Orig1s000rev
2647	1345		ADULT			Recommended	%	0.005		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000MedR.pdf	Homo sapiens													153	open-angle glaucoma								36	week		206185Orig1s000MedR
2648	1345		ADULT			Recommended	%	0.005		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000MedR.pdf	Homo sapiens													25	open-angle glaucoma								8	week		206185Orig1s000MedR
2649	1345		ADULT			Recommended	%	0.005		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000MedR.pdf	Homo sapiens													578	open-angle glaucoma								12	week		206185Orig1s000MedR
2650	1347		adult			Recommended	mg	10		steady			day	1	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021880lbl.pdf	Homo sapiens																									
2651	1347		adult			Recommended	mg	10		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021880s000_Revlimid_MedR.pdf	Homo sapiens							starting			Combined MDS studies			395									28	day		p. 101
2652	1347		adult			Recommended	mg	10		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021880lbl.pdf	Homo sapiens																									
2653	1347					Highest studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32829079	Homo sapiens						35							3	Relapsed or Refractory Classical Hodgkin Lymphoma					35			28	day		
2654	1347						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00109772	Homo sapiens													87	Complex Regional Pain Syndrome								12	week		
2655	1347						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00179621	Homo sapiens													69	Myelodysplastic Syndrome								28	day		
2656	1347						mg	15		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01021423	Homo sapiens													4	Mantle Cell Lymphoma								21	day		
2657	1347						mg	25		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02041325	Homo sapiens													22	Plasma Cell Dyscrasias								14	day		
2658	1347						mg	5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00179621	Homo sapiens													69	Myelodysplastic Syndrome								28	day		
2659	1348		adult				mg	2.5		steady			day	1	healthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00090857	Homo sapiens										Participants in this arm received 2.5 mg of letrozole per day for a duration of 12 months; followed by an optional 4 years. Treatment continued in the absence of unacceptable toxicity or diagnosis of invasive breast cancer, ductal carcinoma in situ, or any non-breast primary cancer.			33	Breast cancer								12	month		
2660	1348		adult				mg	2.5		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00579826	Homo sapiens							total daily dose						29	Breast Cancer								6	month		
2661	1348		adult				mg	2.5		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00754845	Homo sapiens										Related publication: [PMID:27264120]: Within 2 years after completing treatment with the aromatase inhibitor, patients were randomly assigned to receive 2.5 mg of letrozole or placebo orally once a day for another 5 years.			959	Breast Cancer								5	year		
2662	1348					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/11510690/	Homo sapiens						71.6							12	breast cancer								3	month		
2663	1348					Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/8345034/	Homo sapiens						28.4							3									1	day		
2664	1348					Recommended	mg	2.5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20726_FEMARA%202.5MG_MEDR_P4.PDF	Homo sapiens						63.6							174	breast cancer								33	month		20726_FEMARA%202.5MG_MEDR_P4.PDF - p.10
2665	1348					Recommended	mg	2.5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20726_FEMARA%202.5MG_MEDR_P5.PDF	Homo sapiens						66				median duration			185	breast cancer								5	month		20726_FEMARA%202.5MG_MEDR_P5.PDF - p.40
2666	1348					Studied dose	mg	62.5		single			day	1	unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf	Homo sapiens													1									1	day		
2667	1349					Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10845730/	Homo sapiens						40							38	refractory epilepsy								24	week		
2668	1349					MTD	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://www.fda.gov/files/drugs/published/N21-035S040-Levetiracetam-Clinical-BPCA.pdf | https://pubmed.ncbi.nlm.nih.gov/11051122/	Homo sapiens						37							171	refractory partial seizures								12	week		N21-035S040-Levetiracetam-Clinical-BPCA.pdf - p.25
2669	1349					MTD	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://www.fda.gov/files/drugs/published/N21-035S040-Levetiracetam-Clinical-BPCA.pdf | https://pubmed.ncbi.nlm.nih.gov/11051122/	Homo sapiens						37							181	refractory partial seizures								4	week		N21-035S040-Levetiracetam-Clinical-BPCA.pdf - p.25
2670	1349					Recommended	mg/kg	60		multiple			day	1	unhealthy	oral	M+F		https://www.fda.gov/files/drugs/published/N21-035S040-Levetiracetam-Clinical-BPCA.pdf	Homo sapiens						10.2							101	partial onset seizures								10	week		N21-035S040-Levetiracetam-Clinical-BPCA.pdf - p.44
2671	1349					Recommended	mg/kg	60		multiple			day	1	unhealthy	oral	M+F		https://www.fda.gov/files/drugs/published/N21-035S040-Levetiracetam-Clinical-BPCA.pdf	Homo sapiens						10.2							101	partial onset seizures								10	week		N21-035S040-Levetiracetam-Clinical-BPCA.pdf - p.46
2672	1349					Studied dose	g	63		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21210332/	Homo sapiens						41							1	partial seizures					41			1	day		
2673	1349						mg	1500		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01228747	Homo sapiens							max						126	Tonic-clonic Seizures								28	week		
2674	1351		adult				mg	5		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00295022	Homo sapiens													157	Rhinitis, Allergic, Seasonal								2	day		
2675	1351		adult				mg	5		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00621959	Homo sapiens													301	Seasonal Allergic Rhinitis								2	week		
2676	1351		child				mg	1.25		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00619801	Homo sapiens													114	Allergic Rhinitis|Chronic Urticaria								2	week		
2677	1351		child				mg	1.25		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00628108	Homo sapiens													45	Allergic Rhinitis|Chronic Urticaria								2	week		
2678	1351		child				mg/kg	0.125		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00152464	Homo sapiens													255	Asthma								18	month		
2679	1351					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral			https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1398-9995.2011.02606.x	Homo sapiens													13	severe urticaria								2	week		
2680	1351					Recommended	mg	5		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21502689 |https://pubmed.ncbi.nlm.nih.gov/28081586	Homo sapiens												64	2	chronic urticaria					48			2	week		
2681	1351					Recommended	mg	5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022064lbl.pdf	Homo sapiens													428						12			4	month		
2682	1352		adult			Recommended	mg	130		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1019265/	Homo sapiens													30	oligophrenic epileptics								115	day		
2683	1352					Recommended	mg	12.5		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19500717/	Homo sapiens						75				1-2 times/day			1	lung cancer, metastatic to bone and lung					75			6	month		
2684	1353					Recommended	ug	20		multiple			day	1	healthy	intrauterine	F		https://pubmed.ncbi.nlm.nih.gov/25934164	Homo sapiens										Levonorgestrel intrauterine contraceptive (LNG20) contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to half that value after 5 years.		45	1714	Prevention of pregnancy					16			2	year		p.10
2685	1353					Recommended	ug	20		multiple			day	1	healthy	intrauterine	F		https://pubmed.ncbi.nlm.nih.gov/29560743	Homo sapiens						27.3				Liletta contains 52 mg of levonorgestrel (LNG). Initially, LNG is released at a rate of approximately 20 mcg/day. This rate decreases progressively to half that value after 5 years.			1700	Prevention of pregnancy								2	year		p.2
2686	1353					Recommended	ug	90		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19913143	Homo sapiens						27.6							323	Prevention of pregnancy	20 ug; q.d; 1 year			ethinyl estradiol, p.o				1	year		p.507
2687	1354					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10929922/	Homo sapiens						35.3							331	seasonal allergic rhinitis								2	week		
2688	1354					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2572617/	Homo sapiens						29							103	seasonal allergic rhinitis								2	week		
2689	1354					Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-641S007_Loratadine_medr.pdf	Homo sapiens						3.6							60	seasonal allergic rhinitis											
2690	1355		adult			Recommended	mg	2		steady			day	1	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018140s028lbl.pdf	Homo sapiens													130	neuroses								7	day		
2691	1358						mg	75		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/072285s021lbl.pdf	Homo sapiens							starting			An initial dosage of 75 mg daily is sug gested for outpatients with mild to moderate depression. However, in some patients, par ticularly the elderly, an initial dosage of 25 mg daily may be used. Because of the long half-life of maprotiline, the initial dosage should be maintained for 2 weeks. The dos age may then be increased gradually in 25 mg increments as required and tol erated. In most outpatients a maximum dose of 150 mg daily will re sult in therapeutic efficacy.				depressive illness								2	week		
2692	1359					Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18333861/	Homo sapiens						31.3							9									6	day		
2693	1359					Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18333861/	Homo sapiens													9									1	day		
2694	1359					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208984Orig1s000,022128Orig1s017SumR.pdf	Homo sapiens												18	103	HIV-1					2			48	week		nda/2016/208984Orig1s000,022128Orig1s017SumR.pdf - p.16
2695	1359					Studied dose	mg	3		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18333861/	Homo sapiens						29.3							5									7	day		
2696	1359					Studied dose	mg	600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18333861/	Homo sapiens						29.3							9									12	day		
2697	1360					Highest studied dose	mg	2500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18234062	Homo sapiens												81	2	androgendependent prostate cancer |castration-resistant prostate cancer					48						
2698	1360						%	10		multiple			day	2	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/8040425	Homo sapiens													6	actinic keratoses								3	week		
2699	1361					MTD	mg	1600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32400117	Homo sapiens												68	4	Glioblastoma	110 mg/m2; Day 1 for a 42 days cycle			CCNU, p.o	25						p.4681
2700	1361					Recommended	mg	500		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208398s000lbl.pdf	Homo sapiens														Gastrointestinal infections caused by Ascaris lumbricoides and Trichuris trichiura				Metronidazole							p.1
2701	1361					Recommended	mg	500		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208398s000lbl.pdf	Homo sapiens														Gastrointestinal infections caused by Ascaris lumbricoides and Trichuris trichiura											p.1
2702	1362						mg	400		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7016450	Homo sapiens														rheumatoid arthritis								6	month		
2703	1363						mg	500		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/015034s044lbl.pdf	Homo sapiens							starting																		
2704	1364					Highest studied dose	mg	1600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3368800	Homo sapiens														advanced breast cancer											
2705	1364					Recommended	mg	625		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27218795	Homo sapiens						65							1						65			4	week		
2706	1364						mg	40		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16563066	Homo sapiens						85							1	Alzheimer's disease					85			4	month		
2707	1364						mg	400		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15595341	Homo sapiens												68	2						54			6	month		
2708	1364						mg	400		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16563066	Homo sapiens						86							1	Alzheimer's disease					86			10	day		
2709	1365		adult				mg	30		multiple			day	1	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02540265	Homo sapiens										N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.			20	Pain, Post-operative								3	day		
2710	1365		adult				mg	60		multiple			day	1	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02540265	Homo sapiens										N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.			20	Pain, Post-operative								3	day		
2711	1365					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207233Orig1s000MedR.pdf	Homo sapiens						61							131	osteoarthritis pain								12	week		nda/2015/207233Orig1s000MedR.pdf - p.55
2712	1365					Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207233Orig1s000MedR.pdf	Homo sapiens						61							138	osteoarthritis pain								12	week		nda/2015/207233Orig1s000MedR.pdf - p.55
2713	1366		adult			Highest studied dose	mg	400		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021487lbl.pdf	Homo sapiens													1												
2714	1366		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00255086	Homo sapiens													9	Alzheimer's Disease								52	week		
2715	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00294554	Homo sapiens							max			Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.			10	Parkinson's Disease|Cognitive Impairment|Dementia								24	week		
2716	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00462228	Homo sapiens										After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week.			11	Traumatic Brain Injury								12	week		
2717	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00476008	Homo sapiens													22	Alzheimer's Disease								12	month		
2718	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00584948	Homo sapiens										Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.			47	Fragile X-associated Tremor Ataxia Syndrome								1	year		
2719	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01032759	Homo sapiens										Patients in each group will then be randomized to receive either memantine 20 mg or placebo 30-60 minutes preoperatively, followed on postoperative day 1 with either memantine 10 mg in the morning and 10 mg in the evening for memantine patients, or placebo at the same intervals for placebo patients.			32	Pain								1	day		
2720	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01112683	Homo sapiens										The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).			19	Down Syndrome								16	week		
2721	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01535040	Homo sapiens													57	Tobacco Use Disorder								12	week		
2722	1366		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02240589	Homo sapiens										Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.			5	Traumatic Brain Injury								24	week		
2723	1366		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00305578	Homo sapiens							max			Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.			14	Bipolar Depression								8	week		
2724	1366		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00857649	Homo sapiens													182	Alzheimer's Disease								24	week		
2725	1366		child				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01972074	Homo sapiens							max						22	Autism Spectrum Disorder								12	week		
2726	1367		adult				mg/kg	6.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1001284	Homo sapiens													22	Seizure								1	month		
2727	1367					Overdose	mg	12000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/11192466	Homo sapiens						26							1					valproic acid	26						
2728	1367					Overdose	mg	7200		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/11192466	Homo sapiens						17							1						17						
2729	1367						g	0.1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18135085	Homo sapiens						31							1	epileptic attacks	oral; 6 months			phenobarbital	31			6	month		
2730	1368					Recommended	%	3		single			day	1	healthy	parenteral	M+F		https://pubmed.ncbi.nlm.nih.gov/14970775/ | https://pubmed.ncbi.nlm.nih.gov/24428507/	Homo sapiens						27							40									1	day		
2731	1368					Recommended	%	3		single			day	1	healthy	parenteral	M+F		https://pubmed.ncbi.nlm.nih.gov/20951285/ | https://pubmed.ncbi.nlm.nih.gov/24428507/	Homo sapiens						25							50	pain								1	day		
2732	1368					Recommended	%	3		single			day	1	healthy	parenteral	M+F		https://pubmed.ncbi.nlm.nih.gov/3253404/ | https://pubmed.ncbi.nlm.nih.gov/24428507/	Homo sapiens												31	31						21			1	day		
2733	1368					Recommended	%	3		single			day	1	healthy	submucosal	M+F		http://english.tcsurg.org/article/8529.html | https://pubmed.ncbi.nlm.nih.gov/24428507/	Homo sapiens						38.8							66									1	day		
2734	1368					Recommended	mg	270		single			day	1	healthy	parenteral	F		https://pubmed.ncbi.nlm.nih.gov/1783701/	Homo sapiens						5							1						5			1	day		
2735	1369		adult			Recommended	g	1.6		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019651s023lbl.pdf	Homo sapiens							median			0.8 to 2.8 g			155	ulcerative colitis								6	month		
2736	1369		adult			Recommended	g	4.8		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019651s023lbl.pdf	Homo sapiens													155	ulcerative colitis								6	week		
2737	1369		adult				g	6		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00862121	Homo sapiens							total daily dose			Pentasa administered as a 2 g morning dose and a 4 g evening dose			8	Crohn´s Disease								10	week		
2738	1369		adult				mg	1.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00545103	Homo sapiens													148	Diverticulitis								104	week		
2739	1369		adult				mg	2.4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00545103	Homo sapiens													147	Diverticulitis								104	week		
2740	1369		adult				mg	4.8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00545103	Homo sapiens													149	Diverticulitis								104	week		
2741	1369					Overdose	g	14.5		single					unhealthy	oral|rectal	M		https://pubmed.ncbi.nlm.nih.gov/20670990/	Homo sapiens							complex			a 20-year-old male patient took 14.5 g of mesalazine rectally and orally for suicide purpose			1	ulcerative colitis											
2742	1369					Recommended	g	3.2		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20441247/	Homo sapiens						42							1	ulcerative colitis					42			8	day		
2743	1369					Recommended	g	4.8		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30431332/	Homo sapiens										1.2 to 4.8 mg		41	10	Inflammatory bowel disease, breastfeeding mothers					28			7	day		
2744	1369					Studied dose	mg/kg	15.7		steady			day	1	healthy	oral (mother), breasteeding (infant)	M+F		https://pubmed.ncbi.nlm.nih.gov/30431332/	Homo sapiens							mean						10									7	day		
2745	1370		adult				mg	250		multiple			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01702025	Homo sapiens													10	Hypoxia								8	day		
2746	1370					Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/718513	Homo sapiens						67.5							24	Glaucoma					67.5			1	week		
2747	1370						mg	50		multiple			day	2	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=4c9fc6f5-acd4-4fc0-bf4b-c493a08aa3d6&type=display#i4i_warnings_id_warnings	Homo sapiens															high concentration			aspirin							
2748	1372					Recommended	g	1		steady			day	3	pregnant	intramuscular	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11790slr046_robaxin_lbl.pdf	Homo sapiens										For the severest cases or in postoperative conditions in which oral administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.															
2749	1372					Recommended	g	1		steady			day	3	pregnant	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11790slr046_robaxin_lbl.pdf	Homo sapiens										For the severest cases or in postoperative conditions in which oral administration is not feasible, additional doses of 1 gram may be repeated every 8 hours up to a maximum of 3 g/day for no more than 3 consecutive days.															
2750	1372					Recommended	mg	1500		steady			day	4	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/011011Orig1s070s071lbl.pdf	Homo sapiens							starting			750 mg – Adults: Initial dosage: 2 tablets q.i.d. Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.															
2751	1373		adult			Overdose	mg	10		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/15287234	Homo sapiens													1	rheumatoid arthritis											
2752	1373		adult			Overdose	mg	15		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/15287234	Homo sapiens													1	rheumatoid arthritis											
2753	1373		adult			Overdose	mg	2.5		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/15287234	Homo sapiens													1	rheumatoid arthritis								6	day		
2754	1373		adult			Recommended	mg	25		steady			week	1	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/040054s015,s016,s017.pdf	Homo sapiens																									
2755	1373		adult			Recommended	mg	25		steady			week	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/040054s015,s016,s017.pdf	Homo sapiens														Mycosis fungoides											
2756	1373		adult			Recommended	mg	7.5		steady			week	1	pregnant	subcutaneous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens																									
2757	1373		adult			Recommended	mg	7.5		steady			week	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens														rheumatoid arthritis											
2758	1373		adult			Recommended	mg	7.5		steady			week	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens																									
2759	1373		adult				mg	30		multiple			week	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205776s000lbl.pdf	Homo sapiens																		Nonsteroidal anti-inflammatory drugs							
2760	1373					Highest studied dose	g/m2	3		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33608849	Homo sapiens						41							103	aggressive lymphoma	oral, 50 mg at H24 and pursued this treatment every 6 h during 3 days (until day 4) for a total of 12 administrations			calcium folinate	41			2	cycle		
2761	1373					Highest studied dose	g/m2	3		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33608849	Homo sapiens						41							103	aggressive lymphoma	oral, 50 mg at H24 and pursued this treatment every 6 h during 3 days (until day 4) for a total of 12 administrations				41			2	cycle		
2762	1373					Overdose	mg	17.5		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31269978	Homo sapiens												79	1	rheumatoid arthritis					70			6	month		
2763	1373					Overdose	mg	50		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31269977	Homo sapiens												59	1	rheumatoid arthritis					50			1.5	month		
2764	1373					Overdose	mg	50		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/31269977	Homo sapiens												49	1						40						
2765	1373					Overdose	mg	70		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31269977	Homo sapiens												79	2	rheumatoid arthritis					60			6	month		
2766	1373					Overdose	mg	75		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/31269977	Homo sapiens												19	1						10						
2767	1373					Overdose	mg	87.5		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/31269977	Homo sapiens												19	1						10						
2768	1373					Recommended	mg	10		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33772624	Homo sapiens						54		50 mg/day for approximately 3 years.					1	rheumatoid arthritis	40 mg per every other week; 3 years			adalimumab	54			7	year	guratimod	
2769	1375					Highest studied dose	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14487339/	Homo sapiens												68	25	congestive heart failure					22			2	day		
2770	1376		adult				g	1		single					unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21415lbl.pdf	Homo sapiens										Do not apply more than one g of TRADENAME Cream for treatment session. TRADENAME Cream contains methyl aminolevulinate hydrochloride equivalent to 168 mg/g of methyl aminolevulinate			383	actinic keratosis											
2771	1377		newborns			Overdose	mg	0.2		single					healthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/006035s078lbl.pdf	Homo sapiens										accidental injection in newborn infants															
2772	1377					Highest studied dose	mg	0.8		multiple			day		healthy	oral	F		https://www.pdr.net/drug-summary/Methylergonovine-Maleate-Tablets-methylergonovine-maleate-3896	Homo sapiens														uterine atony and hemorrhage prophylaxis								7	day		
2773	1377					Recommended	mg	0.2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/006035s075lbl.pdf	Homo sapiens										should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Methergine® (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.				uterine hemorrhage											
2774	1379					Highest studied dose	mg	100		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													29	nausea and vomiting after cisplatin					30			7	day		
2775	1379					Highest studied dose	mg	50		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													13	nausea and vomiting after cisplatin	200 mg			Diphenhydramine				7	day		
2776	1379					MTD	mg	20		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													13	nausea and vomiting after cisplatin	200 mg			Diphenhydramine				7	day		
2777	1379					MTD	mg	20		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													13	nausea and vomiting after cisplatin								7	day		
2778	1379					MTD	mg	20		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													29	nausea and vomiting after cisplatin					30			7	day		
2779	1379					MTD	mg	50		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3392746/	Homo sapiens													29	nausea and vomiting after cisplatin	200 mg			Diphenhydramine	30			7	day		
2780	1379					Overdose	mg/kg	1		single			day	6	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3405665/	Homo sapiens													1	gastroesophageal reflux								1	day		
2781	1379					Overdose	mg/kg	4.4		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1960984/	Homo sapiens						25				4.4 mg/L			1	attempted suicide	8.49 mg/l			Diltiazem	25						
2782	1380					Highest studied dose	mg	920		steady			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e15714 |https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.200	Homo sapiens						64.9		10 mg oral				84.1		pancreatic cancer	50 mg oral		sirolimus	phenytoin	45.6		0.5 mg oral	4.7	week	methoxsalen	
2783	1381		adult				mg	2.5		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7690382	Homo sapiens													12												
2784	1381					Highest studied dose	mg	90		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31381098	Homo sapiens						49				including 60 mg administered in divided doses for daily maintenance and 30-mg intradialytic doses			1	hypotension					49			1	month		
2785	1381					Overdose	mg	205		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019815s010lbl.pdf	Homo sapiens										41 5-mg tablets			1												
2786	1381					Overdose	mg	250		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019815s010lbl.pdf	Homo sapiens													1												
2787	1381					Overdose	mg	350		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27417951	Homo sapiens						20				seventy 5-mg tablets			1						20						
2788	1381					Recommended	mg	10		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019815s010lbl.pdf	Homo sapiens													1									3	week		
2789	1381						mg	7.5		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11007859	Homo sapiens													2									4	month		
2790	1382		adult			Recommended	mg	1200		multiple			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens													24									15	day		/nda/2012/202107Orig1s000MedR.pdf - p.126
2791	1382		adult			Recommended	mg	1200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens													24									15	day		/nda/2012/202107Orig1s000MedR.pdf - p.126
2792	1382		adult			Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens										300-1200 mg			50	Cushing’s syndrome								24	week		/nda/2012/202107Orig1s000MedR.pdf - p.124
2793	1382		adult			Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens													81	Alzheimer’s disease								16	week		/nda/2012/202107Orig1s000MedR.pdf - p.126
2794	1382		adult			Recommended	mg	600		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens													30									14	week		/nda/2012/202107Orig1s000MedR.pdf - p.126
2795	1382		adult			Recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens										300-1200 mg			50	Cushing’s syndrome								24	week		/nda/2012/202107Orig1s000MedR.pdf - p.124
2796	1382		adult			Recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens													105	Major depressive disorder								7	day		/nda/2012/202107Orig1s000MedR.pdf - p.126
2797	1382		adult			Recommended	mg	900		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens										300-1200 mg			50	Cushing’s syndrome								24	week		/nda/2012/202107Orig1s000MedR.pdf - p.124
2798	1382		adult				mg	300		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00352911	Homo sapiens							max			150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days			16	HIV Infections								14	day		
2799	1382		adult				mg	600		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01212588	Homo sapiens													10	Borderline Personality Disorder								7	day		
2800	1382					Highest studied dose	mg	2000		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19289534/ | https://pubmed.ncbi.nlm.nih.gov/11502780/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens						45				median maximal dose - 600 mg/day			1	adrenal cancer				Mitotane	45			1	month	ketoconazole	
2801	1382					Highest studied dose	mg	2000		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11502780/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202107Orig1s000MedR.pdf	Homo sapiens						51							1	Cushing's disease					51			18	month		
2802	1383		adult			Recommended	mg	100		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf	Homo sapiens													962	diabetes mellitus, type 2											
2803	1383					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20963449/	Homo sapiens						58.4	max			Dose titration at week 12 was performed at the discretion of the investigator. Patients with good tolerance to miglitol 50 mg 3 times daily were titrated to 100 mg 3 times daily. Patients with unsatisfactory, but acceptable, tolerance to the treatment were maintained at 50 mg 3 times daily.			52	diabetes mellitus, type 2								24	week		
2804	1383					Recommended	mg	75		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20558922/	Homo sapiens						39.3				75 mg miglitol per every meal for three days.			22									3	day		
2805	1384					Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca_Medr_P1.pdf	Homo sapiens						44							28	Gaucher disease								337	day		918-001
2806	1385		adult			Highest studied dose	mg	5		multiple			day	4	unhealthy	oral			https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2883%2980095-3	Homo sapiens													6	heart failure								4	week		p.675
2807	1385		adult			Highest studied dose	ug/kg	150		single			day	1	unhealthy	intravenous			https://www.jacc.org/doi/pdf/10.1016/S0735-1097%2883%2980095-3	Homo sapiens													8	heart failure								1	day		p.675
2808	1385		adult				ug/kg/min	0.75		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02712788	Homo sapiens										continuous infusion			2	Cerebral Vasospasm											
2809	1385					Highest studied dose	mg	10		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8376682/	Homo sapiens						60				median duration			254	heart failure	12.5 mg; oral; 2/d			captopril				4.5	month		
2810	1385					Studied dose	ug/kg/min	0.5		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10416916/	Homo sapiens						73.3							9	systemic inflammatory response syndrome				catecholamines				1	day		
2811	1386		adult			Recommended	%	5		steady			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/25807073/	Homo sapiens										foam				hair loss								7	day		
2812	1386		child				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00876200	Homo sapiens							max|total daily dose			Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.			9	Williams-Beuren Syndrome								12	month		
2813	1386					Overdose	mg	1200		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/8131492/	Homo sapiens						52							1						52						
2814	1386					Overdose	mg	650		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/1629592/	Homo sapiens						20							1	suicide gesture					20						
2815	1387		adolescent			Overdose	mg	12		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17267868/	Homo sapiens													1	induce abortion											
2816	1387					Overdose	mg	8400		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15223178/	Homo sapiens						28.8							1	induce abortion											
2817	1387					Recommended	ug	50		steady			day	4	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/31923193/	Homo sapiens						28.8							172	live term single cephalic fetus for indicated labor induction								1	day		
2818	1387					Recommended	ug	50		steady			day	6	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31923193/	Homo sapiens						29.1							167	live term single cephalic fetus for indicated labor induction								1	day		
2819	1387					Studied dose	ug	400		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10640161/	Homo sapiens						30.2							92	induce abortion	600 mg			mifepristone							
2820	1388					Recommended	g	2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22048971	Homo sapiens													12	Adrenal cortical carcinoma								12	week		p.264
2821	1388					Recommended	g	2		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	Homo sapiens										Initial dose: 2 g to 6 g orally daily, in three or four divided doses.				Adrenal cortical carcinoma											p.1
2822	1390		adult			Recommended	g	2		steady			day	1	unhealthy	oral	unknown		https://www.aapharma.ca/downloads/en/PIL/2018/00042393-Nabumetone_PM__en.pdf	Homo sapiens							max			1 to 2 g, 1 to 24 months			1677	rheumatoid arthritis and osteoarthritis								24	month		9
2823	1392		adult			Recommended	%	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019599s013lbl.pdf	Homo sapiens													400	tinea pedis | tinea cruris | tinea corporis								2	week		
2824	1392					Recommended	%	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019599s013lbl.pdf	Homo sapiens													116	tinea pedis | tinea cruris | tinea corporis								2	week		
2825	1392					Recommended	%	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204286Orig1s000MedR.pdf	Homo sapiens													1747	tinea pedis								2	week		1010, 3015, and 3016
2826	1393					Highest studied dose	drop	2		multiple			day	8	healthy	topical			https://www.pdr.net/drug-summary/Naphazoline-naphazoline-hydrochloride-3515	Homo sapiens										16 drops/day in each eye per day				Eye redness											
2827	1393					Recommended	mg/mL	0.25		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/20383847	Homo sapiens						35				naphazoline 0.25/antazoline 5 mg/mL			30	Allergic conjunctivitis	5 mg/ml topical			antazoline				4	week		p.814
2828	1394					Highest studied dose	mg	240		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10720043	Homo sapiens						59							24	Type 2 diabetes					59			7	day		
2829	1394					Overdose	mg	3420		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/15616260	Homo sapiens						30				38 tablets, 90 mg each			1						30						
2830	1394					Recommended	mg	120		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/077463s000lbl.pdf	Homo sapiens													2600	Type 2 diabetes								12	week		
2831	1395		adult			Highest studied dose	mg	200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8665999/	Homo sapiens													12	hepatic cirrhosis											
2832	1395		adult			Highest studied dose	mg	200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8665999/	Homo sapiens													12	renal impairment											
2833	1395		adult			Highest studied dose	mg	430		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10817106/	Homo sapiens							mean						19	Posttraumatic stress disorder								12	week		
2834	1395		adult			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8876863/	Homo sapiens							max			300 to 600 mg			394	major depression								6	week		Table 1
2835	1395		adult			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8876863/	Homo sapiens							max			300 to 600 mg			394	major depression								6	week		Table 2
2836	1395		adult			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8876863/	Homo sapiens							max			50 to 600 mg			565	major depression								6	week		Table 1
2837	1395		elderly			Highest studied dose	mg	200		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8665999/	Homo sapiens													12												
2838	1395		younger			Highest studied dose	mg	200		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8665999/	Homo sapiens													12												
2839	1396					MTD	mg	1250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22425919	Homo sapiens						59							8	Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer					59			14	day		
2840	1396					MTD	mg	1250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24596143	Homo sapiens						52						77	15	Adenoid Cystic Carcinoma					25			3.2	month		
2841	1396						mg	650		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22425919	Homo sapiens						59							5	Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer					59			14	day		
2842	1397					Recommended	drop	1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/24345529	Homo sapiens										0.003			817	Pain and inflammation associated with cataract surgery								14	day		p.209
2843	1397					Recommended	drop	1		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203491s001lbl.pdf	Homo sapiens										One drop of ILEVROTM (nepafenac ophthalmic suspension), 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.				Pain and inflammation associated with cataract surgery								15	day		p.1
2844	1398					Highest studied dose	g	6		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8356223	Homo sapiens												45	6						27						p.136
2845	1398					Highest studied dose	mg/kg	100		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7607932	Homo sapiens										+ accelerated radiotherapy		82	2	Head and neck cancer					75			3	day		p.1116
2846	1398					MTD	mg/kg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7607932	Homo sapiens										+ accelerated radiotherapy		81	7	Head and neck cancer					54			12	day		p.1116
2847	1398					MTD	mg/kg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9165139	Homo sapiens										+ radiotherapy		82	40	Head and neck cancer					41			6	week		p.69
2848	1399						mg	1000		steady			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29856824	Homo sapiens													2	castration-resistant prostate cancer	160 mg, oral, daily			enzalutamide				4	week		
2849	1400		adult			Highest studied dose	mg	180		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019684s023lbl.pdf	Homo sapiens													1000	hypertension and angina								7	day		
2850	1400					Overdose	mg	200		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2362118/	Homo sapiens						34				200 to 250 mg			1	suicide attempt				ethanol	34						
2851	1400					Overdose	mg	2400		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/8523502/	Homo sapiens						37				2400 to 3000 mg			1					ethanol	37						
2852	1400					Overdose	mg	300		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/3416517/	Homo sapiens						54							1	attempt to commit suicide					54						
2853	1400					Overdose	mg	600		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/2261244/	Homo sapiens						57							1						57						
2854	1400					Overdose	mg	90		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17276811/	Homo sapiens						2				90 to 450 mg			1						2						
2855	1400					Overdose	mg	900		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3740090/	Homo sapiens						59							1	with a history of angina, left bundle branch block, and depression					59						
2856	1400					Recommended	mg	30		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27786578/	Homo sapiens						33.3				30 to 90 mg			25	delivered at ≥32 week' gestation with persistent postpartum hypertension								7	day		
2857	1401					Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf|https://pubmed.ncbi.nlm.nih.gov/2810141	Homo sapiens													4	Metastatic prostate cancer											p.9
2858	1401					Overdose	g	13		single					unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf|https://pubmed.ncbi.nlm.nih.gov/2810141	Homo sapiens						79							1	Metastatic prostate cancer											p.9
2859	1401					Recommended	mg	100		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2203517	Homo sapiens												93	53	Metastatic prostate cancer					47						p.1075
2860	1401					Recommended	mg	300		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf	Homo sapiens										The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day.			209	Metastatic prostate cancer				leuprolide				30	day		p.8
2861	1401					Recommended	mg	300		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf	Homo sapiens										The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day.				Metastatic prostate cancer								30	day		p.3
2862	1401					Recommended	mg	300		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf	Homo sapiens										The recommended dosage is 300 mg once a day for 30 days, followed thereafter by 150 mg once a day.				Metastatic prostate cancer								30	day		p.4
2863	1402		adult			Highest studied dose	mg	120		multiple			day	6	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203340s011lbl.pdf	Homo sapiens													4	subarachnoid haemorrhage								21	day		
2864	1402		adult			Recommended	mg/h	2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3725134/	Homo sapiens													120	subarachnoid hemorrhage								5	day		
2865	1402					Recommended	mg	60		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3283595/	Homo sapiens													38	subarachnoid haemorrhage								21	day		
2866	1403		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7726128/	Homo sapiens							max			20 to 40 mg			503	hypertension	50 mg four times daily			atenolol				12	month		
2867	1404		adult			MTD	mg	4		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/12051573/	Homo sapiens													6									2	week		1
2868	1405					Highest studied dose	mg	80		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30443705	Homo sapiens												55							18						
2869	1406		adult			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2892253/	Homo sapiens													2800	duodenal ulcer								6	week		
2870	1407		adult			Recommended	mg	300		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3466701/	Homo sapiens													12									7	day		
2871	1407		adult			Studied dose	mg	400		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8213104/	Homo sapiens													525	induced first-trimester abortions											
2872	1407					Overdose	g	3		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1929271/	Homo sapiens						26							1	acute left-upper-lobe pneumonia, asthma					26						
2873	1407					Recommended	mg	400		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10344402/	Homo sapiens						81	max			200 to 400 mg			1	urinary infections					81			5	day		
2874	1407					Recommended	mg	400		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15197723/	Homo sapiens						43							1	upper respiratory tract infection	75 mg			venlafaxine	43			3	day		
2875	1407					Recommended	mg/kg	20		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26195507/	Homo sapiens							max			15 to 20 mg/kg		15	55	multidrug-resistant tuberculosis					0			5	week		
2876	1408		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00362115	Homo sapiens													63	Essential Hypertension								8	week		
2877	1408		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00696241	Homo sapiens													282	Hypertension								6	week		
2878	1408		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00696436	Homo sapiens										Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks. Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.			290	Hypertension								6	week		
2879	1408					Highest studied dose	mg	320		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21286lbl.pdf	Homo sapiens																									
2880	1408					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11451213	Homo sapiens												75	12	hypertension					65			10	day		
2881	1409		adult			Recommended	mg	120		steady			day	3	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20766lbl.pdf	Homo sapiens													1913									1	year		
2882	1409		adult				mg	120		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00422058	Homo sapiens													95	Obesity								20	week		
2883	1409		child				mg	120		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00001723	Homo sapiens													100	Obesity-Related Diseases								6	month		
2884	1409					Overdose	mg	5160		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19763670	Homo sapiens										In total 43 tablets were unaccounted for, at a dose of 120 mg per tablet			1												
2885	1409					Recommended	mg	120		steady			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7957533	Homo sapiens						52				two capsules of orlistat 60 mg three times daily		65	35						30			8	week		
2886	1409					Recommended	mg	60		steady			day	3	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25826164	Homo sapiens						54							1						54			2	month		
2887	1409						mg	180		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7957533	Homo sapiens						53				one capsule of orlistat 60 mg three times daily		65	35						30			8	week		
2888	1409						mg	30		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7957533	Homo sapiens						51				one capsule of orlistat 10 mg three times daily		65	33						30			8	week		
2889	1409						mg	90		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7957533	Homo sapiens						55				one capsule of orlistat 10 mg and one capsule of orlistat 20 mg three times daily		65	33						30			8	week		
2890	1410		adult				mg	100		multiple			day	2	healthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02717754	Homo sapiens													19									5	day		
2891	1410		adult				mg	200		multiple			day	2	healthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02717754	Homo sapiens													20									5	day		
2892	1410		adult				mg	75		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01314911	Homo sapiens													277	Influenza								5	day		
2893	1410		child|adult				mg	75		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00412737	Homo sapiens							max			Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.			238	Influenza								12	week		
2894	1410					Higher than recommended	mg	450		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20189775	Homo sapiens						33.9							99									5	day		p.464
2895	1410					Highest studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10934667	Homo sapiens												55	6						18						p.841
2896	1410					Highest studied dose	mg	500		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10934667	Homo sapiens												55	6						18			7	day		p.841
2897	1410					Recommended	mg	75		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021087s057lbl.pdf	Homo sapiens													1171	Influenza								5	day		p.10
2898	1411						mg	200		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2231838/	Homo sapiens						75				a patient was hospitalized six hours after ingestion of 200 mg of oxazepam			1	depression following a coronary bypass operation											
2899	1411						mg	3000		single					unknown	oral			https://link.springer.com/article/10.1007/s40278-017-28921-y	Homo sapiens										oxazepam overdose, a case report			1												
2900	1411						mg	4000		single					unknown	oral	M		https://link.springer.com/article/10.1007/s40278-017-28921-y	Homo sapiens						30				oxazepam overdose, a case report			1												
2901	1412		adult			Recommended	mg	300		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/077802s000lbl.pdf	Homo sapiens							starting			Treatment with oxcarbazepine should be initiated with a dose of 600 mg/day, given in a BID regimen.			1524	epilepsy								24	week		
2902	1412		adult			Recommended	mg	300		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/077802s000lbl.pdf	Homo sapiens							starting			Treatment with oxcarbazepine should be initiated with a dose of 600 mg/day, given in a BID regimen.			1537	partial seizures								24	week		
2903	1412					Highest studied dose	mg	2700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22850688	Homo sapiens										The initial dosage of 900 mg, 1,200 mg or 1,500 mg OXC was increased every 5 days by 300 mg up to a maximum daily dosage of 2,700 mg.		70	71						19			26	day		
2904	1412					Overdose	g	15		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19552755	Homo sapiens						13							1						13						
2905	1412					Overdose	mg	30600		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15327594	Homo sapiens						36				102 tablets of 300 mg oxcarbazepine			1						36						
2906	1412					Recommended	mg/kg	8		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/077802s000lbl.pdf	Homo sapiens							starting			In pediatric patients aged 4-16 years, treatment should be initiated at a daily dose of 8-10 mg/kg generally not to exceed 600 mg/day, given in a BID regimen		16	456	partial seizures					4			14	week		
2907	1412					Recommended	mg/kg	8		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/077802s000lbl.pdf	Homo sapiens							starting			In pediatric patients aged 4-16 years, treatment should be initiated at a daily dose of 8-10 mg/kg generally not to exceed 600 mg/day, given in a BID regimen			241	partial seizures								14	week		
2908	1412						mg/kg	12		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28580160	Homo sapiens						6	starting			the starting dose of 12 mg/kg/day for the first 5 days. The dose was increased to 18 mg/kg/day and after using this dose of drug for 5 days			1	f benign rolandic epilepsy					6			5	day		
2909	1413		adult			Highest studied dose	%	1		multiple					unhealthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205076Orig1s000lbl.pdf	Homo sapiens										cream			955	skin infections								1	month		
2910	1414					Highest studied dose	mg	20		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10124	Homo sapiens												29	6						21						
2911	1414					Studied dose	mg	160		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6820501	Homo sapiens													1									22	month		
2912	1414					Studied dose	mg	480		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6352119	Homo sapiens												70	58	Hypertensive patients					22			2	week		
2913	1414						mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6352119	Homo sapiens							starting			titration period: Each patient was randomly assigned to receive oxprenolol in a regimen of 160 mg at 8 A.M. and placebo at 8 P.M. All patients were told to return after two weeks of treatment, at which time the dosage could be doubled, if necessary, until a controlled blood pressure was achieved. A final increase in dosage to 240 mg twice daily or 480 mg once daily and placebo was permitted during the last two weeks of the titration period.		70	58	Hypertensive patients					22			2	week		
2914	1414						mg	160		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6352119	Homo sapiens												70	58	Hypertensive patients					22			2	week		
2915	1417						ug	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23601186	Homo sapiens						48.5				This dose was increased on Day 15 posttransplant to 2 ug/day orally if no hypercalcemia developed			51						48.5			15	day		
2916	1417						ug	16		steady			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28332096	Homo sapiens						13.9	starting			Beginning at week 4, the initial aricalcitol dose could be increased in increments of 1 μg every 4 weeks based on safety observations and blood chemistry evaluations of iPTH		16	18	stages 3 to 5 chronic kidney disease					10			12	week		
2917	1417						ug	23		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22251408/	Homo sapiens						53	starting			Mean initial dose reported; mean maintenance dose was 11 ± 4 µg/week.			40	Secondary Hyperparathyroidism								12	month		
2918	1418					Highest studied dose	mg/m2	1200		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32520407	Homo sapiens						63.7				intravenous infusion over 10–20 minutes every 2 weeks. Two cycles of pemetrexed per dose			7	Recurrent or Progressive Central Nervous System Lymphoma					63.7			28	day		
2919	1418					MTD	mg/m2	900		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32520407	Homo sapiens						63.7				intravenous infusion over 10–20 minutes every 2 weeks. Two cycles of pemetrexed per dose			4	Recurrent or Progressive Central Nervous System Lymphoma					63.7			28	day		
2920	1418						mg/m2	600		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32520407	Homo sapiens						63.7				intravenous infusion over 10–20 minutes every 2 weeks. Two cycles of pemetrexed per dose			6	Recurrent or Progressive Central Nervous System Lymphoma					63.7			28	day		
2921	1419		adult			Recommended	mg/m2	4		multiple			2 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020122s015lbl.pdf	Homo sapiens										The recommended dosage of NIPENT for the treatment of hairy cell leukemia is 4 mg/m2 every other week. NIPENT may be administered intravenously by bolus injection or diluted in a larger volume and given over 20 to 30 minutes. Higher doses are not recommended. No extravasation injuries were reported in clinical studies. The optimal duration of treatment has not been determined. In the absence of major toxicity and with observed continuing improvement, the patient should be treated until a complete response has been achieved.			180	hairy cell leukemia											
2922	1419						mg/m2	2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9848579/	Homo sapiens						60				After pre-hydration with 500 ml of 5% dextrose or normal saline, pentostatin was administered as a slow iv bolus over five minutes at a dose of 2 mg/m2/day for five consecutive days. The initial dose level of 2 mg/m2/day was adjusted up or down by 0.5 mg/m2 in subsequent cycles on the basis of haematological and non-haematological toxicities. Patients whose creatinine clearance was 50–60 ml/minute at entry to the study were started at a pentostatin dose of 1 mg/m2/day. Courses of treatment were repeated at 28-day intervals.		74	29	B-cell chronic lymphocytic leukaemia					44			5	day		
2923	1419						mg/m2	3.75		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/14716770/	Homo sapiens						62	median			Pentostatin (deoxycoformycin, Nipent; SuperGen, Dublin, CA) was administered by intravenous bolus daily over a consecutive 3-day period every 3 weeks. Dose levels were as follows: 1) dose level 0 was 5.0 mg/m2 daily for 3 days; 2) dose level -1 was 3.75 mg/m2 daily for 3 days; 3) dose level -2 was 2.8 mg/m2 daily for 3 days; and 4) dose level +1 was 6.25 mg/m2 daily for 3 days. Patients received a median of 2 courses of pentostatin (range, 1–12 courses) and a median dose of 3.75 mg/m2 (range, 2.8 –5.0 mg/m2).		86	42	T-cell lymphoid malignancies					38			3	day		
2924	1420		adult				mg	400		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02487225	Homo sapiens													45	Acute Pancreatitis								72	hour		
2925	1420		adult				mg	400		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00770328	Homo sapiens													22	Obesity								8	week		
2926	1420		adult				mg	400		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01382303	Homo sapiens													87	Type 2 Diabetes								24	week		
2927	1420		adult and children			Overdose	mg/kg	80		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018631s039lbl.pdf	Homo sapiens													44	peripheral vascular disease											
2928	1420					Overdose	g	10		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/9587798/	Homo sapiens						54							1						54						
2929	1422					Recommended	mg	40		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/008708s025lbl.pdf	Homo sapiens							max			Initially, 10 mg of Dibenzyline (phenoxybenzamine hydrochloride) twice a day. Dosage should be increased every other day, usually to 20 to 40 mg 2 or 3 times a day, until an optimal dosage is obtained, as judged by blood pressure control.				Pheochromocytoma											p.2
2930	1424					Highest studied dose	mg	30		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14606933/	Homo sapiens												40	8	psoriasis					18			28	day		
2931	1424					Highest studied dose	mg	60		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14606933/	Homo sapiens												40	6						18						
2932	1424					Recommended	%	1		steady			day	4	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/16605292/	Homo sapiens										2 to 4 times/day			947	atopic dermatitis								24	week		
2933	1425		adult			Highest studied dose	mg	21		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4214674/	Homo sapiens													51	chronic schizophrenia								24	week		
2934	1425					Overdose	mg	100		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/824116/	Homo sapiens						17							1												
2935	1425					Overdose	mg	6		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15641643/	Homo sapiens						1.5							1												
2936	1425					Overdose	mg	800		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15641643/	Homo sapiens						53							1												
2937	1425					Recommended	mg/kg	0.2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6371107/	Homo sapiens												13	20	Tourette's syndrome					2			6	week		
2938	1426		adult			Highest studied dose	mg	64		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													33	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2939	1426		adult			Recommended	mg	1		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													309	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2940	1426		adult			Recommended	mg	2		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													951	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2941	1426		adult			Recommended	mg	4		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													1540	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2942	1426		adult				mg	16		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													102	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2943	1426		adult				mg	32		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													34	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2944	1426		adult				mg	4		multiple			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02290106	Homo sapiens													25	Fatty Liver, Nonalcoholic								6	month		
2945	1426		adult				mg	8		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022363s000_MedR_P1.pdf	Homo sapiens													479	primary hyperlipidemia or mixed dyslipidemia								12	week		p. 87
2946	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			26	Perianal warts								3	day		
2947	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			82	External genital warts								3	day		
2948	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			86	Anogenital warts								3	day		
2949	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			119	External genital warts								3	day		
2950	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			127	Anogenital warts								3	day		
2951	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9449907/	Homo sapiens										Patients applied the topical 0.5% podofilox gel twice daily for 3 consecutive days followed by a 4-day treatment-free period (1 treatment cycle). At the baseline visit, patients received instructions on proper application of the assigned medication to warts selected for treatment. Treatment was repeated by the patient until all study warts had cleared, for a minimum of 2 and a maximum of 8 treatment cycles. Gel applications could be postponed for up to 1 week if a local reaction occurred. Patients were evaluated for the treatment's efficacy and safety weekly for 4 weeks, then every other week for an additional 4 weeks. Treated areas were assessed for an additional 8 weeks after completion of treatment to quantitate the recurrence rate of the treated warts and to ensure resolution of any adverse events. Thus, total patient study time varied from 9 to 16 weeks depending on the number of treatment cycles and timing of follow-up visits. Patients could be discontinued from the study if no effect was seen after 4 weeks of treatment.			14	Perianal warts								3	day		
2952	1427		adult			Recommended	%	0.5		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf	Homo sapiens										Apply Condylox Gel 0.5% twice daily for 3 consecutive days, then discontinue for 4 consecutive days. This one week cycle may be repeated until there is no visible wart tissue or for a maximum of four cycles. Treatment should be limited to 10 cm2 or less of wart tissue ant to no more than 0.5g the gel per day.				Anogenital warts								3	day		
2953	1429		adult				mg	400		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01377480	Homo sapiens													32	Chagas disease								60	day		
2954	1429					Highest studied dose	mg	1600		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/21189337	Homo sapiens													3	Invasive fungal infections											p.1310
2955	1429					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens													605	Aspergillus infections|Candida infections											p.12
2956	1429					Recommended	mg	300		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28961714	Homo sapiens						51.55				300 mg of posaconazole iv twice on day 1 and thereafter once daily			237	Invasive fungal infections								11.2	day		p.3
2957	1429					Recommended	mg	300		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens										Loading dose: 300 mg Noxafil injection intravenously twice a day on the first day. Maintenance dose: 300 mg Noxafil injection intravenously once a day thereafter.				Aspergillus infections|Candida infections											p.1
2958	1429					Recommended	mg	400		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens										posaconazole oral suspension at a dose of less than or equal to 400 mg QD in 557 HIV-infected patients			557	Oropharyngeal Candidiasis											p.13
2959	1429					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022003s018s020,0205053s002s004,0205596s001s003lbl.pdf	Homo sapiens													239	Oropharyngeal Candidiasis											p.14
2960	1430					Highest studied dose	mg	20		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4883786	Homo sapiens						44						65	23	alcoholics					29			14	day		
2961	1431					Recommended	%	0.25		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/3705676/	Homo sapiens										In a concentration of 0.25%, it can be assigned to corticoid force class III. We think it's remarkable that even extensive application of 20 g daily in patients with affected skin and 30 g daily in healthy persons does not cause any suppression of plasma cortisol.		90	665	dermatitis					10			12	month		
2962	1432		adult			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral			https://doi.org/10.1016/B978-0-12-385157-4.00633-3 | https://pubmed.ncbi.nlm.nih.gov/33663183	Homo sapiens																						3	week		
2963	1432		adult			Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	Homo sapiens													144												p. 92
2964	1432		adult				mg	60		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00668434	Homo sapiens							max|total daily dose			For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.			181	Acute Sciatica								15	day		
2965	1433		adult				mg	100		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00785577	Homo sapiens							max			Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6			45	Diabetic Neuropathy								4	week		
2966	1433		adult				mg	150		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00558753	Homo sapiens										PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.			120	Complex Regional Pain Syndrome								10	day		
2967	1433		adult				mg	150		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00905580	Homo sapiens										1 hour prior to surgery, and 12 hours later			47	Pain								1	day		
2968	1433		adult				mg	150		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00978341	Homo sapiens													15	Pain								7.5	day		
2969	1433		adult				mg	150		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02701764	Homo sapiens													21	Dry Eye								14	day		
2970	1433		adult				mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021446s040,%20022488s017lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_Lyrica%20Capsules_medr.PDF	Homo sapiens										All Premarketing Controlled Clinical Studies : PREGABALIN, 75-600 mg/day			979									6	month		p. 39
2971	1433		adult				mg	150		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00702949	Homo sapiens													66	Hot Flashes								6	week		
2972	1433		adult				mg	225		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00830167	Homo sapiens							max			Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)			250	Fibromyalgia								15	week		
2973	1433		adult				mg	225		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00977197	Homo sapiens							max			Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.			41	Irritable Bowel Syndrome								12	week		
2974	1433		adult				mg	225		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01387607	Homo sapiens							max			Pregabalin capsule, 300-450mg/day, twice daily			170	Fibromyalgia								14	week		
2975	1433		adult				mg	300		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01939366	Homo sapiens										Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.			65	Diabetic Peripheral Neuropathy								8	week		
2976	1433		adult				mg	300		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03031340	Homo sapiens										On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.			1	Spinal Fusion								1	day		
2977	1433		adult				mg	300		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00573261	Homo sapiens							max			The dosage will range from 75 mg twice a day to 300 mg twice a day.			15	Diabetic Neuropathy								4	week		
2978	1433		adult				mg	75		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00905437	Homo sapiens													35	Pain								14	day		
2979	1433		adult				mg	75		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00702949	Homo sapiens													63	Hot Flashes								6	week		
2980	1433					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17580330	Homo sapiens						53.91							22	Essential Tremor					53.91			1	week		
2981	1433					Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30349198	Homo sapiens						24.8				two 300 mg tablets			10						24.8						
2982	1434					Overdose	mg	15		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3312932	Homo sapiens						34	max						1												
2983	1434					Recommended	mg	500		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/009170Orig1s040lbl.pdf	Homo sapiens										For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg MYSOLINE tablets in divided doses (250 mg three times a day or four times a day). If required, an increase to five or six 250 mg tablets daily may be made, but daily doses should not exceed 500 mg four times a day.				Epileptic seizures											p.2
2984	1434					Studied dose	mg	62.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11286044	Homo sapiens												83	19	Essential tremor					18						p.316
2985	1436					Recommended	mg	500		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8022053	Homo sapiens						64							1		30 mg 3 times per day			diltiazem	64			8	week		
2986	1436					Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4605082	Homo sapiens												81	44						34			1	year		
2987	1437					MTD	mg	4100		steady			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4014046	Homo sapiens												79	19	ventricular arrhythmias					25						p.85
2988	1437					Recommended	g	1		single					unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=17e47845-daad-434c-a784-6d3875b0d704&type=display	Homo sapiens										a) Direct injection into a vein or into tubing of an established infusion line should be done slowly at a rate not to exceed 50 mg per minute. It is advisable to dilute either the 100 mg/mL or the 500 mg/mL concentrations of procainamide hydrochloride prior to intravenous injection to facilitate control of dosage rate. Doses of 100 mg may be administered every 5 minutes at this rate until the arrhythmia is suppressed or until 500 mg has been administered, after which it is advisable to wait 10 minutes or longer to allow for more distribution into tissues before resuming. b) Alternatively, a loading infusion containing 20 mg of Procainamide Hydrochloride per mL (1 g diluted to 50 mL with 5% Dextrose Injection, USP) may be administered at a constant rate of 1 mL per minute for 25 to 30 minutes to deliver 500 to 600 mg of PA. Some effects may be seen after infusion of the first 100 or 200 mg; it is unusual to require more than 600 mg to achieve satisfactory antiarrhythmic effects. The maximum advisable dosage to be given either by repeated bolus injections or such loading infusion is 1 g.				ventricular arrhythmias											
2989	1438					Highest studied dose	mg	15		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/12942142	Homo sapiens													13	Schizophrenia											
2990	1438					Overdose	mg	250		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4075281	Homo sapiens						26							1	schizo-affective disorder	2500 mg			amoxapine	26						
2991	1438						mg	10		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3987788	Homo sapiens												48	6						22						
2992	1439		adult			Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22884063 / https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019781s017,020843s011lbl.pdf	Homo sapiens													25												
2993	1439		adult				g	1.125		steady			day	1	pregnant	vaginal	F		https://clinicaltrials.gov/ct2/show/NCT00615550	Homo sapiens										8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation			235	Preterm Delivery								15	week		
2994	1439		adult				mg	100		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01249274	Homo sapiens													25	Cocaine Dependence								12	week		
2995	1439		adult				mg	200		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00218257	Homo sapiens													38	Cocaine Dependence								4	day		
2996	1439					Recommended	mg	200		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019781s017,020843s011lbl.pdf	Homo sapiens												79						estrogen	50			12	day		
2997	1439						mg	400		single					healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/1743318	Homo sapiens						32.6							10												
2998	1440		adult				mg	2		single					pregnant	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT03348683	Homo sapiens													121												
2999	1440		adult				mg	20		multiple					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00916721	Homo sapiens							max			Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.			35	Nicotine Dependence											
3000	1440		adult				mg	40		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03309943	Homo sapiens													22	Tobacco Use Disorder											
3001	1440		Infants			Highest studied dose	mg/kg	3		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27688361/	Homo sapiens													235	Hemangioma								9.4	month		
3002	1440					Overdose	mg	200		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/7356190/	Homo sapiens						20							1	suicide attempt					20						
3003	1440					Recommended	mg	12		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6682990/	Homo sapiens							median					35	15	schizophrenia					20			17	day		
3004	1441		ADULT			Highest studied dose	mg	2		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6417282/	Homo sapiens													85	spinocerebellar degeneration					29			2	week		p.243
3005	1441		ADULT			Highest studied dose	ug	800		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7944876/	Homo sapiens						40.5							13	major depressive disorder											
3006	1442		adult			Recommended	mg	30		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2072481/	Homo sapiens										for 1 to 7 days			41650									7	day		
3007	1442		adult			Studied dose	mg	900		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1757242/	Homo sapiens										Nine cases of pyridostigmine self-poisoning, of which three presented with mixed drug poisoning. Doses ranged between 390 and 900 mg			1									1	day		
3008	1442		adult				mg	120		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00276406	Homo sapiens										Oral pyridostigmine, starting with 60 mg capsules three times per day (TID), increasing by 60 mg every third day (i.e., over 10 days) up to the maximum tolerated dose or 120 mg TID (a total of 360 mg per day). This dose was maintained for 7 days.			16	Constipation								7	day		
3009	1442					MTD	mg	180		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18622640/	Homo sapiens												67	10	autonomic neuropathy | constipation					18			8	week		
3010	1442					Studied dose	mg	160		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18622640/	Homo sapiens												67	10	autonomic neuropathy | constipation					18			8	week		
3011	1443					Overdose	g	1.2		single					healthy	oral	M		http://apps.who.int/iris/bitstream/handle/10665/65774/WHO_MAL_79.907.pdf?sequence=1	Homo sapiens						2							1												p.19
3012	1443					Overdose	g	1.625		single					healthy	oral	M		http://apps.who.int/iris/bitstream/handle/10665/65774/WHO_MAL_79.907.pdf?sequence=1	Homo sapiens						1							1												p.19
3013	1443					Overdose	mg	300		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/08578slr016_daraprim_lbl.pdf	Homo sapiens							min							Toxoplasmosis											p.3
3014	1443					Overdose	mg	400		single					healthy	oral	F		http://apps.who.int/iris/bitstream/handle/10665/65774/WHO_MAL_79.907.pdf?sequence=1	Homo sapiens						2							1												p.19
3015	1443					Overdose	mg	625		single					healthy	oral	F		http://apps.who.int/iris/bitstream/handle/10665/65774/WHO_MAL_79.907.pdf?sequence=1	Homo sapiens						3							1												p.19
3016	1443					Overdose	mg	625		single					healthy	oral			http://apps.who.int/iris/bitstream/handle/10665/65774/WHO_MAL_79.907.pdf?sequence=1	Homo sapiens						1				probably 625-750 mg			1												p.19
3017	1443					Recommended	mg	75		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/08578slr016_daraprim_lbl.pdf	Homo sapiens							max			Toxoplasmosis: starting dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g., sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy.				Toxoplasmosis								2	week		p.2
3018	1444		adult			MTD	mg	600		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/24963729/	Homo sapiens							max			25 to 600 mg			15	cannabis dependence								8	week		
3019	1444		adult				mg	400		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00518973	Homo sapiens							max			Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment.			6	Anorexia Nervosa								8	week		
3020	1444		adult				mg	600		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00457197	Homo sapiens							total daily dose			This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.			45	Bipolar Disorder and Alcohol Dependence								12	week		
3021	1444					Highest studied dose	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20831551/	Homo sapiens							max			50 to 400 mg		72	5	schizophrenia					40			5	day		
3022	1444					Highest studied dose	mg	750		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9193196/	Homo sapiens												61	96	schizophrenia					20			6	week		
3023	1444					Highest studied dose	mg	800		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24385309/	Homo sapiens												60	14	schizophrenia					18						
3024	1444					Overdose	g	1.2		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/28207421/	Homo sapiens						45							1	abuse, hypertension, type 2 diabetes mellitus, and schizoaffective disorder				alcohol	45					smoking cocaine	
3025	1444					Overdose	g	15		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21070111/	Homo sapiens						32							1	bipolar disorder				lithium	32						
3026	1444					Overdose	g	24		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18433934/	Homo sapiens										0.4 to 24 g		84	945	abuse					18						
3027	1444					Overdose	g	24.4		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24199644/	Homo sapiens										6 to 24.4 g		49	9						22						
3028	1446					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12094846	Homo sapiens						45.5							68	Gastroesophageal reflux disease								4	week		p.1337
3029	1446					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9354209	Homo sapiens						41							20	Gastroesophageal reflux disease								8	day		p.978
3030	1446					Recommended	mg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9701531	Homo sapiens						22.5							8												p.670
3031	1447		adult			Recommended	mg	8		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Homo sapiens													3594	insomnia								6	month		
3032	1447		adult				mg	1		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00593736	Homo sapiens													32	Delayed Sleep Phase Syndrome								2	week		
3033	1447		adult				mg	4		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00593736	Homo sapiens													33	Delayed Sleep Phase Syndrome								2	week		
3034	1447		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00756002	Homo sapiens													130	Insomnia								5	week		
3035	1447		adult				mg	8		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00593736	Homo sapiens													35	Delayed Sleep Phase Syndrome								2	week		
3036	1447		adult				mg	8		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02560324	Homo sapiens													58	Tobacco Use Disorder								5	day		
3037	1447		adult				mg	8		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00337272	Homo sapiens													9	Chronic Insomnia								28	day		
3038	1447		adult				mg	8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00502320	Homo sapiens													25	Seasonal Affective Disorder								4	month		
3039	1447		adult				mg	8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00552760	Homo sapiens													42	Bipolar Disorder								6	month		
3040	1447		elderly				mg	8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01048242	Homo sapiens													8	Insomnia								4	week		
3041	1447					Highest studied dose	mg	160		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Homo sapiens																									
3042	1447					Highest studied dose	mg	32		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21955196	Homo sapiens						42.8				doses of ramelteon were administered on 2 consecutive night periods in a sleep laboratory			63	chronic primary insomnia					42.8			2	day		
3043	1447					Overdose	mg	40		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22926624	Homo sapiens						47							1	insomnia					47			3	month		
3044	1448					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1725026/	Homo sapiens							max			After a placebo run-in phase, patients received ramipril as monotherapy in a dose of 2.5 to 5 mg daily for 6 weeks. Nonresponders (diastolic blood pressure greater than 90 mm Hg) entered a double-blind treatment period, and received either 10 mg of ramipril daily, or 5 mg of ramipril in combination with 20 mg of furosemide daily.		75	661	Hypertension					18			12	week		
3045	1448					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1725024/	Homo sapiens						55.7	max			In the beginning, all patients were to receive 5 mg of ramipril/day. The dosage was then adjusted in accordance with response to treatment and ranged from 1.25-20 mg of ramipril daily. Of these patients, 129 also received 25 mg of hydrochlorothiazide daily at some point during the trial.		88	555	Essential hypertension	25 mg; 1/day			hydrochlorothiazide	21			2	year		
3046	1449		adult			Recommended	mg	1000		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021526s000lbl.pdf	Homo sapiens													835	chronic angina								7	week		
3047	1449		adult				mg	1000		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01342029	Homo sapiens							max			500-1,000 mg po bid for 2 week			1	Microvascular Coronary Dysfunction								2	week		
3048	1449		adult				mg	1000		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01342029	Homo sapiens							max			500-1,000 mg po bid for 2 week			142	Microvascular Coronary Dysfunction								2	week		
3049	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00914316	Homo sapiens													3	Peripheral Arterial Disease								12	week		
3050	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01163721	Homo sapiens													39	Type 2 Diabetes								12	week		
3051	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01345188	Homo sapiens							max			1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.			24	Ischemic Cardiomyopathy								12	week		
3052	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01590979	Homo sapiens													27	Atrial Fibrillation								3	week		
3053	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01754259	Homo sapiens							max			During the 28-day treatment periods, ranolazine and matching placebo were administered as 500 mg by mouth twice daily for 1 week and increased to 1000 mg by mouth twice daily for 3 weeks, as tolerated.			23	Coronary Artery Disease								4	week		
3054	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01839110	Homo sapiens													7	Pulmonary Hypertension								26	week		
3055	1449		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02829034	Homo sapiens										Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.			14	Pulmonary Hypertension								26	week		
3056	1449		adult				mg	1500		multiple			day	2	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03070470	Homo sapiens													10									2.5	day		
3057	1449		adult				mg	1500		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01873950	Homo sapiens													22												
3058	1449					Highest studied dose	mg	1500		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15093870	Homo sapiens						64.3							60	Stable Angina					64.3			1	week		
3059	1449					Highest studied dose	mg	2000		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19763194/	Homo sapiens												83	18	Atrial fibrillation					57						
3060	1449					Overdose	g	50		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31119956	Homo sapiens						65		therapeutic or subtherapeutic		fifty 1000 mg ranolazine tablets			1		therapeutic or subtherapeutic		mirtazapine	quetiapine	65		therapeutic or subtherapeutic			valproate	
3061	1450					Recommended	mg	4		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020741s041s042lbl.pdf	Homo sapiens														Type 2 diabetes mellitus											p.1
3062	1451					Highest studied dose	mg	2400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2444379	Homo sapiens						39.9				2400 mg in three divided doses for 2 weeks		51	3	generalized lymphadenopathy					27			2	week		
3063	1451					Highest studied dose	mg/kg	16		multiple			day	4	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/21544005	Homo sapiens										33 mg/kg/dose IV load, followed by 16 mg/kg/dose IV every 6 hours for 4 days, and then 8 mg/kg/dose every 8 hours for 3 days		10	2	La Crosse viral encephalitis					6						
3064	1451					Recommended	mg	1200		multiple			day	1	pregnant	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21511_Copegus_lbl.pdf	Homo sapiens																									
3065	1451					Recommended	mg	1200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21511_Copegus_lbl.pdf	Homo sapiens														chronic hepatitis C virus infection											
3066	1451						mg	600		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33617629	Homo sapiens						21				in three divided doses			1	respiratory syncytial virus (RSV) infection					21			1	week		
3067	1452		adult			Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050689Orig1s018lbl.pdf	Homo sapiens										It is recommended that MYCOBUTIN Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of MYCOBUTIN at doses of 150 mg twice daily taken with food may be useful.			566	Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection											
3068	1453		adult			Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/2319517	Homo sapiens													8	rheumatoid arthritis											
3069	1453		adult			Highest studied dose	mg	1200		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6473487	Homo sapiens													18												
3070	1453					Overdose	g	12		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/6371210	Homo sapiens						14				forty 300 mg rifampin capsules			1						14						
3071	1453					Overdose	g	60		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/702755	Homo sapiens						26	total			200 capsules of rifampin, 300 mg			1						26						
3072	1454		adult				mg	550		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00298038	Homo sapiens													140	Hepatic Encephalopathy								6	month		
3073	1454		adult				mg	550		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00724126	Homo sapiens													315	Non-Constipation Irritable Bowel Syndrome								14	week		
3074	1454		adult				mg	550		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00731679	Homo sapiens													309	Non-Constipation Irritable Bowel Syndrome								14	week		
3075	1454					Highest studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22155172	Homo sapiens													99	Crohn's disease								12	week		p.478
3076	1454					Highest studied dose	mg	800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10741936	Homo sapiens												82	17	Hepatic Encephalopathy					32			7	day		p.207
3077	1454					Recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021361s013lbl.pdf	Homo sapiens												79	320	Travelers’ diarrhea caused by noninvasive strains of Escherichia coli					18						p.4
3078	1454					Studied dose	mg	550		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27528177	Homo sapiens						46.4							2579	Diarrhea-Predominant Irritable Bowel Syndrome								18	week		p.1119
3079	1455		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02155829	Homo sapiens							max			Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeksWeeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks			37	Posttraumatic Stress Disorder								8	week		
3080	1455		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00054704	Homo sapiens							max			Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day.			8	Bipolar Disorder								8	week		
3081	1456					Recommended	%	1		steady			day	4	unhealthy	ophthalmic			https://pubmed.ncbi.nlm.nih.gov/9278798/	Homo sapiens													197	intraocular inflammation after cataract extraction								2	week		
3082	1457		adult				mg	150		multiple			month	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00577395	Homo sapiens													7	Osteoporosis								12	month		
3083	1457		adult				mg	30		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00216060	Homo sapiens							total daily dose						32	Metastatic Prostate Cancer								36	month		
3084	1457		adult				mg	35		steady			week	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00386360	Homo sapiens													110	Osteopenia								1	year		
3085	1457		adult				mg	35		steady			week	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01406444	Homo sapiens													33	Osteopenia								12	month		
3086	1457		adult				mg	5		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01249261	Homo sapiens													31	Osteoporosis								7	year		
3087	1457					Recommended	mg	150		multiple			month	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf	Homo sapiens												88	650	Postmenopausal osteoporosis					50			1	year		p.10
3088	1457					Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf	Homo sapiens												86	613	Postmenopausal osteoporosis					50			2	year		p.9
3089	1457					Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf	Homo sapiens												86	616	Postmenopausal osteoporosis					50			2	year		p.9
3090	1457					Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf	Homo sapiens												88	642	Postmenopausal osteoporosis					50			1	year		p.10
3091	1457					Recommended	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18038273	Homo sapiens						41.6							60	Glucocorticoid-induced bone mineral density loss prevention								6	month		p.362
3092	1457					Recommended	mg	75		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020835s035lbl.pdf	Homo sapiens										two consecutive days per month, the duration of the trial was two years		86	616	Postmenopausal osteoporosis					50			2	day		p.9
3093	1458		adult			Recommended	mg	16		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf	Homo sapiens							max						198	Schizophrenia								6	week		
3094	1458		adult			Recommended	mg	6		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf	Homo sapiens							max						448	Bipolar Mania								3	week		
3095	1458		adult			Recommended	mg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf	Homo sapiens							max						366	Schizophrenia								8	week		
3096	1458		adult				mg	2		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00385801	Homo sapiens							total daily dose			After baseline evaluation participants began treatment with oral risperidone, 1 mg per day the first week and 2 mg per day for the next 3 weeks.			16	Cocaine Dependence								4	week		
3097	1458		adult				mg	3		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01175135	Homo sapiens													36	Schizophrenia								4	week		
3098	1458		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00099983	Homo sapiens							max			Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day).			133	Post-Traumatic Stress Disorder								6	month		
3099	1458		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00694707	Homo sapiens													140	Schizophrenia								6	week		
3100	1458		child			Recommended	mg	6		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf	Homo sapiens							max						106	Schizophrenia								6	week		
3101	1458		child			Recommended	mg	6		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf	Homo sapiens							max						111	Bipolar Mania								3	week		
3102	1459		adult			Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18815591/	Homo sapiens														HIV-1											
3103	1459					Highest studied dose	mg	200		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18815591/	Homo sapiens						29							10		125 mg			elvitegravir	29			21	day		
3104	1459					Studied dose	mg	50		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18815591/	Homo sapiens						29							10		125 mg			elvitegravir	29			21	day		
3105	1460					Overdose	mg	20		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25390127	Homo sapiens						60							1	Type 2 diabetes mellitus											p.73,74
3106	1460					Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18503774	Homo sapiens						53.1							32	Nonalcoholic steatohepatitis								11	month		p.105
3107	1460					Recommended	mg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf	Homo sapiens										Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily				Type 2 diabetes mellitus											p.1
3108	1461		adult				mg	16		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00474058	Homo sapiens							max			Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h.			191	Parkinson's Disease								4	week		
3109	1461		adult				mg	16		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01300819	Homo sapiens										Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients. Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.			223	Parkinson's Disease								12	week		
3110	1461		adult				mg	16		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01744496	Homo sapiens							max			Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.			35	Advanced Idiopathic Parkinson's Disease								12	week		
3111	1461		adult				mg	2		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00522379	Homo sapiens							total daily dose						101	Parkinson's Disease								16	week		
3112	1461		adult				mg	3		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01455012	Homo sapiens							max|total daily dose			Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.			40	Idiopathic Restless Legs Syndrome								28	day		
3113	1461		adult				mg	3		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01537042	Homo sapiens							max			Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.			20	Restless Legs Syndrome								5	week		
3114	1461		adult				mg	3		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01569464	Homo sapiens							max			Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.			101	Restless Legs Syndrome								7	week		
3115	1461		adult				mg	4		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00464737	Homo sapiens							total daily dose			Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)			74	Fibromyalgia								12	week		
3116	1461		adult				mg	4		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00464737	Homo sapiens							total daily dose			Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)			73	Fibromyalgia								12	week		
3117	1461		adult				mg	4		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00522379	Homo sapiens							total daily dose						107	Parkinson's Disease								16	week		
3118	1461		adult				mg	6		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00522379	Homo sapiens							total daily dose						104	Parkinson's Disease								16	week		
3119	1461		adult				mg	8		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00522379	Homo sapiens							total daily dose						94	Parkinson's Disease								16	week		
3120	1461		adult				mg	8		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01523301	Homo sapiens										Transdermal PatchContent:2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance periodFor advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period			184	Parkinson's Disease								12	week		
3121	1461		adult				mg	8		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01536015	Homo sapiens							max			Strength and Form: 4 - 8 mg patches, one patch applied every 24 hoursDosage and Frequency: One patch every 24 hoursDuration: 10 weeks			13	Parkinson's Disease								10	week		
3122	1461		adult				mg	8		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01646268	Homo sapiens										Transdermal PatchContent:2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period			124	Parkinson's disease								24	week		
3123	1461					Highest studied dose	mg	54		multiple			day	1	unhealthy	topical	M+F		https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwitvqTfk73vAhXLl4sKHSWZATIQFjAIegQIBhAD&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F1344%2Fdownload&usg=AOvVaw2Ldihm6CIUQh4H_1DXihmQ	Homo sapiens												88	130	Advanced-stage Parkinson’s disease					29			7	day		p.10
3124	1461					Recommended	mg	8		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf	Homo sapiens										8 mg/24 hours; Rotigotine Content per System - 18 mg				Advanced-stage Parkinson’s disease											p.1
3125	1461					Recommended	mg	8		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf	Homo sapiens										8 mg/24 hours; Rotigotine Content per System - 18 mg				Advanced-stage Parkinson’s disease											p.1, p.5
3126	1461					Studied dose	mg	24		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/19644228	Homo sapiens						68.8				24 mg/24 h			26	Advanced-stage Parkinson’s disease											p.196
3127	1462		adult				mg	1000		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00595231	Homo sapiens										500 mg for 1 week followed by 1000 mg for 7 weeks			115	Generalized Anxiety Disorder								8	week		
3128	1462		child|adult				mg	1600		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00334958	Homo sapiens							max			For the titration phase, Rufinamide will be administered orally in doses starting with 400 mg twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).			176	Epilepsy								12	week		
3129	1462		child|adult				mg	1600		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01146951	Homo sapiens							max			Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.Target maintenance dose:15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)			29	Lennox-Gastaut Syndrome								12	week		
3130	1462					MTD	mg	3600		multiple			day	2	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/18503564	Homo sapiens										7200 mg/day given in two divided daily doses)			15									18	day		p.1125, p.1139
3131	1462					Studied dose	mg/kg	22.5		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf	Homo sapiens										maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses				Lennox-Gastaut Syndrome											p.1
3132	1462					Studied dose	mg/kg	22.5		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf	Homo sapiens										maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses				Lennox-Gastaut Syndrome											p.4
3133	1462					Studied dose	mg/kg	22.5		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf	Homo sapiens										maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses				Lennox-Gastaut Syndrome											p.7
3134	1462					Studied dose	mg/kg	22.5		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021911s012lbl.pdf	Homo sapiens										maximum daily dose of 45 mg/kg, not to exceed 3200 mg, administered in two equally divided doses				Lennox-Gastaut Syndrome											p.8
3135	1463					Recommended	ug	50		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Homo sapiens												11	211	asthma					4			12	week		
3136	1463					Recommended	ug	50		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Homo sapiens													149	asthma								12	week		
3137	1463					Recommended	ug	50		multiple			day	2	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf	Homo sapiens													341	COPD								24	week		
3138	1463						ug	400		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/1349491/	Homo sapiens						34.3				Each subject received three doses of salmeterol (100 ug, 200 ug and 400 ug) as the xinafoate salt, one dose of salbutamol 400 ug (Ventolin©) and placebo on separate occasions at intervals of not less than 6 days.			10												
3139	1463						ug	84		multiple			day	2	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/7909285/	Homo sapiens						30				Adolescents and adults (N = 160) with mild-to-moderate asthma received salmeterol (10.5, 21, 42, or 84 micrograms) or placebo by metered-dose inhaler twice daily for 1 week.			31	asthma								1	week		
3140	1464		adult			Recommended	mg	16.5		single					unhealthy	intraarterial	unknown		https://pubmed.ncbi.nlm.nih.gov/20854063/	Homo sapiens							mean						43	neurological disorders											
3141	1465		adult			Highest studied dose	%	2		steady			day	2	healthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021385s005lbl.pdf	Homo sapiens										cream			202									4	week		6.1
3142	1466		adult			Recommended	%	3		single					unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	Homo sapiens							max			The concentration of sevoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response. Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide. Sevoflurane can be administered with any type of anesthesia circuit.			118	surgical procedures											
3143	1466		all ages			Recommended	%	3		single					unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	Homo sapiens							max			The concentration of sevoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response. Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide. Sevoflurane can be administered with any type of anesthesia circuit.			2906	surgical procedures											
3144	1466		child			Recommended	%	3		single					unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020478s030lbl.pdf	Homo sapiens							max			The concentration of sevoflurane being delivered from a vaporizer during anesthesia should be known. This may be accomplished by using a vaporizer calibrated specifically for sevoflurane. The administration of general anesthesia must be individualized based on the patient's response. Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide. Sevoflurane can be administered with any type of anesthesia circuit.			507	surgical procedures											
3145	1467		adult				mg	40		steady			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01142336	Homo sapiens													26									1	year		
3146	1467		adult				mg	40		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00572468	Homo sapiens										Adverse events were collected at baseline, weekly while on treatment, and at 30-day follow-up. Subjects were on trial for 4-8 weeks (depending on prostatectomy scheduling).			20	Prostate Cancer								8	week		
3147	1467		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00180713	Homo sapiens										Simvastatin 40mg od for 1 month, then uptitrated to 80mg od for 11 months.			19	Pulmonary Hypertension								11	month		
3148	1467					Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9024733/	Homo sapiens						52							148	coronary heart disease								6	week		
3149	1467					Overdose	mg	100		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18819764/	Homo sapiens						39	max						1	obesity					39			4	month		
3150	1467					Overdose	mg	160		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18808756/	Homo sapiens						57							1						57			18	day		
3151	1467					Overdose	mg	320		single			day	1	healthy	oral	F		https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.849.2017&rep=rep1&type=pdf	Homo sapiens						4							1						4			1	day		
3152	1467					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9024733/	Homo sapiens						52							148	coronary heart disease								6	week		
3153	1467					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9024733/	Homo sapiens						52							149	coronary heart disease								6	week		
3154	1468		adult				mg	1		steady			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02874924	Homo sapiens													14	Aging								8	week		
3155	1468					Highest studied dose	mg	40		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31089971	Homo sapiens						48.5						63	8						40						
3156	1468					Recommended	mg	6		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021083s067,021110s085lbl.pdf	Homo sapiens							starting							LIVER TRANSPLANTATION | LUNG TRANSPLANTATION											
3157	1469		adult				mg	10		steady			day	1	healthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00832650	Homo sapiens													22									14	day		
3158	1469		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01340027	Homo sapiens													78	Overactive Bladder								12	week		
3159	1469		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01371994	Homo sapiens							max			Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.			313	Urinary Incontinence								12	week		
3160	1469		adult				mg	2.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01340027	Homo sapiens													79	Overactive Bladder								12	week		
3161	1469		adult				mg	5		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01093534	Homo sapiens													175	Overactive Bladder								12	week		
3162	1469		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01340027	Homo sapiens													156	Overactive Bladder								12	week		
3163	1469		elderly				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01126424	Homo sapiens													23	Cognitive Impairment								21	day		
3164	1469					Highest studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15317830	Homo sapiens												40	6						19						p.1028
3165	1469					Highest studied dose	mg	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15317830	Homo sapiens												35	8						20			29	day		p.1029
3166	1469					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	Homo sapiens													1233	Overactive bladder								12	week		p.4
3167	1469					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf	Homo sapiens														Overactive bladder											p.1
3168	1470		adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02021929	Homo sapiens													16	Hepatopulmonary Syndrome								12	week		
3169	1470		adult				mg	400		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01714609	Homo sapiens													5	Portal Hypertension								3	month		
3170	1470					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15613696/	Homo sapiens						60				Mean duration			5	solid tumors								54.2	day		
3171	1470					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21789159/ | https://pubmed.ncbi.nlm.nih.gov/16061863/	Homo sapiens						53.7				1-week on/1-week off treatment			3	solid tumors								7	day		
3172	1470					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021923lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/21789159/ | https://pubmed.ncbi.nlm.nih.gov/27981711/	Homo sapiens						57				median duration			20	metastatic renal cell carcinoma								177.5	day		
3173	1470					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021923lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/27981711/	Homo sapiens						57				median duration			20	metastatic renal cell carcinoma								177.5	day		
3174	1470					MTD	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21789159/ | https://pubmed.ncbi.nlm.nih.gov/15613696/	Homo sapiens						60				Mean duration			15	solid tumors								230	day		
3175	1470					MTD	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21789159/ | https://pubmed.ncbi.nlm.nih.gov/16061863/	Homo sapiens						53.7				1-week on/1-week off treatment			6	solid tumors								7	day		
3176	1470					Recommended	mg	400		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021923_s000_Nexavar_MedR.pdf	Homo sapiens						58				Median duration			384	renal cell carcinoma								167	day		021923_s000_Nexavar_MedR.pdf - p.68-71
3177	1471		adult			Highest studied dose	mg/day	640		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf	Homo sapiens										Total daily dose given in two or three divided doses			39	ventricular ectopy											
3178	1471		adult			Recommended	mg/day	240		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf	Homo sapiens							max			Total daily dose given in two or three divided doses			153	atrial fibrillation (AFIB) | atrial flutter (AFL)											
3179	1471		adult			Recommended	mg/day	320		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf	Homo sapiens							max|total daily dose			Total daily dose given in two or three divided doses			122	atrial fibrillation (AFIB) | atrial flutter (AFL)											
3180	1471		adult			Recommended	mg/day	320		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf	Homo sapiens										Total daily dose given in two or three divided doses			38	ventricular ectopy											
3181	1471					Recommended	mg	60		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29954667/	Homo sapiens						31.8	mean			Our approach in sotalol dosing was typically cautious, commencing at either 40 mg or 80 mg twice daily, with an average dose of 120 mg / daily across the cohort. Mean follow-up post commencement of sotalol was 8.0 years, of which the median time on drug therapy was 2.8 years (IQR 8.2).		67	82	congenital heart disease					10			2.8	year		
3182	1472		adult			Highest studied dose	mg	1600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10397377/	Homo sapiens													22												
3183	1472					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10090432/	Homo sapiens												99	1585	infections					15			10	day		
3184	1473		adult				mg	100		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02235077	Homo sapiens													182	Acute Heart Failure								4	day		
3185	1473		adult				mg	25		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00141778	Homo sapiens										Spironolactone 25mg daily beginning 4 to 7 days before surgery and continuing through discharge			147	Atrial Fibrillation											
3186	1473		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00094302	Homo sapiens							max			Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets).			1722	Heart Failure											
3187	1473		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02194465	Homo sapiens										25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.			19	Hypertension								4	week		
3188	1473		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02194465	Homo sapiens										25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.			26	Hypertension								4	week		
3189	1473		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02236520	Homo sapiens													16	Hypertension								8	week		
3190	1473					Recommended	mg	100		multiple			day	1	unhealthy	oral	F		https://search.proquest.com/openview/8b2f832c837a7373deb22329c8d12ee3/1?pq-origsite=gscholar&cbl=43703	Homo sapiens						33							1	Hidradenitis suppurativa					33			3	month		
3191	1473					Recommended	mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25138605/	Homo sapiens						45.7							18	central serous chorioretinopathy								12	week		
3192	1473					Recommended	mg	25		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17309946/	Homo sapiens						63	median						1790	hypertension								1.3	year		
3193	1473					Studied dose	mg	200		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/885991/	Homo sapiens												28	9						21			24	week		
3194	1474		adult			Recommended	mg	40		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Homo sapiens													100	HIV infection				lamivudine				48	week	indinavir	
3195	1474		adult			Recommended	mg	40		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Homo sapiens													102	HIV infection				didanosine				48	week	indinavir	
3196	1474		adult			Recommended	mg	40		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20412S017.pdf	Homo sapiens													412	HIV infection								79	week		
3197	1474					Recommended	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15249567/	Homo sapiens						36.5		600 mg; 1/day					285	HIV-1 infection	400 mg; 1/day			didanosine				48	week	efavirenz	
3198	1475		adult			Overdose	ug	45		single					healthy	epidural	F		https://pubmed.ncbi.nlm.nih.gov/19111229/	Homo sapiens										spinal-epidural				laboring											
3199	1475		adult			Recommended	ug	30		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29126259/	Homo sapiens														Postoperative Pain											
3200	1475		adult			Recommended	ug	30		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209128s000lbl.pdf	Homo sapiens													107	Postoperative Pain											
3201	1475					MTD	mg/kg	0.4		single					unknown	intranasal	unknown		https://pubmed.ncbi.nlm.nih.gov/29377056/	Homo sapiens												65	30	gastroscopy	5 mg			MIDAZOLAM	18						
3202	1476		adult				mg	500		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01198145	Homo sapiens													43	Diarrhea								4	week		
3203	1476					Overdose	g	25		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1684211	Homo sapiens						23				suicide attempt			1	Crohn’s colitis | Major depression											p.544
3204	1476					Overdose	g	50		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9656981	Homo sapiens						26				suicide attempt			1	Ankylosing spondylitis	50 g, single			paracetamol, p.o							p.240
3205	1476					Recommended	g	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9588731	Homo sapiens						8.4				The dosage of SSZ for this study was 50 mg/kg/day administered in 2 doses, with a maximum of 2,000 mg/day.			35	Juvenile chronic arthritis								24	week		p.813, 814
3206	1476					Recommended	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11856080	Homo sapiens						43							24	Ulcerative colitis								8	week		p.72
3207	1477					Overdose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1548318/	Homo sapiens						24							1												
3208	1477					Recommended	mg	1000		multiple					unhealthy	oral			https://www.aapharma.ca/downloads/en/PIL/2016/Sulfinpyrazone-PM.pdf	Homo sapiens							max			it is important to distribute the total dose as well as possible over the 24 hour period				Thrombosis											p.2
3209	1477					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.aapharma.ca/downloads/en/PIL/2016/Sulfinpyrazone-PM.pdf	Homo sapiens							max							Gouty arthritis											p.4
3210	1478					Overdose	g	10		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7897758/	Homo sapiens						18							1						18						
3211	1478					Overdose	g	12		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7091952/	Homo sapiens						16							1	minimal brain dysfunction					16						
3212	1478					Overdose	g	12		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/2198051/	Homo sapiens						16							1						16						
3213	1478					Overdose	g	15		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29788733/	Homo sapiens						22							1	bipolar disorder					22						
3214	1478					Overdose	g	24		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7897758/	Homo sapiens						50							1						50						
3215	1478					Overdose	g	4		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7897758/	Homo sapiens						30				4 - 20 g			1					ethanol	30						
3216	1478					Overdose	g	5		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7897758/	Homo sapiens						28				5 - 10 g			1					ethanol	28						
3217	1478					Overdose	g	8		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/7897758/	Homo sapiens						14							1	suicide attempt					14						
3218	1479		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf	Homo sapiens													146									2	week		p. 5
3219	1479		adult			Recommended	mg	80		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf	Homo sapiens													150									2	week		p. 5
3220	1479					Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9236571 | https://pubmed.ncbi.nlm.nih.gov/8139083	Homo sapiens						71.2				after 6 weeks at 120 mg/d, group 4 titrated to 160 mg/d for the last 12 weeks		88	64	Alzheimer's disease					52			4	week		
3221	1480		adult			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	Homo sapiens														erectile dysfunction											
3222	1480		adult			Highest studied dose	mg	500		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf	Homo sapiens																									
3223	1480		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00843635	Homo sapiens													15	Head and Neck Cancer								20	day		
3224	1480		adult				mg	2.5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00855582	Homo sapiens													198	Erectile Dysfunction and Benign Prostatic Hyperplasia								12	week		
3225	1480		adult				mg	2.5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00861757	Homo sapiens													151	Benign Prostatic Hyperplasia								12	week		
3226	1480		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01444651	Homo sapiens													36	Obesity								3	month		
3227	1480		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01970176	Homo sapiens							max			Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.			14	Cardiomyopathy and Renal Impairment								12	week		
3228	1480		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02058095	Homo sapiens							max			Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is >95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is> 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is > 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.			15	Cardiomyopathy and Renal Impairment								12	week		
3229	1480		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01910389	Homo sapiens										Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.			15	Heart Failure								3	year		
3230	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00827242	Homo sapiens													161	Benign Prostatic Hyperplasia								12	week		
3231	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00836693	Homo sapiens													147	Erectile Dysfunction								12	week		
3232	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00855582	Homo sapiens													208	Erectile Dysfunction and Benign Prostatic Hyperplasia								12	week		
3233	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00861757	Homo sapiens													155	Benign Prostatic Hyperplasia								12	week		
3234	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00931528	Homo sapiens													111	Erectile Dysfunction								24	week		
3235	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01130532	Homo sapiens													205	Erectile Dysfunction								12	week		
3236	1480		adult				mg	5		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02595684	Homo sapiens													9	Obesity								28	day		
3237	1480					MTD	mg	40		multiple			day	1	pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/31131648	Homo sapiens						28							3						28						
3238	1480						mg	20		multiple			week	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15925082/	Homo sapiens						54.9							4262	Erectile Dysfunction					54.9			5	week		
3239	1481					Highest studied dose	mg	33.6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12942109	Homo sapiens													6	Advanced cancer								12	week		p.812
3240	1481					MTD	mg	25.2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12942109	Homo sapiens													6	Advanced cancer								12	week		p.812
3241	1481					Recommended	%	0.1		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf	Homo sapiens														Plaque psoriasis|Acne vulgaris											p.1
3242	1482					Highest studied dose	mg	160		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/11014323	Homo sapiens													12												p.159
3243	1482					Highest studied dose	mg	320		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11014323	Homo sapiens													10									7	day		p.161
3244	1482					Recommended	mg	80		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020850s032lbl.pdf	Homo sapiens														Hypertension|Cardiovascular Risk Reduction											p.1
3245	1483						mg	26		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8181199	Homo sapiens												24							18						
3246	1483						mg	40		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2574013	Homo sapiens						42						59	14						22						
3247	1484		adult				mg	100		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00379353	Homo sapiens													16	Advanced Cancers								14	day		
3248	1484					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16520988	Homo sapiens													1	Hepatocellular carcinoma								1	week		p.659
3249	1484					MTD	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16520988	Homo sapiens						57							7	Hepatocellular carcinoma								1	week		p.658
3250	1484					MTD	mg/m2	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15514381	Homo sapiens						11				400 mg/m2/d is equivalent to a fixed dose of approximately 680 mg/d in an adult			10	Cancer	1/21 days			Carboplatin, i.v							p.4397
3251	1484					MTD	mg/m2	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15514381	Homo sapiens						11				400 mg/m2/d is equivalent to a fixed dose of approximately 680 mg/d in an adult			6	Cancer	1/21 days			Carboplatin, i.v							p.4397
3252	1484					Recommended	mg	400		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020785s055lbl.pdf	Homo sapiens														Erythema nodosum leprosum											p.1
3253	1484					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16520988	Homo sapiens						57							2	Hepatocellular carcinoma								1	week		p.658
3254	1485					Highest studied dose	mg/m2	1200		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7105383/	Homo sapiens												70	4	colorectal carcinoma					37						
3255	1485					MTD	mg/m2	300		multiple			week	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7521908/	Homo sapiens													31	advanced malignancies								3	week		
3256	1485						mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17943403/	Homo sapiens							median			The median 6-TG dosage of 20mg in patients without discontinuation after a treatment period of 93 weeks was significantly lower than the median dosage at commencement of 6-TG therapy (40mg, P<0.001).			135	inflammatory bowel disease								93	week		
3257	1485						mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12622758/	Homo sapiens													37	Crohn's disease								24	week		
3258	1485						mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17943403/	Homo sapiens							median			The median 6-TG dosage of 20mg in patients without discontinuation after a treatment period of 93 weeks was significantly lower than the median dosage at commencement of 6-TG therapy (40mg, P<0.001).			296	inflammatory bowel disease								21	week		
3259	1486		adult				ug	18		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00501852	Homo sapiens													54	Chronic obstructive pulmonary disease								7	day		
3260	1486		adult				ug	18		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00929110	Homo sapiens													267	Chronic Obstructive Pulmonary Disease								52	week		
3261	1486		adult				ug	18		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01202188	Homo sapiens													480	Chronic Obstructive Pulmonary Disease								26	week		
3262	1486		adult				ug	18		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01294787	Homo sapiens													83	Chronic Obstructive Pulmonary Disease								3	week		
3263	1486					Overdose	ug	282		single					healthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207070s000lbl.pdf	Homo sapiens													6												p.5
3264	1486					Overdose	ug	90		single					unhealthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/20118141	Homo sapiens						74				Accidental overdose			1	Atrial fibrillation											
3265	1486					Recommended	ug	2.5		multiple			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207070s000lbl.pdf	Homo sapiens										Treatment of COPD: 2 inhalations of SPIRIVA RESPIMAT 2.5 mcg once-daily				Bronchospasm associated with chronic obstructive pulmonary disease											p.1
3266	1487					Overdose	g	0.5		single			day	1	unhealthy	oral	F		https://link.springer.com/article/10.2165/00128415-200711730-00075	Homo sapiens						69							1	diabetes mellitus											
3267	1487					Overdose	g	0.75		single			day	1	unhealthy	oral	F		https://link.springer.com/article/10.2165/00128415-200711730-00075	Homo sapiens						59							1	diabetes mellitus											
3268	1487					Overdose	g	1		single			day	1	unhealthy	oral	F		https://link.springer.com/article/10.2165/00128415-200711730-00075	Homo sapiens						62							1	diabetes mellitus											
3269	1487					Recommended	g	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3041937/	Homo sapiens						50							8	diabetes mellitus								12	week		
3270	1488					Overdose	mg	800		multiple			day	3	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf|https://pubmed.ncbi.nlm.nih.gov/9333106	Homo sapiens								25 mg, tid				75	6		100 mg, tid			L-dopa, po	55					carbidopa, po	p.25|p.304
3271	1488					Overdose	mg	800		multiple			day	3	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens																									p.25
3272	1488					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens													592	Parkinson’s disease				L-dopa, po						carbidopa, po	p.21, p.12
3273	1488					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens														Parkinson’s disease				L-dopa, po						carbidopa, po	p.1, p.21
3274	1488					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens														Parkinson’s disease				L-dopa, po						carbidopa, po	p.10
3275	1488					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens														Parkinson’s disease				L-dopa, po						carbidopa, po	p.11
3276	1488					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf	Homo sapiens														Parkinson’s disease				L-dopa, po						carbidopa, po	p.21
3277	1489		adult			Highest studied dose	mg	300		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204441lbl.pdf	Homo sapiens																						5	day		
3278	1489		adult				mg	1		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/22257581	Homo sapiens													14												
3279	1489		adult				mg	15		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01439009	Homo sapiens													50	Heart Failure								14	day		
3280	1489		adult				mg	15		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01199198	Homo sapiens													17	Hyponatremia								14	day		
3281	1489		adult				mg	7.5		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01050530	Homo sapiens													82	Hepatic Edema								7	day		
3282	1489		adult				mg	90		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00428948	Homo sapiens							max			Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.			961	Autosomal Dominant Polycystic Kidney Disease								36	month		
3283	1489					Highest studied dose	mg	480		single					healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204441lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/17925589	Homo sapiens						32						51	6						20						
3284	1489					Recommended	mg	60		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204441lbl.pdf	Homo sapiens							total							autosomal dominant polycystic kidney disease											
3285	1489						mg	96		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204441lbl.pdf	Homo sapiens						39	mean						961	autosomal dominant polycystic kidney disease					39			3	year		
3286	1490		adult				mg	200		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00802412	Homo sapiens							max|total daily dose			Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).			63	Tobacco Use Disorder								12	week		
3287	1490		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00345371	Homo sapiens							max|total daily dose						69	Methamphetamine Dependence								13	week		
3288	1490		adult				mg	300		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00167245	Homo sapiens							max|total daily dose						83	Alcohol and Cocaine Dependence								13	week		
3289	1490		adult				mg	300		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01087736	Homo sapiens							total daily dose			After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day.			14	Alcohol Use Disorder								12	week		
3290	1490		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01081795	Homo sapiens							max			In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).			130	Migraine								18	week		
3291	1490		child				mg/kg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01581281	Homo sapiens							max						145	Migraine								24	week		
3292	1490		child|adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01641445	Homo sapiens													41	Alcohol Use Disorder								8	week		
3293	1490					Highest studied dose	mg	1400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf |https://pubmed.ncbi.nlm.nih.gov/24861853	Homo sapiens										combined clinical studies (dosages of 200 mg to 1,600 mg per day)			1757	epilepsy								1	week		
3294	1490					MTD	mg	1200		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24861853	Homo sapiens						23.3							8						23.3			1	week		
3295	1490					Overdose	g	96		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Homo sapiens										between 96 and 110 g			1												
3296	1490					Overdose	mg	4000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/19514879	Homo sapiens						24				forty 100-mg topiramate tablets			1						24						
3297	1490					Recommended	mg	400		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Homo sapiens												15	77	Epilepsy					6			1	week		
3298	1490					Recommended	mg	400		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020505s061,020844s052lbl.pdf	Homo sapiens													159	Epilepsy					16			1	week		
3299	1490						mg/kg	30		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205122s000lbl.pdf	Homo sapiens													310	epilepsy								1	week		
3300	1491		adult			Recommended	mg/m2	1.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16249347/	Homo sapiens										Topotecan was administered as a 30-minute i.v. infusion on days 1–5 of a 21-day course at a dose of 1.5 mg/m2 per day.			859	ovarian cancer | small cell lung cancer								5	day		
3301	1491		adult			Recommended	mg/m2	1.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16249347/	Homo sapiens										Topotecan was administered as a 30-minute i.v. infusion on days 1–5 of a 21-day course at a dose of 1.5 mg/m2 per day.			862	ovarian cancer | small cell lung cancer								5	day		
3302	1491					MTD	mg/m2	10.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7602366/	Homo sapiens						54				The starting dose was 2.5 mg/m2. Dose escalation was performed in four steps to 3.75, 5.6, 8.4, and 10.5 mg/m2, which was the MTD. The appropriate dosage of the drug was diluted in 500 mL of 0.9% sodium chloride and was administered intravenously by an infusion pump over 24 hours.		75	25	solid tumors					34						
3303	1491					Recommended	mg/m2	2.3		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11579118/	Homo sapiens						62.1				Topotecan was administered orally for 5 consecutive days every 21 days at a starting target dose of 2.3 mg/m2/d. The minimum oral dose of topotecan allowed was 1.1 mg/m2/d. Dose escalation for the next course, in 0.4-mg/m2/d increments, was recommended if a patient had no toxicity more than grade 2 during the previous course. The maximum oral dose of topotecan allowed was 3.1 mg/m2/d.		86	116	ovarian cancer					38			5	day		
3304	1491					RP2D	mg/m2	8.4		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7602366/	Homo sapiens						54				The starting dose was 2.5 mg/m2. Dose escalation was performed in four steps to 3.75, 5.6, 8.4, and 10.5 mg/m2, which was the MTD. The appropriate dosage of the drug was diluted in 500 mL of 0.9% sodium chloride and was administered intravenously by an infusion pump over 24 hours.		75	25	solid tumors					34						
3305	1492					MTD	mg/m2	400		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1385761/	Homo sapiens												79	5	metastatic breast cancer					38			1	week		175
3306	1492					Recommended	mg/m2	200		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1385761/	Homo sapiens												79	8	metastatic breast cancer					38			18	week		175
3307	1492					Recommended	mg/m2	300		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1385761/	Homo sapiens												79	6	metastatic breast cancer					38			18	week		175
3308	1493		adult				mg	20		multiple			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02813551	Homo sapiens													59	Hypertension								5	day		
3309	1493					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral			https://link.springer.com/article/10.2165/00003495-199549010-00009	Homo sapiens														Chronic renal failure											p.124
3310	1493					Highest studied dose	mg	800		single					unhealthy	intravenous			https://link.springer.com/article/10.2165/00003495-199549010-00009	Homo sapiens														Acute renal failure											p.124, 133
3311	1493					Recommended	mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf	Homo sapiens							max			The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex. If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied.				Edema associated with congestive heart failure, renal disease, or hepatic disease											p.11
3312	1493					Recommended	mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf	Homo sapiens							max			The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex. If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied.				Edema associated with congestive heart failure, renal disease, or hepatic disease											p.6
3313	1493					Studied dose	mg	200		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/9247774	Homo sapiens													44	Advanced chronic renal failure								7	day		
3314	1494					Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9231890/	Homo sapiens						55							151	hypertension								6	week		
3315	1495		adult				g	7.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02317549	Homo sapiens							total daily dose						5	Septic Shock								28	day		
3316	1495		adult				mg/kg	20		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02051686	Homo sapiens										10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.			42	Acetabulum Fractures											
3317	1495					Overdose	g	1		steady			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24434397/	Homo sapiens						45							1	chronic kidney disease					45			2	day		
3318	1495					Recommended	mg	1300		steady			day	3	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022430s004lbl.pdf	Homo sapiens												49	232	cyclic heavy menstrual bleeding					18			5	day		
3319	1495					Recommended	mg	2000		steady			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/14712363/	Homo sapiens						56							1	emergency operation for a bleeding ulcer of the stomach and duodenum					56			2	week		
3320	1495					Recommended	mg	250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27206758/	Homo sapiens						40.7							561	Melasma								4	month		
3321	1496					Overdose	%	0.004		multiple			15 min	1	unhealthy	ophthalmic	F		https://pubmed.ncbi.nlm.nih.gov/25259759	Homo sapiens													1									7	hour		
3322	1496					Recommended	%	0.004		multiple			day	1	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21257lbl.pdf	Homo sapiens																									
3323	1496					Recommended	%	0.004		multiple			day	1	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021994s000_MedR.pdf	Homo sapiens													336									2	week		
3324	1497					Highest studied dose	mg/m2	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7707116	Homo sapiens						4				12 courses			9	Neuroblastoma								2	week		p.897
3325	1497					MTD	mg/m2	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7707116	Homo sapiens						4				12 courses			23	Neuroblastoma								2	week		p.897
3326	1497					MTD	mg/m2	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8995497	Homo sapiens						4				12 courses			16	Neuroblastoma								2	week		p.34
3327	1497					Overdose	mg	1000		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19415591	Homo sapiens						31							1	AIDS											p.74
3328	1497					Overdose	mg/kg	12.5		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8548998	Homo sapiens						29							1	Acne											p.348
3329	1497					Recommended	mg/kg	1		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021951s013lbl.pdf	Homo sapiens														Acne								20	week		p.1
3330	1498						mg	100		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6496322	Homo sapiens						54							9	hypokalemia	50 mg twice daily; 28 days			hydrochlorothiazide							
3331	1498						mg	37.5		single			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/016042s079lbl.pdf	Homo sapiens										The usual dose of DYAZIDE is 1 or 2 capsules given once daily, with appropriate monitoring of serum potassium and of the clinical effect. Each capsule contains 25 mg hydrochlorothiazide and 37.5 mg triamterene.					25 mg			hydrochlorothiazide				28	day		
3332	1499					Highest studied dose	mg	3		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19327	Homo sapiens												60	2	insomnia					21						
3333	1499					Recommended	mg	0.25		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017892s050lbl.pdf	Homo sapiens													1003	insomnia								42	day		
3334	1500						mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5242163	Homo sapiens												75	16	edema					31						
3335	1501		adult			Highest studied dose	mg	24		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6136938/	Homo sapiens							mean						52	torsion dystonia	350 mg			ethopropazine							
3336	1501		children			Highest studied dose	mg	41		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6136938/	Homo sapiens							mean						23	torsion dystonia											
3337	1501					Higher than recommended	mg	40		multiple					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6741602/	Homo sapiens						25							1	drug and alcohol dependence					25						
3338	1501					Higher than recommended	mg	5		multiple			day	28	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6741602/	Homo sapiens						35							1	schizophrenic					35			7	day		
3339	1501					Highest studied dose	mg/kg	0.55		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21310336/	Homo sapiens							mean					18	101	cerebral palsy with dystonia or/and sialorrhea					1			34	month		
3340	1501					Highest studied dose	mg/kg	0.75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17690057/	Homo sapiens							mean					15	26	cerebral palsy					4			9	week		
3341	1501					Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3984771/	Homo sapiens						49.7	mean						22	schizophrenia or mental retardation				neuroleptic				10	year		
3342	1504					Highest studied dose	mg	900		multiple			week	1	unhealthy	intravesical	M+F		https://pubmed.ncbi.nlm.nih.gov/9123721	Homo sapiens													9	Bladder cancer								6	week		p.474
3343	1504					MTD	mg	800		multiple			week	1	unhealthy	intravesical	M+F		https://pubmed.ncbi.nlm.nih.gov/10925084	Homo sapiens						67							14	Bladder cancer											p.234
3344	1504					MTD	mg	800		multiple			week	1	unhealthy	intravesical	M+F		https://pubmed.ncbi.nlm.nih.gov/9123721	Homo sapiens													7	Bladder cancer								6	week		p.474
3345	1505					Overdose	g	1		multiple			day	6	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3239947	Homo sapiens						54							1	Staphylococcus epidermidis infection								10	day		
3346	1505					Recommended	mg/kg	15		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22247123	Homo sapiens						61.6							587	Staphylococcus aureus nosocomial pneumonia								14	day		p.5
3347	1506		adult				mg	0.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01010204	Homo sapiens										Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks.			31	Tobacco Use Disorder								12	week		
3348	1506		adult				mg	1		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01151813	Homo sapiens													15	Alcohol Dependence|Cocaine Dependence								1	week		
3349	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00567008	Homo sapiens													17	Cocaine dependence								8	week		
3350	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00744978	Homo sapiens										0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks			60	Alzheimer's disease								6	week		
3351	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00790569	Homo sapiens										Realated publication: [PMID:23953658]: Participants were instructed to begin with one capsule (0.5 mg) with food the evening of the baseline visit. This dose was continued for three days, then increased to two 0.5 mg pills a day for four days, increasing to 1 mg twice daily after one week (as per the varenicline package insert from Pfizer, Inc.).			137	Tobacco Use Disorder								6	month		
3352	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00794573	Homo sapiens										0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.			151	Tobacco Use Disorder								12	week		
3353	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01011829	Homo sapiens										Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).			10	Methamphetamine Dependence								8	week		
3354	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01027754	Homo sapiens										Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day			57	Tobacco Use Disorder								12	week		
3355	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01146613	Homo sapiens													97	Alcohol Dependence								12	week		
3356	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01244061	Homo sapiens													249	Tobacco Use Disorder								12	week		
3357	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01347112	Homo sapiens													16	Tobacco Dependence								12	week		
3358	1506		adult				mg	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01680887	Homo sapiens													80	Cocaine Dependence								17	week		
3359	1506		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00695500	Homo sapiens							total daily dose						24	Alcohol Drinking								3	week		
3360	1506		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00802919	Homo sapiens							max|total daily dose			1-2 mg/day			45	Tobacco Use Disorder and Schizophrenia								8	week		
3361	1506		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02892110	Homo sapiens													35	Cannabis Use Disorder								8	week		
3362	1506					Overdose	mg	15		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/19274508	Homo sapiens																									
3363	1506					Recommended	mg	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22007690	Homo sapiens						46							36	Smoking addiction								12	week		p.15
3364	1506					Recommended	mg	1		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021928s014s017lbl.pdf	Homo sapiens										Starting week: 0.5 mg once daily on days 1-3 and 0.5 mg twice daily on days 4-7. Continuing weeks: 1 mg twice daily for a total of 12 weeks.				Smoking addiction								12	week		p.1
3365	1506					Recommended	mg	1		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021928s014s017lbl.pdf	Homo sapiens										Starting week: 0.5 mg once daily on days 1-3 and 0.5 mg twice daily on days 4-7. Continuing weeks: 1 mg twice daily for a total of 12 weeks.				Smoking addiction								12	week		p.1,3
3366	1507		adult			Studied dose	mg/kg	0.012		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2890364/	Homo sapiens													21	for relaxation of skeletal muscles											
3367	1507		adult			Studied dose	mg/kg	0.112		single					unknown	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2901271/	Homo sapiens													1												
3368	1507					Overdose	mg	37		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/1979208/	Homo sapiens													1	Down’s syndrome had corrective cardiac surgery for an atrioventricular canal defect											
3369	1507					Overdose	mg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15794110/	Homo sapiens													1	anesthesia											
3370	1507					Studied dose	mg/kg	0.12		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24067332/	Homo sapiens												58	20	27-81% total body surface area (TBSA) burn					23						
3371	1508		adult			Recommended	mg	200		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020943s028lbl.pdf	Homo sapiens													297	arrhythmia								7	day		
3372	1508		adult			Recommended	mg	200		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020943s028lbl.pdf	Homo sapiens													4954	arrhythmia								7	day		
3373	1508		adult				mg	120		multiple			day	3	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03070470	Homo sapiens										Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3			10									2.5	day		
3374	1508		adult				mg	120		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01873950	Homo sapiens													22												
3375	1508		adult				mg	360		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02372253	Homo sapiens							max			13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules			11	Type 1 Diabetes								12	month		
3376	1508		adult				mg	80		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02454608	Homo sapiens													10	Rhinosinusitis								8	week		
3377	1508		adult				mg	80		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02454608	Homo sapiens													29	Rhinosinusitis								1	year		
3378	1508					Overdose	g	4.8		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2006577/	Homo sapiens						38							1	migraine headaches and iron deficiency anemia					38						
3379	1508					Overdose	g	7.2		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8130061/	Homo sapiens						42							1						42						
3380	1508					Overdose	mg	2880		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33006738/	Homo sapiens						14							1	depression and Graves’ disease					14						
3381	1508					Overdose	mg	3200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1477440/	Homo sapiens						18							1	attempted suicide			amoxicillin	trimethoprim/sulfamethoxazole	18					dipyridamole	
3382	1509		adult				g	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01335867	Homo sapiens							max|total daily dose						16	Cocaine and Alcohol Dependence								8	week		
3383	1509		adult				mg	1500		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01281202	Homo sapiens													103	Cocaine Dependence								9	week		
3384	1509					Highest studied dose	g	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1483856	Homo sapiens												63	99	Epilepsy					16			8	week		p.745
3385	1509					Highest studied dose	g	2		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8331204	Homo sapiens						25.8							24									4.5	day		p.460
3386	1509					Highest studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9924905	Homo sapiens						35							41	Complex Partial Seizures											p.81
3387	1509					Highest studied dose	g	4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8331204	Homo sapiens						27							24												p.460
3388	1509					Overdose	g	90		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf	Homo sapiens							max			When reported, the vigabatrin dose ingested ranged from 3 g to 90 g, but most were between 7.5 g and 30 g.				Refractory Complex Partial Seizures											p.16
3389	1509					Recommended	mg	1500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf	Homo sapiens										Adults >16 years of age: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1500 mg twice daily				Refractory Complex Partial Seizures											p.1
3390	1510					Highest studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8087328/	Homo sapiens						37							67	asthma, moderate								6	week		
3391	1510					Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9377612/	Homo sapiens												76	514	asthma, mild-to-moderate					12			13	week		
3392	1511					Highest studied dose	mg	75		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10445371	Homo sapiens												44	14						18						p.41
3393	1511					Overdose	mg	200		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf	Homo sapiens							min							Insomnia											p.12
3394	1511					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf	Homo sapiens							max							Insomnia											p.5
3395	1512					Highest studied dose	mg	600		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23983212	Homo sapiens						47.5							130	influenza					47.5			10	day		
3396	1512					Recommended	mg	5		multiple			day	1	pregnant	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/20095840/	Homo sapiens						25				sixth dose of zanamivir nebulization			1						25						
3397	1512						mg	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23587959	Homo sapiens												79	4						18			30	min		
3398	1512						mg/kg	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29051331	Homo sapiens							starting			Infants and children (6 mo–<6 y): ≥42.8 kg body weigh: 600 mg - initial dose; <42.8 kg body weight: 14 mg/kg initial dose. Adolescents and children (6-18 years): ≥50 kg body weigh: 600 mg - initial dose; <50 kg body weight: 12 mg/kg initial dose.			71	influenza								5	day		
3399	1513		adult			MTD	mg/m2	8000		multiple					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/9261522/	Homo sapiens													29	metastatic colorectal cancer	500 mg/m2			5-fluorouracil							
3400	1513		adult			Overdose	g	40		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2563536/	Homo sapiens													1	HIV-1											
3401	1513		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019910s033lbl.pdf	Homo sapiens													453	HIV-1								3	month		
3402	1513		children			Recommended	mg/m2	160		steady			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019910s033lbl.pdf	Homo sapiens													236	HIV-1	4 mg/kg twice daily			EPIVIR				56	day		
3403	1513					Highest studied dose	mg	1000		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2036464/	Homo sapiens						34							1	HIV-1, homosexual					34			4	week		
3404	1513					Overdose	g	22.5		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2036464/	Homo sapiens						34							1	HIV-1, homosexual					34						
3405	1513					Overdose	g	36		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2563536/	Homo sapiens						35							1	HIV-1					35						
3406	1513					Overdose	mg	134		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21867364/	Homo sapiens													1	HIV postnatal prophylaxis											
3407	1513					Overdose	mg	20000		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2900428/	Homo sapiens						34							1	HIV-1				temazepam	34						
3408	1513					Overdose	mg	20000		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3163102/	Homo sapiens						28							1	HIV-1					28						
3409	1514		adult				mg	600		steady			day	4	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00493974	Homo sapiens													60	Chronic obstructive pulmonary disease								14	day		
3410	1515					Highest studied dose	mg	5		single					unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/12921494	Homo sapiens						41.7							783	Migraine											p.845
3411	1515					Overdose	mg	50		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Homo sapiens														Migraine											p.13
3412	1515					Recommended	mg	5		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020768s019s021,021231s010s011lbl.pdf	Homo sapiens							max							Migraine											p.1
3413	1516		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20789lbl.pdf	Homo sapiens							starting			The initial dose should be 100 mg daily. After two weeks, the dose may be increased to 200 mg/day for at least two weeks. It can be increased to 300 mg/day and 400 mg/day			1336	epilepsy								2	week		
3414	1516		adult				mg	500		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01566370	Homo sapiens										titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose			2	Alcohol Use Disorder and Bipolar Disorder								14	week		
3415	1516		adult				mg	600		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02368431	Homo sapiens							max			Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.			46	Alcohol Use Disorder								15	week		
3416	1516		child				mg/kg	8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00566254	Homo sapiens							total daily dose			Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.			107	Epilepsy								24	week		
3417	1516		child|adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00692003	Homo sapiens							max			25-400 mg capsules orally once daily in the evening. Maximum study duration of 28 weeks comprising:Baseline Period (Week-8/-4 to Week 0) no treatment. Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4. Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events). Down Titration Period (4 weeks)			5	Epilepsy								28	week		
3418	1516		child|adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00693017	Homo sapiens							max			50-400 mg capsules once daily in the evening orally. Maximum study duration 28 weeks comprising: Baseline Period (Week -8 to Week 0): no treatment. Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4. Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events). Down Titration Period (4 Weeks).			2	Epilepsy								28	week		
3419	1516					Highest studied dose	mg	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15144425	Homo sapiens						35						64.1	51	refractory partial epilepsy					17.9			2	week		
3420	1516					Overdose	g	12.6		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21463969	Homo sapiens						25							1						25						
3421	1516					Overdose	g	7.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27749631	Homo sapiens						15							1						15						
3422	1516					Overdose	g	8.7		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21467261	Homo sapiens						20							1						20						
3423	1517					Studied dose	ug/kg	15		multiple			3 weeks	1	healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/15102870/	Homo sapiens												75	15						50			2	times		
3424	1517					Studied dose	ug/kg	15		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/15102870/	Homo sapiens												75	16						50						
3425	1518		adult			Highest studied dose	mg	120		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf	Homo sapiens																									
3426	1518		adult			Highest studied dose	mg	48		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf	Homo sapiens																						7	day		
3427	1518		adult			Recommended	mg	12		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf	Homo sapiens																						7	day		
3428	1518						mg	12		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01704651	Homo sapiens													66	ovarian cancer								7	day		
3429	1519					Overdose	mg	400		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Homo sapiens														Candida infections|Candidemia											p.9
3430	1519					Recommended	mg	200		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23676114	Homo sapiens													43	Candidemia								5	day		p.4
3431	1519					Recommended	mg	200		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Homo sapiens										200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter for at least 14 days after the last positive culture		89	127	Candida infections|Candidemia					16						p.4
3432	1519					Recommended	mg	200		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Homo sapiens										200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter for at least 14 days after the last positive culture				Candida infections|Candidemia											p.1
3433	1520		child				mg	5		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01861522	Homo sapiens													240	Perennial Allergic Rhinitis								2	week		
3434	1520					Recommended	drop	1		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022288lbl.pdf	Homo sapiens										1.5%, 1 drop into the affected eye(s) twice a day				Allergic conjunctivitis											p.1
3435	1521						mg	4		single			day	1	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/8031438	Homo sapiens																									
3436	1522					Highest studied dose	mg	5		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/26460564	Homo sapiens						58.9	starting			5 mg days 1–2; 3 mg days 3–5			27	Rheumatoid Arthritis								2	day		
3437	1523					Recommended	ug/kg/min	9.58		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022156s000_MedR_P1.pdf	Homo sapiens										122 minutes total including 12 min for titration			1301	hypertension											-
3438	1524					Recommended	mg	1.5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020813s010lbl.pdf	Homo sapiens													574	seizure disorders											
3439	1524					Studied dose	mg	6		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3279721	Homo sapiens										maximum dose of 1.5 - 6.0 mg (mean 3.4 mg) 2-3 weeks after the onset of CNZP therapy				depression								3	week		
3440	1524						mg	2		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/12646763	Homo sapiens						30							12						30						
3441	1524						mg	2		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12646763	Homo sapiens						30							12						30						
3442	1524						mg	2		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12646763	Homo sapiens						30							12						30						
3443	1525		adult			Recommended	ug	100		multiple			day	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19722slr006_nascobal_lbl.pdf | https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=562e0ff4-a96c-4390-acbf-afa4baa0b8fe	Homo sapiens													25									6	day		
3444	1525		adult			Recommended	ug	100		multiple			day	1	unhealthy	subcutaneous			https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=562e0ff4-a96c-4390-acbf-afa4baa0b8fe	Homo sapiens													25									6	day		
3445	1525		adult			Recommended	ug	500		multiple			week	1	unhealthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19722slr006_nascobal_lbl.pdf	Homo sapiens													24												
3446	1526		adult			Highest studied dose	g	10		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050573s041,050574s051,050625s055lbl.pdf	Homo sapiens										10 g (about 150 mg/kg)															
3447	1526					Recommended	%	0.09		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210913Orig1s000MedR.pdf	Homo sapiens						61.9				Ophthalmic solution containing cyclosporine 0.9 mg/mL.		91	151						23			11	week		p. 34
3448	1526						mg/kg	3		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00974142	Homo sapiens							total daily dose						8	Chronic Obstructive Pulmonary Disease								16	week		
3449	1526						mg/kg	4		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11313301	Homo sapiens						36.7							15	Ulcerative Colitis					36.7			8	day		
3450	1526						mg/kg	5		steady			week	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00438360	Homo sapiens							total daily dose			twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations			160	Chronic Plaque Psoriasis								24	week		
3451	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			100	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3452	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			15	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3453	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			20	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3454	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			25	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3455	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			30	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3456	1527		adult				mg	2		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017744s026lbl.pdf	Homo sapiens							starting			The recommended starting dose of MOTOFEN® tablets in adults is 2 tablets then 1 tablet after each loose stool or 1 tablet every 3 to 4 hours as needed, but the total dosage during any 24-hour treatment period should not exceed 8 tablet. Each tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg of atropine).			40	acute nonspecific diarrhea	2 tablets			atropine sulfate							
3457	1528					Highest studied dose	mg	30		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205525Orig1s000MedR.pdf	Homo sapiens						36							40	cannabinoid abuse								1	day		nda/2016/205525Orig1s000MedR.pdf - p.40
3458	1528						mg	2.5		multiple			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01253408	Homo sapiens													10	Irritable Bowel Syndrome								2	day		
3459	1528						mg	2.5		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01786109	Homo sapiens													24	Irritable Bowel Syndrome											
3460	1528						mg	20		multiple			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00217971	Homo sapiens													79	Marijuana Addiction											
3461	1528						mg	5		multiple			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01253408	Homo sapiens													13	Irritable Bowel Syndrome								2	day		
3462	1528						mg	5		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01786109	Homo sapiens													24	Irritable Bowel Syndrome											
3463	1529		adult			Recommended	g	1		steady			day	1	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21337_Invanz_Medr_P4.pdf	Homo sapiens													319									14	day		p. 184
3464	1529					Highest studied dose	g	3		steady			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12384357	Homo sapiens												49							18			8	day		
3465	1529					Overdose	g	1		single			day	3	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21337lbl.pdf	Homo sapiens										inadvertent administration of three 1 g doses of INVANZ in a 24 hour period			1												
3466	1529					Recommended	g	1		steady			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27056357	Homo sapiens						71							1	osteomyelitis	1 g daily			daptomycin	71			4	week		
3467	1529						mg	500		steady			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/32487528	Homo sapiens						59	starting			on hospital day 8, the patient’s ertapenem dose was increased to 1000 mg intravenously daily			1		1250 mg intravenous loading dose followed by 500 mg intravenously once the following day			vancomycin	59			10	day		
3468	1530					Overdose	g	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/484952	Homo sapiens						17							1						17						
3469	1530					Overdose	g	15		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/484952	Homo sapiens						16							1						16						
3470	1530					Overdose	g	22		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/484952	Homo sapiens						51							1						51						
3471	1530					Overdose	mg/kg	40		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/942681	Homo sapiens										two capsules (750 mg/capsule, 25 mg/kg of body weight) of Placidyl and four 750-mg (40 mg/kg of body weight) Placidyl capsules during a period of 10 minutes		23	2						22						
3472	1530						mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13927359	Homo sapiens													2	alcoholics								2	day		
3473	1530						mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/417376	Homo sapiens												28	4	insomnia					21			14	day		
3474	1531					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17413684	Homo sapiens													79	HIV-1 infection											F6
3475	1531					Recommended	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022187s009lbl.pdf	Homo sapiens													599	HIV-1 infection											p.5
3476	1531					Recommended	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022187s009lbl.pdf	Homo sapiens														HIV-1 infection											p.1
3477	1532					Highest studied dose	ug	250		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24152086	Homo sapiens												59	79						20						
3478	1532					Highest studied dose	ug	800		multiple			day	1	healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/24152086	Homo sapiens												59	79						20			7	day		
3479	1532						ug	880		single					healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/32485781	Homo sapiens						40.5				Each subject received one total dose of 880 µg fluticasone furoate as 2 sprays in alternating nostrils until 16 sprays had been delivered in each nostril within approximately 2min. (27.5 µg per spray)			17												
3480	1534		adult			Overdose	mg/m2	100		single					unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf	Homo sapiens										100 mg/m2 (total dose 185 mg)			1												
3481	1534		adult			Recommended	mg/m2	40		multiple			3 weeks	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022065lbl.pdf	Homo sapiens										40 mg/m2 administered intravenously over 3 hours every 3 weeks					1000 mg/m2 twice daily for 2 weeks followed by 1 week rest			capecitabine							
3482	1534					MTD	mg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22331549	Homo sapiens						69				every 6 h for three doses, every 3 weeks			9	refractory advanced cancers					69			3	week		
3483	1534					MTD	mg/m2	6		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/12721265	Homo sapiens										Cycle 2. Each cycle: 1-hour intravenous infusion daily for 5 consecutive days every 21 days.		80	16						18			5	day		
3484	1534					MTD	mg/m2	6.8		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20449631	Homo sapiens						54				a 1-h infusion daily for 5 days every 3 weeks.			3	recurrent high-grade gliomas					54			5	day		
3485	1534					MTD	mg/m2	8		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19075272	Homo sapiens						10				a 1-hour intravenous infusion daily for the first 5 consecutive days of a 21-day cycle.		18	6	Refractory Solid Tumors					2			5	day		
3486	1534						mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22331549	Homo sapiens						56				every 6 h for three doses, every 3 weeks			6	refractory advanced cancers					56			3	week		
3487	1534						mg/m2	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19075272	Homo sapiens						10				a 1-hour intravenous infusion daily for the first 5 consecutive days of a 21-day cycle.		18	3	Refractory Solid Tumors					2			5	day		
3488	1534						mg/m2	7		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20449631	Homo sapiens						54				a 1-h infusion daily for 5 days every 3 weeks.			3	recurrent high-grade gliomas					54			5	day		
3489	1534						mg/m2	8		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/12721265	Homo sapiens										1-hour intravenous infusion daily for 5 consecutive days every 21 days.		80	3						18			5	day		
3490	1535		adult			Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Homo sapiens													270	partial-onset seizures								12	week		
3491	1535		adult			Recommended	mg	400		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Homo sapiens													471	partial-onset seizures								12	week		
3492	1535		adult				mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Homo sapiens													203	partial-onset seizures								12	week		
3493	1535					Overdose	g	12		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Homo sapiens													1				gabapentin	zonisamide						topiramate	
3494	1535					Overdose	mg	1200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022253lbl.pdf	Homo sapiens																									
3495	1535					Studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28926353	Homo sapiens													34												
3496	1535					Studied dose	mg/kg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31374487/	Homo sapiens							max			Maximum lacosamide dose was 4 mg/kg/day for 2.1% (1/47), 6 mg/kg/day for 8.5% (4/47), 8 mg/kg/day for 29.8% (14/47), 10 mg/kg/day for 14.9% (7/47), and 12 mg/kg/day for 44.7% (21/47)			21	focal seizures								2	week		
3497	1535						mg	100		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00440518	Homo sapiens													72	Migraine								18	week		
3498	1535						mg	200		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00401830	Homo sapiens													78	Fibromyalgia Syndrome								8	week		
3499	1535						mg	300		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00440518	Homo sapiens													74	Migraine								18	week		
3500	1535						mg	400		steady					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00485472	Homo sapiens							total daily dose						72	Osteoarthritis								12	week		
3501	1535						mg/kg	5.82		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31374487/	Homo sapiens							mean			Maximum lacosamide dose was 4 mg/kg/day for 2.1% (1/47), 6 mg/kg/day for 8.5% (4/47), 8 mg/kg/day for 29.8% (14/47), 10 mg/kg/day for 14.9% (7/47), and 12 mg/kg/day for 44.7% (21/47)			47	focal seizures								2	week		
3502	1537		adult			Recommended	mg	50		multiple			day	6	pregnant	intramuscular	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens										The usual dosage is 50 mg to 150 mg intramuscularly or subcutaneously every 3 or 4 hours															
3503	1537		adult			Recommended	mg	50		multiple			day	6	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf	Homo sapiens														pain											
3504	1537		adult			Recommended	mg	50		multiple			day	6	pregnant	subcutaneous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens										The usual dosage is 50 mg to 150 mg intramuscularly or subcutaneously every 3 or 4 hours															
3505	1537		adult			Recommended	mg	50		multiple			day	6	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens										The usual dosage is 50 mg to 150 mg intramuscularly or subcutaneously every 3 or 4 hours				pain											
3506	1537		adult			Recommended	mg	50		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/005010s059lbl.pdf	Homo sapiens														pain											
3507	1537		adult			Recommended	mg	50		multiple			day	6	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens										The usual dosage is 50 mg to 150 mg intramuscularly or subcutaneously every 3 or 4 hours				pain											
3508	1537		adult			Recommended	mg/mL	10		multiple					pregnant	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens																									
3509	1537		adult			Recommended	mg/mL	10		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021171s032lbl.pdf	Homo sapiens																									
3510	1537					Highest studied dose	mg	1000		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/3941530/	Homo sapiens						37							1	pain					37			3	day		
3511	1537					Highest studied dose	mg	600		multiple			day	1	unknown	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11772223	Homo sapiens						44							7						44			2	day		
3512	1537					Overdose	g	10		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/17364646	Homo sapiens						17				Two hundred 50 mg tablets of meperidine									17						
3513	1537						mg	50		single					unknown	intrathecal	F		https://pubmed.ncbi.nlm.nih.gov/7923521	Homo sapiens												81							24						
3514	1538		adult			Recommended	mg	10		multiple			day	3	pregnant	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	Homo sapiens							starting			usual intravenous methadone starting dose is 2.5 mg to 10 mg every 8 to 12 hours, slowly titrated to effect.															
3515	1538		adult			Recommended	mg	10		multiple			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021624s010lbl.pdf	Homo sapiens							starting			usual intravenous methadone starting dose is 2.5 mg to 10 mg every 8 to 12 hours, slowly titrated to effect.															
3516	1538		adult			Recommended	mg	20		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017058s026lbl.pdf	Homo sapiens							starting			The total daily dose of methadone on the first day of treatment should not ordinarily exceed 40 mg															
3517	1538					Overdose	mg	60		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/23762729/	Homo sapiens						29							1						29						
3518	1538					Overdose	mL	7.5		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/33618681	Homo sapiens						19				consumed 3 × 2.5 mL of liquid methadone (produced for substitution therapy) intravenously			1						19						
3519	1539					Highest studied dose	mg	200		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens														Candidiasis	20 mg			prednisolone, iv, single							p.1, p.4
3520	1539					Highest studied dose	mg/kg	8		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16715107	Homo sapiens										The highest dose given was 900 mg (in the 8.0 mg/kg/day group).		62	8	Haematopoietic stem cell transplantation					19			19.8	day		p.48
3521	1539					Overdose	mg/kg	16		single					unhealthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf	Homo sapiens										In one spontaneous case, it was reported a dosage of 16 mg/kg/day was administered in a newborn patient.				Candidiasis											p.9
3522	1539					Recommended	mg	150		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens														Oesophageal candidiasis								15	day		p.1
3523	1539					Recommended	mg	150		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021506s011s012lbl.pdf	Homo sapiens														Oesophageal candidiasis								15	day		p.1, p.4
3524	1539					Recommended	mg	150		multiple			day	1	unhealthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf	Homo sapiens										The treatment duration of Candidainfection should be a minimum of 14 days. Micafungin should be administered for at least one week after resolution of clinical signs and symptoms.				Candidiasis								15	day		p.5
3525	1539					Recommended	mg	150		multiple			day	1	unhealthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/mycamine-epar-product-information_en.pdf	Homo sapiens										The treatment duration of Candidainfection should be a minimum of 14 days. Micafungin should be administered for at least one week after resolution of clinical signs and symptoms.				Candidiasis								15	day		p.8
3526	1540					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16540931	Homo sapiens													68	Weight loss								12	week		p.308
3527	1540					Recommended	mg	5		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/13718s20s21lbl.pdf	Homo sapiens										The daily adult dosage is 2.5 to 20 mg given in 2 to 4 divided doses.				Weight loss											p.1
3528	1541					Highest studied dose	mg	79.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15629415	Homo sapiens							mean					47.5	71	Back pain					45.5			16	day		p.26
3529	1541					Recommended	mg	0.5		multiple			day	5	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf	Homo sapiens										Intravenous: 0.5 mg initially. In non debilitated patients the dose can be cautiously increased until satisfactory pain relief is obtained.				Pain											p.6
3530	1541					Recommended	mg	1.5		multiple			day	5	unhealthy	intramuscular|subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/011707s031lbl.pdf	Homo sapiens							max			Subcutaneous or intramuscular administration: initially 1 mg to 1.5 mg, repeated every 4 to 6 hours as needed.				Pain											p.6
3531	1541					Recommended	mg	20		multiple			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15777102	Homo sapiens													23									8	day		p.97
3532	1541					Recommended	mg	20		multiple			day	5	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021611s010lbl.pdf	Homo sapiens							max			Initiate treatment with 10 to 20 mg orally every four to six hours.				Pain											p.1
3533	1542					Recommended	mg	105		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018074s036lbl.pdf	Homo sapiens														exogenous obesity				anorectic agents							
3534	1542					Recommended	mg	105		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018074s036lbl.pdf	Homo sapiens														exogenous obesity				dexfenfluramine							
3535	1542					Recommended	mg	105		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018074s036lbl.pdf	Homo sapiens														exogenous obesity				fenfluramine							
3536	1544		adult			Recommended	mg	15		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018708s023lbl.pdf	Homo sapiens													267	insomnia								7	day		
3537	1544					Highest studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6113910/	Homo sapiens												58	18	insomnia					22			12	day		
3538	1544					Recommended	mg	15		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6705450/	Homo sapiens												39	11						19			14	day		
3539	1544					Studied dose	mg	20		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15385836/	Homo sapiens						30.6							20						30.6						
3540	1545		adult				mg	0.4		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT00863707	Homo sapiens													334	Renal Impairment											
3541	1545		child|adult				ug/kg	1.44		single			hour	1	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01788631	Homo sapiens										1.44 mcg/kg/hour infused over 48 hours			52	Sickle Cell Anemia								48	hour		
3542	1545					Highest studied dose	ug/kg	30		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in supine position					18						1211
3543	1545					MTD	ug/kg	10		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in standing position					18						1211
3544	1545					MTD	ug/kg	10		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in supine position					18						1211
3545	1545					MTD	ug/kg	20		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in standing position					18						1211
3546	1545					MTD	ug/kg	20		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in supine position					18						1211
3547	1545					Recommended	ug/kg	3		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in standing position					18						1211
3548	1545					Recommended	ug/kg	3		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/17112296/	Homo sapiens												50	4	in supine position					18						1211
3549	1546		child				%	1		multiple			day	2	unhealthy	topical	M+F		https://clinicaltrials.gov/ct2/show/NCT03304873	Homo sapiens										Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.			23	Mupirocin Resistant Methicillin Resistant Staphylococcus Aureus								5	day		
3550	1546					Recommended	%	1		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022055s004lbl.pdf	Homo sapiens										Apply a thin layer of ALTABAX (1% Retapamulin) to the affected area (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) twice daily for 5 days.				impetigo due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes								5	day		p.1
3551	1547		adult				mg	4		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00740779	Homo sapiens													52	Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome								12	week		
3552	1547		adult				mg	8		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00224120	Homo sapiens													233	Benign Prostatic Hyperplasia								12	week		
3553	1547		adult				mg	8		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00740779	Homo sapiens													45	Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome								12	week		
3554	1547					Highest studied dose	mg	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21804212	Homo sapiens						23							8												p.1242
3555	1547					Highest studied dose	mg	48		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21114397|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022206s000_MedR_P1.pdf#page=54	Homo sapiens										Study participants received 3-day regimens of supratherapeutic doses ranging from 16–48 mg/day		45	6						19			3	day		p.1309|p.6,21
3556	1547					Recommended	mg	8		multiple			day	1	unhealthy	oral	M		https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/rapaflo-pm_eng-12march2018.pdf	Homo sapiens													466	Benign prostatic hyperplasia								12	week		p.6
3557	1547					Recommended	mg	8		multiple			day	1	unhealthy	oral	M		https://www.ema.europa.eu/en/documents/product-information/silodyx-epar-product-information_en.pdf	Homo sapiens														Benign prostatic hyperplasia											p.3
3558	1550						%	0.02		multiple			day	1	unhealthy	ophthalmic	M		https://pubmed.ncbi.nlm.nih.gov/2931241	Homo sapiens						70							1	conjuctivitis				chloramphenicol	70			3	week	neomycin-bacitracin-polimixin B	
3559	1550						%	0.2		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31616212	Homo sapiens						51						85	58						14			1	year		
3560	1550						%	0.2		multiple			day	2	unhealthy	otic			https://pubmed.ncbi.nlm.nih.gov/5436960	Homo sapiens										two drops twice a day or 3 drops 3 times a day			46	ears infection	0.01			hydrocortisone acetate							
3561	1552		ADULT			Highest studied dose	mg	1500		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/576887/	Homo sapiens						60	total daily dose						130	breast cancer								12	week		2079-8
3562	1553					Studied dose	mg	600		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13520554	Homo sapiens							starting			600 mg. initially, followed by 400 mg. on the second and third days		89	52	Vascular disease					47						p.76
3563	1555					Recommended	g	1.6		multiple			day	1.1	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						35.44	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 1.6 (0.16-35.5). Daily application (number/day) median(range): 1.1 (0.95-3.01). Treatment duration (days) median(range): 356 (1-376).		83.43	248				titanium dioxide	ecamsule	12.04			356	day	octocrylene	
3564	1555					Recommended	g	3.1		multiple			day	1.2	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						6.69	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 3.1 (0.07-26.85). Daily application (number/day) median(range): 1.2 (1-7.78). Treatment duration (days) median(range): 44.5 (1-363).		67.95	246				titanium dioxide	ecamsule	0.5			44.5	day	octocrylene	
3565	1555					Recommended	g	3.7		multiple			day	1.3	healthy	topical	M+F		https://www.fda.gov/media/71361/download	Homo sapiens						3.69	median			Helioblock-SX SPF40 Sunscreen Cream contains ecamsule 3%, avobenzone USP 2%, octocrylene USP 10%, and titanium dioxide USP 5%. Daily usage in grams median(range): 3.7 (0.86-29.6). Daily application (number/day) median(range): 1.3 (1-2.8). Treatment duration (days) median(range): 31 (1-225).		48.15	79				titanium dioxide	ecamsule	0.64			31	day	octocrylene	
3566	1556					Highest studied dose	mg	1600		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/32615	Homo sapiens													16	chronic bronchitis											
3567	1556					Highest studied dose	mg	3200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4028617	Homo sapiens												41	12						22						
3568	1557		adult			Highest studied dose	g	5		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6603385	Homo sapiens													47	ancreatic exocrine insufficiency											
3569	1559		ADOLESCENT			Overdose	mg/kg	50.9		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33041720/	Homo sapiens						14				14 capsules of 200 mg			1												p.642, 643
3570	1559		ADULT			Overdose	mg	5200		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/34219543/	Homo sapiens						43							1												p.8
3571	1559		CHILD			Overdose	mg	10000		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/34219543/	Homo sapiens						12							1												p.7
3572	1559		CHILD|ADOLESCENT|ADULT			Recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011210s053lbl.pdf	Homo sapiens														respiratory airway obstruction											p.1
3573	1559					Overdose	mg	3600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9865240/	Homo sapiens						39							1												p.714
3574	1562					Studied dose	mg	100		steady			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14286057/	Homo sapiens										25 to 100 mg		60	28	acutely psychotic					18			25	day		
3575	1564		ADULT			Higher than recommended	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7889959/	Homo sapiens													110	pneumonia								10	day		p.854
3576	1564		ADULT			Highest studied dose	mg	1000		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2393281/	Homo sapiens						26.6							12									10	day		p.1200
3577	1564		ADULT			Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11686426/	Homo sapiens						50							150	bronchitis								10	day		p.332
3578	1564		ADULT			Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7889959/	Homo sapiens													90	pneumonia								10	day		p.853
3579	1564		ADULT			Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050664s024,050665s024lbl.pdf	Homo sapiens							max							bacterial infectious disease								10	day		p.9
3580	1565		adult			Recommended	mg	0.4		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/11129127/	Homo sapiens													1263	hypercholesterolaemia								8	week		
3581	1565		adult			Recommended	mg	0.4		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/11129127/	Homo sapiens													2816	hypercholesterolaemia								8	week		
3582	1565					Higher than recommended	mg	0.8		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10898118/	Homo sapiens						57.2							776	hypercholesterolaemia					57.2			8	week		
3583	1565					Recommended	mg	0.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10898118/	Homo sapiens						57.3							195	hypercholesterolaemia					57.3			8	week		
3584	1566		adult			Recommended	mg	20		steady			day	3	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6749701/	Homo sapiens													12	cough								7	day		
3585	1567					Overdose	g	4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1936060	Homo sapiens						46							1		18 g			acetaminophen, p.o							p.45
3586	1567					Recommended	mg	400		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1936060	Homo sapiens													10	Painful muscular spasms								5	day		p.44, p.45
3587	1567					Studied dose	mg	800		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1936060	Homo sapiens										5 patients received a loading dose of 800 mg and then repeated doses of 3 x 200 mg chlormezanone daily.			5	Painful muscular spasms											p.44
3588	1569						mg	72		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/453287	Homo sapiens						21							24						21			2	day		
3589	1570					Recommended	g	0.375		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14439455/	Homo sapiens						53	mean			0.25 g to 0.5 g			1	Diabetes Mellitus					53			10	day		
3590	1570					Recommended	g	0.375		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5340346/	Homo sapiens						62	mean			0.25 g to 0.5 g			394	Diabetes Mellitus								96	month		
3591	1572		adult			Recommended	mg	1000		steady			day	3	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/30509675/	Homo sapiens													148	infections				IMIPENEM ANHYDROUS				14	day		
3592	1574					Highest studied dose	mg	200		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3559339	Homo sapiens												60	6	Lepromatous leprosy					30						p.1986
3593	1574					Recommended	mg	100		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf	Homo sapiens														Lepromatous leprosy											p.1
3594	1574					Recommended	mg	100		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf	Homo sapiens														Lepromatous leprosy											p.1, p.3
3595	1574					Recommended	mg	100		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf	Homo sapiens														Lepromatous leprosy											p.3
3596	1574					Recommended	mg	200		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf	Homo sapiens														Lepromatous leprosy											p.4
3597	1577					Overdose	%	1		multiple			5 min	1	unknown	topical	F		https://pubmed.ncbi.nlm.nih.gov/22908101	Homo sapiens										One drop 1% cyclopentolate was instilled 6 times in each eye at 5-minute intervals			1	mydriasis induction								6	times		e704
3598	1577					Recommended	%	2		single					unknown	topical			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ad85b220-6003-4a78-b900-5195ceaf0fd5&type=display	Homo sapiens														mydriasis induction											
3599	1578					Highest studied dose	mg/kg	121		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25139979	Homo sapiens							total daily dose						6	Parenteral nutrition											
3600	1578					Recommended	mg/g aminoacid	22		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210660lbl.pdf	Homo sapiens							total daily dose			For pediatric patients from birth to less than 12 years of age, the recommended dosage of ELCYS is 22 mg/gram of amino acids. For adults and pediatric patients 12 years of age and older, the recommended dosage of ELCYS is 7 mg/gram of amino acids.				Parenteral nutrition											p.1
3601	1580					Highest studied dose	mg	6		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13817998	Homo sapiens							max			from 2 mg. t.d.s. increasing by 1 mg. t.d.s. per week up to 6 mg. t.d.s. (18 mg. daily) for a total period of three months.			13	Schizophrenia								1	week		p.1115
3602	1583		adult			Recommended	mg	8		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/14204552/	Homo sapiens							max			2 to 8 mg, to 6 months			18	diabetic								6	month		
3603	1584					Highest studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/95337/	Homo sapiens										160 mg/day during the first half of the study but this was increased to 200 mg/day for the remainder			71									1.5	month		
3604	1584					Overdose	mg	2100		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/18920084	Homo sapiens													1												
3605	1588					Recommended	mg	3		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16542051/	Homo sapiens						25.1							220		20 mug			ethinylestradiol				13	month		
3606	1588					Recommended	mg	3		steady			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021098s019lbl.pdf	Homo sapiens												40	2837						17			13	month		
3607	1589		adult			Studied dose	mg	250		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/6957527/	Homo sapiens													2	asthmatics											
3608	1589		adult			Studied dose	mg	375		single					unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/6957527/	Homo sapiens													2	asthmatics											
3609	1589					Studied dose	mg/kg	5		single					healthy	intragluteal	F		https://pubmed.ncbi.nlm.nih.gov/7309903/	Homo sapiens												35	20						20						
3610	1590						%	4		single					unhealthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/1200833	Homo sapiens						25							1	cholecystitis					25						
3611	1591		adult			Highest studied dose	mg	600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8741236/	Homo sapiens							max			100 to 600 mg, 2 or 3 times/day, 5 to 14 days			20060	Gram-negative urinary tract pathogens								14	day		
3612	1591					Highest studied dose	mg	600		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2764538/	Homo sapiens						41.9							79	cystitis					41.9						
3613	1591					Recommended	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2764538/	Homo sapiens						43.8							75	cystitis					43.8			3	day		
3614	1592		ADULT			Highest studied dose	mg	9		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11215321/	Homo sapiens						34.6							20												p.5
3615	1592		ADULT			Studied dose	mg	2.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30177490/	Homo sapiens						69.6							20	Parkinson's disease								6	week		p.72
3616	1592		ADULT				mg	2		multiple			day	3	unhealthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/762369/	Homo sapiens												84	14	dementia					62			12	week		p.81
3617	1595					Recommended	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10568486	Homo sapiens						23							86	psoriasis vulgaris								9	week		
3618	1595					Studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3508553	Homo sapiens												32	12						20						
3619	1595						mg	75		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2244393	Homo sapiens						75							1	psoriasis					75			6	week		
3620	1596					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5328c194-5650-4d1f-9e28-8cea038cce81&type=display|https://pubmed.ncbi.nlm.nih.gov/577673	Homo sapiens							max							Conditions associated with a deficiency or absence of endogenous testosterone|Metastatic mammary cancer											
3621	1597		children				mg	5.25		multiple			day	1	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/002187076290093X	Homo sapiens													45	asthma								6	month		
3622	1597					Highest studied dose	mg/m2	5.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13884715	Homo sapiens							max			fluprednisolone was given in a daily dosage of 5 to 5.25 mg each day until asthma was suppressed		16	45	Bronchial asthma					0						
3623	1599		adult			Highest studied dose	mg	3		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31376478/	Homo sapiens							min						480526	pregnant								9	month		
3624	1599		adult			Recommended	ug	400		steady			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31421417/	Homo sapiens													1257	pregnant								9	month		
3625	1599		adult				mg	5.1		steady			day	1	pregnant	oral	F		https://clinicaltrials.gov/ct2/show/NCT01355159	Homo sapiens										Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid			1227	Preeclampsia											
3626	1600					Overdose	g	10		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/512618	Homo sapiens							min																		
3627	1600					Overdose	g	4		multiple			day		unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5709841	Homo sapiens						42	max						1	alcohol addiction								6	month		p.561
3628	1600					Overdose	mg	15000		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18818183	Homo sapiens													1												p.72, 74
3629	1602		adult			Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10090425/	Homo sapiens													86	lower respiratory tract infections or sexually transmitted infections								6.92	day		
3630	1602		adult			Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10090425/	Homo sapiens													1069	lower respiratory tract infections or sexually transmitted infections								6.92	day		
3631	1602		adult			Recommended	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10090425/	Homo sapiens													1406	lower respiratory tract infections or sexually transmitted infections								6.92	day		
3632	1602					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9449270/	Homo sapiens						47.7							207	infections					47.7			10	day		
3633	1602					Recommended	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9449270/	Homo sapiens						48.4							204	infections					48.4			10	day		
3634	1603					Highest studied dose	mg	32		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6084121	Homo sapiens												65	12	hypertension					39						p.S764
3635	1603					Overdose	mg	240		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3994191	Homo sapiens						45	max						1												p.787
3636	1603					Overdose	mg	480		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/3994191	Homo sapiens							max						3												p.787-788
3637	1603					Recommended	mg	16		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6084122	Homo sapiens												55							22						p.S767
3638	1603					Recommended	mg	16		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6084121	Homo sapiens												65	12	hypertension					39						p.S764
3639	1603					Recommended	mg	24		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6084121	Homo sapiens												65	12	hypertension					39						p.S764
3640	1605					Overdose	%	4		single					unhealthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/276284	Homo sapiens						3	min						1	anesthesia for dental disorder											p.212
3641	1606					Recommended	%	3		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/6222704	Homo sapiens												26	9	acne vulgaris					18			4	week		
3642	1607					Highest studied dose	% * h	1382.4		multiple					unhealthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/20841413	Homo sapiens						25				Isoflurane was maintained for 34 days, with end-tidal concentrations ranging from 0.7% to 2.2%			1						25			34	day		
3643	1607					Highest studied dose	% * h	1975.2		multiple					unhealthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/20841413	Homo sapiens						4				Isoflurane was maintained for 85 days, with end-tidal concentration ranging from 0.5% to 2.5%.			1						4			85	day		
3644	1609		adult			Recommended	%	0.5		steady			day	1	unhealthy	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019219s029lbl.pdf	Homo sapiens														glaucoma								1	month		
3645	1611					Recommended	%	1		multiple					unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/006309lotionlbl.pdf	Homo sapiens										repeat or prolonged application				scabies											p.1
3646	1611					Recommended	%	1		single					unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/006309lotionlbl.pdf	Homo sapiens														scabies											p.1
3647	1614						drop	1		multiple			day	12	unhealthy	ophthalmic	F		https://pubmed.ncbi.nlm.nih.gov/5554878	Homo sapiens						44													44			1	day		
3648	1615					Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1839628	Homo sapiens										Initial dose 4-6 mg/day		31	12	Hyperandrogenism					16			58	month		p.142
3649	1615					Studied dose	mg	40		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/28579148	Homo sapiens						71							1	Lupus nephropathy								1	year		p.2
3650	1617					Recommended	%	2		steady			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/17177746/	Homo sapiens						55.8				solution			159	solar lentigines	0.0001			tretinoin	55.8			24	week		
3651	1618		adult				ug	50		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/4853600	Homo sapiens																									
3652	1618						ug	80		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4429085	Homo sapiens										6 monthly cycles of Ortho Novurn SQ* (80 ug of mestranol per day, Days 5 to 18, then 80 ug of mestranol plus 2.0 mg. of norethindrone per day, Days 19 to 24)		26							20			6	month		
3653	1619					Recommended	mg/mL	16		multiple			day	5	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019193s021lbl.pdf	Homo sapiens							max			five inspiratory capacity inhalations				Bronchial airway hyperreactivity											p.1
3654	1623					Highest studied dose	g	1		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/879745	Homo sapiens													10												
3655	1623					Highest studied dose	g	12		single					unhealthy|healthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/26976858	Homo sapiens						54							160						54						
3656	1623						g	12		single					unhealthy|healthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/26976858	Homo sapiens						54							160						54						
3657	1624					Recommended	mg	6		multiple			week	1	healthy	transdermal	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021180s043lbl.pdf	Homo sapiens										A new patch is applied each week for three weeks (21 total days). Week Four is patch-free				Pregnancy prevention	0.75 mg/week			ethinyl estradiol, transdermal				3	week		p.1
3658	1624					Recommended	ug	150		multiple			day	1	healthy	transdermal	F		https://pubmed.ncbi.nlm.nih.gov/11704172	Homo sapiens						28.7				Patch treatment for each cycle was three consecutive 7-day patches (21 days) followed by 1 patch-free week. Of 1672 subjects, 1171 were to receive six cycles of treatment, and 501 were to receive 13 cycles of treatment.A 20-cm2 patch designed to deliver 150 ug norelgestromin and 20 ug ethinyl estradiol daily to the systemic circulation			1672	Pregnancy prevention	20 ug/day			ethinyl estradiol, transdermal				21	day		p.803
3659	1625					Highest studied dose	mg	20		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12255392	Homo sapiens						25							1	Contraception								3	week		p.122
3660	1626					Studied dose	ug	215		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12814811/	Homo sapiens							median			180 ug - 1 week, 215 ug - 1 week, 250 ug - 1 week		40	48		35 ug			ethinyl estradiol	18			21	day		
3661	1626					Studied dose	ug	305		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12814811/	Homo sapiens							mean			180/250 ug alternation after 1 days		40	49		35 ug			ethinyl estradiol	18			21	day		
3662	1626					Studied dose	ug	305		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12814811/	Homo sapiens							mean			180/250 ug alternation after 2 days		40	48		35 ug			ethinyl estradiol	18			21	day		
3663	1627					Studied dose	g	2		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11083648/	Homo sapiens						49.2				mean duration			419	complicated skin and soft tissue infections	500 mg orally; 4 per day			dicloxacillin				13.4	day		
3664	1627					Studied dose	g/day	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24936596/	Homo sapiens						51				median duration			34	complicated bacteremia								31	day		
3665	1627					Studied dose	mg/kg/day	175		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7172968/	Homo sapiens						4.96				mean duration			8	sternal osteomyelitis								7.63	day		
3666	1627					Studied dose	mg/kg/day	175		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7172968/	Homo sapiens						4.96				mean duration			8	submandibular adenitis								7.63	day		
3667	1628						mL	10		single					unhealthy	intraocular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022193lbl.pdf	Homo sapiens								10 mL or 20 mL of intraocular irrigating solution (each mL contains: calcium chloride, magnesium chloride, dextrose, gluthathione disulfide (oxidized glutathione))		10 mL or 20 mL of intraocular irrigating solution (each mL contains: calcium chloride, magnesium chloride, dextrose, gluthathione disulfide (oxidized glutathione))				surgical procedures	10 mL or 20 mL of intraocular irrigating solution (each mL contains: calcium chloride, magnesium chloride, dextrose, gluthathione disulfide (oxidized glutathione))			hypromellose						dextrose	
3668	1629					Highest studied dose	mg	20		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/5395537	Homo sapiens													5	Peptic ulcer											p.13
3669	1629					Recommended	mg	10		multiple			day	3	unhealthy	oral			https://www.mims.com/philippines/drug/info/oxyphencyclimine?mtype=generic	Homo sapiens							max							Peptic ulcer											
3670	1629					Studied dose	mg	5		single					unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/5395537	Homo sapiens													5	Peptic ulcer											p.13
3671	1630		adult			Studied dose	mg	300		steady			day	3	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4193708/	Homo sapiens														pregnancies								1	week		
3672	1630					Studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1185541/	Homo sapiens												41	3						30						
3673	1633		children			Studied dose	ug/mL	52		steady					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/3683877/	Homo sapiens													13	complex partial seizures											
3674	1633					Studied dose	g	1.5		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3956382/	Homo sapiens						16							1	psychomotor retardation					16			18	month		
3675	1633					Studied dose	g	2		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3956382/	Homo sapiens						18							1	psychomotor retardation					18			4	year		
3676	1633					Studied dose	g	2		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/630790/	Homo sapiens						16				1.5 or 2 g			1	uncontrollable psychomotor epilepsy					16			2	month		
3677	1633					Studied dose	g	2.5		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3956382/	Homo sapiens						18							1	psychomotor seizures					18			4	year		
3678	1633					Studied dose	g	3.5		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/630790/	Homo sapiens						16				3 or 3.5 g			1	uncontrollable psychomotor epilepsy					16				month		
3679	1633					Studied dose	g	4		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/630790/	Homo sapiens						23				3 or 4 g			1	uncontrollable psychomotor epilepsy					23			13	month		
3680	1634					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14485373	Homo sapiens						63	mean						1						63			28	day		
3681	1634					Studied dose	mg	75		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14485373	Homo sapiens						53	mean						1						53			28	day		
3682	1635					Overdose	g	5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16554322	Homo sapiens						16							1	Graves' disease											p.2338
3683	1635					Recommended	mg	150		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21234410/	Homo sapiens						34							1	Graves' disease								6	week		p.2
3684	1635					Recommended	mg	150		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9177371	Homo sapiens						14							1	Graves' disease								4	month		p.1727
3685	1635					Recommended	mg	300		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006188s025lbl.pdf	Homo sapiens										The initial dose is 300 mg daily. In patients with severe hyperthyroidism, very large goiters, or both, the initial dose may be increased to 400 mg daily; an occasional patient will require 600 to 900 mg daily initially. The usual maintenance dose is 100 to 150 mg daily. The total daily dosage is usually given in 3 equal doses at approximately 8-hour intervals.				Graves' disease|Hyperthyroidism											p.1
3686	1635					Recommended	mg	300		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/006188s025lbl.pdf	Homo sapiens										The initial dose is 300 mg daily. In patients with severe hyperthyroidism, very large goiters, or both, the initial dose may be increased to 400 mg daily; an occasional patient will require 600 to 900 mg daily initially. The usual maintenance dose is 100 to 150 mg daily. The total daily dosage is usually given in 3 equal doses at approximately 8-hour intervals.				Graves' disease|Hyperthyroidism											p.2
3687	1636					Highest studied dose	mg	15		single					unhealthy	parenteral			https://pubmed.ncbi.nlm.nih.gov/13313540	Homo sapiens													3	hypertension											
3688	1636					Highest studied dose	mg	4		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13313540	Homo sapiens													10	hypertension								2	month		
3689	1637						mg	0.25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17628352	Homo sapiens						41.2				When dose reduction was warranted, participants were given one tablet (0.25 mg tablet of reserpine)			60	cocaine dependence					41.2			12	week		
3690	1637						mg	0.25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17628352	Homo sapiens						41.2							60	cocaine dependence					41.2			12	week		
3691	1638		adult			Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19453292/	Homo sapiens													2200000	various									month		
3692	1638					Higher than recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17664473/	Homo sapiens												76	33	non small-cell lung cancer	250 mg			Gefitinib	44			56	day		
3693	1638					Recommended	mg	12.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17664473/	Homo sapiens												76	6	non small-cell lung cancer	250 mg			Gefitinib	44			56	day		
3694	1638					Recommended	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12495363/	Homo sapiens						66.8	max			12.5 to 25 mg			2896	painful osteoarthritis of the knee or hip					66.8			139	day		
3695	1638					Recommended	mg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17652651/	Homo sapiens													1167	colorectal cancer								7.4	month		
3696	1641		adult			Recommended	mg	500		single			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf	Homo sapiens														malaria	25 mg/3 times/day			pyrimethamine							
3697	1641		adult			Recommended	mg	500		single			day	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18557slr015_fansidar_lbl.pdf	Homo sapiens														malaria				pyrimethamine							
3698	1642					Highest studied dose	g	6		multiple					unhealthy	oral			https://jamanetwork.com/journals/jama/article-abstract/268209	Homo sapiens							starting			The high dose was 6 Gm. followed by 1 Gm. every four hours)			35												
3699	1644		adult			Recommended	mg	1600		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/4936539/	Homo sapiens													14	renal transplantation	320 mg; daily			TRIMETHOPRIM				10	day		
3700	1644					Highest studied dose	mg	2400		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6724874/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-105_Zotrim_medr.pdf	Homo sapiens						20							31	urinary tract infection	480 mg; single			TRIMETHOPRIM				1	day		nda/2001/21-105_Zotrim_medr.pdf - p.54
3701	1644					Recommended	mg	1200		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6794406/	Homo sapiens						47		800 mg; day					26	acute nonlymphocytic leukaemia	240 mg; 2/day			TRIMETHOPRIM						amphotericin B	
3702	1644					Recommended	mg	800		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24268951/	Homo sapiens						86							1	lower urinary infection	160 mg; 2/day			TRIMETHOPRIM	86			2	day		
3703	1644					Recommended	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4885025/	Homo sapiens						58							41	urinary infection	160 mg; 2/day			TRIMETHOPRIM				7	day		
3704	1644					Studied dose	mg	1200		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12963573/	Homo sapiens						69	mean			mean duration; The mean dose of TMP-SMZ was 1400 mg/d (range, 800-2400 mg/d)			91	septicemia	240 mg; day			TRIMETHOPRIM				37	day		
3705	1645		adult			Recommended	%	15		steady			day	1	unhealthy	topical	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/006530s019lbl.pdf	Homo sapiens										vaginal cream				bacterial infection (Candida albicans)								30	day		
3706	1647		adult			Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3741528	Homo sapiens										600 mg sustained release tablets			12												
3707	1647		adult				mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3741528	Homo sapiens										capsule (2 X 200 mg)			12												
3708	1647						mg	400		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6361789	Homo sapiens													41						18						
3709	1648		adult			Recommended	g	0.5		multiple			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens										The ZERBAXA (ceftolozane/tazobactam) for Injection dose was 1 g/0.5 g intravenously every 8 hours, adjusted to match renal function where appropriate.			1015	Infections	1 g; 3/day			ceftolozane							
3710	1648		adult			Recommended	g	0.5		multiple			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens										The ZERBAXA (ceftolozane/tazobactam) for Injection dose was 1 g/0.5 g intravenously every 8 hours, adjusted to match renal function where appropriate.			482	Complicated Intra-abdominal Infections	1 g; 3/day			ceftolozane							
3711	1648		adult			Recommended	g	0.5		multiple			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206829lbl.pdf	Homo sapiens										The ZERBAXA (ceftolozane/tazobactam) for Injection dose was 1 g/0.5 g intravenously every 8 hours, adjusted to match renal function where appropriate.			533	Complicated Urinary Tract Infections, Including Pyelonephritis	1 g; 3/day			ceftolozane							
3712	1648					Recommended	g	0.5		multiple			day	3	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/29517862/	Homo sapiens						39				Study treatment was administered as a 1-hour intravenous infusion.			4		1 g; 3/day			ceftolozane				10	day		
3713	1648						g	1		multiple			day	3	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/29517862/	Homo sapiens						36				3 g (2 g/1 g) ceftolozane/tazobactam q8h is twice higher than approved dose. Study treatment was administered as a 1-hour intravenous infusion.			8		2 g; 3/day			ceftolozane				10	day		
3714	1649		children			Recommended	mg/m2	165		multiple			week	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf	Homo sapiens														acute lymphoblastic leukemia	300 mg/m2, twice weekly for 8 to 9 doses			cytarabine							
3715	1649						mg/m2	60		multiple			3 weeks	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9305702	Homo sapiens						64				60 mg/m2 on 5 consecutive days every 3 weeks			41	small cell lung carcinoma					64			10	course		
3716	1651					Overdose	mg/kg	0.3		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21740144	Homo sapiens													2												
3717	1651					Overdose	ug	15000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8530784	Homo sapiens						41				30 ml of 0.05% Visisne			1						41						
3718	1651					Overdose	ug	250		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20723124	Homo sapiens										3 *0.5 mL/day			1	mild fever								1	day		
3719	1651					Overdose	ug	250		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20723124	Homo sapiens										3 *0.5 mL/day			1									1	day		
3720	1651					Overdose	ug	7500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15388224	Homo sapiens						16				15 mL of Visine (containing 0.05% tetrahydrozoline (500 ug/mL))			1						16						
3721	1652		adult			Recommended	mg/kg	25		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15571478/	Homo sapiens													31	strongyloidiasis								3	day		
3722	1653					Highest studied dose	mg/kg	10		multiple					unhealthy	rectal			https://pubmed.ncbi.nlm.nih.gov/3789788	Homo sapiens							starting			maintenance infusion of 2-4 mg-h-1 -kg-1			15												
3723	1653						mg	500		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2759548	Homo sapiens						31	starting			The initial infusion of thiopental comprised a median dose of 250 mg thiopental (range: 185 to 500 mg). The subsequent maintenance infusions required a rate of between 50 and 250 mg per hr (median: 112.5 mg per hr). The median cumulative dose of thiopental was 6,390 mg.		44	13						19						
3724	1654					Highest studied dose	mg/kg	80		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3777901	Homo sapiens												26	8						22						p.360
3725	1654					Overdose	g	3		multiple			day	5	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Homo sapiens										The usual recommended dosage for systemic and urinary tract infections for adults is 3.1 grams of TIMENTIN (3 grams ticarcillin and 100 mg clavulanic acid) given every 4 to 6 hours				Bacterial infections	>100 mg			ciavuianate potassium iv							p.1
3726	1654					Recommended	g	3		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/4073101	Homo sapiens										Three g of ticarcillin plus 200 mg of clavuianate potassium was administered by intravenous infusion over 20 to 30 minutes every six or eight hours.		91	37	Urinary tract infections	200 mg/kg/day			ciavuianate potassium iv	19						p.90
3727	1654					Recommended	g	3		multiple			day	5	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050590s069,050658s031lbl.pdf	Homo sapiens										The usual recommended dosage for systemic and urinary tract infections for adults is 3.1 grams of TIMENTIN (3 grams ticarcillin and 100 mg clavulanic acid) given every 4 to 6 hours				Bacterial infections	100 mg			ciavuianate potassium iv				14	week		p.1
3728	1655					Highest studied dose	mg/kg	2		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6970261	Homo sapiens										a loading dose of 1-2 mg/kg was infused over a 15-min period through, thereafter, an infusion of 1-2 mg/kg/hr was administered. The infusion was continued for a maximum of 8 hr if no effect had been achieved			47									8	hour		
3729	1656					Studied dose	g	24		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18896724	Homo sapiens													1	tetanus											
3730	1656						g	0.3		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20995214	Homo sapiens						23	starting			A month later no benefits had been noted and the dosage of Tridione was increased to five times daily			1	petit mal seizures	4 grains (0.25 Gm.) daily			phénobarbital	23			10	month		
3731	1656						g	0.3		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20995214	Homo sapiens						23	starting			A month later no benefits had been noted and the dosage of Tridione was increased to five times daily			1	petit mal seizures					23			10	month		
3732	1656						mg	150		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13760024	Homo sapiens						16							1	petit mal seizures	15 mg. four times daily.			phenobarbital	16			3	week		
3733	1657		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12846423/	Homo sapiens						53						75	22	breast cancer					36			6	month		391-7
3734	1657		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9652997/	Homo sapiens							max|total daily dose			6 and 16 weeks duration		65	2	diabetes mellitus	40 mg/day		lisinopril	atenolol	44		20 mg/day	6	week	furosemide	36-8
3735	1657		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9652998/	Homo sapiens						55							1	type 2 diabetes mellitus								3.5	month		38-41
3736	1658					Recommended	g	2		multiple			day		unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3496378	Homo sapiens						62							1	bronchitis								7	day		p.327
3737	1659					Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_medr_P3.pdf	Homo sapiens										duration 1-3 months			430	Rheumatoid arthritis								3	month		p.71
3738	1659					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_medr_P2.pdf	Homo sapiens												92	420	Rheumatoid arthritis					18			26	week		p.28
3739	1659					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://ec.europa.eu/health/documents/community-register/2005/200501269150/anx_9150_en.pdf	Homo sapiens														Osteoarthritis | Adult rheumatoid arthritis											p.3
3740	1659					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf	Homo sapiens														Osteoarthritis | Adult rheumatoid arthritis											p.1
3741	1659					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf	Homo sapiens														Osteoarthritis | Adult rheumatoid arthritis											p.1, 9
3742	1659					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf	Homo sapiens														Osteoarthritis | Adult rheumatoid arthritis											p.9
3743	1659					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_medr_P3.pdf	Homo sapiens							max			10-20 mg/day, combined; duration 1-3 months			1114	Rheumatoid arthritis								3	month		p.70
3744	1659					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17133774	Homo sapiens						32.3				40 mg twice daily on day 1 followed by 40 mg once daily on days 2 – 7 for 7 days. (The maximum recommended dose is 40 mg once daily https://ec.europa.eu/health/documents/community-register/2004/200411258827/anx_8827_en.pdf)			101	Acute ankle sprain								7	day		p.462
3745	1659					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-341_Bextra_medr_P3.pdf	Homo sapiens										duration 1-3 months			430	Arthritis								3	month		p.69
3746	1660					Highest studied dose	mg/kg	0.06		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2536257	Homo sapiens						42							18	HIV infection								12	week		p.191
3747	1660					Overdose	mg	1.5		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens										Eighty percent of patients who received approximately 2 times the current total daily recommended dose experienced peripheral neuropathy by week 12				HIV infection								12	week		p.18
3748	1660					Overdose	mg	4.5		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens										In the early Phase 1 studies, all patients receiving zalcitabine at approximately 6 times the current total daily recommended dose experienced peripheral neuropathy by week 10				HIV infection								10	week		p.18
3749	1660					Overdose	mg/kg	0.25		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens										25 times (0.25 mg/kg every 8 hours) the currently recommended dose				HIV infection								1.5	week		p.18
3750	1660					Recommended	mg	0.75		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens														HIV infection											p.1
3751	1660					Recommended	mg	0.75		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens														HIV infection											p.1, p.7
3752	1660					Recommended	mg	0.75		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s014lbl.pdf	Homo sapiens														HIV infection											p.7
3753	1660						mg/kg	0.03		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2536257	Homo sapiens						42							18	HIV infection								12	week		p.191
3754	1660						mg/kg	0.09		multiple			day	6	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2558314	Homo sapiens										The patients were then given ddC (Zalcitabine) intravenously for 14 days according to the following regimens: 0.09 mg/kg every 4 h; dose was administered over 1 h. Patients who completed the intravenous therapy then received oral ddC at the same dose schedule for an additional 4 weeks. Patients who tolerated this initial 6-week period of therapy were given the option of continuing on oral ddC for an additional 6-8 weeks.		57	5	HIV infection					26			2	week		p.858
3755	1662					Overdose	mg	2000		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29124988	Homo sapiens						67		1600 mg oral; single					1	Headache	13000 mg oral; single		codeine	acetylsalicylic acid			1200 mg oral; single			caffeine	p.1,2
3756	1662					Recommended	mg	100		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/3244271	Homo sapiens								80 mg oral				41	5		660 mg oral			acetylsalicylic acid	27					caffeine	
3757	1663					Highest studied dose	mg	10		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens												52	24						18						
3758	1663					Highest studied dose	mg	10		single					healthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens												52	24						18						
3759	1663					Highest studied dose	mg	20		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3709625	Homo sapiens												52	12						18						
3760	1664		adult				mg	100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4606631	Homo sapiens													9									1	month		
3761	1665					Overdose	g	15		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14446369	Homo sapiens						24				30 tablets of """"""""""""""""valmidate""""""""""""""""			1						24						
3762	1666					Overdose	g	30		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5897795	Homo sapiens						36				one hundred 300-mg capsules of methyprylon			1		one hundred 50-mg capsules			dimenhydrinate	36						
3763	1667		adult			Highest studied dose	ug	400		multiple			day	2	healthy	intranasal	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019886s030lbl.pdf	Homo sapiens													18									22	day		
3764	1667		children			Highest studied dose	ug	600		multiple			day	1	unhealthy	intranasal	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019886s030lbl.pdf	Homo sapiens													155	early puberty								80	month		
3765	1669						mg	80		multiple			day	3	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/13688462	Homo sapiens						58				For the next 20 months the patient received pentolinium in doses varying between 40 and 70 mg. three times daily.			1	hypertension					58			20	month		
3766	1670		ADULT			Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10192753/	Homo sapiens												32	18						19			1	day		929-35
3767	1670		ADULT			Highest studied dose	mg/m2	400		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9815633/	Homo sapiens						64							22	cancer								56	day		2347-54
3768	1671		ADULT			Studied dose	mg/kg	2		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20629974/	Homo sapiens										second dose administered 30-45 days apart in patients undergoing photodynamic therapy.			19	cancer								2	month		
3769	1671		ADULT			Studied dose	mg/kg	2		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20629974/	Homo sapiens													24	cancer											
3770	1675					Recommended	mg/kg	96.3		multiple			day	2	unhealthy	oral	M+F		https://ojrd.biomedcentral.com/articles/10.1186/s13023-016-0406-2	Homo sapiens													21	methylmalonic aciduria								15	day		
3771	1680		adult			Highest studied dose	mg	800		multiple					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/33852164	Homo sapiens							total			chewed caffeine gum for 5 minutes at 2-hour intervals over a 6-hour treatment period (800 mg total caffeine)			12												
3772	1680		adult			Overdose	g	24		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/24079989	Homo sapiens													1												
3773	1680					Overdose	g	1.6		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25632790	Homo sapiens						44							1						44						
3774	1680					Overdose	g	12.4		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/30734410	Homo sapiens						14				taking 124 Estaron Mocha tablets (SS Pharmaceutical, Tokyo, Japan; 12.4 g caffeine)			1						14						
3775	1680					Overdose	g	50		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/23396922	Homo sapiens						27							1						27						
3776	1680					Overdose	mg	4000		single					pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/32021978	Homo sapiens						33				ingested 200 caffeine tablets containing approximately 4000 mg of caffeine			1						33						
3777	1680					Overdose	mg	5000		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29884665	Homo sapiens						32	total			total of 5000 mg (89mg/kg)			1						32						
3778	1680					Recommended	mg/kg	20		multiple			day	1	unhealthy	intravenous|oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020793_000_Cafcit_Medr.pdf	Homo sapiens							starting			20 mg/kg caffeine citrate providing 10 mg/kg as caffeine base) loading dose was administered intravenously, followed by a 0.25 mL/kg (5 mg/kg caffeine citrate providing 2.5 mg/kg of caffeine base) daily maintenance dose administered orally			2									5	day		p.25
3779	1681					MTD	mg	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30604205/	Homo sapiens						44							15	familial Mediterranean fever					44						
3780	1681					Overdose	mg	12		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/31348292	Homo sapiens						56				12mg (0.17mg/kg)			1						56						
3781	1681					Overdose	mg	50		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/33128536	Homo sapiens						42				50 mg (approximately 0.7 mg/kg)			1						42						
3782	1681					Overdose	mg/kg	0.4		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/32923329/	Homo sapiens						19							1		50 tablets, single			Procydin	19						
3783	1681					Recommended	mg	1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17692130	Homo sapiens						79							1						79			2	day		
3784	1681						mg	1		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30604205	Homo sapiens						44				infused during 10–20 min, on a weekly basis			15	familial Mediterranean fever					44			12	month		
3785	1682						mg	27		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/671679/	Homo sapiens						48				a case report			1												
3786	1682						mg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/2670244/	Homo sapiens						63				a case report			1	heart failure											
3787	1682						mg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/671679/	Homo sapiens						46				a case report			1												
3788	1682						mg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/671679/	Homo sapiens						66				a case report			1												
3789	1682						mg/kg	0.5		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/671679/	Homo sapiens						70				a case report			1												
3790	1683					Highest studied dose	mg/kg	15		single					healthy	oral	M+F		https://www.epa.gov/sites/production/files/2017-01/documents/ache_white_paper_for_hsrb_122016.pdf	Homo sapiens												50	34						18						
3791	1683					Highest studied dose	mg/m3	85		single					healthy	respiratory			https://www.fs.fed.us/foresthealth/pesticide/pdfs/0520202c_Malathion.pdf	Homo sapiens																									p. 24
3792	1683					Lethal dose	mg/kg	1000		single					healthy	oral			https://www.fs.fed.us/foresthealth/pesticide/pdfs/0520202c_Malathion.pdf	Homo sapiens																									p.20
3793	1683						g	1.8		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3612901	Homo sapiens						24							1						24						
3794	1685		adult			Recommended	mg/h	0.2		multiple			day	1	unhealthy	transdermal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020145s027lbl.pdf	Homo sapiens							starting						307									1	month		
3795	1685		adult				mg	1.5		multiple			day	2	unhealthy	rectal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021359s000lbl.pdf	Homo sapiens										1 inch of ointment (375 mg of ointment equivalent to 1.5 mg of nitroglycerin) intra-anally every 12 hours for up to 3 weeks												3	week		
3796	1685		pediatric				ug/kg	5		single			day	1	unhealthy	subcutaneous			https://pubmed.ncbi.nlm.nih.gov/32282432	Homo sapiens													57												
3797	1685					Highest studied dose	mg/h	0.6		multiple			day	1	unhealthy	transdermal	F		https://pubmed.ncbi.nlm.nih.gov/26263283	Homo sapiens						51.4							11	menopausal hot flashes								1	week		
3798	1685					Overdose	mg	40		single					unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021134s009lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/6771417	Homo sapiens						80				one hundred 0.4-mg nitroglycerin tablets			1	angina pectoris					80			36	hour		
3799	1685						%	2		multiple			day	6	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/110268	Homo sapiens										2% topical nitroglycerin ointment, 1.27 cm (0.5 in) every six hours, spread over a 15.2 x 15.2-cm (6 x 6-in) area.		71	2						57			2	day		
3800	1685						ug/kg/min	1		multiple					pregnant	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9916961	Homo sapiens						26	starting			Nitroglycerin was administered as a 100-ug bolus, then at an initial infusion rate of 1 ug/kg/min. The infusion rate was increased incrementally, as needed, to a maximum rate of 10 ug/kg/min to control contractions.			16	Preterm labor					26						
3801	1685						ug/kg/min	35		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18680075	Homo sapiens						50				0.1 mg, then 35 ug/kg per minute intravenously (maximum dose 9 mg) for 6 h			105						50			6	hour		
3802	1685						ug/kg/min	8		multiple					pregnant	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9916961	Homo sapiens						26				Nitroglycerin was administered as a 100-ug bolus, then at an initial infusion rate of 1 ug/kg/min. The infusion rate was increased incrementally, as needed, to a maximum rate of 10 ug/kg/min to control contractions.			1	Preterm labor					26						
3803	1686					Highest studied dose	mg	250		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13520609	Homo sapiens												73	13	Heart failure					48			14	day		p.499
3804	1686					Recommended	mg	125		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13817990	Homo sapiens										In the majority of patients 125 mg. of ethoxzolamide was administered, in addition to the miotic regimen, at six hourly intervals. A number of patients required only 62.5 mg. every six hours and one patient tolerated only 31.5 mg. of ethoxzolamide three times a day and 62.5 mg. at night.			18	Chronic simple glaucoma								12	month		p.149/433
3805	1686					Recommended	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13520609	Homo sapiens										Ethoxzolamide is supplied in a 125 mg tablet and prescribed in doses of 62.5–250 mg every 4–8 hours. (https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/ethoxzolamide)		73	13	Heart failure					48			14	day		p.499
3806	1689		ADULT			Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8489205/	Homo sapiens						63.4							48	Parkinson's disease								6	week		p.352, 353
3807	1692		ADULT			Highest studied dose	mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens						32						45	18						19						p.402
3808	1692		ADULT				mg	125		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12968984/	Homo sapiens						31						49	6						22			10	day		p.402
3809	1693		adult			Highest studied dose	ug	80		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10828309/	Homo sapiens													3									4	day		
3810	1693		adult			MTD	ug/m2	7		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10828309/	Homo sapiens							median						36	advanced cancer								5	day		
3811	1693		adult			Studied dose	ug	15		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10828309/	Homo sapiens							median						13									16	day		
3812	1693		adult			Studied dose	ug/m2	12.5		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10828309/	Homo sapiens							median						36	advanced cancer								5	day		
3813	1693					Highest studied dose	ug/m2	17.7		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9662243/	Homo sapiens							median			0.15 and 17.0 microg m(-2) day(-1)		65	3	advanced breast					45			90	day		
3814	1693					MTD	ug/m2	7		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9662243/	Homo sapiens							median			0.15 and 17.0 microg m(-2) day(-1)		80	36	advanced breast and colorectal cancer					44			90	day		
3815	1694					Highest studied dose	mg	1600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21625235	Homo sapiens						61				Oral tipifarnib was administered twice daily on days 1–7 and days 15–21 of each 28-day cycle.			6	acute myeloid leukemia					61			28	day		
3816	1694					MTD	mg	1200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21625235	Homo sapiens						61				Oral tipifarnib was administered twice daily on days 1–7 and days 15–21 of each 28-day cycle.			13	acute myeloid leukemia					61			28	day		
3817	1694					MTD	mg/m2	125		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18417739	Homo sapiens						5.9							17	brainstem glioma					5.9			21	day		
3818	1694					MTD	mg/m2	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										21 days followed by a 7-day rest period for a 28-day treatment cycle		18	12	neurofibromatosis type I | plexiform neurofibromas					4			21	day		
3819	1694					MTD	mg/m2	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										continuous dosing with no rest		18	6	neurofibromatosis type I | plexiform neurofibromas					4			28	day		
3820	1694					Recommended	mg/m2	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20860038/	Homo sapiens						8.5				300 mg/m2/dose administered twice daily for 21 days, repeated every 28 days is the recommended dose for children with hematological malignancies		15	18	refractory hematological malignancies					1.5			21	day		
3821	1694						mg	1400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21625235	Homo sapiens						61				Oral tipifarnib was administered twice daily on days 1–7 and days 15–21 of each 28-day cycle.			6	acute myeloid leukemia					61			28	day		
3822	1694						mg/m2	150		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18417739	Homo sapiens						5.9	starting						17	brainstem glioma					5.9			21	day		
3823	1694						mg/m2	150		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18417739	Homo sapiens						5.9	starting						3	brainstem glioma					5.9			21	day		
3824	1694						mg/m2	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										continuous dosing with no rest		18	6	neurofibromatosis type I | plexiform neurofibromas					4			28	day		
3825	1694						mg/m2	275		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										21 days followed by a 7-day rest period for a 28-day treatment cycle		18	12	neurofibromatosis type I | plexiform neurofibromas					4			21	day		
3826	1694						mg/m2	375		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										21 days followed by a 7-day rest period for a 28-day treatment cycle		18	6	neurofibromatosis type I | plexiform neurofibromas					4			21	day		
3827	1694						mg/m2	375		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16421428	Homo sapiens										DLT was developed during cycle 6		18	6	neurofibromatosis type I | plexiform neurofibromas					4			21	day		
3828	1695		ADULT			Highest studied dose	g	430		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/795261/|https://pubmed.ncbi.nlm.nih.gov/21994147/	Homo sapiens							max|total daily dose						52									64	day		217-39|2468-72
3829	1695		ADULT			Overdose	g	500		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/32357847/	Homo sapiens						39							1	psychotic disorder								8	day		157
3830	1696		adult			Highest studied dose	g	10		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/18123174	Homo sapiens														psoriasis								3	week		
3831	1696						%	2		multiple			day	1	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/832943	Homo sapiens										powder containing 20% zinc undecylenate and 2% undecylenic acid in talc.			29	TINEA PEDIS	0.2			zinc undecylenate				5	week		
3832	1696						g	1		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/18123174	Homo sapiens												14	4	psoriasis | NEURODERMATITIS					8			2	month		
3833	1696						g	2.2		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15412274	Homo sapiens						56				5 capsules of 0.44 grams each three times a day			1	psoriasis	50 mgm. morning and night			nicotinic acid	56			3	day		
3834	1698					Highest studied dose	g	6		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28841667	Homo sapiens						22.4							10									12	week		
3835	1700		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01409096	Homo sapiens										This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.			38	Bipolar Disorder								12	week		
3836	1700		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01898013	Homo sapiens										Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued.			45	Lower Back Pain								5	week		
3837	1700		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01956279	Homo sapiens										Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days			82	Gulf War Illnesses								8	week		
3838	1700					Highest studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24849255	Homo sapiens						22.5				was initiated at a dose of 50 mg twice daily for the first 2 weeks and was increased by 50 mg twice daily every 2 weeks until reaching the maximal dosage of 250 mg twice daily from weeks 9 to 12.			12	Autism Spectrum Disorder					22.5			3	week		
3839	1707					Overdose	mg	30		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1578320	Homo sapiens						4				30 mg of astemizole (1.7 mg/kg)			1						4						
3840	1707					Overdose	mg	740		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8189766	Homo sapiens						22							1						22						
3841	1707					Overdose	mg/kg	6		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/1578320	Homo sapiens						1.5							1						1.5						
3842	1711					Highest studied dose	mg/kg	25		multiple			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29392450	Homo sapiens						58				day 1 and 8 on a 21-day cycle			2	advanced solid tumor malignancies					58			80	day		
3843	1711					MTD	mg/kg	18		multiple			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29392450	Homo sapiens						58				day 1 and 8 on a 21-day cycle. MTD as determined by investigators			6	advanced solid tumor malignancies					58			80	day		
3844	1711					Recommended	mg/kg	2.4		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf	Homo sapiens							complex			IV at 0 hours, 12 hours, 24 hours, and 48 hours followed by oral antimalarial therapy		72	92	malaria					1			2	day		
3845	1711					Recommended	mg/kg	2.4		multiple			day	1	unhealthy	intravenous|oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/16125588/	Homo sapiens							complex			IV at 0, 12 and 24 hours and then every 24 hours until the patient could tolerate oral medication (median 4 doses were given), then oral 7 for 7 days		87	730	malaria					2			7	day		
3846	1711					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8205643/	Homo sapiens										200 mg of artesunate as an initial dose, followed by 100 mg 12 hours later, and 100 mg daily		35	31	Uncomplicated Malaria					15			5	day		
3847	1711					Studied dose	mg/kg	12		multiple			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29392450	Homo sapiens						58				day 1 and 8 on a 21-day cycle			6	advanced solid tumor malignancies					58			80	day		
3848	1713						%	20		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/18971079 | https://pubmed.ncbi.nlm.nih.gov/17694687	Homo sapiens										gel impregnated on a stick that the patient was asked to take into her mouth or spray topically		71	2						17						
3849	1713						mg	8		multiple			2 hours	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20533760	Homo sapiens						49.4				Each patient took a total of six doses within 12 h			246						49.4			6	times		
3850	1714					Highest studied dose	mg	1600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3304952	Homo sapiens												60	10	Familial hypercholesterolaemia	16g, b.i.d			Cholestyramine, p.o	36			3	month		p.132
3851	1716		ADULT			Studied dose	%	3		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31353997/	Homo sapiens													59	soft-tissue injuries				ibuprofen							
3852	1718					Highest studied dose	mL	60		multiple			day	1	unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/32593381 | https://pubmed.ncbi.nlm.nih.gov/3452163/	Homo sapiens										maximum concentration of 0.8% and 60 ml of methoxyflurane			2									14	day		
3853	1718						mL	2		multiple			day	2	unhealthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/3971205	Homo sapiens										1-2 times a day			1									6	week		
3854	1720		ADULT			Higher than recommended	g	1.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19337387/	Homo sapiens						49							7	insulin resistance											p.40
3855	1720		ADULT			MTD	g	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19337387/	Homo sapiens						51							8	type 2 diabetes								1	month		p.40
3856	1720		ADULT			Recommended	g	1.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8595635/	Homo sapiens						57						94	771	arthritis					19			3	week		p.833
3857	1722		adult				g	1.5		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/2314425	Homo sapiens							median															2	week		
3858	1722					Highest studied dose	g	10		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/4541674	Homo sapiens												40							18						
3859	1722						mg	1800		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2219890	Homo sapiens						52	mean			daily dose range: 750 - 3500 mg			7						52			39	month		
3860	1726		ADULT			Accidental dose	mg	1500		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/24569128/	Homo sapiens							max			1125–1500 mg			1												
3861	1726		ADULT			Accidental dose	mg	3750		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/24569128/	Homo sapiens							max			450–3750 mg			6												
3862	1726		ADULT			Accidental dose	mg	750		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/19821637/	Homo sapiens							max			375-750 mg			1						46						
3863	1726		ADULT			Accidental dose	mg	750		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/24569128/	Homo sapiens							max			375–750 mg			1												
3864	1726		ADULT			Studied dose	mg	7.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26872077/	Homo sapiens												64	31	insomnia					20			4	week		
3865	1727		ADULT			Lethal dose	g	2		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/493954/	Homo sapiens						23							1		2 g			aminophylline						ephedrine	p.246
3866	1727		ADULT			Overdose	g	15		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12458639/	Homo sapiens						29							1												
3867	1728		ADULT			Overdose	mg	180		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/20040343/	Homo sapiens						73							1		900 ng/ml at admission			zolpidem							
3868	1728		ADULT			Overdose	mg	220		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27663828/	Homo sapiens						37							1	anxiety											
3869	1728		ADULT			Overdose	mg	9		steady			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1292648/	Homo sapiens						41							1	anxiety								2	day		
3870	1728		ADULT			Recommended	mg	1.5		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2571196/	Homo sapiens												90	7	anxiety					70			9	day		
3871	1728		ADULT			Recommended	mg	6		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20667143/	Homo sapiens						82							1	anxiety								2	year		
3872	1728		ADULT			Studied dose	mg	5		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/237849/	Homo sapiens												69	30	anxiety					22			3	week		
3873	1729		ADULT			Highest studied dose	mg	300		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24692809/	Homo sapiens						24						27	9						22						p.329
3874	1729		ADULT			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15231450/	Homo sapiens						68.9	max|total daily dose			a multiple-dose regimen of a soy isoflavone formulation (delivering approximately 300 or 600 mg/day genistein and half this much daidzein) for 84 days.		82	20	prostate cancer	300 mg			daidzein	53			84	day		p.164, 165
3875	1731					Highest studied dose	ug/kg	59		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15652790	Homo sapiens						45							1						45						
3876	1731					Studied dose	g	0.008		multiple			day	4	healthy	oral	M		https://jamanetwork.com/journals/jama/article-abstract/278354	Homo sapiens						28							5						28						
3877	1732		ADULT			Highest studied dose	mg	750		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17532963/	Homo sapiens						65							301	cardiovascular system disease								30	day		p.1606
3878	1736					Studied dose	%	1		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/13826897/	Homo sapiens						22				patch test			1						22			1	day		
3879	1736					Studied dose	g	2.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5567745/	Homo sapiens						35							8	intestinal capillariasis								12	day		
3880	1738		adult			Overdose	g	2		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4443787	Homo sapiens										ate 2-3g of cocaine hydrochloride			1												
3881	1738		adult			Recommended	mg	160		single					unhealthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf	Homo sapiens										The recommended dose of GOPRELTO is two soaked cottonoid pledgets placed in each nasal cavity, equivalent to 40 mg cocaine hydrochloride per pledget, for a total dose of 160 mg for four pledgets.															
3882	1738					Highest studied dose	%	8		single					unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf	Homo sapiens						45				total dose 320 mg		83	275						17						p. 56, 74
3883	1738						mg	25		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8926741	Homo sapiens												43	6						30						
3884	1738						mg	32		single					healthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/8926741	Homo sapiens												43	6						30						
3885	1738						mg	42		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/8926741	Homo sapiens												43	6						30						
3886	1740					Overdose	mg	10		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5297643/	Homo sapiens						11							1	Hypoparathyroidism								4	week		p.896, 897
3887	1740					Overdose	mg	4		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12751020/	Homo sapiens						31							1	Hypoparathyroidism											
3888	1740					Overdose	mL	2.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20507648	Homo sapiens						74							1	Hypoparathyroidism								7	week		p.2
3889	1740					Overdose	mL	2.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20507648	Homo sapiens						74							1	Hypoparathyroidism								7	week		p.5
3890	1742					Studied dose	mg	75		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3092623	Homo sapiens						57							111	Ventricular Arrhythmias					57			10	day		
3891	1742						mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3083665	Homo sapiens												83	17	benign or potentially lethal ventricular arrhythmias					24			2	week		
3892	1743		ADULT			Highest studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22978309/	Homo sapiens						52.3							126	asthma								6	month		849-53
3893	1745		ADULT			Highest studied dose	g	10		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10660865/	Homo sapiens							total daily dose			two equal doses			7									10	day		333-44
3894	1747					Recommended	mg	325		multiple			episode	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1107267/	Homo sapiens						49				two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months			25	migraine	325 mg; two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules in four hours; during 2 weeks to 2 months			acetaminophen				2	month		
3895	1747					Recommended	mg	65		multiple			hour	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11318886/	Homo sapiens						40.9		1625 mg per 12 h		two capsules at once, followed by one capsule every hour until relieved, up to 5 capsules within a twelve hour period			65	migraine	500 mg per 12 h			dichloralphenazone				5	times	acetaminophen	
3896	1747					Studied dose	mg	120		multiple			episode	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22288671/	Homo sapiens								120 mg				65	76	primary headache	1200 mg			dipyrone	18			6	week	caffeine	
3897	1747					Studied dose	mg	780		multiple			episode	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1100566/	Homo sapiens						33				Patients were seen at intervals ranging from two weeks to two months.			36	migraine								4	episode		
3898	1749					Highest studied dose	g	10		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/61500	Homo sapiens							max|total			30 patients at risk of hepatic damage from paracetamol (acetaminophen) ingestion were given 2-5 g oral methionine every four hours up to a total dose of 10 g.			30	Acetaminophen toxicity											p.829
3899	1749					Studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15477550	Homo sapiens						42.5				Dose higher than recommended			28	AIDS-associated myelopathy											p.1273
3900	1749					Studied dose	g	3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9674817	Homo sapiens										Dose higher than recommended		62	12	AIDS-associated myelopathy					31			6	month		p.267
3901	1750					MTD	mg/kg	128		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26927672/	Homo sapiens						72.7							4	Essential tremor					72.7						
3902	1754		ADULT			Highest studied dose	g	20		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20572756/	Homo sapiens												45	5						24			1	day		509-15
3903	1754		ADULT			Highest studied dose	mg/h	30000		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9527195/	Homo sapiens						69.6						80	11	coronary heart disease					40			1	day		684-90
3904	1756					Studied dose	g	0.9		multiple			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5327673/	Homo sapiens												44	10						18			1	day		
3905	1756					Studied dose	g	1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/831357/	Homo sapiens						56				5 or 6 phenacetin-containing analgesic tablets daily. at least 6 Kg. of phenacetin during 20 years			1	knee pain					56			20	year		
3906	1756					Studied dose	g	1.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6025701/	Homo sapiens						34							1	migraine					34			9	year		
3907	1756					Studied dose	mg	250		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5915057/	Homo sapiens						54		10 mg; 40 years					1	migraine	250 mg; 40 years			acetylsalicylic acid	54			40	year	codeine phosphate	
3908	1756					Studied dose	mg	625		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21318943/	Homo sapiens						85	mean			500 - 750 mg			1	migraine					85			40	year		
3909	1757		adult			Highest studied dose	g	8.2		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6853713/	Homo sapiens							total			The doses of phenylalanine was 1.56, 3.13, 6.25, and 12.5 mmol/h; over a 4-h period			1												
3910	1757						g	1.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3995775	Homo sapiens						36													36						
3911	1759					Highest studied dose	mg/kg	40		single					healthy	oral	M		https://www.ncbi.nlm.nih.gov/books/NBK396259/|https://pubmed.ncbi.nlm.nih.gov/759070	Homo sapiens													5												
3912	1760					Highest studied dose	mg	180		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11488779	Homo sapiens										three times the recommended dose		40	24						18						p.203
3913	1760					Highest studied dose	mg	240		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2574627	Homo sapiens												47	12						23						p.610
3914	1760					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9338537	Homo sapiens												66	41	Adverse reactions to specific immunotherapy with Hymenoptera venom					19			50	week		p.462
3915	1760					Recommended	mg	60		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2884152	Homo sapiens												45	24	Seasonal allergic rhinitis					18			14	day		p.69
3916	1760					Recommended	mg	60		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9129557	Homo sapiens												40	12						23						p.406
3917	1769		ADULT			Recommended	mg	100		multiple			2 days	1	unhealthy	oral	M+F		https://www.lundbeck.com/content/dam/lundbeck-com/americas/canada/products/files/clopixol_product_monograph_english.pdf	Homo sapiens							max|total daily dose			For acute psychosis, the usual starting dose of Clopixol tablets is 10-50 mg/day, which may be increased by 10-20 mg every 2-3 days, according to the patient’s response. The usual therapeutic range is 20 mg to 60 mg daily. Daily dosage higher\nthan 100 mg is not recommended.				schizophrenia											p.4
3918	1769		ADULT			Recommended	mg	600		multiple			4 weeks	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/1681680/	Homo sapiens						39	max			Zuclopenthixol decanoate; 100-600 mg every 4 weeks			34	schizophrenia								9	month		p.17
3919	1773		ADULT			Higher than recommended	mg/kg	20		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/20302582/	Homo sapiens						37.5						68	37	psoriasis					19			8	week		p.1362
3920	1773		ADULT			Recommended	mg/kg	4		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11952541/	Homo sapiens						44						76	304	psoriasis					15			18	month		p.419
3921	1776		ADULT			Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2906457/	Homo sapiens						25							10									1	day		135-41
3922	1776		ADULT			Recommended	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2905241/	Homo sapiens												80	218	gastric ulcer					18			8	week		127-33
3923	1778		ADULT			Highest studied dose	ug	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33339609/	Homo sapiens						43.8				started 48 h before surgery			45	heart valve disease								6	day		e1-e18
3924	1778		ADULT			Highest studied dose	ug	3		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21401359/	Homo sapiens						49	total weekly dose			1/week - 3 ug or 3/week - 1 ug			36	hyperparathyroidism								6	month		329-33
3925	1778		ADULT			Recommended	ug	1		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30461612/	Homo sapiens						70							62	osteoporosis	500 mg			calcium				9	month		e13159
3926	1779					Highest studied dose	mg	20		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/28801850	Homo sapiens													18												
3927	1779					Highest studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28793958	Homo sapiens													20												
3928	1779					Overdose	g	6		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20531221	Homo sapiens						29				range: 1.2-120 g		40	23						23						
3929	1779					Overdose	g	6		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20531221	Homo sapiens						29				range: 1.2-120 g		40	49						23						
3930	1779					Overdose	g	80		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20531221	Homo sapiens						29				range: 1.2-120 g		40	49						23						
3931	1779					Overdose	mg	1200		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf	Homo sapiens																									
3932	1779					Overdose	mg	3000		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7779461	Homo sapiens													1												
3933	1780		ADULT			Recommended	mg	1000		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2188276/	Homo sapiens						51							19	psychotic disorder								3	month		p.46
3934	1780		ADULT			Recommended	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1822317/	Homo sapiens						71.1							55	senile dementia								6	month		p.515
3935	1782		ADULT			Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3912186/	Homo sapiens						45							27	asthma								14	day		425-7
3936	1782		ADULT			Highest studied dose	mg/kg	0.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3061311/	Homo sapiens						47.6							22	asthma								7	day		573-6
3937	1783		ADULT			Higher than recommended	ug	120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31119846/	Homo sapiens													300	chronic kidney disease								4	year		p.8
3938	1783		ADULT			Higher than recommended	ug	200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12821234/	Homo sapiens						42	max						60	pulmonary hypertension								12	month		p.2122
3939	1784		adult			Overdose	mg	728		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17061910/	Homo sapiens													1												
3940	1784					Highest studied dose	mg	72		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1958439/	Homo sapiens												31	12						20			3	day		
3941	1785		ADULT			Overdose	mg	200		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7870241/	Homo sapiens													1	hyperlipidemia					64			8	week		
3942	1785		ADULT			Overdose	mg	400		multiple			week	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7870241/	Homo sapiens										400 mg every second day			1	hyperlipidemia					63			8	week		
3943	1786		ADULT			Recommended	%	1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1458667/	Homo sapiens													51	dermatomycosis								4	week		p.58, 59, 60
3944	1787		ADULT			Highest studied dose	mg	80		multiple			day	1	unhealthy	transdermal	M+F		https://pubmed.ncbi.nlm.nih.gov/31471246/	Homo sapiens						40.6							194	schizophrenia								6	week		p.410
3945	1787		ADULT			Studied dose	mg	8		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23417765/	Homo sapiens												40	10						18			7	day		p.138
3946	1788		ADULT			Higher than recommended	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6127218/	Homo sapiens						39	max					53	13	hypertension					25			12	week		p.492
3947	1788		ADULT			Recommended	mg	2		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2866965/	Homo sapiens						54	max					63	13	essential hypertension					35			1	year		p.284
3948	1788		ADULT			Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2906897/	Homo sapiens						50							30	hypertension								28	day		p.436
3949	1790		ADULT			Highest studied dose	mg	800		multiple			day	4	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33982445/	Homo sapiens						27.2	max						14												p.1972
3950	1794		ADULT			Highest studied dose	g	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/365537/	Homo sapiens						59							20	bronchitis											p.179
3951	1794		ADULT			Studied dose	g	2.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8739489/	Homo sapiens						60.7							223	bronchitis											p.5
3952	1795					Highest studied dose	mg/kg	61.5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205750Orig1s000MedR.pdf	Homo sapiens													1												p. 58
3953	1795					Recommended	mg/kg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205750lbl.pdf	Homo sapiens												36	31	single enzyme defects					19			3	year		
3954	1796		ADULT			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9140677/	Homo sapiens						52.9	max						6	hypertension								2	week		43-8
3955	1797		CHILD			Overdose	mg	225		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/16636115/	Homo sapiens						2.5							1												
3956	1797					Studied dose	mg	150		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1504403/	Homo sapiens							mid range			150 mg/day-40 mg/kg		57	4	Vertigo, vestibular disorder					50			1	year		
3957	1797					Studied dose	mg	75		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10190745/	Homo sapiens						81								tinnitus								4	week		
3958	1797					Studied dose	mg	75		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18286231/	Homo sapiens												60	67	migraine					13			12	week		
3959	1798		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9015467/	Homo sapiens						56.3						69	83	hyperlipidaemia					25			8	week		p.742
3960	1799		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2946604/	Homo sapiens										daily from days 5 to 25 of each month for 12 months			76	hirsutism								10	day		
3961	1799		children			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9337516/ | https://pubmed.ncbi.nlm.nih.gov/11393581/	Homo sapiens										mean duration of CPA use				precocious puberty								2.7	year		
3962	1799					Recommended	mg	200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19249153/	Homo sapiens						72.6							293	prostate cancer	monthly depot injections			LHRH analogue				1	month		
3963	1799					Recommended	mg	300		multiple			day	1	unhealthy	oral	M		https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2009-PI-01092-3&d=202012161016933	Homo sapiens																									
3964	1800		ADULT			Studied dose	mg	10		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8096549/	Homo sapiens												66	10	Angina at rest					48			7	day		p.180
3965	1801		ADULT			Studied dose	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2956874/	Homo sapiens						52						63	8	congestive heart failure					29			12	week		77C
3966	1801		ADULT			Studied dose	mg/kg	1		multiple			8 hours	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2145236/	Homo sapiens						79						92	22	pulmonary edema					65			48	hour		S3
3967	1801		ADULT			Studied dose	mg/kg	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2956865/	Homo sapiens						61.7						75	11	congestive heart failure					46						36C
3968	1802		ADULT			Recommended	mg	120		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12638395/	Homo sapiens						36	max					50	24						25			10	day		p.275
3969	1802		ADULT			Recommended	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17304660/	Homo sapiens						63.7							3593	osteoarthritis											p.415, 418
3970	1803		ADULT			Studied dose	mg	30		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22027241/	Homo sapiens						48.7							63	hemorrhagic disorder								14	day		p.681
3971	1803		ADULT			Studied dose	mg	40		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12409984/	Homo sapiens						63.7							31	heart disease											p.758
3972	1803		ADULT			Studied dose	mg	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31166081/	Homo sapiens						38.9							30	congenital heart disease											p.3
3973	1804					Recommended	mg	20		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33128055	Homo sapiens						50							166	E. bieneusi intestinal microsporidiosis					50			14	day		
3974	1804					Recommended	mg	20		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/33128055	Homo sapiens													5	E. bieneusi intestinal microsporidiosis								14	day		
3975	1805		ADULT			Overdose	g	2.1		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26150642/	Homo sapiens						44							1	type 2 diabetes mellitus	35 g			metformin							p.1,2
3976	1805		ADULT			Overdose	mg	1200		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11592575/	Homo sapiens						14							1												p.1157
3977	1805		ADULT			Recommended	mg	198		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15787663/	Homo sapiens							mean|total daily dose					75	1270	type 2 diabetes					35			52	week		p.403
3978	1806		ADULT			Recommended	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1560186/	Homo sapiens						49	max			30 to 120 mg/day of gliquidone (Glurenor®, Guidotti,\nPisa, Italy) in 2 doses, at breakfast and dinner.			22	type II diabetes mellitus											p.2
3979	1807		ADULT			Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30157388/	Homo sapiens						55	max						129	multiple sclerosis								96	week		846-855
3980	1807		ADULT			Studied dose	mg	30		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19032723/	Homo sapiens						29.3						70	14						18			14	day		792-801
3981	1808		ADULT			Highest studied dose	mg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30756527/	Homo sapiens													20	drug dependence								84	day		90-99
3982	1810		adult			Recommended	mg	5		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206143Orig1s000MedR.pdf	Homo sapiens													5477												p. 171
3983	1810		adult				mg	7.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02441218	Homo sapiens							max			2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.			3232	Heart Failure								42	month		
3984	1810		adult				mg	7.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02446990	Homo sapiens							max			5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.			9539	Coronary Artery Disease								48	month		
3985	1810					Highest studied dose	mg	10		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23755867	Homo sapiens						27.7							9						27.7			4.5	day		
3986	1810					Highest studied dose	mg	10		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18341671	Homo sapiens													9	asthma								4.5	day		
3987	1810					Overdose	mg	150		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32322492	Homo sapiens						19				20–30 tabs of 7.5 mg			1						19						
3988	1810					Overdose	mg	250		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/26856350	Homo sapiens						26				50 tablets, 5 mg each			1						26						
3989	1810					Overdose	mg	280		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24711296	Homo sapiens						47							1						47						
3990	1810						mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30115103	Homo sapiens						61				a fast infusion of 10 mg over 10 min, followed by a continuous slow infusion of 10 mg over 24 h.		67	14	low cardiac output syndrome					59			1	day		
3991	1812		ADULT			MTD	mg	2.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7241162/	Homo sapiens							median			0.6 to 5 mg			7	Shy-Drager syndrome								7	day		
3992	1812		CHILD			Overdose	mg	10		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23723628/	Homo sapiens						1.8							1												
3993	1813		ADULT			Highest studied dose	mg	32		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7665721/	Homo sapiens						26.7							48	pain disorder											p.609
3994	1813		ADULT			Recommended	mg	8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17163260/	Homo sapiens						39.3							110	pain disorder								7	day		p.274
3995	1813		ADULT			Recommended	mg	8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20701400/	Homo sapiens						39						94	1838	pain disorder					17			3	day		p.692
3996	1814		ADULT			Highest studied dose	mg	800		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15017615/	Homo sapiens						30							24									8	day		p.117
3997	1814		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15153172/	Homo sapiens						50.6							227	rheumatoid arthritis								13	week		p.1195
3998	1815		ADULT			Studied dose	ug	12		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33685864/	Homo sapiens						66	max			Patients with secondary hyperparathyroidism receiving maintenance hemodialysis		71	159	secondary hyperparathyroidism					57			12	month		VICTORY; UMIN000030636 and jRCTs051180156
3999	1817		ADULT			Higher than recommended	mg	56		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23774552/	Homo sapiens						75							1	nephrotic syndrome								1	day		1383-7
4000	1817		ADULT			Highest studied dose	mg	4		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25748293/	Homo sapiens						21.8						28	12						19			1	day		869-76
4001	1817		ADULT			Highest studied dose	mg	6		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17118761/	Homo sapiens						60							1	multiple myeloma								33	month		343-5
4002	1819		ADULT			Overdose	mg	1550		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1546127/	Homo sapiens													1												S 128
4003	1819		ADULT			Overdose	mg	20550		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1546127/	Homo sapiens													1												S 128
4004	1819		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7617806/	Homo sapiens						45	max					78	51	major depressive disorder					19						p.185, 186
4005	1820		ADULT			Studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2646350/	Homo sapiens						72.1	total daily dose						154	dementi											p.299, 301
4006	1821		ADULT			Studied dose	ug/kg/day	200		single					unhealthy	intravenous	M+F		https://www.pmda.go.jp/drugs/2007/P200700050/45004500_20500AMZ00348000_X103_1.pdf#page=27	Homo sapiens						72				Initial dose: 50 mcg/kg/5 min; Dosage would be adjusted between 50 mcg/kg/h and 200 mcg/kg/h during infusion.		83	22	heart failure					58			48	hour		
4007	1822		ADULT			Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15969895/	Homo sapiens						54.9						79.1	76	essential hypertension					31.3			90	day		p.955
4008	1822		ADULT			Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21905098/	Homo sapiens						69.3							56	Alzheimer disease								6	week		p.1043
4009	1823		ADULT			Higher than recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14624289/	Homo sapiens						61							57	osteoarthritis											p.470, 471
4010	1823		ADULT			Highest studied dose	mg	400		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7506187/	Homo sapiens												29	8						19			7	day		p.265
4011	1823		ADULT			Overdose	mg/kg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11724052/	Homo sapiens						1.7							1												p.510
4012	1824		ADULT			Higher than recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2744062/	Homo sapiens						52	max					69	15	hypertension					40			6	week		p.225
4013	1824		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12923404/	Homo sapiens						53.3							82	hypertension								24	week		p.1713
4014	1824		ADULT			Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2183868/	Homo sapiens						52.5	max						32	essential hypertension								12	week		p.460
4015	1827		ADOLESCENT|ADULT			Lethal dose	mg	2400		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30761754/	Homo sapiens						49	max			A 15‐year‐old male overdosed on approximately 2000 mg to 2400 mg pipamperone			2	schizophrenia					15			1	day		626-630
4016	1827		ADOLESCENT|ADULT			Overdose	mg	638		single					unknown	oral	M+F		https://www.clinicaltherapeutics.com/article/S0149-2918(13)00655-3/fulltext	Homo sapiens						41	mean					90	35						14			1	day		e92
4017	1827		ADULT			Lethal dose	mg	4000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30761754/	Homo sapiens						46							1									1	day		626-630
4018	1827		ADULT			Recommended	mg	80		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27111131/	Homo sapiens						78	total daily dose						1	Alzheimer disease								4	day		213-214
4019	1829		ADULT			Highest studied dose	g	12		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9527146/	Homo sapiens						30						43	20	epilepsy					17			2	week		p.347
4020	1829		ADULT			Recommended	g	1.6		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11099714/	Homo sapiens						58							256	cardiovascular system disease								2	year		p.70
4021	1830		ADULT			Studied dose	mg	12		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6840162/	Homo sapiens						53.9							11	congestive heart failure											
4022	1830		ADULT			Studied dose	mg	48		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7213511/	Homo sapiens						44							8	impaired renal function											
4023	1830		ADULT			Studied dose	mg	6		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7060317/	Homo sapiens												38	18						20			14	day		
4024	1831		ADULT			Studied dose	mg	0.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2074163/	Homo sapiens													58	migraine								8	week		p.5
4025	1831		ADULT			Studied dose	mg	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1095308/	Homo sapiens							max			Pizotifen (0.5 mg.) and placebo were supplied in identical tablet form and on\ncommencing the trial the tablets were introduced slowly, i.e. Days 1 and 2, 1 tablet\nin the evening; Days 3 and 4, 1 tablet at midday, and 1 tablet in the evening; Day\n5, 1 tablet in the morning, 1 at midday and 1 in the evening; and from thereon, 1\ntablet t.i.d. Patients returned after 2 weeks and, if required, the dose was adjusted to\n2 tablets t.i.d. but no more than 6 tablets a day (3 mg.). The dose most commonly given was\n3 mg. daily.			27	migraine											p.70
4026	1832		ADULT			Studied dose	mg	1200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26518/	Homo sapiens						45.6						62	15	peptic ulcer disease					21			28	day		p.381
4027	1833					Highest studied dose|MTD	mg/m2	4.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10499608/ | https://pubmed.ncbi.nlm.nih.gov/11432631/	Homo sapiens						55.5							9	solid tumors								60	week		
4028	1833					Studied dose	mg/m2	2.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11432631/	Homo sapiens						62				median number of courses administered per patient was 2 (range 1-10)			3	Colorectal Cancer	10400 mg/m2 IV; every 3 weeks			5-iodo-2'-deoxyuridine				6	week		
4029	1833					Studied dose	mg/m2	3		multiple			3 weeks	1	unhealthy	intravenous	M+F		http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Raltitrexed_monograph_1June2013_formatted.pdf | https://www.pfizer.ca/sites/default/files/201710/TOMUDEX_PM.pdf	Homo sapiens													861	Colorectal Cancer											Raltitrexed_monograph_1June2013_formatted.pdf - p.2
4030	1833					Studied dose	mg/m2	3		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://www.pfizer.ca/sites/default/files/201710/TOMUDEX_PM.pdf	Homo sapiens													861	Colorectal Cancer											201710/TOMUDEX_PM.pdf - p.9
4031	1833					Studied dose	mg/m2	3.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10499608/ | https://pubmed.ncbi.nlm.nih.gov/11432631/	Homo sapiens						55.5							13	solid tumors								135	week		
4032	1833					Studied dose	mg/m2	4		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10499608/ | https://pubmed.ncbi.nlm.nih.gov/11432631/	Homo sapiens						55.5							12	solid tumors								84	week		
4033	1834		ADULT			Studied dose	mg	75		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8620702/	Homo sapiens						24.1						42	12	asthm					18			2	week		p.341
4034	1835		ADULT			Recommended	mg	0.3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12166337/	Homo sapiens												76	43	cancer					24						p.216
4035	1835		ADULT			Studied dose	ug	5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21920001/	Homo sapiens						43.4							175	irritable bowel syndrome								4	week		p.1102
4036	1836		ADULT			Higher than recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11564000/	Homo sapiens												80	88	digestive system disorder					18			8	week		p.1608, 1609
4037	1836		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33827990/	Homo sapiens						46.8							225	gastritis								2	week		p.847
4038	1836		ADULT			Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33827990/	Homo sapiens						47.1							229	gastritis								2	week		p.847
4039	1838		ADULT			Higher than recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16886837/	Homo sapiens						60						78	121	intermittent claudication					41			24	week		p.81
4040	1839		ADOLESCENT			Recommended	mg	24		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22609816/	Homo sapiens						35	max					65	294	schizophrenia					18			18	month		p.233
4041	1839		ADULT			Overdose|Highest recorded dose	mg	1792		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20163279/	Homo sapiens						42							1	schizoaffective disorder	unknown quantity			fluoxetine						zopiclone	p.1
4042	1839		ADULT			Recommended	mg	17		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22850268/	Homo sapiens						34.4	mean						196	schizophrenia								12	week		p.330
4043	1841		ADULT			Highest studied dose	mg	3200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6367362/	Homo sapiens						35	max|total daily dose			median dose - 1600 mg/day			16	schizophrenia								4	week		31-41
4044	1842		ADULT			Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2000/g000710/32ctdp_219-402.pdf#page=102	Homo sapiens						56.3						80	168	spinocerebellar tract degeneration					30			52	week		
4045	1843		ADULT			Studied dose	mg/m2	6		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21820159/	Homo sapiens						69	total daily dose						1	acute promyelocytic leukemia								5	day		213-4
4046	1843		CHILD			Highest studied dose	mg/m2	12		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33829292/	Homo sapiens						8	total daily dose			RP2D			6	cancer								12	day		99-107
4047	1844		ADULT			Higher than recommended	mg	40		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9202910/	Homo sapiens						53.3							258	pain disorder								2	day		p.255
4048	1844		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2692947/	Homo sapiens						69							58	arthritis								12	week		p.455
4049	1844		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8894360/	Homo sapiens						56.4						70	147	rheumatoid arthritis					29			3	month		p.475, 476
4050	1845		ADULT			Highest studied dose	mg	1.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20039417/	Homo sapiens						48.5	max						65	fibromyalgia								12	week		p.297
4051	1845					Studied dose	mg	1		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3127243/	Homo sapiens												25	7						23						p.592
4052	1847		ADULT			Recommended	g	2.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6240785/	Homo sapiens						21						30	191	gonorrhea					13						p.384
4053	1847		ADULT			Recommended	mg	500		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6523326/	Homo sapiens													61	Nongonococcal urethritis								14	day		p.461
4054	1848		ADOLESCENT			Overdose	mg	2000		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6333878/	Homo sapiens						14							1									1	day		836-7
4055	1848		ADULT			Highest studied dose	mg	400		multiple			day	3	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8612471/	Homo sapiens													60									2	week		1050-75
4056	1848		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10319030/	Homo sapiens						77							1	osteoarthritis	1000 mg/day		thyroxine	nifedipine			100 mg/day	2	year	metformin	17
4057	1848		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2870297/	Homo sapiens						56							1	rheumatoid arthritis								4	week		803
4058	1849		ADULT			Recommended	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9563211/	Homo sapiens						39							47	migraine											p.205
4059	1850					MTD	ug/m2	1100		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15701855	Homo sapiens						57				as a single 1-h i.v. infusion every 21 days			6	solid tumours					57			13	cycle		
4060	1850					MTD	ug/m2	1800		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15701855	Homo sapiens						57				as a single 3-h i.v. infusion every 21 days			4	solid tumours					57			5	cycle		
4061	1850					Recommended	mg/m2	1.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207953s000lbl.pdf	Homo sapiens						57				1.5 mg/m2 as a 24-hour continuous intravenous infusion once every 3 weeks		81	345						17			13	week		
4062	1850					RP2D	ug/m2	1650		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15701855	Homo sapiens						57				as a single 3-h i.v. infusion every 21 days			13	solid tumours					57			55	cycle		
4063	1854		ADULT			Highest studied dose	mg	5		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8536820/	Homo sapiens						27.3							12									7	day		p.497, 498
4064	1854		ADULT			Recommended	mg	0.2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20590736/	Homo sapiens						60.6							156	type 2 diabetes								12	week		p.619
4065	1854		ADULT			Recommended	mg	0.2		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21806314/	Homo sapiens						59.1							83	type 2 diabetes mellitus								12	week		p.1789
4066	1855		ADULT			Studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16789795/	Homo sapiens												75	463	hypertension	12.5 mg/day			hydrochlorothiazide	18			12	week		1113
4067	1856		ADULT			Highest studied dose	mg	397.1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23422395/	Homo sapiens							mean|total daily dose					65	35	schizophrenia					20			12	week		p.212
4068	1856		ADULT			Recommended	mg	131		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15551193/	Homo sapiens						39.8	mean			The mean dose was 131  /- 49 mg/day (range 25±\n225 mg) in the zotepine group			38	schizophrenia								8	week		p.4
4069	1857		ADULT			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7957524/	Homo sapiens							max			CZ was administered as a powder in doses of 50, 70 an 100 mg/day in the first, second and third weeks, respectively, during the trial period of one month.		64	15	schizophrenia					28			1	month		p.369
4070	1858		ADULT			Recommended	g	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/1519685/	Homo sapiens						34.5				3% gel			50	thrombophlebitis											p.326
4071	1858		ADULT			Recommended	g	1		multiple			day	4	unhealthy	topical	M+F		https://www.medicines.org.uk/emc/product/3422/smpc#CLINICAL_PRECAUTIONS	Homo sapiens										Rub 1g Traxam Gel (approximately 1 inch (2.5cm) of gel) into the affected area(s) 2 to 4 times a day. Do not use for longer than 7 days.				pain disorder								7	day		
4072	1859		ADULT			Highest studied dose	mg	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3316304/	Homo sapiens						58	max						122	hypertension								6	week		46-51
4073	1860		ADULT			Recommended	mg	30		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23761568/	Homo sapiens						47							1	Small cell gall bladder carcinoma and syndrome of inappropriate secretion of antidiuretic hormone								2	month		
4074	1860		ADULT			Studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21087977/	Homo sapiens												78	16	Ectopic antidiuretic hormone syndrome					48			7	day		
4075	1861					Highest studied dose	mg/day	60		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3134879/	Homo sapiens						11							1	Valsalva's maneuver					11						
4076	1861					Studied dose	mg/kg/day	0.2		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30146701	Homo sapiens						11.7							13	Lennox‐Gastaut syndrome (LGS)								4	week		
4077	1861					Studied dose	mg/kg/day	0.7		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212102s000lbl.pdf	Homo sapiens													40									16	week		
4078	1862		ADULT			Highest studied dose	mg/m2	1700		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19499186	Homo sapiens						62				imexon was given intravenously over 60 min on days 1-5 every 21 days; median number of cycles per patient was two (range 1 to 12); the mean duration of therapy was 66 days.		78	3	cancer	Docetaxel was administered intravenously at a fixed dose of 75 mg/m(2) immediately following imexon on day 1 every 21 days.			Docetaxel	34			5	day		p.636
4079	1862		ADULT			MTD	mg/m2	1300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19499186	Homo sapiens						62				imexon was given intravenously over 60 min on days 1-5 every 21 days; median number of cycles per patient was two (range 1 to 12); the mean duration of therapy was 66 days.		78	11	cancer	Docetaxel was administered intravenously at a fixed dose of 75 mg/m(2) immediately following imexon on day 1 every 21 days.			Docetaxel	34			5	day		p.636
4080	1862		ADULT			MTD	mg/m2	875		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17470869	Homo sapiens						64				Patients with metastatic cancer received intravenous imexon over 30 to 45 minutes for 5 consecutive days (one course) every other week (days 1 through 5 and 15 through 19) monthly.		81	9	cancer					35			5	day		p.1781, 1782
4081	1862		ADULT			Studied dose	mg/m2	1000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17470869	Homo sapiens						64				Patients with metastatic cancer received intravenous imexon over 30 to 45 minutes for 5 consecutive days (one course) every other week (days 1 through 5 and 15 through 19) monthly.		81	2	cancer					35			5	day		p.1781, 1782
4082	1862		ADULT			Studied dose	mg/m2	1500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19499186	Homo sapiens						62				imexon was given intravenously over 60 min on days 1-5 every 21 days; median number of cycles per patient was two (range 1 to 12); the mean duration of therapy was 66 days.		78	5	cancer	Docetaxel was administered intravenously at a fixed dose of 75 mg/m(2) immediately following imexon on day 1 every 21 days.			Docetaxel	34			5	day		p.636
4083	1863					Highest studied dose	mg/m2	11		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19451434/	Homo sapiens						53.7				every 3 week via 20-minute infusion			6	cancer								1	cycle		
4084	1863					Highest studied dose	mg/m2	2.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										3 week on/1 week off		79	28	advanced solid tumors					20			1	cycle		
4085	1863					Highest studied dose	mg/m2	3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										3 week on/1 week off		79	5	advanced solid tumors					20			1	cycle		
4086	1863					Highest studied dose	mg/m2	3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										6 week on/3 week off		79	9	advanced solid tumors					20			1	cycle		
4087	1863					Highest studied dose	mg/m2	3.6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										6 week on/3 week off		79	5	advanced solid tumors					20			1	cycle		
4088	1863					MTD	mg/m2	2.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										6 week on/3 week off		79	14	advanced solid tumors					20			1	cycle		
4089	1863					Studied dose	mg/m2	0.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										6 week on/3 week off		79	7	advanced solid tumors					20			1	cycle		
4090	1863					Studied dose	mg/m2	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24470546/	Homo sapiens										20-min intravenous infusion once every 3 week		68	55	brain metastases from breast cancer					31			2	cycle		
4091	1863					Studied dose	mg/m2	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26308485/	Homo sapiens										every 3 week		74	50	brain metastases from non-small cell lung cancer					33			13	cycle		
4092	1863					Studied dose	mg/m2	2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16301595/	Homo sapiens										6 week on/3 week off		79	4	advanced solid tumors					20			1	cycle		
4093	1864		ADULT			Highest studied dose	mg	3		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19776093/	Homo sapiens							max			Patients were dosed up to 9mg/day (3 mg, 3 times daily); however, only 2/6 patients could be dosed beyond 7.5mg/day			6	multiple sclerosis								8	month		p.3, 4
4094	1864		ADULT			Studied dose	mg	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1475038/	Homo sapiens						47							19	major depressive disorder								3	day		p.62
4095	1866		ADULT			Highest studied dose	mg	20		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4141306/	Homo sapiens													9	myocardial infarction								32	hour		2443-7
4096	1872		ADULT			Highest studied dose	mg/kg	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17095018/	Homo sapiens						69							8	stroke								7	day		50-6
4097	1874		ADULT			Highest studied dose	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8693647/	Homo sapiens						72				Patients self-administered bropirimine as outpatients, taking 3.0 g/day in three divided doses of 1.0 g each at 6, 8, and 10 PM daily for 3 consecutive days each week, weekly for up to 1 year.		80	24	bladder carcinoma					50			1	year		p.29
4098	1874		ADULT			Highest studied dose	g	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9495702/	Homo sapiens						67				3.0 g daily in three equal doses at approximately 6 PM, 8 PM, and 10 PM for 3 consecutive days per week; therapy was continued to complete 1 year.			86	bladder carcinoma								3	day		p.228
4099	1874		ADULT			Studied dose	mg	750		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9693244/	Homo sapiens												79	17	bladder carcinoma					45						p.109
4100	1876		adult			Highest studied dose	mg	6		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1773908/	Homo sapiens													60												
4101	1876					Highest studied dose	%	0.1		single			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/10337458/	Homo sapiens										3 g			24												
4102	1876					Recommended	mg	0.28		multiple			day	2	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/14579656/	Homo sapiens												69	76	seasonal allergic rhinitis					18			2	week		
4103	1879		ADULT			Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11574441/	Homo sapiens						57.3							90	peripheral neuropathy								52	week		p.1778
4104	1880		ADULT			Studied dose	mg	100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7021261/	Homo sapiens						56.8							34	rheumatoid arthritis											p.255
4105	1880		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/75392/	Homo sapiens						22.6							44	uterine disease								3	month		p.349, 350
4106	1883					Recommended	%	1		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/6138212	Homo sapiens						41							41	Dermatisis											p.429
4107	1883					Studied dose	mg	72		multiple			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13792589	Homo sapiens							max			Dosage range: 8-72 mg/day			72	Urticaria | sensitization dermatitis|dermatoses								26	week		p.160
4108	1884		ADULT			Highest studied dose|Studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7551370/	Homo sapiens						36.5						65	13	asthma					22			2	week		1198-202
4109	1888		ADULT			Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.medsafe.govt.nz/profs/Datasheet/n/Neulactiltab.pdf	Homo sapiens							max|total daily dose			Initially 75 mg per day in divided doses. Dosage should be increased by 25 mg per day at weekly\nintervals until optimum effect is achieved. Maintenance therapy would not normally be expected\nto exceed 300mg per day.				schizophrenia											p.3
4110	1888		ADULT			Studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24474865/	Homo sapiens						31.1	max|total daily dose			Patients received a 4-week regime of pericyazine, which\nconsisted of up to 8 × 2.5 mg tablets per day as one tablet\nevery 3 hours and two tablets at night for 2 weeks, then up\nto six tablets per day for the following week and up to four\ntablets per day for the last week.			21	cannabis dependence								4	week		p.45
4111	1890		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17098084/	Homo sapiens						56							339	type 2 diabetes								1	year		p.1668
4112	1890		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18678611/	Homo sapiens						57.8							138	type 2 diabetes								6	month		p.2174
4113	1891		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6340974/	Homo sapiens						65.4							35	urinary tract infection	trimethoprim (250 mg)/sulfamethopyrazine (200 mg) combination given once daily after a double, loading dose on the first day			trimethoprim				2	week		p.343
4114	1891		CHILD			Studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20705516/	Homo sapiens						12						15	106	schistosomiasis	12.5 mg; every 24 h for 3 days			artesunate	7			3	day	pyrimethamine	p.607
4115	1892		ADULT			Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14211703/	Homo sapiens							max|total daily dose						16	schizophrenia											p.853
4116	1892		ADULT			Recommended	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14011164/	Homo sapiens							max					66	46	schizophrenia	2 mg. b.d.			benztropine	20			4	week		p.863
4117	1892		ADULT			Recommended	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pdf.hres.ca/dpd_pm/00018702.PDF	Homo sapiens							max|total daily dose			It is recommended to start treatment at a low dosage of about 5 mg\nper day in a single dose or in di vided doses. This initial dosage is gradually increased by the same amount every 2 to 3 days until the usual effective dosage of 30 to 40 mg per day is reached.\nIn some cases higher dosages of 90 mg or more per day, are necessary to control the psychotic manifestations.				schizophrenia											p.1, 2
4118	1892		ADULT			Studied dose	mg	15		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13864564/	Homo sapiens						34	max					49	55	schizophrenia					15						p.289
4119	1893					Highest studied dose	mg/m2	1000		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21590448	Homo sapiens						38							4												
4120	1893					Highest studied dose	mg/m2	310.5		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 450 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			6		139.5 mg/m2			TEGAFUR				28	day		
4121	1893					Highest studied dose	mg/m2	621		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 900 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. A 5-day schedule repeated every 21 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			5		279 mg/m2			TEGAFUR				5	day		
4122	1893					RP2D	mg/m2	248.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9348565 | https://pubmed.ncbi.nlm.nih.gov/8949982	Homo sapiens						54				tegafur and uracil (UFT): 360 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			6	carcinoma	111.6 mg/m2			TEGAFUR	54			28	day		
4123	1893					RP2D	mg/m2	552		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9348565 | https://pubmed.ncbi.nlm.nih.gov/8949982	Homo sapiens						59				tegafur and uracil (UFT): 800 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. A 5-day schedule repeated every 21 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			8	carcinoma	248 mg/m2			TEGAFUR	59			5	day		
4124	1893						mg/m2	276		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9348565	Homo sapiens										tegafur and uracil (UFT): 400 mg/m2. Uracil and tegafur in a 4:1 molar concentration ratio. 28-day schedule repeated every 35 days. The total dose was divided by three and administered three times daily at 8-hour intervals.			8		124 mg/m2			TEGAFUR				28	day		
4125	1896					Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18551622/	Homo sapiens						53.6							20	amyotrophic lateral sclerosis								12	week		
4126	1896					Studied dose	mg	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18551622/	Homo sapiens						52.6	unknown						19	amyotrophic lateral sclerosis								12	week		
4127	1899		ADULT			Recommended	mg	0.75		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8529781/	Homo sapiens													20	diabetes mellitus								12	week		377-80
4128	1900		ADULT			Highest studied dose	mg	8		multiple			day	1	unhealthy	oral	M		https://link.springer.com/article/10.1007/BF00429228	Homo sapiens													1	sleep disorder								13	day		371–379
4129	1900		ADULT			Highest studied dose	mg/kg	1.3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8214408/	Homo sapiens							total			mean duration			25	alcohol dependence								85.1	hour		753-7
4130	1903		ADULT			Recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15120701/	Homo sapiens						58.7						72	61	polyneuropathy					41			8	week		p.82
4131	1903		ADULT			Recommended	mg	600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21187189/	Homo sapiens						41.4							120	obesity								20	week		8500000
4132	1903		ADULT			Recommended	mg	600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27276401/	Homo sapiens						40.5	max						10	schizophrenia								12	week		p.270
4133	1921		ADULT			Higher than recommended	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6340562/	Homo sapiens						65.8	max					78	25	intermittent claudication					51						p.262
4134	1921		ADULT			Overdose	g	15		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7248034/	Homo sapiens						61							1	schizophrenia											p.418
4135	1921		ADULT			Overdose	g	8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12811723/	Homo sapiens						41							1												p.245
4136	1925						g	15		single					unknown	oral	M		https://jamanetwork.com/journals/jama/article-abstract/280892	Homo sapiens						60							1						60						
4137	1925						mg	250		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/15483758	Homo sapiens						46							1						46						
4138	1930		ADULT			Highest studied dose	%	25		single					healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/12110454/	Homo sapiens						25.5							57									1	day		205-10
4139	1935					Highest studied dose	g	7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8132703	Homo sapiens						52.8	total daily dose						7	Cancer	300 mg; 4/day			cimetidine, p.o							S 40
4140	1935					Studied dose	mg	1600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2591993	Homo sapiens							max			The majority of the 2173 patients took 100 mg/day of coumarin for 1 month, followed by 50 mg/day for 2 years (the other patients were taking between 25 and 2000 mg/day). Patient P5 received 1600 mg/day (1 of 17 patients with AE).			2173	Cancer|Infections								6	month		p.502
4141	1935					Studied dose	mg	200		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9929524	Homo sapiens												84	139	Lymphedema					33			6	month		p.349
4142	1936		ADULT			Studied dose	mg/kg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30567535/	Homo sapiens						38.84	max						19	irritable bowel syndrome								4	week		p.7
4143	1941		ADULT			Recommended	mg/kg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/5319723/	Homo sapiens						74							1	Urinary Bladder Disease											p.973, 974
4144	1945					Highest studied dose	mg	3		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22128200	Homo sapiens						23						35	102						18			72	day		
4145	1948		adult				mg	10		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02656160	Homo sapiens													10												
4146	1948		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01444300	Homo sapiens													12	Multiple Sclerosis								12	week		
4147	1948		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02219932	Homo sapiens													316	Multiple Sclerosis								24	week		
4148	1948					Overdose	mg	300		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf	Homo sapiens													1	Multiple sclerosis											p.3
4149	1948					Overdose	mg	40		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf	Homo sapiens													1	Multiple sclerosis											p.3
4150	1948					Overdose	mg	60		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf	Homo sapiens													1	Multiple sclerosis											p.3
4151	1948					Recommended	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25583832	Homo sapiens						52.1							269	Multiple sclerosis								5	year		p.3
4152	1948					Recommended	mg	10		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf	Homo sapiens													400	Multiple sclerosis								14	week		p.2
4153	1948					Recommended	mg	10		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022250s000lbl.pdf	Homo sapiens														Multiple sclerosis											p.1
4154	1949					Highest studied dose	mg	400		single			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17506785	Homo sapiens													8												p.301
4155	1949					Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17506785	Homo sapiens													6												p.301
4156	1949					Recommended	mg	150		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s027lbl.pdf	Homo sapiens							max							Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism											p.1
4157	1949					Recommended	mg	150		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s027lbl.pdf	Homo sapiens													6059	Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism								20.3	month		p.5
4158	1949					Recommended	mg	150		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s027lbl.pdf	Homo sapiens													6059	Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism								20.3	month		p.6
4159	1949					Recommended	mg	150		multiple			day	6	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32474728	Homo sapiens													14												p.605
4160	1950						g	3		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/21552054/	Homo sapiens						23							39						23						
4161	1956					Studied dose	g	5		steady			day	4	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/622610/	Homo sapiens						57								interstitial nephritis					57			5	day		
4162	1958		ADULT			Studied dose	mg	40		single					healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/11291200/	Homo sapiens												38	6						25						
4163	1958		ADULT			Studied dose	mg	40		single					unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/11291200/	Homo sapiens													6	cystic fibrosis											
4164	1958		CHILD			Studied dose	mg	40		single					unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/11291200/	Homo sapiens												15	6	cystic fibrosis					6						
4165	1961		adult			Recommended	mg	250		steady			day	4	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/3524647/	Homo sapiens													369	cough and cold								7	day		
4166	1962					Recommended	mL	200		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013295s070lbl.pdf	Homo sapiens										Conray contains 60% w/v iothalamate meglumine. Each milliliter contains 600 mg of iothalamate meglumine. 200 mL is a max dose for cranial computerized angiotomography				Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography											p.5
4167	1962					Recommended	mL	200		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013295s070lbl.pdf	Homo sapiens										Conray contains 60% w/v iothalamate meglumine. Each milliliter contains 600 mg of iothalamate meglumine. 200 mL is a max dose for cranial computerized angiotomography				Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography											p.6
4168	1962					Recommended	mL	200		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/013295s070lbl.pdf	Homo sapiens										Conray contains 60% w/v iothalamate meglumine. Each milliliter contains 600 mg of iothalamate meglumine. 200 mL is a max dose for cranial computerized angiotomography				Excretory urography|cerebral angiography| peripheral arteriography|venography| arthrography |direct cholangiography |endoscopic retrograde cholangiopancreatography|contrast enhancement of computed tomographic brain images| cranial computerized angiotomography| intravenous digital subtraction angiography|arterial digital subtraction angiography											p.7
4169	1966					Highest studied dose	mg/m2	1000		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20859231	Homo sapiens													3	Malignant melanoma	5 mg/day; 14 days			Lenalidomide, p.o							p.503, 504
4170	1966					Highest studied dose	mg/m2	1000		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23735514	Homo sapiens													45	Malignant melanoma											p.5
4171	1966					MTD	mg/m2	800		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20859231	Homo sapiens													16	Malignant melanoma	5 mg/day; 14 days			Lenalidomide, p.o							p.503
4172	1966					Recommended	mg/m2	250		multiple			day	1	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b6b97e41-5f15-498c-abfb-d8443ea4d216&type=display	Homo sapiens										The recommended dosage is 2 to 4.5 mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. An alternate recommended dosage is 250 mg/square meter body surface/day I.V. for 5 days. Treatment may be repeated every 3 weeks.				Malignant melanoma								5	day		
4173	1966					Recommended	mg/m2	850		multiple			3 weeks	1	unhealthy	intravenous			https://www.ema.europa.eu/en/documents/referral/summary-information-referral-opinion-following-arbitration-pursuant-article-29-directive-2001/83/ec-formerly-article-10-paragraph-2-directive-75/319/eec-20-may-1975-amended-dacarbazine-fauld_en.pdf	Homo sapiens										It is also possible to give 850 mg/m2 body surface area on day 1 and then once every 3 weeks as intravenous infusion.				Malignant melanoma											
4174	1967					MTD	mg/kg	62		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21868742/	Homo sapiens						70							6	intracerebral hemorrhage								3	day		
4175	1967					Recommended	mg/kg/h	15		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/16250288/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf	Homo sapiens										girl ingested 30 tablets of iron preparation (110 mg/kg/dose) elementary iron)			1	iron poisoning								3	day		
4176	1967					Studied dose	mg/kg	135		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7840508/	Homo sapiens							mean			five days every other week			10	recurrent neuroblastoma								5	day		
4177	1967					Studied dose	mg/kg	240		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7840508/	Homo sapiens										five days every other week			10	recurrent neuroblastoma								5	day		
4178	1967					Studied dose	mg/kg	700		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/12644925/	Homo sapiens						17							1	sickle cell-beta thalassemia					17			8	hour		
4179	1968					MTD	mg/m2	200		multiple			3 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/10394119	Homo sapiens													3	Ovarian carcinoma											p.13,14
4180	1968					Overdose	mg/m2	320		single					unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf	Homo sapiens						63							1	Breast cancer and liver metastasis											p.11
4181	1968					Overdose	mg/m2	95		multiple			day	1	unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf	Homo sapiens						36							1	non-Hodgkin’s lymphoma								5	day		p.11
4182	1968					Recommended	mg/m2	120		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf	Homo sapiens										Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. •The recommended starting dose of ELLENCE is 100 to 120 mg/m2.				Axillary node tumor involvement following resection of primary breast cancer											p.1
4183	1968					Recommended	mg/m2	120		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf	Homo sapiens										Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle. The recommended starting dose of ELLENCE is 100 to 120 mg/m2.				Axillary node tumor involvement following resection of primary breast cancer											p.1
4184	1970					Recommended	%	0.016		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202317lbl.pdf	Homo sapiens										Applied as a thin film once daily to affected areas of the skin. Gel: 0.016% w/w of mechlorethamine				Stage IA and IB mycosis fungoides‐type cutaneous T‐cell lymphoma											p.1
4185	1970					Recommended	%	0.02		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/2933055	Homo sapiens						44							20	Psoriasis											p.517
4186	1970					Recommended	mg/kg	0.4		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/4569376	Homo sapiens												80	26	Reticulum cell sarcoma					14						p.413
4187	1970					Recommended	mg/kg	0.4		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/4569376	Homo sapiens												81	18	Lymphosarcoma					32						p.413
4188	1970					Recommended	mg/kg	0.4		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/06695slr031_mustargen_lbl.pdf	Homo sapiens							total			A total dose of 0.4 mg/kg of body weight for each course usually is given either as a single dose or in divided doses of 0.1 to 0.2 mg/kg per day.				Hodgkin's disease| lymphosarcoma|chronic myelocytic leukemia| chronic lymphocytic leukemia| polycythemia vera| mycosis fungoides|bronchogenic carcinoma											p.2
4189	1971					Highest studied dose	mg	1800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19602718/	Homo sapiens													8									2	week		
4190	1971					Recommended	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19066958/	Homo sapiens							max						7	Wilson disease								1	year		
4191	1971					Recommended	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19066958/	Homo sapiens													16	Wilson disease								2	week		
4192	1972		adult			Recommended	mg	300		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9935261/	Homo sapiens							max			200 or 300 mg			1257	lower respiratory tract infections or sexually transmitted infections	200 mg			trovafloxacin							
4193	1974					Recommended	mg/kg	7		single			day	1	unhealthy	supraperiosteal injection	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/020971_SEPTOCAINE_MEDR_P1.PDF	Homo sapiens						33.7				The additional anesthesia may be administered: however, dosages are not to exceed 7 mg/kg			159	pain											96001.02
4194	1975		adult			Highest studied dose	mg/m2	280		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205580s000lbl.pdf	Homo sapiens													4												
4195	1975					Recommended	mg/m2	100		steady			4 weeks	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205580s000lbl.pdf	Homo sapiens										100 mg/m2 intravenously over 30 minutes on Days 1 and 2 every 28 days		77	153	Chronic Lymphocytic Leukemia					45			28	day		
4196	1975						mg/m2	150		steady			4 weeks	2	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12756557	Homo sapiens						48				150 mg/m(2) administered on two consecutive days and repeated every 4 weeks			1	advanced progressive breast cancer					48			28	day		
4197	1976		adult			Recommended	g	5		single			day	1	unknown	vaginal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19881slr009_gynazole_lbl.pdf	Homo sapiens													314									3	day		
4198	1977		children			MTD	mg/m2	210		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3521846	Homo sapiens										4 weekly 1-hour infusions followed by a 2-week rest				solid tumors								4	week		
4199	1977					Highest studied dose	mg/m2	160		multiple			week	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8420690	Homo sapiens													93	ovarian carcinoma					60						
4200	1977					MTD	mg/m2	600		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3900302	Homo sapiens						60						80	2						21						
4201	1977						mg/m2	550		multiple			4 weeks	1	unhealthy	intraperitoneal	F		https://pubmed.ncbi.nlm.nih.gov/8307496	Homo sapiens						54.2						77.3	47	ovarian carcinoma					36.9						
4202	1978						g	0.5		single			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26527863/	Homo sapiens						22.3				In the multiple-dose phase, subjects were assigned to receive 0.25 or 0.5 g every 6 hours for 3 days in a 2-way crossover design.			16									3	day		
4203	1978						g	2		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26527863/	Homo sapiens						22.2				In the single-dose phase, subjects were randomly assigned to receive single doses of 0.25, 0.5, 1.0, and 2.0 g of dicloxacillin sodium capsule in a 4-way crossover design with a 5-day washout period between administrations.			16												
4204	1978						mg/kg	25		multiple			day		unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/8396081/	Homo sapiens										The total daily dose of dicloxacillin was 12-5-25 mg/kg, depending on the severity of the infection, which was administered as oral 62-5 mg/5 mL or 125 mg/5 mL suspensions, depending on local availability.		12	49	skin infection					2			7	day		
4205	1979		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00855062	Homo sapiens													36	HIV-associated Cognitive Impairment								24	week		
4206	1979					Higher than recommended	mg	100		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17551382/	Homo sapiens						18							1	acne vulgaris					18			4	week		
4207	1979					Recommended	g	2		steady			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/33841618/	Homo sapiens						43.7				foam			20	papulopustular rosacea								14	day		
4208	1979					Recommended	mg/kg	1		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050808s014lbl.pdf	Homo sapiens													674	acne vulgaris					12			12	week		
4209	1980		adult			Recommended	mg/m2	85		multiple			2 weeks	1	unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022160s012lbl.pdf	Homo sapiens														advanced colorectal cancer	200 mg/m2 intravenous infusion in 5% Dextrose Injection given over 120 minutes			leucovorin				120	min		
4210	1980						mg/m2	130		multiple			3 weeks	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/32670652	Homo sapiens						64		initial dose of 8 mg/kg and 6 mg/kg every 21 days thereafter					1	gastric cancer	2000 mg/m2 for 14 days followed by 7 days of rest			capecitabine	64					trastuzumab	
4211	1980						mg/m2	130		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/33131450	Homo sapiens						56				130 mg/m2 on day 1 as a 2–3 hour infusion			1	colorectal cancer					56			2	hour		
4212	1980						mg/m2	135		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2295116	Homo sapiens						57				The initial duration of perfusion was 1 h, which was prolonged to 6 h for doses of > 60 mg/m 2. The drug was given at 4-week intervals		81	14	advanced cancer					26			6	hour		
4213	1980						mg/m2	150		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2295116	Homo sapiens						57				The initial duration of perfusion was 1 h, which was prolonged to 6 h for doses of > 60 mg/m 2. The drug was given at 4-week intervals		81	14	advanced cancer					26			6	hour		
4214	1980						mg/m2	150		single			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8343268	Homo sapiens						60	total			30 mg/m2/day x 5 days; total dose: 150 mg/m2, which was repeated every 21 days (16-day interval).		75	29						33						
4215	1980						mg/m2	175		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2295116	Homo sapiens						57				The initial duration of perfusion was 1 h, which was prolonged to 6 h for doses of > 60 mg/m 2. The drug was given at 4-week intervals		81	7	advanced cancer					26			6	hour		
4216	1980						mg/m2	200		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2295116	Homo sapiens						57				The initial duration of perfusion was 1 h, which was prolonged to 6 h for doses of > 60 mg/m 2. The drug was given at 4-week intervals		81	5	advanced cancer				highest studied dose	26			6	hour		
4217	1980						mg/m2	55		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/33012678/	Homo sapiens						58							1	colon cancer				5-fluoruracil	58					leucovorin	
4218	1980						mg/m2	725		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8343268	Homo sapiens						60	total					75	29						33						
4219	1980						mg/m2	900		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8343268	Homo sapiens						60	total					75	29						33						
4220	1980						mg/m2	925		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8343268	Homo sapiens						60	total					75	29						33						
4221	1981		adult			Recommended	%	0.1		steady			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/12772816/	Homo sapiens													39	allergic conjunctivitis								8	week		
4222	1983		adult			Highest studied dose	mg	30		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26366319/	Homo sapiens													120	Plasmodium vivax parasite								7	day		
4223	1983		adult			Highest studied dose	mg/kg	0.6		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/12932090/	Homo sapiens													18	acute, symptomatic Plasmodium vivax malaria	artesunate							14	day	50 mg	
4224	1983		adult			Recommended	mg	15		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26366319/	Homo sapiens													118	Plasmodium vivax parasite								14	day		
4225	1983		adult			Recommended	mg	15		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26366319/	Homo sapiens													120	Plasmodium vivax parasite								14	day		
4226	1984					Highest studied dose	mg/m2	150		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10944597	Homo sapiens							max			PCB was administered orally at a starting dosage of 125 mg/m2/day for 28 consecutive days (days 1–28) to those who had received previous chemotherapy or at a dosage of 150 mg/m2/day to patients who had not received previous chemotherapy. Treatment cycles were repeated every 56 days.			113	Glioblastoma multiforme								28	day		p.593
4227	1985		adult			Recommended	%	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/3281821/	Homo sapiens													286	Tinea pedis | Tinea cruris | Tinea corporis | Cutaneous candidiasis | Tinea versicolor								5	week		RS 44872
4228	1987						mL	15		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/13343095/	Homo sapiens						75				A case report on overdose. At 4.15 p.m. on July 30, the patient received 5 c.c. of Salyrgan in 10% Travert in water due to misinterpretation of the surgeon's handwriting. In the following 46 hours a total of 15 c.c. of Salyrgan was given in this manner before the mistake was discovered.			1	carcinoma of the stomach								46	hour		
4229	1989		adult			Studied dose	mg/kg	45		multiple					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6761007/	Homo sapiens							mean			2-9 days, once daily or twice daily or alternate days			20	onchocerciasis								5	day		
4230	1989					Studied dose	mg	600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17046467/	Homo sapiens						20				600 mg amodiaquine for 2 days and 300 mg on the third day			220	malaria								3	day		
4231	1989					Studied dose	mg	71.6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3082410/	Homo sapiens						35	mean			average duration			2	malaria								81	day		
4232	1989					Studied dose	mg	73.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3082410/	Homo sapiens							mean			average duration		76	7	malaria					17			49	day		
4233	1989					Studied dose	mg/kg	10		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18415093/	Homo sapiens												45	15						18			1	day		
4234	1989					Studied dose	mg/kg	10		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18415093/	Homo sapiens												45	7						18			1	day		
4235	1989					Studied dose	mg/kg	10		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18415093/	Homo sapiens												45	8		4 mg/kg; single dose			artesunate	18			1	day		
4236	1989					Studied dose	mg/kg	10		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18415093/	Homo sapiens												45	8						18			1	day		
4237	1993		infant				%	2		multiple			day	10	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1451385	Homo sapiens										The mother obtained a 2% solution and painted it in the child’s mouth before each breast-feeding, at least 10 to 12 times daily for four days.			1									4	day		
4238	1993						%	1		single					unhealthy	ophthalmic	F		https://pubmed.ncbi.nlm.nih.gov/434094	Homo sapiens						55							1						55						
4239	1995		adult				mg	250		multiple			week	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02488980	Homo sapiens										Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.			101	Falciparum Parasitaemia								24	week		
4240	1995					Highest studied dose	mg/kg	25		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8846489	Homo sapiens												88	873	Acute falciparum malaria					0.4						p.836
4241	1995					Recommended	mg	1250		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens														Malaria				chloroquine							p.12
4242	1995					Recommended	mg	1250		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens														Malaria				Halofantrine							p.12
4243	1995					Recommended	mg	1250		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens														Malaria				Ketoconazole							p.12
4244	1995					Recommended	mg	1250		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens														Malaria				quinine							p.12
4245	1995					Recommended	mg	1250		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf	Homo sapiens														Malaria											p.12
4246	1996		adult			Studied dose	mg	600		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4968585/	Homo sapiens													62	bronchitis								2	week		
4247	1997					Recommended	g	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10366112	Homo sapiens							max						66	Diffuse systemic sclerosis								24	month		p.1200
4248	1997					Recommended	g	4		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf	Homo sapiens							max			Wilson's Disease: a dose between 0.75 and 1.5 g that results in an initial 24-hour cupriuresis of over 2 mg should be continued for about three months. The usual dosage of CUPRIMINE in the treatment of cystinuria is 2 g/day for adults, with a range of 1 to 4 g/day.				Wilson's disease|Cystinuria											p.4
4249	2000		adult			Recommended	mg/kg	3		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/10595867/	Homo sapiens										0.3 to 3 mg/kg			1300	planned operation											
4250	2005					Highest studied dose	mg/kg	75		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/4340029 |https://pubmed.ncbi.nlm.nih.gov/13148513	Homo sapiens														tubersulosis								6	week		
4251	2005						mg/kg	15		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/4340029	Homo sapiens						58							1	tubersulosis				pyrazinamide	58			7	week		
4252	2009					Recommended	mL/kg	0.5		single					unhealthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/teslascan-epar-product-information_en.pdf	Homo sapiens										Each ml contains 7.57 mg of anhydrous mangafodipir trisodium, 0.01 mmol (10 μmol), equivalent to 6.91 mg of mangafodipir. Should be administered as an intravenous infusion at the rate of 2-3 ml/min for liver imaging and at a rate of 4-6 ml/min for imaging of the pancreas.				Liver lesions											
4253	2009					Recommended	umol/kg	5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10931579	Homo sapiens													546	Liver lesions											
4254	2010		children			Highest studied dose	mg/kg	100		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/15238906	Homo sapiens																									
4255	2015		ADULT			Highest studied dose	mg	400		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens						34.7	total daily dose						6									8	day		271-279
4256	2015		ADULT			Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29681381/	Homo sapiens						34.7							6									1	day		271-279
4257	2016		ADULT			Highest studied dose	mg/m2	0.6		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/14586557/	Homo sapiens						56	max			Treatment consisted of a daily infusion of exatecan mesylate (DX-8951f) at 0.3 mg/m(2) per day (except for one minimally pretreated patient who started at 0.5 mg/m(2) per day) over 30 min for five consecutive days every 3 weeks. In the patient treated at 0.5 mg/m2 per day for 5 days, the dose was escalated to 0.6 mg/m2 per day.		65	16	cancer					33			5	day		p.4
4258	2016		ADULT			Highest studied dose	mg/m2	0.6		multiple			day	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10963644/	Homo sapiens						3				minimally pretreated patients		22	6	cancer					1			30	course		p.3156
4259	2016		ADULT			MTD	mg/m2	0.5		multiple			day	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10963644/	Homo sapiens						3				minimally pretreated patients		22	6	cancer					1			14	course		p.3156
4260	2016		ADULT			RP2D	mg/m2	0.5		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12942555/	Homo sapiens						52	max					69	39	breast carcinoma					29			5	day		p.901, 903, 904
4261	2016		ADULT			RP2D	mg/m2	0.5		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12942555/	Homo sapiens						52						69	5	breast carcinoma					29			5	day		p.901, 903, 904
4262	2021					Studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7159691	Homo sapiens												30	4						20						p.376
4263	2023		ADULT			Recommended	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11706098/	Homo sapiens						68							453	stroke								6	week		p.1598
4264	2025		adult			Studied dose	mg	20		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/25201353/	Homo sapiens													30	cough											
4265	2026					Studied dose	%	0.1		single			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/16426305/	Homo sapiens										patch test		55	8						28			1	day		
4266	2030						mg/mL	1.69		single					healthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/31124982	Homo sapiens						34				Preparation of Fit Test Solution: Add 337.5 mg of Denatonium Benzoate to 200 mL of the previously prepared 5% NaCl solution.			1						34						
4267	2030						ppm	300		single					healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/30502985	Homo sapiens						27				a series of 3 drops of the experimental solution applied to the conjunctival cul-de-sac, spaced 1 minute apart. (100 parts per million [ppm] denatonium benzoate in sterile water			14						27						
4268	2030						umol/kg	1		single					healthy	intragastric	M+F		https://pubmed.ncbi.nlm.nih.gov/28148502/	Homo sapiens						29				1 umol Denatonium benzoat/kg body weight was administered directly into the upper part of the stomach through a Flocare nasogastric feeding tube (Nutricia)			65						29						
4269	2041		ADULT			Recommended	mg	60		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2569485/	Homo sapiens						25							75	pain disorder	650 mg			Acetaminophen							p.664
4270	2045		ADULT			Abused dose	mg	30		multiple			day	6	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27213892/	Homo sapiens						35				He had used 15 mg of Zoletil per injection 5–6 times per day at intervals of 4 h to seek euphoria and a distorted sense of time.  Over  the  following  6 months,  he  had attempted doubling the dose			1									6	month		p.364
4271	2046		adult			Studied dose	mg/kg	4		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/4176446/	Homo sapiens							mean			3 to 5 mg/kg btw			27									1	day		
4272	2046					Studied dose	mg/kg	2		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/30349973/	Homo sapiens						27				dosage from: https://pubmed.ncbi.nlm.nih.gov/4655681/			1	Lipedema					27			1	day		
4273	2047					Studied dose	%	1		multiple					healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/6705520/	Homo sapiens						48.5				several months			2									2	month		
4274	2050		ADULT			Studied dose	mg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16417778/	Homo sapiens						31.8						48	60	leukopenia					19			1	month		p.281
4275	2056		ADULT			Abused dose	mg	100		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/11527235/	Homo sapiens						30							1		100 mg			tiletamine hydrochloride							p.400
4276	2056		ADULT			Abused dose	mg	1125		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27341080/	Homo sapiens						30	total			Intravenous injection. The patient may have consumed a total of 2,250 mg of Zoletil® or 1,125 mg tiletamine and 1,125 mg zolazepam, over a period\nof 9 days.			1		1125 mg			tiletamine							p.762, 763
4277	2056		ADULT			Abused dose	mg	875		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/27341080/	Homo sapiens						83				The patient was suspected to have been injected with 7 vials of Zoletil® 50 (250 mg/vial), or 875 mg tiletamine and 875 mg zolazepam			1		875 mg			tiletamine							p.762
4278	2058		ADULT			Studied dose	mg	390		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10397378/	Homo sapiens												32	10						24						
4279	2058		ADULT			Studied dose	mg	390		single					healthy	rectal	M+F		https://pubmed.ncbi.nlm.nih.gov/10397378/	Homo sapiens												32	10						24						
4280	2058		ADULT			Studied dose	mg/kg	75		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9880383/	Homo sapiens						71.7				intravenous infusion over a 24-hour period			679	stroke											
4281	2059		ADULT			Highest studied dose	mg	270		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8576295/	Homo sapiens						49							60	irritable bowel syndrome								6	week		277-82
4282	2059		ADULT			Highest studied dose	mg	50		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/5318612/	Homo sapiens													14	irritable bowel syndrome								1	day		848-51
4283	2063		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17011409/	Homo sapiens						44.2						90	363	sinusitis					18			10	day		p.515
4284	2064		ADULT			Recommended	%	0.75		multiple			day	2	unhealthy	intranasal	F		https://pubmed.ncbi.nlm.nih.gov/2523279/	Homo sapiens						60							1	sinusitis								10	day		154
4285	2064		ADULT			Recommended	mg	90		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24824664/	Homo sapiens						18	total daily dose						1	respiratory system disease	300 mg/d			levetiracetam				1	day	zonisamide	84-7
4286	2064		NEWBORN			Highest studied dose	mg/kg	40		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26130623/	Homo sapiens						1.37	total daily dose						32	respiratory distress syndrome of newborn								10	day		339-50
4287	2068		ADOLESCENT|ADULT			Studied dose	mg	50.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11972485/	Homo sapiens						35.1	total			The doses of benzydamine administered were 4.8 mg,\n8.4 mg, 15.6 mg, and 21.6 mg, respectively, with a total therapeutic dose being 50.4 mg. Increased\ndrug doses were given at 60 min intervals.		79	137	allergy					14						p.444
4288	2068		ADULT			Recommended	mg/mL	1.5		multiple			3 hours	1	unhealthy	oromucosal	M+F		https://pubmed.ncbi.nlm.nih.gov/3521255/	Homo sapiens													37	mucositis											p.133
4289	2068		ADULT			Studied dose	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28961427/	Homo sapiens						24.03						39	30	pain disorder					18			7	day		p.7
4290	2069		ADULT			Studied dose	mg	32		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32881359/	Homo sapiens						53						62	12	COVID-19					50			14	day		
4291	2069		ADULT			Studied dose	mg	8		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33722999/	Homo sapiens													48	COVID-19								28	day		
4292	2071		ADULT			Highest studied dose	g	2		multiple			day	3	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3364953/	Homo sapiens						22.2						26	12						18						p.356
4293	2071		ADULT			Studied dose	g	1		multiple			day	3	unhealthy	parenteral	M+F		https://pubmed.ncbi.nlm.nih.gov/3377459/	Homo sapiens						56						81	30	urinary tract infection					22			14	day		p.475
4294	2072		ADULT			Highest studied dose	mg	200		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1503438/	Homo sapiens						32							8									8	day		762-8
4295	2072		ADULT			Highest studied dose	mg	450		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15587753/	Homo sapiens							total daily dose						83	respiratory system disease								14	day		590-607
4296	2074					Studied dose	mg	200		multiple			week	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7881024/	Homo sapiens												86	101	gastric ulcer					17			8	week		
4297	2075		ADULT			Studied dose	g	1		steady			day	2	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/3444025/	Homo sapiens													27	urinary tract infection								5	day		
4298	2076					Studied dose	ug	900		multiple			day	1	unhealthy	respiratory	unknown		https://pubmed.ncbi.nlm.nih.gov/7886652/	Homo sapiens							total					78	20	obstructive pulmonary disease					56						
4299	2077					Highest studied dose	g	130		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3552029/	Homo sapiens										In a dose-escalating study on 21 patients, 130g/day was max tested dose. This dose was tolerated by 2 subjects of 21		48	21						23						
4300	2077					MTD	g	74		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3552029/	Homo sapiens										threshold dose in a dose escalating study		48	21						23			10	day		
4301	2077					Recommended	g	20		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211281s000lbl.pdf	Homo sapiens												87	298	chronic idiopathic constipation					18						
4302	2077					Recommended	g	20		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211281s000lbl.pdf	Homo sapiens												88	291	chronic idiopathic constipation					18			6	month		
4303	2080		ADULT			Highest studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6615689/	Homo sapiens												39	24						20						p.155
4304	2080		ADULT			Overdose	g	10		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3623579/	Homo sapiens						61							1												
4305	2081		ADULT			MTD	mg/m2	100		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26831498/	Homo sapiens						49.3				The regimen consisted of 1.8-2.0 Gy daily radiation for 5 days a week and NDP with dose escalation of 100 mg/m(2) on day 1. The cycles were repeated every 21 days (day 1, day 22 and day 43)		68	4	Nasopharyngeal carcinoma					39						p.646
4306	2081		ADULT			MTD	mg/m2	160		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12477999/	Homo sapiens						52				5-FU was administered at a fixed dose (700 mg/m2/d on days 1-5) and NDP was administered on day 6 at a dose of 160 mg/m2.		74	6	cancer	5-FU was administered at a fixed dose (700 mg/m2/d on days 1-5) and NDP was administered on day 6 at a dose of 160 mg/m2.			5-FU	30						p.566, 567
4307	2081		ADULT			MTD	mg/m2	90		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16821599/	Homo sapiens						60				NDP was administered intravenously over 1 h on\nday 8. The schedule was repeated every\n4 weeks.		74	3	head and neck cancer	Oral administration of S-1 (days 1-14). S-1 (Taiho Pahrmaceutical Co., Ltd., Tokyo, Japan) is an\noral anticancer agent (tegafur, gimeracil and oteracil\npotassium at a molar ratio 1:0.4:1)		oteracil	tegafur	38		Oral administration of S-1 (days 1-14). S-1 (Taiho Pahrmaceutical Co., Ltd., Tokyo, Japan) is an\noral anticancer agent (tegafur, gimeracil and oteracil\npotassium at a molar ratio 1:0.4:1)			gimeracil	p.2266
4308	2081		ADULT			RP2D	mg/m2	90		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26831498/	Homo sapiens						49.3				The regimen consisted of 1.8-2.0 Gy daily radiation for 5 days a week and NDP with dose escalation of 90 mg/m(2) on day 1. The cycles were repeated every 21 days (day 1, day 22 and day 43)		68	8	Nasopharyngeal carcinoma					39						p.646
4309	2082		ADULT			Higher than recommended	mg	120		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/479385/	Homo sapiens												73	30	pain disorder					18						p.398
4310	2082		ADULT			Highest studied dose	mg/kg	0.4		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/391253/	Homo sapiens						54						69	25	pain disorder					22						p.963, 964
4311	2082		ADULT			Lethal dose	g	1.8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20360495/	Homo sapiens						19							1		700 mg			diclofenac sodium							p.407
4312	2082		ADULT			Overdose	g	1.8		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17868209/	Homo sapiens						44							1												p.1509
4313	2082		ADULT			Recommended	mg	90		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7357809/	Homo sapiens													25	pain disorder											p.506
4314	2083		ADULT			Highest studied dose	mg/m2	90		multiple			5 weeks	1	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/16739319/	Homo sapiens						54.5	max					67	17	glioblastoma					41						p.555
4315	2083		ADULT			Highest studied dose	mg/m2	90		multiple			5 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16739319/	Homo sapiens						58	max					69	16	glioblastoma					32						p.555
4316	2083		ADULT			MTD	mg/m2	40		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27725524/	Homo sapiens						54						75	6	malignant glioma	The fixed dose of TMZ was 150 mg/m2 . TMZ was taken for 5 consecutive days (Day 1-5) followed by a 23-day rest period; one cycle was 28 days. ACNU was administered at day 14 on each cycle.			Temozolomide	42						p.20,21
4317	2083		ADULT			Studied dose	mg/m2	45		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27725524/	Homo sapiens						57						67	3	malignant glioma	The fixed dose of TMZ was 150 mg/m2 . TMZ was taken for 5 consecutive days (Day 1-5) followed by a 23-day rest period; one cycle was 28 days. ACNU was administered at day 14 on each cycle.			Temozolomide	45						p.20,21
4318	2083		ADULT			Studied dose	mg/m2	75		multiple			6 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1312909/	Homo sapiens						61						68	24	lung cance					47						p.410
4319	2085		adult			Recommended	mg	250		multiple			day	3	unhealthy	oral	M+F		https://www.nejm.org/doi/full/10.1056/NEJM196011032631805	Homo sapiens													437	Infection											
4320	2085					Highest studied dose	g	1		single			day	1	unhealthy	oral	M+F		https://www.mdpi.com/2079-6382/8/3/119/htm	Homo sapiens													84	Infection											
4321	2085					Highest studied dose	mg	250		multiple			day	4	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/pii/S1198743X14614919	Homo sapiens													120	Infection								7	day		
4322	2086		ADULT			Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25632806/	Homo sapiens													218	irritable bowel syndrome											p.11
4323	2093		ADULT			Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=33966	Homo sapiens							max			In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to the disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.				bacterial infectious disease											
4324	2093		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18462354/	Homo sapiens						68.9				300 mg tosufloxacin tosilate (including 204 mg tosufloxacin) twice daily for 2 days			124	urinary tract infection								2	day		p.604
4325	2094		ADULT			Highest studied dose	mg	600		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/344090/	Homo sapiens						45.3	total daily dose						40	irritable bowel syndrome								3	day		86-8
4326	2095		ADULT			Recommended	mg	1		multiple			day	2	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=35977	Homo sapiens														respiratory airway obstruction											
4327	2095		ADULT			Recommended	mg	2		multiple			day	1	unhealthy	transdermal	M+F		https://pubmed.ncbi.nlm.nih.gov/18344636/	Homo sapiens						71.8							16	chronic obstructive pulmonary disease								4	week		p.507
4328	2095		ADULT			Studied dose	ug	400		multiple			day	4	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/1974678/	Homo sapiens						40.8						68	17	chronic obstructive lung disease					18			2	month		p.202, 208
4329	2095		CHILD|ADOLESCENT|ADULT			Recommended	mg	2		multiple			day	1	unhealthy	transdermal	M+F		https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=34505	Homo sapiens														respiratory airway obstruction											
4330	2096		ADULT			Recommended	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12664248/	Homo sapiens						58							5	artery disease								6	month		p.51
4331	2098		ADULT			Recommended	mg	10		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14686764/	Homo sapiens						70							1	bladder disease								6	month		1156
4332	2098		ADULT			Recommended	mg	10		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11868380/	Homo sapiens						78	total daily dose						1	prostatic hypertrophy								6	day		21-3
4333	2098		ADULT			Recommended	mg	10		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16180710/	Homo sapiens						74	total daily dose						1	constipation								2	day		600-2
4334	2098		ADULT			Recommended	mg	5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14611928/	Homo sapiens						31							1	multiple sclerosis								6	week		318-9
4335	2098		ADULT			Studied dose	mg	0.5		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/6132645/	Homo sapiens						71							46	prostatectomy voiding								4	day		229-32
4336	2103		ADULT			Highest studied dose	ug/m2	2250		multiple			3 weeks	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7743508	Homo sapiens						54.1						72	1	cancer					30			1	cycle		p.2092
4337	2103		ADULT			Highest studied dose	ug/m2	940		multiple			4 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10501914	Homo sapiens						59						75	3	cancer					42						p.406
4338	2103		ADULT			MTD	ug/m2	1500		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7743508	Homo sapiens						54.1						72	6	cancer					30			4	cycle		p.2092
4339	2106					Studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3540874/	Homo sapiens						24.3				extraction of impacted teeth			40												
4340	2107					Recommended	mg	220		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6105412/	Homo sapiens						27							1	pain	30 mg; 1-2 tablets once or twice per day for 18 days			allobarbitone	27			18	day		
4341	2107					Recommended	mg	220		multiple			day	2	unhealthy	rectal	M+F		https://pubmed.ncbi.nlm.nih.gov/4589282/	Homo sapiens						6.4		30 mg; 2 per day					43	pain	5 mg; 2 per day			codeine				1	day	diallymal	
4342	2107					Studied dose	%	10		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/6627934/	Homo sapiens						28							1						28			1	day		
4343	2107					Studied dose	mg	286		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3125269/	Homo sapiens						24.3		20 mg; 2 per day during 2.5 days					84	pain	114 mg; 2 per day during 2.5 days			barbital				2.5	day	aethylmorphin hydrochlorid	
4344	2109		ADULT			Studied dose	mg/m2	240		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/77191/	Homo sapiens							total daily dose						29	malignant melanoma								10	day		
4345	2109		CHILD|ADULT			Studied dose	mg/kg	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1057949/	Homo sapiens							max|total daily dose						43	acute leukemia								7.5	day		p.754
4346	2110					Studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4380496/	Homo sapiens												47	12						23						
4347	2111		ADULT			Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5750161/	Homo sapiens							total daily dose							ptosis								21	day		594-9
4348	2111		ADULT			Highest studied dose	mg	5		single					healthy	intramuscular	M+F		https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/119934	Homo sapiens																						1	day		833-44
4349	2112		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1794296/	Homo sapiens													31	dementia								10	week		
4350	2112		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7490169/	Homo sapiens													52	depression								8	week		
4351	2112		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7923314/	Homo sapiens													10	aphasia								2	month		
4352	2112		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8846747/	Homo sapiens													13	cerebral infarction								3	month		
4353	2112		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8851457/	Homo sapiens													20	glaucoma								48	month		
4354	2113		ADULT			Higher than recommended	mg	120		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/1729516/	Homo sapiens						46				5 ml Avafortan (1 ml. Avafortan contains 24 mg. camylofin bis and 240 mg. noramidopyrine methanesulfonate sodium) intramuscular injection			16	pain disorder	1200 mg			noramidopyrine methanesulfonate sodium							p.17
4355	2115		ADULT			Highest studied dose	mg/kg	0.9		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1606084/	Homo sapiens						50						79	6	cancer					22			1	day		141-3
4356	2115		ADULT			Recommended	mg	1.5		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8419802/	Homo sapiens						82	total daily dose						1	gastrointestinal disorder	6 mg/day			Biperiden				8	month		125-6
4357	2115		ADULT			Recommended	mg	1.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1557073/	Homo sapiens							max|total daily dose			mean duration		61	2	gastrointestinal disorder					60			2.5	month		89-90
4358	2115		ADULT			Studied dose	mg	0.68		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31145322/	Homo sapiens						19							1	gastrointestinal disorder	150 mg		bismuth	tiropramide			100 mg	1	day	ranitidine	
4359	2117		ADULT			Higher than recommended	mg	210		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3090971/	Homo sapiens						29	max|total daily dose						1	digestive system disorder								5	year		515-8
4360	2117		ADULT			Highest studied dose	mg	90		single					unhealthy	oral	M+F		http://www.medrech.com/index.php/medrech/article/view/239	Homo sapiens												60	16	obesity					18			1	day		252-265
4361	2127		ADULT			Recommended	mg	500		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1883797/	Homo sapiens										Treatment was started on the first day of\nbleeding and continued until the end of\nbleeding			16	uterine disease											p.709
4362	2128					Recommended	mg	100		multiple			day	6	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13469802	Homo sapiens													83	Pain											p.416
4363	2129		ADULT			Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8815393/	Homo sapiens						71.7	total daily dose					82	9	Alzheimer disease					63			12	week		89-94
4364	2129		ADULT			Highest studied dose	mg	300		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/31534090/	Homo sapiens						48							1	thiamine deficiency disease								1	day		373-376
4365	2129		NEWBORN			Highest studied dose	mg	500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/413089/	Homo sapiens						0.5	total daily dose						1	lactic acidosis								6	week		1198-202
4366	2132		ADULT			Highest studied dose	mg	8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9215605/|https://link.springer.com/article/10.2165/00126839-199902040-00003	Homo sapiens													15	cancer								3	day		436-44|243–4
4367	2132		ADULT			Highest studied dose	ug/kg	280		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10378635/	Homo sapiens													7	cancer								1	day		99-104
4368	2134					Highest studied dose	mg	150		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11122017/	Homo sapiens												69	34	psoriasis					23			12	week		
4369	2134					MTD	mg	300		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8591087/	Homo sapiens												80	18	hormone-refractory carcinoma of the prostate					51			2	week		
4370	2134					MTD	mg	300		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8591087/	Homo sapiens												80	3	hormone-refractory carcinoma of the prostate					51			11	day		
4371	2134					Studied dose	mg	150		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8591087/	Homo sapiens												80	1	hormone-refractory carcinoma of the prostate					51			11	day		
4372	2134					Studied dose	mg	37.5		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8591087/	Homo sapiens												80	1	hormone-refractory carcinoma of the prostate					51			144	day		
4373	2134					Studied dose	mg	75		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8591087/	Homo sapiens												80	1	hormone-refractory carcinoma of the prostate					51			31	day		
4374	2134					Studied dose	mg	75		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11703279/	Homo sapiens												74	7	palmoplantar pustular psoriasis					47			12	week		
4375	2136		ADULT			Highest studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/350498/	Homo sapiens						55.4	max|total daily dose			first week of treatment		65	15	bronchitis					37			6	week		461-71
4376	2137		ADULT			Overdose	mg	276		single					pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/18818182/	Homo sapiens							mean			between 60 and 500 mg			835												
4377	2137		ADULT			Studied dose	mg	10		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4923930/	Homo sapiens													24	Anxiety								3	week		
4378	2145		ADULT			Higher than recommended	mg	32		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7437255/	Homo sapiens						60						68	30	heart disease					49						p.441
4379	2145		ADULT			Recommended	mg	24		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7002181/	Homo sapiens						60.3						69	23	heart disease					43						p.214
4380	2147		ADULT			Recommended	mg	3		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33835016/	Homo sapiens						32				4 mg pridinol mesylate (equivalent to 3 mg pridinol)		55	34						19						p.475, 476
4381	2148		ADULT			Studied dose	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/37142/	Homo sapiens												66	9	Irritable colon					25			6	week		p.501
4382	2149		ADULT			Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28965354/	Homo sapiens						60.2						80	16	urinary tract disease					31						p.3
4383	2150		ADULT			Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2135070/	Homo sapiens						22.3							12									3	day		159-64
4384	2150		ADULT			Recommended	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15001508/	Homo sapiens							total daily dose			dose range: 400-600 mg; mean duration		41	6	psychotic disorder					18			19	day		572-4
4385	2154		ADULT			Highest studied dose	mg	150		multiple			day	3	unhealthy	oral	M+F		https://link.springer.com/article/10.1007/BF00567114	Homo sapiens							total daily dose					69	7	chronic obstructive pulmonary disease					44			2	week		197–200
4386	2154		ADULT			Highest studied dose	mg	20		single					healthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/7173296/	Homo sapiens													2									1	day		267-70
4387	2154		ADULT			Highest studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8689817/	Homo sapiens						26							9									1	day		89-98
4388	2155		ADULT			Highest studied dose	mg	15		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3436156/	Homo sapiens						60						70	12	ureterolithiasis					46			1	day		596-600
4389	2155		ADULT			Recommended	mg	30		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12361147/	Homo sapiens						57							1	ureterolithiasis				allopurinol				1	month		316-7
4390	2157		CHILD|ADOLESCENT|ADULT			Recommended	mg	0.09		multiple			day	4	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/26539289/	Homo sapiens						27.2				a single puff of spray (0.07 mL spray containing 0.09 mg tramazoline) into\neach nostril, up to 4 times daily			300	acute rhinitis								10	day		p.3
4391	2160		ADULT			MTD	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15204011/	Homo sapiens													27	amyotrophic lateral sclerosis											p.105, 106
4392	2162		ADULT			Recommended	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2044395/	Homo sapiens						61						75	38	peripheral artery disease					37			12	month		p.360, 361
4393	2164		UNKNOWN			Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	unknown		https://www.info.pmda.go.jp/go/interview/2/400315_1179030D1050_2_100_1F.pdf#page=26	Homo sapiens														psychotic disorder											
4394	2166		adult			Recommended	mg	25		steady					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6037449/	Homo sapiens													22		0.1 mg			ethinyl estradiol				42	month		
4395	2175					Studied dose	mg	7.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4149736	Homo sapiens						42				Initial dosage was 2.5 mg morning and noon. The dosage could be adjusted by adding an additional tablet at either time or by reducing to the 1.0-mg tablets, but medication was not to be taken after 4 p.m. and the total daily dosage was not to exceed 7.5 mg.			47	mild depression					42			2	week		
4396	2177						mg	30		multiple			day	1	unhealthy	oral	unknown		https://link.springer.com/content/pdf/10.1007%2F978-3-319-56015-1_224-1.pdf	Homo sapiens													29												
4397	2179		ADULT			Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M		https://www.sciencedirect.com/science/article/abs/pii/S037860808380021X	Homo sapiens						44							1	asthma	200 mg			theophylline				5	week		189-192
4398	2179		ADULT			Recommended	mg	200		multiple			day	4	unhealthy	oral	F		https://www.sciencedirect.com/science/article/abs/pii/S037860808380021X	Homo sapiens						64				two doses of medication			1	asthma	12 mg/day			salbutamol				1	day		189-192
4399	2180		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://www.aci-bd.com/Brand/Tynium.pdf	Homo sapiens							max			The usual dosage is 2 to 6 tablets (100 to 300mg) daily in divided doses as required.				dystonia											
4400	2182		ADULT			MTD	mg/m2	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15809877	Homo sapiens						56				300 mg/m2 orally every 12 h for 3 days weekly for 3 weeks		73	3	cancer	22.5 mg/m2 IV weekly for 3 weeks every 28 days			vinorelbine	40			3	day		p.157, 158
4401	2188		ADULT			Higher than recommended	mg	80		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/841782/	Homo sapiens						66							1	cystitis								1	day		180-1
4402	2188		ADULT			Recommended	mg	40		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8048206/	Homo sapiens						72							1	urinary system disease	1 g		atracurium	cefazolin				1	day	propofol	271-2
4403	2188		ADULT			Recommended	mg	40		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18835972/	Homo sapiens												64	2	urinary system disease	4%		morphine	bupivacaine	49		8 mg	1	day	desflurane	717-8
4404	2190						%	0.01		multiple			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/8112079	Homo sapiens						54							1						54						
4405	2191		ADULT			Studied dose	mg	100		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8523500/	Homo sapiens												45	10						19			5	day		p.719
4406	2191		ADULT			Studied dose	mg/kg	30		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9581027/	Homo sapiens						43						65	12	gastrointestinal system disease					26						p.92
4407	2196					Recommended	%	0.05		multiple			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9402834/	Homo sapiens						62							1						62			30	year		
4408	2197		ADULT			Recommended	mg	80		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21837534/	Homo sapiens						40.5							50	calculus of kidney and ureter								12	week		p.331
4409	2197		ADULT			Recommended	mg	80		single					pregnant	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/30167045/	Homo sapiens						26.6							61												p.1
4410	2197		ADULT			Recommended	mg	80		single					unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/25956954/	Homo sapiens						38							60	pain disorder											p.11
4411	2198		ADULT			Studied dose	g	2		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25027339/	Homo sapiens							max			Patients received 1.0 g of Cefoselis for moderate infection or 2.0 g intravenous infusion for severe infection administered\nat an interval of 12 hours for 7 to 14 days.		70	124	bacterial infectious disease					18			14	day		p.2010
4412	2210					Highest studied dose	mg	8		multiple			hour	2	healthy	intravenous	F		https://www.jemds.com/data_pdf/3_Sunita%20%20%20%20Ruksa--%20GU.pdf	Homo sapiens												30	50	Labour					20			3	hour		Page 13676
4413	2210					Toxic dose	mg	60		single					healthy	intravenous|intramuscular	F		https://www.jemds.com/data_pdf/3_Sunita%20%20%20%20Ruksa--%20GU.pdf	Homo sapiens														Labour											Page 13674
4414	2215		adult				mg/kg	0.15		multiple			week	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01090180	Homo sapiens													33	PTSD								4	week		
4415	2215		children				mg/kg	0.6		single					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02794441	Homo sapiens													6	Migraine											
4416	2215						%	0.1		multiple			day	3	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/25135542	Homo sapiens						68.3						83	77						51			3	week		
4417	2215						mg	10		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00122278	Homo sapiens													106	Migraine											
4418	2215						mg	12		multiple			day	1	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT02271698	Homo sapiens													10	Knee Arthroplasty								2	day		
4419	2215						mg	20		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/33743063	Homo sapiens																									
4420	2215						mg	24		multiple			day	1	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT02271698	Homo sapiens													10	Knee Arthroplasty								2	day		
4421	2215						mg	8		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01248585	Homo sapiens													147	Radiation-Induced Pain Flare								5	day		
4422	2215						mg	8		single					pregnant	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT01734161	Homo sapiens													55												
4423	2215						mg	96		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31139529	Homo sapiens						63	total			mean cumulative dose of dexamethasone was 96±34 mg with a mean duration of 17±7 days.			21						63			17	day		
4424	2216					Recommended	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11192131	Homo sapiens								300 mg, BID				62	113	HIV-1 infection	150 mg, BID			lamivudine, po	21					zidovudine, po	p.1387
4425	2216					Recommended	mg	1200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf	Homo sapiens														HIV-1 infection											p.11
4426	2216					Recommended	mg	1200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10390223	Homo sapiens													12	HIV-1 infection											p.1688
4427	2217		newborn			Studied dose	ug	250		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/30451018/	Homo sapiens													1	interrupted aortic arch								1	day		
4428	2217					Recommended	ug	10.5		multiple			day	1	unhealthy	intracavernosal	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-212_Caverject_medr.pdf	Homo sapiens						59	mean			dose range: 2.5-20 ug			87	erectile dysfunction								12	day		nda/2002/21-212_Caverject_medr.pdf - p.15
4429	2217					Recommended	ug	18.7		multiple			week	2	unhealthy	intracavernosal	M		https://pubmed.ncbi.nlm.nih.gov/8733986/	Homo sapiens						48.3	mean			dose range 5-60 ug; optimal dose establishment; maximum - 10 injections per week			150	erectile dysfunction								1	week		
4430	2217						ug	40		steady			day	2	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00596752	Homo sapiens													416	Peripheral Arterial Occlusive Disease								4	week		
4431	2217						ug	60		steady			day	1	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00619229	Homo sapiens							total daily dose						18	Macular Degeneration								15	day		
4432	2218		adult			Recommended	mg	2550		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf	Homo sapiens													141	type 2 diabetes mellitus											
4433	2218		adult			Recommended	mg	850		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf	Homo sapiens																									
4434	2218		adult				g	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00366301	Homo sapiens							max|total daily dose						126	Type 2 Diabetes								14	week		
4435	2218		adult				mg	1000		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01099618	Homo sapiens													17	Type 2 Diabetes								3	year		
4436	2218		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01447927	Homo sapiens										Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.			38	Barrett's Esophagus								12	week		
4437	2218		adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01483560	Homo sapiens										Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily			219	Type 1 Diabetes								3	year		
4438	2218		adult				mg	1700		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02432287	Homo sapiens							total daily dose						15	Aging								6	week		
4439	2218		adult				mg	2000		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00736385	Homo sapiens							total daily dose						4	Nonalcoholic Fatty Liver Disease								12	week		
4440	2218		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00328172	Homo sapiens							max						65	Type 2 Diabetes								12	week		
4441	2218		adult				mg	500		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01217307	Homo sapiens													191	Heart Failure								4	month		
4442	2218		adult				mg	850		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01280409	Homo sapiens										Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks			46	Obesity								6	week		
4443	2218		adult				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00105066	Homo sapiens										850mg tablet once a day for one month, then twice a day for 3 months			50	Metabolic Syndrome								3	month		
4444	2218		adult				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01632020	Homo sapiens										Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days			3	Colorectal Neoplasms								21	day		
4445	2218		adult				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01717482	Homo sapiens													4	Non-small Cell Lung Cancer								2	year		
4446	2218		adult				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01804049	Homo sapiens							max			Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.			77	Prediabetes								3	year		
4447	2218		adult				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03416127	Homo sapiens													12	Type 2 Diabetes								12	week		
4448	2218		adult				mg	850		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01319994	Homo sapiens													26	Iatrogenic Cushing Disease								12	week		
4449	2218		child				g	1		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02274948	Homo sapiens							max			8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.			166	Obesity								12	month		
4450	2218		child				mg	500		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01410604	Homo sapiens													15	Insulin Resistance								3	month		
4451	2218		child				mg	850		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01825798	Homo sapiens							max			Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.			28	Overweight								16	week		
4452	2218		child|adult				mg	1000		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01808690	Homo sapiens													25	Type 1 Diabetes								3	month		
4453	2219					Highest studied dose	%	5		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/9797239	Homo sapiens													96	Recurrent genital herpes											p.2998
4454	2219					Highest studied dose	mg/kg	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8739595	Homo sapiens													5	Acquired immunodeficiency syndrome (AIDS)											p.154
4455	2219					Highest studied dose	mg/kg	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8739595	Homo sapiens													5	Acquired immunodeficiency syndrome (AIDS)											p.154
4456	2219					Recommended	mg/kg	5		multiple			week	1	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90639fc6-0295-4115-98f0-054b783850ce&type=display	Homo sapiens										The recommended maintenance dose of VISTIDE (cidofovir) is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over 1 hr), administered once every 2 weeks.				CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)											p.1
4457	2220		adult			Highest studied dose	mg	7.2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/014215s009s015lbl.pdf	Homo sapiens																									
4458	2220						mg	6		multiple			day	1	pregnant	intramuscular	F		https://clinicaltrials.gov/ct2/show/NCT01222247	Homo sapiens													1429									2	day		
4459	2221					Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2140547/	Homo sapiens						44							120	streptococcal pharyngitis								10	day		
4460	2221					Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/241119/	Homo sapiens						30							35	maxillary sinusitis								10	day		
4461	2221					Recommended	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/241119/	Homo sapiens						30							41	maxillary sinusitis								10	day		
4462	2221					Studied dose	g	5		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1408521/	Homo sapiens						12							1						12			1	day		
4463	2221					Studied dose	g	5.3		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16215473/	Homo sapiens						15							1						15			1	day		
4464	2221						mg	100		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT02005029	Homo sapiens													9	Parkinson's Disease											
4465	2222		adult			Recommended	%	3		multiple			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/33378750/	Homo sapiens										ointment			23	cancer patients with (EGFRI)-induced papulopustular rash								30	day		
4466	2222					Recommended	%	0.5		multiple			day	4	unhealthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/15993231/	Homo sapiens												12	163	acute infective conjunctivitis					0.5			7	day		
4467	2222					Recommended	g	0.25		multiple			3 months	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						11				1 time in 2-3 months			1	infection					11			9	month		
4468	2222					Recommended	g	1		multiple			day	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						68							1	infection					68			15	day		
4469	2222					Recommended	g	1		multiple			day	1	unhealthy	parenteral	M		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						39							1	infection					39			2	month		
4470	2222					Recommended	g	2		multiple			day	1	unhealthy	parenteral	F		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						71							1	infection					71			17	day		
4471	2222					Recommended	g	2.5		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						27							1	infection					27			12	day		
4472	2222					Recommended	g	3		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						23							1	infection					23			13	day		
4473	2222					Recommended	g	4		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						61							1	infection					61			7	day		
4474	2222					Recommended	mg	750		steady			day	4	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3055188/	Homo sapiens						54							1	purulent drainage from the surgical wound				tobramycin	54			27	day	nafcillin	
4475	2222					Recommended	mg/kg	70		steady			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28186714/	Homo sapiens						15							1	Cystic Fibrosis and infection	meropenem				15			8	day	120 mg/kg/day	
4476	2224					Highest studied dose	mg/mL	20		steady					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8119049	Homo sapiens						39				A loading dose of theophylline (20 mg/ml) 0.5 ml/kg was given over 60 minutes then followed by a maintenance infusion at 0.04 ml/h/kg.			87	COPD|asthma					39						p.500
4477	2224					Overdose	mg	1600		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d863a5-63ab-4b29-b181-6d7db38234ba&type=display	Homo sapiens							max			Chronic overdosage, i.e., ingestion of repeated doses that are excessive for the patient's rate of theophylline clearance (Serum Concentration >30 mcg/mL). The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400- 1600 mg/day in adults <60 years old and 10-36 mg/kg/day in children 1-9 years old). Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients.			102	asthma|emphysema|chronic bronchitis											
4478	2224					Overdose	mg	1600		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d863a5-63ab-4b29-b181-6d7db38234ba&type=display	Homo sapiens							max			Chronic overdosage, i.e., ingestion of repeated doses that are excessive for the patient's rate of theophylline clearance (Serum Concentration >30 mcg/mL). The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400- 1600 mg/day in adults <60 years old and 10-36 mg/kg/day in children 1-9 years old). Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients.			92	asthma|emphysema|chronic bronchitis											
4479	2224					Overdose	mg	1600		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d863a5-63ab-4b29-b181-6d7db38234ba&type=display	Homo sapiens							max			Chronic overdosage, i.e., ingestion of repeated doses that are excessive for the patient's rate of theophylline clearance (Serum Concentration >30 mcg/mL). The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400- 1600 mg/day in adults <60 years old and 10-36 mg/kg/day in children 1-9 years old). Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients.				asthma|emphysema|chronic bronchitis											
4480	2224					Overdose	mg/kg	10		single					unknown	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d863a5-63ab-4b29-b181-6d7db38234ba&type=display	Homo sapiens							min			Acute overdose, i.e., ingestion of a single large excessive dose (>10 mg/kg)			14												
4481	2224					Overdose	mg/kg	10		single					unknown	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=88d863a5-63ab-4b29-b181-6d7db38234ba&type=display	Homo sapiens							min			Acute overdose, i.e., ingestion of a single large excessive dose (>10 mg/kg)			157												
4482	2224					Recommended	mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3671893	Homo sapiens						66							6	COPD								5	day		p.149
4483	2224					Recommended	mg	800		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3671893	Homo sapiens						66							6	COPD											p.146
4484	2224					Recommended	mg	800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3671893	Homo sapiens						66							16	COPD								8	day		p.148
4485	2225		adult			Highest studied dose	g	5		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens													9	Bacterial infections	500 mg; 3/day			Sulbactam							nda/pre96/050608Orig1s000rev.pdf - p.161
4486	2225		adult			Recommended	g	0.5		single			day	1	healthy	intramuscular	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens													12									1	day		nda/pre96/050608Orig1s000rev.pdf - p.36
4487	2225		adult			Studied dose	g	1		single			day	1	healthy	intramuscular	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens													11		0.5 g; single dose			Sulbactam				1	day		nda/pre96/050608Orig1s000rev.pdf - p.40
4488	2225					Studied dose	g	2		multiple			day	3	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens						27.1							21	Endomyometritis	1 g; 3/day			Sulbactam				7	day		nda/pre96/050608Orig1s000rev.pdf - p.53
4489	2225					Studied dose	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens						27.4							131	Peritonitis associated with appendicitis	1 g; 3/day			Sulbactam				14	day		nda/pre96/050608Orig1s000rev.pdf - p.57
4490	2225					Studied dose	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens						60.1				mean duration; range 8-12 days			15	Pneumonia	1 g; 3/day			Sulbactam				10.3	day		nda/pre96/050608Orig1s000rev.pdf - p.155
4491	2225					Studied dose	g	2		single			day	1	unhealthy	intramuscular	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens						25.8		1 g; single					101	Acute uncomplicated gonorrhea	1 g; single			Sulbactam				1	day	probenecid	nda/pre96/050608Orig1s000rev.pdf - p.160
4492	2225					Studied dose	mg	650		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/050608Orig1s000rev.pdf	Homo sapiens							mean			2-3 days			4	acute pyelonephritis	300-350 mg; 3/day			Sulbactam				2.5	day		nda/pre96/050608Orig1s000rev.pdf - p.48
4493	2227		adult			Overdose	mg	500		single					unknown	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019201s035lbl.pdf	Homo sapiens										500 to 2000 mg															
4494	2227					Studied dose	mg	50		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31131893/	Homo sapiens												51	24						21						
4495	2227					Studied dose	mg/mL	75		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31077065/	Homo sapiens												53							18						
4496	2228		adult			Recommended	mg/m2	500		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3376977/	Homo sapiens							complex			plus 400-800 mg 4/d for 1 month or longer			28	Human herpesvirus 4								1	day		
4497	2228					Highest studied dose	mg	1000		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8275615/	Homo sapiens						26.6				valaciclovir - aciclovir prodrug			8									1	day		
4498	2228					Highest studied dose	mg	2000		multiple			day	4	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8275615/	Homo sapiens						25.5				valaciclovir - aciclovir prodrug			8									11	day		
4499	2228					Recommended	mg	500		multiple			day	3	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8213806/	Homo sapiens						78							1	herpes zoster					78			1	day		
4500	2228					Studied dose	g	1		multiple			day	3	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8430717/	Homo sapiens						77							1	herpes zoster					77			2	day		
4501	2228					Studied dose	mg	220		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2771532/	Homo sapiens										before were 13 normal doses of acyclovir during 4 days			1	herpes zoster								1	day		
4502	2228					Studied dose	mg	250		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2771532/	Homo sapiens													1	herpes zoster								1	day		
4503	2230					Studied dose	mg	48		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4008807/	Homo sapiens						34						52	10						13			3	day		
4504	2230						mg	4		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/31852144	Homo sapiens												54	2						50						
4505	2230						mg	5		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7106172	Homo sapiens												40	2						27						
4506	2231		adult			Recommended	%	1		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf	Homo sapiens										AzaSite1% ocular 2 drops daily x 2 days, then daily			301	bacterial conjunctivitis								2	week		Study 003
4507	2231		adult			Recommended	%	1		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/050810s000_MedR.pdf	Homo sapiens										AzaSite1% ocular 2 drops daily x 2 days, then daily			333	bacterial conjunctivitis								2	week		Study 004
4508	2231		adult			Recommended	g	0.5		multiple			day	2	unknown	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050809lbl.pdf	Homo sapiens																						5	day		
4509	2231		adult				mg	600		steady			week	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00266851	Homo sapiens										Treatment is azithromycin tablets, 600 milligrams orally once daily for 3 days, then 600 milligrams once weekly for an additional 11 weeks (total dose 8400 milligrams).			20	Asthma								12	week		
4510	2231		adult				mg	600		steady			week	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00266851	Homo sapiens										Treatment is azithromycin tablets, 600 milligrams orally once daily for 3 days, then 600 milligrams once weekly for an additional 11 weeks (total dose 8400 milligrams).			35	Asthma								12	week		
4511	2231		child				mg/kg	10		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01486758	Homo sapiens							max			Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.			19	RSV Bronchiolitis								14	day		
4512	2231		child|adult				mg	500		steady			week	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00431964	Homo sapiens							max			One (1) tablet three times weekly for patients who weigh 40-79 lbs. Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs.			131	Cystic Fibrosis								24	week		
4513	2231					Highest studied dose	g	2		single			day	1	unhealthy	oral	M+F		https://www.nejm.org/doi/full/10.1056/nejm199209243271304	Homo sapiens													237	urethral or endocervical infections with Chlamydia trachomatis.											
4514	2231					Recommended	g	0.5		single			day	1	healthy	intravenous			https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1016/S0009-9236(97)90098-9	Homo sapiens													12												
4515	2232					Recommended	mg	3000		multiple			day	3	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50643s11lbl.pdf	Homo sapiens										Cefuroxime sodium				Bacterial infections								10	day		p.9
4516	2232					Recommended	mg	500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050605s048,050672s034lbl.pdf	Homo sapiens							max			Cefuroxime axetil				Bacterial infections											p.1
4517	2232					Studied dose	mg	500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050605s048,050672s034lbl.pdf	Homo sapiens							max			Cefuroxime axetil			912	Bacterial infections								7	day		p.11
4518	2233					Recommended	%	1		multiple			day	12	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020629Orig1s000rev.pdf	Homo sapiens						39							782	Recurrent Herpes Simplex Labialis								4	day		Study 024
4519	2234		adult			Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	Homo sapiens													214	depression								8	week		
4520	2234		adult			Recommended	mg	600		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018644s043lbl.pdf	Homo sapiens							max			300 to 600 mg 3 to 4 week			2400	depression								4	week		
4521	2235					Highest studied dose	mg	150		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/729619	Homo sapiens						24							17						24			7	day		
4522	2235					Highest studied dose	mg	720		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23918202	Homo sapiens						38.8				Maximum daily dose, median; range: 240 (60–720) mg			38						38.8			32	day		
4523	2235					Overdose	mg	1500		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/19006543	Homo sapiens						16				25 tablets of Sudafed (each containing 60 mg of pseudoephedrine HCl and lactose)			1						16						
4524	2235					Overdose	mg	720		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18608273	Homo sapiens						87				three tablets of Wal-phed D (240mg of sustained release pseudoephedrine per tablet)			1						87						
4525	2235					Overdose	mg	90		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18365604	Homo sapiens						3							1						3			10	day		
4526	2235						mg	120		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10484004	Homo sapiens						46							1	chronic sinusitis | allergic rhinitis					46			6	month		
4527	2235						mg	30		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10484004	Homo sapiens						37							1	sinusitis	500 mg twice daily, oral			acetominophen	37			1	week		
4528	2235						mg	30		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10484004	Homo sapiens						50		2 mg; twice daily, oral					1	rhinitis	500 mg twice daily, oral			acetominophen	50			1	week	chlorpheniramine maleate	
4529	2235						mg	30		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10484004	Homo sapiens						44							1	upper airway infection					44			1	week		
4530	2236						mg	500		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30915263	Homo sapiens						90							1						90			15	day		
4531	2236						mg/kg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23811740	Homo sapiens							median			Median cephalexin dose was 40 (19–51) mg/kg/dose administered every 8 hours, and mean duration of cephalexin therapy was 28 (13–146) days		16	12	Osteoarticular Infections					1			28	day		
4532	2239					Overdose	mg	2000		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7055513	Homo sapiens						31				suicide attempt			1	Schizophrenia	8 g, single			caffeine, p.o							p.52
4533	2239					Overdose	mg	225		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7901355	Homo sapiens						14				suicide attempt			1		36 mg, single			brompheniramine, p.o							p.825
4534	2239					Recommended	mg	150		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4002267	Homo sapiens						56				diet pills (nonprescription)			1	Weight control	280 mg, single			caffeine, p.o							p.510
4535	2239					Recommended	mg	25		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12734532	Homo sapiens						25				diet pills (nonprescription)			1	Weight control								3	day		p.100
4536	2240		adult			Recommended	%	0.5		steady			day	2	unhealthy	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/19270s031lbl.pdf	Homo sapiens														glaucoma								1	month		
4537	2241		adult			Recommended	mg	40		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022020s000_MedR.pdf	Homo sapiens													8									7	day		nda/2007/022020s000_MedR.pdf - p.26
4538	2241					Recommended	mg	40		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20988_Protonix_medr_P2.pdf	Homo sapiens												45	4						18			1	day		nda/2001/20988_Protonix_medr_P2.pdf - p.41
4539	2241					Studied dose	mg	120		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20988_Protonix_medr_P2.pdf	Homo sapiens												45	5						18			1	day		nda/2001/20988_Protonix_medr_P2.pdf - p.41
4540	2241					Studied dose	mg	20		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20988_Protonix_medr_P2.pdf	Homo sapiens												45	6						18			1	day		nda/2001/20988_Protonix_medr_P2.pdf - p.41
4541	2242		adult				mg	10		steady			day	2	unhealthy	sublingual	M+F		https://clinicaltrials.gov/ct2/show/NCT00764478	Homo sapiens													119	Bipolar Disorder								21	day		
4542	2242		adult				mg	5		steady			day	2	unhealthy	sublingual	M+F		https://clinicaltrials.gov/ct2/show/NCT00764478	Homo sapiens													122	Bipolar Disorder								21	day		
4543	2242		pediatric patients			Recommended	mg	10		multiple			day	2	unhealthy	sublingual			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf	Homo sapiens													99	Bipolar Mania											p.16
4544	2242					Recommended	mg	10		multiple			day	2	unhealthy	sublingual			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf	Homo sapiens													1953	Schizophrenia|Bipolar I disorder											p.12
4545	2242					Recommended	mg	10		multiple			day	2	unhealthy	sublingual			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf	Homo sapiens														Schizophrenia|Bipolar I disorder											p.1
4546	2243						ug	30		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf	Homo sapiens						66	starting					85	285	secondary hyperparathyroidism					25			6	month		
4547	2244						mg/kg	15		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8295811/	Homo sapiens													113	skin infections								10	day		
4548	2244						mg/kg	50		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3803250	Homo sapiens							max			dose range: 25 mg/kg/day once daily - 100 mg/kg/day divided into 2 equal doses (50 mg/kg) every 12 hours			395	infections								10	day		
4549	2244						mg/kg	50		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3803251	Homo sapiens							max			100 mg/kg/day divided into 2 equal doses (50 mg/kg) every 12 hours			366	infections								10	day		
4550	2245						mg	1200		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3044876	Homo sapiens						49.8								unstable bladder								4	week		
4551	2245						mg	200		multiple			day	3	unhealthy	oral	F		http://www.jiaci.org/issues/vol22issue5/8-20.pdf | https://pubmed.ncbi.nlm.nih.gov/10385348	Homo sapiens						26							1	urinary infection					26						
4552	2246		adult			Recommended	mg	400		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1621747/	Homo sapiens													235	bacterial infections								7	day		
4553	2246		children and adults			Highest studied dose	mg/kg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1621742/	Homo sapiens							max						4506	bacterial infections								23	day		
4554	2247					Overdose	mg	300		single					healthy	intravascular	F		https://pubmed.ncbi.nlm.nih.gov/17680197	Homo sapiens						25				6.25 mg x kg(-1)			1						25						
4555	2248					Studied dose	drop	9		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/19998578	Homo sapiens						3.44	median|total daily dose			1 g of the target medication (Otalgan eardrops, Südmedica GmbH, München, Germany) contains 50 mg phenazone and 10 mg procaine hydrochloride; the total daily dose ranged from 5 up to >20 drops/d with a median of 9 drops per day. The accumulated dose per treatment cycle ranged from 20 to >100 drops/treatment cycle with a median of 45 drops per treatment cycle.			428	Acute otitis media	9 drops, 1/day, 5.15 days			phenazone, topical				5.15	day		p.507
4556	2248					Studied dose	mg	50		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6362368	Homo sapiens						72.8				An oral form of procaine, bound to haematoporphyrin was used			119	Age-related decline								2	year		p.304
4557	2249		adult				mg	1000		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01233609	Homo sapiens							max			One to four 250mg softgels by mouth daily (dose determined by body weight)			46	Retinitis Pigmentosa								52	week		
4558	2249		adult				mg	500		steady			day	2	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01729598	Homo sapiens							max			Seven healthy volunteers will be enrolled into 2 sequential cohorts, for a total of 14 enrolled subjects.  The study will be conducted using two doses of valproate (250 mg PO bid, followed by 500 mg PO bid).			10									35	day		
4559	2249					Highest studied dose	mg/kg	120		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17579623	Homo sapiens						62.5				VPA was administered as an 1-h infusion daily for 5 consecutive days in a 21-day cycle.			5	Cancer								5	day		p.179
4560	2249					Highest studied dose	mg/kg	150		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28497259	Homo sapiens						30.2							3												p.6
4561	2249					MTD	mg/kg	140		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28497259	Homo sapiens						30.2							6												p.6
4562	2249					MTD	mg/kg	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17579623	Homo sapiens						62.5				VPA was administered as an 1-h infusion daily for 5 consecutive days in a 21-day cycle.			3	Cancer								5	day		p.178
4563	2249					Overdose	g	100		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18082799	Homo sapiens						41				suicide attempt			1	Epilepsy											110000
4564	2249					Overdose	g	25		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29053479	Homo sapiens						37				suicide attempt			1	Seizures |Bipolar disorder											p.1
4565	2249					Recommended	mg/kg	60		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018081s065_018082s048lbl.pdf	Homo sapiens										Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day.				Seizures											p.1
4566	2251					MTD	mg/kg	1.2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2591437	Homo sapiens										Prochlorperazine, as a solution of the mesylate salt in 5% dextrose, was given as an intravenous infusion over 20 min, commencing 30 min prior to the chemotherapy.			3	Nausea|Vomiting											p.1469
4567	2251					MTD	mg/m2	180		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8070004	Homo sapiens										Subsequent courses were repeated every 21 days.		77	4	Cancer	60 mg/m2; q.d.			doxorubicin, i.v.	38						p.380
4568	2251					Recommended	mg	75		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/010571s096lbl.pdf	Homo sapiens							total daily dose							Psychiatric Disorders											p.3
4569	2252		adult			Recommended	mg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf	Homo sapiens							min						1250	Hypertension								7	day		
4570	2252		adult			Recommended	mg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf	Homo sapiens													268	Hypertension								7	day		
4571	2252		adult			Recommended	mg	2.5		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf	Homo sapiens													275	Hypertension								7	day		
4572	2252		adult			Recommended	mg	5		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf	Homo sapiens													296	Hypertension								7	day		
4573	2252		adult			Recommended	mg	5.6		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31345083/	Homo sapiens							mean						231	Hypertension, Pregnancy								65	day		
4574	2252					Overdose	mg	75		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9220044/	Homo sapiens						42	mean						1	Hypertension					42						
4575	2253					Accidental dose	mg	5		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9060031	Homo sapiens						62				fentanyl citrate			1	Pain											p.199
4576	2253					Higher than recommended	ug	400		multiple			30 min	1	healthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/28942715	Homo sapiens						37.1							6									1.5	hour		p.3
4577	2253					Higher than recommended	ug	800		single					healthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/28942715	Homo sapiens						33.4							8												p.13, 14
4578	2253					Higher than recommended	ug	800		single					healthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/28942715	Homo sapiens						33.4							8												p.13, 15
4579	2253					Higher than recommended	ug	800		single					healthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/28942715	Homo sapiens						33.4							8												p.13, 16
4580	2253					Highest studied dose	ug	1600		multiple			15 min	1	unhealthy	sublingual	M+F		https://pubmed.ncbi.nlm.nih.gov/10068176	Homo sapiens						53	max			Up to two breakthrough pains each day could be treated with up to four OTFC unit doses per pain (at 15 min intervals). OTFC in unit doses containing 200, 400, 600, 800, 1200 or 1600 microg of fentanyl citrate were available for the study.			65	Pain								4	hour		p.309
4581	2253					Overdose	mg	6		single					healthy	transdermal	F		https://pubmed.ncbi.nlm.nih.gov/22561319	Homo sapiens						15	total			suicide attempt, a patient had applied 5 fentanyl patches to her body: 100 ug/h each for 12 hours; total dose, 6 mg, 120 ug/kg			1												p.463
4582	2253					Overdose	ug	150		multiple			hour	1	unknown	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/9695458	Homo sapiens						31							1												
4583	2253					Overdose	ug	225		multiple			hour	1	unhealthy	transdermal	F		https://pubmed.ncbi.nlm.nih.gov/25736329	Homo sapiens						32				Misuse, three patches of fentanyl 75 ug/h			1	Knee pain											p.51
4584	2253					Recommended	ug	200		multiple			day	6	unhealthy	sublingual			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf	Homo sapiens										The initial dose of ACTIQ to treat episodes of breakthrough cancer pain is always 200 mcg. The ACTIQ unit should be consumed over 15 minutes. Patients must wait at least 4 hours before treating another episode of breakthrough pain with ACTIQ.				Pain											p.1
4585	2253					Recommended	ug	50		multiple			30 min	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28942715	Homo sapiens						35.6				fentanyl citrate			6									1.5	hour		p.3
4586	2254		adult			Overdose	mg	7500		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4051285/	Homo sapiens													1												
4587	2254					Overdose	mg	5000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/7283217/	Homo sapiens						39							1	suicide attempt					39						
4588	2255					Overdose	g	7		multiple					unhealthy	intrapleural	M		https://pubmed.ncbi.nlm.nih.gov/10571097	Homo sapiens						41	total			An infusion of 1 g tetracycline in 50 ml of normal saline was commenced and continued at the rate of 5 ml/h after a bolus of 20 ml. This was continued for 3 days leading to a total dose of approximately 7 g tetracycline.			1						41			3	day		
4589	2255					Recommended	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2140332	Homo sapiens										two 250 mg tetracycline tablets twice daily for the first 4 weeks		35	31	acne					14			4	week		
4590	2255					Recommended	mg	250		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8740345	Homo sapiens						38							1	pharyngitis					38			3	day		
4591	2255						%	2		multiple			day	2	unhealthy	intralesional	M+F		https://pubmed.ncbi.nlm.nih.gov/24841733	Homo sapiens						63				Patients received up to 0.75ml (mean, 0.24ml) of tetracycline 2% per side.			21	lower eyelid festoons					63			1	day		
4592	2255						mg/mL|mg	2.2 |500		multiple			day	2	unhealthy	topical|oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2140332	Homo sapiens							complex			toplcally twice daily with 2.2 mg/ml tetracycline and two 250 mg tetracycline tablets twice daily for the first 4 weeks		35	36	acne					14			4	week		
4593	2256					Recommended	mg	0.3		single			day	1	healthy	intramuscular	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/201739Orig1s000MedR.pdf	Homo sapiens												45	66						18			1	day		nda/2012/201739Orig1s000MedR.pdf - p.55
4594	2257					Highest studied dose	mg	100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6397333/	Homo sapiens						55.7				After 1 or 2 weeks of study, the daily dosage of flurbiprofen could be lowered to 200 mg			25	soft tissue rheumatism								4	week		
4595	2257					Recommended	mg	100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6397333/	Homo sapiens						55.7							25	rheumatism								4	week		
4596	2257					Recommended	mg	100		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17936240/	Homo sapiens						63							1	hypercholesterolemia					63			1	day		
4597	2257					Recommended	mg	225		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/334475/	Homo sapiens						56	mean						8	rheumatoid arthritis								6	month		
4598	2257					Recommended	mg	40		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/27168463/	Homo sapiens						67.1							316	osteoarthritis								2	week		
4599	2257						mg	8.75		multiple			hour	5	unhealthy	sublingual			https://clinicaltrials.gov/ct2/show/NCT01049334	Homo sapiens										participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.			102	Pharyngitis								5	times		
4600	2258					Highest studied dose	%	0.5		multiple			day	1	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/27101751	Homo sapiens						10.3				Eye drops			77	progressive myopia					10.3			12	month		
4601	2258					Overdose	mg	1		single					unhealthy	sublingual			https://pubmed.ncbi.nlm.nih.gov/33521988	Homo sapiens													1												
4602	2258						mg/kg	0.1		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/29316984	Homo sapiens						10							1						10						
4603	2259		adult				g	1		steady			day	2	unhealthy	topical	M+F		https://clinicaltrials.gov/ct2/show/NCT01694433	Homo sapiens													33	Acne Vulgaris								12	week		
4604	2259					Recommended	%	0.005		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/22587791/	Homo sapiens						48.2				Subjects were instructed to apply calcipotriene foam or vehicle foam twice daily (morning and evening) for 8 weeks.			437	psoriasis								8	week		
4605	2259					Recommended	%	0.005		multiple			day	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	Homo sapiens						48				Twice daily topical application of the smallest amount necessary of Calcipotriene foam or vehicle foam to cover all treatable lesions (excluding the face and scalp). The integrated summary of safety analysis set contains all subjects who are randomized and receive study product in the Phase 3 trials or are randomized and receive Sorilux (calcipotriene) Foam, 0.005% or vehicle foam in the Phase 2 trial.			473	psoriasis								8	week		
4606	2260		Elderly Patients			Recommended	mg	100		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	Homo sapiens										In general, dosages in the lower range are sufficient for most elderly patients. Since they appear to be more susceptible to hypotension and neuromuscular reactions, such patients should be observed closely.				Dementia-Related Psychosis								10	week		
4607	2260		Elderly Patients				mg	25		multiple			day	1	unhealthy	intramuscular			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	Homo sapiens										In general, dosages in the lower range are sufficient for most elderly patients.				Dementia-Related Psychosis								10	week		
4608	2260					Highest studied dose	mg	75		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30558470	Homo sapiens						52				IV chlorpromazine dose is administered as a slow infusion at a rate of 1 mg/min to potentially mitigate and minimize the negative hemodynamic effects.		65.6		agitation					36.5						
4609	2261		adult			Overdose	g	3		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7919575/	Homo sapiens										3 - 4 g			2												
4610	2261		preterm neonates			Recommended	mg/kg	10		steady			day	2	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/15523125/	Homo sapiens													24	neonatal sepsis								7	day		
4611	2261					Highest studied dose	mg	750		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17660035/	Homo sapiens													2	Infection					70			1	day		
4612	2261					Overdose	g	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7919575/	Homo sapiens						16							1						16						
4613	2261					Overdose	g	28		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7919575/	Homo sapiens						29							1						29						
4614	2261					Overdose	g	7.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9531191/	Homo sapiens						15				7.5 to 10 g			1	depression and posttraumatic stress disorder					15						
4615	2261					Recommended	mg	228		steady			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2686431/	Homo sapiens						50	mean						1869	Infection								56	day		
4616	2261					Recommended	mg	500		steady			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22726802/	Homo sapiens													122	acute pyelonephritis								14	day		
4617	2261					Recommended	mg	500		steady			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22726802/	Homo sapiens													126	acute pyelonephritis								7	day		
4618	2261					Recommended	mg/kg	15		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s086lbl.pdf	Homo sapiens							median					17	335	Infection					1			11	day		
4619	2261					Recommended	mg/kg	20		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16182896/	Homo sapiens												15	90	childhood cholera					2						
4620	2261						mg	500		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01789203	Homo sapiens													133	Renal Transplant Recipients								3	month		
4621	2261						mg	500		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00609973	Homo sapiens													17	Crohn's Disease								6	month		
4622	2261						mg	500		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02068846	Homo sapiens													9	BK Virus Infection								28	day		
4623	2262		adult				mg	20		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01543685	Homo sapiens													91	Acute Postoperative Pain								2	day		
4624	2262		adult				mg	20		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01626118	Homo sapiens													92	Acute Postoperative Pain								2	day		
4625	2262		adult				mg	40		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01543685	Homo sapiens													91	Acute Postoperative Pain								2	day		
4626	2262		adult				mg	40		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01626118	Homo sapiens													93	Acute Postoperative Pain								2	day		
4627	2262		adult				mg	40		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01543685	Homo sapiens													93	Acute Postoperative Pain								2	day		
4628	2262		adult				mg	40		multiple			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01626118	Homo sapiens													94	Acute Postoperative Pain								2	day		
4629	2262					Overdose	g	0.9		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3712524	Homo sapiens						15							1	Knee pain											p.152
4630	2262					Recommended	mg	50		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016059s100lbl.pdf	Homo sapiens														Bursitis|Tendinitis|Gouty arthritis											
4631	2264					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11563998/	Homo sapiens						45.2							161	reflux oesophagitis								4	week		
4632	2264					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019810s088,022056s003lbl.pdf	Homo sapiens													3096	Duodenal ulcer | Resistant ulcer | Zollinger-Ellison syndrome								4	week		
4633	2266		adult			Highest studied dose	mg	84		steady			day	1	healthy	transdermal	unknown		https://pubmed.ncbi.nlm.nih.gov/30370685/	Homo sapiens										21 to 84 mg			36	adult smokers								4	week		
4634	2266		adult				mg	1		steady			hour	4	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01296698	Homo sapiens										Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks			13	Tobacco Dependence								12	week		
4635	2266		adult				mg	7		single					unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01400243	Homo sapiens													63	Marijuana Withdrawal											
4636	2266					Highest studied dose	mg	6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27613939/	Homo sapiens												49	44	adult smokers					19						
4637	2266					Highest studied dose	mg	6		steady			hour	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27613939/	Homo sapiens												50	50	adult smokers					19			11	hour		
4638	2266					Highest studied dose	mg	8		steady			hour	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27613939/	Homo sapiens										4mg lozenge and 4mg gum		50	50	adult smokers					19			11	hour		
4639	2266					Overdose	mg	111		single					healthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/32146302/	Homo sapiens						41							1	adult smoker					41						
4640	2266					Studied dose	mg	4		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27613939/	Homo sapiens												49	44	adult smokers					19						
4641	2267						drop	1		steady			day	2	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019463s031lbl.pdf	Homo sapiens							starting			The usual starting dose is one drop of 0.25% Preservative-free TIMOPTIC in OCUDOSE in the affected eye(s) administered twice a day.			8	elevated intraocular pressure											
4642	2268					Overdose	mg	125		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14639058	Homo sapiens						43				suicide attempt			1	Deep venous thromboses	200 mg, single			oxycodone, p.o							p.718
4643	2268					Overdose	mg	150		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14639058	Homo sapiens						44				suicide attempt			1	Aortic valve replacement	3 g, single			chlorpromazine, p.o							p.718
4644	2268					Overdose	mg	540		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24674108	Homo sapiens						59				suicide attempt			1		4 mg, single			clonazepam, p.o							p.1
4645	2268					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf	Homo sapiens							max			If the patient’s CYP2C9 and VKORC1 genotypes are not known, the initial dose of COUMADIN is usually 2 to 5 mg once daily. Typical maintenance doses are 2 to 10 mg once daily.				Venous thrombosis|Atrial fibrillation|Myocardial infarction											p.1
4646	2268					Recommended	mg	5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26658807	Homo sapiens						64				Patient was supposed to take 1.25 mg warfarin daily. Laboratory findings revealed very high levels of International Normalized Ratio (INR) (16), and the patient referred that he self-increased warfarin dose to 5 mg daily			1	Cardiomyopathy |Atrial fibrillation											p.1
4647	2269		adult				mg	20		multiple			day	2	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01211522	Homo sapiens							max						190	Delirium								2	week		
4648	2269					Higher than recommended	mg	20		steady			day	2	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/16816018/	Homo sapiens										10 - 20 mg, 1 or 2 times/day			21	Schizophrenia								3	day		
4649	2269					Higher than recommended	mg	40		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10714048/	Homo sapiens										5 - 40 mg			28	Tourette's syndrome								56	day		
4650	2269					Overdose	mg	1120		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16232029/	Homo sapiens						35							1	Schizophrenia					35						
4651	2269					Overdose	mg	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19369840/	Homo sapiens													1												
4652	2269					Overdose	mg	4400		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16232029/	Homo sapiens						57		4 mg					1	Manic-depressive disorder	768 mg			Clomethiazole	57					flunitrazepam	
4653	2269					Overdose	mg	4480		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16232029/	Homo sapiens						22							1	Paranoid Schizophrenia	192 mg			Clomethiazole	22						
4654	2269					Overdose	mg	780		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16232029/	Homo sapiens						31							1	Mixed personality disorder					31						
4655	2269					Studied dose	mg	20		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16721322/	Homo sapiens												16	24	Tourette's disorder or chronic tic disorder					7						
4656	2270					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18975369	Homo sapiens						52	max			Allopurinol dose was dependent on renal function; subjects with normal renal function received 300 mg, whereas subjects with renal impairment received 100 mg. Results from these 2 allopurinol doses were analyzed together. Ten subjects received 100 mg and 258 subjects received 300 mg of allopurinol based on renal function.			268	Hyperuricemia| Gout								28	week		p.1544
4657	2270					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18975369	Homo sapiens						52	max			Allopurinol dose was dependent on renal function; subjects with normal renal function received 300 mg, whereas subjects with renal impairment received 100 mg. Results from these 2 allopurinol doses were analyzed together. Ten subjects received 100 mg and 258 subjects received 300 mg of allopurinol based on renal function.			268	Hyperuricemia| Gout								28	week		p.1545
4658	2270					Recommended	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26989892	Homo sapiens						53.4							54	Gout								12	week		p.2031
4659	2270					Recommended	mg	335.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21279998	Homo sapiens						58.7	mean			In the 45 patients who underwent dose escalation, the mean baseline dosage of allopurinol was 221.4 mg/day (range 100–400; median 200). For the 35 patients who completed the 12-month study visit, the mean final dosage of allopurinol was 335.7 mg/day (range 0–600, median 350)			83	Chronic gout								12	month		p.417
4660	2270						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00174915	Homo sapiens							max			Subjects with serum creatinine <=1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and <=2.0 mg/dL received 100 mg once daily.			268	Gout								28	week		
4661	2271		adult			Recommended	ug	480		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207932Orig1s000MedR.pdf	Homo sapiens							mean			There were 504 subjects exposed for 6 months and 253 for one year.			2127	pain								12	week		nda/2015/207932Orig1s000MedR.pdf - p.53
4662	2271					Highest studied dose	mg	32		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8181201/	Homo sapiens						32.3							4									1	day		
4663	2271					Studied dose	ug/kg	5.714		single			day	1	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207932s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/16547090/	Homo sapiens										0.4 mg/70 kg = 5,714285714285714 ug/kg (the exact dose)		35	5						22			1	day		
4664	2271						mg	0.125		multiple			day	3	unhealthy	sublingual			https://clinicaltrials.gov/ct2/show/NCT02634788	Homo sapiens													82	postoperative pain								3	day		
4665	2271						mg	0.25		multiple			day	3	unhealthy	sublingual			https://clinicaltrials.gov/ct2/show/NCT02634788	Homo sapiens													80	postoperative pain								3	day		
4666	2271						mg	0.5		multiple			day	3	unhealthy	sublingual			https://clinicaltrials.gov/ct2/show/NCT02634788	Homo sapiens													81	postoperative pain								3	day		
4667	2273		adult			Studied dose	mg	20		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf	Homo sapiens										Relief of Mild and Moderate Anxiety Disorders and Symptoms of Anxiety: 5 mg or 10 mg, 3 or 4 times daily. Relief of Severe Anxiety Disorders and Symptoms of Anxiety: 20 mg or 25 mg, 3 or 4 times daily. Geriatric Patients, or in the presence of debilitating disease: 5 mg, 2 to 4 times daily.				Severe Anxiety Disorders				opioids							
4668	2273					Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/413145	Homo sapiens												74							24						
4669	2274					Highest studied dose	mg	600		multiple			day	2	pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/30195996	Homo sapiens						20.7	starting			2 doses of 600 mg day-1, 600 mg day-2, 300 mg day-3			300	malaria					20.7			3	day		
4670	2274					Overdose	g	3		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/33722251	Homo sapiens						14							1						14						
4671	2275		adult			Highest studied dose	mg	2		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/5454324/	Homo sapiens													1	hypertension								2	year		
4672	2275		children				ug/kg	3		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT02361476	Homo sapiens													191	Surgery											
4673	2275					Recommended	mg	0.1		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf	Homo sapiens						9							76	attention deficit hyperactivity disorder								8	week		nda/2010/022331Orig1s001.pdf - p.108
4674	2275					Recommended	mg	0.2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf	Homo sapiens						10		54 mg/day		plus Amphetamine or Methylphenidate			102	attention deficit hyperactivity disorder				Amphetamine				8	week	Methylphenidate	nda/2010/022331Orig1s001.pdf - p.108
4675	2275					Recommended	mg	0.2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf	Homo sapiens						9							78	attention deficit hyperactivity disorder								8	week		nda/2010/022331Orig1s001.pdf - p.108
4676	2275					Studied dose	mg	0.25		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022331Orig1s001.pdf	Homo sapiens						13							1	attention deficit hyperactivity disorder	54 mg/day			Methylphenidate	13			1	day		nda/2010/022331Orig1s001.pdf - p.139
4677	2275						mg	0.1		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00884832	Homo sapiens													22	Fecal Incontinence								4	week		
4678	2276		children|adults				mg	360		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00319982	Homo sapiens													18	Cardiomyopathy											
4679	2276					Recommended	mg	225		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3543092/	Homo sapiens							mean			dose range 90-360 mg		74	15	coronary artery spasm					35			4	week		
4680	2276					Recommended	mg	315		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-392_Cardizem%20LA_medr.PDF	Homo sapiens						52.6	mean			dose range 120-540 mg			409	hypertension								7	week		
4681	2276					Recommended	mg	360		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3511660/	Homo sapiens						57							40	hypertension								12	week		
4682	2276					Studied dose	g	4.2		single			day	1	unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/1940240/	Homo sapiens						42							1						42			1	day		
4683	2276					Studied dose	g	9		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8249857/	Homo sapiens						51							1	hypercholesterolemia					51			1	day		
4684	2277		adult			Recommended	mg	700		steady			day	1	unhealthy	transdermal	unknown		https://pubmed.ncbi.nlm.nih.gov/31469302/	Homo sapiens													404	Neuropathic pain								12	week		
4685	2277		adult			Studied dose	%	5		steady			day	1	unhealthy	transdermal	M+F		https://pubmed.ncbi.nlm.nih.gov/19485723/	Homo sapiens													300	post-herpetic neuralgia and diabetic polyneuropathy								4	week		
4686	2277		adult				mg	1.5		single					unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00913003	Homo sapiens										Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)			11	Pain											
4687	2277		adult				mg/kg	1		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT00938964	Homo sapiens										Related publication: [PMID:27470233]: intravenous lidocaine bolus (1 mg/kg) on induction, followed by a continuous infusion of 48 μg/kg/min for one hour, 24 μg/kg/minfor the second hour, and 10 μg/kg/min for the subsequent 46 hr			241	Cognitive Decline											
4688	2277					Overdose	mg	800		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7081027/	Homo sapiens						57							1	hypertensive, severe precordial pain					57						
4689	2277					Studied dose	mg	2		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19222600/	Homo sapiens										1 to 2 mg		66	68	chronic daily headache and chronic cluster headache					17			15	day		
4690	2278		adult			Overdose	mg	252		single					healthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf	Homo sapiens																									
4691	2278		adult			Overdose	mg	500		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf	Homo sapiens																									
4692	2278		adult			Recommended	%	2		steady			day	3	unhealthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf	Homo sapiens										cream			339	various skin lesions								5	day		
4693	2278		adult			Recommended	%	2		steady			day	3	unhealthy	topical	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050746s013lbl.pdf	Homo sapiens										cream			82	secondarily infected eczema								5	day		
4694	2278		children			Recommended	%	2		steady			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/29728181/	Homo sapiens										cream			8	tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus								7	month		
4695	2279		adult				mg	8		single					healthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf	Homo sapiens										Two Nasal Sprays			28												
4696	2279					Highest studied dose	mg/m2	160		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/2339451	Homo sapiens							starting			loading dose of 160 mg/m2 over 15 minutes followed by a 24-hour infusion at the rate of 80 mg/m2/hr		85	38	acute ischemic stroke					35						
4697	2279						mg	0.8		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/29568976	Homo sapiens						23.8							12						23.8						
4698	2280		adult				mg	500		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02262754	Homo sapiens													74	Low Back Pain								4	week		
4699	2280					Highest studied dose	g	4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/954349/	Homo sapiens						20							4												p.272
4700	2280					Overdose	g	12.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2552870	Homo sapiens						15				suicide attempt			1												1102/129
4701	2280					Overdose	g	26		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31742906	Homo sapiens						58				suicide attempt			1	Depressive syndrome|Anxiety											p.458
4702	2280					Overdose	g	70.4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24756481	Homo sapiens						28				suicide attempt			1					alcohol, p.o							p.103
4703	2280					Recommended	mg	550		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017581s113,018164s063,020067s020lbl.pdf	Homo sapiens														Pain|Primary Dysmenorrhea| Acute Tendonitis| Acute Bursitis											p.1
4704	2281					Recommended	mg	10		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20763_Amerge_Medr_P1.pdf	Homo sapiens						39							96	migraine											Study 2004
4705	2281					Recommended	mg	2.5		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20763_Amerge_Medr_P1.pdf	Homo sapiens						40.4							127	migraine								3	day		Study 3002
4706	2282		adult			Highest studied dose	mg	64		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31181225/	Homo sapiens																						1	day		
4707	2282		adult			Overdose	mg	72		single			day	1	unknown	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020007s042,020403s020lbl.pdf	Homo sapiens													1									1	day		
4708	2282					Overdose	mg	56		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18803119/	Homo sapiens													1									1	day		
4709	2282					Overdose	mg	60		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22668671/	Homo sapiens						8							1	B-cell lymphoblastic lymphoma					8			1	day		
4710	2282					Studied dose	mg	8		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20781_Zofran.pdf	Homo sapiens						32.1							6									1	day		
4711	2282					Studied dose	mg	8		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20781_Zofran.pdf	Homo sapiens						27							24									1	day		
4712	2283		adult			Highest studied dose	mg	500		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1220958	Homo sapiens														depression								4	day		
4713	2283		adult			Overdose	g	2		single					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/012157s028lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/013055s021lbl.pdf	Homo sapiens										the minimum lethal dose was found to be 2-3 grams for adults; however, the range of toxicity is variable and unpredictable.															
4714	2283		adult			Overdose	g	2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/012157s028lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/013055s021lbl.pdf	Homo sapiens										the minimum lethal dose was found to be 2-3 grams for adults; however, the range of toxicity is variable and unpredictable.															
4715	2283		adult			Overdose	g	2		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/012157s028lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/013055s021lbl.pdf	Homo sapiens										the minimum lethal dose was found to be 2-3 grams for adults; however, the range of toxicity is variable and unpredictable.															
4716	2284		adult			Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Homo sapiens							mean			stabilization period			120	chronic pain								5	day		/nda/98/20932_medr_P2.pdf - p.21
4717	2284		adult			Recommended	mg	20		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Homo sapiens							mean			treatment period			125	chronic pain								7	week		/nda/98/20932_medr_P2.pdf - p.21
4718	2284		adult			Recommended	mg	5		multiple			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Homo sapiens										stabilization period			63	chronic pain								5	day		/nda/98/20932_medr_P2.pdf - p.21
4719	2284		adult			Recommended	mg	5		multiple			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20932_medr_P2.pdf	Homo sapiens										treatment period			126	chronic pain								7	week		/nda/98/20932_medr_P2.pdf - p.21
4720	2284		adult				mg	5		multiple			day	3	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01500317	Homo sapiens													12									2	day		
4721	2284					Studied dose	mg	15		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf	Homo sapiens						36							40									1	day		nda/2011/202080Orig1s000MedR.pdf - p.22
4722	2284					Studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1994955/	Homo sapiens						30		1/4 g; single					1		1950 mg; single			acetaminophen	30			1	day	cocaine	
4723	2284					Studied dose	mg	6		single			day	2	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202080Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/22717418/	Homo sapiens						33	mean			5 separate single dose: 1x5 mg; 2x5 mg; 2x7.5 mg; 2x7.5 mg (fed); 1x15 mg			35									1	day		nda/2011/202080Orig1s000MedR.pdf - p.22
4724	2285						mg	30		single					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016194s081lbl.pdf	Homo sapiens										Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse. The recommended single parenteral dose is 30 mg by intramuscular, subcutaneous, or intravenous route.								benzodiazepines							
4725	2285						mg	30		single					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/016194s081lbl.pdf	Homo sapiens										Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse. The recommended single parenteral dose is 30 mg by intramuscular, subcutaneous, or intravenous route.															
4726	2286					Highest studied dose	mg	17.4		multiple			day	1	unhealthy	transdermal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022083lbl.pdf	Homo sapiens													303									8	week		
4727	2286					MTD	mg	10		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/10362894	Homo sapiens							mean						45									8	week		
4728	2286					Overdose	mg	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28328690	Homo sapiens						3				6 mL of Exelon solution (2 mg/1 mL), which contains 12 mg of rivastigmine (as tartrate).			1						3						
4729	2286					Overdose	mg	288		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/16440521	Homo sapiens						59				48 tablets of Exelon1 (288 mg of rivastigmine)			1		280 mg, single			citalopram	59						
4730	2286					Overdose	mg	9.5		multiple			day	6	unhealthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/22663954	Homo sapiens						87							1	dementia					87			1	day		
4731	2286					Overdose	mg	90		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/16373816	Homo sapiens						38							1						38						
4732	2286					Recommended	mg	6		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20823lbl.pdf	Homo sapiens										12 week forced dose titration phase			1189									12	week		
4733	2287		adult			Recommended	mg	1000		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020628s034-021785s011lbl.pdf	Homo sapiens													148	HIV-1 infection	100 mg; 2/day			ritonavir							
4734	2287		adult				mg	1600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16926775/	Homo sapiens													81	HIV-1 infection	100 mg; 1/day			ritonavir				48	week		
4735	2288		adult			Highest studied dose	mg	12		multiple			day	1	unhealthy	transdermal	M+F		https://pubmed.ncbi.nlm.nih.gov/17568687/	Homo sapiens										Selegiline transdermal system (STS) dose delivered per 24 h: 3 mg (10 cm2) only, 6 mg (20 cm2) only, or 9 mg (30 cm2) or 12 mg (40 cm2) as maximum dose received. Overall STS exposure in the clinical trials was: up to 12 weeks (n= 1238); 12 to 24 weeks (n= 538); 24 to 48 weeks (n= 205); and over 48 weeks (n= 55).			116	major depressive disorder								48	week		
4736	2288		adult			Recommended	mg	12		multiple			day	1	unhealthy	transdermal	M+F		https://pubmed.ncbi.nlm.nih.gov/17568687/	Homo sapiens							max			Selegiline transdermal system (STS) dose delivered per 24 h: 3 mg (10 cm2) only, 6 mg (20 cm2) only, or 9 mg (30 cm2) or 12 mg (40 cm2) as maximum dose received. Overall STS exposure in the clinical trials was: up to 12 weeks (n= 1238); 12 to 24 weeks (n= 538); 24 to 48 weeks (n= 205); and over 48 weeks (n= 55).			817	major depressive disorder								48	week		
4737	2288		adult			Recommended	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf	Homo sapiens										Orally Disintegrating Tablets are available for oral administration (not to be swallowed). Because the controlled trials performed during premarketing development both used a titration design (1.25 mg per day for 6 weeks, followed by 2.5 mg per day for 6 weeks), with a resultant confounding of time and dose, it was impossible to adequately evaluate the effects of dose on the incidence of adverse events.			194	Parkinson’s disease				levodopa				6	week		
4738	2288		adult				mg	6		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT01330030	Homo sapiens													121	Nicotine Dependence								8	week		
4739	2288		child				mg	12		steady			day	1	unhealthy	transdermal	M+F		https://clinicaltrials.gov/ct2/show/NCT00531947	Homo sapiens							max|total daily dose			EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours			152	Major Depression								12	week		
4740	2289		adult			Highest studied dose	mg	100		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020132s028,020626s025lbl.pdf	Homo sapiens										relief of an attack			437	migraine with or without aura											
4741	2289		adult				mg	100		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01248468	Homo sapiens													271	Migraine											
4742	2289					Overdose	mg	300		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20051552/	Homo sapiens						35							1	migraine	SUMATRIPTAN				35					12 mg subcutaneous injections	
4743	2289					Overdose	mg	6		multiple			day	2	unhealthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/11531904/	Homo sapiens						36				relief of an attack, >2 times/day			1	episodic cluster headache					36			4	week		
4744	2289					Studied dose	mg	200		multiple			month	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1313746/	Homo sapiens												65	94	acute migraine with aura					18			3	month		
4745	2290					Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16445509	Homo sapiens						31							27	Eumycetoma								274	day		p.155
4746	2290					Overdose	g	5		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020539s029,022071s013lbl.pdf	Homo sapiens														Fingernail onychomycosis|Toenail onychomycosis											p.6
4747	2290					Recommended	%	1		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/20846s001lbl.pdf	Homo sapiens										Each gram of Lamisil® (terbinafine) DermGel™, 1%, contains 10 mg of terbinafine				Tinea|tinea pedis|tinea corporis|tinea cruris											p.8
4748	2290					Recommended	mg	250		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020539s029,022071s013lbl.pdf	Homo sapiens													465	Fingernail onychomycosis|Toenail onychomycosis								9	week		p.3
4749	2290					Recommended	mg	250		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020539s029,022071s013lbl.pdf	Homo sapiens													465	Fingernail onychomycosis|Toenail onychomycosis								9	week		p.4
4750	2290					Recommended	mg	250		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020539s029,022071s013lbl.pdf	Homo sapiens														Fingernail onychomycosis|Toenail onychomycosis								9	week		p.1
4751	2290					Recommended	mg	250		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020539s029,022071s013lbl.pdf	Homo sapiens														Fingernail onychomycosis|Toenail onychomycosis								9	week		p.3
4752	2291					Recommended	mg	800		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6145728	Homo sapiens																		lithium							
4753	2291						mg	400		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/646545	Homo sapiens																						2	day		
4754	2292		Elderly Patients			Studied dose	mg	20		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016584s059lbl.pdf	Homo sapiens										20-30 mg				Dementia-Related Psychosis											
4755	2292					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016584s059lbl.pdf	Homo sapiens																									
4756	2292					Studied dose	mg	20		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016584s059lbl.pdf	Homo sapiens										20-30 mg															
4757	2292					Studied dose	mg	20		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016584s059lbl.pdf	Homo sapiens										20-30 mg															
4758	2293		adult			MTD	mg/m2	100		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11843245/	Homo sapiens													6	advanced breast cancer								13	week		
4759	2293		adult			RP2D	mg/m2	80		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11843245/	Homo sapiens													13	advanced breast cancer								151	week		
4760	2293					Recommended	mg/m2	25		multiple			week	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020388s037lbl.pdf	Homo sapiens										NAVELBINE 25 mg/m2 administered every week of each 28-day cycle and cisplatin 100 mg/m2 administered on day 1 of each 28-day cycle versus cisplatin alone at the same dose and schedule in patients with previously untreated NSCLC			212	NSCLC	100 mg/m^2; 1/month			cisplatin							
4761	2293					Recommended	mg/m2	30		multiple			week	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020388s037lbl.pdf	Homo sapiens						61						79	143	metastatic NSCLC					32						
4762	2294					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M		https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf	Homo sapiens						32.9							9									14	day		28
4763	2294					Highest studied dose	mg	900		single					healthy	oral	M		https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf	Homo sapiens						27.5							6												28
4764	2294					MTD	mg	450		multiple			day	1	healthy	oral	M		https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf	Homo sapiens						34.9							9									14	day		28
4765	2294					MTD	mg	750		single					healthy	oral	M		https://www.longdom.org/open-access/pharmacokinetics-pharmacodynamics-and-safety-of-desvenlafaxine-a-serotonin-norepinephrine-reuptake-inhibitor-jbb.1000130.pdf	Homo sapiens						23.95							11												28
4766	2294					Overdose	mg	3500		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27622824	Homo sapiens						33							1												p.6
4767	2294					Recommended	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021992s030lbl.pdf	Homo sapiens														Major depressive disorder											p.1
4768	2294						mg	100		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01316302	Homo sapiens							max						30	Social Anxiety Disorder								12	week		
4769	2294						mg	100		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01537068	Homo sapiens							max						30	Chronic Depression								24	week		
4770	2295					Highest studied dose	mg/m2	190		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16880787	Homo sapiens						10							6	Cancer								7	cycle		p.573, 575
4771	2295					MTD	mg/m2	155		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16880787	Homo sapiens						10							6	Cancer								7	cycle		p.573, 575
4772	2295					MTD	mg/m2	80		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/14597873	Homo sapiens						60		40 mg/day, days 1–4 and 9–12		liposomal daunorubicin (DaunoXome) i.v., day 1 (in 250 ml 5% dextrose, 60-min infusion), the treatment courses were repeated every 3 weeks (day 22)			3	Multiple myeloma	1.4 mg/m2, day 1			vincristine, i.v						dexamethasone, p.o	p.795
4773	2295					Recommended	mg/m2	20		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf	Homo sapiens						38.7							705	AIDS-related Kaposi’s sarcoma								127	day		p.11
4774	2295					Recommended	mg/m2	50		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf	Homo sapiens												87	239	Ovarian Cancer					27			98	day		p.11
4775	2295					Recommended	mg/m2	50		multiple			4 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf	Homo sapiens														Ovarian Cancer								4	course		p.1
4776	2295					Studied dose	mg/m2	100		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12173332	Homo sapiens						63		40 mg/day, days 1–4					38	Multiple myeloma								6	cycle	dexamethasone, p.o	p.2648
4777	2295					Studied dose	mg/m2	100		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/14597873	Homo sapiens						60		40 mg/day, days 1–4 and 9–12		liposomal daunorubicin (DaunoXome) i.v., day 1 (in 250 ml 5% dextrose, 60-min infusion), the treatment courses were repeated every 3 weeks (day 22)			3	Multiple myeloma	1.4 mg/m2, day 1			vincristine, i.v						dexamethasone, p.o	p.795
4778	2296						mg	20		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/799980	Homo sapiens												72	39						29			6	week		
4779	2296						mg	5		multiple			hour	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/8629678/	Homo sapiens						35				The nebulized treatments were repeated every hour. Each nebulized treatment lasted on average 12 minutes															
4780	2297					Recommended	mg	0.2		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010515s031lbl.pdf	Homo sapiens							max			Bolus intravenous injection. Initial Dose: 0.02 mg to 0.06 mg; Subsequent Dose: 0.01 mg to 0.2 mg. Intravenous infusion: 5 mcg/min				Heart block|Adams-Stokes attacks|Cardiac arrest											p.2
4781	2297					Recommended	mg	1		multiple					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/010515s031lbl.pdf	Homo sapiens							max							Heart block|Adams-Stokes attacks|Cardiac arrest											p.2
4782	2297					Studied dose	mg	15		multiple			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/375857	Homo sapiens							max			1.25, 2.5, 5, 10, and 15 mg of isoproterenol hydrochloride administered by intermittent positive pressure breathing		67	12	Bronchial asthma					27			5	day		p.642
4783	2298		adult				mg	30		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01896700	Homo sapiens										An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.			12	Multiple Sclerosis								6	week		
4784	2298		adult				mg	54		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00549640	Homo sapiens							total daily dose			54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).			40	Tobacco Dependence								8	week		
4785	2298		adult				mg	80		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00526630	Homo sapiens							total daily dose			Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.			20	Parkinson's Disease								27	week		
4786	2298		child				mg	18		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01238822	Homo sapiens													96	Attention Deficit Hyperactivity Disorder								4	week		
4787	2298		child				mg	54		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00763971	Homo sapiens							max			18, 36, or 54 mg tablet one per day			111	Attention-Deficit/Hyperactivity Disorder								7	week		
4788	2298					Recommended	mg	12.5		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-284_Ritalin%20LA_medr.pdf	Homo sapiens						9	mean						65	Attention Deficit Hyperactivity Disorders								2	week		nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
4789	2298					Recommended	mg	15		single			day	2	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-284_Ritalin%20LA_medr.pdf	Homo sapiens						30	mean						61									1	day		nda/2002/21-284_Ritalin%20LA_medr.pdf - p.15
4790	2298					Studied dose	mg	210		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20158630/	Homo sapiens						8							1	Attention Deficit Hyperactivity Disorders					8			1	day		
4791	2298					Studied dose	mg	700		multiple					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12444349/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/010187s091,018029s059lbl.pdf	Homo sapiens						45							1	Attention Deficit Hyperactivity Disorders					45			3	day		
4792	2299					Recommended	%	10		multiple			day	2	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019931s019lbl.pdf	Homo sapiens														Acne vulgaris											
4793	2299					Recommended	drop	2		multiple			3 hours	1	unhealthy	topical			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5e0415cd-5803-44b2-be24-af823c48c6d0&type=display	Homo sapiens							max							Conjunctivitis								7	day		
4794	2300		adult			Highest studied dose	mg	500		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/31932197/	Homo sapiens													19	various patients											
4795	2301					Highest studied dose	mg	150		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/99115/	Homo sapiens							max					53	10	schizophrenia					22			23	day		
4796	2301					Overdose	mg	100		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4184863/	Homo sapiens						12							1	migraine											
4797	2302					Overdose	mg	800		multiple			day	1	unhealthy	oral			http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de	Homo sapiens										2.5 times the normal therapeutic maximum				Psychotic disorders											
4798	2302					Recommended	mg	150		multiple			day	1	unhealthy	intramuscular			http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de	Homo sapiens														Psychotic disorders											
4799	2302					Recommended	mg	3		multiple			day	1	unhealthy	intravenous			http://www.jodrugs.com/products/39197-triflupromazine.aspx#cite4_de	Homo sapiens														Nausea											
4800	2303					Studied dose	mg	450		multiple					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7541439	Homo sapiens						41	total daily dose|max			the patient was receiving a total of 300-450 mg of anileridine per day in divided doses.			1	Pain								8	week		p.319
4801	2305		adult			Highest studied dose	mg	100		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2720580/	Homo sapiens																									
4802	2305		adult			Studied dose	mg	180		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/28530786/	Homo sapiens													152	neuropathic pain								3	month		
4803	2305		adult				mg	4		multiple					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02820324	Homo sapiens							min			The loading dose for the morphine treatment regimen was 4 mg with 1 mg demand doses. Supplemental doses of 2 mg were permitted, beginning 1 hour after the loading dose, and hourly thereafter, as needed. A lockout interval of 6 minutes was used for all PCA regimens.			83	Pain											
4804	2306		adult			Recommended	mg	325		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/17208597/	Homo sapiens							starting						70	spirin-exacerbated respiratory disease								1	year		
4805	2306		adult			Recommended	mg	650		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/17208597/	Homo sapiens							starting						67	spirin-exacerbated respiratory disease								1	year		
4806	2306					Recommended	mg	300		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3590391/	Homo sapiens						3							1	febrile illness					3			3	day		
4807	2306					Studied dose	g	4		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26085469/	Homo sapiens						61							1	fever					61			1	day		
4808	2306						mg	750		steady			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00467584	Homo sapiens													17	Multiple Sclerosis								8	week		
4809	2307		adult				mg/kg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01977820	Homo sapiens													1	Phenylketonuria								26	week		
4810	2307		child			Overdose	mg/kg	45		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022181s013lbl.pdf	Homo sapiens													1	Hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4 -) responsive Phenylketonuria											p.10
4811	2307		child				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00272792	Homo sapiens										Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks.			33	Phenylketonurias								6	week		
4812	2307					Recommended	mg/kg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19261295	Homo sapiens						7.7							33	Phenylketonuria								10	week		p.705
4813	2307					Recommended	mg/kg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022181s013lbl.pdf	Homo sapiens														Hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4 -) responsive Phenylketonuria											p.1
4814	2309					Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10856535/	Homo sapiens						22							13	familial hypercholesterolaemia								4	week		
4815	2309					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16287954/	Homo sapiens						61.8				median duration			4439	myocardial infarction								4.8	year		
4816	2309					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9666952/	Homo sapiens												70	54	familial hypercholesterolaemia					18			3	month		
4817	2310					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26063503	Homo sapiens							starting			600 mg loading followed by 150 mg/day maintenance dose		45	27						20			5	day		
4818	2310					Overdose	mg	1650		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/17286151	Homo sapiens						49		120 mg; single		22 tablets of clopidogrel			1		1400 mg; single			phenytoin sodium	49					simvastatin	
4819	2310						mg	600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16878371	Homo sapiens						59	starting			clopidogrel 75 mg/day for three days			1						59			7	day		
4820	2311					Highest studied dose	mg	1200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10049274	Homo sapiens						38				Abacavir was supplied as 100-mg white, biconvex caplets. Each subject took the abacavir doses (12 caplets) with 200 ml of water and fasted for another 3 h postdosing.			12	HIV-1-infection					38						
4821	2311					Highest studied dose	mg	600		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10898676	Homo sapiens													20	HIV-1-infection					13			4	week		
4822	2311					Recommended	mg	600		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201107Orig1s000lbl.pdf	Homo sapiens										combined 9 clinical trials			2670	HIV infection								6	week		
4823	2311						mg	150		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/10453964	Homo sapiens													6	HIV-1-infection								60	min		
4824	2312					Highest studied dose	g	2		multiple			day	6	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/7405988/	Homo sapiens										intravenous infusion of 2 gm every 4 hours or, less often, every 3 hours.			20									6	day		
4825	2312						g	1		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/426510	Homo sapiens													24	renal impairment											
4826	2312						g	5.1		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3718099	Homo sapiens										average : 5.1 -6 g		58	2						43			4	day		
4827	2314		adult			Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15156449/	Homo sapiens														human immunodeficiency virus								48	week		
4828	2314					Overdose	g	30		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29706057/	Homo sapiens						40							1	human immunodeficiency virus					40						
4829	2316					Highest studied dose	g	1.5		multiple			day	8	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/4147580/	Homo sapiens										one patient had 30 days treatment duration		34	4	endocarditis					21			42	day		
4830	2316					Recommended	g	1		multiple			day	4	healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3510836/	Homo sapiens						75							1						75			4	day		
4831	2316					Studied dose	g	4		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/526003/	Homo sapiens												35	7						21			9.5	day		
4832	2316						g	1		multiple			day	3	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00610987	Homo sapiens													75	closed fractures								1	day		
4833	2317					Studied dose	g	2		steady			day	2	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6321356	Homo sapiens														complicated urinary tract infections								7	day		
4834	2317					Studied dose	mg	500		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/6272631	Homo sapiens												43							25						
4835	2317					Studied dose	mg/kg	100		steady			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/6296023	Homo sapiens													1									3	day		
4836	2318		adult			Highest studied dose	mg	360		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14508384	Homo sapiens																						1	week		
4837	2318		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00048815	Homo sapiens													11	Depression								12	week		
4838	2318		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00048815	Homo sapiens													24	Depression								12	week		
4839	2318		adult				mg	20		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00477165	Homo sapiens										20mg/day for 4 weeks, then 40 mg/day for 4 weeks			27	Irritable Bowel Syndrome								8	week		
4840	2318		adult				mg	40		steady			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00825825	Homo sapiens							max			One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.			21									2	week		
4841	2318		child				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00962039	Homo sapiens							total daily dose			Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.			40	Anxiety								12	week		
4842	2318					Overdose	mg	2800		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf	Homo sapiens													1												
4843	2318					Overdose	mg	760		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/31257122	Homo sapiens						25							1						25						
4844	2318					Overdose	mg	800		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/30185094	Homo sapiens						14							1						14						
4845	2318					Studied dose	mg	80		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20822lbl.pdf	Homo sapiens							max					66	1063	depression					18			6	week		
4846	2319		adult				ug	25		steady			day	1	unhealthy	sublingual	F		https://clinicaltrials.gov/ct2/show/NCT01223937	Homo sapiens													135	Nocturia								3	month		
4847	2319		children|adolescents				ug	240		steady			day	1	unhealthy	sublingual			https://clinicaltrials.gov/ct2/show/NCT01078753	Homo sapiens							max						45	Nocturnal enuresis								14	day		
4848	2319					MTD	ug/kg	0.5		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32166534/	Homo sapiens						55.5							6	bleeding								2	day		
4849	2319					Recommended	ug	0.75		multiple			day	1	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/201656Orig1s000MedR.pdf	Homo sapiens						65.5							454	nocturia								99	day		nda/2017/201656Orig1s000MedR.pdf
4850	2319					Recommended	ug	1.5		multiple			day	1	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/201656Orig1s000MedR.pdf	Homo sapiens						65.5							448	nocturia								99	day		nda/2017/201656Orig1s000MedR.pdf
4851	2319					Studied dose	mg	6		single			3 days	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16137482/	Homo sapiens						75							1	nocturia					75			3	day		
4852	2319					Studied dose	ug/kg	1		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32166534/	Homo sapiens						55.5							6	bleeding								2	day		
4853	2319					Studied dose	ug/kg	1		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32166534/	Homo sapiens						55.5							2	bleeding								2	day		
4854	2320		adult			Recommended	mg	1500		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/007409s040,007961s026,008370s031lbl.pdf	Homo sapiens													1	functional bowel/irritable bowel syndrome											
4855	2320		adult			Recommended	mg	40		multiple			day	4	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/007409s041lbl.pdf	Homo sapiens													100	functional bowel/irritable bowel syndrome											
4856	2320					Recommended	mg	600		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/007409s040,007961s026,008370s031lbl.pdf	Homo sapiens													1	functional bowel/irritable bowel syndrome											
4857	2321					Highest studied dose	mg	200		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/10086835	Homo sapiens												45	24						19						p.33
4858	2321					Highest studied dose	mg	200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10086835	Homo sapiens												45	24						19						p.33
4859	2321					Recommended	mg	100		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020623s010lbl.pdf%2C020624s023lbl.pdf	Homo sapiens														Nausea and vomiting associated with cancer chemotherapy											p.5
4860	2322					Highest studied dose	mg	0.8		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12028321	Homo sapiens										30-min infusion		37	12						21						S56
4861	2322					Highest studied dose	mg	40		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12028321	Homo sapiens												37	12						21						S56
4862	2322					Highest studied dose	mg	40		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12028323	Homo sapiens						40.4							207	Migraine											S76
4863	2322					Recommended	mg	7.5		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf	Homo sapiens										Tablets: 2.5 mg. Second tablet may be taken 2 hours after initial dose if headache recurs following initial relief. Total dose not to exceed 3 tablets in any 24-hour period.				Migraine											p.1
4864	2322					Recommended	mg	7.5		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021006s019lbl.pdf	Homo sapiens										Tablets: 2.5 mg. Second tablet may be taken 2 hours after initial dose if headache recurs following initial relief. Total dose not to exceed 3 tablets in any 24-hour period.				Migraine											p.3
4865	2323					Recommended	mg	400		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15303456/	Homo sapiens						84							1	type 2 diabetes mellitus and nonproductive cough	5 mg/day			glyburide	84			3	day		
4866	2323					Recommended	mg	400		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15303456/	Homo sapiens						79							1	type 2 diabetes mellitus and pneumonia	10 mg/day			glyburide	79			2	day		
4867	2323					Recommended	mg	400		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17213006/	Homo sapiens						86							1	small bowel obstruction and suspected pneumonia				metoprolol, diltiazem, subcutaneous heparin, ranitidine, vancomycin, piperacillin/tazobactam, and aspirin	86			4	day		
4868	2323					Recommended	mg/kg	10		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14614364/	Homo sapiens													160	acute otitis media								10	day		
4869	2324					Studied dose	mg	650		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1104667	Homo sapiens						43				the maintenance dose is 100 mg/day			1						43						
4870	2324						mg	30		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1802491	Homo sapiens													120	algodystrophy											
4871	2324						mg	75		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/541046	Homo sapiens						69							1	hypertension	40 mg twice daily			furosemide	69			12	month		
4872	2325		adult			Recommended	mg	2.5		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Homo sapiens													465	postmenopausal osteoporosis								1	year		p. 24
4873	2325		adult				mg	2		multiple			2 months	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Homo sapiens													442	postmenopausal osteoporosis								1	year		p. 24
4874	2325		adult				mg	3		multiple			3 months	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021858s000_MedR_P1.pdf	Homo sapiens													458	postmenopausal osteoporosis								1	year		p. 24
4875	2325						mg	100		multiple			month	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28389932	Homo sapiens													183	osteoporosis											
4876	2325						mg	150		multiple			month	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00545051	Homo sapiens													70	Osteoporosis								12	month		
4877	2325						mg	150		multiple			month	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00397839	Homo sapiens													86	Osteoporosis								12	month		
4878	2326					Highest studied dose	mg	2		single					healthy	intrathecal	M+F		https://pubmed.ncbi.nlm.nih.gov/12406536/	Homo sapiens												50	5						18						
4879	2326					Highest studied dose	mg	30		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/17192497/	Homo sapiens												45	15						19						
4880	2326					Highest studied dose	mg	30		single					healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/17192497/	Homo sapiens												45	15						19						
4881	2326					Recommended	mg	31.5		multiple			day	3	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/19594851/	Homo sapiens						51.7							199	pain								5	day		
4882	2326						mg	90		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00765128	Homo sapiens													8	Percutaneous Nephrolithotomy operation											
4883	2326						mg	90		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00765232	Homo sapiens													57	Laparoscopic Donor Nephrectomy											
4884	2327					Recommended	mg	250		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Homo sapiens						50							7537	infectious diseases								10	day		19
4885	2327					Recommended	mg	500		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Homo sapiens						50							7537	infectious diseases								10	day		19
4886	2327					Recommended	mg	750		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021721s020_020635s57_020634s52_lbl.pdf	Homo sapiens						50							7537	infectious diseases								10	day		19
4887	2328						mg	10		single			hour	4	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2751185	Homo sapiens						38							1						38						
4888	2329		adult			Overdose	mg	100		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Homo sapiens													1												
4889	2329		adult			Overdose	mg	3		multiple			day	1	unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Homo sapiens													1												
4890	2329		adult			Recommended	mg	1		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/201971Orig1s000lbl.pdf	Homo sapiens													149	Parkinson’s disease								26	week		
4891	2329		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00977665	Homo sapiens													84	Multiple System Atrophy								48	week		
4892	2329		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01479530	Homo sapiens													163	Parkinson's Disease								16	week		
4893	2329		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01723228	Homo sapiens													86	Parkinson's Disease								24	week		
4894	2329		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02337725	Homo sapiens													117	Parkinson's Disease								26	week		
4895	2329		adult				mg	1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02359552	Homo sapiens										Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit).			25	Alzheimer's Disease								24	week		
4896	2329		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01786603	Homo sapiens													60	Amyotrophic Lateral Sclerosis								12	month		
4897	2329					Highest studied dose	mg	2		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30218626	Homo sapiens						33							16						33						
4898	2329					Highest studied dose	mg	2		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30218626	Homo sapiens						33							16						33			10	day		
4899	2329					Highest studied dose	mg	4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15300656	Homo sapiens						62							14	Early Parkinson’s Disease					62			3	week		
4900	2329						mg	2.5		single					healthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/29159774	Homo sapiens										transdermal patch size 4 cm2; total drug amount 2.5 mg			4												
4901	2330					Recommended	g	1		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/8540716	Homo sapiens													94	Brucellosis	100 mg oral; 2/day			Doxycycline				14	day		p.2066
4902	2330					Recommended	g	1		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6989067	Homo sapiens								600 mg iv; 1/day				70	119	Pulmonary tuberculosis	300 mg iv; 1/day		pyrazinamide	lsoniazid	15		2 g iv; 1/day	2	month	rifampicin	p.47
4903	2330					Recommended	mg	1225		steady			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15156439	Homo sapiens										Duration of therapy, median weeks (range) 14 (2–107); Dose, median mg (range) 1225 (800–1900)			13	Mycobacterium avium complex								14	week		p.1539
4904	2330					Recommended	mg	1225		steady			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15156439	Homo sapiens										Duration of therapy, median weeks (range) 14 (2–107); Dose, median mg (range) 1225 (800–1900)			3	Mycobacterium tuberculosis								14	week		p.1539
4905	2330					Recommended	mg	800		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15156439	Homo sapiens										Duration of therapy, median weeks (range) 9 (2–38); Dose, median mg (range) 800 (500–1150)			10	Mycobacterium avium complex								9	week		p.1539
4906	2330					Recommended	mg	800		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15156439	Homo sapiens										Duration of therapy, median weeks (range) 9 (2–38); Dose, median mg (range) 800 (500–1150)			6	Mycobacterium tuberculosis								9	week		p.1539
4907	2331		adult			Highest studied dose	mg	5.2		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204096s000lbl.pdf	Homo sapiens													60	kidney transplantation								14	day		
4908	2331		adult			Highest studied dose	mg	8		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050708s052,050709s044,210115s004lbl.pdf	Homo sapiens													1												
4909	2331		adult			Recommended	mg/kg	0.1		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050708s052,050709s044,210115s004lbl.pdf	Homo sapiens										0.2 mg/kg/day, divided in two doses, administered every 12 hours								Azathioprine							
4910	2331		adult				mg	3		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00106392	Homo sapiens										Preoperatively: Tacrolimus 2 mg oral daily from 4 to 10 days prior to surgery through hospital discharge; Postoperatively: Tacrolimus 3 mg oral daily at time of hospital discharge through 6 months of follow up.			59	Erectile Dysfunction								6	month		
4911	2331		adult				mg/kg	0.02		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050708s052,050709s044,210115s004lbl.pdf	Homo sapiens													12	Renal Impairment								4	hour		
4912	2331						%	0.03		multiple			day	1	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/33657259	Homo sapiens													31	non-segmental vitiligo								24	week		
4913	2331						mg/kg	0.15		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210115Orig1s000MedR.pdf	Homo sapiens						1.9				0.3 mg/kg/day PO in 2 divided dose		15	91	Primary Liver Transplantation					3			12	month		p. 79
4914	2332					Highest studied dose	mg	4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10223495	Homo sapiens						52							58	Overactive bladder											p.997
4915	2332					Recommended	mg	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12028164	Homo sapiens												93	507	Overactive bladder					20			12	week		p.804
4916	2332					Recommended	mg	2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020771s022lbl.pdf	Homo sapiens													986	Overactive bladder								12	week		p.11
4917	2333					Highest studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33495312	Homo sapiens										Cycles were 21 days in length			3	Acute myeloid leukemia|Myelodysplasia	45 mg/m2; q.d			all-trans retinoic acid, p.o				3	day		p.1895
4918	2333					MTD	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33495312	Homo sapiens										Cycles were 21 days in length			6	Acute myeloid leukemia|Myelodysplasia	45 mg/m2; q.d			all-trans retinoic acid, p.o				3	day		p.1895
4919	2333					Overdose	mg	250		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7263132	Homo sapiens						35							1	Major depressive disorder											
4920	2333					Overdose	mg	4000		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/9316000|https://pubmed.ncbi.nlm.nih.gov/23791433	Homo sapiens													1												
4921	2333					Overdose	mg	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5014984	Homo sapiens						27							1	Major depressive disorder											p.64
4922	2333					Overdose	mg	600		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4939226	Homo sapiens						42				The number of tablets consumed was certainly more than 60 (tranylcypromine 600mg, trifluoperazine 60mg) and was very probably as many as 90 (tranylcypromine 900mg, trifluoperazine 90mg)			1	Major depressive disorder	60 mg; single			trifluoperazine, p.o							
4923	2333					Recommended	mg	30		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012342s064lbl.pdf	Homo sapiens										Recommended daily dosage is 30 mg in divided doses. If no adequate response, increase dosage in increments of 10 mg per day every 1 to 3 weeks to a maximum dosage of 30 mg twice daily (60 mg per day)				Major depressive disorder											p.1
4924	2334					MTD	mg/m2	1.3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15269145	Homo sapiens												73	6	Renal Cell Carcinoma	10 mg/kg/d			valspodar, i.v	18			3	day		p.4727
4925	2334					MTD	mg/m2	10		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7747714	Homo sapiens												70	3	Renal Cell Carcinoma	17 mg/kg/d			cyclosporine, p.o	31			2	cycle		p.254
4926	2334					Recommended	mg/m2	18.5		multiple			week	1	unhealthy	intravenous			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f073b58e-56d6-4c8d-a2ce-b37719402d77&type=display	Homo sapiens										First dose -3.7 mg/m 2 bsa, Second dose 5.5 mg/m 2 bsa, Third dose 7.4 mg/m 2 bsa, Fourth dose 9.25 mg/m 2 bsa, Fifth dose 11.1 mg/m 2 bsa. The above-mentioned increases may be used until a maximum dose not exceeding 18.5 mg/m 2 bsa for adults is reached.				Generalized Hodgkin’s disease|Lymphocytic lymphoma|Histiocytic lymphoma|Mycosis fungoides|Advanced carcinoma of the testis|Kaposi’s sarcoma|Letterer-Siwe disease|Choriocarcinoma|Carcinoma of the breast											
4927	2334					Studied dose	mg/m2	2.6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15269145	Homo sapiens												73	3	Renal Cell Carcinoma	5 mg/kg/d			valspodar, i.v	18			3	day		p.4726
4928	2334					Studied dose	mg/m2	2.6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15269145	Homo sapiens												73	4	Renal Cell Carcinoma	4 mg/kg/d			valspodar, i.v	18			3	day		p.4726
4929	2335		adult				mg	4		multiple			3 months	1	unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00333229	Homo sapiens													6	Bone Loss								24	month		
4930	2335		adult				mg	4		multiple			3 months	1	unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00375505	Homo sapiens													34	Bone Loss								24	month		
4931	2335		adult				mg	5		multiple			year	1	unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00132808	Homo sapiens													198	Osteopenia								2	year		
4932	2335		adult				mg	5		multiple			year	1	unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00145327	Homo sapiens													1221	Osteoporosis								3	year		
4933	2335		adult				mg	5		multiple			year	1	unhealthy	intravenous	F		https://clinicaltrials.gov/ct2/show/NCT00145327	Homo sapiens													613	Osteoporosis								6	year		
4934	2335		adult				mg	5		multiple			year	1	unhealthy	intravenous	M		https://clinicaltrials.gov/ct2/show/NCT00439647	Homo sapiens													588	Osteoporosis								3	year		
4935	2335		child|adult				mg	5		multiple			year	1	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01267279	Homo sapiens										patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery			27	Osteoporosis											
4936	2335					Highest studied dose	mg	16		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12412821	Homo sapiens										15-minute infusion		79	12	cancer					40						
4937	2335					Highest studied dose	mg	16		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11148571	Homo sapiens						54				intravenous bolus injection over 30 – 60 seconds			10	cancer					54						
4938	2338		ADULT			Recommended	drop	2		single					healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/2693136/	Homo sapiens										antazoline sulphate 0.5 per cent w/v; two drops of drug solution were instilled 30 seconds apart to one eye		59	16		0.05 per cent w/v			xylometazoline hydrochloride	19						p.296
4939	2338		ADULT			Studied dose	mg	250		multiple			5 min	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28339554/	Homo sapiens						69	total			Patients assigned to the antazoline group were administered antazoline\nin boluses of 50 mg diluted to 10 cm3 every 5 min up to a total dose of\n250 mg—50 cm3.			36	atrial fibrillation											p.5
4940	2339					Accidental dose	g/kg	3.9		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9365430/	Homo sapiens						1.75							1	Short stature											p.621
4941	2339					Highest studied dose	mg/kg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15640324	Homo sapiens						24							11	Cystic fibrosis								6	week		p.63
4942	2339					Studied dose	g	15		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29858688	Homo sapiens						34							12	Dietary supplementation								90	day		p.1
4943	2339					Studied dose	g	7		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9918901	Homo sapiens						43							10	Hypercholesterolaemia								12	week		p.200
4944	2340		adult			Recommended	mg	500		steady			day	4	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/1921491/	Homo sapiens										500 to 1000 mg, 3-4 time/day			2516	infections								5	day		
4945	2340		adult			Recommended	mg	500		steady			day	4	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf	Homo sapiens										500 to 1000 mg, 3-4 time/day			1723	infections				CILASTATIN				5	day		
4946	2340					Recommended	mg/kg	15		steady			day	4	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf	Homo sapiens										15 to 25 mg/kg, 3-4 time/day			135	infections				CILASTATIN				5	day		
4947	2340					Recommended	mg/kg	25		steady			day	4	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf	Homo sapiens										15 to 25 mg/kg, 3-4 time/day			178	infections				CILASTATIN				5	day		
4948	2341		adults				mL	10		multiple			day	3	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=43ff5156-e08b-4dc4-93a6-8c727676daa1&type=display	Homo sapiens										combined data from 44 clinical trials			1120	bronchial asthma											
4949	2343		adult			Recommended	%	0.3		steady			day	1	unhealthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/1687324/	Homo sapiens														Allergic conjunctivitis								7	day		
4950	2343					Studied dose	mg	50		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8079504/	Homo sapiens												38	3						32						
4951	2346					Overdose	mg	40		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf	Homo sapiens							min			extended-release formulation				Attention Deficit Hyperactivity Disorder											p.11
4952	2346					Recommended	mg	30		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf	Homo sapiens										extended-release formulation				Attention Deficit Hyperactivity Disorder											p.7
4953	2346					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf	Homo sapiens							max			extended-release formulation				Attention Deficit Hyperactivity Disorder											p.1
4954	2346					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021802s033lbl.pdf	Homo sapiens							max			extended-release formulation				Attention Deficit Hyperactivity Disorder											p.8
4955	2347					Recommended	g	3		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/050717Orig1s000rev.pdf	Homo sapiens						32							426	Infection											MON-US-02
4956	2348		adults				mg	400		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018084s052,017628s068lbl.pdf	Homo sapiens							starting			For the relief of juvenile rheumatoid arthritis, the recommended starting dose for pediatric patients (2 years and older) is 20 mg/kg/day in divided doses (t.i.d. or q.i.d.). TOLECTIN 600 (tolmetin sodium) tablets for oral administration contain tolmetin sodium as the dihydrate in an amount equivalent to 600 mg of tolmetin.			800	rheumatoid arthritis and osteoarthritis								1	year		
4957	2349		adult				mg	100		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01989793	Homo sapiens							max						18	Sarcopenia								8	week		
4958	2349		adult				mg	100		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02676466	Homo sapiens							max						26	difficulty walking								6	month		
4959	2349					Highest studied dose	mg	200		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1577054/ | https://pubmed.ncbi.nlm.nih.gov/8471405/	Homo sapiens						32.6							12									1	day		
4960	2349					Recommended	mg	50		multiple			day	1	pregnant	oral	F		https://pubmed.ncbi.nlm.nih.gov/11211003/	Homo sapiens						31							1						31			14	week		
4961	2349					Recommended	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9074572/	Homo sapiens						74							352	heart failure								48	week		
4962	2349					Studied dose	g	2.7		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27355173/	Homo sapiens						54							1	hypertension	200 mg; 1/d			amlodipine	54			1	day		
4963	2349					Studied dose	mg	16640		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21629799/	Homo sapiens						50							1	hypertension	770 mg; 1/d			amlodipine	50			1	day		
4964	2350					Recommended	%	1		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-307_Lotrimin_medr.pdf	Homo sapiens												12	100	Tinea corporis					2			2	week		CL2001-01
4965	2351		adult			Recommended	mg	666		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21431lbl.pdf	Homo sapiens										is two 333 mg tablets (each dose should total 666 mg) taken three times daily.			1539	alcohol-dependence								6	month		
4966	2351		adult			Recommended	mg	666		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-431_Campral_Medr_P2.pdf	Homo sapiens										pooled data			1346	alcohol (ethanol)-dependence								6	month		p. 93
4967	2351					Overdose	g	56		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21431lbl.pdf	Homo sapiens																									
4968	2351						mg	66		steady			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00466661	Homo sapiens													14	Alcohol Dependence								8	week		
4969	2352					Highest studied dose	g	0.8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/87291/	Homo sapiens												63	11	hypertension					31			12	week		
4970	2352					Overdose	g	4		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10729673/	Homo sapiens						43							1												
4971	2352					Overdose	g	6		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10729673/	Homo sapiens						16							1												
4972	2352					Overdose	g	9.2		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6617679/	Homo sapiens						24							1												
4973	2353					Highest studied dose	mg	375		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-575_Fosamax_medr.pdf	Homo sapiens												65	25						18			1	day		
4974	2353					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020560Orig1s000rev.pdf	Homo sapiens						69.5				median duration			110	Paget's disease								1680	day		
4975	2353					Studied dose	mg	70		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23288794/	Homo sapiens						77							1		daily			aspirin	77			5	day		
4976	2353					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020560Orig1s000rev.pdf	Homo sapiens						69.5				median duration			42	Paget's disease								1680	day		
4977	2353						mg	70		steady			week	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00043186	Homo sapiens													46	Low Bone Mineral Density								24	month		
4978	2353						mg	70		steady			week	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00504166	Homo sapiens													26	Microarchitectural Deterioration of Trabecular Bone								24	month		
4979	2353						mg	70		steady			week	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01512446	Homo sapiens													188	Osteoporosis											
4980	2355					Highest studied dose	mg	40		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-287_Uroxatral_Medr_P3.pdf	Homo sapiens						27							45									1	day		
4981	2355					Recommended	mg	2.5		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8821687/	Homo sapiens						66.9							13389	benign prostatic hypertrophy								3	month		
4982	2355					Recommended	mg	4.4		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15049986/	Homo sapiens						62.6	mean			5-10 mg divided in two or three daily doses. Mean final dosage of alfuzosin - 8.8 mg/day			93	benign prostatic hypertrophy								14	week		
4983	2356					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17367658	Homo sapiens						53							166	Hypertension								8	week		p.1161
4984	2356					Highest studied dose	mg	600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18538111	Homo sapiens												45	8						18						
4985	2356					Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021985s023lbl.pdf	Homo sapiens														Hypertension											p.1
4986	2356						mg	150		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01437943	Homo sapiens													7	Kidney Transplant								180	day		
4987	2356						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00768040	Homo sapiens													20	diabetic macular edema								12	week		
4988	2356						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00894387	Homo sapiens							max						808	acute decompensated Heart Failure								6	month		
4989	2356						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00982033	Homo sapiens													25	Heart Failure and a Normal Ejection Fraction											
4990	2356						mg	300		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01417104	Homo sapiens							max						34	Atherosclerosis								34	week		
4991	2357		adult			Highest studied dose	mg	100		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	Homo sapiens													1									38	hour		
4992	2357		adult			Highest studied dose	mg	200		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21001_Axert_prntlbl.pdf	Homo sapiens													6												
4993	2357					Highest studied dose	mg	10		single					unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/11768838	Homo sapiens						42						72	31	acute migraine					18						
4994	2357					Recommended	mg	12.5		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12005273	Homo sapiens						42				12.5-mg dose of almotriptan at the onset of a migraine attack. If migraine pain did not disappear in 2 hours, escape medication could be taken; if relapse occurred in less than 24 hours, a second 12.5-mg dose could be taken		72	582	acute migraine					18			6	month		
4995	2357						mg	3		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/12463724	Homo sapiens												33	24						19						
4996	2358					MTD	mg	8		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21107a_Lotronex_medr_P15.pdf	Homo sapiens						45							68	irritable bowel syndrome								12	week		S3BA2001
4997	2359					Recommended	%	10		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208081Orig1s000MedR.pdf	Homo sapiens													384									12	week		p. 44
4998	2359					Recommended	mg/kg	20		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29999205	Homo sapiens						70.5							61	primary or recurrent non-muscle-invasive bladder cancer					70.5						
4999	2359						mg	100		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/11961050	Homo sapiens													6												
5000	2359						mg	100		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/11961050	Homo sapiens													6												
5001	2359						mg	1328		single					unhealthy	intravesical			https://pubmed.ncbi.nlm.nih.gov/11961050	Homo sapiens										total dose of ALA hydrochloride was 1.698 g, equivalent to 1.328 g of ALA			8	recurrent bladder cancer											
5002	2360		adult			Highest studied dose	mg	400		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf	Homo sapiens													192	ventricular tachyarrhythmias								6	month		
5003	2360					Highest studied dose	mg	800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6191299/	Homo sapiens						62				800-1000 mg per day			58	symptomatic ventricular tachycardia or ventricular fibrillation					62			2.6	month		
5004	2360					Recommended	mg	100		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31198686/	Homo sapiens						88							1	hypothyroidism, hypertension, sick sinus syndrome with pacemaker, paroxysmal atrial fibrillation, prostate cancer, and neurogenic bladder					88			6	year		
5005	2360					Recommended	mg	150		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10921701/	Homo sapiens						66							74	prevention of atrial fibrillation after coronary artery bypass grafting					66			3	day		
5006	2361						mg	775		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/050813s000medr.pdf	Homo sapiens										pivotal studies			302	pharyngitis secondary to Streptococcus pyogenes					12			10	day		
5007	2362					Recommended	mg	1		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020333s024lbl.pdf	Homo sapiens										Adults: The recommended starting dosage of AGRYLIN is 0.5 mg four times daily or 1 mg twice daily. The dose increment should not exceed 0.5 mg/day in any one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose.			942	Thrombocythemia											p.4
5008	2362					Recommended	mg	1.9		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10200810	Homo sapiens						58	mean			The commencement dose of anagrelide was 0.5 mg, two to four times daily. Each patient's dose was adjusted according to clinical response, to a maximum of 5 mg/day.			16	Thrombocythemia											p.33
5009	2362					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020333s024lbl.pdf	Homo sapiens							total daily dose			Adults: The recommended starting dosage of AGRYLIN is 0.5 mg four times daily or 1 mg twice daily. The dose increment should not exceed 0.5 mg/day in any one week. Dosage should not exceed 10 mg/day or 2.5 mg in a single dose.				Thrombocythemia											p.1
5010	2363		adult			Highest studied dose	mg	125		single					unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022485lbl.pdf	Homo sapiens													568	thrombosis											6.1
5011	2363					Overdose	mg	125		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/16449547/	Homo sapiens						74							1	Crohn’s disease, ileorectal fistula					74						
5012	2363					Overdose	mg	225		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15981224/	Homo sapiens						65							1	critically ill in thepost-operative period					65						
5013	2364		adult			Higher than recommended	mg	120		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/21265936/	Homo sapiens							max			40 to 120 mg			45	attention deficit hyperactivity disorder								8	week		
5014	2364		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00190775	Homo sapiens							max			Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally			266	Attention Deficit Hyperactivity Disorder								24	week		
5015	2364		adult				mg	120		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00962104	Homo sapiens							max			40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.			193	Attention Deficit Hyperactivity Disorder								10	week		
5016	2364		adult				mg	80		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00611533	Homo sapiens							total daily dose			Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.			16	Cognitive Disturbances								6	week		
5017	2364		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00304161	Homo sapiens							max			40 to 80 mg orally once daily for 8 weeks			28	Depression in Parkinson's Disease								8	week		
5018	2364		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01557569	Homo sapiens										During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)			6	Methamphetamine Dependence								10	week		
5019	2364		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01738191	Homo sapiens										The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.			15	Parkinson's Disease								10	week		
5020	2364		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03091400	Homo sapiens										Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)			10	Multiple Sclerosis								6	week		
5021	2364		child				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01244490	Homo sapiens							max			Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose			112	Attention Deficit Hyperactivity Disorder								9	week		
5022	2364		child				mg/kg	1.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00380692	Homo sapiens							max			atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks			48	Attention Deficit Disorder With Hyperactivity								28	week		
5023	2364		child				mg/kg	1.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00406354	Homo sapiens							max			0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks			61	Attention Deficit Hyperactivity Disorder and Oppositional Defiant Disorder								9	week		
5024	2364		child				mg/kg	1.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00406354	Homo sapiens							max			0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks			60	Attention Deficit Hyperactivity Disorder and Oppositional Defiant Disorder								9	week		
5025	2364		child				mg/kg	1.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00546910	Homo sapiens										A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day.			63	Attention-Deficit/Hyperactivity Disorder								8	week		
5026	2364		child				mg/kg	1.4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00716274	Homo sapiens							max			Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks			45	Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia								16	week		
5027	2364		child				mg/kg	1.8		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00498173	Homo sapiens							max|total daily dose			Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.			29	Attention deficit hyperactivity disorder								8	week		
5028	2364		children			Highest studied dose	mg	249		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15870137/	Homo sapiens							mean						40	attention deficit hyperactivity disorder											
5029	2364					Highest studied dose	mg	480		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15870137/	Homo sapiens						14							1	attention deficit hyperactivity disorder					14						
5030	2364					Highest studied dose	mg/kg	1.8		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21422081/	Homo sapiens												6	44	attention deficit hyperactivity disorder					5			8	week		
5031	2364					Overdose	g	1.2		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/15171487/	Homo sapiens						19		9 mg					1		36 g			oxcarbazepine	19					Quetiapine	
5032	2364					Overdose	mg	180		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15732449/	Homo sapiens						12							1	mistakenly instead of dextroampheta					12						
5033	2364					Overdose	mg	2840		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17307628/	Homo sapiens						17							1	attempted suicide					17						
5034	2364					Recommended	mg	40		steady			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27123802/	Homo sapiens						26							1	temper outbursts, impulsivity, difficulty paying attention, marital discord				fluoxetine	26			4	day		
5035	2365					Recommended	ug	274		multiple			day	2	unhealthy	intranasal			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20114S006_Astelin%20Nasal%20Spray_medr_P2.pdf	Homo sapiens										Two Sprays Per Nostril Twice Daily. Each spray of Astelin Nasal Spray delivers a volume of 0.137 mL solution containing 137 mcg of azelastine hydrochloride			216	seasonal allergic rhinitis.					12			20	day		p. 44
5036	2365						mg	0.015		multiple			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/9787982/	Homo sapiens										0.015 mg azelastine.HCl/drop. one drop per eye, twice daily		12	51	seasonal allergic conjunctiviti					4			14	day		
5037	2365						mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11316966/	Homo sapiens						38.5						64	16	Chronic Idiopathic Urticaria					18			21	day		
5038	2366		adult			Recommended	g	6.6		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022205Orig1s000MedR.pdf	Homo sapiens										total daily dose (6.6g/day) for tablet formulation is similar to that of the capsule formulation (6.75g/day)			210									8	week		p. 61
5039	2366						g	6.75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19633577	Homo sapiens						12.8				total daily dose (6.6g/day) for tablet formulation is similar to that of the capsule formulation (6.75g/day)		17	33						5			8	week		
5040	2367		adult			Recommended	mg	10		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11464260/	Homo sapiens													116	Essential hypertension											
5041	2367					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1893640/	Homo sapiens													193	Essential hypertension											
5042	2367					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1893640/	Homo sapiens													1145	Essential hypertension											
5043	2367					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1893640/	Homo sapiens													771	Essential hypertension											
5044	2367					Recommended	mg	5		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1893640/	Homo sapiens							max						184	Essential hypertension											
5045	2367					Recommended	mg	80		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1893640/	Homo sapiens													86	Essential hypertension											
5046	2368					Higher than recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3919556/	Homo sapiens												77	44	angina					34			14	week		
5047	2368					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19359813/	Homo sapiens						63.5							33	angina					63.5			12	week		
5048	2368					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19359813/	Homo sapiens						64.6							29	angina					64.6			12	week		
5049	2368					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3919556/	Homo sapiens												84	43	angina					39			14	week		
5050	2368					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3919556/	Homo sapiens												80	46	angina					43			14	week		
5051	2370		adult				drop	1		steady			day	2	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/NCT03521791	Homo sapiens													76	Pterygium								20	day		
5052	2370					Highest studied dose	%	0.1		single					unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/19049295	Homo sapiens						72.2							54	cataract					72.2						
5053	2370					Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9690243/	Homo sapiens						23.7							21						23.7						
5054	2370					Recommended	%	0.09		steady			day	2	unhealthy	ophthalmic	F		https://pubmed.ncbi.nlm.nih.gov/17720085	Homo sapiens						20							1						20			2	week		
5055	2370					Recommended	mg	25		steady			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10492497	Homo sapiens						60							1						60			3	month		
5056	2371					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/2758194|https://www.healthline.com/health/bromocriptine-oral-tablet#about	Homo sapiens														Parkinson's Disease											p.320
5057	2371					Highest studied dose	mg	300		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/22216518	Homo sapiens													1	Parkinson's Disease											p.978
5058	2371					MTD	mg	4.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11139820	Homo sapiens													314	Type 2 diabetes mellitus											p.1691, 1699
5059	2371					MTD	mg	4.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20332352	Homo sapiens													2054	Type 2 diabetes mellitus											p.1505, 1507
5060	2371					Recommended	mg	30		multiple			day	1	unhealthy	oral			https://www.medicines.org.uk/emc/product/1202/smpc#POSOLOGY	Homo sapiens							total							Prolactinomas|Hypogonadism|Galactorrhea syndromes|Infertility											
5061	2371					Recommended	mg	4.8		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf	Homo sapiens							max					80	3070	Type 2 diabetes mellitus					27						p.3
5062	2374		adult			Highest studied dose	%	2		multiple			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/1554974/	Homo sapiens													43	ocular hypertension & open angle glaucoma								26	week		
5063	2374					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6697637/	Homo sapiens						55.6							20	hypertension								7	day		
5064	2374					Highest studied dose	mg	60		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1349493/	Homo sapiens						23							8												
5065	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens													200	infections											
5066	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens													40	infections											
5067	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens													50	infections											
5068	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens													500	infections											
5069	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens													70	infections											
5070	2375		adult				mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens														infections											
5071	2375		pediatric				mg/kg/day	20		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50521slr027,50522slr027_cefaclor_lbl.pdf	Homo sapiens														infections											
5072	2376					Recommended	mg	600		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf	Homo sapiens													5093	Bacterial infections											p.13
5073	2376					Recommended	mg	600		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050739s013,050749s017lbl.pdf	Homo sapiens														Bacterial infections								10	day		p.9
5074	2377		ADULT			Highest studied dose	mg	800		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29624558/	Homo sapiens												45	7	pharyngeal gonococca					18						p.10
5075	2377		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8451674/	Homo sapiens						43						83	118	sinusitis					20			10	day		p.332
5076	2377		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202091s005,203195s006lbl.pdf	Homo sapiens														bacterial infectious disease											p.1
5077	2378					Studied dose	g	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6097122	Homo sapiens						55.5						88	2	intra abdominal infection					19			14	day		
5078	2378					Studied dose	mg/kg	150		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/3865630	Homo sapiens												15							1			18	day		
5079	2380					Highest studied dose	g	4		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/526003	Homo sapiens												35	7						21			10	day		
5080	2380					Highest studied dose	g	4		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/526003	Homo sapiens												35	7						21						
5081	2380					Highest studied dose	mg/kg	15		steady			day	3	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/6634466	Homo sapiens													1	childhood infections								7	day		
5082	2381					Highest studied dose	mg/kg	13.3		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/50675-S14_Vantin_medr_P2.pdf	Homo sapiens													76	Infection								10	day		1140/0013
5083	2383					Recommended	g	1		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/833342/	Homo sapiens												28	7						23						
5084	2383					Recommended	g	2		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12495602/	Homo sapiens										1 or 2 g 2 or 3 times/day		91	159	infections					18			21	day		
5085	2385		adult			Recommended	%	0.24		multiple			day	2	unhealthy	ophthalmic			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208694s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208694Orig1s000MedR.pdf	Homo sapiens										one drop in each affected eye twice daily			511	ocular itching											p. 13
5086	2385					Overdose	mg	180		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9215262	Homo sapiens										18 ml of cetirizine solution, corresponding to a dose of 180 mg of cetirizine			1												
5087	2385					Overdose	mg	270		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15521622	Homo sapiens						18							1						18						
5088	2385					Overdose	mg	60		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9786037	Homo sapiens						4							1						4						
5089	2385					Recommended	mg	10		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23673913	Homo sapiens						18							1	allergic rhinitis					18			7	day		
5090	2385					Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022155s000_MedR_P1.pdf	Homo sapiens													2034						12						p. 24
5091	2385					Recommended	mg	10		single					unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211415s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211415Orig1s000MultidisciplineR.pdf	Homo sapiens						39							127	acute urticaria					39						p. 62
5092	2385						mg	2.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20375960/	Homo sapiens													1	chronic rhinitis								14	day		
5093	2385						mg	5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32946371	Homo sapiens						6							1	allergic rhinitis					6			3	day		
5094	2385						mg	50		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12769407	Homo sapiens						46							1	chronic idiopathic urticaria					46						
5095	2386					MTD	mg	60		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/20-989_Evoxac_medr_P3.pdf	Homo sapiens						54.2							362	Sjogren's syndrome								52	week		SB96US03
5096	2387		newborns			Higher than recommended	mg/kg	2		steady			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9925843/	Homo sapiens													2	premature infants, <36 week											
5097	2387		newborns			Recommended	mg/kg	0.2		steady			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9925843/	Homo sapiens										0.1 to 0.2 mg/kg, 3 to 4 times/day			1	premature infants, <36 week				erythromycin							
5098	2387		newborns			Recommended	mg/kg	0.2		steady			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9925843/	Homo sapiens										0.1 to 0.2 mg/kg, 3 to 4 times/day			58000	premature infants, <36 week								3	month		
5099	2388		adult			Recommended	mg	200		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf	Homo sapiens										Two ampules four times daily, taken one-half hour before meals and at bedtime. Each 5 mL ampule contains 100 mg cromolyn sodium				mastocytosis											
5100	2388		adult				%	2		multiple					unhealthy	ophthalmic			https://pubmed.ncbi.nlm.nih.gov/22118312	Homo sapiens										Each cromolyn sodium 2% ophthalmic solution was randomized to apply on either eye			37	allergic conjunctivitis								4	week		
5101	2388						mg	62.4		multiple			day	1	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/402406	Homo sapiens						25				The nasal spray was to be used six times per day, providing a total daily cromolyn dose of 62.4 mg.		51	45						5			4	week		
5102	2389		children and adults			Higher than recommended	mg/kg	5		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7062687/	Homo sapiens													38	nausea and vomiting											
5103	2389		children and adults			Lethal dose	mg/kg	80		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7062687/	Homo sapiens														nausea and vomiting											
5104	2389					Recommended	mg	50		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12603456/	Homo sapiens						34							1	pregnancy	10 mg			morphine	34						
5105	2390					Overdose	mg	600		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6620442	Homo sapiens						24							1												p.283
5106	2390					Overdose	mg	900		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6620442	Homo sapiens						18							1												p.282
5107	2390					Recommended	mg	10		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12809957	Homo sapiens						41.5							249	Muscle spasm								7	day		p.1068
5108	2390					Recommended	mg	30		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021777s017lbl.pdf	Homo sapiens														Muscle spasm											p.1
5109	2390						mg	15		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02814565	Homo sapiens													90	Cervical and/or Lower Back Pain								14	day		
5110	2391					Overdose	mg	3200		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens																									p.22
5111	2391					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20010070	Homo sapiens						43							127	HIV-1 infection	100 mg; qd			ritonavir, oral							p.227
5112	2391					Recommended	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens														HIV-1 infection	100 mg; qd			ritonavir, oral							p.1
5113	2391					Recommended	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021976s021lbl.pdf	Homo sapiens														HIV-1 infection	100 mg; qd			ritonavir, oral							p.8
5114	2392					Highest studied dose	mg	400		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf	Homo sapiens													412												
5115	2392					Highest studied dose	mg	400		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10348755	Homo sapiens													30	HIV infection					18			24	week		
5116	2393		adult			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/32413603	Homo sapiens													1												
5117	2393		children | adolescents | and young adults			Recommended	mg	25		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014399s071lbl.pdf	Homo sapiens														major depressive disorde											
5118	2393					Overdose	mg	2500		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5588337	Homo sapiens						2				100 tablets of Pertofranc| (2500 mg desipramine)			1						2						
5119	2394		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00294671	Homo sapiens													64	Familial Amyloidosis								24	week		
5120	2394					Highest studied dose	mg	1500		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2591467	Homo sapiens						35							8		100 mg single-dose rectally			indometacin	35						
5121	2394						mg	500		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26017328	Homo sapiens						60.7						80	40	Hereditary ATTR amyloidosis					25			116	month		
5122	2395		adult			Highest studied dose	mg	4		steady			day	1	unhealthy	intranasal	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20148s7s8lbl.pdf	Homo sapiens														migraine								7	day		
5123	2395		adult			Recommended	mg	1		single					unhealthy	subcutaneous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20148s7s8lbl.pdf	Homo sapiens														migraine											
5124	2395		adult			Recommended	mg	1		steady			day	1	unhealthy	subcutaneous	unknown		https://pubmed.ncbi.nlm.nih.gov/8984085/	Homo sapiens							max						51	migraine								21	week		
5125	2395		adult				mg	1		steady			day	1	unhealthy	subcutaneous	unknown		https://pubmed.ncbi.nlm.nih.gov/8984085/	Homo sapiens							max						51	migraine								21	week		
5126	2395					Highest studied dose	mg	2		single					unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020148Orig1s025lbl.pdf	Homo sapiens										Maximum dose for relief of one attack		65	1796	migraine					18						
5127	2396		adult			Highest studied dose	mg/kg	15		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/1091418/	Homo sapiens							max			0.5 to 15 mg/kg			18	tachyarrhythmias											
5128	2397					Highest studied dose	ug/kg/min	40		multiple					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7671905	Homo sapiens						43						72	6						20						
5129	2397						ug/kg/min	2		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15081466	Homo sapiens						46							1						46						
5130	2397						ug/kg/min	30		multiple					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7671905	Homo sapiens						43						72	5						20						
5131	2398		adult			Recommended	mg	10		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	Homo sapiens													315									6	week		
5132	2398		adult			Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21719lbl.pdf	Homo sapiens													350									6	week		
5133	2398		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00369785	Homo sapiens							max|total daily dose			Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day			96									24	week		
5134	2398		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01278407	Homo sapiens										Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.			96	Dementia With Lewy Bodies								12	week		
5135	2398		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01278407	Homo sapiens										Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.			37	Dementia With Lewy Bodies								12	week		
5136	2398		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01278407	Homo sapiens										Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.			49	Dementia With Lewy Bodies								12	week		
5137	2398		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00708552	Homo sapiens										Participants received Donepezil capsule by one-step titration 5mg Donepezil once daily (Week 1 to Week 4) before up-titrating at Visit 4 (Week 4) to 10 mg once daily dose for the remaining 20 weeks of the treatment period (Week 4 to 24) along with matching placebo to SB-747457.			151	Alzheimer's disease								24	week		
5138	2398		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01250977	Homo sapiens													14	Tobacco Use Disorder								28	day		
5139	2398		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01278407	Homo sapiens										Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.			47	Dementia With Lewy Bodies								12	week		
5140	2398		child				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00754013	Homo sapiens							total daily dose			All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.			4	Cognitive Dysfunction											
5141	2398					Overdose	mg	50		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10466911	Homo sapiens						79							1	Alzheimer disease					79						
5142	2398						mg	175		single					healthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/32440098	Homo sapiens						24.9							9												
5143	2398						mg	175		steady			3 days	1	healthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/32440098	Homo sapiens						24.9							9									15	day		
5144	2398						mg	23		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022568Orig1s000MedR.pdf	Homo sapiens						73.9							967	Alzheimer disease					73.9			24	week		p. 50
5145	2398						mg	30		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25202036	Homo sapiens						80							1	Alzheimer disease					80			25	day		
5146	2399					Highest studied dose	drop	1		multiple			day	3	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/14733709/	Homo sapiens						61.1				In the initial observation period, patients continued to receive dorzolamide 0.5% plus other antiglaucoma agents for 4 weeks (weeks 24 to 0). After this period, the concentration of dorzolamide was escalated to 1.0% (week 0); this dosage was then administered for 12 weeks (weeks 0–12). Administration of the other antiglaucoma agents remained unchanged. Dorzolamide was administered three times a day, at fixed times chosen by each individual patient, throughout the study.		83	78	ocular hypertension | open-angle glaucoma | angle-closure glaucoma					23			12	week		
5147	2399					Recommended	drop	1		multiple			day	3	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/9715679/	Homo sapiens						62.1				2 % ophtalmic solution		88	148	ocular hypertension | open-angle glaucoma					20			1	year		
5148	2400		adult			Highest studied dose	mg	16		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019668s028lbl.pdf	Homo sapiens							max			1 to 16 mg			665	Hypertension											
5149	2400		adult			Recommended	mg	4		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10594469/	Homo sapiens													35									7	day		
5150	2400					Highest studied dose	mg	16		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19353415/	Homo sapiens						59	max			2 to 16 mg			97	Hypertension								21	month		
5151	2400					Overdose	mg	60		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16004202/	Homo sapiens						19							1						19						
5152	2400						mg	8		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01953432	Homo sapiens													22	cocaine dependence								9	week		
5153	2401		adult			Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf	Homo sapiens													989	atrial fibrillation | atrial flutter								12	month		p. 103
5154	2401		adult				mg	400		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01135017	Homo sapiens													57	Atrial Fibrillation								12	week		
5155	2401		adult				mg	400		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01198873	Homo sapiens													35	Atrial Fibrillation and Left Atrial Enlargement								6	month		
5156	2401		adult				mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Homo sapiens														NYHA Class IV heart failure | NYHA Class II - III heart failure											
5157	2401		adult				mg	600		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf	Homo sapiens													66	atrial fibrillation | atrial flutter								12	month		p. 103
5158	2401		adult				mg	800		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_MedR_P2.pdf	Homo sapiens													62	atrial fibrillation | atrial flutter								12	month		p. 103
5159	2401					Highest studied dose	mg	1600		multiple			day	2	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/17056831	Homo sapiens												40							21			10	day		
5160	2401					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022425lbl.pdf	Homo sapiens										combined 5 placebo-controlled studies		97	3282	atrial fibrillation | atrial flutter					20			12	month		
5161	2402						mg	150		multiple			day	1	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/32410819	Homo sapiens												55							18			3	day		
5162	2402						mg	24		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205175s000lbl.pdf	Homo sapiens																									
5163	2403					Recommended	mg	80		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21016_Relpax_Medr_P3.pdf	Homo sapiens						41.9	typical			second dose could be taken as soon as 2 hours after the first dose			312	migraine											Study 102
5164	2404		adult			Recommended	mg	2		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/17229605/	Homo sapiens													192	idiopathic chronic urticaria								4	week		
5165	2404					Higher than recommended	mg	4		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11949773/	Homo sapiens												45	19	lower respiratory tract infections or sexually transmitted infections					21			5	day		
5166	2404					Recommended	%	0.05		steady			day	1	healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/11952024/	Homo sapiens						43							14	conjunctival allergen challenge model					43			14	day		
5167	2405					Recommended	drop	1		multiple			day	1	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/results/NCT02251613	Homo sapiens						33.8				Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye			50	Allergic Conjunctivitis								7	day		
5168	2406					Highest studied dose	ng/kg/min	110.5		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22481098	Homo sapiens						42	max						1	pulmonary hypertension					42			685	day		
5169	2406					Highest studied dose	ng/kg/min	8		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22515646	Homo sapiens						33.7							20						33.7			2	hour		
5170	2406						ug/kg/min	0.05		multiple					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/23683572	Homo sapiens						56.4	complex			is recommended to start iEPO at 0.05 μg/kg per minute and decrease by 0.01 μg/kg per minute increments every 1 to 2 hours as tolerated until iEPO has been weaned off			52	refractory hypoxemia											
5171	2407		ADULT			Recommended	mg/kg	0.3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19573904/	Homo sapiens						57							234	disease											p.297
5172	2408					Highest studied dose	ug/kg/min	1.5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1967592	Homo sapiens						46				continuous intravenous infusion			9	Hypertension											1-61
5173	2408					Recommended	ug/kg/min	0.8		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019922s016lbl.pdf	Homo sapiens										Pediatrics: Initiate dosing at 0.2 mcg/kg/minute by continuous infusion and titrate dose by 0.3 to 0.5 mcg/kg/min every 20-30 minutes to a maximum dose of 0.8 mcg/kg/minute				Hypertension											p.1
5174	2409		adult				mg	60		multiple			day	2	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01586091	Homo sapiens													18									1	day		
5175	2409					Highest studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15209959	Homo sapiens										pooled studies		11		seasonal allergic rhinitis					6			2	week		
5176	2409					Highest studied dose	mg	690		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9871426	Homo sapiens												55	4						18			28	day		
5177	2409					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9871426	Homo sapiens						26.9							8						26.9						
5178	2409					Recommended	mg	30		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021909s000_MedR.pdf	Homo sapiens										pivotal studies															p. 22
5179	2409						mg	180		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22346270	Homo sapiens						69							1						69			3	day		
5180	2410		adolescent				mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02431806	Homo sapiens													134	Major Depressive Disorder								7	week		
5181	2410		adolescent				mg	80		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00245635	Homo sapiens							max						25	Body Dysmorphic Disorder								6	month		
5182	2410		adult			Overdose	mg	544		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1586402/	Homo sapiens							mean						37	mental disorders											
5183	2410		adult			Recommended	mg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Homo sapiens													425	Panic Disorder								7	day		
5184	2410		adult			Recommended	mg	20		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Homo sapiens													1728	Major Depressive Disorder								7	day		
5185	2410		adult			Recommended	mg	20		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Homo sapiens													266	OCD								7	day		
5186	2410		adult			Recommended	mg	60		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1728831/	Homo sapiens							median						391	obese diabetic								6	week		
5187	2410		adult			Recommended	mg	60		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Homo sapiens													450	Bulimia								7	day		
5188	2410		children			Recommended	mg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Homo sapiens													228	mental disorders								7	day		
5189	2410		children|adolescent				mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02372799	Homo sapiens													97	Major Depressive Disorder											
5190	2410		children|adolescents				mg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01372150	Homo sapiens													112	Major Depressive Disorder											
5191	2410		children|adolescents				mg	40		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00849901	Homo sapiens							max						117	Major Depressive Disorder								38	week		
5192	2410					Overdose	mg	1000		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						21							1	mental disorders					21						
5193	2410					Overdose	mg	1120		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						51							1	mental disorders					51						
5194	2410					Overdose	mg	120		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						42							1	mental disorders					42						
5195	2410					Overdose	mg	1200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												46	2	mental disorders					29						
5196	2410					Overdose	mg	140		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												42	2	mental disorders					18						
5197	2410					Overdose	mg	1500		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						21							1	mental disorders					21						
5198	2410					Overdose	mg	200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												40	6	mental disorders					15						
5199	2410					Overdose	mg	240		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												19	2	mental disorders					12						
5200	2410					Overdose	mg	260		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												25	2	mental disorders					15						
5201	2410					Overdose	mg	280		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												19	3	mental disorders					14						
5202	2410					Overdose	mg	320		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						15							1	mental disorders					15						
5203	2410					Overdose	mg	340		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												22	2	mental disorders					18						
5204	2410					Overdose	mg	400		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						31							2	mental disorders					31						
5205	2410					Overdose	mg	500		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						28							1	mental disorders					28						
5206	2410					Overdose	mg	600		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens												45	2	mental disorders					20						
5207	2410					Overdose	mg	640		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						50							1	mental disorders					50						
5208	2410					Overdose	mg	700		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						36							1	mental disorders					36						
5209	2410					Overdose	mg	800		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2231832/	Homo sapiens						18							1	mental disorders					18						
5210	2410						mg	20		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01569126	Homo sapiens													8												
5211	2410						mg	20		steady			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01569126	Homo sapiens													12									28	day		
5212	2410						mg	20		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01635218	Homo sapiens													46	Depression								6	week		
5213	2410						mg	40		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01569126	Homo sapiens													8												
5214	2410						mg	40		steady			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01569126	Homo sapiens													12									28	day		
5215	2410						mg	80		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00288574	Homo sapiens							max						49	Anorexia Nervosa											
5216	2411					Highest studied dose	mg	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16702893/	Homo sapiens													18												
5217	2413		adult			Overdose	g	5.45		multiple			day	2	unknown	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Homo sapiens													9									3	day		
5218	2413		adult			Overdose	g	6.25		multiple			day	2	unknown	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020068s023lbl.pdf	Homo sapiens													1									3	day		
5219	2413		adult			Recommended	mg/kg	60		multiple			day	2	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/10918402/	Homo sapiens										Maintenance 60-120 mg/kg QD 5 days/week			20	allogeneic bone marrow transplantation								30	day		
5220	2413					Highest studied dose	ug	2400		multiple			week	2	unhealthy	intravitreal	M+F		https://pubmed.ncbi.nlm.nih.gov/8123619/	Homo sapiens						36.6							11	AIDS								3	week		
5221	2414		adult			Highest studied dose	mg	32		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18088197/	Homo sapiens													429	Alzheimer's disease								4	week		
5222	2414		adult				mg	16		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01669538	Homo sapiens										For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.			40	Tobacco Use Disorder								23	day		
5223	2414		adult				mg	24		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00679627	Homo sapiens							max|total daily dose						1024	Alzheimer's disease								2	year		
5224	2414					Studied dose	mg	8		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23552705/	Homo sapiens						90							1	Alzheimer's disease					90			2	week		
5225	2415					Recommended	mg	320		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21158_Factive_medr_P1.pdf	Homo sapiens						59.6							172	Community-Acquired Pneumonia								14	day		Study 185
5226	2416		adult			Highest studied dose	%	4		steady			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens													19	hyperhidrosis								4	week		145
5227	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf	Homo sapiens										1 cloth to each axilla per day		76	459	Axillary Hyperhidrosis					9			4	week		
5228	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/31111409/	Homo sapiens						33				1 cloth to each axilla per day			564	Axillary Hyperhidrosis								44	week		
5229	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/31111409/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens						33				1 cloth to each axilla per day			564	Axillary Hyperhidrosis								44	week		
5230	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210361lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens										1 cloth to each axilla per day		76	459	Axillary Hyperhidrosis					9			4	week		
5231	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens						31				1 cloth to each axilla per day			459	Axillary Hyperhidrosis								4	week		
5232	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens						33				1 cloth to each axilla per day			564	Axillary Hyperhidrosis								44	week		
5233	2416					Recommended	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens										1 cloth to each axilla per day		76	459	Axillary Hyperhidrosis					9			4	week		
5234	2416					Studied dose	%	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens							mean			1% to 4%			338	Axillary Hyperhidrosis					18			4	week		
5235	2416					Studied dose	%	2.4		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/33433785/	Homo sapiens						20.4				1 cloth to each axilla per day			31									5	day		
5236	2416					Studied dose	%	2.4		single			day	6	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210361Orig1s000MultidisciplineR.pdf	Homo sapiens										6 applications to each axilla			1	Axillary Hyperhidrosis											
5237	2416					Studied dose	mg	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17459043/	Homo sapiens						33	typical			Eight patients were treated with glycopyrrolate 2 mg twice daily and 10 tolerated 2 mg three times daily. One patient with generalized hyperhidrosis required up to 4 mg twice daily for symptom control. One patient took 2 mg once daily and four patients varied between 2 mg twice and thrice daily depending on their symptoms.			24	hyperhidrosis											
5238	2416					Studied dose	mg	3		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33433785/	Homo sapiens						44	max			1.0 mg/8 h, then increased by 1.0-mg increments every 5 days to a maximum of 3.0 mg/8 h			18									15	day		
5239	2417		children				mg	4		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01069523	Homo sapiens													16	Attention Deficit Hyperactivity Disorder								4	week		
5240	2417		children and adolescents			Recommended	mg	4		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022037s009lbl.pdf	Homo sapiens										1 - 4 mg			513	ADHD								1	week		
5241	2417					Overdose	mg	12		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23925253/	Homo sapiens						12							1	ADHD and Tourette syndrome					12						
5242	2417					Overdose	mg	80		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33069545/	Homo sapiens						17							1	ADHD					17						
5243	2418					Highest studied dose	mg	0.03		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/16695374	Homo sapiens													4	asthma											
5244	2418					Highest studied dose	mg	0.2		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/16695374	Homo sapiens													1	asthma											
5245	2419					MTD	mg/m2	18		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26750985/	Homo sapiens										The induction therapy consisted of a fixed dose of cytarabine and escalated doses of idarubicin. Cytarabine 100 mg/m2/day was administered by continuous infusion for seven days. Idarubicin was administered intravenously over 15 min for three days at the dose of given level as followed: 12 mg/m2 /day at level 1, 15 mg/m2 /day at level 2, and 18 mg/m2 /day at level 3. The study design was adopted from traditional 3 + 3 design for phase I cancer clinical trials. The first three patients were treated at a starting dose (level 1). If none of the three patients experienced a DLT, another group of three patients would be treated at the next higher dose level. However, if one of the first three patients experienced a DLT, three more patients would be treated at the same dose level. The dose increment continued until at least two patients among a cohort of three to six patients experienced DLTs. The MTD was defined as the dose level just below this toxic dose level.		60	3	acute myeloid leukemia	100 mg/m^2/day			cytarabine	23			3	day		
5246	2419						mg/m2	15		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/2208149/	Homo sapiens						66				The initial dose of idarubicin in this study was 45 mg/m2 p.o. divided into three single daily doses (15 mg/m2/day p.o.) on an empty stomach on three sequential days. All patients received metoclopramide (10 mg) 1.5 h before each dose of idarubicin and 10 mg 6 hours after each dose of idarubicin). Therapy was repeated every 3 weeks if there was adequate bone marrow recovery.		85	46	non-Hodgkin's lymphoma	10 mg; 2/day			metoclopramide	40			3	day		
5247	2420		adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01151852	Homo sapiens										The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.			41	Gastrointestinal Stromal Tumors											
5248	2420		adult				mg	400		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01781975	Homo sapiens													45	Type 1 Diabetes								2	year		
5249	2420		adults			Overdose	mg	1200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf	Homo sapiens													1	myeloid blast crisis								6	day		
5250	2420		adults			Overdose	mg	1600		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf	Homo sapiens													1									6	day		
5251	2420					MTD	mg	500		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens						53.3							35	malignant glioma	200 mg/m2;1 time/day			temozolomide	53.3			28	day		
5252	2420					MTD	mg	800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16914578	Homo sapiens						47						73	23	Recurrent Malignant Gliomas					18			28	day		
5253	2420					Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s009lbl.pdf	Homo sapiens						51						70	551	Newly Diagnosed Chronic myeloid leukemia (CML)					18			31	month		
5254	2420					Recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s009lbl.pdf	Homo sapiens						51				The first 77 patients were started at 400 mg, with the remaining 158 patients starting at 600 mg.		70	235	Accelerated Phase CML					18			31	month		
5255	2420						mg	400		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15803362	Homo sapiens						55	starting						16	breast cancer					55			14	day		
5256	2420						mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens						53.3							35	malignant glioma	200 mg/m2;1 time/day			temozolomide	53.3			28	day		
5257	2420						mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18359865	Homo sapiens						53.3							35	malignant glioma	200 mg/m2;1 time/day			temozolomide	53.3			28	day		
5258	2421					Highest studied dose	ug	168		steady			day	3	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/15702820/	Homo sapiens												5	43	common colds					2			4	day		
5259	2421					Highest studied dose	ug	168		steady			day	3	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/7751529/	Homo sapiens												75	96	perennial allergic rhinitis					18			6	month		
5260	2421					Highest studied dose	ug	200		single					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/2150695/	Homo sapiens						40.7							20	stable chronic asthma											
5261	2421					Highest studied dose	ug	84		steady			day	3	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/15702820/	Homo sapiens												5	187	allergies					2			14	day		
5262	2421					Recommended	ug	42		steady			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/7751528/	Homo sapiens						42.6							99	rhinorrhea								8	week		
5263	2422		adult				mg	300		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00249795	Homo sapiens							max			150 mg for 2 weeks, then up-titrated to 300 mg up to final follow-up visit			4518	Atrial Fibrillation								4.5	year		
5264	2422		adult				mg	300		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00635232	Homo sapiens													58	Hypertension								12	week		
5265	2422					Highest studied dose	mg	900		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9549663	Homo sapiens												45	9						20			7	day		p.247, p.250
5266	2422					Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Homo sapiens							max							Hypertension|diabetic nephropathy											p.1
5267	2422					Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020757s059s067lbl.pdf	Homo sapiens														Diabetic nephropathy											p.6
5268	2423		adult			MTD	mg/m2	21		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30406838/	Homo sapiens													12	solid tumors								14	day		
5269	2423		adult			MTD	mg/m2	290		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10873073/	Homo sapiens										90-min i.v. infusion every 3 weeks			7	solid tumors											
5270	2423		adult			MTD	mg/m2	320		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10873073/	Homo sapiens										90-min i.v. infusion every 3 weeks			8	solid tumors											
5271	2424					MTD	mg	1250		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24197661	Homo sapiens						50				750 mg twice on day one followed by 1250 mg once daily			27	(HER2)-positive breast cancer				whole brain radiotherapy	50			6	cycle		
5272	2424					MTD	mg	1800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19052038	Homo sapiens						60							6	Solid Tumors					60			21	day		
5273	2424					Recommended	mg	1250		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf	Homo sapiens						53				1,250 mg once daily (continuously) plus capecitabine 2,000 mg/m2 /day on Days 1-14 every 21 days			198	stage IV breast cancer | estrogen receptor+ |progesterone receptor+	2000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle			capecitabine	53			21	day		
5274	2424					Recommended	mg	1250		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf	Homo sapiens						63				1,250 mg once daily (continuously) with letrozole, the recommended dose of letrozole is 2.5 mg once daily			111	stage IV breast cancer | estrogen receptor+ |progesterone receptor+	2.5 mg/day			Letrozole	63			21	day		
5275	2424						mg	1500		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24197661	Homo sapiens						50				On day 1, a loading dose of lapatinib 750 mg orally for two doses was administered. Starting on day 2, once daily lapatinib were evaluated: 1500 (DL3) mg			5	(HER2)-positive breast cancer				whole brain radiotherapy	50			4	week		
5276	2425						mg/kg	50		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6456688	Homo sapiens							mean			The dosage ranged from 10 to 146 mg/kg per day (mean dose, 50 mg/kg per day).			50	nfectious disorders								10	day		
5277	2425						mg/kg	50		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6479022	Homo sapiens													40									21	day		
5278	2426		adult			Highest studied dose	mg	30		multiple			month	1	unhealthy	subcutaneous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf	Homo sapiens													49	cancer								4	month		
5279	2426		adult			Recommended	mg	7.5		multiple			month	1	unhealthy	subcutaneous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019010s033,019732s031s035s036,020517s024s028s029lbl.pdf	Homo sapiens													56	cancer								1	month		
5280	2428		children			Recommended	mg	75 - 2400		multiple			day	4	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7017577/	Homo sapiens							complex			Duration of therapy ranged from five to 63 days, with a mean of 15 days. The lincomycin dose ranged from 75 to 2,400 mg every six hours. The majority of patients received the drug intravenously, but 25.7% received it only intramuscularly.			265	infection								15	day		
5281	2428					Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5282	2428					Recommended	mg	501		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5283	2428					Recommended	mg	502		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5284	2428					Recommended	mg	503		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5285	2428					Recommended	mg	504		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5286	2428					Recommended	mg	505		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5287	2428					Recommended	mg	506		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5288	2428					Recommended	mg	507		multiple			day	2	unhealthy	oral	M+F		https://www.sciencedirect.com/science/article/abs/pii/S0011393X97800598	Homo sapiens						17.5				Lincomycin hydrochloride capsules or suspension (according to patient age): adults--two 500-mg capsules two times a day (BID) for 10 days; children--60 mg/kg per day divided BID for 10 days (maximum dose, 1000 mg/d). No AEs were given separetely for adults and children.			91	acute streptococcal tonsilitis/pharyngitis								10	day		
5289	2428					Studied dose	mg	2100		multiple			day	4	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/4936143/	Homo sapiens										The total volume of each infusion, 250 mL, was administered over a 120 minute period.		46	10						21			7	day		
5290	2429					Highest studied dose	ug	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32120028	Homo sapiens						39							2	Multiple sclerosis								7	day		p.3
5291	2429					MTD	ug	37.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32120028	Homo sapiens						39							4	Multiple sclerosis								7	day		p.3
5292	2429					Overdose	ug	10794.4		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32158485	Homo sapiens						20				ingested 2 doses			1	Fatigue								1	day		p.2
5293	2429					Overdose	ug	15000		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32158485	Homo sapiens						30				ingested 2 doses			1	Hypothyroidism								16	day		p.2
5294	2431					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3214495/	Homo sapiens												24	5						21						
5295	2431					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://sci-hub.do/10.1016/s0090-4295(97)00708-5	Homo sapiens													165	urinary tract infections								14	day		
5296	2432					Overdose	mg	400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28506439|https://pubmed.ncbi.nlm.nih.gov/25817442	Homo sapiens						30							1	Opiate abuse								7	day		p.247|p.495
5297	2432					Overdose	mg	400		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28506439|https://pubmed.ncbi.nlm.nih.gov/25935922	Homo sapiens						26							1	Opiate abuse								18	month		p.247|p.1
5298	2432					Overdose	mg	792		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25345436	Homo sapiens						28	total daily dose						1	Opiate abuse								1	year		p.954
5299	2432					Recommended	mg	16		multiple			day	8	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017690s005lbl.pdf	Homo sapiens							total daily dose			The recommended initial dose is 4mg (two capsules) followed by 2 mg (one capsule) after each unformed stool. The maximum daily dose is 16mg (eight capsules).				Diarrhea											p.1, 3
5300	2432					Recommended	mg	16		multiple			day	8	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/017690s005lbl.pdf	Homo sapiens							total daily dose			The recommended initial dose is 4mg (two capsules) followed by 2 mg (one capsule) after each unformed stool. The maximum daily dose is 16mg (eight capsules).				Diarrhea											p.3
5301	2433		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00563797	Homo sapiens										Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.			11	Depression and Alcohol Dependence								12	week		
5302	2433					Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29319910/	Homo sapiens												45	29						18			1	day		
5303	2433					Recommended	mg	5		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8033499/	Homo sapiens						34.1							24									2	week		
5304	2434					Highest recorded dose	mg	500		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/10679slr029_cantil_lbl.pdf	Homo sapiens						4							1						4						
5305	2434					Highest recorded dose	mg	750		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/10679slr029_cantil_lbl.pdf	Homo sapiens						30							1						30						
5306	2435					Highest studied dose	mg/m2	1250		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8120558/	Homo sapiens										different number of courses; 12 is a maximum number of courses		14	12	acute leukemia	500 mg/m2 IV; 4 days			cytarabine	4			12	course		
5307	2435					MTD	mg/m2	35		multiple			day	1	unhealthy	parenteral			https://pubmed.ncbi.nlm.nih.gov/9713314/	Homo sapiens						60				490 mg/m2 per cycle			7	colon cancer								14	day		
5308	2435					Studied dose	mg	100		multiple			day	3	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205919s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/19555631/	Homo sapiens						37							1	hyperthyroidism					37			6	day		
5309	2435					Studied dose	mg/m2	1125		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8120558/	Homo sapiens							mean			different number of courses; 12 is a maximum number of courses		17	23	acute leukemia	500 mg/m2 IV; 4 days			cytarabine	2			12	course		
5310	2435					Studied dose	mg/m2/hour	50		multiple			2 days	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/1600597/	Homo sapiens						9.5				different number of courses			51	leukemia											
5311	2435					Studied dose	mg/m2/hour	50		multiple			3 weeks	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/4038917/	Homo sapiens						10				13 cycles of 14-21 day, 60 hr infusion once per cycle			10	cancer								60	hour		
5312	2439					Highest studied dose	mg	120		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13090	Homo sapiens												45	12						21						
5313	2440					Studied dose	mg	15		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6061274	Homo sapiens										Methysergide was first given orally, starting with 3 mg. daily and increasing over five days to 15 mg. a day in eight patients and 12 mg. a day in the other six		24	14	schizophrenia					17			10	day		
5314	2440						mg	0.753		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3709634	Homo sapiens										1.0 mg of methysergide maleate intravenously, corresponding to 0.753 mg of the free base of methysergide		28	5						23						
5315	2440						mg	10 |5		multiple|multiple			day	1	unhealthy	oral|intravenous			https://pubmed.ncbi.nlm.nih.gov/6061274	Homo sapiens							complex			Twelve patients received oral and intravenous methysergide for 18 days		24	12	schizophrenia					17			18	day		
5316	2440						mg	10 |5| 2		multiple|multiple|single			day	1	unhealthy	oral|intravenous|intrathecal	M+F		https://pubmed.ncbi.nlm.nih.gov/6061274	Homo sapiens							complex			Six patients from Group 2 who had shown no noticeable response to 18 days of oral and intravenous methysergide received 2 mg. of methysergide intrathecally.		24	6	schizophrenia					17						
5317	2440						mg	8		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14171102	Homo sapiens																									
5318	2442					Highest studied dose	mg	150		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5082545	Homo sapiens													2	Chronic renal failure											p.197
5319	2442					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0b619826-2567-49d7-8972-b6da5e4467df&type=display	Homo sapiens							max							Edema											
5320	2442					Recommended	mg	20		multiple			day	1	unhealthy	oral			https://products.sanofi.ca/en/zaroxolyn.pdf	Homo sapiens							max							Edema											p.3
5321	2443					Overdose	g	2		steady			day	2	unknown	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/012911s036lbl.pdf	Homo sapiens						6							1						6						
5322	2443						mg	1600		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/26353009	Homo sapiens							mean						48	Cushing's Syndrome											
5323	2444					Highest studied dose	g	5		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/742869	Homo sapiens												29							22						
5324	2444					Studied dose	g	6		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6218102	Homo sapiens												56	6	surgical infections					19			5	day		
5325	2444						g	4		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6218102	Homo sapiens												74	4	surgical infections					27			7	day		
5326	2445		adult			Highest studied dose	mg	10		single					unhealthy	intranasal	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf	Homo sapiens										5 mg + 5 mg			43	intermittent, stereotypic episodes of frequent seizure activity											
5327	2445		adult			Highest studied dose	mg/kg	0.03		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/9258787/	Homo sapiens														generalized seizures, status epilepticus, and behavioral emergencies											
5328	2445		adult			Highest studied dose	mg/kg	0.07		single					unhealthy	intramuscular	unknown		https://pubmed.ncbi.nlm.nih.gov/9258787/	Homo sapiens														generalized seizures, status epilepticus, and behavioral emergencies											
5329	2445		adult			Highest studied dose	mg/kg	0.2		single					unhealthy	intranasal	unknown		https://pubmed.ncbi.nlm.nih.gov/9258787/	Homo sapiens														generalized seizures, status epilepticus, and behavioral emergencies											
5330	2445		adult			Highest studied dose	mg/kg	0.2		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/9258787/	Homo sapiens														generalized seizures, status epilepticus, and behavioral emergencies											
5331	2445		adult			Recommended	mg	5		single					unhealthy	intranasal	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf	Homo sapiens													91	intermittent, stereotypic episodes of frequent seizure activity											
5332	2445		adult			Recommended	mg/kg	0.3		single					unhealthy	rectal	unknown		https://pubmed.ncbi.nlm.nih.gov/9258787/	Homo sapiens														generalized seizures, status epilepticus, and behavioral emergencies											
5333	2445		adult				mg	1.5		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02532647	Homo sapiens							min			Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.			30	Colonoscopy											
5334	2445		adult				mg	2.75		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02290873	Homo sapiens							min			Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill			102	Colonoscopy											
5335	2445		adult				mg	2.75		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02296892	Homo sapiens							min			Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill			69	Bronchoscopy											
5336	2445		adult and children			Recommended	mg	5		single					unknown	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/33329768/	Homo sapiens							mean						87740	gastroscopy											
5337	2445					MTD	mg	5		single					unknown	intranasal	unknown		https://pubmed.ncbi.nlm.nih.gov/29377056/	Homo sapiens												65	30	gastroscopy	0.4 mg/kg			sufentanil	18						
5338	2445					Recommended	mg	5		multiple			month	1	unhealthy	intranasal	unknown		https://pubmed.ncbi.nlm.nih.gov/31353457/	Homo sapiens							mean						161	seizure clusters					12			16.8	month		
5339	2446		adult			Highest studied dose	mg/m2	39		multiple			4 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/10445421/	Homo sapiens										Mitoxantrone was administered at a starting dose of 25 mg/m2 over 10 min every 28 days. The dose was escalated by 25% in subsequent courses in individual patients if the MTD was not reached. The median cumulative dose of mitoxantrone was 93 mg/m2 (range 25–205).			11	metastatic breast cancer											
5340	2446		adult			Recommended	mg/m2	12		multiple			3 months	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf	Homo sapiens										The recommended dosage of NOVANTRONE is 12 mg/m2 given as a short (approximately 5 to 15 minutes) intravenous infusion every 3 months.			62	multiple sclerosis								2	year		
5341	2447					Recommended	mg/kg	0.2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020098s018lbl.pdf	Homo sapiens										Doses of 0.15 mg/kg administered over 5 to 15 seconds, 0.2 mg/kg administered over 30 seconds, or 0.25 mg/kg administered in divided doses (0.15 mg/kg followed in 30 seconds by 0.1 mg/kg) are recommended for facilitation of tracheal intubation for most patients				Skeletal muscle relaxation during surgery								30	sec		p.12
5342	2449					Highest studied dose	mg	140		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20494268	Homo sapiens												19		Early-Onset Schizophrenia					8			44	week		
5343	2449						mg	76.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20494268	Homo sapiens							mean			flexible doses of molindone (10–140 mg/day), the mean doses of study medication at week 52/end of study was 76.5±47.2 mg/day for patients receiving molindone		19	20	Early-Onset Schizophrenia					8			44	week		
5344	2450		adult				mg	0.1		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens													7	Asthma											
5345	2450		adult				mg	0.3		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens													7	Asthma											
5346	2450		adult				mg	1		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period.			12	Asthma								5	day		
5347	2450		adult				mg	10		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00295022	Homo sapiens													156	Rhinitis, Allergic, Seasonal								2	day		
5348	2450		adult				mg	10		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00359073	Homo sapiens													8	Asthma								14	day		
5349	2450		adult				mg	10		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.			19	Asthma								10	day		
5350	2450		adult				mg	3		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00636207	Homo sapiens										Part I: Administered as a single dose followed by at least a 3-day washout period. Part II: Administered QD for 5 days followed by at least a 3-day washout period. Part III: Administered QD for 10 days followed by at least a 7-day washout period.			18	Asthma								10	day		
5351	2450					Highest studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8828530	Homo sapiens						34						54	28	chronic asthma					18			10	day		
5352	2450					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8527292	Homo sapiens												40	18						21						
5353	2450					Overdose	mg	135		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11931512	Homo sapiens						5							1	asthma					5						
5354	2450					Overdose	mg	80		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11931512	Homo sapiens						3							1	asthma					3						
5355	2450					Recommended	mg	10		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15069001	Homo sapiens						37							1						37			3	week		
5356	2450					Recommended	mg	10		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/20829Orig1s073,20830Orig1s075,21409Orig1s075lbl.pdf	Homo sapiens																			15			1	week		
5357	2450						mg	7		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10722763	Homo sapiens						29.8							50	asthma					29.8						
5358	2450						ug	1000		single					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/20936994	Homo sapiens						39.1							36	chronic asthma					39.1						
5359	2451		adult				mg	400		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00398411	Homo sapiens													34	Bacteremia								10	day		
5360	2451		adult				mg	400		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01195675	Homo sapiens													29												
5361	2451		adult				mg	400		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01297062	Homo sapiens													80												
5362	2451		adult				mg	400		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01460368	Homo sapiens													58												
5363	2451		adult				mg	400		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03465436	Homo sapiens													52												
5364	2451					Higher than recommended	mg	600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11352436	Homo sapiens						30							7									10	day		p.5
5365	2451					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23343427	Homo sapiens						57.8							5	Chronic bronchitis								6.4	day		p.7
5366	2451					Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9687407	Homo sapiens						33.6							8												p.2062
5367	2451					Recommended	mg	400		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens						50								Bacterial infections								9	day		p.8.9
5368	2451					Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens						50								Bacterial infections								9	day		p.8.9
5369	2451					Recommended	mg	400		multiple			day	1	unhealthy	oral|intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30722059	Homo sapiens						59.6							273	Community-acquired bacterial pneumonia	600 mg q12h			Linezolid, IV				7	day		p.1863
5370	2451					Recommended	mg	400		multiple			day	1	unhealthy	oral|intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s063lbl.pdf	Homo sapiens														Bacterial infections								21	day		p.1
5371	2452		adult			Recommended	mg	10		single					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens										10 mg for a 70 kg individual. This dose may be repeated every 3 to 6 hours as necessary															
5372	2452		adult			Recommended	mg	10		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens										10 mg for a 70 kg individual. This dose may be repeated every 3 to 6 hours as necessary															
5373	2452		adult			Recommended	mg	10		single					unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens										10 mg for a 70 kg individual. This dose may be repeated every 3 to 6 hours as necessary															
5374	2452		adult			Studied dose	mg	160		multiple					unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens							total																		
5375	2452		adult			Studied dose	mg	160		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens							total																		
5376	2452		adult			Studied dose	mg	160		multiple					unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018024s042lbl.pdf	Homo sapiens							total																		
5377	2452						mg	15		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6690170	Homo sapiens													39												
5378	2452						mg	40		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3769586	Homo sapiens						37							1						37						
5379	2453		adult			Highest studied dose	mg	300		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens													4									7	day		
5380	2453		adult			Highest studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3680580/	Homo sapiens													4												
5381	2453		adult			Highest studied dose	ug/kg	0.75		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10754620/	Homo sapiens													3	postoperative pain											
5382	2453		adult			MTD	ug/kg	0.5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10754620/	Homo sapiens													18	postoperative pain											
5383	2453		adult			Recommended	mg	20		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7847600/	Homo sapiens													7	alcohol dependence								12	week		
5384	2453		adult			Studied dose	mg	5		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7847600/	Homo sapiens													7	alcohol dependence								12	week		
5385	2453					Recommended	mg	18		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30829564/	Homo sapiens						39							1	alcohol dependence and Schizoaffective Disorder					39			2	day		
5386	2454		adult				mg	4		single					unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01061333	Homo sapiens													16	Asthma											
5387	2454					Highest studied dose	%	2		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21009lbl.pdf	Homo sapiens										1 drop/eye bid		61	289	allergic conjunctivitis					12			4	week		CR 1957
5388	2455					Overdose	mg	2160		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019734s017lbl.pdf	Homo sapiens													1	Hypertension											p.21
5389	2455					Recommended	mg	100		multiple			day	2	unhealthy	oral			https://www.medicines.org.uk/emc/product/3322/smpc#gref	Homo sapiens										Maintenance dose: Transition to an oral route - A switch can be made to oral nicardipine 20mg capsules at dosage of 60 mg/day in 3 daily doses, or to nicardipine 50 mg extended-release tablets, at dosage of 100mg/day, in 2 daily doses.				Hypertension											
5390	2455					Recommended	mg/h	15		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019734s017lbl.pdf	Homo sapiens							max						144	Hypertension											p.21
5391	2455					Studied dose	mg	60		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020005s014lbl.pdf	Homo sapiens							max						322	Hypertension											p.10
5392	2455					Studied dose	mg	60		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020005s014lbl.pdf	Homo sapiens							max						322	Hypertension											p.9
5393	2455					Studied dose	mg	60		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020005s014lbl.pdf	Homo sapiens							max							Hypertension											p.5
5394	2457					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1316075	Homo sapiens						32						96	357						18			10	day		
5395	2457					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3158272	Homo sapiens						46							190						46			3	day		
5396	2457					Studied dose	mg	1600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6220672/	Homo sapiens						24							14												
5397	2458					MTD	mg	50.1		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19796802/	Homo sapiens							mean					73	50	neuropathic pain	2180 mg			gabapentin	53			7	day		
5398	2458					MTD	mg	61.6		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19796802/	Homo sapiens							mean					73	50	neuropathic pain					53			7	day		
5399	2458					Overdose	mg	1000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/18568805/	Homo sapiens						54							1	smoker					54						
5400	2458					Overdose	mg	5000		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8031432/	Homo sapiens						52							1	clinical depression					52						
5401	2459		adult			Recommended	drop	1		multiple			day	1	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/18167176/	Homo sapiens										After a run-in period, patients were randomized to receive either olopatadine hydrochloride 0.2% or a tear saline, and self-dosed once-daily for 1 week.			25	ocular allergy | dry eye, mild-to-moderate								1	week		
5402	2459					Recommended	drop	1		multiple			day	1	healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/17803435/	Homo sapiens										Subjects instilled lopatadine hydrochloride ophthalmic solution 0.2% in both eyes each morning on a once-daily regimen for the duration of the 6-week study		17	88	asymptomatic eyes					3			6	week		
5403	2459					Recommended	drop	1		multiple			day	1	healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/28435218/	Homo sapiens						32.4				Subjects received 1 drop of olopatadine 0.77% or vehicle in each eye once daily in the morning throughout the study.			330									6	week		
5404	2459					Recommended	drop	1		multiple			day	1	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/12462286/	Homo sapiens						33				Olopatadine 0.1% ophthalmic solution instilled (1 drop) in the morning and evening		77	91	conjunctivitis, seasonal allergic					4			6	week		
5405	2460		adult			Recommended	g	0.6		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3067337/	Homo sapiens							mean			Total dose 1.2 (0.5-4.0) g/day			804									365	day		
5406	2460					Highest studied dose	g	1		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2840367/	Homo sapiens													31	Ulcerative colitis								12	month		
5407	2460					Highest studied dose	g	4		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens												44	5						27						
5408	2460					Highest studied dose	mg	10		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/3203708/	Homo sapiens												44	7						27						
5409	2461		adult			Highest studied dose	%	1.5		multiple			day	2	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/29462230	Homo sapiens										15 mg				Erythema								28	day		
5410	2461						%	0.05		single					unhealthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/23679077	Homo sapiens						4				Both nares were treated with oxymetazoline nasal spray, oxymetazoline hydrochloride 0.05%			1						4						
5411	2461						%	1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/29409914	Homo sapiens						53.1							440	Erythema					53.1			52	week		
5412	2462		adult			Recommended	mg	0.75		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/15139789/	Homo sapiens							max			0.25 or 0.75 mg			667	HIV-1	chemotherapy										
5413	2463		adult			Highest studied dose	mg/kg	5.6		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	Homo sapiens										APD was administered orally at a dose of 16.8 mg/kg/day (in 3 divided doses) for 5 days followed by 4.2 mg/kg/day for additional five days. A			9	hypercalcemia								5	day		
5414	2463		adult			Overdose	mg/kg	120		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Homo sapiens														hypercalcemia								2.5	day		
5415	2463		adult			Overdose	mg/kg	285		multiple			day	1	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Homo sapiens														hypercalcemia								3	day		
5416	2463		adult			Recommended	mg/kg	90		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Homo sapiens													182	hypercalcemia											
5417	2464					Highest studied dose	mg/kg	0.15		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8364264	Homo sapiens						17							1						17						
5418	2465		adult			Recommended	mg	40		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018976s012lbl.pdf	Homo sapiens													628												
5419	2465					Studied dose	mg	120		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6995132	Homo sapiens						55.7				final dosage at the end of the twelve week period was for penbutolol a mean of 61.4 mg (range: 20-120mg)		64	8						43			12	week		
5420	2465					Studied dose	mg	4		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6315039	Homo sapiens												62	10	ANGINA PECTORIS					33						
5421	2466					Overdose	mg	14		multiple			day		unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens													1	Parkinson’s disease								23	day		p.11
5422	2466					Overdose	mg	19		multiple			day		unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens													1	Parkinson’s disease								3	day		p.11
5423	2466					Overdose	mg	60		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens													1												p.11
5424	2466					Overdose	mg	7		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens													1	Parkinson’s disease											p.11
5425	2466					Overdose	mg	7		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens													1	Parkinson’s disease											p.11-12
5426	2466					Recommended	mg	0.05		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15965310	Homo sapiens												75	14	Parkinson’s disease				levodopa oral	46						p.123
5427	2466					Recommended	mg	1		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens										Administration of Permax (pergolide) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. In clinical studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day.			1200	Parkinson’s disease	650 mg/day			l-dopa/carbidopa oral							p.7
5428	2466					Recommended	mg	1		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens										Administration of Permax (pergolide) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. In clinical studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day.				Parkinson’s disease	650 mg/day			l-dopa/carbidopa oral							p.4
5429	2466					Recommended	mg	1		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens										Administration of Permax (pergolide) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. In clinical studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day.				Parkinson’s disease	650 mg/day			l-dopa/carbidopa oral							p.4-5
5430	2466					Recommended	mg	1		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens										Administration of Permax (pergolide) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. In clinical studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day.				Parkinson’s disease	650 mg/day			l-dopa/carbidopa oral							p.5
5431	2466					Recommended	mg	1		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf	Homo sapiens										Administration of Permax (pergolide) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved. In clinical studies, the mean therapeutic daily dosage of Permax was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day.				Somnolence	650 mg/day			l-dopa/carbidopa oral							p.4
5432	2466					Recommended	mg	1		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15965310	Homo sapiens												75	14	Parkinson’s disease				levodopa oral	46						p.123
5433	2466					Recommended	mg	2.2		multiple			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11746615	Homo sapiens						65.5	mean			0.05 mg tablets as a starting dose followed by dose titration with 0.25 mg tablets. For the first 2 days, pergolide was given at a dose of 0.05 mg/day with breakfast. From day 3 to day 17, the pergolide dose was increased by 0.15 mg/day every third day. Subsequent increases of 0.25 mg/day were made every third day (up to a maximum dose of 5 mg/day) until an optimum therapeutic dose was achieved. Mean final dose 2.2 mg/day			102	Parkinson’s disease	562.5 mg/day			levodopa oral				12	week		p.863
5434	2468					Overdose	g	0.93		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21264008	Homo sapiens						42		14 mg; single					1	Depression	5.6 g; single		salicylate	maprotiline, p.o						triazolam, p.o	p.2627, 2631
5435	2468					Overdose	mg	200		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1729053	Homo sapiens						48							1	Schizophrenia											p.104
5436	2468					Recommended	mg	30		multiple			day	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Homo sapiens							total daily dose			The usual initial dose is 5 mg (1 mL). This may be repeated every 6 hours. The total daily dosage should not exceed 15 mg in ambulatory patients or 30 mg in hospitalized patients.				Schizophrenia											p.3
5437	2468					Recommended	mg	30		multiple			day	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Homo sapiens							total daily dose			The usual initial dose is 5 mg (1 mL). This may be repeated every 6 hours. The total daily dosage should not exceed 15 mg in ambulatory patients or 30 mg in hospitalized patients.				Schizophrenia											p.4
5438	2468					Recommended	mg	64		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Homo sapiens							total daily dose			Hospitalized patients with schizophrenia: Tablets 8 to 16 mg bid to qid; avoid dosages in excess of 64 mg daily.				Schizophrenia											p.3
5439	2468					Recommended	mg	64		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/10775s311213s24lbl.pdf	Homo sapiens							total daily dose			Hospitalized patients with schizophrenia: Tablets 8 to 16 mg bid to qid; avoid dosages in excess of 64 mg daily.				Schizophrenia											p.4
5440	2468					Studied dose	mg	20		single					unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/3588517/	Homo sapiens													1	Schizophrenia											
5441	2469					Highest studied dose	mg	80		multiple			month	10	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12152116	Homo sapiens													691	Erectile dysfunction								13	month		p.268
5442	2469					Recommended	mg	5		single					unhealthy	intravenous|intramuscular			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fe1e10f5-4ff3-4616-9534-489648d88d33&type=display	Homo sapiens										For preoperative reduction of elevated blood pressure, 5 mg of Phentolamine Mesylate for Injection, USP (1mg for children) is injected intravenously or intramuscularly 1 or 2 hours before surgery, and repeated if necessary.				Pheochromocytoma											
5443	2469					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12161768	Homo sapiens										Patients were to take one tablet approximately 30 min (phentolamine) before anticipated sexual activity but were not to take more than one tablet daily.			119	Erectile dysfunction								8	week		S51
5444	2470					Highest studied dose	mg	75		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2466178	Homo sapiens						53.1							31						53.1			21	day		
5445	2470						mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2758730	Homo sapiens						53.6																4	week		
5446	2470						mg	37.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2758730	Homo sapiens						53.6																4	week		
5447	2471		adult				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01301027	Homo sapiens							total daily dose			15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks			48	End Stage Renal Disease								26	week		
5448	2471		adult				mg	45		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00708175	Homo sapiens										Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.			78	Bone Metabolism								52	week		
5449	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00220961	Homo sapiens													303	Type 2 Diabetes								2.4	year		
5450	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00736996	Homo sapiens							max|total daily dose			30 - 45mg tablet daily for 6 months			25	Cognitive Impairment								6	month		
5451	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00742326	Homo sapiens													6	Hepatic Steatosis								48	week		
5452	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00760578	Homo sapiens													21	Type 2 Diabetes								4	week		
5453	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01280695	Homo sapiens													26	Type 2 diabetes								28	day		
5454	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01631630	Homo sapiens							total daily dose			Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days			8	Alcohol Dependence								13	day		
5455	2471		adult				mg	45		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01717040	Homo sapiens							max			Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.			17	Bipolar Disorder								8	week		
5456	2471		adult				mg	45		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00868140	Homo sapiens													26	Polycystic Ovary Syndrome								6	month		
5457	2471					MTD	mg/kg	0.75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30498564	Homo sapiens												12	18	Autistic disorder|Asperger syndrome					5			16	week		p.7, 9
5458	2471					Overdose	mg	180		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf	Homo sapiens										male patient took 120 mg per day for four days, then 180 mg per day for seven days.				Type 2 diabetes mellitus								7	day		p.21
5459	2471					Recommended	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27322798	Homo sapiens						58.1							60	Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus								24	week		p.983, 984
5460	2471					Recommended	mg	45		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf	Homo sapiens														Type 2 diabetes mellitus											p.1
5461	2472						g	2		multiple			day	4	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Homo sapiens														serious infections caused by susceptible strains											
5462	2472						g	4		multiple			day	4	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050545s053lbl.pdf	Homo sapiens														serious infections caused by susceptible strains											
5463	2473					Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6112039	Homo sapiens						62						71	26	chronic heart failure					42						
5464	2473						ug	400		single					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/7910819	Homo sapiens						32						56	14	asthma					21						
5465	2474		adult				g	2000		multiple			day	2	healthy	oral			https://www.tandfonline.com/doi/abs/10.1080/00039896.1967.10664975	Homo sapiens										Chronic oral administration was studied in 29 subjects who received pralidoxime daily for periods up to six months. Each subject was started on an initial dosage of 250 mg once a day. The dose was gradually increased to a daily dosage of 4,000 mg, given in two doses. The total quantity of material ingested by each individual ranged from 100 to 400 gm. These subjects were maintained at the highest dosage for four to six weeks and then given a placebo for four to six weeks.			29									5	week		
5466	2474		adult				g	4		single					healthy	oral			https://www.tandfonline.com/doi/abs/10.1080/00039896.1967.10664975	Homo sapiens										Single doses of 1, 2, 3, or 4 gm of pralidoxime were given to ten fasting subjects in such a way that each individual received each dose at weekly intervals.			10												
5467	2474		adult				mg/kg	45		single					healthy	intramuscular			https://www.tandfonline.com/doi/abs/10.1080/00039896.1967.10664975	Homo sapiens										Single doses of 15, 30 or 45 mg/kg of pralidoxime were given i.m.															
5468	2474		adult				mg/kg	45		single					healthy	intravenous			https://www.tandfonline.com/doi/abs/10.1080/00039896.1967.10664975	Homo sapiens										Single doses of 15, 30 or 45 mg/kg of pralidoxime were given i.v.															
5469	2474					Recommended	g	1.2		single					healthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/014134s022lbl.pdf	Homo sapiens													6												
5470	2474					Recommended	g	1.8		single					healthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/014134s022lbl.pdf	Homo sapiens													6												
5471	2475		adult			Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12667578/	Homo sapiens													272	primary hyper-cholesterolemia								6	week		
5472	2475					Studied dose	mg	18.75		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/019898s062.pdf	Homo sapiens							mean			mean duration; dose range 5 - 40 mg		76	902	Coronary Heart Disease					20			14	week		
5473	2476		adult				mg	16		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01916941	Homo sapiens													18	Alcohol Use Disorder								6	week		
5474	2476		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00532493	Homo sapiens							max|total daily dose			Study drug will be increased using a flexible dose titration schedule based on clinical response and adverse effects to an optimum maintenance dose (1-20 mg/day).			152	Posttraumatic stress disorder								26	week		
5475	2476		adult				mg	4		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01126099	Homo sapiens							max						11	Alzheimer's Disease								12	week		
5476	2476		adult				mg	8		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00744055	Homo sapiens													50	Alcohol Dependence and Post Traumatic Stress Disorder								12	week		
5477	2476					Highest studied dose	mg/kg	0.18		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30233728/	Homo sapiens												42	7	gestational hypertension					22			4	week		
5478	2476					MTD	mg/kg	0.1		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30233728/	Homo sapiens										0.10-0.14 mg/kg		42	15	gestational hypertension					22			4	week		
5479	2476					Overdose	mg	30.5		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/6632112/	Homo sapiens						25							1						25						
5480	2477						mg	50		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28766806	Homo sapiens						79				oral drops (promazine hydrochloride, 50 mg daily)			1	Alzheimer’s disease					79			2	week		
5481	2477						mg	50		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13458245	Homo sapiens													16												
5482	2478		adult			Highest studied dose	mg	425		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-416_Rythmol%20SR_Medr_P1.pdf	Homo sapiens													135	atrial fibrillation								39	week		
5483	2480					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/073645s028,073644s023lbl.pdf	Homo sapiens														mental depression											
5484	2481		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019885s038lbl.pdf	Homo sapiens							max			5 to 40 mg			1563	Hypertension								12	month		11
5485	2481		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019885s038lbl.pdf	Homo sapiens							max			5 to 40 mg			585	Hypertension								12	month		12
5486	2482		adult			Studied dose	mg	180		multiple					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf	Homo sapiens																									
5487	2482		adult				mg	60		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00030147	Homo sapiens													16	Perimenopausal Depression								8	week		
5488	2482					Highest studied dose	mg	600		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8725181/	Homo sapiens						53.2							63									8	week		
5489	2482					Recommended	mg	60		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022042s000_MedR_P3.pdf	Homo sapiens						68				for at least 5 years			10101									5	year		022042s000_MedR_P3.pdf - p.25
5490	2482					Recommended	mg	60		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022042s000_MedR_P3.pdf | https://pubmed.ncbi.nlm.nih.gov/12450599/	Homo sapiens						68				for at least 5 years			10101									5	year		022042s000_MedR_P3.pdf - p.25
5491	2482					Studied dose	g	1.5		single			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf	Homo sapiens																						1	day		
5492	2482					Studied dose	mg	180		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022042lbl.pdf	Homo sapiens													2									1	day		
5493	2483					Recommended	mg	300		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7347558/	Homo sapiens						32.1				200 mg in the morning and 100 mg in the afternoon			64									4.5	day		
5494	2484					Studied dose	mg	120		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2641984	Homo sapiens														preterm labor											
5495	2484						mg	10		multiple					unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/3044111	Homo sapiens						29.8	starting			Subsequent intramuscular injections of 5 or 10 mg were repeated at intervals of 2 to 4 hours.			21	preterm labor					29.8						
5496	2484						mg/h	6.4		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/29372151	Homo sapiens						31.6	starting			Usually ritodrine was administered with an initial dose of 6.4 mg/hr with increment of 3.2 mg/hr every 15 minutes until the cessation of uterine contractions			177	preterm labor					31.6			5	day		
5497	2484						mg/min	0.15		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3963086	Homo sapiens										The intravenous infusion varied from 0.15 to 0.3 mg/min.			1	preterm labor								1	week		
5498	2484						mg/min	100		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/3044111	Homo sapiens						31	starting			an initial dose of 100 ug/min. This dose was increased by 50 ug/min increments every 10 to 20 minutes until uterine quiescence was obtained or a maximal dose of 350 ug/min was achieved.			24	preterm labor					31						
5499	2485		adult				mg	10		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00246337	Homo sapiens													50	Migraine											
5500	2485					Overdose	mg	80		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20864lbl.pdf	Homo sapiens						29							2						29						
5501	2485					Overdose	mg	80		single					unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20864lbl.pdf	Homo sapiens						25							2						25						
5502	2485					Overdose	mg	80		single					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20864lbl.pdf	Homo sapiens												29	2						25						
5503	2485					Recommended	mg	10		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17112920	Homo sapiens						43							1		8.5 mg/day; oral			tacrolimus	43						
5504	2485					Recommended	mg	10		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23084593	Homo sapiens						17							1						17						
5505	2486					Recommended	mg/kg	0.15		single					unhealthy	intravenous	M+F		https://www.fda.gov/media/71700/download	Homo sapiens										The maintenance Zemuron regimen began at the reappearance of T3 following an initial 0.6 mg/kg bolus dose of Zemuron administered to all patients to facilitate intubation. At the reappearance of T3, patients randomized to maintenance bolus dosing received 0.15 mg/kg bolus doses of Zemuron. The anesthetic regimen was standardized to control the possible synergy between Zemuron and general anesthetics in causing neuromuscular blockade. Sevoflurane 2.0 – 2.5 MAC to up to 7%-8% inspired concentration in 0%-70% nitrous oxide was used for induction of anesthesia until loss of consciousness. At loss of consciousness, nitrous oxide at 0%-70% and sevoflurane of only up to 5% end tidal concentration was administered. Sevoflurane was to be continued until the endotracheal tube was placed. In term neonates only, anesthesia was induced with propofol if rapid sequence intubation was clinically indicated. Depth of anesthesia was to be sustained with inhalation of isoflurane (1.0+0.2% expired end tidal concentration) in 0%-70% nitrous oxide.		17	64	surgical procedures	2-2.5 MAC			sevoflurane	0						
5506	2486					Recommended	mg/kg	0.45		single					unhealthy	intravenous	M+F		https://www.fda.gov/media/71700/download	Homo sapiens										The anesthetic regimen was standardized to control the possible synergy between Zemuron and general anesthetics in causing neuromuscular blockade. Sevoflurane 2.0 – 2.5 MAC to up to 7%-8% inspired concentration in 0%-70% nitrous oxide was used for induction of anesthesia until loss of consciousness. At loss of consciousness, nitrous oxide at 0%-70% and sevoflurane of only up to 5% end tidal concentration was administered. Sevoflurane was to be continued until the endotracheal tube was placed. In term neonates only, anesthesia was induced with propofol if rapid sequence intubation was clinically indicated. Depth of anesthesia was to be sustained with inhalation of isoflurane (1.0+0.2% expired end tidal concentration) in 0%-70% nitrous oxide.		17	63	surgical procedures	2-2.5 MAC			sevoflurane	0						
5507	2486					Recommended	mg/kg	0.6		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/9836032/	Homo sapiens						33.1		1.8 mg/kg		The patients were premedicated with 1-2 mg midazolam up to 90 min before the induction of anaesthesia. Anaesthesia was achieved by an infusion of propofol (1.8 mg/kg) and alfentanil (9 ug/kg) iv, and the lungs were ventilated with nitrous oxide 70% in oxygen via a face mask. After obtaining a satisfactory control recording of the mechanomyogram for two minutes, the patients were randomized to received rocuronium 0.6 mg/kg administered as a bolus dose injected over five seconds into a fast flowing iv infusion.			20	surgical procedures	1-2 mg		alfentanil	midazolam			9 ug/kg			propofol	
5508	2486					Recommended	mg/kg	0.6		single					unhealthy	intravenous	M+F		https://www.fda.gov/media/71700/download	Homo sapiens										The anesthetic regimen was standardized to control the possible synergy between Zemuron and general anesthetics in causing neuromuscular blockade. Sevoflurane 2.0 – 2.5 MAC to up to 7%-8% inspired concentration in 0%-70% nitrous oxide was used for induction of anesthesia until loss of consciousness. At loss of consciousness, nitrous oxide at 0%-70% and sevoflurane of only up to 5% end tidal concentration was administered. Sevoflurane was to be continued until the endotracheal tube was placed. In term neonates only, anesthesia was induced with propofol if rapid sequence intubation was clinically indicated. Depth of anesthesia was to be sustained with inhalation of isoflurane (1.0+0.2% expired end tidal concentration) in 0%-70% nitrous oxide.		17	66	surgical procedures	2-2.5 MAC			sevoflurane	0						
5509	2486					Recommended	mg/kg	1		single					unhealthy	intravenous	M+F		https://www.fda.gov/media/71700/download	Homo sapiens										The anesthetic regimen was standardized to control the possible synergy between Zemuron and general anesthetics in causing neuromuscular blockade. Sevoflurane 2.0 – 2.5 MAC to up to 7%-8% inspired concentration in 0%-70% nitrous oxide was used for induction of anesthesia until loss of consciousness. At loss of consciousness, nitrous oxide at 0%-70% and sevoflurane of only up to 5% end tidal concentration was administered. Sevoflurane was to be continued until the endotracheal tube was placed. In term neonates only, anesthesia was induced with propofol if rapid sequence intubation was clinically indicated. Depth of anesthesia was to be sustained with inhalation of isoflurane (1.0+0.2% expired end tidal concentration) in 0%-70% nitrous oxide.		17	56	surgical procedures	2-2.5 MAC			sevoflurane	0						
5510	2486					Recommended	ug/kg/min	10		single					unhealthy	intravenous	M+F		https://www.fda.gov/media/71700/download	Homo sapiens										The maintenance Zemuron regimen began at the reappearance of T3 following an initial 0.6 mg/kg bolus dose of Zemuron administered to all patients to facilitate intubation. At the reappearance of T2, subjects in each age group randomized to receive a continuous infusion, were administered Zemuron at an initial rate of 10 mcg/kg/min (0.6 mg/kg/hr) and then adjusted approximately to 2-5 mcg/kg/min (0.1-0.3 mg/kg/hr) every three minutes until one or two twitches were maintained. The anesthetic regimen was standardized to control the possible synergy between Zemuron and general anesthetics in causing neuromuscular blockade. Sevoflurane 2.0 – 2.5 MAC to up to 7%-8% inspired concentration in 0%-70% nitrous oxide was used for induction of anesthesia until loss of consciousness. At loss of consciousness, nitrous oxide at 0%-70% and sevoflurane of only up to 5% end tidal concentration was administered. Sevoflurane was to be continued until the endotracheal tube was placed. In term neonates only, anesthesia was induced with propofol if rapid sequence intubation was clinically indicated. Depth of anesthesia was to be sustained with inhalation of isoflurane (1.0+0.2% expired end tidal concentration) in 0%-70% nitrous oxide.		17	73	surgical procedures	2-2.5 MAC			sevoflurane	0						
5511	2487					Highest studied dose	mg	50		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/28442303	Homo sapiens													1	Parkinson's disease with severe dyskinesias								12	month		
5512	2487					Overdose	mg	435		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020658Orig1s037lbl.pdf	Homo sapiens																						7	day		p. 18
5513	2487					Recommended	mg	0.5		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020658Orig1s037lbl.pdf	Homo sapiens										Patients were titrated for up to 10 weeks, starting at 0.5 mg twice daily, with weekly increments of 0.5 mg twice daily to a maximum of 5 mg twice daily.			157	Parkinson’s disease								12	week		
5514	2487					Recommended	mg	24		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/28442303	Homo sapiens													61	Parkinson's disease								12	week		
5515	2488		adult				mg	10		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01068626	Homo sapiens													30	Obesity								26	week		
5516	2488		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00929734	Homo sapiens													47	Chronic Obstructive Pulmonary Disease								3	month		
5517	2488		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00979121	Homo sapiens										Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.			379	Acute Lung Injury								28	day		
5518	2488		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01813357	Homo sapiens													44	Atherosclerosis								96	week		
5519	2488		child				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00355615	Homo sapiens													44	Familial Hypercholesterolemia								12	week		
5520	2488		child				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00355615	Homo sapiens													44	Familial Hypercholesterolemia								12	week		
5521	2488		child				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00355615	Homo sapiens													42	Familial Hypercholesterolemia								12	week		
5522	2488					Highest studied dose	mg/kg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27036206	Homo sapiens						58				Rosuvastin was administered as follows: 1 week off, then daily for 2 weeks, then 1 week off. For all subsequent cycles, rosuvastatin was given daily for the first 3 weeks of each 28-day cycle. Oral administration of rosuvastatin was once daily if daily dose was <80 mg, twice if 81–160 mg, three times a day if 161–240 mg and four times a day if >240 mg daily dose.			8	Cancer	150 mg; q.d			erlotinib, p.o				3	week		p.4, 8
5523	2488					MTD	mg/kg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27036206	Homo sapiens						58				Rosuvastin was administered as follows: 1 week off, then daily for 2 weeks, then 1 week off. For all subsequent cycles, rosuvastatin was given daily for the first 3 weeks of each 28-day cycle. Oral administration of rosuvastatin was once daily if daily dose was <80 mg, twice if 81–160 mg, three times a day if 161–240 mg and four times a day if >240 mg daily dose.			10	Cancer	150 mg; q.d			erlotinib, p.o				3	week		p.4, 8
5524	2488					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22085316	Homo sapiens						57.4							691	Coronary atherosclerosis								104	week		p.2085
5525	2489		adult				mg	100		multiple			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00536198	Homo sapiens							max			At a baseline study visit, participants will then be randomly assigned to receive either sertraline or placebo for six menstrual cycles.  Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.			125	Premenstrual Dysphoric Disorder								6	month		
5526	2489		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00704379	Homo sapiens													48	Mood Disorders								6	month		
5527	2489		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02504931	Homo sapiens													26	Post-traumatic Stress Disorder and Alcohol Use Disorder								12	week		
5528	2489		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00233103	Homo sapiens							max|total daily dose			Daily oral sertraline in doses starting at 25mg and increasing to therapeutic levels (up to 200mg).			22	Depression								10	week		
5529	2489		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00946998	Homo sapiens							total daily dose			Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d			97	Depression								12	week		
5530	2489		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01407094	Homo sapiens							max|total daily dose			50-200mg/day			283	Depression								8	week		
5531	2489		child				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01474746	Homo sapiens							max			Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.			27	Fragile X Syndrome								6	month		
5532	2489		child				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02385799	Homo sapiens										Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.			32	Autism Spectrum Disorder								6	month		
5533	2489					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019839ap.pdf	Homo sapiens						12.5	max						92	Attention deficit hyperactivity disorder								12	week		
5534	2489					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/019839ap.pdf	Homo sapiens						12.8	max						20	Obsessive compulsive disorder or depression								42	day		
5535	2489					Studied dose	mg	133		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf	Homo sapiens							median			mean duration; starting dose - 25 mg and 200 mg - maximal dose		65	374	Post-traumatic stress disorder					18			73	day		
5536	2490		adult				mg	20		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00853112	Homo sapiens													6	Pulmonary Arterial Hypertension											
5537	2490		adult				mg	20		steady			day	3	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01334554	Homo sapiens													23	Obesity								4	week		
5538	2490		adult				mg	40		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01132482	Homo sapiens										During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.			12	Cystic Fibrosis								4	week		
5539	2490		adult				mg	40		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02626182	Homo sapiens										Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.			9	Cystic Fibrosis								12	week		
5540	2490		adult				mg	60		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00763867	Homo sapiens										Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks			113	Diastolic Heart Failure								24	week		
5541	2490		adult				mg	60		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01726049	Homo sapiens										Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks			26	Pulmonary Hypertension								12	week		
5542	2490		child|adult				mg	80		steady			day	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00492531	Homo sapiens							max			Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.			37	Pulmonary Hypertension								16	week		
5543	2490					Highest studied dose	mg	80		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21546436	Homo sapiens						47.5							135	Pulmonary arterial hypertension								3	year		p.1278
5544	2490					Overdose	g	6.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26139313	Homo sapiens						56				suicide attempt			1												p.1
5545	2490					Overdose	mg	2000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26139313	Homo sapiens						33							1												p.2
5546	2490					Overdose	mg	2400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26139313	Homo sapiens						33							1												p.2
5547	2490					Overdose	mg	250		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24661860	Homo sapiens						45							1	Erectile dysfunction											p.258
5548	2490					Overdose	mg	400		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30473955	Homo sapiens						67							1	Erectile dysfunction											p.1,2
5549	2490					Overdose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26139313|https://pubmed.ncbi.nlm.nih.gov/12507258	Homo sapiens						56							1												p.2
5550	2490					Recommended	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9580646	Homo sapiens						58	max			25, 50, or 100 mg of sildenafil (approximately one hour before planned sexual activity but not more than once daily) for 24 weeks.			316	Erectile dysfunction								24	week		p.1400
5551	2490					Recommended	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9580646	Homo sapiens						60	max			25, 50, or 100 mg of sildenafil (approximately one hour before planned sexual activity but not more than once daily) for 24 weeks.			163	Erectile dysfunction								24	week		p.1403
5552	2490					Recommended	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9580646	Homo sapiens						60	max			25, 50, or 100 mg of sildenafil (approximately one hour before planned sexual activity but not more than once daily) for 32 weeks.			225	Erectile dysfunction								32	week		p.1401
5553	2491		adult			Recommended	mg	24		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7601014/	Homo sapiens							max			12 to 24 mg			133	hypertension								8	week		
5554	2492					Highest studied dose	mg	350		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_MedR.pdf / https://pubmed.ncbi.nlm.nih.gov/14654525	Homo sapiens																									
5555	2492					Studied dose	mg	175		steady					unhealthy	oral			https://cancerres.aacrjournals.org/content/66/8_Supplement/684.2	Homo sapiens										was administered as an LD on day 1 followed by daily treatment for 13 days and then a 1-week treatment break to comprise a 3-week cycle (Schedule 2/1).				advanced solid tumors											
5556	2492						mg	25		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25757921	Homo sapiens						74							1	Renal Cell Carcinoma					74			28	day		
5557	2492						mg	50		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25757921	Homo sapiens							starting					77	5	Renal Cell Carcinoma					52			28	day		
5558	2492						mg	50		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_MedR.pdf	Homo sapiens							starting						202												
5559	2493		adult			Recommended	mg	10		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/017970Orig1s052.pdf	Homo sapiens													902	breast cancer								5	year		nda/2004/017970Orig1s052.pdf - p.15
5560	2493					Highest studied dose	mg	700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7564501/	Homo sapiens						50							3	acute leukemia	50 mg/m2 intravenously on days 5, 6 and 7			daunorubicin				7	day		
5561	2493					Highest studied dose	mg/m2	680		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1359155/	Homo sapiens						58				Loading dose. Maintenance dose 260 mg/m2 2 per day			3	epithelial tumors	1.5 mg/m2 per day intravenous; on days 9-13			Vinblastine				1	day		
5562	2493					MTD	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9041168/	Homo sapiens						53							3	metastatic melanoma	80 mg/m2 intravenous; once weekly			cisplatin				3	week		
5563	2493					MTD	mg	240		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1358168/	Homo sapiens						50				beginning 3 days before etoposide			16	cancer	300 mg orally; day-1 for 3 days			etoposide				6	day		
5564	2493					MTD	mg/m2	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21353747/	Homo sapiens						51				in combination with radiotherapy 60 Gy/2 Gy fractions			3	high-grade glioma	75 mg/m2 orally; 6 weeks			temozolomide				6	week		
5565	2493					Studied dose	mg	280		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9041168/	Homo sapiens						53							3	metastatic melanoma	80 mg/m2 intravenous; once weekly			cisplatin				3	week		
5566	2493					Studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12395333/	Homo sapiens						61							74	hepatocellular carcinoma								3	month		
5567	2493					Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12395333/	Homo sapiens						61							120	hepatocellular carcinoma								3	month		
5568	2493					Studied dose	mg/m2	125		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21353747/	Homo sapiens						51				in combination with radiotherapy 60 Gy/2 Gy fractions			6	high-grade glioma	75 mg/m2 orally; 6 weeks			temozolomide				6	week		
5569	2493					Studied dose	mg/m2	230		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1359155/	Homo sapiens						58				Maintenance dose			3	epithelial tumors	1.5 mg/m2 per day intravenous; on days 9-13			Vinblastine				13	day		
5570	2493					Studied dose	mg/m2	250		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/17970s37s44s49lbl.pdf	Homo sapiens							starting			doses higher than 250 mg/m2 loading dose, followed by maintenance doses of 80 mg/m2 of tamoxifen given twice a day				advanced metastatic cancer											
5571	2493					Studied dose	mg/m2	400		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021807lbl.pdf	Homo sapiens							starting			400 mg/m2 loading dose, followed by maintenance doses of 150 mg/m2 of tamoxifen given twice a day				advanced metastatic cancer											
5572	2493					Studied dose	mg/m2	75		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21353747/	Homo sapiens						51				in combination with radiotherapy 60 Gy/2 Gy fractions			4	high-grade glioma	75 mg/m2 orally; 6 weeks			temozolomide				6	week		
5573	2494		adult				mg	0.2		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00861757	Homo sapiens													152	Benign Prostatic Hyperplasia								12	week		
5574	2494		adult				mg	0.4		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02486653	Homo sapiens										Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.Outline of schedule:Day 1-7: tamsulosin 0.4mg in the eveningDay 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocolDay 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function.			76	Urinary Retention											
5575	2494					Recommended	mg	0.4		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31541583	Homo sapiens						54							1	benign prostatic hyperplasia					54			2	week		
5576	2494					Recommended	mg	0.8		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020579s033lbl.pdf	Homo sapiens													492									13	week		
5577	2495		adult			Recommended	%	0.8		multiple			day	1	unhealthy	vaginal	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021735s000_Terconazole_Vaginal_MedR.pdf	Homo sapiens										one applicatorful (5g) intravaginally once daily at bedtime for 3 days			243	vulvovaginal candidiasis								3	day		
5578	2496		adult			Overdose	g	1		single					unknown	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	Homo sapiens										ranged from 100 mg to 1 g			8												
5579	2496		adult			Recommended	mg	12.5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	Homo sapiens							starting							Huntington’s disease								7	day		
5580	2497					Overdose	mg	320		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7670769	Homo sapiens						30				suicide attempt			1	Seizures	400 mg, single			phenytoin, p.o							p.155
5581	2497					Overdose	mg	72		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15388215	Homo sapiens						46				suicide attempt			1	Depression											p.271
5582	2497					Overdose	mg	90		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18072137	Homo sapiens						2				Accidental			1												p.160
5583	2497					Recommended	mg	56		multiple			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020646s017lbl.pdf	Homo sapiens							max|total daily dose			In adults, GABITRIL should be initiated at 4 mg once daily. Modification of concomitant antiepilepsy drugs is not necessary, unless clinically indicated. The total daily dose of GABITRIL may be increased by 4 to 8 mg at weekly intervals until clinical response is achieved or, up to 56 mg/day. The total daily dose should be given in divided doses two to four times daily.			2531	Epilepsy											p.17
5584	2498		adult			Recommended	mg	250		multiple			day	2	unhealthy	oral			https://pdf.hres.ca/dpd_pm/00015633.PDF	Homo sapiens													2048	stroke											
5585	2498					Recommended	mg	250		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20704700/	Homo sapiens						70							1	stroke											
5586	2498						mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18033957/	Homo sapiens						64.7							578	stroke								52	week		
5587	2500		adult			Highest studied dose	%	6.5		multiple			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/3524439/	Homo sapiens										ointment			80	vulvovaginal candidiasis								3	day		
5588	2501					Highest studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15097154	Homo sapiens						35.2							10	HIV-1 infection								14	day		p.381
5589	2501					Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26730818	Homo sapiens													186	HIV-1 infection	200 mg, b.i.d.			ritonavir, oral							p.11
5590	2501					Recommended	mg	500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf	Homo sapiens														HIV-1 infection	200 mg, b.i.d.			ritonavir, oral							p.1
5591	2501					Recommended	mg	500		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf	Homo sapiens														HIV-1 infection	200 mg, b.i.d.			ritonavir, oral							p.1, 5
5592	2502					Recommended	mg/kg	10		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8606262/	Homo sapiens						58.2				Patients received one of three gratiuated regimens of tirofiban intravenously with a bohrs dose of 5, 10 and 10 mg/kg and continuous infusion doses of 0.05,O.lO and 0.15 mkg/ml/min (16 to 24 h) in dose panels I, II and III, mpectively.			73	High Risk Patients Undergoing Coronary Angioplasty											
5593	2503					Recommended	mg	12		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021447s011_020397s026lbl.pdf	Homo sapiens										Recommended starting dose: 2 mg; dose can be repeated at 6 to 8 hour intervals, up to a maximum of 3 doses in 24 hours (2.1 ) •Dosage can be increased by 2 mg to 4 mg per dose, with 1 to 4 days between increases; total daily dose should not exceed 36 mg				Spasticity											p.1
5594	2503					Recommended	mg	19.36		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3286129	Homo sapiens							mean			The initial dosage was 3 capsules per day, each containing 2 mg tizanidine. This dosage was progressively increased, if tolerated, by 1 capsule every 2 days for the first 2 weeks, up to a maximum dosage of 12 capsules daily (24 mg tizanidine). The optimum dosage in terms of efficacy and tolerability was then maintained for a period of 6 weeks. Each drug was taken orally in 3 or 4 doses through the day.		77	51	Spasticity					18			8	week		p.716
5595	2504						mg	250		single			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6439023	Homo sapiens							starting			initial bolus of 250 mg and a second bolus of 250 mg 15 minutes later. Each dose administered over 1 to 2 minutes, plus an i.v. infusion at 1.04 mg/min started at the time of the first bolus injection		75	50	Acute Ventricular Arrhythmias					34						
5596	2504						mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3931448	Homo sapiens						59						83	67	benign and potentially lethal ventricular arrhythmias					28			8	week		
5597	2505		adult			Recommended	mg	300		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf	Homo sapiens										Tramadol hydrochloride extended-release capsules Capsules were administered to a total of 1987 patients in clinical trials. These included four double-blind and one long-term, open-label study in patients with osteoarthritis of the hip and knee. A total of 812 patients were 65 years or older. Adverse reactions with doses from 100 mg to 300 mg in the four pooled, randomized, double-blind, placebo-controlled studies in patients with chronic non-malignant pain are presented in the following table (see Table 1).			1054	osteoarthritis											
5598	2505						mg	1500		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31208192/	Homo sapiens						41	median			Tramadol overdose (i.e., doses greater than the maximum recommended dose of 400 mg). Only 15 (2.9%) patients had a previous history of overdose, while 162 (31.6%) were in the process of quitting drug use at the time of admission.			359												
5599	2505						mg	600		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28881493/	Homo sapiens						28				Highest tramadol dose tested was 600 mg/day (supratherapeutic dose). Participants in each treatment cohort received a total of 9 oral doses of tramadol or placebo. The first dose of the study drug was given at 8:00 AM on day 1, with doses administered every 6 hours thereafter (ie, at 6, 12, 18 hours [day 1], 24, 30, 36, 42 hours [day 2], and 48 hours [day 3];). Morning doses on days 1 (first dose), 2 (fourth dose), and 3 (ninth dose) were administered before breakfast.			8									3	day		
5600	2506					Overdose	mg	2000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/31879415/	Homo sapiens						55							1						55						
5601	2506					Overdose	mg	2000		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/6838028/	Homo sapiens						22							1	suicide attempt	200 mg			methyltestosterone	22						
5602	2506					Overdose	mg	2900		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/6838028/	Homo sapiens						25							1	suicide attempt	8 mg			alprazolam	25						
5603	2506					Overdose	mg	6450		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/28816830/	Homo sapiens						37							1	suicide attempt					37						
5604	2508		adult			Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13662943/	Homo sapiens													62	pruritic dermatoses								12	week		
5605	2511		adult				mg	60		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01089751	Homo sapiens													162	Overactive Bladder								14	week		
5606	2511		adult				mg	60		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01922115	Homo sapiens													28	Urinary Bladder, Overactive								4	week		
5607	2511		elderly				mg	60		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01178827	Homo sapiens													6	Overactive Bladder								10	day		
5608	2511					Highest studied dose	mg	360		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8494577|https://pubmed.ncbi.nlm.nih.gov/18360555	Homo sapiens													8												
5609	2511					Recommended	mg	20		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021595s009lbl.pdf	Homo sapiens													591	Overactive bladder											p.3
5610	2511					Recommended	mg	20		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021595s009lbl.pdf	Homo sapiens														Overactive bladder											p.1
5611	2512		adult			Recommended	mg	225		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s015lbl.pdf	Homo sapiens										Acute therapy of major depressive disorder (up to 12 weeks; dose range of 75 to 225 mg/day)			357	Major Depressive Disorder								12	week		
5612	2512		adult			Recommended	mg	225		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022104s015lbl.pdf	Homo sapiens										Acute therapy of Social Anxiety Disorder (up to 12 weeks; dose range of 75 to 225 mg/day)			277	Social Anxiety Disorder								12	week		
5613	2512		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00735670	Homo sapiens							max|total daily dose			The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week.			10	Depression								13	week		
5614	2512		adult				mg	50		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02714400	Homo sapiens													20	Obstructive Sleep Apnea								7	day		
5615	2513		adult			Highest studied dose	mg	50		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019908s035,021774s016lbl.pdf	Homo sapiens							max			1 to 50 mg			1959	sleep disturbances								5	day		
5616	2513		adult			Highest studied dose	mg	90		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019908s035,021774s016lbl.pdf	Homo sapiens							max			1.25 to 90 mg			1701	sleep disturbances								5	day		
5617	2513		adult			Overdose	mg	600		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10517569/	Homo sapiens										300 - 600 mg			344	sleep disturbances											
5618	2513		adult			Overdose	mg	600		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/8693299/	Homo sapiens													54	sleep disturbances											
5619	2513					Highest studied dose	mg/kg	0.5		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17957186/	Homo sapiens												12	65	sleep disturbances					2						
5620	2513					Overdose	mg	300		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8635759/	Homo sapiens						68							1	sleep disturbances					68						
5621	2514		adult			Recommended	%	0.5		multiple			day	2	unhealthy	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020258s026lbl.pdf	Homo sapiens														intraocular pressure								7	day		
5622	2515					Recommended	mg/kg	3.58		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7594028/	Homo sapiens							mean					79	134	diagnostic test					37						
5623	2515					Recommended	mg/kg	4.62		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7594028/	Homo sapiens							mean					70	53	diagnostic test					20						
5624	2516						mg	80		multiple			day	3	unhealthy	oral	F		https://academic.oup.com/ajcn/article-abstract/9/5/632/4730120?redirectedFrom=fulltext	Homo sapiens						54	max			The dose of benzphetamine varied from 40 to 80 mg. three times daily.			20	Obesity								20	week		
5625	2518		adult			Highest studied dose	mg	250		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206110lbl.pdf	Homo sapiens													6												
5626	2518		adult				mg	50		multiple			day	1	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01045798	Homo sapiens										70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)			6	Invasive Candidiasis								7	day		
5627	2518					Overdose	mg	113		multiple			day	1	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206110lbl.pdf	Homo sapiens						16	starting			a single dose of caspofungin of 113 mg (on Day 1), followed by 80 mg daily for an additional 7 days			1						16			7	day		
5628	2518					Recommended	mg/m2	50		multiple			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/19779392	Homo sapiens							starting			5 clinical studies. 50 mg/m2 with sequential dose escalation to 70 mg/m2 (max. 70 mg)		11	171						2			7	day		
5629	2518						mg	70		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/20407030	Homo sapiens						86	starting						1						86						
5630	2518						mg	70		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/23761719	Homo sapiens						58	starting						1						58						
5631	2519		adult			Recommended	mg	90		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017105_S070_Tranxene_APPROVAL_PACKAGE.pdf	Homo sapiens																									
5632	2519					Recommended	mg	60		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/017105_S070_Tranxene_APPROVAL_PACKAGE.pdf	Homo sapiens												12							9						
5633	2520		adult			Highest studied dose	mg	120		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021697lbl.pdf	Homo sapiens										Combined clinical data. Administered as a 20 mg loading dose on Day 1 followed by continuous infusion up to 120 mg/day for 2 days				Congestive heart failure								2	day		
5634	2520		adult			Recommended	mg	40		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021697s000_Vaprisol_MEDR.pdf	Homo sapiens										Combined clinical data. Administered as a 20 mg loading dose on Day 1 followed by continuous infusion up to 120 mg/day for 2 days			445									2	day		p. 64
5635	2520					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16522696	Homo sapiens						68.7							27	euvolemic hyponatremia | hypervolemic hyponatremia					68.7			5	day		
5636	2520						mg	12.5		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00592475	Homo sapiens										Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours			6	Liver Cirrhosis											
5637	2520						mg	20		multiple			day	1	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00478192	Homo sapiens													20	Euvolemic or Hypervolemic Hyponatremia								48	hour		
5638	2520						mg	20		multiple			day	2	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00478192	Homo sapiens													20	Euvolemic or Hypervolemic Hyponatremia								48	hour		
5639	2520						mg	22.5		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00592475	Homo sapiens										Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours			9	Liver Cirrhosis											
5640	2520						mg	60		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00843986	Homo sapiens										20mg loading dose followed by a 20mg/day continuous intravenous infusion for 48 hours			6	Acute Decompensated Heart Failure											
5641	2522					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24120380	Homo sapiens						52							9	Thrombocytopenia								27	day		p.1747
5642	2522					Recommended	mg	75		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207027s000lbl.pdf	Homo sapiens							max			Initiate PROMACTA at 50 mg once daily, do not exceed 75 mg per day				Thrombocytopenia|Aplastic anemia											p.1
5643	2522						mg	50		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01000051	Homo sapiens													39	Thrombocytopenia								8	week		
5644	2523		adult			Highest studied dose	mg	33.8		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18090508/	Homo sapiens							mean						64	obsessive-compulsive disorder								12	week		
5645	2523		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00248651	Homo sapiens													98	Dyspepsia								12	week		
5646	2523		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01787240	Homo sapiens													5	Major Depressive Disorder								30	month		
5647	2523		adult				mg	20		steady			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00825825	Homo sapiens							max			One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.			22									2	week		
5648	2523		adult				mg	20		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00894543	Homo sapiens							max			10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.			104	Hot Flashes								8	week		
5649	2523		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00536172	Homo sapiens										Participants take 10 mg for 1 week and then 20 mg for 15 weeks.			74	Depression								16	week		
5650	2523		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00574847	Homo sapiens							max			Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks).			64	Myocardial Ischemia								6	week		
5651	2523		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00621946	Homo sapiens							max			Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.			13	Asthma and Major Depressive Disorder								12	week		
5652	2523		child|adult				mg	20		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00523705	Homo sapiens							max			Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.			7	Premenstrual Syndrome								5	month		
5653	2523					Overdose	mg	140		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19556032/	Homo sapiens							median					36	46						18						
5654	2523					Overdose	mg	140		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19556032/	Homo sapiens							median					43	33					coingested drugs	24						
5655	2523					Overdose	mg	332		single					unknown	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20170390/	Homo sapiens							mean					84	63						16						
5656	2523					Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27736049/	Homo sapiens						46.2							4185	Psychiatric diagnoses					46.2						
5657	2524		adolescents				mg	30		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00735371	Homo sapiens													78	Attention-Deficit/Hyperactivity Disorder								3	week		
5658	2524		adult				mg	20		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01096680	Homo sapiens													27	Acute Sleep Loss											
5659	2524		adult				mg	50		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01096680	Homo sapiens													27	Acute Sleep Loss											
5660	2524		adult				mg	70		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01096680	Homo sapiens													27	Acute Sleep Loss											
5661	2524		adult				mg	70		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01101022	Homo sapiens							max						79	Attention-Deficit/Hyperactivity Disorder								10	week		
5662	2524					Overdose	mg	1200		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30730334	Homo sapiens						17							1												e771
5663	2524					Recommended	mg	70		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf	Homo sapiens							max			Patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of VYVANSE		12	218	Attention Deficit Hyperactivity Disorder					6			4	week		p.8
5664	2524					Recommended	mg	70		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf	Homo sapiens							max			Patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of VYVANSE		17	233	Attention Deficit Hyperactivity Disorder					13			4	week		p.8
5665	2524					Recommended	mg	70		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf	Homo sapiens							max			Patients were randomized to receive final doses of 30 mg, 50 mg, or 70 mg of VYVANSE		55	358	Attention Deficit Hyperactivity Disorder					18			4	week		p.8
5666	2524					Recommended	mg	70		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf	Homo sapiens														Attention Deficit Hyperactivity Disorder|Binge Eating Disorder											p.1
5667	2524						mg	50		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01148979	Homo sapiens							max						28	Major Depressive Disorder								4	week		
5668	2525		adult				mg/mL	2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/011559s057lbl.pdf	Homo sapiens										For continuous drip anesthesia, prepare a 0.2% solution by adding 500 mg of BREVITAL Sodium to 250 mL of diluent. BREVITAL is a methohexital sodium for injection.															
5669	2525						mg/kg	30		single					unhealthy	rectal			https://pubmed.ncbi.nlm.nih.gov/7486084	Homo sapiens										Each patient received a single dose of 30 mg/kg of a 10% solution of rectal methohexital			648												
5670	2526					Highest studied dose	mg	8		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23443718/	Homo sapiens						30							11									7	day		
5671	2526					Recommended	mg	2		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018677Orig1s000rev.pdf#147	Homo sapiens												78	24	cancer					20			5	day		Protocol 28
5672	2526					Recommended	mg	2		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/018677Orig1s000rev.pdf#36	Homo sapiens												77	67	cancer					18						
5673	2528		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01124604	Homo sapiens							max			Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.			60	Pain								12	week		
5674	2528		adult				mg	250		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01124617	Homo sapiens							max			Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.			60	Pain								12	week		
5675	2528		adult				mg	75		multiple			day	3	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01500317	Homo sapiens													13									2	day		
5676	2528					Recommended	mg	100		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022304s003lbl.pdf	Homo sapiens										The dose is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.				Acute pain											p.7
5677	2528					Recommended	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20602712	Homo sapiens						56.8	max			Tapentadol ER. Duration 0.5-1 year			894	Chronic low back pain|Osteoarthritis pain								1	year		p.424
5678	2528					Recommended	mg	700		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022304s003lbl.pdf	Homo sapiens							total			The dose is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.				Acute pain											p.1
5679	2529		adult			Recommended	mg	125		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf	Homo sapiens														infections	250 to 875 mg			amoxicillin				10	day		
5680	2529					Recommended	mg/kg	10		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf	Homo sapiens										6.4 to 10 mg/kg			575	acute otitis media	40 to 45 mg/kg			amoxicillin				10	day		
5681	2532					Studied dose	mg	1000		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14234274	Homo sapiens																									
5682	2532						mg	10		multiple			2 days	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14234274	Homo sapiens						81							1	pernicious anemia					81			2	day		
5683	2532						mg	5		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14234274	Homo sapiens						31							1	chronic cystitis					31			2	week		
5684	2533						g	17		multiple			day	1	unhealthy	intravenous|intramuscular			https://pubmed.ncbi.nlm.nih.gov/6619026	Homo sapiens													21												
5685	2534					Recommended	drop	2		multiple					unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208582Orig1s000lbl.pdf	Homo sapiens							max							pain	Recommended			fluorescein sodium							p.1
5686	2534					Recommended	drop	2		single					unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208582Orig1s000lbl.pdf	Homo sapiens							max							pain	Recommended			fluorescein sodium							p.1
5687	2535					Highest studied dose	mg/kg	40		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3897340	Homo sapiens													1									8	day		
5688	2536						mg	2500		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7586312	Homo sapiens						66				Initial rapid infusion: 350 mg over 10 min, loading infusion: 1.5 mg/min for 6 h, maintenance infusion 1.5 mg/min for the remainder of 48 h			103												
5689	2538					Highest studied dose	g	2		single			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8215267	Homo sapiens						59.9							30	Spontaneous bacterial peritonitis											
5690	2538						g	1		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6395280	Homo sapiens												88	57						19						
5691	2538						g	1		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6395280	Homo sapiens												88	57						19						
5692	2538						mg/kg	50		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2917594	Homo sapiens										was given intramuscularly in the dose of 50 mg-kg -1 body weight on the first day of therapy			17	respiratory infection | urinary tract infection											
5693	2539					Highest studied dose	g	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3435107	Homo sapiens						42						62	30						42						
5694	2539					Highest studied dose	mg	500		multiple			day	2	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/6655847	Homo sapiens													8									15	day		
5695	2540					Highest studied dose	g	2		multiple			day	6	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6703681	Homo sapiens						31.4							16	Staphylococcus aureus Endocarditis					31.4			4	day		
5696	2540						g	1		multiple			day	4	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/4680807	Homo sapiens						50							1						50			6	day		
5697	2543					Highest studied dose	mg	600		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/103083/	Homo sapiens						64							1	meningitis					64			6	day		
5698	2543						mg	150		multiple			day	4	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050261s101lbl.pdf	Homo sapiens																									
5699	2543						mg	150		multiple			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050261s101lbl.pdf	Homo sapiens																									
5700	2545					Highest studied dose	%	2		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/2190054	Homo sapiens												66	15	Frey's syndrome					27						
5701	2545					Highest studied dose	mg	2		single					unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/6696291	Homo sapiens						25						40	20	asymptomatic asthma					19			20	min		
5702	2545						mg	250		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1623915	Homo sapiens						30.8						42	6						26						
5703	2547		adult			Recommended	mg	8		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2376253/	Homo sapiens													10												
5704	2549					Overdose	mg	12		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14173188	Homo sapiens						40	max	300 mg, 42 days		A patient had been taking """"""""""""""""migril"""""""""""""""" tablets, which contain ergotamine tartrate 2 mg., cyclizine hydrochloride 50 mg., and caffeine 100mg., for four months. At first she had taken three to four tablets for an attack, but for the previous six weeks she had taken six tablets a day- that is, 12 mg. of ergotamine tartrate daily, amounting to a total of 504 mg. in six weeks.			1	Migraine	600 mg, 42 days			caffeine, p.o				42	day	cyclizine hydrochloride, p.o	p.552
5705	2549					Overdose	mg	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23243949	Homo sapiens						21							1		2000 mg, single			caffeine, p.o							
5706	2549					Recommended	mg	2		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1399547	Homo sapiens													41	Migraine											p.2
5707	2549					Recommended	mg	2		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1653139	Homo sapiens													289	Migraine	200 mg, single			caffeine, p.o							p.319
5708	2552					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13487546	Homo sapiens													33	Duodenal ulcer											p.18
5709	2554					MTD	mg	40		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/234981	Homo sapiens							max			The maximum tolerated dose varied from 20 to 40 mg/dose		53	7	Duodenal ulcer					27						p.537
5710	2555		adult			Recommended	%	2		multiple			day	1	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021946lbl.pdf	Homo sapiens										Each gram of cream contains: 20 mg Ketoconazole			545	seborhheic dermatitis								2	week		
5711	2555		adult			Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf	Homo sapiens																		dofetilide							
5712	2555		adult			Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf	Homo sapiens																									
5713	2555					Highest studied dose	mg	400		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3659003	Homo sapiens						64.8				400 mg every eight hours (3 dd) (n =17) or 600 mg every twelve hours (2 dd) (n =11)		80	28	relapsing prostatic cancer					52						
5714	2557					Highest studied dose	%	11.2		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/981	Homo sapiens													24	burns											p.1447
5715	2557					Recommended	%	5		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/981	Homo sapiens													24	burns											p.1447
5716	2558					Abused dose	mg	1000		multiple			week	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/23759255	Homo sapiens						23				His consumption increased from 300 mg per 2 weeks to approximately 1000 mg of intravenous mephentermine per week in 2012. Since August 2012 until mid-October 2012 (around 6 weeks), the patient was injecting around 150 mg of mephentermine every 2–3 days in order to avoid withdrawal features			1						23			6	month		
5717	2558						mg	30		multiple			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/32404042	Homo sapiens						32							1						32			3	week		
5718	2559					Overdose	g	3.1		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3177997/	Homo sapiens						20							1	suicide attempt					20						
5719	2559					Overdose	ug/mL	16		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3824877/	Homo sapiens						23							1	mentally retarded					23						
5720	2559					Recommended	mg	10		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/1140909/	Homo sapiens												62	7						48			3	week		
5721	2560					Highest studied dose	mg	50		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20683	Homo sapiens						46.6						65	34	detrusor hyperreflexia					25			14	day		
5722	2561					Highest studied dose	g	24		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/646562	Homo sapiens						28	max|total daily dose			12 g/day - 24 g/day			41	Staphylococcal infections								27	day		p.910
5723	2561					Recommended	mg/kg	106		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7172968	Homo sapiens						4				Recommended dose value is taken from here: """"""""""""""""http://antimicrobe.org/drugpopup/methicillin.htm""""""""""""""""			28	Infections								9	day		p.119
5724	2563		adult				mg	150		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01811355	Homo sapiens													23	Amyotrophic Lateral Sclerosis								14	day		
5725	2563					Highest studied dose	mg	500		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/2419687	Homo sapiens												78	9	Myocardial infarction					55						p.24, 25
5726	2563					MTD	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2451577	Homo sapiens						55.5							16	Ventricular arrhythmias								12	week		p.132
5727	2563					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens							max						39	Myotonic disorders								7	week		p.109
5728	2563					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens										mexiletine dosing 200 mg/day for 3 days, 400 mg/day for 3 days and 600 mg/day for an additional 12-16 days; and total treatment duration of 19 days (mean 19 days, median 19 days, range 10-21 days).			25	Myotonic disorders								14	day		p.105, 106, 112
5729	2563					Recommended	mg	200		multiple			day	3	unhealthy	oral			https://www.ema.europa.eu/en/documents/assessment-report/namuscla-epar-public-assessment-report_en.pdf	Homo sapiens													58	Myotonic disorders								4	week		p.109
5730	2564		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01337700	Homo sapiens							max						5	Autism Spectrum Disorder								12	week		
5731	2564		adult				mg	100		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01173055	Homo sapiens							max						20	Fibromyalgia								6	week		
5732	2564		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01077375	Homo sapiens							max			Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period.			85	Fibromyalgia								10	week		
5733	2564		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01225068	Homo sapiens							max			milnacipran 50 mg bid; can be increased to 100 mg bid			20	Chronic Neuropathic Low Back Pain								6	week		
5734	2564		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01510457	Homo sapiens										Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.			26	Osteoarthritis								6	week		
5735	2564		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01288937	Homo sapiens										Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):Day 1: 12.5 mg once Day 2, 3: 25 mg/day (12.5 mg twice daily) Day 4, 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)			4	Idiopathic Neuropathy Pain								11	week		
5736	2564		child				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01328002	Homo sapiens							max			Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.Oral administration, twice daily dosing			14	Fibromyalgia								16	week		
5737	2564					Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24188161	Homo sapiens						48.6				milnacipran dosing was escalated as follows: 12.5to 50 mg/day (25 mg BID) over 1 week; 100 mg/day(50 mg BID) for 3 weeks; 150 mg/day (75 mg BID) for1 week; 200 mg/day (100 mg BID) for 2 weeks			181	Fibromyalgia								2	week		p.593
5738	2564					Recommended	mg	100		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022256s011lbl.pdf	Homo sapiens														Fibromyalgia											p.1
5739	2564					Recommended	mg	100		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022256s011lbl.pdf	Homo sapiens														Fibromyalgia											p.11
5740	2564					Recommended	mg	100		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022256s011lbl.pdf	Homo sapiens														Fibromyalgia											p.5
5741	2565		adult			Recommended	mg	900		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2407091/	Homo sapiens							max			600 to 900 mg			1256	arrhythmias								3	month		
5742	2566		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01522950	Homo sapiens										5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.			20	Hypertension								8	month		
5743	2566		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01415531	Homo sapiens							max			Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration			427	Hypertension								8	week		
5744	2566		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00734630	Homo sapiens							max			Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily			258	Hypertension								12	week		
5745	2566					Overdose	mg	500		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	Homo sapiens													1		>100 mg			acetylsalicylic acid, oral							p.8
5746	2566					Recommended	mg	40		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	Homo sapiens										Doses ranged from 0.5 mg to 40 mg. Patients received BYSTOLIC for up to 24 months, with over 1900 patients treated for at least 6 months, and approximately 1300 patients for more than one year.			6545	Hypertension								24	month		p.4
5747	2566					Recommended	mg	5		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf	Homo sapiens														Hypertension	80 mg, qd			valsartan, oral							p.1
5748	2568					Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4184850	Homo sapiens										Daily dosage of oxyphenbutazone was 100-800 mg. with an average of 148 mg		72	66	gout					31			2	year		
5749	2568						mg	100		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13684302	Homo sapiens						64							1	rheumatoid arthritis					64			5	week		
5750	2568						mg	200		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7368966	Homo sapiens						48							1	progressive shoulder pain					48			8	day		
5751	2569						%	5		multiple			day	6	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/13196761 |https://pubmed.ncbi.nlm.nih.gov/13396161	Homo sapiens										Oxyphenonium drops (One drop of 5% oxyphenonium bromide) were used once to six times daily.			100									7	day		
5752	2569						mg	10		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6329769	Homo sapiens												29	8						15			4	week		
5753	2573					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3907678	Homo sapiens						52.8				phenylbutazone 800 mg daily for the first 2 days then 400 mg daily, in four equal divided doses for 10 days		89		acute gouty arthritis					24			2	day		
5754	2573					Overdose	g	8		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7427601	Homo sapiens						17				40 phenylbutazone tablets			1						17						
5755	2575					Overdose	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021078s016lbl.pdf	Homo sapiens							max			Adverse experiences occasionally associated with proguanil hydrochloride doses of 100 to 200 mg/day, such as epigastric discomfort and vomiting, would be likely to occur with overdose				P. falciparum malaria											
5756	2575					Overdose	mg	200		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021078s016lbl.pdf	Homo sapiens							max							P. falciparum malaria											
5757	2575					Recommended	mg	100		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10363739	Homo sapiens												65	175	malaria prophylaxis	250 mg oral; 1/day			atovaquone	16			10	week		p.745
5758	2575					Recommended	mg	100		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11130385	Homo sapiens										The average duration of travel was about 2.5 weeks			511	malaria prophylaxis	155 mg; oral; 2/week			chloroquine				2.5	week		p.1891
5759	2575					Recommended	mg	150		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15227617	Homo sapiens							max			dosing based on body weight			111	malaria prophylaxis	77.5-310 mg; oral; 1/week			chloroquine				43	day		p.1720
5760	2576					Higher than recommended	mg	120		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/20166438	Homo sapiens						22.7							10												p.199
5761	2576					Highest studied dose	mg	160		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/20166438	Homo sapiens						21.4							6												p.199
5762	2576					Highest studied dose	mg	80		multiple			day	1	healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/20166438	Homo sapiens						24.2							10									3	day		p.199
5763	2576					Overdose	mg	1150		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17516189	Homo sapiens						14							1	Depression	200 mg, single			cyproheptadine, p.o							p.242
5764	2576					Recommended	mg	50		single					unhealthy	intramuscular|intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/040454_s006_promethazine_hydrochloride_injection.pdf	Homo sapiens							max			Nighttime sedation may be achieved by a dose of 25 to 50 mg of promethazine hydrochloride injection.				Allergic Conditions|Nausea and Vomiting|Sedation											p.1
5765	2576					Recommended	mg	50		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/07935s030lbl.pdf	Homo sapiens							max			Sedation: 25 to 50 mg for nighttime, presurgical, or obstetrical sedation; Pre- and Postoperative Use: 50 mg				Perennial and seasonal allergic rhinitis|Vasomotor rhinitis|Allergic conjunctivitis|Allergic urticaria|Dermographism|Anaphylactic reactions|Motion sickness|Sedation											p.2, 3
5766	2579					Higher than recommended	mg/kg	1.5		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/10700783	Homo sapiens						31							22	General anesthesia											p.866
5767	2579					Recommended	mg/kg	1.1		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/008453s027lbl.pdf	Homo sapiens							max			An IV injection of 0.3 to 1.1 mg/kg may be given initially, followed, at appropriate intervals, by further injections of 0.04 to 0.07 mg/kg to maintain the degree of relaxation required.				General anesthesia|Skeletal muscle relaxation											p.1
5768	2580		adult			Highest studied dose	g	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14841400	Homo sapiens														eczema-dermatiti											
5769	2580						g	11		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20322240	Homo sapiens						72	total						1						72			56	hour		
5770	2580						g	30		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/21017364	Homo sapiens						52	total			Sulphapyridine therapy was restarted, 4.5 g. being given during the next five days.			1	pneumonia					52			7	day		
5771	2580						g	75		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30436280	Homo sapiens						32	total						1						32			1	month		
5772	2580						mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8759268	Homo sapiens						74.5						86	20	ocular inflammation					53			12.3	month		
5773	2581					Studied dose	g	2.4		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13661194	Homo sapiens						50				the patient took 2.4 gm. daily in error				leprosy					50						
5774	2581					Studied dose	g	2.4		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13661194	Homo sapiens						50				the patient took 2.4 gm. daily in error a				leprosy					50						
5775	2581						g	0.3		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12996073	Homo sapiens						52							1	leprosy					52			2	month		
5776	2581						g	1.2		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13661194	Homo sapiens						50								leprosy					50			1	week		
5777	2583					Accidental dose	mg	40		single					unhealthy	intrathecal	M		https://pubmed.ncbi.nlm.nih.gov/4406747	Homo sapiens						33							1						33						
5778	2583					Highest studied dose	mg/kg	6		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7371706	Homo sapiens													7												
5779	2583						mg	100		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13998750	Homo sapiens																									
5780	2584		adult			MTD	mg/m2	10		steady			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/1831340/	Homo sapiens													17	solid cancer								5	day		
5781	2584		adult			MTD	mg/m2	100		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													4	solid cancer								3	week		
5782	2584		adult			MTD	mg/m2	110		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													3	solid cancer								3	week		
5783	2584		adult			MTD	mg/m2	130		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													7	solid cancer								3	week		
5784	2584		adult			MTD	mg/m2	15		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/1831340/	Homo sapiens													18	solid cancer											
5785	2584		adult			MTD	mg/m2	155		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens							max			50 to 155 mg/m2			29	solid cancer								3	week		
5786	2584		adult			MTD	mg/m2	155		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													2	solid cancer								3	week		
5787	2584		adult			MTD	mg/m2	50		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													7	solid cancer								3	week		
5788	2584		adult			MTD	mg/m2	75		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													8	solid cancer								3	week		
5789	2584		adult			MTD	mg/m2	90		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens													6	solid cancer								3	week		
5790	2584					MTD	mg/m2	100		multiple			week	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens						49							1	pulmonary and pleural metastasis from cutaneous angiosarcoma					49			2	week		
5791	2584					MTD	mg/m2	75		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2953412/	Homo sapiens						63							1	adenocarcinoma of the lung					63						
5792	2586		adult			Recommended	mg	30		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4913869/	Homo sapiens													32	anxiety								4	week		
5793	2586		adult			Recommended	mg	30		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4913869/	Homo sapiens													40	anxiety								2	week		
5794	2586					Recommended	mg	15		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4262210/	Homo sapiens						36							16	low back syndrome								4	day		
5795	2587					Highest studied dose	ug	20		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/6714795	Homo sapiens												32	16	Pain					20						p.517
5796	2587					Studied dose	ng/kg/h	100		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/3065099	Homo sapiens										intravenous infusion of synthetic cerulein plus secretin was given for 90 min		55	6	Chronic pancreatitis	1 CU/kg/h			secretin iv	24						p.226
5797	2587					Studied dose	ug/kg	0.6		multiple			day	2	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/3907376	Homo sapiens						16				Each patient received a total of 17 injections of ceruletide: one injection a day for 3 days followed by two injections a day for 7			16	Schizophrenia								7	day		p.1483
5798	2587					Studied dose	ug/kg	0.6		multiple			day	2	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/3907376	Homo sapiens										Each patient received a total of 17 injections of ceruletide: one injection a day for 3 days followed by two injections a day for 7			16	Schizophrenia								7	day		p.1483
5799	2590					Highest studied dose	mg	400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3296725	Homo sapiens						67				Drug administration over 3 days, during which, on the first day, an initial dose of 60 to 100 mg of indecainide was administered intravenously at an infusion rate of 12.5 to 15 pg/kg/min. Up to a maximal total daily dose of 400 mg			10						67			3	day		
5800	2590					Studied dose	mg	100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2225716	Homo sapiens										Patients received indecainide, 50 mg by mouth, every 6 hours and the dose was increased until - 80% suppression was noted, adverse effects occurred, or a maximum dose of 100 mg indecainide was given every 6 hours			11									4	day		
5801	2591					Recommended	g	4		multiple			day	4	unhealthy	oral			https://academic.oup.com/ajhp/article-abstract/17/4/255/5237544?redirectedFrom=PDFhttps://academic.oup.com/ajhp/article-abstract/17/4/255/5237544?redirectedFrom=PDF	Homo sapiens							max							Bronchial asthma											p.258
5802	2591					Recommended	mg	0.5		single					unhealthy	intramuscular|subcutaneous			https://academic.oup.com/ajhp/article-abstract/17/4/255/5237544?redirectedFrom=PDFhttps://academic.oup.com/ajhp/article-abstract/17/4/255/5237544?redirectedFrom=PDF	Homo sapiens							max							Acute bronchial asthma											p.258
5803	2592					Highest studied dose	mg/kg	9.3		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/32359890	Homo sapiens										the one patient required sedation with 9.3 mg/kg of thiamylal. He needed 5.2 mg/kg of thiamylal for induction and was administered an additional 4.1 mg/kg for awakening.															
5804	2592						mg/kg	10		single					healthy	rectal			https://pubmed.ncbi.nlm.nih.gov/16368209	Homo sapiens						3				When sedation was not sufficient, the same dose of thiamylal was administered rectally again more than 30 min after the first dose. We usually limited the use of thiamylal up to 2 doses. Only if the patient defecated immediately after a rectal administration, we allowed the third rectal dose.					80–100 mg/kg, orally			triclofos	3						
5805	2592						mg/kg	25		single					healthy	rectal			https://pubmed.ncbi.nlm.nih.gov/7900578	Homo sapiens							starting			Initial dosage was 25 mg/kg into the distal rectum. A second dose of 15 mg/kg was given if the child was awake 20 minutes later. No absolute total dose limit was used, although a total dose of greater than 40 mg/kg was not given.			462												
5806	2593		adult			Studied dose	mg/kg	0.115		single			day	1	pregnant	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13059864/	Homo sapiens							mean			from 0.03 to 0.2 mg per kilogram of body weight			56									1	day		
5807	2593					Studied dose	mg/min	9		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/938175/	Homo sapiens							mean					66	4	hypertension					23						
5808	2594		adult			Recommended	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	Homo sapiens														advanced renal cell carcinoma											
5809	2594		adult				mg	800		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00866697	Homo sapiens													477	Ovarian Cancer								24	month		
5810	2594					Highest studied dose	mg	2000		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	Homo sapiens													3									3	week		p. 83
5811	2594					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831954	Homo sapiens						61							8	Hepatocellular Carcinoma					61			28	day		
5812	2594					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	Homo sapiens						59							290	renal cell carcinoma					59			7.4	month		p. 61
5813	2594					Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		PAZOPANIB	Homo sapiens						59							290	renal cell carcinoma					59			7.4	month		p. 61
5814	2594						mg	1000		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	Homo sapiens													3									3	week		p. 83
5815	2594						mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831954	Homo sapiens						61							5	Hepatocellular Carcinoma					61			28	day		
5816	2596					Overdose	mg	100		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/020237s012lbl.pdf	Homo sapiens													2												
5817	2596					Overdose	mg	20		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15093850	Homo sapiens						46				four pilocarpine tablets (5 mg). The patient mistakenly interpreted these verbal instructions as meaning four pills in the morning instead of one pill every 6 h.			1	xerostomia					46						
5818	2596					Recommended	%	1.54		multiple			day	3	unhealthy	topical			https://pubmed.ncbi.nlm.nih.gov/32248594/	Homo sapiens										to apply one spray on each side of the buccal mucosa and one spray on the floor of the mouth every 8 hr. This therapy scheme (pilocarpine 1.54% every 8 hr) corresponded to 5 mg of pilocarpine/ day			20	xerostomia											
5819	2596					Recommended	%	2		multiple			day	4	unhealthy	ophthalmic	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200890s000MedR.pdf	Homo sapiens										one drop in the eye(s) up to four times daily		75	2						44						p. 36
5820	2597		adult				mg	0.5		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15792397	Homo sapiens													6									15	min		
5821	2597					Highest studied dose	mg	0.4		single					healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/25187210/	Homo sapiens										scopolamine hydrobromide		47	12						21						
5822	2597					Highest studied dose	mg	0.9		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6873137	Homo sapiens						21.4							35						21.4			3	day		
5823	2597					Highest studied dose	mg	1.2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3088662	Homo sapiens						24						38	12						19						
5824	2597					Overdose	mg	10		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25395072	Homo sapiens						83							1						83						
5825	2597						ug/kg	6		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6873137	Homo sapiens						22.8				scopolamine hydrobromide 7.4 ug/kg			9						22.8						
5826	2598					MTD	mg	50		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6124217	Homo sapiens												71	9	duodenal ulcer (patients after proximal gastric vagotomy)					31						
5827	2598					Overdose	mg	50		multiple			day	4	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5513ddc8-90c8-4548-8188-5a807465cdc4&type=display	Homo sapiens										more than 10 to 50 mg four times a day				urinary retention											
5828	2598					Recommended	mg	20		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21546875	Homo sapiens													31	bladder dysfunction after type III radical hysterectomy								4	day		
5829	2598					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16927740	Homo sapiens							max						18	xerostomia								2	week		
5830	2599		adult				mg	3.25		steady			day	1	unhealthy	vaginal	F		https://clinicaltrials.gov/ct2/show/NCT01256684	Homo sapiens													86	Vaginal Atrophy								12	week		
5831	2599		adult				mg	3.25		steady			day	1	unhealthy	vaginal	F		https://clinicaltrials.gov/ct2/show/NCT01358760	Homo sapiens													143	Vaginal Atrophy								12	week		
5832	2599					Highest studied dose	mg	1600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2961787	Homo sapiens												25	5						22			28	day		
5833	2599						mg	400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16784956	Homo sapiens						44.9							29	HIV infection					44.9			8	week		
5834	2601					MTD	mg	700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16943527/	Homo sapiens												78	7	advanced cancer					24			2	cycle		
5835	2601					MTD	mg	750		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20707806/	Homo sapiens										28-day cycle		71	4	advanced solid tumors					27			2	cycle		
5836	2601					RP2D	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20707806/	Homo sapiens										28-day cycle		71	6	advanced solid tumors					27			2	cycle		
5837	2601					RP2D	mg	525		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16943527/	Homo sapiens												78	15	advanced cancer					24			2	cycle		
5838	2601					Studied dose	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16943527/	Homo sapiens							median					78	47	advanced cancer					24			2	cycle		
5839	2601					Studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24180331/	Homo sapiens										28-day cycles, 1,125-mg loading dose on day 1 of cycle 1 only		81	14	multiple myeloma					59			8	cycle		
5840	2601					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20124186/	Homo sapiens										6-week cycle, 1,125-mg loading dose on day 1			167	recurrent intracranial glioblastoma								1	cycle		
5841	2602		ADULT			Studied dose	drop	1		single					healthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/17324205/	Homo sapiens						37.1				1% eye drops; a single drop of rose bengal was instilled in one eye		77	61						19						p.164
5842	2603					Recommended	g	3		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15774254/	Homo sapiens						49							51	Peyronie’s disease								12	month		
5843	2603					Studied dose	g	2		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18624965/	Homo sapiens						70							1	Peyronie’s disease				tamsulosin	70			1	month	finasteride	
5844	2603					Studied dose	g	9		multiple					unhealthy	oral	M		https://hellenicurology.com/wp-content/uploads/2019/09/hellenic_urology_vol-31_issue-02_LR_compressed.pdf#page=52	Homo sapiens						45				9 g per day			1	Peyronie’s disease					45			6	week		
5845	2603					Studied dose	mg	150		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/8931866/	Homo sapiens						56.6	mean			100-200 mg daily for 7 to 26 days			12	pemphigus vulgaris	36.1 mg; daily			prednisolone	56.6			26	day		
5846	2604		adult			Highest studied dose	g/m2	80		multiple			4 weeks	1	healthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206333Orig1s000MedR.pdf	Homo sapiens													63									24	week		
5847	2604					Studied dose	g/m2	15		multiple			4 weeks	1	healthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/24147933/	Homo sapiens						46.3	mean						240									12	week		
5848	2606		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19335742/	Homo sapiens						29							55	pulmonary hypertension											p.17
5849	2608		ADULT			Studied dose	g	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18299710/	Homo sapiens						48.6				Ecabet sodium			263	gastritis								2	week		
5850	2609		ADULT			Overdose	mg	560		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21251326/	Homo sapiens						49							1												
5851	2609		ADULT			Recommended	mg	10		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/28485829/	Homo sapiens						80							1	hypertension	3 mg		folic acid	torasemide			5 mg	1	year	bromazepam	
5852	2609		ADULT			Studied dose	mg	10		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17581601/	Homo sapiens						65.8						85	62	hypertension	20 mg			enalapril	60			4	week		
5853	2609		ADULT			Studied dose	mg	10		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17581601/	Homo sapiens						65.8						85	62	hypertension					60			4	week		
5854	2610					Highest studied dose	mg/kg	72		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17026773	Homo sapiens							total			Group A = 4x daily CQ-MB, Group B = 2x daily CQ-MB		4.9	123	Malaria	10 mg/kg on days 0 and 1, and 5 mg/kg on day 2			chloroquine, p.o	0.5						p.3
5855	2610					Overdose	g	1		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/973698	Homo sapiens						3							1												
5856	2612					Highest studied dose	mg	75		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30711416	Homo sapiens													12	Chronic hepatitis C								28	day		Supplemental Table 3 p.9
5857	2612					Recommended	mg	25		multiple			day	3	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d50b5154-20a3-4c5b-ad7b-08c081340b12&type=display	Homo sapiens										1 tablet by mouth every 6-8 hours, not to exceed 3 tablets in 24 hours				Respiratory allergies											
5858	2614					Recommended	ug	500		single					unhealthy	intramuscular			https://www.medicines.org.uk/emc/product/6265/smpc#CLINICAL_PRECAUTIONS	Homo sapiens							max							Postpartum Haemorrhage											
5859	2615						mg	8.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20158595	Homo sapiens										dose range: 8.5 - 12.5 mg			1												
5860	2615						mg/kg	1.5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7654478	Homo sapiens						24				Cosylan 0.88 ml kg-1 body weight was administered as a single oral dose. Cosylan contains ethylmorphine hydrochloride 1.7 mg			10						24						
5861	2618						g	2		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4952370	Homo sapiens										2 g. of the drug daily in four divided oral doses												2	day		
5862	2625					Overdose	mg	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22633759/	Homo sapiens						22							1												
5863	2625					Overdose	ug	108.75		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18072161/	Homo sapiens						31							1												
5864	2625					Recommended	ug	40		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32908823/	Homo sapiens						22							1									1	week		
5865	2626		ADULT			Highest studied dose	g	1		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8739093/	Homo sapiens						27						31	12						21						p.189
5866	2626		ADULT			Studied dose	g	5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17953792/	Homo sapiens						26.4	total daily dose			Loading dose of 600 mg i.v., followed by 10 mg h21 basal infusion, 130 mg bolus dose, lockout time 45 min (total maximum dose of dipyrone: 5 g 24 h21).			35	pain disorder											p.180
5867	2627		ADULT			Recommended	mg	20		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10235199/	Homo sapiens						39						69	48	gastroparesis					19						p.1233
5868	2627		ADULT			Recommended	mg	20		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6357963/	Homo sapiens						31						61	31	irritable bowel syndrome					19						p.1137
5869	2630		ADULT			Higher than recommended	mg	400		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/7039289/	Homo sapiens						74	total daily dose			Intravenous aprindine was given in an initial dose of 300 mg. Three\nhours later a second dose of 100 mg was given.			1	atrial fibrillation											p.1299
5870	2630		ADULT			Recommended	mg	200		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7039289/	Homo sapiens						53							1	myocardial infarction								3	day		p.1298
5871	2630		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12074271/	Homo sapiens						60							47	atrial fibrillation								6	month		p.555
5872	2632		ADULT			Highest studied dose	mg	1200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8390369/	Homo sapiens												32	8						22			1	day		341-8
5873	2632		ADULT			Recommended	mg	200		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8098286/	Homo sapiens						60							1	hypertension	20 mg/day			LISINOPRIL				20	month		588-91
5874	2634		ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3893736/	Homo sapiens													120	migraine								24	month		p.157
5875	2634		ADULT			Recommended	mg	5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27306581/	Homo sapiens						35.2							29	migraine								8	week		p.6
5876	2634		ADULT			Studied dose	mg	20		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3180201/	Homo sapiens						41							36	migraine											p.39
5877	2634		CHILD|ADOLESCENT|ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3052850/	Homo sapiens												95	1435	migraine					6			6	month		p.18,19
5878	2635		ADULT			Studied dose	mg	600		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17351806/	Homo sapiens						61							34	pancreatitis											p.164
5879	2636		ADULT			Highest studied dose	mg	192		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/780059/	Homo sapiens						47	mean|max|total daily dose			The average daily doses of indoramin for Weeks 1 to 4 were 100 mg, 125 mg,\n148 mg (range 125 to 150) and 192 mg (range 125 to 200) per day respectively.			19	hypertension								8	week		p.182
5880	2636		ADULT			Studied dose	mg	122		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2423807/	Homo sapiens						62	mean|total daily dose					64	42	hypertension					60						S91, S92
5881	2638		ADULT			Overdose	g	3.36		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/2408087/	Homo sapiens						20							1												p.24
5882	2638		ADULT			Overdose	g	3.78		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/2408087/	Homo sapiens						20							1												p.24
5883	2638		ADULT			Overdose	g	4.9		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/2408087/	Homo sapiens						66							1												p.24
5884	2638		ADULT			Recommended	mg	210		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/395129/	Homo sapiens						44	total daily dose					58	11	major depressive disorder					25			4	week		p.302
5885	2638		ADULT			Recommended	mg	70		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/320827/	Homo sapiens						41	max						31	major depressive disorder								5	week		p.17
5886	2639		ADULT			Overdose	mg	300		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20203131/	Homo sapiens						37							1												p.888
5887	2639		ADULT			Overdose	mg	580		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/589080/	Homo sapiens						39							1		30 mg			diazepam						nitrazepam	
5888	2639		ADULT			Overdose	mg	900		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3679249/	Homo sapiens						62							1												p.401
5889	2639		ADULT			Recommended	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1806624/	Homo sapiens						49.4	max						159	major depressive disorder								28	day		p.189
5890	2640		ADULT			Higher than recommended	mg	45		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16263322/	Homo sapiens							total daily dose					78	5	Parkinson's disease					69						p.500
5891	2640		ADULT			Recommended	mg	5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15719424/	Homo sapiens						67						77	14	constipation					55						p.682
5892	2640		ADULT			Recommended	mg	5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22004457/	Homo sapiens						46							274	digestive system disorder											p.65
5893	2641		ADULT			Studied dose	mg	20		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33495919/	Homo sapiens						72				intravenous drip infusion over 6 h		96	292	pancreatitis					28						p.5
5894	2641		ADULT			Studied dose	mg	50		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21775918/	Homo sapiens						63.3				Infusion began within 1 hour before\nERCP and was continued for 24 hours.			197	pancreatitis											p.1216
5895	2641		ADULT			Studied dose	ug/kg/day	1200		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1554918/	Homo sapiens													6	Hemorrhagic disease											p.59
5896	2644		ADULT			Recommended	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3302005/	Homo sapiens						46.15							39	duodenal ulcer								1	year		p.315
5897	2644		CHILD			Recommended	%	2		multiple			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/15629825/	Homo sapiens						8.7							282	myopia								12	month		p.87
5898	2646		ADULT			Studied dose	mg	0.05		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2862893/	Homo sapiens												61	24	asthma					18			1	day		
5899	2646		ADULT			Studied dose	mg	0.1		multiple			day	2	unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/2861219/	Homo sapiens						36						55	15	asthma					18			2	week		
5900	2651		ADULT			Highest studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1876437/	Homo sapiens						41							38	migraine disorder								3	month		283-291
5901	2651		ADULT			Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1876437/	Homo sapiens						42							50	migraine disorder								3	month		283-291
5902	2651		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2885485/	Homo sapiens						42							1	ileum cancer								2	day		1494
5903	2652		ADULT			Highest studied dose	mg	12		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8298071/	Homo sapiens						42						52	12						27						p.783
5904	2652		ADULT			Highest studied dose	mg	2		multiple			day	2	unhealthy	oral	F		https://www.ncbi.nlm.nih.gov/pubmed/8595171	Homo sapiens						62.8						79.4	28	breast cancer					36.8						p.541
5905	2652		ADULT			Studied dose	mg	1		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8839901/	Homo sapiens						65						87	105	breast cancer					39						p.476
5906	2653					Recommended	mg	0.54		steady			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens						34	max			2.16 mg per day. The following equivalencies should be useful for reference: 2.4 mg/day regimen of Lofexidine HCl (development program) = 2.16 mg/day regimen of Lofexidine (labeling)		74	229	facilitation of abruption opioid discontinuation					19			14	day		
5907	2653					Recommended	mg	0.54		steady			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens						34	max			starting dose 0.18 mg; total daily dose 2.16 mg per day. The following equivalencies should be useful for reference: 2.4 mg/day regimen of Lofexidine HCl (development program) = 2.16 mg/day regimen of Lofexidine (labeling)		74	229	facilitation of abruption opioid discontinuation					19			14	day		
5908	2653					Recommended	mg	0.54		steady			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens						34	starting			starting dose 0.18 mg; total daily dose 2.16 mg per day. The following equivalencies should be useful for reference: 2.4 mg/day regimen of Lofexidine HCl (development program) = 2.16 mg/day regimen of Lofexidine (labeling)		74	229	facilitation of abruption opioid discontinuation					19			14	day		
5909	2653					Recommended	mg	0.54		steady			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209229s000lbl.pdf	Homo sapiens							max			starting dose 0.18 mg; total daily dose 2.16 mg			229	facilitation of abruption opioid discontinuation								14	day		
5910	2653					Studied dose	mg	0.72		steady			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens						34	max			2.88 mg per day. The following equivalencies should be useful for reference: 3.2 mg/day regimen of Lofexidine HCl (development program) = 2.88 mg/day regimen of Lofexidine (labeling)		74	390	facilitation of abruption opioid discontinuation					19			14	day		
5911	2653					Studied dose	mg	0.72		steady			day	4	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209229Orig1s000MultidisciplineR.pdf	Homo sapiens						34	starting			starting dose 0.18 mg; total daily dose 2.88 mg per day. The following equivalencies should be useful for reference: 3.2 mg/day regimen of Lofexidine HCl (development program) = 2.88 mg/day regimen of Lofexidine (labeling)		74	390	facilitation of abruption opioid discontinuation					19			14	day		
5912	2653					Studied dose	mg	0.72		steady			day	4	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209229s000lbl.pdf	Homo sapiens							max			starting dose 0.18 mg; total daily dose 2.88 mg			222	facilitation of abruption opioid discontinuation								14	day		
5913	2656					Recommended	mg	60		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15259090/	Homo sapiens						34							1	esophagitis and pangastritis	300 mg; 3 times per day			simeticone	34			29	day		
5914	2656					Recommended	mg	60		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20003095/	Homo sapiens						46.5							207	irritable bowel syndrome	300 mg; 3 times per day, during 4 weeks			simeticone				4	week		
5915	2657					Studied dose	g	5		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1163482/	Homo sapiens						19							1	drug withdrawal					19			1	day		
5916	2657					Studied dose	mg	250		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6730996/	Homo sapiens						44				Day 1: 2 tablets 1-3 times daily, Day 2-6: 1 tablet 1-3 times daily. The maximum daily dose allowed was 8 tablets. The maximum duration of treatment was 6 days.			35	alcohol withdrawal symptoms								6	day		
5917	2658		ADULT			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1266576/	Homo sapiens						66.7	max|total daily dose			daily maximum dosage of 800 mg levodopa   200 mg benserazide		79	46	Parkinson disease					51			24	week		p.379
5918	2658		ADULT			Highest studied dose	mg	200		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9241095/	Homo sapiens												54	8		250 mg levodopa			levodopa	30						p.43
5919	2659		adult			Studied dose	mg	500		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/13126825/	Homo sapiens													18	hypertension								20	month		
5920	2662					Highest studied dose|MTD	mg	3.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16815702/	Homo sapiens						58							3	solid tumours								2	week		
5921	2662					Studied dose	mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16815702/	Homo sapiens						58							6	solid tumours								8	week		
5922	2665		ADULT			Studied dose	mg	40		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9114916/	Homo sapiens						66							8	hypertension											p.272
5923	2666		ADULT			Highest studied dose	mg	200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3028816/	Homo sapiens												30	3						25			1	day		419-22
5924	2672		ADULT			Highest studied dose	mg	100		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9400452/	Homo sapiens						58						69	22	erectile dysfunction					28			1	day		122-4
5925	2672		ADULT			Overdose	mg	350		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11744068/	Homo sapiens						38							1	diabetes mellitus								1	day		215-43
5926	2675					Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16618013	Homo sapiens												70	24	Parkinson disease					47			19	day		
5927	2675						mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9925236	Homo sapiens						64				starting with a dose of 10 mg/day of a-dihydroergocryptine was gradually increased after 4,8,18,22,26 days of treatment up to 60 mg/ day			32	idiopathic Parkinson’s disease								3	month		
5928	2677					Highest studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7589764/	Homo sapiens												80	20	chronic cerebro-vascular disease					55			45	day		
5929	2684		adult				mg	60		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01421134	Homo sapiens							max			20, 40, 60 mg, flexible dose, once daily PM 6 weeks			109	Major Depressive Disorder								8	week		
5930	2684		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01435928	Homo sapiens							max			Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating			144	Schizophrenia								28	week		
5931	2684		child				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01911429	Homo sapiens													110	Schizophrenia								6	week		
5932	2684		child				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01911429	Homo sapiens										Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6			104	Schizophrenia								6	week		
5933	2684		child				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02046369	Homo sapiens							max			Lurasidone flexibly dosed 20-80 mg once daily			175	Bipolar I Depression								6	week		
5934	2684					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://www.researchgate.net/publication/247194772_ASSESSMENT_OF_THE_MAXIMUM_TOLERATED_DOSE_MTD_OF_LURASIDONE_IN_PATIENTS_WITH_SCHIZOPHRENIA	Homo sapiens						42								Schizophrenia								2	day		p.382
5935	2684					MTD	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.researchgate.net/publication/247194772_ASSESSMENT_OF_THE_MAXIMUM_TOLERATED_DOSE_MTD_OF_LURASIDONE_IN_PATIENTS_WITH_SCHIZOPHRENIA	Homo sapiens						42								Schizophrenia								7	day		p.382
5936	2684					Overdose	mg	560		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf	Homo sapiens														Schizophrenia											p.37
5937	2684					Recommended	mg	120		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf	Homo sapiens														Schizophrenia											p.30
5938	2684					Recommended	mg	160		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf	Homo sapiens							max							Schizophrenia											p.1
5939	2702		ADULT			Studied dose	mg/kg	12		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4901414/	Homo sapiens													35	helminth infection											p.916, 917, 918
5940	2703						g	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13186082	Homo sapiens												64	3						21			7	day		
5941	2703						g	2		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13186082	Homo sapiens						29							1						29			6	day		
5942	2704					Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13595202/	Homo sapiens													73	Helminthiasis								3	day		
5943	2704					Studied dose	mg	200		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13722979	Homo sapiens													35	Helminthiasis								4	day		
5944	2710		ADULT			Studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/559569/	Homo sapiens						39						50	10	schizophrenia					19			28	day		p.533
5945	2710		ADULT			Studied dose	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/561037/	Homo sapiens						32.9	max|total daily dose						20	schizophrenia								30	day		p.115
5946	2715		ADULT			Recommended	%	0.375		multiple			day	2	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/4241818/	Homo sapiens						32							1	vulvovaginitis	0.25%			furazolidone				4	week		557-8
5947	2718		ADULT			Highest studied dose	mg/kg	60		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30745383/	Homo sapiens						25.3							56												p.8
5948	2718		ADULT			Studied dose	mg/kg	15		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32816721/	Homo sapiens						30.1							8									5	day		p.7
5949	2725		ADULT			Studied dose	ug/mL	0.5		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/31226893/	Homo sapiens						43				tiamulin in serum samples			1									1	day		287-289
5950	2732		ADULT			Highest studied dose	g	2		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6995193/	Homo sapiens													77	trichomoniasis								1	day		325-8
5951	2757		ADULT			Highest studied dose	g	27		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19522983	Homo sapiens						55.9							20									90	day		p.503
5952	2768		ADULT			Abused dose	mg	1000		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/24769343/	Homo sapiens						34	total						1												p.16
5953	2768		ADULT			Abused dose	mg	2400		single					healthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/24769343/	Homo sapiens						37							1												p.16
5954	2768		ADULT			Abused dose	mg	400		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24769343/	Homo sapiens						20							1												p.16
5955	2768		ADULT			Overdose	mg	1500		single					healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/24769343/	Homo sapiens						27							1												p.17
5956	2770					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24247616/	Homo sapiens						61							2572	Acute Coronary Syndrome								16	week		
5957	2772					MTD	mg/m2	26		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8005825/	Homo sapiens													7	malignant glioma, implant group				radiotherapy				2	week		
5958	2772					MTD	mg/m2	32		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8005825/	Homo sapiens													38	malignant glioma, nonimplant patients				radiotherapy				2	week		
5959	2772					MTD	mg/m2	42		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12654425/	Homo sapiens							median						18	diffuse brainstem glioma				HRT				6	week		
5960	2772					Studied dose	mg/m2	19.5		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8005825/	Homo sapiens													14	malignant glioma, implant group				radiotherapy				2	week		
5961	2772					Studied dose	mg/m2	36		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12654425/	Homo sapiens							median						18	diffuse brainstem glioma				HRT				6	week		
5962	2773					MTD	mg/m2	150		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12671715/	Homo sapiens										every 3 weeks		71	6	Tumour					33			3	cycle		
5963	2773					RP2D	mg/m2	120		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12671715/	Homo sapiens										every 3 weeks		71	14	Tumour					33			3	cycle		
5964	2773					Studied dose	mg/m2	130		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12671715/	Homo sapiens										every 3 weeks		71	5	Tumour					33			3	cycle		
5965	2773					Studied dose	mg/m2	150		multiple			month	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12460786/	Homo sapiens							max			120 to 150 mg/m2 every 3 weeks, 1 - 8 cycles		75	94	ovarian cancer					27			4	cycle		
5966	2773					Studied dose	mg/m2	150		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12647701/	Homo sapiens							max			120 to 150 mg/m2 every 3 weeks, 1 - 8 cycles		75	47	mesothelioma					37			3	cycle		
5967	2773					Studied dose	mg/m2	150		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19289620/	Homo sapiens										every 3 weeks		79	77	small-cell lung cancer					34			2	cycle		
5968	2775					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11945098/	Homo sapiens						38.2							64	epilepsy								8	week		
5969	2775					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11162750/	Homo sapiens						32.9							27	epilepsy								4	week		
5970	2775					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11162751/	Homo sapiens						36.3							13	epilepsy								1	month		
5971	2775					Studied dose	mg	500		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10471426/	Homo sapiens						70.4							6	ischemic stroke								3	day		
5972	2775					Studied dose	mg	600		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10471426/	Homo sapiens						67.2							7	ischemic stroke								3	day		
5973	2776					Studied dose	mg	400		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/results/NCT02454283	Homo sapiens						68.1	unknown						26	atrial fibrillation											
5974	2779		ADULT			Highest studied dose	mg	8		single					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/11745909	Homo sapiens						30.7							12	asthma											p.78
5975	2780					Studied dose	mg	4		multiple			week	6	unhealthy	intravesical	M+F		https://pubmed.ncbi.nlm.nih.gov/22335860	Homo sapiens						67.5	unknown					85	53	bladder cancer					37			4	day		
5976	2782		ADULT			Highest studied dose	mg/m2	330		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.4087	Homo sapiens													2	hepatocellular carcinoma											
5977	2782		ADULT			Highest studied dose	mg/m2	330		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15831236	Homo sapiens						62							18	malignant glioma								2	cycle		p.185
5978	2782		ADULT			MTD	mg/m2	300		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.4087	Homo sapiens										weekly 3-hour infusion; the MTD of T138067 administered as a weekly 3-hour infusion in HCC subjects is within the window of 220–300 mg/m2			7	hepatocellular carcinoma											
5979	2787		ADULT			Highest studied dose	mg/m2	400		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10037175	Homo sapiens						49				175 mg/m2 as a 3-h infusion			3	breast cancer	175 mg/m2 as a 3-h infusion			Paclitaxel				4	cycle		p.277
5980	2787		ADULT			MTD	mg/m2	350		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10037175	Homo sapiens						49				i.v. infusion over 1 h			5	breast cancer	175 mg/m2 as a 3-h infusion			Paclitaxel				4	cycle		p.277
5981	2787		ADULT			Studied dose	mg/m2	270		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12094542	Homo sapiens						55				intravenous infusion over 20 min			3	cancer											p.476
5982	2787					MTD	mg/m2	3750		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9816135	Homo sapiens						58				2-h infusion			3	cancer	10 mg/m2, every 6 h for 10 doses			leucovorin				3	week		p.1822
5983	2791		ADULT			Highest studied dose	mg	2.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859672/	Homo sapiens						44.8							12	multiple sclerosis								4	week		p.5
5984	2791		ADULT			Studied dose	mg	0.6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28243182/	Homo sapiens						38.1							983	multiple sclerosis											p.18, Sup. p.2
5985	2794		ADULT			Studied dose	mg	500		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18258749/	Homo sapiens						37.2							12												p.568
5986	2796					Highest studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10942739/	Homo sapiens												72	34	coronary or cerebral atherosclerotic disease	300 mg			aspirin	53			12	week		
5987	2801		ADULT			Studied dose	mg	320		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21071997	Homo sapiens						29.2	unknown						6												297-305
5988	2804						mg	5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9571226/	Homo sapiens													6												
5989	2806					Highest studied dose	mg/m2	2750		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2380015/	Homo sapiens						55				5-day i.v. bolus schedule, every 21 days		78	4	cancer				Allopurinol	24			4	cycle		
5990	2807		ADULT			Highest studied dose	mg/m2	450		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815534	Homo sapiens						51							3	cancer											p.32-34
5991	2807		ADULT			MTD	mg/m2	390		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815534	Homo sapiens						51							4	cancer											p.32-34
5992	2812					Highest studied dose	mg	50		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17339234	Homo sapiens							unknown					44	8						23			28	day		
5993	2813		adult			Highest studied dose	ug/kg/day	270		single			day	1	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211371Orig1s000OtherR.pdf	Homo sapiens													32									1	day		
5994	2813					Recommended	ug/kg/day	60		multiple			60 hours	3	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf	Homo sapiens										A titration to a target dosage of 60 mcg/kg/hour (patients received 30 mcg/kg/hour for 4 hours, 60 mcg/kg/hour for 52 hours, then 30 mcg/kg/hour for 4 hours)		45	38	postpartum depression					18			4	week		
5995	2813					Recommended	ug/kg/day	60		multiple			60 hours	3	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/30177236/	Homo sapiens										A titration to a target dosage of 60 mcg/kg/hour (patients received 30 mcg/kg/hour for 4 hours, 60 mcg/kg/hour for 52 hours, then 30 mcg/kg/hour for 4 hours)		45	38	postpartum depression					18			4	week		
5996	2813					Recommended	ug/kg/day	75		multiple			60 hours		unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf	Homo sapiens							mean					45	140	postpartum depression					18			4	week		
5997	2813					Recommended	ug/kg/day	90		multiple			60 hours	5	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28619476/	Homo sapiens										30 µg/kg per h (0–4 h); 60 µg/kg per h (4–24 h); 90 µg/kg per h (24–52 h); 60 µg/kg per h (52–56 h); 30 µg/kg per h (56–60 h)		40	10	postpartum depression					20			30	day		
5998	2813					Recommended	ug/kg/day	90		multiple			60 hours	5	unhealthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf	Homo sapiens										A titration to the recommended target dosage of 90 mcg/kg/hour was evaluated in both studies (patients received 30 mcg/kg/hour for 4 hours, 60 mcg/kg/hour for 20 hours, 90 mcg/kg/hour for 28 hours, followed by a taper to 60 mcg/kg/hour for 4 hours and then 30 mcg/kg/hour for 4 hours)		45	102	postpartum depression					18			4	week		
5999	2815		CHILD			Highest studied dose	mg/kg	36		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11074186	Homo sapiens							total daily dose			Dosing began at 4.5 mg/kg/d and was increased to 9 mg/kg/d after 3 days. At week 2, the dose was increased to 18 mg/kg/d and progressed through weekly increases of 9 mg/kg/d to a maximum allowable dose of 36 mg/kg/d			20	spasms syndrom								2	week		
6000	2815					Studied dose	mg	1500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28230252	Homo sapiens						39.1	unknown						98	seizures								8	week		
6001	2818					Highest studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15240529	Homo sapiens						55	unknown					83	9	Refractory Malignancies					26			12	month		
6002	2818					MTD	mg	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18477765	Homo sapiens						52	unknown					70	11	malignant glioma					25			12	month		
6003	2818					Studied dose	mg	0.75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24722445	Homo sapiens						65	unknown						78	diabetic neuropathy								12	week		
6004	2818					Studied dose	mg	1.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24722445	Homo sapiens						64.5	unknown						83	diabetic neuropathy								12	week		
6005	2818					Studied dose	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18477765	Homo sapiens						52	unknown					70	3	malignant glioma					25			12	month		
6006	2819		ADULT				mg	200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17991768	Homo sapiens						26.4	unknown					43	8						19						
6007	2822		ADULT			Studied dose	mg	160		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26465780	Homo sapiens												45	24						18			28	day		p.10
6008	2826					Highest studied dose	mg	45		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11250974/	Homo sapiens						62							16	coronary artery disease					62			2	day		
6009	2826					Highest studied dose	mg	60		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11250974/	Homo sapiens						60							21	coronary artery disease					60			2	day		
6010	2826					Recommended	mg	30		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11250974/	Homo sapiens						65							16	coronary artery disease					65			2	day		
6011	2827		adult			Highest studied dose	mg	300		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	Homo sapiens													29	AML											p. 23
6012	2827					Recommended	mg	50		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig1Orig2s000lbl.pdf	Homo sapiens						47						60	345	AML					18			42	day		
6013	2827					Recommended	mg	50		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207997Orig1Orig2s000MedR.pdf	Homo sapiens						47						60	345	AML					18			42	day		p.75
6014	2828					Studied dose	mg	25		multiple			week	12	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8452107	Homo sapiens						72	unknown						1	transitional cell carcinoma								18	week		
6015	2829		ADULT			Highest studied dose	mg	120		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14551179	Homo sapiens						45							6						18						p.1250
6016	2829		ADULT			Studied dose	mg	16		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14551179	Homo sapiens						45							6						18			7	day		p.1250
6017	2830		ADULT			Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8749872	Homo sapiens						54				300 mg ridogrel was injected intravenously in addition to alteplase and heparin. Ridogrel was continued orally (300 mg) twice daily for 5 days.			50	myocardial infarction	A loading dose of 5000 IU; Heparin was continued for at least 24 h at a rate of 1000 IV/h			alteplase				5	day	Heparin	p.129
6018	2830		ADULT			Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11856082	Homo sapiens						44							108	ulcerative colitis								12	week		p.97
6019	2831		ADULT			Highest studied dose	mg	300		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9607384/	Homo sapiens						53						69	55	hypertension					30			4	week		
6020	2832					Highest studied dose	ug	300		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23989533	Homo sapiens						57	unknown						7	atrial fibrillation											
6021	2834		adult			Recommended	mg	50		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6415865/	Homo sapiens										After a test dose of 10 mg, patients on aurothioglucose received 50 mg weekly up to the 20th week, after which the dose was reduced to 50 mg every 2-4 weeks.			25	rheumatoid arthritis								20	week		
6022	2834					Recommended	mg	50		multiple			4 days	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/6421293/	Homo sapiens						43				initial dose of 10 mg, followed by 20 mg and 50 mg doses at intervals of 4 days			1	rheumatoid arthritis					43			15	day		
6023	2834					Recommended	mg	50		multiple			week	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/13703724/	Homo sapiens						56							1	rheumatoid arthritis					56			12	week		
6024	2834					Recommended	mg	50		multiple			week	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/1978639/	Homo sapiens						56				50 mg weekly for 5 months, 5 mg monthly for 4 months and 50 mg single dose			1	rheumatoid arthritis				sulphasalazine	56					hydroxychloroquine	
6025	2834					Recommended	mg	50		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6432414/	Homo sapiens						56				Test dose of 10 mg after which 50 mg weekly was given up to a cumulative dose of 1000 mg; thereafter the dose was reduced to 50 mg every 2-4 weeks			26	rheumatoid arthritis								52	week		
6026	2834					Studied dose	mg	500		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/3130212/	Homo sapiens												86	3	rheumatoid arthritis					35			1	week		
6027	2836					Highest studied dose	mg/kg	40		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/3972652/	Homo sapiens													2	recurrent primary brain tumors or metastatic malignancies	130 mg/m2			CCNU				3	day		
6028	2836					Recommended	mg/kg	2.5		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf	Homo sapiens												12	55	Chagas' disease					6			60	day		2017/209570Orig1s000SumR.pdf - p.19 | 209570Orig1s000MedR.pdf - p.177
6029	2836					Recommended	mg/kg	2.5		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf	Homo sapiens												50	283	Chagas' disease					30			30	day		209570Orig1s000SumR.pdf - p.20 | 209570Orig1s000MedR.pdf - p.177
6030	2836					Recommended	mg/kg	3.25		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf	Homo sapiens												12	39	Chagas' disease					2			60	day		209570Orig1s000SumR.pdf - p.25 | 209570Orig1s000MedR.pdf - p.177
6031	2836					Recommended	mg/kg	3.25		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/30509941/	Homo sapiens												45	45	Chagas' disease					18			12	month		209570Orig1s000SumR.pdf - p.26 | 209570Orig1s000MedR.pdf - p.73
6032	2836					Recommended	mg/kg	3.75		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf	Homo sapiens												12	64	T. cruzi infection					7			60	day		209570Orig1s000SumR.pdf - p.18 | 209570Orig1s000MedR.pdf - p.177
6033	2836					Recommended	mg/kg	6.5		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000SumR.pdf | https://pubmed.ncbi.nlm.nih.gov/24853169/	Homo sapiens							mean					12	39	Chagas' disease					2			60	day		209570Orig1s000SumR.pdf - p.25
6034	2836					Studied dose	mg	75		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209570Orig1s000MedR.pdf	Homo sapiens													26	Chagas' disease								60	day		209570Orig1s000MedR.pdf - p.178
6035	2837		ADULT			Recommended	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15649191/	Homo sapiens						63.9							1019	herpes zoster								7	day		p.52, 53
6036	2837		ADULT			Recommended	mg	125		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7561799/	Homo sapiens						36.1							24	herpes zoster								5	day		p.254, 255
6037	2838		ADULT			Recommended	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1673051/	Homo sapiens						33.4							16	Raynaud's syndrome											p.293
6038	2839		ADULT			Highest studied dose	mg	90		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24995954/	Homo sapiens						25							37									1	day		1272-80
6039	2839		CHILD			Recommended	mg	7.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23283272/	Homo sapiens						4							1	upper respiratory tract disease								1	day		80-1
6040	2840		ADULT			Highest studied dose	mg	120		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8838434/	Homo sapiens						26						34	16						21						p.95
6041	2843		ADULT			Recommended	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31884206/	Homo sapiens						38.2							309	asthma								52	week		p.3
6042	2844		CHILD			Highest studied dose	mg	600		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30650076/	Homo sapiens												12	65	helminthiasis					6						
6043	2845		ADULT			Highest studied dose	%	4		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/11105539/	Homo sapiens						35.3							31	Vulvovaginal Candidiasis								9	day		355-65
6044	2846		ADULT			Studied dose	mg	250		multiple			2 weeks	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/15183852/	Homo sapiens						69						87	22	breast cancer					42						p.258
6045	2846		ADULT			Studied dose	mg	500		multiple			week	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/2201397/	Homo sapiens						68						83	19	prostatic cancer					58						p.276
6046	2848		ADULT			Highest studied dose	mg	200		multiple			day	2	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/8012322/	Homo sapiens													10	pain disorder								2	day		932-6
6047	2848		ADULT			Highest studied dose	mg	60		single					unhealthy	intramuscular	unknown		https://onlinelibrary.wiley.com/doi/epdf/10.1002/ana.410170119	Homo sapiens						42							15	brain disease								1	day		90-95
6048	2848		ADULT			Recommended	%	5		multiple			day	1	unhealthy	topical	F		https://link.springer.com/article/10.2165/00128415-201012840-00094	Homo sapiens						57							1	Lupus Erythematosus, systemic								4	week		28
6049	2848		ADULT			Recommended|Highest studied dose	mg	1200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/788760/	Homo sapiens						58	total daily dose					82		brain disease					27			6	week		879-82
6050	2849		ADULT			Higher than recommended	mg	75		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9701421/	Homo sapiens						62							69	lung cancer								7	day		p.100
6051	2849		ADULT			Higher than recommended	mg	90		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29872264/	Homo sapiens												55	47						20						p.1417
6052	2851		ADULT			Highest studied dose	mg	2		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7855939/	Homo sapiens						54.2						87	20	erectile dysfunction					29			1	day		214-6
6053	2851		ADULT			Highest studied dose	mg	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2488105/	Homo sapiens						63.7						74	10	heart disease					48			1	day		557-61
6054	2852		ADULT			Highest studied dose	mg/m2	520		multiple			day	3	unhealthy	oral	M+F		https://www.karger.com/Article/Abstract/225888	Homo sapiens						55							6	cancer								28	day		60–65
6055	2853		CHILD			Highest studied dose	mg/kg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21063221/	Homo sapiens						8	total daily dose						5	neuroblastoma								21	day		25-30
6056	2853		CHILD			Highest studied dose	mg/kg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21063221/	Homo sapiens						8							4	neuroblastoma	0.75 mg/m2 IV daily on days 1 to 5			cyclophosphamide				63	day	topotecan	25-30
6057	2853		CHILD			MTD	mg/kg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21063221/	Homo sapiens						8							6	neuroblastoma	0.75 mg/m2 IV daily on days 1 to 5			cyclophosphamide				63	day	topotecan	25-30
6058	2856		ADULT			Recommended	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1603291/	Homo sapiens						71.7							30	dementia								90	day		p.26
6059	2857		ADULT			Studied dose	mg	140		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7107969/	Homo sapiens							max			60 to 140 mg/week, 4 - 12 week			59	schizophrenia								12	week		
6060	2860		ADULT			Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1684749/	Homo sapiens						55	max						78	hypertension								12	week		p.398
6061	2861		adult				g	1		single					unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02147899	Homo sapiens													71	Bacterial Vaginosis											
6062	2861		adult				g	2		single					unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02147899	Homo sapiens													72	Bacterial Vaginosis											
6063	2861					Recommended	g	2		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf	Homo sapiens												54	197	bacterial vaginosis					15						Table 1
6064	2861					Studied dose	g	1		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf	Homo sapiens												54	71	bacterial vaginosis					15						6.1
6065	2863		ADULT			Highest studied dose	mg	1480		multiple			day	1	unhealthy	oral	F		https://journals.ashs.org/hortsci/view/journals/hortsci/44/1/article-p102.xml	Homo sapiens						36.2	max|total daily dose						40	thyroid gland disease								5	day		102-5
6066	2864		ADULT			Highest studied dose	mg	750		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7194059/	Homo sapiens							total daily dose						47	familial hyperlipidemia								4	month		2053-8
6067	2864		ADULT			Highest studied dose	mg	750		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7194062/	Homo sapiens							total daily dose						50	familial hyperlipidemia								8	week		2068-72
6068	2865		adult | children			Recommended	mg/kg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11421375/	Homo sapiens													82	fascioliasis								1	day		
6069	2865		adult | children			Recommended	mg/kg	10		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf	Homo sapiens										Divided doses were given 6-48 hours apart			28	fascioliasis								2	day		
6070	2865		adult | children			Recommended	mg/kg	15		single					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf	Homo sapiens							mean			single and double administration type trials			214	fascioliasis								2	day		
6071	2865		adult | children				mg/kg	10		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf	Homo sapiens													186	fascioliasis								1	day		
6072	2865					Highest studied dose	mg/kg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21909440/	Homo sapiens						16.3							4	fascioliasis								2	day		
6073	2865						mg/kg	10		multiple			8 hours	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf	Homo sapiens							typical			TCBZ 10 mg/kg x1; TCBZ 10 mg/kg q6-8h x 2		68	154	Paragonimiasis					4			3	times		
6074	2865						mg/kg	10		multiple			8 hours	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf	Homo sapiens							typical			TCBZ 5 mg/kg q24h x 3; TCBZ 10 mg/kg q6-8h x 2; TCBZ 10 mg/kg x1		54	35	Paragonimiasis					5			3	times		
6075	2865						mg/kg	10		multiple			8 hours	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208711Orig1s000MultidisciplineR.pdf	Homo sapiens							typical			TCBZ 5 mg/kg x 3; TCBZ 10 mg/kg q6-8h x 2; TCBZ 10 mg/kg x1		60	47	Paragonimiasis					12			3	times		
6076	2865						mg/kg	10		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21909440/	Homo sapiens						14.4							16	fascioliasis								1	day		
6077	2868		ADULT			MTD	mg/m2	40		multiple			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens										on three consecutive days every 3 weeks for a total of 43 courses			3	lung cancer								3	day		
6078	2868		ADULT			MTD	mg/m2	50		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16012792/	Homo sapiens							total daily dose			150 mg/m2/course			5	NSCLC								3	day		
6079	2868		ADULT			MTD	mg/m2	65		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22237957/	Homo sapiens													4	lung cancer								3	week		
6080	2868		ADULT			Studied dose	mg/m2	30		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens										on three consecutive days every 3 weeks for a total of 43 courses			6	lung cancer								3	day		
6081	2868					RP2D	mg/m2	35		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16028099/	Homo sapiens										on three consecutive days every 3 weeks for a total of 43 courses			6	lung cancer								3	day		
6082	2870		ADULT			Highest studied dose	mg/m2	0.55		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens						60				Belotecan was administered i.v. as intermittent 30-min infusions on days\n1 to 4		69	5	lung cancer	Cisplatin (60 mg/m2) was given on day 1.			Cisplatin	52			4	day		p.6183
6083	2870		ADULT			MTD	mg/m2	0.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17947485/	Homo sapiens						60				Belotecan was administered i.v. as intermittent 30-min infusions on days\n1 to 4		69	6	lung cancer	Cisplatin (60 mg/m2) was given on day 1.			Cisplatin	52			4	day		p.6183
6084	2870		ADULT			Studied dose	mg/m2	0.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/33191408/	Homo sapiens										five consecutive daily intravenous infusions of belotecan (0.5 mg/m2), every 3 weeks, for six cycles.			80	lung cancer					18			5	day		p.716
6085	2871		ADULT			Highest studied dose	mg	200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19705924/	Homo sapiens													54									7	day		543-54
6086	2871		ADULT			Highest studied dose	mg	220		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19705924/	Homo sapiens													54									1	day		543-54
6087	2873		ADULT			Studied dose	mg	20		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3302121/	Homo sapiens												80	16	Parksinson's disease	125 - 700 mg/day			levodopa	48			12	week	benserazide	
6088	2874		ADULT			Highest studied dose	mg	75		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16448575/	Homo sapiens												72	59	Falciparum Malaria					16						
6089	2874					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16969059/	Homo sapiens						26.7						51	70	Malaria by Plasmodium vivax					16			7	day		
6090	2875		ADULT			Studied dose	mg	145		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6353270/	Homo sapiens						46	mean			Mean daily doses were 145 mg after 2 weeks, and 77.5 mg after 4 weeks		70	41	depression					18			6	week		
6091	2875		ADULT			Studied dose	mg	75		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6894708/	Homo sapiens												40	14						20						
6092	2875					Overdose	mg	3425		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7967544/	Homo sapiens						16							1												
6093	2876		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3323257/	Homo sapiens												72	9	hyperuricemia					29			21	day		p.802
6094	2876		ADULT			Studied dose	mg	150		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22278145/	Homo sapiens						44.4						69	18	hypertension					32						p.824
6095	2877		ADULT			Studied dose	mg	50		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2182401/	Homo sapiens						45						67	35	irritable bowel syndrome					24			3	month		
6096	2878		ADULT			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15239097/	Homo sapiens						33							7	hepatitis B								28	day		p.142
6097	2879		ADULT			Highest studied dose	mg	12.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6374803/	Homo sapiens						42.1	max					75	16	asthma					19			2	year		p.9
6098	2882		ADULT			Highest studied dose	%	2		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/8559197/	Homo sapiens						27.5							15	tinea corporis								6	week		317-24
6099	2887		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2698939/	Homo sapiens						57.5							1337	essential hypertension								12	week		S278, S279
6100	2888		ADULT			Highest studied dose	mg/kg	1.5		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6113885/	Homo sapiens						35						53	30		4 mg/kg		CC(=O)C1CCC2C1(CC(=O)C3C2CCC4C3(CCC(C4)O)C)C.CC(=O)OCC(=O)C1CCC2C1(CC(=O)C3C2CCC4C3(CCC(C4)O)C)C	atropine	20		0.075 ml/kg	1	day	thiopentone	149-52
6101	2888		ADULT			Studied dose	mg	37		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/42323/	Homo sapiens						55				women weight - 73 kg			1	intestinal disease	0.6 mg		thiopentone	Pethidine			300 mg	1	day	atropine	661-5
6102	2888		ADULT			Studied dose	mg	45		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6124175/	Homo sapiens						25				patient weight - 60 kg			1	epilepsy	40 mg			atropine				1	day	suxamethonium bromide	696
6103	2889		ADULT			Studied dose	g	5		multiple			day	1	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/3542628/	Homo sapiens										2% FNT			27	Candidiasis of vulva and vagina								7	day		p.309
6104	2889		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/12017948/	Homo sapiens													40	vulvovaginitis								3	day		
6105	2889		ADULT			Studied dose	mg	600		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/2202548/	Homo sapiens						26.7								Candidiasis of vulva and vagina											p.119
6106	2889					Highest studied dose	mg	1000		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/3315778/	Homo sapiens						34.1							20	Candidiasis of vulva and vagina											p.323
6107	2890		ADULT			Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/153973/	Homo sapiens							max			The mean daily dose of glibornuride was 35.8 mg at the onset and 50.0 mg at the end of the trial.			26	diabetes								12	week		p.902
6108	2899		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20814970/	Homo sapiens						69.6				100-mg infusion for 2 consecutive days			28	Paget disease of bone								2	day		p.515
6109	2899		ADULT			Studied dose	mg	25		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/20814970/	Homo sapiens						65.9							29	Paget disease of bone								2	month		p.515
6110	2901		ADULT			Studied dose	g/m2	2.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12559522/	Homo sapiens							total daily dose			The drug was given orally 90 min before\nirradiation. A dose of 1.2 g/m2 was given with the morning fraction, 0.9 g/m2\nwith the midday fraction and 0.6 g/m2 with the evening\nfraction.			61	head and neck cancer											p.67
6111	2907		ADULT			Highest studied dose	mg/m2	240		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11094309/	Homo sapiens						56				BBR 2778 was administered 3 weekly by a 1 h intravenous (i.v.) infusion		66	5	cancer					27			11	cycle		p.2358
6112	2907		ADULT			Highest studied dose|RP2D	mg/m2	84		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11432625/	Homo sapiens						59.5						74	6	non-Hodgkin lymphoma					33			3	week		p.663
6113	2907		ADULT			RP2D	mg/m2	180		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11094309/	Homo sapiens						56						66	6	cancer					27			9	cycle		p.2358
6114	2909		ADULT			Highest studied dose	mg	1600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4008675/	Homo sapiens												50	12						22						p.293
6115	2916		ADULT			Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6694801/	Homo sapiens													30	biliary dyskinesia								15	day		33-37
6116	2916		ADULT			Highest studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3370360/	Homo sapiens												44	4						22			1	day		205
6117	2917						g	1		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7200786/	Homo sapiens																									
6118	2917						g	2		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2353326/	Homo sapiens																									
6119	2922					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												11	100	attention deficit hyperactivity disorder					6			12	week		p83-84/812P303
6120	2922					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												17	99	attention deficit hyperactivity disorder					12			11	week		812P304
6121	2922					Studied dose	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												11	154	attention deficit hyperactivity disorder					6			10	week		48, 83-84/812P301
6122	2922					Studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												11	268	attention deficit hyperactivity disorder					6			10	week		812P301/812P303
6123	2922					Studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												17	99	attention deficit hyperactivity disorder					12			10	week		812P302
6124	2922					Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/211964Orig1s000IntegratedR.pdf	Homo sapiens												17	205	attention deficit hyperactivity disorder					12			10	week		812P302/812P304
6125	2925		ADULT			Highest studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16984212	Homo sapiens													11												p.995
6126	2925		ADULT			Highest studied dose	mg/kg	0.75		multiple			hour	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18759356	Homo sapiens						50				Four-hour infusion; “High dose” CP 101,606 was administered at 0.75 mg/kg/hr for 2 hours and then at 0.36 mg/kg/hr for 2 hours, targeting a minimum plasma concentration of 200 ng/ml			12	Parkinson disease	25mg, was administered orally			levodopa				2	hour	Carbidopa	p.5, 13
6127	2926					Highest studied dose	mg/kg	0.125		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7995977/ | https://www.ingentaconnect.com/content/ben/cdth/2007/00000002/00000002/art00004	Homo sapiens						37.1							48	HIV infection								12	week		
6128	2927		adult				mg	2		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6859892	Homo sapiens										the total dose varying in individual cases from 14 to 140 mg. over periods of time from 10 days to 9 months.			18	psoriasis | indurative dermatoses								10	day		
6129	2927		child				mg	0.5		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/18860765	Homo sapiens													1	acute leukemia								5	day		
6130	2927		children				mg	1		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/18860765	Homo sapiens													3	acute leukemia								7	day		
6131	2928		adult			Highest studied dose	mg	1000		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/3235519	Homo sapiens																									
6132	2928					Highest studied dose	mg	1200		multiple					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27256357	Homo sapiens						25.1	total			Ebselen was administered in 6 × 200 mg capsules in three doses given over 2 days.			12						25.1			2	day		
6133	2929		adult			MTD	mg/m2	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15744595/	Homo sapiens										for 7 days in a 21-day cycle			19	renal carcinoma								2	cycle		
6134	2929		adult			Recommended	mg	200		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11250995/	Homo sapiens													1432	breast cancer								5	year		
6135	2929					Highest studied dose	mg/m2	333		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21498721/	Homo sapiens										for 7 days in a 21-day cycle		76	4	solid tumors and lymphomas					40			2	cycle		
6136	2929					Highest studied dose	mg/m2	4000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			4	neuroblastoma								2	cycle		
6137	2929					Highest studied dose	mg/m2	650		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21498721/	Homo sapiens										for 7 days in a 21-day cycle		76	1	solid tumors and lymphomas					40			24	cycle		
6138	2929					Highest studied dose	mg/m2	650		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21498721/	Homo sapiens										for 7 days in a 21-day cycle		76	3	solid tumors and lymphomas					40			2	cycle		
6139	2929					Highest studied dose	mg/m2	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19139014/	Homo sapiens										days 1 through 7, repeated every three week		77	15	oral leukoplakia					39			4	cycle		
6140	2929					Highest studied dose	mg/m2	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19225720/	Homo sapiens										days 1 through 7, repeated every three week		80	18	recurrent small cell lung cancer					43			2	cycle		
6141	2929					MTD	mg/m2	267		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21498721/	Homo sapiens										for 7 days in a 21-day cycle		76	6	solid tumors and lymphomas					40			2	cycle		
6142	2929					MTD	mg/m2	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21498721/	Homo sapiens										for 7 days in a 21-day cycle		76	3	solid tumors and lymphomas					40			2	cycle		
6143	2929					Studied dose	mg/m2	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			6	neuroblastoma								3	cycle		
6144	2929					Studied dose	mg/m2	1300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			3	neuroblastoma								4	cycle		
6145	2929					Studied dose	mg/m2	1700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			3	neuroblastoma								3	cycle		
6146	2929					Studied dose	mg/m2	2300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			3	neuroblastoma								2	cycle		
6147	2929					Studied dose	mg/m2	3000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796365/	Homo sapiens										28 days, followed by a 7-day interruption			3	neuroblastoma								3	cycle		
6148	2933					Highest studied dose	mg	200		steady			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1360528/	Homo sapiens												56	42						26			7	day		
6149	2934					Highest studied dose	mg	150		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15569974/	Homo sapiens										150 mg p.o. x 6 doses load and 100 mg p.o. once daily maintenance		79	14	advanced cancer					37			2	cycle		
6150	2934					Highest studied dose	mg	150		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15569974/	Homo sapiens										150 mg p.o. x 6 doses load and 150 mg p.o. once daily maintenance		79	6	advanced cancer					37			2	cycle		
6151	2934					MTD	mg	150		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15569974/	Homo sapiens										150 mg p.o. x four doses load and 100 mg p.o. once daily maintenance		79	12	advanced cancer					37			2	cycle		
6152	2934					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28521076/	Homo sapiens							median			100 mg b.i.d., 50 or 100 mg q.d. on alternating days		22	19	neuroblastoma					2			29	day		
6153	2934					Studied dose	mg	150		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15569974/	Homo sapiens										150 mg p.o. x four doses load and 50 mg p.o. once daily maintenance		79	7	advanced cancer					37			2	cycle		
6154	2934					Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23863122/	Homo sapiens										28-day cycle		87	17	chronic lymphocytic leukemia					62			6	cycle		
6155	2936					Highest studied dose	mg	40		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14990642/	Homo sapiens										EM-800, the orally active precursor of acolbifene		86	22	breast cancer					43			6	month		
6156	2938		ADULT			Studied dose	mg	20		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11607045	Homo sapiens							max						13	Parkinson disease											
6157	2938					Highest studied dose	mg	40		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10360765	Homo sapiens						60	unknown					66	14	Parkinson disease					49			2	day		
6158	2939					Highest studied dose	mg	400		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23706639	Homo sapiens						49.3	unknown						116	distal subungual onychomycosis								36	week		
6159	2940		ADULT			MTD	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9488097	Homo sapiens						70.2	unknown						4	Alzheimer disease								7	day		
6160	2940		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9488097	Homo sapiens						68.7	unknown						4	Alzheimer disease								7	day		
6161	2941					Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16184030	Homo sapiens						36.5	unknown					52	8	HIV infection					32			14	day		
6162	2942					Studied dose	mg	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16356023/	Homo sapiens													12	cystic fibrosis lung disease					18			15	day		
6163	2942					Studied dose	mg	300		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16356023/	Homo sapiens													12	cystic fibrosis lung disease					18						
6164	2942					Studied dose	mg	75		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16356023/	Homo sapiens												17	12	cystic fibrosis lung disease					6			15	day		
6165	2946		ADULT			Highest studied dose	mg	200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9542476/	Homo sapiens						23						40	8						18			15	day		p.327
6166	2946		ADULT			Studied dose	mg	100		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9542476/	Homo sapiens						23						40	8						18			15	day		p.327
6167	2946		ADULT			Studied dose	mg	150		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9542476/	Homo sapiens						23						40	8						18			15	day		p.327
6168	2950		ADULT			Highest studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7674813/	Homo sapiens						65				Doses were 10 mg bid (Days 1-2), 20 mg bid (Days 3-4), 30 mg bid (Days 5-6), and 40 mg bid (Days 7-8),\nfollowed by 50 mg bid (Days 9-13), and 60 mg bid (Days 14-17).		75	9	Alzheimer's disease					58			4	day		p.1243
6169	2950		ADULT			MTD	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7674813/	Homo sapiens						65				Doses were 10 mg bid (Days 1-2), 20 mg bid (Days 3-4), 30 mg bid (Days 5-6), and 40 mg bid (Days 7-8),\nfollowed by 50 mg bid (Days 9-13), and 60 mg bid (Days 14-17).		75	9	Alzheimer's disease					58			5	day		p.1243
6170	2952		ADULT			Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21876349	Homo sapiens						31.8							11	lupus nephritis								24	week		p.370
6171	2953		ADULT			Highest studied dose	mg	100		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25448190/	Homo sapiens						52.9							15	spinal cord disease								1	day		103-8
6172	2955		ADULT			Highest studied dose	mg/m2	17.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11052630	Homo sapiens						58	total			5-day continuous intravenous (CIV) infusion			3	cancer								5	day		p.322
6173	2955		ADULT			MTD	mg/m2	12.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11052630	Homo sapiens						58	total			5-day continuous intravenous (CIV) infusion			6	cancer								5	day		p.323
6174	2955		ADULT			MTD	mg/m2	2.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens						53				LU103793 was administered daily for 5 days every 3 weeks.			12	cancer								5	day		p.2774
6175	2955		ADULT			Studied dose	mg/m2	3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9704730	Homo sapiens						53				LU103793 was administered daily for 5 days every 3 weeks.			6	cancer								5	day		p.2773
6176	2956		ADULT			Studied dose	%	0.15		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/12174103	Homo sapiens						33.1				Cipamfylline cream contained 1.5mg/g cipamfylline.			54	atopic dermatitis								14	day		p.305
6177	2960					Highest studied dose	mg/m2	6		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16261364	Homo sapiens						55	total daily dose					71	3	malignant solid tumour					34			75	cycle		
6178	2960					MTD	mg/m2	5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16261364	Homo sapiens						55	total daily dose					71	4	malignant solid tumour					34			75	cycle		
6179	2965					MTD	mg/m2	120		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12651198	Homo sapiens						57	unknown					77	6	advanced solid cancers					32			6	week		
6180	2967					Highest studied dose|Studied dose	mg	200		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11704395	Homo sapiens						59	unknown					80	91	acute myocardial infarction					37			42	day		
6181	2969					Highest studied dose|MTD	mg	60		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9590466/ | https://pubmed.ncbi.nlm.nih.gov/12177685/	Homo sapiens						62							8									1	day		
6182	2970		ADULT			Studied dose	mg	1.5		multiple			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/16272182	Homo sapiens							unknown			Eptapirone given in the morning															
6183	2972		adult			Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9491826/	Homo sapiens													8												
6184	2973					Highest studied dose	mg	90		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22744665/	Homo sapiens													48	Parkinson diseas					30			28	day		
6185	2973					Studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22744665/	Homo sapiens													43	Parkinson diseas					30			28	day		
6186	2973					Studied dose	mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22744665/	Homo sapiens													39	Parkinson diseas					30			28	day		
6187	2975					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3902675	Homo sapiens												69	20	coronary heart disease					44			2	week		p.294
6188	2976		adult			Highest studied dose	mg	1800		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/11327444	Homo sapiens													39												
6189	2976					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens						34							10						34			4	week		
6190	2976						mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10839658	Homo sapiens						34							10						34			4	week		
6191	2977		ADULT			Studied dose	mg/kg	1.22		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/16368813	Homo sapiens							total					45	12						18						
6192	2984					Highest studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9721156	Homo sapiens													8												p.593
6193	2985		adult			Highest studied dose	mg	400		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16918491/	Homo sapiens							max			once daily on days 1-4, twice daily on days 5-9, and three times daily on days 10-15				Type 2 diabetes mellitus								15	day		
6194	2998		ADULT			Highest studied dose	mg	1200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30329038/	Homo sapiens												70	40	organ transplant					20			24	week		
6195	2998		ADULT			Studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18316526/	Homo sapiens						30							19												
6196	2998		ADULT			Studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18316526/	Homo sapiens						30							20		400 mg			ketoconazole							
6197	2998		ADULT			Studied dose	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30329038/	Homo sapiens												74	40	organ transplant					18			24	week		
6198	2998		ADULT			Studied dose	mg	800		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30329038/	Homo sapiens												74	40	organ transplant					19			24	week		
6199	3001		ADULT			Highest studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30703444	Homo sapiens						22.83							4												p.169
6200	3001		ADULT			Studied dose	mg	200		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30703444	Homo sapiens						22.83							4									5	day		p.169
6201	3003		ADULT			Studied dose	mg	500		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18757783	Homo sapiens										odiparcil 500 mg orally every 12 hours on days 1-5			24									5	day		
6202	3004					Highest studied dose	mg/m2	1000		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8787684/	Homo sapiens						61							6									1	day		
6203	3004					Studied dose	mg	400		multiple			week	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15824161/	Homo sapiens						43							29	chronic smokers								12	week		
6204	3007					Highest studied dose	mg	7		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15007535/	Homo sapiens						41							3									1	day		
6205	3008		ADULT			Highest studied dose	mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8527269	Homo sapiens						33.6							6												p.61
6206	3008		ADULT			Studied dose	mg	125		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8527269	Homo sapiens						33.6							6									10	day		p.61
6207	3008		ADULT			Studied dose	mg	250		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8033491	Homo sapiens						22							6									9.5	day		p.26
6208	3010		adult			Highest studied dose	mg	200		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/15987289/	Homo sapiens													43	Onychomycosis								12	week		
6209	3010		adult			Studied dose	mg	400		multiple			week	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/15987289/	Homo sapiens													40	Onychomycosis								12	week		
6210	3018		adult			Highest studied dose	mg/kg	1		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7486632/	Homo sapiens													8									1	day		
6211	3018		adult			Highest studied dose	mg/kg	1.25		multiple			day	3	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7486634/	Homo sapiens										loading dose - 2.5 mg/kg			7	acute stroke								3	day		
6212	3018					Highest studied dose	mg/kg/h	0.5		multiple			3 days	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11070372/	Homo sapiens						83				loading dose over 1 h - 4 mg/kg; continuous infusion			2	acute stroke								65	hour		
6213	3027		adult				mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32019723	Homo sapiens													29	type 2 diabetes mellitus								28	day		
6214	3027		adult				mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32019723	Homo sapiens													30	type 2 diabetes mellitus								28	day		
6215	3045		CHILD|ADOLESCENT			Highest studied dose	mg/m2	31		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729948/	Homo sapiens										30-minute IV bolus daily for 5 days		21	4	cancer								5	day		p.213
6216	3045		CHILD|ADOLESCENT			MTD	mg/m2	26		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729948/	Homo sapiens										30-minute IV bolus daily for 5 days		21	7	cancer								5	day		p.213
6217	3059		ADULT			Highest studied dose	mg/kg	0.55		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/31124836/	Homo sapiens						28							4									1	day		704-714
6218	3059		ADULT			Studied dose	mg	0.0225		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/6830684/	Homo sapiens						20				Althesin 9 mg alphaxolone   3 mg alphadolone			1					lorazepam				1	day		256
6219	3059		ADULT			Studied dose	ug/kg/min	16.4		single					healthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/6536519/	Homo sapiens										ED95		80	105		0.15 mg/kg			morphine	55			1	day		319-25
6220	3059		ADULT			Studied dose	ug/kg/min	21		single					healthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/6536519/	Homo sapiens										ED95		40	105		0.15 mg/kg			Morphine	20			1	day		319-25
6221	3075					Studied dose	g	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2672925	Homo sapiens						50.9	unknown						98	rheumatoid arthritis								12	week		
6222	3076		CHILD|ADOLESCENT|ADULT			Recommended	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4161578/	Homo sapiens										Isoniazid 300 mg plus thioacetazone 150 mg,\ndaily for one year; the two drugs were prescribed\ntogether as a single morning dose of six tablets.			75	pulmonary tuberculosis	Isoniazid 300 mg plus thioacetazone 150 mg,\ndaily for one year; the two drugs were prescribed\ntogether as a single morning dose of six tablets.			Isoniazid	12			1	year		p.501, 502
6223	3088		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral	M		https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5831a3.htm	Homo sapiens						52							1	gastrointestinal system disease								10	day		mm5831a3
6224	3088		CHILD|ADOLESCENT|ADULT			Highest studied dose	g	3.2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3887571/|https://pubmed.ncbi.nlm.nih.gov/3550324/|https://www.sciencedirect.com/science/article/abs/pii/0378517391902138	Homo sapiens							max|total						247	malaria								3	day		1049-55|29-52|83-92
6225	3090						mg	100		steady			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/13151835	Homo sapiens						52	max			final suspension. Patients received 5 mg. initially. The dose was then increased by 5 mg. a week until 100 mg. was reached. When, after several months of trial, no toxic manifestations had appeared, the initial dose for new cases was changed to 10 mg. and progressively increased by 10 mg. a week until a total weekly dose of 100 mg. was attained. Injections of 100 mg. a week were continued until a total of 3 gm. was administered.		72	56	rheumatoid arthritis					18						
6226	3094					Studied dose	mg	400		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13383414	Homo sapiens													18	schizophrenia								49	day		
6227	3096					Highest studied dose	mg/kg	270		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14234861	Homo sapiens												80	10	PSORIASIS					30			10	day		
6228	3096						mg/kg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1243822	Homo sapiens						47				Azaribine was administered orally with 500-mg tablets at doses varying from 60 to 200 mg/kg/day in 3 or 4 divided doses. Most patients received 125 mg/kg/day for a period of 8 weeks.		73	25	PSORIASIS					16			8	week		
6229	3096						mg/kg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1243822	Homo sapiens						47				Azaribine was administered orally with 500-mg tablets at doses varying from 60 to 200 mg/kg/day in 3 or 4 divided doses. Most patients received 125 mg/kg/day for a period of 8 weeks.		73	25	PSORIASIS					16			8	week		
6230	3096						mg/kg	163		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1243822	Homo sapiens						47				Azaribine was administered orally with 500-mg tablets at doses varying from 60 to 200 mg/kg/day in 3 or 4 divided doses. Most patients received 125 mg/kg/day for a period of 8 weeks.		73	25	PSORIASIS					16			8	week		
6231	3103					Overdose	mg	1300		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/5699594	Homo sapiens													1												p.86
6232	3103					Overdose	mg	200		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/5699594	Homo sapiens													1												p.86
6233	3116					Recommended	g	5		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12913463/	Homo sapiens												79	51	hookworm infested					8						
6234	3130		ADULT			Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2866786/	Homo sapiens						45.9							6	essential hypertension											p.398
6235	3130		ADULT			Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6147080/	Homo sapiens						52						64	14	hypertension					42						p.355
6236	3138		ADULT			Highest studied dose	mg	200		multiple			day	4	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/973942/	Homo sapiens							total daily dose					65	12						18			6	day		201-4
6237	3138		ADULT			Highest studied dose	mg	200		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/32398047/	Homo sapiens												75	80	atrial fibrillation					40			1	day		397
6238	3138		ADULT			Recommended	%	2		multiple			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/17680878/	Homo sapiens						38							1	alopecia	1%		panthenol	minoxidil			1%	5	day	biotin	197
6239	3163						g	0.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13470708	Homo sapiens						59							1						59			10	day		
6240	3163						mg	300		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1679861	Homo sapiens							mean					67	3	gout					57			3	month		
6241	3163						mg	485.9		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20778752	Homo sapiens						38				The total amount of cinchophen taken was only 37,5 grains, at the rate of one tablet on five successive days.			1	acute rheumatism					38			5	day		
6242	3163						mg	485.9		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18741907	Homo sapiens						19				a total of about fifty-five grams; 7.5 grains tid			1						19			1	month		
6243	3173		ADULT			Recommended	mg	750		multiple			day	2	unhealthy	rectal	M+F		https://www.mims.com/philippines/drug/info/clofoctol?mtype=generic	Homo sapiens														infectious disease											
6244	3175		ADULT			Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6991549/	Homo sapiens						41.6						70	29	pain disorder					17						p.307
6245	3177		ADULT			Studied dose	mg	200		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18545786/	Homo sapiens						31						48	15	migraine					18						p.218
6246	3202		ADULT			Highest studied dose	mg	200		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3513767	Homo sapiens						24							9									2	week		p.764
6247	3218		ADULT			Studied dose	%	50		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/19744033/	Homo sapiens						25				product was applied on the skin of one leg, from knee to ankle (about\n15 mL of product)		62	99						16						p.592
6248	3228						mg	3		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5818811	Homo sapiens						5				3-4 tablets									5						
6249	3238		ADULT			Studied dose	mg	90		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4401506/	Homo sapiens												48	11						19						248 S
6250	3238		CHILD			Studied dose	mg/kg	1		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7649341/	Homo sapiens						5.6							126	respiratory airway obstruction								3	day		p.179
6251	3239		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10577446	Homo sapiens						62	max						31	Cardiac Failure Congestive								13	week		p.1142
6252	3240						mg	300		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13578110	Homo sapiens						35							1	mild anxiety					35			14	day		
6253	3246					Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1761079/	Homo sapiens												32	12						20			1	day		
6254	3246					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8093942/	Homo sapiens						32.2	max						9	schizophrenia | mental retardation								12	week		
6255	3246					Highest studied dose	mg	8		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/2288834/	Homo sapiens												45	12						18			1	day		
6256	3251		ADULT			Highest studied dose	mg	1350		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3315535	Homo sapiens														gastric ulcer								8	week		
6257	3251		ADULT			Highest studied dose	mg	900		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3803702	Homo sapiens													6	gastrointestinal disorder											
6258	3254					Highest studied dose	mg	10000		multiple					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/14000228	Homo sapiens						21				Ethamivan, 1000 mg was given by intravenous drip at 20 to 30 drops per minute. Then concentration was increased. The patient received 5500 mg. of ethamivan. The drip containing 3000 mg. of ethamivan was continued during the following 12 hours and during this period a further 4500 mg. of ethamivan was used.			1	barbiturate poisoning					21			48	hour		
6259	3254					Highest studied dose	mg	500		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14226094	Homo sapiens													5	CHRONIC RESPIRATORY DISEASE											
6260	3254					Highest studied dose	mg/kg	2.5		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/14226094	Homo sapiens													5	CHRONIC RESPIRATORY DISEASE											
6261	3260		ADULT			Studied dose	%	2		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/6972853/	Homo sapiens						20							1	pain disorder								1	day		50-1
6262	3260					Highest studied dose	g	1		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/28561421/	Homo sapiens												38	12						18			1	day		423-9
6263	3263		ADULT			Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17319797	Homo sapiens						61.2							108	congestive heart failure								6	month		p.210
6264	3264					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13750393	Homo sapiens												93	5	depression					61			3	week		
6265	3264					Overdose	mg	700		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/3776356	Homo sapiens										The exact amount of etryptamine taken several hours before death are not known, but it could have been in the range of 700 mg.			1												
6266	3264					Studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13750393	Homo sapiens												93	24	depression					61			3	week		
6267	3266					Highest studied dose	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10656435/	Homo sapiens												44	6	familial adenomatous polyposis					22			6	month		
6268	3266					MTD	mg	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10656435/	Homo sapiens												45	6	familial adenomatous polyposis					31			6	month		
6269	3268		adult			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10513457/	Homo sapiens							max			reaching 600 mg/day in 8 days with 200-mg increases every 3 days			6	schizophrenic								8	day		
6270	3268					Studied dose	mg	250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10080558/	Homo sapiens						38							63	schizophrenic					38			28	day		
6271	3272		ADULT			Highest recorded dose	mg	1200		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/486951/	Homo sapiens						71	total daily dose			during 4 months			1	rheumatoid arthritis								10	month		391
6272	3272		ADULT			Highest studied dose	mg	1800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3518772/	Homo sapiens						56	total daily dose					74	18	rheumatoid arthritis					22			12	day		409-16
6273	3273		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4903319/	Homo sapiens							total daily dose						24	rheumatoid arthritis								10	day		595-601
6274	3273		ADULT			Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4903318/	Homo sapiens													3									1	day		590-4
6275	3274		ADULT			Highest studied dose	mg	1200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3566858/	Homo sapiens													6									1	day		58-62
6276	3274		ADULT			Highest studied dose	mg	400		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3566858/	Homo sapiens													9									5	day		58-62
6277	3277		ADULT			Recommended	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17163246/	Homo sapiens						57							25	COPD								6	month		p.157
6278	3297		ADULT			Studied dose	mg	350		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7006613/	Homo sapiens							max|total daily dose					47	11	systemic lupus erythematosus				prednisone	18						p.1382
6279	3314		ADULT			Studied dose	mg	626		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2096108/	Homo sapiens						59.6							10	Parkinsonian-pyramidal syndrome											p.702
6280	3318		adult			MTD	mg/m2	60		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7448830/	Homo sapiens													2	breast cancer								5	day		
6281	3318		adult			Studied dose	mg/m2	100		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/526930/	Homo sapiens													4	advanced cancer								5	day		
6282	3318		adult			Studied dose	mg/m2	90		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/356976/	Homo sapiens													15	metastatic cancer								5	day		
6283	3318					Studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26882015/	Homo sapiens													136	Sleeping sickness					12			10	day		
6284	3321		adult			Highest studied dose	mg/kg	0.3		single			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/6125202/	Homo sapiens													5									1	day		
6285	3321					Highest studied dose	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10701483/	Homo sapiens						42.6							7	bipolar depressive disorder								6	week		
6286	3324		adult			Highest studied dose	mg/kg	7		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/3328028/	Homo sapiens													4	cancer								9	month		
6287	3324		adult			Highest studied dose	mg/m2	650		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/14977826/	Homo sapiens										2 hr			3	advanced solid tumors								8	week		
6288	3324					Highest studied dose	mg/m2	650		multiple			week	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729947/	Homo sapiens										2 hr		68	3	cancer					38			1	week		
6289	3324					Highest studied dose	mg/m2	800		multiple			week	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729947/	Homo sapiens										24 hr		68	3	cancer					38			1	week		
6290	3324					MTD	mg/m2	550		multiple			week	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729947/	Homo sapiens										2 hr		68	6	cancer					38			1	week		
6291	3324					Recommended	mg	225		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1320033/	Homo sapiens							mean					79	102	malignant tumours					25			8.5	week		
6292	3334					Studied dose	mg	150		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/13575123	Homo sapiens							starting			The maximum initial dose for ambulatory patients is 50 mg. per day; for institutionalized patients under close medical supervision, the initial dose should not exceed 150 mg. per day															
6293	3345		ADULT			Highest studied dose	%	5		single					healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/18279165/	Homo sapiens						20				patch test			1		5%			N-Vinyl-2-pyrrolidone				1	day	1-Hexadecene	178-9
6294	3346		ADULT			Studied dose	mg	14.8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3551969/	Homo sapiens							total daily dose					70	16	diarrhoea					22			3	week		p.349
6295	3357		CHILD			Highest studied dose	mg	500		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5320882/	Homo sapiens												7	17	diarrhea					0						669
6296	3366					Highest studied dose	mg	10		multiple			day	10	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18392145	Homo sapiens										All patients were treated with Vitamin C: K3 (5,000 mg. of VC and 50 mg. of VK3 each day, Apatone) for a total of 12 weeks. Apatone in capsular form (500 mg VC as ascorbate and 5mg VK3 as bisulfite) at a dose of 2 capsules on arising, then 1 capsule every two hours for six doses followed by two capsules at bedtime for a total of ten capsules per day. The 3 “non-responders” each volunteered to have their dose of Apatone doubled following the trial.			3	Prostate cancer	500 mg; 10 times/day			Vitamin C, p.o				24	month		p.64
6297	3369					Overdose	g	7.5		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17209942	Homo sapiens						48				Working from the former study, and given that death ensued at the peak concentration time, the present observed concentration is 15-fold greater than the maximum concentration that would result from a single intake of a 500 mg formulation.			1						48						
6298	3369						mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24814457	Homo sapiens						25							1						25						
6299	3377						mg	15		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/837689	Homo sapiens												48	15						20			2	month		
6300	3387					Highest studied dose	mg	50		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8740048	Homo sapiens							unknown					40	9						18						
6301	3387					Overdose	mg	25		multiple			day	2	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8740048	Homo sapiens							unknown					40	9						18			1	week		
6302	3389		adult			Highest studied dose	mg/m2	17.5		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6480455/	Homo sapiens													2	cancer				palliative radiation				3	week		
6303	3389		adult			Studied dose	mg/m2	11.25		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6480455/	Homo sapiens													7	cancer				palliative radiation				3	week		
6304	3389		adult			Studied dose	mg/m2	15.5		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6480455/	Homo sapiens													10	cancer				palliative radiation				3	week		
6305	3389					Studied dose	mg/m2	11		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3066854/	Homo sapiens													36	cancer of the larynx and pharynx								4	week		
6306	3399		ADULT			Studied dose	mg	60		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1095121	Homo sapiens						63							49	breast cancer								12	week		p.713
6307	3399		ADULT			Studied dose	mg	60		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4561336	Homo sapiens													23	breast cancer								3	month		p.388
6308	3407					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/222145/	Homo sapiens										300 to 600 mg		66	20	hyperlipoproteinemia					30			12	week		
6309	3411		ADULT			Studied dose	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9365765/	Homo sapiens													10	microsporidiosis	200 mg doxycycline once daily			doxycycline							p.1608
6310	3415		CHILD			Highest studied dose	mg/kg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5917843/|https://pubmed.ncbi.nlm.nih.gov/5331463/	Homo sapiens							total daily dose						1	schistosomiasis								5	day		1261|1047-9
6311	3415		CHILD			Studied dose	mg/kg	34		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5917843/	Homo sapiens						1.5	total daily dose						1	schistosomiasis								3	day		1261
6312	3418		ADULT			Highest studied dose	mg	250		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24217699/	Homo sapiens						25							3									3	day		713-21
6313	3418		ADULT			Highest studied dose	mg	400		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/30184207/	Homo sapiens													8									1	day		2916-2926
6314	3430		ADULT			Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16770616/	Homo sapiens						54							53	rheumatoid arthritis								3	month		
6315	3431		ADULT			Studied dose	mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17417987/	Homo sapiens												75	167	osteoarthritis					40			3	week		
6316	3431		ADULT			Studied dose	mg	200		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10088941/	Homo sapiens						56.5							62	osteoarthritis								20	day		
6317	3436		CHILD			Overdose	mL	15		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2716683/	Homo sapiens						3							1	respiratory airway obstruction											p.450
6318	3437						mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4616804	Homo sapiens						35.7						77	30	urinary tract infection					16			14	day		
6319	3439						mg	5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4605276/	Homo sapiens												84	32	chronic non-alcoholic liver disease					19			7	day		
6320	3439						mg	7.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5113720	Homo sapiens						65							1						65			8	month		
6321	3446					Highest studied dose	mg	900		multiple			day		unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13444479	Homo sapiens													2	schizophrenia											p.144
6322	3446					Recommended	mg	300		multiple			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13436861	Homo sapiens						37.1				https://apps.who.int/iris/bitstream/handle/10665/265528/PMC2537976.pdf?sequence=1&isAllowed=y - dose classification			50	schizophrenia											p.80
6323	3446					Recommended	mg	50		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13377680	Homo sapiens						35				https://apps.who.int/iris/bitstream/handle/10665/265528/PMC2537976.pdf?sequence=1&isAllowed=y - dose classification			1	depisssion								1	month		
6324	3446					Recommended	mg	75		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14405543	Homo sapiens										https://apps.who.int/iris/bitstream/handle/10665/265528/PMC2537976.pdf?sequence=1&isAllowed=y - dose classification		59	33	schizophrenia					20			8	week		p.729
6325	3446					Studied dose	mg	25		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13444479	Homo sapiens													2	schizophrenia								6	day		p.144
6326	3447		ADULT			Studied dose	mg	15		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13803123/	Homo sapiens							max			Treatment was usually started with a dose of\n2.5 mg 4 times a day, and raised rapidly by increasing each\ndose by 2.5 mg daily. The dosage of pempidine required to produce an adequate\nhypotensive effect varied from 10 mg to 60 mg daily.			10	hypertension											p.771
6327	3448					Recommended	mg	130		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13457651/	Homo sapiens										In the second group, of severe problems, the initial dose was 1/2 grain t. i. d. and this was gradually increased to as much as 2 grains (130 mg.) t. i. d.		11	26	mental deficiency					4			9	month		
6328	3448					Recommended	mg	200		multiple			day	3	unhealthy	oral	M+F		https://jamanetwork.com/journals/jamapsychiatry/article-abstract/490516	Homo sapiens										All of the patients were started off with one capsule twice daily and were increased to one capsule three times per day subsequently.		93	19	psychiatric disorder					65			12	week		
6329	3448					Recommended	mg	200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4932747/	Homo sapiens										Patients received one tablet daily during the first week, one tablet twice daily during the second week, and one tablet four times daily during the following weeks of the clinical trial.		82	10	memory impairment					65			4	week		
6330	3448					Recommended	mg	32		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13457651/	Homo sapiens												7	23	mental deficiency due to Mongolism					1			9	month		
6331	3448					Recommended	mg	97		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13457651/	Homo sapiens												17	72	mental deficiency					5			9	month		
6332	3451		CHILD|ADOLESCENT|ADULT			Highest studied dose	mL/kg	80		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7034658/	Homo sapiens							max|total			Fluosol-DA (20%) dose; Perfluorodecalin - 14%		84	186	Hemorrhagic disease	2.7%		Hydroxyethyl starch	Perfluorotripropylamine	7		3%	1	day	Pluronic F68	60-9
6333	3454					Highest studied dose	mg	6		single					unhealthy	intramuscular			https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.834.2450&rep=rep1&type=pdf	Homo sapiens														Chronic pain due to cancer											p.338
6334	3458						mg	400		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12921508	Homo sapiens						70							1						70			12	day		
6335	3466		CHILD			Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32711565/	Homo sapiens						5.5	total daily dose						22	pharyngitis								3	month		p.5
6336	3471		adult			Highest studied dose	g/m2	1.3		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3947818/	Homo sapiens													5	brain tumor								3	week		
6337	3471		adult			Highest studied dose	g/m2	3		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6480458/ | https://pubmed.ncbi.nlm.nih.gov/3947818/	Homo sapiens										total dose - 4.95 g			1	solid tumors								1	day		
6338	3471		adult			MTD	g/m2	750		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6480459/	Homo sapiens										in combination with radiotherapy			6	solid tumors								20	day		
6339	3475		adult			Recommended	mg	10		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/13252923/	Homo sapiens													1	overdose of adrenaline (5 mg)											
6340	3475		adult			Recommended	mg	15		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/14850300/	Homo sapiens													62	hypertension											
6341	3479		ADULT			Highest studied dose	mg	900		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11287080/	Homo sapiens						26.8						34	9						21			7	day		93-101
6342	3488		ADULT			Highest studied dose	mg/kg	11		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6037374/	Homo sapiens						28							40	dental extraction											
6343	3491		adult			Recommended	mg	600		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18147853/	Homo sapiens													10									3	week		
6344	3491					Studied dose	mg	600		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1354982/	Homo sapiens						23							1	heroin addict				heroin	23						
6345	3508		,ADULT			Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2088768	Homo sapiens						27							6												p.320
6346	3510		ADULT			Highest studied dose	mg	7.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10802775/	Homo sapiens						46.2						66	173	multiple sclerosis					24						p.1729, 1730
6347	3513		ADULT			Highest studied dose	mg/m2	930		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21257722	Homo sapiens						54							6	cancer	60 mg/m(2), every 3 weeks			cisplatin							p.4
6348	3513		ADULT			MTD	mg/m2	840		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21257722	Homo sapiens						54							6	cancer	60 mg/m(2), every 3 weeks			cisplatin							p.4
6349	3516		ADULT			Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13446417/	Homo sapiens													19	pulmonary tuberculosis	100 mg b.i.d.			Isonicotinic acid hydrazide	18						p.266, 267
6350	3520		ADULT			Studied dose	mg/m3	36		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6861164/	Homo sapiens													16	cancer								12	week		
6351	3525		ADULT			Highest studied dose	mg	60		multiple			day	3	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/2757885/	Homo sapiens						32							12	asthma								1	week		626-8
6352	3525		ADULT			Recommended	%	4.9		multiple			day	6	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/9226074/	Homo sapiens						19							1	conjunctiv								4	year		686-7
6353	3536		adult			Studied dose	g	1.3		single			day	1	unhealthy	oral	M		https://jamanetwork.com/journals/jama/article-abstract/463394	Homo sapiens													1	insomnia								1	day		
6354	3536					Studied dose	g	1		multiple			2 days	1	unhealthy	oral	M		https://zenodo.org/record/1789312/files/article.pdf?download=1	Homo sapiens						50							1	depression, insomnia, gastric disorders					50			2	month		
6355	3536					Studied dose	g	1		multiple			day	1	unhealthy	oral	F		https://www.nejm.org/doi/pdf/10.1056/NEJM192409111911105	Homo sapiens						44				plus 2 g few weeks			1	nervousness, insomnia					44			2	year		
6356	3536					Studied dose	g	1		single			day	1	unhealthy	oral	M		https://jamanetwork.com/journals/jama/article-abstract/452306	Homo sapiens						39				15 grains = 1 g			1	chronic neurasthenia	12 grains; 12 per 24 hr, during 4 to 5 weeks			sulphonal	39			1	day		
6357	3538						mg	450		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6395955	Homo sapiens													2	heart attack								2	day		
6358	3554						mg	25		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13762246 | https://pubmed.ncbi.nlm.nih.gov/13917095	Homo sapiens						41	starting			25 mg. t.d.s. started. He was reviewed on 9th March, and although rather better, pruritus persisted. The thenalidine tartrate was increased to 25 mg. q.d.s			1						41			1	month		
6359	3555		ADULT			Studied dose	%	0.25		multiple			day	3	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/36589351/	Homo sapiens						38.3				Topical applications were applied on the painful area in the lumbar region, on lesion-free/intact skin.		64	147	low backache					18			7	day		
6360	3557					Recommended	mg	400		steady			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1598734/	Homo sapiens						44							16	detrusor incontinence					44			2	week		
6361	3561					Recommended	mg	250		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7351817	Homo sapiens												69	3	arterial hypertension					30						
6362	3561					Recommended	mg	250		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/7091125	Homo sapiens													57												
6363	3563		ADULT			Studied dose	mg/kg	8.1		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7446671/	Homo sapiens							max|total daily dose					50	2	cancer					34			2	month		846-53
6364	3563		ADULT			Studied dose	mg/kg	8.4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6243446/	Homo sapiens							max					64	5	cancer					34			105	day		46-53
6365	3576		ADULT			Highest studied dose	mg/m2	350		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6825123	Homo sapiens										iv infusion over 15 minutes once every 3 weeks				cancer											
6366	3576		ADULT			MTD	mg/m2	30		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8529286	Homo sapiens						49.5				24-h infusion (CI) daily for 5 days every 6 weeks			10	breast cancer								5	day		p.256, 257
6367	3576		ADULT			MTD	mg/m2	55		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23993427	Homo sapiens						70				infused intravenously over 1 hour on days 1, 8, and 15 every 28 days			9	Hematological tumors								3	week		p.6
6368	3576		ADULT			Studied dose	mg/m2	40		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8529286	Homo sapiens						49.5				24-h infusion (CI) daily for 5 days every 6 weeks			5	breast cancer								5	day		p.256, 257
6369	3576		ADULT			Studied dose	mg/m2	65		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23993427	Homo sapiens						70				infused intravenously over 1 hour on days 1, 8, and 15 every 28 days.			7	Hematological tumors								3	week		p.6
6370	3577		ADULT			Studied dose	mg	5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4389944/	Homo sapiens										5 mg 1-6 times/day			11	schizophrenia								6	day		
6371	3577		ADULT			Studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/5329635/	Homo sapiens							max			4 - 6 mg/day			11	schizophrenia								1	month		
6372	3581					Highest studied dose	mg	1500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4230196	Homo sapiens						23							1						23			6	week		
6373	3581					Recommended	mg	250		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5846503	Homo sapiens						70							1						70			2	week		
6374	3581					Recommended	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14451692	Homo sapiens							starting			started 250 mg each morning. The dose was increased to 500 mg/day when the reduction of apparent cholesterol was inadequate.		66	15						42			2	month		
6375	3581					Recommended	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4230196	Homo sapiens												59	8						6			1	month		
6376	3588		ADULT			Highest recorded dose	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1421679/	Homo sapiens						73	max					89	6	Alzheimer disease					56			5	day		p.1120
6377	3588		ADULT			Highest studied dose	mg	100		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2229455/	Homo sapiens						63.1						70	14						61			28	day		p.954
6378	3641					Highest studied dose	%	2		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/17631786/	Homo sapiens						8		topical;2/d					20	atopic dermatitis	topical;2/d		Sodium pyroglutamate	Hyaluronic acid			topical;2/d	4	week	Phytosphingosine	
6379	3676					Highest studied dose	unit	1000000		multiple			day	1	unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/13182618	Homo sapiens						23				On June 3, 1952, a course of 1,000,000 units of penicillin-procaine daily was begun.			1	rheumatoid spondylitis					23			2	day		
6380	3676						unit	600000		single					unhealthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/13182618	Homo sapiens						23				aqueous solution containing 600,000 units of penicillin 0 was administered intramuscularly on June 17			1	rheumatoid spondylitis					23						
6381	3725						mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13316073	Homo sapiens							max			dose range 400-800 mg			22	congestive heart failure								10	day		
6382	3730					Studied dose	mg	800		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13651512	Homo sapiens													12	congestive heart failure								2	day		
6383	3811					Highest studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11427213	Homo sapiens						55	unknown						26	hyperlipidemia								8	week		
6384	3847		CHILD|ADOLESCENT|ADULT			Recommended	mg	100		multiple			day	4	unhealthy	oral			https://www.medindia.net/doctors/drug_information/bamipine.htm	Homo sapiens							max							allergy											
6385	3885					Highest studied dose	mg	900		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6803978	Homo sapiens												86	5						18			6	month		
6386	3885					Recommended	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6407402/	Homo sapiens						35						43	20	arthritis					26			4	week		
6387	3898		ADULT			Highest studied dose	mg	30		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7423681/ | https://pubmed.ncbi.nlm.nih.gov/4708167/	Homo sapiens													23	urinary system disease								1	day		363-4 | 151-7
6388	3898		ADULT			Highest studied dose	mg	35		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3841410/	Homo sapiens						34							10									7	day		1101-9
6389	3904		ADULT			Highest studied dose	mg	2		multiple			6 hours	3	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/13084384/	Homo sapiens										The average number of injections administered was 2.8			40	urinary system disease								6	hour		269
6390	3971					Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/4570903	Homo sapiens													1	Parkinson's disease								1	week		p.28
6391	4009					Overdose	g	4.5		multiple					unhealthy	oral			https://books.google.ru/books?id=2u8pAQAAMAAJ&pg=PA703&lpg=PA703&dq=bunamiodyl+sodium+maximum+dose&source=bl&ots=Ux8g_vaMhw&sig=ACfU3U2OaU8fRsN_eTNs9aUsIzm0HxwPVA&hl=ru&sa=X&ved=2ahUKEwje0ePX_vXtAhVk-SoKHRkZD14Q6AEwCHoECAcQAg#v=onepage&q=bunamiodyl%20sodium%20maximum%20dose&f=false	Homo sapiens										repeat doses >4.5g				Diagnostic media											p.706
6392	4009					Overdose	g	9		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14085024	Homo sapiens						65				In the evening of the third hospital day the patient was given 4.5 g of bunamiodyl sodium. On the evening of the fourth hospital day, the patient was given 9.0 g of bunamiodyl sodium by mouth.			1	Epigastric pain											p.108
6393	4009					Overdose	g	9		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14085024	Homo sapiens						73				The patient was given 4.5 g of bunamiodyl sodium. Next day she received a second dose of bunamiodyl sodium, this time 12 tablets (9.0 g). Two hours after ingestion, an unknown quantity of pills was vomited.			1	Pneumonia											p.109
6394	4009					Recommended	g	4.5		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/14085024	Homo sapiens														Pneumonia											p.112
6395	4012		ADULT			Highest studied dose	mg	2000		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1097150/	Homo sapiens							max|total daily dose					40	3	hypertension					20			3	day		145-53
6396	4012		ADULT			Studied dose	mg	625		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/782220/	Homo sapiens							max					59	10	hypertension					34			5	day		335-9
6397	4067		ADULT			Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://digitalcommons.unmc.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1037&context=mdtheses	Homo sapiens												84	13	arthritis					33						p.8
6398	4068					Recommended	mg	260		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14081558/	Homo sapiens										Case reports on nonthrombocytopenic purpura in subjects taking Carbrital (Carbromal 4 grains, plus pentobarbital sodium 1.5 grains.) as a night time sedative for a period of 6 weeks to three months		65	3	sleep problems	97 mg; 1/day			pentobarbital sodium	60			1.5	month		
6399	4068					Recommended	mg	780		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13230580/	Homo sapiens										Case reports of drug eruptions in subjects taking """"""""""""""""persomnia"""""""""""""""" (each containing carbromal 195 mg. and bromvaletone 65 mg.) 1-4 tablets nightly for 5 weeks to one year		53	6	sleep problems	65-260 mg; 1/day			bromvaletone	27			12	month		
6400	4068						mg	5850		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13671224/	Homo sapiens						54				Patient had been taking about 30 tablets of """"""""""""""""persomnia"""""""""""""""" (each containing carbromal 195 mg. and bromvaletone 65 mg.) daily for some months and had become lethargic, confused, and ataxic.			1	sleep problems	1950 mg; 1/day			bromvaletone				1	month		
6401	4134					Highest studied dose	mg	600		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13640980	Homo sapiens														Parkinson's Disease											p.102, 105
6402	4313		UNKNOWN			Highest studied dose	mg	1200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/369076/	Homo sapiens														worm infection								1	day		423-6
6403	4341					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23912694/	Homo sapiens										starting dose was 5 mg/day for 7 days in 28-day cycle to 400 mg/day		75	4	advanced solid tumors and lymphomas					19			7	day		
6404	4341					Studied dose	mg	80		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23912694/	Homo sapiens							median			starting dose was 5 mg/day for 7 days in 28-day cycle to 400 mg/day		75	31	advanced solid tumors and lymphomas					19			7	day		
6405	4346		ADULT			Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8582540	Homo sapiens						52							9	non-insulin-dependent diabetes mellitus								14	day		
6406	4384		ADULT			Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10559567	Homo sapiens						74.7							94	dementia								16	week		p.506
6407	4412		ADULT			Studied dose	mg	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14270339	Homo sapiens							unknown						74												
6408	4427					Studied dose	%	1		single			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/5910875/	Homo sapiens						55.5				patch test - 1%; the exact content of dibromsalan in the Lifebuoy soap is unknown			2									1	day		
6409	4440		ADULT			Studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7028532	Homo sapiens							max						14	depression								7	day		
6410	4477					Studied dose	mg	50		multiple			day	1	unhealthy	oral			https://apps.who.int/iris/bitstream/handle/10665/39030/Codeine_1970_eng_part2.pdf?sequence=3&isAllowed=y	Homo sapiens													15	Cough											p.200
6411	4653		ADULT			Recommended	mg	4.5		multiple			day	3	unhealthy	oral	M+F		https://sante.lefigaro.fr/medicaments/3555951-geneserine-4-5mg-cpr-30	Homo sapiens														gastrointestinal disorder											
6412	4684		ADOLESCENT|ADULT			Overdose	mg	2000		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/26588183/	Homo sapiens						20	max						11									1	day		147-52
6413	4684		ADULT			Highest studied dose	mg	300		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1250945/	Homo sapiens												25	6						18			1	week		301-3
6414	4684		ADULT			Recommended	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22633197/	Homo sapiens						48.3	median|total daily dose						18	anxiety disorder								18	day		e85-8
6415	4758						mg	500		multiple			day	1	unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/1095283	Homo sapiens																						6	week		
6416	4780		ADULT			Highest studied dose	mg	3600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens						27.8						40	6						18			14	day		p.569
6417	4780		ADULT			Highest studied dose	mg	3600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens						27						45	6						19						p.569
6418	4780		ADULT			Studied dose	mg	2400		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24535888/	Homo sapiens						27.8						40	6						18			14	day		p.569
6419	4782					Studied dose	mg/m2	200		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3525694	Homo sapiens						51							15	varicella								5	day		p.435
6420	4783		ADULT			Highest studied dose	mg/kg	0.25		multiple			day	2	unhealthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pubmed/7565947	Homo sapiens						44	max			Patients received either 0.10 or 0.25 mg of fialuridine per kilogram of body weight per day given orally in two or three divided doses.		64	15	chronic hepatitis B					29			24	week		p.1100
6421	4798		adult			Recommended	mg	100		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2668206/	Homo sapiens													18	severe heart failure after myocardial infarction											
6422	4798					Recommended	mg	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1884731/	Homo sapiens												70	10	severe heart failure					42						
6423	4798					Recommended	mg	100		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8207686/	Homo sapiens						43							9	compromised hepatic function					43						
6424	4823					Highest studied dose	g	4		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13626810	Homo sapiens													5	Hypertension											p.485
6425	4823					Highest studied dose	mg	1000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13825522	Homo sapiens												68	10	Congestive heart failure					42			2	day		p.870
6426	4823					Studied dose	g	2000		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13801925	Homo sapiens													2	Hypertension											p.468
6427	4823					Studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13825522	Homo sapiens												68	13	Congestive heart failure					42			2	day		p.870
6428	4851						%	3		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/4150704	Homo sapiens						47		0.6					1	low back pain	300 mg			thiopental	47					nitrous oxide	
6429	4876		ADULT			Highest studied dose	mg/m2	47		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/14739664	Homo sapiens						60				daily bolus infusion for five consecutive days			4	cancer								5	day		p.163
6430	4876		ADULT			Studied dose	mg/m2	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10070885	Homo sapiens						50				Fostriecin was administered intravenously over 60 min on days 1-5 at 4-week intervals.			4	cancer								5	day		
6431	4923		ADULT			Highest studied dose	mg	120		steady			day	1	healthy	oral	M		https://link.springer.com/article/10.2165/00044011-200222120-00002	Homo sapiens												40	13						18			7	day		819–826
6432	4932		ADULT			Highest studied dose	mg	20		multiple			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/668777/	Homo sapiens													3									6	day		219-22
6433	4932		ADULT			Highest studied dose	mg	20		single					healthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/668777/	Homo sapiens													4									1	day		219-22
6434	4932		ADULT			Highest studied dose	mg	20		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/668777/	Homo sapiens													4									1	day		219-22
6435	4970		ADULT			Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14295356/	Homo sapiens							total daily dose			highest daily outpatient dose			20	hypertension								22.8	week		111-24
6436	4970		ADULT			Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14085968/	Homo sapiens						69	total daily dose			the highest daily dose administered			36	hypertension					30			11	month		402-6
6437	5053		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9158644/	Homo sapiens						72.8	total daily dose						462	atrial fibrillation								12	month		1015-21
6438	5160					Highest studied dose	mg	300		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11157184/	Homo sapiens						69							15	ischemic stroke								1	day		
6439	5160					Highest studied dose	mg	350		multiple			3 weeks	2	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15910512/	Homo sapiens						52							8	sleep disordered breathing								28	day		
6440	5160					MTD	mg	250		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11157184/	Homo sapiens						69							15	ischemic stroke								1	day		
6441	5225		adult			Highest studied dose	mg	160		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20068091/	Homo sapiens													2	CNS tumor								1	day		
6442	5225					MTD	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20039040/	Homo sapiens						62.5				median 6 cycles per patient			6	colorectal cancer	300 mg/m2; IV; 1/21 day			Irinotecan				21	day		
6443	5225					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20039040/	Homo sapiens						62.5				median 6 cycles per patient			6	colorectal cancer	250 mg/m2; IV; 1/21 day			Irinotecan				21	day		
6444	5225					Studied dose	mg/m2	10		multiple			2 weeks	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16533784/	Homo sapiens						60				2 cycles			2	solid tumors	175 mg/m2; IV; 5/4 weeks			temozolomide				28	day		
6445	5250						mg	10		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9712921	Homo sapiens						64.2				10 mg (loading dose 7.5 mg over 1 h)			13	schemic Stroke					64.2			5	day		
6446	5250						mg	5		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9712921	Homo sapiens						71.3				5 mg (loading dose 3.75 mg over 1 h)			12	schemic Stroke					71.3			5	day		
6447	5261		adult			Recommended	mg	60		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13282524/	Homo sapiens								60 mg; 4/day		The dosage was two tablets four times daily for a six-month period. Each tablet composed of powdered whole root from Rauwolfia micrantha (30 mg) combined with rutin (30 mg) and mannitol hexanitrate (Maxitate) (30 mg).			11	hypertension	60 mg; 4/day			Rauwolfia micrantha (powdered whole root)				6	month	Rutin	
6448	5261					Recommended	mg	360		multiple			day	4	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13250697/	Homo sapiens													15	hypertension								8	day		
6449	5289					Highest studied dose	mg	15		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1097740/	Homo sapiens													5	benign prostatic hyperplasia								15	week		
6450	5353					Studied dose	mg	6		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20291241	Homo sapiens										6 mg. daily were prescribed for a shorter period of two weeks												2	week		
6451	5358					Studied dose	mg	1200		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13637265	Homo sapiens												50	29						20						
6452	5442		ADULT			Highest studied dose	mg	48		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7554709	Homo sapiens						30							3												p.349
6453	5442		ADULT			Studied dose	mg	24		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7554709	Homo sapiens						30							3									28	day		p.349
6454	5475					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20368213	Homo sapiens						54.1							237	Type 2 diabetes								24	week		p.209
6455	5518					Highest studied dose	mg	18		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1913699	Homo sapiens						62	max						48	Parkinson's disease								12	week		p.324
6456	5545		adult			Studied dose	mg	600		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1915428/	Homo sapiens							max						103	ventricular arrhythmia								4	day		
6457	5545					Studied dose	mg/kg/h	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2269541/	Homo sapiens						43							29	tachycardias											
6458	5545					Studied dose	mg/kg/h	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2419677/	Homo sapiens						59	max						23	heart disease											
6459	5563		ADULT			Studied dose	%	1		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/6851539/	Homo sapiens						53				patch test			1	vulvovaginitis								1	day		166
6460	5563		CHILD			Highest studied dose	mg/kg	30		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17309749/	Homo sapiens							total daily dose					14	73	gastritis	50 mg/kg/day, q.d.s.			bismuth subcitrate	9			10	day	amoxicillin	132-5
6461	5608		ADULT			Highest studied dose|Higher than recommended	mg	12.5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24777591/	Homo sapiens						36							42		7.5 mg			17beta-estradiol				14	day		p.419
6462	5608		ADULT			Recommended	mg	2.5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2725335/	Homo sapiens						51				first 12 days of each calendar month, 4 calendar months		63	12		50 mg oestradiol implants			oestradiol	38			12	day		p.26
6463	5608		ADULT			Studied dose	mg	55		single					healthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/8838490/	Homo sapiens						27.5	total			implant			1803												p.123
6464	5619						mg	20		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13851171	Homo sapiens						57							1		5.0 mg. daily			Prednisone	57			9	month		
6465	5619						mg	300		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13851171	Homo sapiens						43							1						43			6	month		
6466	5619						mg	40		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13851177	Homo sapiens						75							1	generalized purpura | weakness					75			1.5	month		
6467	5669		adult			MTD	mg/m2	88.4		single					unhealthy	intraperitoneal	unknown		https://pubmed.ncbi.nlm.nih.gov/8244179/	Homo sapiens													3	tumors											
6468	5669		adult			Studied dose	mg/m2	66.5		multiple			month	1	unhealthy	intraperitoneal	unknown		https://pubmed.ncbi.nlm.nih.gov/8244179/	Homo sapiens													1	tumors								6	month		
6469	5669					Highest studied dose	mg/m2	123		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10555124/	Homo sapiens												77	5	tumors					19			3	month		
6470	5669					Highest studied dose	mg/m2	15		steady			day	1	unhealthy	intraperitoneal	M+F		https://pubmed.ncbi.nlm.nih.gov/7858283/	Homo sapiens							median					75	5	tumors					35			5	day		
6471	5669					Highest studied dose	mg/m2	60.8		multiple			month	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8306332/	Homo sapiens												84	4	tumors					37			1	month		
6472	5669					Studied dose	mg/m2	7		steady			day	1	unhealthy	intraperitoneal	M+F		https://pubmed.ncbi.nlm.nih.gov/7858283/	Homo sapiens							median					75	35	tumors					35			5	day		
6473	5669					Studied dose	mg/m2	98		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10555124/	Homo sapiens												77	8	tumors					19			3	month		
6474	5685					Highest studied dose	g	4.8		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13638840	Homo sapiens										a twelve- month study in which 60 chronically psychotic female patients were treated with oxanamide in dosage of 0.8 gm. to 4.8gm. daily.				Psychosis								12	month		p.275
6475	5685					Studied dose	mg	800		multiple			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13638840	Homo sapiens							max						45	Anxiety											p.277
6476	5733					Recommended	mg	10		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21019545/	Homo sapiens								100 mg; 3/day for 5 days		Pamaquine dose or regimen: 10 mg for 5 days (thrice daily for British and twice daily for Indian troops). Other antimalarial agents given: Quinine at 10 grains (0.65 g) thrice daily for 2 days, mepacrine at 100 mg thrice daily for 5 days, rest for 2 days, then pamaquine.			10000	malaria	650 mg; 3/day for 2 days			quinine				5	day	mepacrine	
6477	5733					Recommended	mg	10		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21019545/	Homo sapiens										Pamaquine dose or regimen: Blanket treatment: 10 mg for 3 days; most Indians received 5 days’ treatment. Other antimalarial agents given: mepacrine at 100 mg thrice daily for 5 days, rest for 2 days, then pamaquine			10000	malaria	100 mg; 3/day for 5 days			mepacrine				5	day		
6478	5733					Recommended	mg	40		multiple			day	1	unhealthy	oral	M		Green R. The treatment of “crescent carriers” with plasmoquine compound. Kuala Lumpur, Government Printing Office, 1929:1–20 (Bulletins Institute for Medical Research (Malaysia), Issue 3).	Homo sapiens										Eight tablets of pamaquine compound given as directly observed therapy for a total daily dose of 40 mg pamaquine (and 500 mg quinine) for 10–14 days. Reference and location: Green, 1929 (2), Federation of Malay States (now part of Malaysia)			56	crescents in blood	500 mg; 1/day			quinine				14	day		
6479	5733					Recommended	mg	60		multiple			day	1	unhealthy	oral	M		Green R. The treatment of quartan malaria with plasmoquine. Kuala Lumpur, Government Printing Office, 1929 (Bulletins Institute for Medical Research (Malaysia), Issue 3).	Homo sapiens													40	quartan malaria											
6480	5733						mg	10		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20991220/	Homo sapiens										Pamaquine dose or regimen: 10 mg thrice daily for 5 days after mepacrine; 61 of the 258 patients did not finish the 5 days of pamaquine. Other antimalarial agents given: 100 mg mepacrine thrice daily for 5 days, then 2 days’ rest, followed by pamaquine			258	malaria	100 mg; 3/day for 5 days			mepacrine				5	day		
6481	5814					Studied dose	mg	1000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13583888	Homo sapiens										The daily dosage of phenaglycodol ranged from 300 to 3000 mg. in divided doses after meals and at bedtime.		18	44	Cerebral palsy					1						p.284
6482	5814					Studied dose	mg	300		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4557536	Homo sapiens										A flexible dosage schedule of between 600 and 1200 mg phenaglycodol (two to four capsules) daily was used		65	70	Anxiety|depression					21			4	week		p.280
6483	5821					Highest studied dose	mg	25		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13894598	Homo sapiens													1	Depression								15	day		p.2
6484	5821					Highest studied dose	mg	25		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13894598	Homo sapiens													1	Depression								26	day		p.2
6485	5821					Recommended	mg	9		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13993059	Homo sapiens						50							1	Depression								30	month		
6486	5821					Studied dose	mg	18		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13798229	Homo sapiens						65	max						1	Hypertension								2	week		p.1959
6487	5824		ADULT			Studied dose	mg	2		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7047171/	Homo sapiens						53.1							95	pain disorder	0.4 mg			atropine							p.145
6488	5866					Overdose	mg	100		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						2.5							1	Morning sickness											p.165
6489	5866					Overdose	mg	100		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						2							1	Morning sickness											p.164
6490	5866					Overdose	mg	100		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						3	max						1	Morning sickness											p.164
6491	5866					Overdose	mg	125		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						2.5							1	Morning sickness											p.165
6492	5866					Overdose	mg	20		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						3	max						1	Morning sickness											p.164
6493	5866					Overdose	mg	25		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens						3							1	Morning sickness											p.165
6494	5866					Recommended	mg	5		multiple			day	4	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13807442	Homo sapiens														Morning sickness											p.164
6495	5867					Overdose	mg/mL	40		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7180211	Homo sapiens										800 mg (66.1 mg/kg)			1												
6496	5971		ADULT			Studied dose	mg	10		multiple			week	3	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/31246661/	Homo sapiens						57.21							24	postmenopausal atrophic vaginitis								14	week		p.835
6497	5995					Overdose	g	4		single					unknown	oral			https://pubmed.ncbi.nlm.nih.gov/7915105	Homo sapiens										These results are in agreement with limited, previously reported data and indicate that more then 4 g of prothipendyl is fatal overdose															
6498	5995					Studied dose	mg	1280		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5325240	Homo sapiens						20				In the men, the best results were obtained with doses ranging from 360 mg to 1280 mg daily in divided doses		31	10	long-standing behaviour disorders					16			16	week		
6499	5995					Studied dose	mg	960		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5325240	Homo sapiens						26				in the women with slightly lower doses, 480 mg to 960 mg daily		42	10	long-standing behaviour disorders					14			16	week		
6500	6001					Highest studied dose	mg/kg	0.6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28353056	Homo sapiens						43							12												p.1549
6501	6006					Studied dose	mg/m2	200		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/157807	Homo sapiens													21	cancer											
6502	6031		CHILD			Studied dose	mg	100		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12139216/	Homo sapiens						7.4							132	helminthiasis											p.252
6503	6031		CHILD			Studied dose	mg/kg	4.3		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23315350/	Homo sapiens						6.795							112	Amoebic Non-Dysenteric Colitis											p.92
6504	6112		ADULT			Higher than recommended	mg	40		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27632557/	Homo sapiens						27							7									5	day		p.11
6505	6112		ADULT			Highest studied dose	mg	100		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20406224/	Homo sapiens						26.7							41									5	day		p.407
6506	6112		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30391169/	Homo sapiens						36.7							300	allergic rhinitis								13	day		p.211
6507	6177		ADULT			MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10235511	Homo sapiens						33						42	18	HIV infection					23			21	day		p.29
6508	6177		ADULT			Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10235511	Homo sapiens						33						42	8	HIV infection					23			21	day		p.29
6509	6177		CHILD,ADULT			Studied dose	mg/kg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16354802	Homo sapiens						21.7						60	28	visceral leishmaniasis					5			28	day		p.1008
6510	6226					Highest studied dose	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13809733	Homo sapiens												83	53	Muscle spasm					30			2	month		p.289
6511	6292		adolescents; adults			Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens							starting			200 mg daily for 3 days, then 200 mg weekly			825	malaria								3	day		
6512	6292		adult				mg	200		multiple			week	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02488980	Homo sapiens										Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.			104	Falciparum Parasitaemia								24	week		
6513	6292					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens										600 mg daily for 2 days, then 300 mg weekly for 4 weeks			36									2	day		
6514	6292					Highest studied dose	mg	600		multiple			week	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens													36									10	week		
6515	6292					Highest studied dose	mg	600		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens													75												
6516	6292					Recommended	mg	200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf	Homo sapiens						29	starting			200 mg daily for 3 days, then 200 mg weekly		69	492						17			3	day		
6517	6292					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607lbl.pdf	Homo sapiens						29	starting			200 mg daily for 3 days, then 200 mg weekly		69	333	malaria					17			3	day		
6518	6292					Studied dose	mg	400		multiple			day	1	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens													52									3	day		
6519	6292					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens						34	starting			400 mg once daily for 3 days, then weekly for 10-15 weeks		50	62	malaria					18			3	day		
6520	6292					Studied dose	mg	600		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210607Orig1s000MultidisciplineR.pdf	Homo sapiens													52												
6521	6302					Highest studied dose	mg	144		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11193166/	Homo sapiens						67.1	total daily dose						3	Alzheimer's disease								4	week		
6522	6302					Highest studied dose	mg	160		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10188789/	Homo sapiens												41	6						21			1	day		
6523	6390					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4555826	Homo sapiens												70	4	Tardive dyskinesia					44			1	week		p.100
6524	6390					Recommended	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/381595	Homo sapiens												69	15	Tardive dyskinesia					39			6	month		p.578
6525	6390					Recommended	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4130307	Homo sapiens												60	10	Huntington’s chorea					33			14	day		p.105
6526	6505					Highest studied dose	mg	80		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19723122	Homo sapiens						40.5	unknown						109	migraine											
6527	6505						mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19222510	Homo sapiens						37	total daily dose					55	58	migraine					18			2	week		
6528	6547					Highest studied dose|Studied dose	mg	250		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13637055	Homo sapiens										The OED of Tricyclamot varied from 50 mg in one patient to 250 mg in another, and in 8 of the 9 patients the OED was two to four times the single dose of 50 mg			9	duodenal ulcer											
6529	6547						mg	50		single					unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/14351747/	Homo sapiens													3												
6530	6548						mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13032924	Homo sapiens							starting			The initial course of TEM consisted of 5 mg. daily for four days (a total of 20 mg.) taken in the morning on an empty stomach. If no significant decrease of the hematocrit occurred in four weeks and white-cell depression was not present, a second course was given. Further dosage then ranged from 10 to 20 mg. per course with the dose and frequency of administration depending on the initial response to therapy		70	6	POLYCYTHEMIA VERA					41			4	day		
6531	6588					Highest studied dose	mg	350		steady			day	4	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4890013/	Homo sapiens												41		psychosomatic symptoms in infertility patients					22						
6532	6588					Highest studied dose	mg	750		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14138831/	Homo sapiens						49.5							66	anxious neurotic					49.5			4	week		
6533	6588					Recommended	mg	350		steady			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/4890013/	Homo sapiens												41	17	psychosomatic symptoms in infertility patients					22			7	week		
6534	6604		ADULT			Highest studied dose	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28605109/	Homo sapiens						44.9							71	Manic Bipolar Affective disorder								3	week		p.5
6535	6619					Recommended	mg	32		single					healthy	oral			https://link.springer.com/article/10.1007/BF01563338	Homo sapiens													10												
6536	6694		ADULT			Highest studied dose	mg/kg	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16202888	Homo sapiens										Subjects received an intravenous loading infusion over 1 hour, which had to be completed before the vascular cross-clamping, followed by a continuous intravenous maintenance infusion. The goal of treatment was 3 days, but could be continued for up to 7 days if there was evidence of ongoing myocardial ischemia or a cardiac event.		92	266	peripheral vascular disease					28			7	day		p.573
6537	6697		ADULT			Recommended	mg/kg	5		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7826833/	Homo sapiens							total daily dose					69	32	emesis					20						
6538	6697		ADULT			Studied dose	mg	100		single					unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6502497/	Homo sapiens													6												
6539	6697		ADULT			Studied dose	mg	100		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6502497/	Homo sapiens													6												
6540	6697		CHILD			Studied dose	mg/kg	4		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11468033/	Homo sapiens												15	17	cancer					0						
6541	6697					Studied dose	mg	100		single					unhealthy	rectal	M+F		https://pubmed.ncbi.nlm.nih.gov/6502497/	Homo sapiens													6												
6542	6700		ADULT			Studied dose	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12637119/	Homo sapiens						72.2						80	132	Alzheimer disease					60			180	day		p.189
6543	6702		ADULT			Higher than recommended	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22044433/	Homo sapiens						58.9							84	bladder disease								12	week		p.824
6544	6702		ADULT			Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22970658/	Homo sapiens						58.6							119	pain								4	week		p.1629
6545	6703		ADULT			Highest studied dose	mg	23		multiple			week	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/3512622/|https://pubmed.ncbi.nlm.nih.gov/17253464/	Homo sapiens						40						60	20	schizophrenia					18			4	week		21-6|CD001718
6546	6703		ADULT			Studied dose	mg	3		multiple			week	1	unhealthy	intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/2224229/	Homo sapiens						89							1	dementia								2	month		668-9
6547	6704		ADULT			Highest studied dose	mg	10		single					unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/2840293/	Homo sapiens						53						81	10	Raynaud's syndrome					21			1	day		267-71
6548	6704		ADULT			Highest studied dose	mg	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6812750/	Homo sapiens						40.1						67	9	Raynaud's syndrome					21			1	day		1069-71
6549	6704		ADULT			Highest studied dose	mg	60		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6353879/	Homo sapiens						52						69	10	hypertension					29			10	week		125-30
6550	6708		ADULT			Accidental dose	mg	6500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15228400/	Homo sapiens						61							1	hypertension								1	day		361-3
6551	6708		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6263960/	Homo sapiens						78							1	ischemia								5	month		259-62
6552	6708		ADULT			Studied dose	mg	300		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6572824/	Homo sapiens							total daily dose						1	heart disease								3	year		202-4
6553	6709		ADULT			Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17013922/	Homo sapiens						62.4							197	Parkinson disease								7	month		p.2113
6554	6711		adult				mg	400		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01142089	Homo sapiens													199	Traveler's Diarrhea								3	day		
6555	6711					Recommended	mg	388		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf	Homo sapiens						36.2						87	199	travelers’ diarrhea					18			3	day		
6556	6711					Recommended	mg	388		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf	Homo sapiens						36.2						87	420	travelers’ diarrhea					18			3	day		
6557	6711					Recommended	mg	388		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210910s000lbl.pdf	Homo sapiens						36.2						87	619	travelers’ diarrhea					18			3	day		
6558	6711					Recommended	mg	400		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1s000MultidisciplineR.pdf	Homo sapiens													199	travelers’ diarrhea								3	day		
6559	6711						mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210910Orig1s000MultidisciplineR.pdf	Homo sapiens																						3	day		
6560	6712					Highest studied dose	mg	250		multiple			day	1	healthy	transdermal	M		https://pubmed.ncbi.nlm.nih.gov/11932266 |https://pubmed.ncbi.nlm.nih.gov/3935902	Homo sapiens						58						70	60						50			3	month		
6561	6714		ADULT			Highest studied dose	ug	3900		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8325946/	Homo sapiens							max|total daily dose						14									3	week		221-8
6562	6714		ADULT			Highest studied dose	ug/kg	24		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9215287/	Homo sapiens						48						72	24	thyroid carcinoma					21			92	day		2153-8
6563	6715		ADULT			Overdose	g	18		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15119534/	Homo sapiens						29							1	mental or behavioural disorder	amount unknown			olanzapine							p.146
6564	6715		ADULT			Overdose	g	36		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15119534/	Homo sapiens						29							1	bipolar disorder											p.146
6565	6715		ADULT			Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11112935/	Homo sapiens						43.1							15	mood disorder											p.430
6566	6716		ADULT			Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2139340/	Homo sapiens						60.4						73	12	heart disease					52			7	day		p.451
6567	6717		ADULT			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14567168/	Homo sapiens													14	major depressive disorder								8	week		165-71
6568	6717		ADULT			Highest studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9140018/	Homo sapiens						27							8									1	day		R1178-88
6569	6719					Overdose	ug/kg	300		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/26024789	Homo sapiens										overdosed with only cangrelor bolus			3												
6570	6719					Overdose	ug/kg/min	12		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/26024789	Homo sapiens										overdosed with only cangrelor infusion			1												
6571	6719					Recommended	ug/kg	30		single					unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204958Orig1s000Lbl.pdf	Homo sapiens										30 mcg/kg bolus followed by 4 mcg/kg/min infusion for 2 to 4 hours			5529									4	hour		
6572	6721		ADULT			Recommended	mg	120		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23473285/	Homo sapiens						50							1	alcoholism	2 mg/day			risperidone				6	month	alprazolam	
6573	6721		ADULT			Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16118830/	Homo sapiens						41.9	starting			Starting from D(2), the compounds were given twice a day in progressively decreasing doses during a maximum period of 13 days (D(end))			43	alcoholism								13	day		
6574	6721		ADULT			Studied dose	mg	50		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16243418/	Homo sapiens							max			25 - 50 mg/day		65	77	alcoholism					18			4	week		
6575	6725		ADULT			Highest studied dose	mg	0.2		steady			day	1	unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/22285095/	Homo sapiens												87	142	vaginal atrophy					44			12	week		
6576	6725		ADULT			Recommended	mg	0.5		steady			day	1	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/7493689/	Homo sapiens												90	214						60			3	week		
6577	6726		adult				mg	100		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00996164	Homo sapiens													543	Hypoactive Sexual Desire Disorder								24	week		
6578	6726		adult				mg	100		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01057901	Homo sapiens													376	Hypoactive Sexual Desire Disorder								24	week		
6579	6726					MTD	mg	250		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000MedR.pdf	Homo sapiens													6												p. 127
6580	6726					Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Homo sapiens													25		0.4 g/kg			alcohol							
6581	6726					Recommended	mg	100		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526lbl.pdf	Homo sapiens						36						56	1543	hypoactive sexual desire disorder					18			24	week		
6582	6726						mg	20		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22219166	Homo sapiens													12									30	min		
6583	6726						mg	600		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/28814122	Homo sapiens													1												
6584	6727		ADULT			MTD	mg/m2	125		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11508814/	Homo sapiens						54				Induction cycle consisting of 100 mg/day oral PCZ for 12 consecutive days and a 1-h intravenous infusion of fotemustine given 4 h after PCZ on days 5 and 12. After a 6-week rest period, a maximum of 4 maintenance cycles (PCZ 300 mg/day, 4 days; fotemustine, day 4) was given every 4 weeks.		63	6	malignant glioma	Sixteen patients received an induction cycle consisting of 100 mg/day oral PCZ for 12 consecutive days. After a 6-week rest period, a maximum of 4 maintenance cycles (PCZ 300 mg/day, 4 days; fotemustine, day 4) was given every 4 weeks.			procarbazine	20			6	cycle		p.152
6585	6727		ADULT			Studied dose	mg/m2	100		multiple			week	1	unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/24510314/	Homo sapiens						58				100 mg/m(2) on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.		80	86	uveal melanoma					29						p.744
6586	6727		ADULT			Studied dose	mg/m2	100		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12649110/	Homo sapiens						64				100 mg/m(2) on an outpatient basis on days 1 and 8 of the induction cycle, followed after a 6-week rest period by fotemustine 100 mg/m(2) every 3 weeks		76	21	multiple myeloma					48						p.620
6587	6727		ADULT			Studied dose	mg/m2	100		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24510314/	Homo sapiens						60				100 mg/m(2) on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.		80	85	uveal melanoma					24						p.744
6588	6728					Highest studied dose	mg	120		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf	Homo sapiens													142									12	week		p. 53
6589	6728					Highest studied dose	mg	300		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf	Homo sapiens														Parkinson’s disease											p. 16
6590	6728					Overdose	mg	120		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf	Homo sapiens										6 tablets (120 mg, 3 times the maximum recommended dosage)			1												
6591	6728					Recommended	mg	40		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf	Homo sapiens						65						84	124						33			12	week		
6592	6728					Recommended	mg	40		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022075Orig1s000MedR.pdf	Homo sapiens													378									12	week		p. 38
6593	6730		ADULT			Highest studied dose	mg	4		multiple			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/8907133/	Homo sapiens													5	ischemia								2	day		S63-9
6594	6730		ADULT			Highest studied dose	mg	5		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7867680/	Homo sapiens						25						29	5						23			1	day		267-74
6595	6731		ADULT			Recommended	ug	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19926718/	Homo sapiens						59.6							114	kidney disease								14	day		p.1255
6596	6731		ADULT			Recommended	ug	5		multiple			week	3	unhealthy	intravenous	M+F		https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-winfuran_en.pdf	Homo sapiens													146	renal failure								52	week		p.102
6597	6733					Highest studied dose	mg	10		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf	Homo sapiens													60									3	day		
6598	6733					Recommended	mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210166s000lbl.pdf	Homo sapiens						47						95	1251	chronic idiopathic constipation					17			12	week		
6599	6735					Higher than recommended	mg	350		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22948897/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens						41.2							18		100 to 700 mg; 7 days			tyramine				10	day		207145Orig1s000MedR.pdf - p.227(195)
6600	6735					Higher than recommended	mg	350		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22948897/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens						41.2							18									6	day		207145Orig1s000MedR.pdf - p.227(195)
6601	6735					Higher than recommended	mg	350		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000CrossR.pdf	Homo sapiens													59									6	day		207145Orig1s000CrossR.pdf - p.13(14)
6602	6735					Highest studied dose	mg	400		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24136086/	Homo sapiens						28.7				(14)C safinamide methanesulphonate			6									1	day		
6603	6735					Recommended	mg	100		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													317	Parkinson’s disease											207145Orig1s000MedR.pdf - p.121(153)
6604	6735					Recommended	mg	100		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													498	Late/Advanced Stage Parkinson's disease											207145Orig1s000MedR.pdf - p.124(156)
6605	6735					Recommended	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													1	Parkinson’s disease								20	day		207145Orig1s000MedR.pdf - p.18(19)
6606	6735					Recommended	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													223	Late/Advanced Stage Parkinson's disease											207145Orig1s000MedR.pdf - p.124(156)
6607	6735					Recommended	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													226	Parkinson’s disease											207145Orig1s000MedR.pdf - p.121(153)
6608	6735						mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207145Orig1s000MedR.pdf	Homo sapiens													89	Parkinson’s disease											207145Orig1s000MedR.pdf - p.121(153)
6609	6736					MTD	mg/m2	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32998965/	Homo sapiens								60 mg/m2		0 mg/m2 i.v. over 30 minutes followed by 60 mg/m2 i.v. infusion over 4 hours.		65	23	Acute Myeloid Leukemia	100 mg/m2			Cytarabine	33			3	cycle	Daunorubicin	
6610	6737					Highest studied dose	mg	337.5		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16899614	Homo sapiens						64	total daily dose					78	7	advanced nonhematologic malignancies					23			27	cycle		
6611	6737					Highest studied dose	mg	500		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16899614	Homo sapiens						64	total daily dose					78	3	advanced nonhematologic malignancies					23			27	cycle		
6612	6737					Highest studied dose	mg	750		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17505003	Homo sapiens							total daily dose			seven consecutive days beginning on day 1 of a 21-day treatment cycle.			3	refractory cancer								7	day		
6613	6737					MTD	mg	225		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16899614	Homo sapiens						64	total daily dose					78	7	advanced nonhematologic malignancies					23			27	cycle		
6614	6737					MTD	mg	650		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17505003	Homo sapiens						53	total daily dose			seven consecutive days beginning on day 1 of a 21-day treatment cycle.		81	8	Refractory cancer					31			7	day		
6615	6737					Studied dose	mg	200		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16110019	Homo sapiens						57	total daily dose			the daily dose for 21 days in a 28-day cycle		83	52	ovarian cancer					38			21	day		
6616	6737					Studied dose	mg	50		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16110019	Homo sapiens						57	total daily dose			the daily dose for 21 days in a 28-day cycle		50	53	ovarian cancer					35			21	day		
6617	6737					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17505003	Homo sapiens						53	total daily dose			seven consecutive days beginning on day 1 of a 21-day treatment cycle.		81	7	Refractory cancer					31			7	day		
6618	6737					Studied dose	mg	560		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17505003	Homo sapiens						53	total daily dose			seven consecutive days beginning on day 1 of a 21-day treatment cycle.		81	8	refractory cancer					31			7	day		
6619	6739					Highest studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16527696/	Homo sapiens						36							32	Crohn's disease								8	week		
6620	6739					Highest studied dose	mg	600		single			day	1	healthy	oral	M		https://www.infona.pl/resource/bwmeta1.element.elsevier-a1ebd336-ca9c-3af7-9873-8f6170365345	Homo sapiens						30							6									1	day		
6621	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222604	Homo sapiens						77							55						77			3	month		
6622	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222605	Homo sapiens						77							55						77			3	month		
6623	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222606	Homo sapiens						77							55						77			3	month		
6624	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222607	Homo sapiens						77							55						77			3	month		
6625	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222608	Homo sapiens						77							55						77			3	month		
6626	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222609	Homo sapiens						77							55						77			3	month		
6627	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222610	Homo sapiens						77							55						77			3	month		
6628	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222611	Homo sapiens						77							55						77			3	month		
6629	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222612	Homo sapiens						77							55						77			3	month		
6630	6740					Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222613	Homo sapiens						77							55						77			3	month		
6631	6740						mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222614	Homo sapiens						79							49						79			3	month		
6632	6740						mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222615	Homo sapiens						79							49						79			3	month		
6633	6740						mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21222616	Homo sapiens						79							49						79			3	month		
6634	6741					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7042771	Homo sapiens						41.2	max					59	29	anxiety					25			6	week		
6635	6742		adult			Recommended	mg	690		steady			day	1	unhealthy	rectal	M		https://pubmed.ncbi.nlm.nih.gov/28736321/	Homo sapiens													24	prostate cancer								6	month		
6636	6742		adult			Recommended	mg	920		steady			day	1	unhealthy	rectal	M		https://pubmed.ncbi.nlm.nih.gov/28736321/	Homo sapiens										920 to 1740 mg			23	prostate cancer								8	week		
6637	6745		ADULT			Highest studied dose	mg/m2	190		multiple			week	2	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/16222321	Homo sapiens							unknown							advanced malignancies								28	week		
6638	6746		adult			Highest studied dose	ug/kg	1000		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/9815786/	Homo sapiens													3	solid tumor								1	day		
6639	6746		adult			Highest studied dose|MTD	ug/kg	550		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8137247/	Homo sapiens										every 28 days			1	colon cancer								5	day		
6640	6746					Highest studied dose	ug/kg	600		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9815786/	Homo sapiens						53				median duration			2	lung cancer | pancreatic cancer								4.5	week		
6641	6746					MTD	ug/kg	300		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9815786/	Homo sapiens						53				median duration			5	solid tumor								10	week		
6642	6746					Studied dose	ug/kg	150		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9815786/	Homo sapiens						53				median duration			8	solid tumor								4	week		
6643	6746					Studied dose	ug/kg	37.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16034517/	Homo sapiens						58.4	starting			and 1 week of rest; 2-4 four week cycles cycles			17	renal cell carcinoma								3	week		
6644	6748		ADULT			MTD	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16617323	Homo sapiens							unknown						31	myeloid leukemia								28	day		
6645	6748		ADULT			Studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16617323	Homo sapiens						67.8	unknown					74	18	myeloid leukemia					47			28	day		
6646	6748					Studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16617323	Homo sapiens						72.4	unknown					84	35	myelodysplastic syndrome					39			28	day		
6647	6749		ADULT			Highest studied dose	mg/m2	1800		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1988134	Homo sapiens						46				Amonafide was given i.v. over 2-4 h daily for 5 days.			4	acute leukemia								5	day		p.936
6648	6749		ADULT			Studied dose	mg/m2	1104		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2549205	Homo sapiens						62				single intravenous (IV) infusion over 30 to 120 minutes repeated every 28 days			5	cancer											p.1354
6649	6751					Highest studied dose	mg	300		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21059888/	Homo sapiens												45	6						18			14	day		
6650	6751					Highest studied dose	mg	350		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21059888/	Homo sapiens												45	6						18			1	day		
6651	6752		ADULT				mg	0.15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18466359	Homo sapiens						45.6	unknown						146	irritable bowel syndrome								12	week		
6652	6752		ADULT				mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18466359	Homo sapiens						47.3	unknown						148	irritable bowel syndrome								12	week		
6653	6752						mg	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18466359	Homo sapiens							unknown						142	irritable bowel syndrome								12	week		
6654	6753		ADULT			Highest studied dose|Studied dose	mg/m2	300		single					unhealthy	intrapleural	F		https://pubmed.ncbi.nlm.nih.gov/10100701/	Homo sapiens													3	breast cancer											
6655	6761					Highest studied dose	mg	800		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15246912	Homo sapiens						60							19	congestive heart failure											p.238
6656	6770		adult			Studied dose	g	1.2		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/12493263/	Homo sapiens													9	malaria								5	day		
6657	6770		adult			Studied dose	g	4		steady			day	1	healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/12937969/	Homo sapiens													127									5	day		
6658	6770		adult			Studied dose	g	4		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12937969/	Homo sapiens													127									7	day		
6659	6770		adult			Studied dose	g	8		steady			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/12937969/	Homo sapiens													127									7	day		
6660	6770		adult			Studied dose	mg	1200		steady			day	3	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/12937969/	Homo sapiens													20	malaria								7	day		
6661	6777		ADULT			Highest studied dose	mg/m2	6		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8320744	Homo sapiens						53	unknown					78	10	malignant solid tumors					26			3	week		
6662	6778		ADULT			Highest studied dose	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11181683/	Homo sapiens						56						77	3	cancer					28			40	day		
6663	6778		ADULT			Studied dose	mg	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11181683/	Homo sapiens						56						77	3	cancer					28			40	day		
6664	6779					Studied dose	mg	180		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/15190231/	Homo sapiens						56							5	Parkinson disease	50 mg higher than the usual effective dose taken in the morning; 1/9 days			levodopa				9	day		
6665	6780					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19852040	Homo sapiens						49.3		1000 or 1200 mg/day					118	Chronic hepatitis C	180 ug; 1/wk			Peg-IFN-alfa-2a, s.c				24	week	ribavirin; p.o	p.1724
6666	6782		ADULT				mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25602710	Homo sapiens						40.46							13	cocaine abuse				сocaine				7	day		p.8
6667	6787					Studied dose	mg	80		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19567409/	Homo sapiens						65.5							67	symptomatic heart failure								24	week		
6668	6790					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27550361/	Homo sapiens						37							14	Tuberculosis								14	day		
6669	6790					Highest studied dose	mg	1200		single			day	1	unhealthy	oral	M		https://www.wipo.int/export/sites/www/research/en/data/AZD584_preclinical_002.pdf	Homo sapiens						26.2							6	Tuberculosis								1	day		
6670	6790					Highest studied dose	mg	600		single			day	1	unhealthy	intravenous	M		https://www.wipo.int/export/sites/www/research/en/data/AZD584_preclinical_002.pdf	Homo sapiens						36.2	max						10	Tuberculosis								1	day		
6671	6790					Highest studied dose	mg	600		single			day	3	unhealthy	oral	M		https://www.wipo.int/export/sites/www/research/en/data/AZD584_preclinical_002.pdf	Homo sapiens						26.2							6	Tuberculosis								1	day		
6672	6790					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27550361/	Homo sapiens						35							13	Tuberculosis								14	day		
6673	6791		adult			Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/17311555/ | https://pubmed.ncbi.nlm.nih.gov/16375749/	Homo sapiens													285	Rheumatoid arthritis								12	week		
6674	6792					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14871966/	Homo sapiens						54				at least 3 months			6	solid tumors								3	month		
6675	6792					Studied dose	mg	5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14871966/	Homo sapiens						54				at least 3 months			14	solid tumors								3	month		
6676	6794					Highest studied dose	mg	8		multiple			day	6	healthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/11796347/	Homo sapiens						23							6									7	day		
6677	6794					Highest studied dose	mg	8		single			day	1	healthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/11796347/	Homo sapiens						37							4									1	day		
6678	6796					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15023570	Homo sapiens						39.2							91	Schizophrenia					39.2			6	week		
6679	6796						mg	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15023570	Homo sapiens						36.6							96	Schizophrenia					36.6			6	week		
6680	6796						mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15023570	Homo sapiens						38.2							99	Schizophrenia					38.2			6	week		
6681	6797					MTD	mg/m2	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11291827/	Homo sapiens						60							8	solid tumors								2	week		
6682	6797					MTD	mg/m2	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11291827/	Homo sapiens						60							7	solid tumors								8	week		
6683	6798					Studied dose	mg	35		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12581229/	Homo sapiens							mean					57	11	chronic intractable epilepsy					29			21	day		
6684	6798					Studied dose	mg	50		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19961264/	Homo sapiens												75	40	amyotrophic lateral sclerosis					27			9	month		
6685	6803		ADULT			Highest studied dose	mg	225		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9109749	Homo sapiens						75	total daily dose					90	87	Alzheimer disease					60			6	month		
6686	6804		ADULT			Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens												37	8						22			15	day		760-6
6687	6804		ADULT			Highest studied dose	mg	1200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7929871/	Homo sapiens												37	4						18			1	day		760-6
6688	6804		ADULT			Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14747227/	Homo sapiens						52.6	min						45	diabetes mellitus								12	month		448-54
6689	6806		ADULT			Studied dose	%	0.032		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/16246781/	Homo sapiens						32.8	max						10	open-angle glaucoma											p.1771
6690	6807		ADULT			Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4028627	Homo sapiens						51.5							13	hyperlipoproteinemia								10	week		p.315
6691	6809		ADULT			Highest studied dose	mg	3		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/14439724/	Homo sapiens						25				on 38th day of experiment; 0.2 mg IV was done on 28th day			1	paralysis periodica paramyotonica								1	day		376-85
6692	6809		ADULT			Highest studied dose	mg	6		multiple			day	3	healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/13587664/	Homo sapiens						30	total daily dose						1									22	day		1549-55
6693	6816		ADULT			Studied dose	mg	18		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8905533/	Homo sapiens						36	max|total daily dose					62	66	schizophrenia					19			6	week		p.244, 247
6694	6821		ADULT				mg	20		multiple			4 days	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/24697004/	Homo sapiens						45							1	alcoholic pancreatitis								9	day		
6695	6826		adult			Highest studied dose	ug/kg	350		single			day	1	healthy	intravenous			https://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.1984.tb00460.x	Homo sapiens													4									1	day		
6696	6831		ADULT			Studied dose	mg	10		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3168394/	Homo sapiens												76	757						14						
6697	6831		ADULT			Studied dose	mg	69		single					unhealthy	oral	unknown		https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/576442	Homo sapiens							mean			from 20 to 140 mg, averaging 69 mg, was given in divided doses at 6- to 12-hour intervals			28	hypertension											
6698	6840					Studied dose	mg	200		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2895433/	Homo sapiens							max			individually adjusted, ranging from 25 mg up to 200 m		59	29	schizophrenic					22			20	day		
6699	6840					Studied dose	mg	600		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6149595/	Homo sapiens							max			200-600 mg/day		71	11	tardive dyskinesia and parkinsonism					42			7	day		
6700	6842					Studied dose	mg	10		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19094161	Homo sapiens							unknown					75	14						65						
6701	6842					Studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19346160	Homo sapiens						48.3	unknown						153	primary insomnia								2	week		
6702	6845					Studied dose	mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1352928/	Homo sapiens												47	4						37						
6703	6852		ADULT			Highest studied dose	mg/kg	10		multiple			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/11565955	Homo sapiens						60.5							4	cancer											p.174
6704	6853		adult			Overdose	mg	320		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/845494/ | https://pubmed.ncbi.nlm.nih.gov/29408722/	Homo sapiens													1									1	day		
6705	6853					Overdose	ug	1200		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32048609/	Homo sapiens						15	max						1	bipolar disorder					15			1	day		
6706	6859					MTD	mg	87.5		steady			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28371832/	Homo sapiens												80.5	27	High-grade gliomas					19.8			7	day		
6707	6861					Highest studied dose	mg	500		multiple			day	1	unhealthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/4950287	Homo sapiens						43.06				schedule: intravenously during the first 8 days and intramuscularly from the 9th to the 20th day. Nialamide was applied intravenously with 250 ml of glucohyposaline serum early in the morning. Dosage was 100 mg the 1st day, 250 mg the 2nd day, and then 500 mg daily from the 3rd to the 20th day			15	Depression								17	day		p.94
6708	6861					Highest studied dose	mg	75		multiple			day	3	unhealthy	oral	M+F		https://www.ajconline.org/article/0002-9149(60)90378-7/fulltext	Homo sapiens													25	Hypertension								8	week		p.1142
6709	6861					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/4864297	Homo sapiens						59.3							32	Intermittent claudication								2	year		p.761
6710	6866					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2651559	Homo sapiens												44	18	attention deficit disorder					18			6	week		
6711	6866						mg	100		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/3956054	Homo sapiens										Intravenous nomifensine was given as a 50 ml infusion of 282.49 uM nomifensine in 20 minutes with a perfusion pump.		41							22						
6712	6870		ADULT			Highest studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18308795/	Homo sapiens						23.2						29	15		co-administration of 100 mg CBD 3 hours before\nand 50 mg CBD 3 hours after administration of 5-HTP			carbidopa	19						p.429
6713	6872					Overdose	mg	2500		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/1020609	Homo sapiens													1												
6714	6872					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.mims.com/philippines/drug/info/phenformin?mtype=generic	Homo sapiens							max							Type 2 diabetes mellitus											
6715	6880		ADULT			Highest recorded dose	mg	16		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7871044/	Homo sapiens						35				After the initial 8 mg dose on day 1 of the study, repeated plasma samples were collected over the ensuing 36 h. Subsequently, patients received raclopride 8 mg b.i.d. through day 7, 12 mg b.i.d. through day 14, and, if tolerated, 16 mg b.i.d. through day 21. Six reached the highest dose level, and received 16 mg b.i.d, during the entire third week.		52	6	schizophrenia					22			21	day		p.372
6716	6880		ADULT			Highest studied dose	mg	8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1485530/	Homo sapiens						35.6	max			2-8 mg twice daily			44	schizophrenia								4	week		p.393
6717	6880		ADULT			Highest studied dose	mg	8		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2531773/	Homo sapiens						37	max			The starting dose of raclopride was 2 mg increasing to 4 mg twice daily in the first week, further increments to 6 mg twice daily at day 14, and 8 mg twice daily at day 21 depending on response.		63	15	schizophrenia					19			4	week		p.63, 64
6718	6880					Studied dose	mg	16		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2526172/	Homo sapiens						27						34	4						22						p.123
6719	6881					Highest studied dose	mg	5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8956382/	Homo sapiens						41.6							144	alcohol dependence								12	week		
6720	6881					Studied dose	mg	10		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8590616/	Homo sapiens						26.6							20		0.5 g/kg			alcoho							
6721	6881					Studied dose	mg	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1910052/	Homo sapiens												49	5	Chronic glomerulonephritis					23						
6722	6883		ADULT			Highest studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7870927/	Homo sapiens						53.25						64	12	major depressive disorder					36			28	day		p.125
6723	6892					Highest studied dose	mg	800		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1318680/	Homo sapiens												28	6						19			7	day		
6724	6892					Overdose	mg	400		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8806150/	Homo sapiens						4							1	urinary tract infaction					4						
6725	6892					Recommended	mg	600		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1664833/	Homo sapiens												91	49	bacterial pneumonia					18			10	day		
6726	6895		adult			Studied dose	mg	375		single			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15434379/	Homo sapiens							mean						7									1	day		
6727	6895		adult			Studied dose	mg/kg	41		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/20238897/	Homo sapiens													3	hypertension								1	day		
6728	6899		ADULT			Highest studied dose	mg	1500		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1451725/	Homo sapiens												26	12						21			1	day		427-30
6729	6899		ADULT			Highest studied dose	mg	600		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1451725/	Homo sapiens												26	5						21			11	day		427-30
6730	6904					Studied dose	mg	6		steady			day	5	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/1426207/	Homo sapiens						31						54	12	asthma					21			1	day		
6731	6907					Highest studied dose	mg	800		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6883915	Homo sapiens													10	opioid abuse											
6732	6907						mg	100		multiple			day	6	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6222714	Homo sapiens						28							1						28			16	day		
6733	6907						mg	300		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/6222714	Homo sapiens												72	2						36			1	week		
6734	6908						mg	250		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13726185	Homo sapiens						40	starting			Initially he received 250 mg. (1 tablet) 4 times a day. Then, the dosage of the drug was reduced to 250 mg. twice a day. Hereafter, the dosage was further decreased to 250 mg. daily.			1	chronic polyartieular gout					40			1	month		
6735	6927		ADULT			Highest studied dose	mg/m2	2600		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2591433	Homo sapiens						54							1	cancer								2	course		p.1406, 1407
6736	6927		ADULT			MTD	mg/m2	210		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8499153	Homo sapiens						51				10 min intravenous (i.v.) infusion for 5 consecutive days, every 4 weeks; patients received a median of two courses (range 1-7)			5	cancer								5	day		p.986
6737	6927		ADULT			MTD	mg/m2	2300		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2591433	Homo sapiens						54							3	cancer								2.6	course		p.1406, 1407
6738	6927		ADULT			MTD	mg/m2	600		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2591433	Homo sapiens						54				At a biweekly schedule the MTD was found to be 600 mg/m2 in previously treated patients.			4	cancer								21	course		p.1407
6739	6927		ADULT			MTD	mg/m2	850		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2591433	Homo sapiens						54				At a biweekly schedule the MTD was found to be 850 mg/m2 in previously untreated patients			4	cancer								17	course		p.1407
6740	6927		ADULT			Studied dose	mg/m2	350		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8499153	Homo sapiens						51				10 min intravenous (i.v.) infusion for 5 consecutive days, every 4 weeks; patients received a median of two courses (range 1-7)			1	cancer								5	day		p.986
6741	6929					Studied dose	mg	300		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5457511	Homo sapiens													22	Breast Cancer								7	month		
6742	6929						mg	200		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/141327	Homo sapiens													45	Advanced Breast Cancer											
6743	6931					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15383182	Homo sapiens												55	40	Benzodiazepine withdrawal syndrome					25			6	week		p.1349
6744	6939					Highest studied dose	mg/m2	100		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18927309/	Homo sapiens						53							1	solid tumors								21	day		
6745	6939					Studied dose	mg/m2	24		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18927309/	Homo sapiens						53							4	solid tumors								21	day		
6746	6939					Studied dose	mg/m2	72		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18927309/	Homo sapiens						53							19	solid tumors								21	day		
6747	6940		ADULT			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17917503	Homo sapiens						62							76	hypertension								10	week		p.766, 767
6748	6941		adult			Highest studied dose	mg	2500		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7767953/	Homo sapiens													3	cancer								7	day		
6749	6941		adult			Studied dose	mg	1000		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7767953/	Homo sapiens													4	cancer								7	day		
6750	6941		adult			Studied dose	mg	2000		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7767953/	Homo sapiens													3	cancer								7	day		
6751	6941		adult			Studied dose	mg	500		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/7767953/	Homo sapiens													8	cancer								7	day		
6752	6948					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16192835	Homo sapiens						41	unknown						18	panic disorder								9	week		
6753	6949		ADULT			Highest studied dose	mg	1000		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17545533	Homo sapiens						55.5							4	cancer	1000 mg of elacridar on days 1 and 8 1 h before or simultaneously with 2.0 mg oral topotecan			topotecan							p.3279
6754	6950						mg	90		multiple			day	1	healthy	oral	M		https://www.ecnp.eu/~/media/Files/ecnp/Projects and initiatives/Medicines Chest/XBD173.pdf	Homo sapiens													14									7	day		
6755	6961						%	10		multiple			day	1	unhealthy	ophthalmic			https://pubmed.ncbi.nlm.nih.gov/14829485	Homo sapiens													21	glaucoma								6	month		
6756	6962					Highest studied dose	mg	2400		single					unhealthy	oral			https://journals.lww.com/jonmd/Citation/1956/02000/CLINICAL_OBSERVATIONS_ON_THE_SOMNIFACIENT_EFFICACY.4.aspx	Homo sapiens																									
6757	6964					Recommended	mg	25		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11238495/	Homo sapiens												85	111	osteoporosis	10 mg			alendronate	64			18	month		
6758	6964					Recommended	mg	25		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11238495/	Homo sapiens												85	36	osteoporosis					64			12	month		
6759	6964					Recommended	mg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21067829/	Homo sapiens						79.3							62	hip fracture					79.3			24	week		
6760	6964					Recommended	mg/kg	0.2		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11452249/	Homo sapiens						10.6							18	idiopathic GH deficiency					10.6			7	day		
6761	6967					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18246982	Homo sapiens							unknown					64	91	insomnia					18			4	week		
6762	6972		ADULT			Highest studied dose	mg	1		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16735934/	Homo sapiens												74	82	osteoporosis					47			2	year		
6763	6972		ADULT			Studied dose	mg	0.25		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16397281/	Homo sapiens													6												
6764	6972		ADULT			Studied dose	mg	0.25		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16735934/	Homo sapiens												74	82	osteoporosis					47			2	year		
6765	6972		ADULT			Studied dose	mg	20		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18372400/	Homo sapiens										single 20-mg dose of [(14)C]lasofoxifene		45	4						18						
6766	6975					Highest studied dose	ug/g	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/7817684/	Homo sapiens						51.5							27	psoriasis								6	week		
6767	6976		ADULT			Highest studied dose	mg	300		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12395330	Homo sapiens						49						52	5	Cirrhosis					45						p.1202
6768	6976		ADULT			Studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12500203	Homo sapiens						51.3							10	cirrhosis of liver								1	week		p.187, 188
6769	6978					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9626215	Homo sapiens							unknown					77	6	lung cancer					45			8	week		
6770	6978					Studied dose	mg	20		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15958628	Homo sapiens						59	total daily dose					71	13	prostate cancer					52			8	month		
6771	6978					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15958628	Homo sapiens							total daily dose						9	prostate cancer								8	month		
6772	6978					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15958628	Homo sapiens						58	total daily dose					77	17	prostate cancer					48			6	month		
6773	6982		adult				mg/m2	65		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/6969632	Homo sapiens													71	advanced cancer								4	week		
6774	6987					Highest studied dose	mg	90		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20041911	Homo sapiens						44.9							31						44.9			28	day		
6775	6988					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15706463	Homo sapiens						34.5							37	Panic disorder								4	week		p.27
6776	6992					Studied dose	mg	4.8		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16702891	Homo sapiens						26.4							25						26.4						
6777	6992						mg	0.3		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20075648	Homo sapiens												65	82						18			6	week		
6778	6997					Studied dose	mg	2		multiple			day	6	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/7726484	Homo sapiens						20							53	Rhinovirus colds								5	day		p.293
6779	6998		ADULT			Highest studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10354965/	Homo sapiens													8									1	day		613-8
6780	6998		ADULT			Highest studied dose	mg	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12802751/	Homo sapiens						33						82	1046	common cold					18			5	day		1523-32
6781	7005		ADULT			Highest studied dose	mg/kg	0.02		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17532523	Homo sapiens						45.6							11	hepatitis C infection								4	week		p.177
6782	7005		ADULT			Studied dose	%	0.1		multiple			week	3	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/18476957	Homo sapiens						70.3				0.1% gel was applied once daily three times a week for 4 weeks to a contiguous 25-cm(2) area with four to eight lesions			34	actinic keratosis								4	week		p.208
6783	7007					Highest studied dose	mg	20		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18775020/	Homo sapiens												70	133	irritable bowel syndrome					18			12	week		
6784	7007					Studied dose	mg	5		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18775020/	Homo sapiens												70	131	irritable bowel syndrome					18			12	week		
6785	7008					Highest studied dose	mg	64		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16199243	Homo sapiens						46.2							71	Diabetic peripheral neuropathy								1	year		p.1170
6786	7022						mg	217.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2885367	Homo sapiens						29	mean						9	schizophrenia					29			6	week		
6787	7026		ADULT			Highest studied dose	mg	300		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens						31.6							6									8	day		
6788	7026		ADULT			Highest studied dose	mg	600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8300896/	Homo sapiens						31.6							6												
6789	7028					Highest studied dose	g	25		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10341162/	Homo sapiens						43.6							8									8	week		
6790	7028					Highest studied dose	g	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10341162/	Homo sapiens						53.8							8	Type 2 diabetes mellitus								8	week		
6791	7028					Highest studied dose	g	29		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10341163/	Homo sapiens						30.7							33									1	day		
6792	7028					Highest studied dose	g	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10341164/	Homo sapiens												40	8						21			15	day		
6793	7064		ADULT			Highest studied dose	%	15		multiple			day	4	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/2988845/	Homo sapiens						31						48	16	herpes simplex					25			5	day		56-9
6794	7064		ADULT			Overdose	g	80		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3765608/	Homo sapiens						24							1	Herpes Genitalis								1	day		245-6
6795	7080					Highest studied dose	g	1.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4613319	Homo sapiens							max						9	Mania|Depression|Hypomania								20	day		p.650
6796	7080					Studied dose	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/331875	Homo sapiens						77				Fusaric acid was administered in 50-mg capsules t.i.d. for 1 week, then 100 mg t.i.d. for the 2nd week, and 150 mg t.i.d. for the 3rd week.			15	Tardive dyskinesia|Psychotic disorders								3	week		p.59
6797	7092		ADULT			Studied dose	%	2		multiple			week	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/19951427/	Homo sapiens						10							36	Lice infestation	4%			dimeticone				2	week		p.7
6798	7098					Studied dose	mg	100		multiple			day	1	healthy	oral	F		https://www.bfr.bund.de/cm/349/health-assessment-of-sports-and-weight-loss-products-containing-synephrine-and-caffeine.pdf	Homo sapiens						27							1		400 mg, q.d, 2 weeks			caffeine, p.o				2	week		p.11
6799	7098					Studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26388707	Homo sapiens						22.3							12												p.5
6800	7395					Highest studied dose	g	15		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8815168/	Homo sapiens												60	5	McArdle's disease					20			7	day		
6801	7423					Recommended	uL/kg	10		multiple			30 min	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Homo sapiens										May be injected by either an intravenous (IV) bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. The recommended bolus dose for activated DEFINITY® is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement.		93	1716	Coronary artery disease					18			2	times		p.6
6802	7423					Recommended	uL/kg	10		multiple			30 min	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Homo sapiens										May be injected by either an intravenous (IV) bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. The recommended bolus dose for activated DEFINITY® is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement.				Coronary artery disease								2	times		p.1
6803	7423					Recommended	uL/kg	10		multiple			30 min	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021064s017lbl.pdf	Homo sapiens										May be injected by either an intravenous (IV) bolus or infusion. The maximum dose is either two bolus doses or one single intravenous infusion. The recommended bolus dose for activated DEFINITY® is 10 microliters (microL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (microL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement.				Coronary artery disease								2	times		p.1, 5
6804	7426					Recommended	%	0.44		multiple			day	1	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200740Orig1s000MedR.pdf	Homo sapiens										The total daily dose of 0.44% cysteamine HCl ophthalmic solution is estimated to be 7.8 mg/day based on a 100 μL dose per hour × 12 waking hours. The recommended daily maintenance dose approved for orally administered cysteamine ranges from 400 mg/day for an infant with body weight <10 pounds to 2000 mg/day for adults. Therefore, the total daily ophthalmic dose is less than 2% of the recommended oral daily dose of cysteamine.			20	cystinosis								6	month		98 EI0109S
6805	7426					Recommended	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203389Orig1s000MedR.pdf	Homo sapiens													20									2	week		RP103-05
6806	7433		adult				mL	100		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT03119662	Homo sapiens										320 mg I/ml			2	Chronic Kidney Disease											
6807	7433					Highest studied dose	g/kg	2.44399185336049		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1601604	Homo sapiens						29				1.2 g I/kg; 49.1% iodine content		44	10						21						
6808	7433						mg/mL	651.73116089613		single					unhealthy	intrathecal			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020351s048,020808s028lbl.pdf	Homo sapiens										320 mg I /mL; 49.1% iodine content, total dose unknown															
6809	7434					Highest studied dose	mg/kg	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21317681/	Homo sapiens												6	6	bacterial infection					2						
6810	7434					Recommended	mg/kg	10		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32725216/	Homo sapiens												80	81	bacterial infection					62			16	week		
6811	7434					Recommended	mg/kg	10		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32725216/	Homo sapiens												80.8	74	bacterial infection	2 g			fosfomycin	60.8			16	week		
6812	7434					Recommended	mg/kg	6		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25361023/	Homo sapiens														proven/suspected bacterial infection											
6813	7434					Recommended	mg/kg	6		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16914701/	Homo sapiens												87	120	bacterial infection					21			42	day		
6814	7435		adult			Recommended	mg	60		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens													2311									4	month		p. 36
6815	7435		adult				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00627016	Homo sapiens													152	Gastroesophageal Reflux Disease								4	week		
6816	7435		adult				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02873689	Homo sapiens													107	Gastroesophageal Reflux Disease								4	week		
6817	7435		adult				mg	60		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02873702	Homo sapiens													17	Erosive Esophagitis								8	week		
6818	7435		adult				mg	90		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens													2142									4	month		p. 36
6819	7435		child				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01642615	Homo sapiens													25	Erosive Esophagitis								16	week		
6820	7435		child				mg	60		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01642615	Homo sapiens													62	Erosive Esophagitis								8	week		
6821	7435					Highest studied dose	mg	300		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19826060	Homo sapiens						35						50	36						18						
6822	7435					Overdose	mg	60		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf	Homo sapiens																						8	week		
6823	7435					Recommended	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208056lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens						48						90	2218						18			8	week		p. 35
6824	7435					Recommended	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens						48						90	2218						18			8	week		p. 35
6825	7435						mg	30		multiple			day	2	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28138748	Homo sapiens												29	18						18			5	day		
6826	7435						mg	30		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens						48						90	455						18			8	week		p. 35
6827	7435						mg	90		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28138748	Homo sapiens												29	8						18						
6828	7435						mg	90		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022287s000_MedR_P1.pdf	Homo sapiens						48						90	1754						18			8	week		p. 35
6829	7443					Overdose	mg/kg	15		single					healthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf	Homo sapiens																									p.8
6830	7443					Recommended	mg/kg	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24450506	Homo sapiens						62							751	Nosocomial pneumonia											p.285
6831	7443					Recommended	mg/kg	10		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf	Homo sapiens										10 mg/kg administered over 60 minutes by intravenous infusion once every 24 hours for 7 to 14 days			929	Skin and skin structure infections caused by susceptible Gram-positive bacteria								14	day		p.1,5
6832	7443					Recommended	mg/kg	10		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf	Homo sapiens										10 mg/kg administered over 60 minutes by intravenous infusion once every 24 hours for 7 to 14 days			929	Skin and skin structure infections caused by susceptible Gram-positive bacteria								14	day		p.9
6833	7443					Recommended	mg/kg	10		multiple			day	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022110s000lbl.pdf	Homo sapiens										10 mg/kg administered over 60 minutes by intravenous infusion once every 24 hours for 7 to 14 days				Skin and skin structure infections caused by susceptible Gram-positive bacteria								14	day		p.1
6834	7443					Recommended	mg/kg	10		multiple			day	1	unhealthy	intravenous			https://www.ema.europa.eu/en/documents/product-information/vibativ-epar-product-information_en.pdf	Homo sapiens														Nosocomial pneumonia								14	day		p.4
6835	7455		adult			Highest studied dose	mg	100		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14010800/	Homo sapiens													50	nonproductive cough								2	day		
6836	7465					Highest studied dose	mg	370		multiple			day	6	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6747817	Homo sapiens										quinidine sulfate capsule with designed doses (279-370 mg quinidine base)			1						23			2	day		
6837	7465					Overdose	g	4		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/5557506	Homo sapiens						57				20 200 mg quinidine tablets			1						57						
6838	7465						mg	1650		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/6747817	Homo sapiens										The total dose in the five subjects ranged from 1380 to 1650 mg quinidine gluconate			1						23			1	hour		
6839	7465						mg	200		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1269875	Homo sapiens						47							1						47			10	day		
6840	7465						mg	324		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7604299	Homo sapiens						79				Quinidine sulfate (400 mg orally) was given, and maintenance quinidine gluconate (324 mg orally every 8 hours) was begun. 324 mg of quinidine gluconate (202 mg of quinidine base)			1				crystalline warfarin sodium	digoxin	79			2	week	levothyroxine sodium	
6841	7465						mg	324		multiple			day	5	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7604299	Homo sapiens										324 mg, 5 pills per day. 324 mg of quinidine gluconate (202 mg of quinidine base)			1									2	week		
6842	7490		adult			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209321Orig1s000MedR.pdf	Homo sapiens										maximum per day															
6843	7490		adult			Recommended	mg	10		multiple			day	3	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209321s000lbl.pdf	Homo sapiens										15 mg to 30 mg daily, in divided doses (2 to 3 times per day). Maximum Single Dose = 30 mg			52												
6844	7490		adult			Studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209321Orig1s000MedR.pdf	Homo sapiens							typical						162									1.7	year		
6845	7503		adult			Studied dose	mL	10.3		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf	Homo sapiens							mean			Healthy volunteers and patients (128 healthy volunteers and 5147 patients). The majority (77%) of subjects received SonoVue at cumulative doses of 10 mL or less. This includes subjects who received multiple bolus doses of SonoVue.			5275									1	day		nda/2014/203684Orig1s000MedR.pdf - p.150
6846	7503		adult			Studied dose	mL	10.3		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf	Homo sapiens							mean			Healthy volunteers and patients (128 healthy volunteers and 5147 patients). The majority (77%) of subjects received SonoVue at cumulative doses of 10 mL or less. This includes subjects who received multiple bolus doses of SonoVue.			5275									1	day		nda/2014/203684Orig1s000MedR.pdf - p.161
6847	7503		adult			Studied dose	mL	10.3		single			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/203684Orig1s000MedR.pdf	Homo sapiens							mean			Healthy volunteers and patients (128 healthy volunteers and 5147 patients). The majority (77%) of subjects received SonoVue at cumulative doses of 10 mL or less. This includes subjects who received multiple bolus doses of SonoVue.			5275									1	day		nda/2014/203684Orig1s000MedR.pdf - p.58
6848	7504					Overdose	g	10		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9725981	Homo sapiens						68							1	Depression											p.545
6849	7504					Overdose	g	20		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31110633	Homo sapiens						42							1												p.246
6850	7504					Overdose	g	20		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31110633	Homo sapiens						27							1												p.246
6851	7504					Overdose	g	30		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31110633	Homo sapiens						39							1												p.246
6852	7504					Overdose	g	30		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31110633	Homo sapiens						67							1												p.232
6853	7504					Overdose	g	38		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/624775	Homo sapiens						38							1	Depression											p.136
6854	7504					Overdose	mg/kg	39		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8632499	Homo sapiens						3							1												p.102
6855	7504					Overdose	mg/kg	88		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8632499	Homo sapiens						1.25							1												p.102
6856	7505		adult			Highest studied dose	g	4		multiple			day	1	unhealthy	intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Homo sapiens													3									2	week		
6857	7505		adult			Recommended	g/mL	0.2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Homo sapiens										1 gram in 5 mL															
6858	7505		adult				g/mL	0.2		single					unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021749lbl.pdf	Homo sapiens										1 gram in 5 mL															
6859	7522		ADULT			Studied dose	%	0.02		multiple			day	1	unknown	intraurethral	unknown		https://pubmed.ncbi.nlm.nih.gov/32641131/	Homo sapiens										catheter irrigation			32									5	day		
6860	7523		ADULT			Highest studied dose	mg	50		multiple			day	2	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/17638394/	Homo sapiens						48.5							183	pain disorder								2	day		533-43
6861	7524		ADULT			Highest studied dose	mg	3000		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16168682/	Homo sapiens						28.5						40	12						23			3	day		p.1045
6862	7524		ADULT			Recommended	mg	1500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11214126/	Homo sapiens						66							106	osteoarthritis								3	year		p.254
6863	7530		adult			MTD	ug/m2	20		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24674872/	Homo sapiens							max						25	metastatic renal cell carcinoma and soft tissue sarcoma	37.5 mg			temsirolimus				4	month		
6864	7530		adult			MTD	ug/m2	20		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24674872/	Homo sapiens													25	metastatic renal cell carcinoma and soft tissue sarcoma	37.5 mg			temsirolimus				1	month		
6865	7530		adult			Studied dose	ug/m2	20		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24674872/	Homo sapiens													25	metastatic renal cell carcinoma and soft tissue sarcoma	15 mg			temsirolimus				1	month		
6866	7530					Highest studied dose	ug/m2	180		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9440723/	Homo sapiens												79	3	relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia					38			2	cycle		
6867	7530					MTD	ug/m2	120		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9440723/	Homo sapiens												79	6	relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia					38			4	cycle		
6868	7530					MTD	ug/m2	50		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens							max					80	59	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	25 mg/m2			fludarabine	38			30	day		
6869	7530					MTD	ug/m2	50		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Bryostatin 1 - fludarabine		77	7	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	25 mg/m2			fludarabine	38			5	day		
6870	7530					MTD	ug/m2	50		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Fludarabine - bryostatin 1		80	9	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	25 mg/m2			fludarabine	43			5	day		
6871	7530					Studied dose	ug/m2	16		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Bryostatin 1 - fludarabine		77	6	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	12.5 mg/m2			fludarabine	38			5	day		
6872	7530					Studied dose	ug/m2	16		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Bryostatin 1 - fludarabine		77	6	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	19 mg/m2			fludarabine	38			5	day		
6873	7530					Studied dose	ug/m2	16		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Fludarabine - bryostatin 1		80	7	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	12.5 mg/m2			fludarabine	43			5	day		
6874	7530					Studied dose	ug/m2	25		multiple			month	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19738452/	Homo sapiens												81	19	advanced pancreatic carcinoma	90 mg/m			paclitaxel	21			2	month		
6875	7530					Studied dose	ug/m2	25		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17020988/	Homo sapiens										consistency: Bryostatin 1 - fludarabine		77	6	chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma	25 mg/m2			fludarabine	38			5	day		
6876	7555					Highest studied dose	mg	150		multiple			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens																						7	day		
6877	7555					Highest studied dose	mg	2000		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens																									
6878	7555					Highest studied dose	mg	250		multiple			2 days	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens														Fabry disease								48	week		
6879	7555					Highest studied dose	mg	250		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens														Fabry disease								2	week		
6880	7555					Highest studied dose	mg	450		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens														Fabry disease											
6881	7555					Highest studied dose	mg/kg	10		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens																									
6882	7555					Recommended	mg	123		steady			2 days	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208623lbl.pdf	Homo sapiens										The recommended dosage regimen is 123 mg orally once every other day at the same time of day.		72	34	Fabry disease | amenable galactosidase alpha gene (GLA) variant					16			6	month		
6883	7555					Recommended	mg	123		steady			2 days	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208623Orig1s000MultidisciplineR.pdf	Homo sapiens										migalastat is formulated as a 123-mg tablet to be administered orally once every other day			34	Fabry disease					16			6	month		
6884	7610		adult			Studied dose	mg	650		single			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/18867938/	Homo sapiens													2	yaws								1	day		
6885	7610					Studied dose	g	0.5		multiple			2 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/13058286/	Homo sapiens						39							1	rheumatoid arthritis.					39			7	week		
6886	7625					Overdose	mL	30		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27788591	Homo sapiens						30	max			99% liquid chloroform			1												p.1,2
6887	7625					Recommended	g/m3	73		single					unknown	respiratory			https://www.who.int/ipcs/publications/cicad/en/cicad58.pdf	Homo sapiens										exposure at 24–73 g/m3 air and maintain 12–48 g/m3 air for duration of surgical operation				anaesthesia											p.26
6888	7625					Studied dose	ppm	1030		single					healthy	respiratory			https://www.ncbi.nlm.nih.gov/books/NBK208286/	Homo sapiens										7 min															
6889	7635						mL	300		multiple			day	1	unknown	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/21676535	Homo sapiens						28							1						28			4	month		
6890	7666		ADULT			Highest studied dose	mg	2400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/476356/	Homo sapiens							max			160 mg/day until a maximum of 2,400 mg/day		46	8	schizophrenia					26			21	day		
6891	7666		ADULT			Highest studied dose|RP2D	mg	30		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33127652/	Homo sapiens						65						76	3	melanoma	200 mg every 3 weeks			pembrolizumab	35			6	month		
6892	7666		ADULT			Overdose	mg	2000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/7356190/	Homo sapiens						20							1												
6893	7666		ADULT			Overdose	mg	260		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/3799650/	Homo sapiens						21							1												
6894	7706						%	10		multiple			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/20315216	Homo sapiens						28							1						28			3	day		
6895	7817		adult			Highest studied dose	mg	1		multiple			day	1	unhealthy	intravenous	M+F		https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2534154	Homo sapiens													296	severe sepsis								21	day		
6896	7817					Highest studied dose	mg/m2	15.3		multiple			day	1	unhealthy	intravenous	M+F		https://www.mdpi.com/2072-6643/7/6/4978	Homo sapiens										OPD; 5 d/week; 2 weeks			6	cancer								2	week		
6897	7850					Recommended	drop	1		multiple			day	3	unhealthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022308s013lbl.pdf	Homo sapiens										1 drop of 0.6% solution in the affected eye(s) 3 times a day, 4 to 12 hours apart for 7 days				Bacterial conjunctivitis								7	day		p.3
6898	7852					MTD	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19924121/	Homo sapiens						56.2							18	CML: blastic phase, accelerated phase, and chronic phase) | Ph-positive ALL											
6899	7852					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_MedR_P2.pdf	Homo sapiens						56						85	132	Philadelphia chromosome positive chronic myelogenous leukemia - chronic phase ((CML-CP)					26						
6900	7852					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_MedR_P2.pdf	Homo sapiens						59						79	64	Philadelphia chromosome positive chronic myelogenous leukemia - accelerated phase (CML-AP)					22						
6901	7852						mg	1200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068s000_ClinPharmR.pdf |https://pubmed.ncbi.nlm.nih.gov/16775235	Homo sapiens						60						83	10	Ph-positive ALL | CML					15						
6902	7853					Highest studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24988438	Homo sapiens													12												p.123
6903	7853					Overdose	mg	24000		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31534087	Homo sapiens						42							1	HIV-1 infection											p.1
6904	7853					Recommended	mg	400		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24988438	Homo sapiens													12												p.123
6905	7853					Recommended	mg	400		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022145s021,203045s001lbl.pdf	Homo sapiens														HIV-1 infection											p.1
6906	7855		adult			Recommended	mg	50		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf	Homo sapiens													765	heart failure								6	month		
6907	7855		adult				mg	20		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf	Homo sapiens													54									8	day		p. 61
6908	7855		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01354444	Homo sapiens													14	Alzheimer's Disease								6	month		
6909	7855		adult				mg	25		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf	Homo sapiens										starting dose of 3.125 mg twice daily to the maximum tolerated dose or up to 25 mg twice daily over a minimum of 6 weeks. Most subjects achieved the target dose of 25 mg			1156	severe heart failure								6	week		
6910	7855		adult				mg	6.25		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf	Homo sapiens													54									1	week		p. 61
6911	7855		adult				mg	6.25		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022012s000_MedR_P1.pdf	Homo sapiens													54									8	day		p. 61
6912	7855					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22240593	Homo sapiens						66.7							7	chronic heart failure								2	week		
6913	7855					Overdose	mg	300		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/31988787	Homo sapiens						41							1		7 mg			lorazepam	41						
6914	7855					Overdose	mg	375		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18598302	Homo sapiens						84				sixty 6.25-mg tablets			1		fifteen 20-mg tablets			simvastatin	84						
6915	7856					Higher than recommended	ug	90		steady			day	4	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/18219836/	Homo sapiens													496	Asthma					12			52	week		
6916	7856					Recommended	ug	90		steady			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/16846555/	Homo sapiens												11	76	Asthma					4			28	day		
6917	7857		adult			Highest studied dose	g	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020576s014lbl.pdf	Homo sapiens																									
6918	7857						g	3		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15069409	Homo sapiens						4.5				3 g/d (150 mg/kg)			1						4.5			5	week		
6919	7860		adult			Recommended	mg	6		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/16678076/	Homo sapiens													881	chronic constipation/ idiopathic constipation								12	week		609
6920	7860		adult			Studied dose	mg	2		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/16678076/	Homo sapiens													861	chronic constipation/ idiopathic constipation								12	week		609
6921	7860					Recommended	mg	6		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021200Orig1s015lbl.pdf	Homo sapiens													1184	IBS-C								4	week		4
6922	7863					Recommended	mg	15		single					healthy	rectal	M+F		https://pubmed.ncbi.nlm.nih.gov/24499492/	Homo sapiens												60	24						18						
6923	7866					Recommended	mg	240		multiple			4 weeks	1	unhealthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/22457321	Homo sapiens						74.2				Starting dose - 240 mg given; maintenance dose - 160 mg administered as a single injection every 28 days.			137	Advanced prostate cancer								12	month		p.482
6924	7866					Recommended	mg	240		multiple			4 weeks	1	unhealthy	subcutaneous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022201lbl.pdf	Homo sapiens										Treatment is started with a dose of 240 mg given as two injections of 120 mg each. The starting dose is followed by maintenance doses of 80 mg administered as a single injection every 28 days.				Advanced prostate cancer											p.1
6925	7866						mg	10		single					unhealthy	subcutaneous			https://clinicaltrials.gov/ct2/show/NCT00947882	Homo sapiens													101	Lower Urinary Tract Symptoms											
6926	7866						mg	20		single					unhealthy	subcutaneous			https://clinicaltrials.gov/ct2/show/NCT00947882	Homo sapiens													100	Lower Urinary Tract Symptoms											
6927	7866						mg	30		single					unhealthy	subcutaneous			https://clinicaltrials.gov/ct2/show/NCT00947882	Homo sapiens													105	Lower Urinary Tract Symptoms											
6928	7868		adult				mg	8		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00928070	Homo sapiens							max			Fesoterodine 4 mg oral tablet once daily for 4 weeks followed by an optional dose-escalation to 8 mg once daily at investigator's discretion for remaining 8 weeks.			281	Overactive Bladder								8	week		
6929	7868					Highest studied dose	mg	28		multiple			day	1	unhealthy	oral			https://ec.europa.eu/health/documents/community-register/2012/20121025124795/anx_124795_en.pdf	Homo sapiens														Overactive bladder											p.9, 18
6930	7868					Recommended	mg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s007lbl.pdf	Homo sapiens										The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily.			785	Overactive bladder											p.4
6931	7868					Recommended	mg	8		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022030s007lbl.pdf	Homo sapiens										The recommended starting dose of Toviaz is 4 mg once daily. Based upon individual response and tolerability, the dose may be increased to 8 mg once daily.				Overactive bladder											p.1
6932	7868						mg	8		steady			day	1	healthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00832650	Homo sapiens													25									14	day		
6933	7868						mg	8		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00862745	Homo sapiens													322	Urge Urinary Incontinence								8	week		
6934	7868						mg	8		steady			day	1	unhealthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT00546637	Homo sapiens							max			Subjects initially treated with fesoterodine 4 mg once-daily for 4 weeks. At Week 4 visit, the dose of study drug was adjusted through collaborative decision by the investigator and the subject. For those subjects who desired greater symptom improvement and reported acceptable safety and tolerability, fesoterodine dose was increased to 8 mg in a blinded fashion. For the rest of subjects, the dose was maintained at fesoterodine 4 mg.			471	Overactive Bladder								8	week		
6935	7868						mg	8		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00444925	Homo sapiens													679	Overactive Bladder								11	week		
6936	7868						mg	8		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00911937	Homo sapiens							max			Fesoterodine 4 mg oral tablet once daily for 4 weeks followed by dose-escalation to 8 mg once daily depending on investigator's discretion for remaining 8 weeks.			463	Overactive Bladder								8	week		
6937	7868						mg	8		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01302054	Homo sapiens													308	Overactive Bladder								11	week		
6938	7869					Highest studied dose	mg/kg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3056073	Homo sapiens													4												p.519
6939	7869					Recommended	mg/kg	15		multiple			day	2	unhealthy	intravenous	M+F		https://www.aafp.org/afp/1999/0701/p294.html	Homo sapiens										Patients were given intravenous fomepizole, in a loading dose of 15 mg per kg of body weight followed by 10 mg per kg every 12 hours for 48 hours. This regimen was followed by a repeat dosing of 15 mg per kg every 12 hours to compensate for increased fomepizole metabolism. The patients were treated until their ethylene glycol level was less than 20 mg per dL.			23	Ethylene glycol poisoning											
6940	7870					Recommended	mg	2.5		steady			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/33027192/	Homo sapiens													38	COVID-19								28	day		
6941	7871					Recommended	ug	20		steady			day	2	unhealthy	respiratory	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022007s004lbl.pdf	Homo sapiens												90	123	COPD					40			12	week		
6942	7872					Recommended	mg	150		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29873529	Homo sapiens						33				infused over 30 min			50												
6943	7872					Recommended	mg	150		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022023s017lbl.pdf	Homo sapiens										Administer EMEND for injection on Day 1 as an intravenous infusion over 20 to 30 minutes (adults), 30 minutes (12 years to 17 years) or 60 minutes (6 months to less than 12 years) completing the infusion approximately 30 minutes prior to chemotherapy				Prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy											p.1
6944	7873					Highest studied dose	mg	0.5		steady			day	1	healthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/10593372	Homo sapiens						22.1							15						22.1			7	day		
6945	7873						mg	0.25		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/10593371	Homo sapiens						22.4						31	15						19						
6946	7873						mg	6		single					healthy	intranasal	F		https://pubmed.ncbi.nlm.nih.gov/9091332	Homo sapiens												43	5						23						
6947	7874					Highest studied dose	mg/kg	40		single			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/17439737	Homo sapiens										(40 mg/kg) was administered twice on day 10		18	10	allogeneic transplantation					2						
6948	7874					MTD	mg/kg	26.7		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/32472611/	Homo sapiens												18		sickle cell anemia					2						
6949	7874					Overdose	mg/kg	105		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32743869	Homo sapiens										accidental Overdose			1	sickle cell anemia											
6950	7874					Overdose	mg/kg	17.5		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32743869	Homo sapiens						2				accidental Overdose			1	sickle cell anemia					2						
6951	7874					Overdose	mg/kg	40		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208843Orig1s000MedR.pdf	Homo sapiens						12				accidental Overdose			1						12			3	day		
6952	7874					Recommended	mg/kg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208843s000lbl.pdf	Homo sapiens												18							2						
6953	7874						mg	1000		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33936725	Homo sapiens						63							1	essential thrombocytosis					63			4	year		
6954	7874						mg	1500		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31938603	Homo sapiens						61							1		81 mg, 1 time a day			aspirin	61			3	month		
6955	7874						mg/kg	20		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01976416	Homo sapiens													104	Malaria								12	month		
6956	7875		adult				ug	24		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00595946	Homo sapiens													221	Opioid-Induced Bowel Dysfunction								12	week		
6957	7875		adult				ug	24		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00597428	Homo sapiens													223	Opioid-Induced Bowel Dysfunction								12	week		
6958	7875		adult				ug	24		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03097861	Homo sapiens										capsule			130	Chronic Idiopathic Constipation								7	day		
6959	7875		adult				ug	24		multiple			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03097861	Homo sapiens										sprinkle			275	Chronic Idiopathic Constipation								7	day		
6960	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01170039	Homo sapiens													37	Constipation								8	week		
6961	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01298219	Homo sapiens													219	Opioid-induced Bowel Dysfunction								12	week		
6962	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01993875	Homo sapiens													82	Chronic Idiopathic Constipation								7	week		
6963	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02651155	Homo sapiens													105	Chronic Idiopathic Constipation								4	week		
6964	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02695719	Homo sapiens													81	Chronic Idiopathic Constipation								4	week		
6965	7875		adult				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02729909	Homo sapiens													105	Chronic Idiopathic Constipation								4	week		
6966	7875		adult				ug	8		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02544152	Homo sapiens													37	Irritable Bowel Syndrome								12	week		
6967	7875		child				ug	24		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02042183	Homo sapiens							max			12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1			400	Functional Constipation								12	week		
6968	7875					Recommended	ug	24		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf	Homo sapiens													1113	Chronic idiopathic constipation											p.1, 4
6969	7875					Studied dose	ug	144		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021908s010lbl.pdf	Homo sapiens													51												p.8
6970	7876		adult				mg	12		multiple			day	1	unhealthy	subcutaneous	M+F		https://clinicaltrials.gov/ct2/show/NCT00640146	Homo sapiens										Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.			18	Opioid-Induced Constipation								7	day		
6971	7876		adult				mg	12		multiple			day	4	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT00528970	Homo sapiens													124	Post Operative Ileus								10	day		
6972	7876		adult				mg	150		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00605644	Homo sapiens													19	Opioid-Induced Bowel Dysfunction											
6973	7876		adult				mg	24		multiple			day	4	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT00528970	Homo sapiens													125	Post Operative Ileus								10	day		
6974	7876		adult				mg	300		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00605644	Homo sapiens													20	Opioid-Induced Bowel Dysfunction											
6975	7876		adult				mg	450		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00605644	Homo sapiens													30	Opioid-Induced Bowel Dysfunction											
6976	7876		adult				mg	450		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01186770	Homo sapiens													200	Opioid-Induced Constipation								4	week		
6977	7876		adult				mg	600		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00605644	Homo sapiens													30	Opioid-Induced Bowel Dysfunction											
6978	7876					Highest studied dose	mg/kg	0.45		multiple			6 hours	1	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_MedR_P3.pdf|https://pdf.hres.ca/dpd_pm/00015521.PDF	Homo sapiens										0.45 mg/kg every six hours for five doses			8									5	times		p.17|p.42
6979	7876					Highest studied dose	mg/kg	0.5		single					healthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_ClinPharmR.pdf|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_MedR_P3.pdf	Homo sapiens												45	119						18						p.4|p.17
6980	7876					Highest studied dose	mg/kg	0.64		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021964s000_MedR_P3.pdf	Homo sapiens																									p.17
6981	7876					Recommended	mg	12		multiple			day	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208271s000lbl.pdf	Homo sapiens													150	Opioid-induced constipation in adults with chronic non-cancer pain								4	week		p.9
6982	7876					Recommended	mg	12		multiple			day	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208271s000lbl.pdf	Homo sapiens														Opioid-induced constipation in adults with chronic non-cancer pain											p.1
6983	7876					Recommended	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30613162	Homo sapiens						51.6							200	Opioid-induced constipation in adults with chronic non-cancer pain								4	week		p.144
6984	7876					Recommended	mg	450		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208271s000lbl.pdf	Homo sapiens														Opioid-induced constipation in adults with chronic non-cancer pain											p.1
6985	7878		adult			Highest studied dose	ug/kg	320		single					healthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf	Homo sapiens													10												p. 83
6986	7878		adult			Recommended	mg/kg	0.24		multiple			day	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022311s000_MedR.pdf	Homo sapiens													72									4	day		p.97
6987	7878					Highest studied dose	ug/kg/h	160		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15385732	Homo sapiens						40.2				administered for 10 days by continuous intravenous infusion			3	HIV-1 Infection					40.2			10	day		
6988	7878						ug/kg	160		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10817726	Homo sapiens													3						18						
6989	7878						ug/kg	80		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10817726	Homo sapiens													12						18			15	min		
6990	7878						ug/kg/h	20		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15385732	Homo sapiens						40.2							8	HIV-1 Infection					40.2			10	day		
6991	7878						ug/kg/h	40		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15385732	Homo sapiens						40.2							8	HIV-1 Infection					40.2			10	day		
6992	7878						ug/kg/h	5		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15385732	Homo sapiens						40.2							7	HIV-1 Infection					40.2			10	day		
6993	7878						ug/kg/h	80		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15385732	Homo sapiens						40.2							5	HIV-1 Infection					40.2			10	day		
6994	7879					Highest studied dose	mg/m2	325		steady			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21841501	Homo sapiens						55.3		1 mg orally once daily		bolus injections over 3 to 5 minutes			3	non-small cell lung cancer	1 mg intramuscular every 8 to 10 weeks			vitamin B12	55.3			4	week	folic acid	
6995	7879					Highest studied dose	mg/m2	45		steady			week	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/19652067	Homo sapiens										45 mg/m2 weekly for 6 of 7 weeks			11	relapsed or refractory NHL | HL								6	week		
6996	7879					MTD	mg/m2	270		steady			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21841501	Homo sapiens						60.7		1 mg orally once daily		bolus injections over 3 to 5 minutes			16	non-small cell lung cancer	1 mg intramuscular every 8 to 10 weeks			vitamin B12	60.7			4	week	folic acid	
6997	7879					Recommended|MTD	mg/m2	30		steady			week	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022468lbl.pdf	Homo sapiens						59				30 mg/m2 administered as an intravenous push over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles		85	111	peripheral T-cell lymphoma					21			70	day		
6998	7880		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01560780	Homo sapiens													42	Early Saphenous Vein Graft Thrombosis								12	month		
6999	7880		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01167023	Homo sapiens													41	Sickle Cell Disease								30	day		
7000	7880		child				mg/kg	0.12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01794000	Homo sapiens							total daily dose			Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.			170	Sickle Cell Disease								24	month		
7001	7880		child				mg/kg	0.12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01794000	Homo sapiens							total daily dose			Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.			87	Sickle Cell Disease								24	month		
7002	7880					Highest studied dose	mg	20		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17076696	Homo sapiens													6									10	day		
7003	7880					Highest studied dose	mg	75		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16769598	Homo sapiens						30.4							5						30.4						
7004	7880					Recommended	mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022307s000lbl.pdf	Homo sapiens										Initiate treatment with a single 60 mg oral loading dose and then continue at 10 mg orally once daily															
7005	7881		adult			Highest studied dose	mg	10		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19650754/	Homo sapiens													98	type 2 diabetes								24	week		table 4
7006	7881		adult			Recommended	mg	2.5		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	Homo sapiens													882	type 2 diabetes								24	week		4
7007	7881		adult			Recommended	mg	5		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022350lbl.pdf	Homo sapiens													882	type 2 diabetes								24	week		4
7008	7881		adult				mg	2.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00614939	Homo sapiens													85	Type 2 Diabetes								12	week		
7009	7881		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01107886	Homo sapiens							max			5 mg or 2.5 mg once daily			8280	Type 2 Diabetes								3	year		
7010	7881		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01765270	Homo sapiens													4	Type 2 Diabetes and Cardiovascular Disease								35	day		
7011	7881		adult				mg	5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02024477	Homo sapiens													21	Type 2 Diabetes								12	week		
7012	7882					Highest studied dose	mg/m2	220		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15136596	Homo sapiens						54						63	9	solid tumor refractory					30			1	month		
7013	7882					Recommended	mg	25		steady			week	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022088lbl.pdf	Homo sapiens						59							208	renal cell carcinoma					59			17	week		
7014	7882					Recommended	mg	25		steady			week	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_MedR.pdf	Homo sapiens													208									17	week		p.80
7015	7882						mg/m2	10		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28295182	Homo sapiens						9	starting			The initial temsirolimus dose level (DL1) was 10 mg/m2 weekly × three doses.		21	5	acute lymphoblastic leukaemia					1			42	day		
7016	7882						mg/m2	150		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21690471	Homo sapiens						11						21	7	Recurrent/Refractory Solid Tumors					4						
7017	7882						mg/m2	7.5		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28295182	Homo sapiens						9				Subsequent patient cohorts received temsirolimus 7.5 mg/m2 weekly × three doses (DL0) or, secondary to toxicity, 7.5 mg/m2 weekly × two doses (DL-1)		21	5	acute lymphoblastic leukaemia					1			42	day		
7018	7882						mg/m2	7.5		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28295182	Homo sapiens						9				Subsequent patient cohorts received temsirolimus 7.5 mg/m2 weekly × three doses (DL0) or, secondary to toxicity, 7.5 mg/m2 weekly × two doses (DL-1)		21	6	acute lymphoblastic leukaemia					1			42	day		
7019	7883		adult			Highest studied dose	g	1.8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23442/	Homo sapiens													23									12	month		
7020	7883					Recommended	g	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3294442/	Homo sapiens						49							121	Urinary Stones								12	month		
7021	7886		adult			Recommended	%	0.3		steady			day	1	unhealthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/1687324/	Homo sapiens													1	Allergic conjunctivitis								7	day		
7022	7886		adult			Recommended	mg	6		steady			day	4	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3981411/	Homo sapiens													12		120 mg			pseudoephedrine sulfate				7	day		
7023	7888					Overdose	g	310		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19514878	Homo sapiens						72	total						1						72						
7024	7902					Higher than recommended	mg/m2	250		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16197624	Homo sapiens						39		850 mg/m2					254	Colorectal cancer	200 mg/m2			irinotecan, i.v						5-fluorouracil, i.v	p.207
7025	7902					Highest studied dose	mg/m2	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9703859	Homo sapiens						66		500 mg/m2/day; days 1-5		every 4 weeks			36	Gastric cancer	100 mg/m2/day; days 2-4			etoposide, i.v				5	day	5-fluorouracil, i.v	p.320
7026	7904		ADULT			Highest studied dose	mg	1200		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/3279968/	Homo sapiens						41	total daily dose						5	familial hyperlipidemia								3	month		249-55
7027	7904		ADULT			Highest studied dose	mg	1200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7028536/	Homo sapiens							total daily dose					28	4						22			1	day		381-6
7028	7909					Highest studied dose	mg	160		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25563429/	Homo sapiens												85	12	myelofibrosis					23			24	week		
7029	7909					Highest studied dose	mg/m2	120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21340605/	Homo sapiens										5 days out of seven in 28-day cycle		29.1	6	neuroblastoma					3.5			5	cycle		
7030	7909					MTD	mg	140		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25563429/	Homo sapiens												85	8	myelofibrosis					23			24	week		
7031	7909					Studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25563429/	Homo sapiens												85	7	myelofibrosis					23			24	week		
7032	7909					Studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16857985/	Homo sapiens												81	29	acute myeloid leukemia					67			8	week		
7033	7909					Studied dose	mg/m2	55		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21340605/	Homo sapiens										5 days out of seven in 28-day cycle		29.1	7	neuroblastoma					3.5			14	cycle		
7034	7909					Studied dose	mg/m2	70		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21340605/	Homo sapiens										5 days out of seven in 28-day cycle		29.1	1	neuroblastoma					3.5			13	cycle		
7035	7909					Studied dose	mg/m2	70		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21340605/	Homo sapiens										5 days out of seven in 28-day cycle		29.1	10	neuroblastoma					3.5			4	cycle		
7036	7909					Studied dose	mg/m2	92.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21340605/	Homo sapiens										5 days out of seven in 28-day cycle		29.1	3	neuroblastoma					3.5			14	cycle		
7037	7910					Overdose	mg	50		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/7781638/	Homo sapiens						2							1						2						
7038	7923		adult				g	8.64		single					healthy	rectal			https://pubmed.ncbi.nlm.nih.gov/8826536	Homo sapiens													10												
7039	7923		children				mg/kg	173		single					healthy	rectal			https://pubmed.ncbi.nlm.nih.gov/8826536	Homo sapiens													4												
7040	7923						g	20.7		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4032274	Homo sapiens												65	16		oral solution			sodium phenytoin	18			3	day		
7041	7923						g	41.4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4032274	Homo sapiens												65	6		oral solution			sodium phenytoin	18			3	day		
7042	7923						g/kg	0.8		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28331645	Homo sapiens						13	mean			The average daily PG exposure during the first three hospital days was 1 g/kg/day, 0.8 g/kg/day, and 0.8 g/kg/day, respectively.			1	refractory myoclonic status epilepticus					13			3	day		
7043	7936					Highest studied dose	mg	300		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20043009	Homo sapiens						27							12						27			14	day		
7044	7936					Highest studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20043009	Homo sapiens						27							12						27						
7045	7938					Recommended	mL	50		single					unhealthy	intravesical			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022555s000lbl.pdf	Homo sapiens										The recommended dose for adults is 50 mL of reconstituted solution of Cysview, instilled into the bladder via a urinary catheter. Once reconstituted, the solution contains 2 mg/mL (8mmol/L) of hexaminolevulinate hydrochloride.				Cystoscopic detection of non-muscle invasive papillary cancer of the bladder											p.1
7046	7957		adult			Studied dose	mg	400		multiple			day	1	unhealthy	intravenous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/091526lbl.pdf	Homo sapiens							complex			Diphenhydramine in the injectable form is indicated when the oral form is impractical.															
7047	7957					Overdose	mg	1450		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/21656083	Homo sapiens						28				29 capsules containing 50 mg of diphenhydramine (DPH) per capsule, for a total of 1450 mg			1						28						
7048	7957					Overdose	mg	600		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/22158278/	Homo sapiens										25-mg diphenhydramine tablets, 24 pills			1												
7049	7957						mg	400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28246565	Homo sapiens						28							1	insomnia					28			4	month		
7050	7957						mg	50		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/32675136	Homo sapiens						29							1						29						
7051	7957						mg	50		single					unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT01967433	Homo sapiens													61	Opioid dependence											
7052	7958					Highest recorded dose	mg	360		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf	Homo sapiens														pain disorder											
7053	7959		child|adult				%	2		multiple			day	2	unhealthy	otic	M+F		https://clinicaltrials.gov/ct2/show/NCT03130738	Homo sapiens													22	Otomycosis								14	day		
7054	7959		child|adult				%	2		multiple			day	2	unhealthy	otic	M+F		https://clinicaltrials.gov/ct2/show/NCT03130738	Homo sapiens													23	Otomycosis								7	day		
7055	7959		newborns			Recommended	%	0.25		steady			day	7	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/16570675/	Homo sapiens										ointment			330	Diaper dermatitis complicated by candidiasis								7	day		
7056	7959					Recommended	mg	1200		single					unhealthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/2270767/	Homo sapiens												60	50	vaginal candidosis					18						
7057	7959					Studied dose	mg	200		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9085333/	Homo sapiens						54							1					amphotericin B	54			2	day	itraconazole	
7058	7959					Studied dose	mg	800		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9085333/	Homo sapiens						54							1					amphotericin B	54					itraconazole	
7059	7960		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02431806	Homo sapiens										Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.			134	Major Depressive Disorder								8	week		
7060	7960		adult				mg	80		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02431806	Homo sapiens										Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.			138	Major Depressive Disorder								8	week		
7061	7960					MTD	mg	120		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204168s004lbl.pdf	Homo sapiens														Major Depressive Disorder											p.22
7062	7960					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23999912	Homo sapiens							max					80	825	Major Depressive Disorder					18			48	week		p.766
7063	7960					Recommended	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24172209	Homo sapiens							max					80	217	Major Depressive Disorder					18			8	week		p.52
7064	7960					Recommended	mg	120		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204168s004lbl.pdf	Homo sapiens							max						1583	Major Depressive Disorder											p.12
7065	7960					Recommended	mg	120		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204168s004lbl.pdf	Homo sapiens							max							Major Depressive Disorder											p.1
7066	7961					Recommended	drop	1		multiple			week	1	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/NCT00889330	Homo sapiens						37.8				0.25% Ophthalmic Solution administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).			30	Allergic Conjunctivitis								8	day		
7067	7963		adult				mg	150		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01896128	Homo sapiens													8	Stroke								10	day		
7068	7963		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01305408	Homo sapiens							max			Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.			200	Bipolar I Disorder								8	week		
7069	7963		adult				mg	150		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01400958	Homo sapiens										Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).			3	Fatigue								42	day		
7070	7963					Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens													6												
7071	7963					Highest studied dose	mg	400		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19133704	Homo sapiens													4									7	day		
7072	7963					Recommended	mg	150		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29734973	Homo sapiens						21							1	idiopathic hypersomnia					21			12	day		
7073	7963					Recommended	mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021875lbl.pdf	Homo sapiens													645												
7074	7963					Recommended	mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021875s000_MedR_P1.pdf	Homo sapiens													645												p.6
7075	7964		adult			Recommended	mg/m2	25		multiple			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf	Homo sapiens															oral 10 mg daily			prednisone							
7076	7964					Highest studied dose	mg/m2	35		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29750396	Homo sapiens						7				1 hr on day 1 of every 21-day cycle			7	refractory solid tumors					7			9	week		
7077	7964					MTD	mg/m2	15		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28058445	Homo sapiens						56				during a 1-hour intravenous (IV) infusion on Day 1 of each 3-week cycle			7	advanced, non-hematologic cancer, moderate hepatic impairment					56			6	week		
7078	7964					MTD	mg/m2	20		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28058445	Homo sapiens						59				during a 1-hour intravenous (IV) infusion on Day 1 of each 3-week cycle			12	advanced, non-hematologic cancer, mild hepatic impairment					59			6	week		
7079	7964					MTD	mg/m2	30		multiple			3 weeks	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22975213	Homo sapiens						63				a 1-h intravenous infusion every 3 weeks			5	advanced solid tumours					63			65	cycle		
7080	7964					MTD	mg/m2	30		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29750396	Homo sapiens						9.5				1 hr on day 1 of every 21-day cycle			16	refractory solid tumors					9.5			6	week		
7081	7964					Recommended	mg/m2	25		multiple			3 weeks	1	unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf	Homo sapiens						68						92	371	hormone-refractory metastatic prostate cancer	oral 10 mg daily			prednisone	46			10	cycle		
7082	7964					Recommended	mg/m2	25		multiple			3 weeks	1	unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000MedR.pdf	Homo sapiens						68						92	371	hormone-refractory metastatic prostate cancer	oral 10 mg daily			prednisone	46			10	cycle		p. 59
7083	7964					Recommended	mg/m2	25		multiple			3 weeks	1	unhealthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201023s000MedR.pdf	Homo sapiens						68						92	371	hormone-refractory metastatic prostate cancer				prednisone	46			10	cycle		p. 59
7084	7964						mg/m2	20		multiple			3 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/28058445	Homo sapiens						54				during a 1-hour intravenous (IV) infusion on Day 1 of each 3-week cycle			2	advanced, non-hematologic cancer, moderate hepatic impairment					54			3	week		
7085	7964						mg/m2	20		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22975213	Homo sapiens						49				a 1-h intravenous infusion every 3 weeks			7	advanced solid tumours					49			65	cycle		
7086	7964						mg/m2	20		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29750396	Homo sapiens						11				1 hr on day 1 of every 21-day cycle			6	refractory solid tumors					11			8.9	week		
7087	7964						mg/m2	25		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28058445	Homo sapiens						54				during a 1-hour intravenous (IV) infusion on Day 1 of each 3-week cycle			6	advanced, non-hematologic cancer, mild hepatic impairment					54			3	week		
7088	7965					Highest studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56				Once Daily Capsules. Patients continued to take cabozantinib until disease progression or unacceptable adverse events			6	solid tumors											
7089	7965					Highest studied dose	mg	265		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56				Once Daily Suspension.Patients continued to take cabozantinib until disease progression or unacceptable adverse events			10	solid tumors											
7090	7965					MTD	mg	175		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56				Once Daily Capsules. Patients continued to take cabozantinib until disease progression or unacceptable adverse events			40	solid tumors											
7091	7965					Recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000MedR.pdf	Homo sapiens													331	Renal Cell Carcinoma								21.4	month		208692Orig1s000MedR.pdf - p.90
7092	7965					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/28352985/	Homo sapiens						64.8							13	non-small cell lung cancer	50 mg; 1/day			Erlotinib				28	day		
7093	7965						mg	162.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56	mean			Once Daily Capsules. Patients continued to take cabozantinib until disease progression or unacceptable adverse events			40	solid tumors											
7094	7965						mg	175		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56				suspension daily dosing				solid tumors											
7095	7965						mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf	Homo sapiens													1	renal cell carcinoma								9	day		
7096	7965						mg/kg	11.52		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21606412/	Homo sapiens						56							3	solid tumors								5	day		
7097	7966					Recommended	mg	6		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2972549/	Homo sapiens						27							12												
7098	7966					Recommended	mg	6		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16390354/	Homo sapiens												45	4						22			1	day		
7099	7967					Highest studied dose	mg	800		single					healthy	oral	M		https://www.natap.org/2006/CROI/CROI_11.htm	Homo sapiens													6												
7100	7967					Highest studied dose	mg	800		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16936557	Homo sapiens						39							6	HIV-1 infection					39			10	day		
7101	7967					Recommended	mg	85		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203093s000lbl.pdf	Homo sapiens						45		300 mg orally once daily					354	HIV-1 infection	100 mg, 1 time per day			ritonavir	45			96	week	Atazanavir	
7102	7968					MTD	mg/m2	1		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509177	Homo sapiens						57.4				on days 1, 8, and 15 of a 28-d cycle			9	Advanced Solid Malignancies					57.4			28	day		
7103	7968					MTD	mg/m2	2		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509146	Homo sapiens										1-h infusion every 21 d		73	7	advanced solid tumors					29			21	day		
7104	7968					Overdose	mg/m2	5.6		multiple			3 weeks	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf	Homo sapiens										on Days 1 and 8 of a 21-day cycle												21	day		
7105	7968					Recommended	mg/m2	1.4		steady			3 weeks	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf	Homo sapiens						58				1.4 mg/m2 on Days 1 and 8 of a 21-day cycle		91	503	multiple tumors					58			21	day		
7106	7968					Recommended	mg/m2	1.4		steady			3 weeks	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/201532Orig1s000MedR.pdf	Homo sapiens						55				1.4 mg/m2 on Days 1 and 8 of a 21-day cycle		85	508						28			21	day		p. 125
7107	7968						mg/m2	0.5		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509177	Homo sapiens						57.4				on days 1, 8, and 15 of a 28-d cycle			8	Advanced Solid Malignancies					57.4			28	day		
7108	7968						mg/m2	1.4		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509177	Homo sapiens						57.4				on days 1, 8, and 15 of a 28-d cycle			9	Advanced Solid Malignancies					57.4			28	day		
7109	7968						mg/m2	2.8		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509146	Homo sapiens										1-h infusion every 21 d		73	3	advanced solid tumors					29			21	day		
7110	7968						mg/m2	4		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19509146	Homo sapiens										1-h infusion every 21 d		73	4	advanced solid tumors					29			21	day		
7111	7969		adult				mg	0.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01625182	Homo sapiens													54	Chronic Inflammatory Demyelinating Polyradiculoneuropathy								12	month		
7112	7969					Highest studied dose	mg	1.25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28129749	Homo sapiens						36							46	relapsing multiple sclerosis					36			3	year		
7113	7969					Highest studied dose	mg	3.5		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11912269/	Homo sapiens						43.2							3						43.2						
7114	7969					Overdose	mg	14		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24178903	Homo sapiens						33				28×0.5 mg			1	multiple sclerosis	2000 mg, single			phenoxymethylpenicillin	33						
7115	7969					Overdose	mg	40		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf	Homo sapiens													6												
7116	7969					Recommended	mg	0.5		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022527s000lbl.pdf	Homo sapiens						37							425	relapsing remitting MS					37			715	day		
7117	7970		adult				ug	150		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00677807	Homo sapiens													144	Chronic Obstructive Pulmonary Disease								52	week		
7118	7970		adult				ug	150		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02418468	Homo sapiens													11	Chronic Obstructive Pulmonary Disease								26	week		
7119	7970		adult				ug	300		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00570778	Homo sapiens													141	Chronic Obstructive Pulmonary Disease								7	day		
7120	7970		adult				ug	300		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00677807	Homo sapiens													146	Chronic Obstructive Pulmonary Disease								52	week		
7121	7970		adult				ug	600		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT00570778	Homo sapiens													141	Chronic Obstructive Pulmonary Disease								7	day		
7122	7970		adult				ug	75		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01068600	Homo sapiens													159	Chronic Obstructive Pulmonary Disease								12	week		
7123	7970					Highest studied dose	ug	800		multiple			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/18219838	Homo sapiens						43.5							59	COPD					43.5			28	day		
7124	7970						ug	75		multiple			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022383s000lbl.pdf	Homo sapiens														asthma											
7125	7972					Highest studied dose	mg/kg	3.5		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/11454092	Homo sapiens												12	28	pediculosis capitis					7			10	day		
7126	7972					Overdose	mg	250		single					unknown	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/33180273	Homo sapiens						52				A quarter-full 10 ml veterinary syringe was found next to the body. A 100 mg/ml bottle of levamisole			1						52						
7127	7972						mg	100		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24552411	Homo sapiens						34							1						34			5	day		
7128	7972						mg	150		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31570359	Homo sapiens						20							1	skin disorder	10 mg two times per day for 17 day			methoxsalen	20			17	day		
7129	7972						mg	150		multiple			week	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/923464 |https://pubmed.ncbi.nlm.nih.gov/366143	Homo sapiens																									
7130	7972						mg	50		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32851655	Homo sapiens						15				(2.5 mg/kg/day)			1						15			10	day		
7131	7973					Recommended	%	0.5		steady			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/18289898/	Homo sapiens												6	48	pediatric glaucomas					1			12	week		
7132	7974						mg	142.5		single					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/10512284	Homo sapiens						77							1						77						
7133	7974						mg/kg	1.75		single					unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/18761239	Homo sapiens										0.35 mL/kg of 0.5% levobupivacaine (levobupivacaine hydrochloride 5.0 mg/mL)			12						66						
7134	7974						mg/kg	2		single					unhealthy	caudal epidural	M+F		https://pubmed.ncbi.nlm.nih.gov/16100236	Homo sapiens										2.5 mg/ml			22									30	sec		
7135	7976					Highest studied dose	ug	1500		single					healthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/22713526	Homo sapiens													6												
7136	7976					Highest studied dose	ug	750		steady			day	2	healthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/22713526	Homo sapiens													6									8	day		
7137	7976					MTD	mg	120		steady			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/28721067	Homo sapiens						60							16	neuroendocrine tumors					60			9	month		
7138	7976					Overdose	mg	2.1		multiple			day	2	healthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200677lbl.pdf	Homo sapiens																									
7139	7976					Recommended	mg	0.6		steady			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000MedR.pdf	Homo sapiens						40	starting						82	Cushing’s disease					40			6	month		p. 71-72
7140	7976					Recommended	mg	0.9		multiple			day	2	healthy	subcutaneous	M		https://pubmed.ncbi.nlm.nih.gov/24088755	Homo sapiens						27				first dose was a single s.c. dose of 900 μg of pasireotide on day 1, followed by a 2-week washout period from days 1 to 14. This was followed by multiple s.c. doses of 900 μg bid (twice a day) on days 15 to 18. Another single s.c. dose of 900 μg was given on the morning of day 19, followed by a 2-week washout period from days 19 to 32.			1						27			3	month		
7141	7976					Recommended	mg	0.9		steady			day	2	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/200677Orig1s000MedR.pdf	Homo sapiens						40							80	Cushing’s disease					40			6	month		p. 71-72
7142	7976						mg	80		steady			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/28721067	Homo sapiens						58							13	neuroendocrine tumors					58			6.7	month		
7143	7977					Highest studied dose	mg/m2	24.9		steady			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11895901	Homo sapiens						53				on a day-1 and -5 schedule every 21 days			8						53			1	month		
7144	7977					MTD	mg/m2	17.8		steady			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11895901	Homo sapiens						53				on a day-1 and -5 schedule every 21 days			9						53			1	month		
7145	7977					Recommended	mg/m2	14		steady			month	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf	Homo sapiens						57	starting			at a starting dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days.		89	96	cutaneous T-cell lymphoma (CTCL)					21			1	month		
7146	7977					Recommended	mg/m2	14		steady			month	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022393s000_MedR.pdf	Homo sapiens						57	starting			at a starting dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days.		89	96	cutaneous T-cell lymphoma (CTCL)					21			1	month		p. 51
7147	7979					Highest studied dose	mg	50		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23550906	Homo sapiens													8									10	day		
7148	7979					Overdose	mg	200		single					healthy	oral	F		https://www.ema.europa.eu/en/documents/product-information/ellaone-epar-product-information_en.pdf	Homo sapiens														Pregnancy prevention											p.8
7149	7979					Recommended	mg	30		single					healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf	Homo sapiens										one tablet orally as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure				Pregnancy prevention											p.2
7150	7979					Recommended	mg	30		single					healthy	oral	F		https://www.fda.gov/media/83203/download	Homo sapiens						24.5				one tablet orally taken between 0 and 72 hours after unprotected intercourse			1104	Pregnancy prevention											p.33, 59
7151	7981		ADULT			Highest studied dose	mg	140		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9200635/	Homo sapiens						34.12							59	Opioid type dependence								17	week		p.1948, 1949
7152	7984		adult			Recommended	ug/kg/min	0.3		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209387s000lbl.pdf	Homo sapiens																						30	min		
7153	7984					Overdose	mg	234		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1628477	Homo sapiens						4	total			234 mg in 60 hours (5.4 um/kg/min )			1	hypertension					4			60	hour		
7154	7984					Recommended	ug/kg/min	10		multiple					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209387s000lbl.pdf	Homo sapiens																									
7155	7985		adult			Recommended	mg	135		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022224s003lbl.pdf	Homo sapiens													490												
7156	7993					Highest studied dose	mg/kg	115		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24347782/	Homo sapiens						6							1	abdominal pain due to probable worm infestation					6			3	day		
7157	7993					Recommended	mg/kg	65		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7673626/	Homo sapiens						9							1	pinworm or roundworm infections					9			7	day		
7158	7993					Studied dose	mg/m3/h	10		single					unhealthy	respiratory	F		https://pubmed.ncbi.nlm.nih.gov/16689189/	Homo sapiens						42				inhalation challenge of 5 mg/m3 for 30 minutes			1	Occupational asthma					42			30	min		
7159	7996		adult			Highest studied dose	mg	1600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17163261/	Homo sapiens													26												
7160	7996		adult			Highest studied dose	mg	1600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16816554/	Homo sapiens													13	HIV-1 infection								10	day		
7161	7996					Highest studied dose	mg	1200		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18211121/	Homo sapiens						33.9							5	HIV-1 infection								10	day		
7162	7996					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18211616/	Homo sapiens												40	16		960 mg			trimethoprim-sulphamethoxazole	18			28	day		
7163	7996					Highest studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18211616/	Homo sapiens												40	16		480 mg			trimethoprim-sulphamethoxazole	18						
7164	7996					Highest studied dose	mg	800		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18211121/	Homo sapiens						33.9							13	HIV-1 infection								10	day		
7165	7998					Studied dose	mg/m2	150		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27621408/	Homo sapiens										days 1 to 3 every 21 days		85	220	metastatic soft tissue sarcoma	75 mg/m2			doxorubicin	19			6	cycle		
7166	8002		ADULT			Highest studied dose	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19843057	Homo sapiens												45	6						18						p.544
7167	8002		ADULT			Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23958252	Homo sapiens							total daily dose					75	41	dyslipidemia					20			8	week		p.57, 58
7168	8003					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28472437	Homo sapiens						62	unknown						343	NSCLC								12	week		
7169	8004					Highest studied dose	mg	480		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24002508	Homo sapiens						68				At doses >300 mg (at least 10 capsules total), patients were allowed to switch to a twice-daily regimen, taking half of the capsules in the morning and half in the evening.			3	castration-resistant prostate cancer					68						
7170	8004					Recommended|MTD	mg	240		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210951s000lbl.pdf	Homo sapiens						74						97	803						48			16.9	month		
7171	8004					Recommended|MTD	mg	240		steady			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210951Orig1s000MultidisciplineR.pdf	Homo sapiens						74						97	803						48			16.9	month		p. 130
7172	8004						mg	300		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24002508	Homo sapiens						68				At doses >300 mg (at least 10 capsules total), patients were allowed to switch to a twice-daily regimen, taking half of the capsules in the morning and half in the evening.			5	castration-resistant prostate cancer					68						
7173	8006		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01355289	Homo sapiens													16	Thrombocytopenia								21	day		
7174	8006		adult				mg	30		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01355289	Homo sapiens													14	Thrombocytopenia								21	day		
7175	8006					Recommended	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	Homo sapiens						58				The recommended daily dose is based on the patient’s platelet count prior to the scheduled procedure. Platelet count 40 to less than 50x10^9/L, once daily dose: 40 mg		86	115	thrombocytopenia					19			5	day		
7176	8006					Recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	Homo sapiens						58				The recommended daily dose is based on the patient’s platelet count prior to the scheduled procedure. Platelet count less than 40x10^9/L, once daily dose: 60 mg		86	159	thrombocytopenia					19			5	day		
7177	8006					Recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	Homo sapiens						58				Platelet count 40 to less than 50x10^9/L, once daily dose: 40 mg		86	115	thrombocytopenia					19			5	day		
7178	8006					Recommended	mg	60		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	Homo sapiens						58				Platelet count less than 40x10^9/L, once daily dose: 60 mg		86	159	thrombocytopenia					19			5	day		
7179	8006						mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30203841	Homo sapiens						25.5				Avatrombopag was well tolerated, with no significant drug related AEs or DLTs following a single dose of up to 100 mg			6						25.5						
7180	8007		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21328517	Homo sapiens						61	unknown						97	type 2 diabetes								26	week		
7181	8007		ADULT			Studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21328517	Homo sapiens						60.5	unknown						97	type 2 diabetes								26	week		
7182	8009		adult			Highest studied dose	mg	550		single			day	1	healthy	oral	M		https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf	Homo sapiens													59									1	day		dexxience-epar-refusal-public-assessment-report_.pdf - p.50
7183	8009		adult			MTD	mg	360		single			day	1	healthy	oral	M		https://www.ema.europa.eu/en/documents/assessment-report/dexxience-epar-refusal-public-assessment-report_.pdf	Homo sapiens										in the fasting state			59									1	day		dexxience-epar-refusal-public-assessment-report_.pdf - p.50
7184	8009					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29977165/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208383Orig1s000MedR.pdf	Homo sapiens						76.6				median exposure			3716	Venous thromboembolism								36	day		208383Orig1s000MedR.pdf - p.76
7185	8009					Recommended	mg	80		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	Homo sapiens						76.6							3716	Venous thromboembolism								42	day		208383Orig1s000MedR.pdf - p.76
7186	8009														unknown				https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf	Homo sapiens																									
7187	8011					Highest studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31749238/	Homo sapiens						59.5							76	type 2 diabetes								12	week		
7188	8011					Studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31161692/	Homo sapiens						59.3							191	type 2 diabetes								24	week		
7189	8011					Studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31297965/	Homo sapiens						56.2							145	type 2 diabetes								96	week		
7190	8012					Highest studied dose	mg	20		single			day	1	healthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/14963471/	Homo sapiens													24									1	day		
7191	8012					Highest studied dose	mg	20		single			day	1	healthy	intranasal	M		https://pubmed.ncbi.nlm.nih.gov/14963471/	Homo sapiens													6									1	day		
7192	8012					MTD	mg	10		single			day	1	healthy	subcutaneous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf	Homo sapiens													6									1	day		
7193	8012					Recommended	mg	1.75		multiple			24 weeks	10	unhealthy	subcutaneous	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf	Homo sapiens										two to three times per month and no more than once a week. the median number of VYLEESI injections was 10 in the 24-week double-blind treatment period		56	627	hypoactive sexual desire disorder					19			24	week		
7194	8012						mg	1.75		multiple			week	3	unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/31599840/	Homo sapiens										maximum of 12 doses as needed in each 4-week period			627	hypoactive sexual desire disorder								24	week		
7195	8013					Highest studied dose	mg	3000		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24106141/	Homo sapiens						51.3							6									10	day		
7196	8013					Highest studied dose	mg	3000		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24106141/	Homo sapiens						51.4							6									1	day		
7197	8013					Studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26248357/	Homo sapiens						53.6							20	Clostridium difficile Infection								10	day		
7198	8015		adult			Recommended|MTD	mg	60		steady			month	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf	Homo sapiens										60 mg or 0.8 mg/kg equivalent. : 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle			168	hematologic malignancies								22	week		
7199	8015		adult			Recommended|MTD	mg	60		steady			month	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209936Orig1s000MultidisciplineR.pdf	Homo sapiens										60 mg or 0.8 mg/kg equivalent. : 60 mg administered as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle			168	hematologic malignancies								22	week		зю 99
7200	8015					Highest studied dose	mg/kg	1.2		steady			month	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27672108	Homo sapiens						62				as a 1-hour intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle			3						62						
7201	8018		adult			Recommended	mg	300		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf	Homo sapiens										Administer 300 mg of BAXDELA for Injection every 12 hours over 60 minutes by intravenous infusion for 5 to 14 days				acute bacterial skin and skin structure infections								14	day		
7202	8018					Highest studied dose	mg	1200		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26718605	Homo sapiens												64	8						19						
7203	8018					Recommended	mg	300		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf	Homo sapiens										Administer 300 mg of BAXDELA for Injection every 12 hours over 60 minutes by intravenous infusion for 5 to 14 days			741	acute bacterial skin and skin structure infections								14	day		p. 163
7204	8018					Recommended	mg|mg	300 |450		multiple			day	2	unhealthy	intravenous|oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208610Orig1s000,208611Orig1s000MedR.pdf	Homo sapiens							complex			Administer 300 mg for Injection every 12 hours over 60 minutes by intravenous infusion, then switch to a 450 mg tablet orally every 12 hours at the discretion of the physician for a total duration of 5 to 14 days			741	acute bacterial skin and skin structure infections								5-14	day		p. 163
7205	8019		adult			MTD	mg/m2	150		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7636539/	Homo sapiens							total daily dose	1.6 mg/m2; IV; 96 hrs		2 cycles; 21-day cycle			26	lymphoma | sarcoma	200 mg/m2; IV; 96 hrs		doxorubicin	etoposide			40 mg/m2; IV; 96 hrs	12	day	vincristine	
7206	8019		adult			Studied dose	mg/m2	120		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7636539/	Homo sapiens								1.6 mg/m2; IV; 96 hrs		21-day cycle			19	lymphoma | sarcoma	200 mg/m2; IV; 96 hrs		doxorubicin	etoposide			40 mg/m2; IV; 96 hrs	6	day	vincristine	
7207	8019		adult			Studied dose	mg/m2	175		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7636539/	Homo sapiens							total daily dose	1.6 mg/m2; IV; 96 hrs		2 cycles; 21-day cycle			6	lymphoma | sarcoma	200 mg/m2; IV; 96 hrs		doxorubicin	etoposide			40 mg/m2; IV; 96 hrs	12	day	vincristine	
7208	8019		adult			Studied dose	mg/m2	200		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7636539/	Homo sapiens							total daily dose	1.6 mg/m2; IV; 96 hrs		21-day cycle			2	lymphoma | sarcoma	200 mg/m2; IV; 96 hrs		doxorubicin	etoposide			40 mg/m2; IV; 96 hrs	6	day	vincristine	
7209	8019					Highest studied dose	mg	500		multiple			day	6	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8698736/	Homo sapiens						61							6	renal cell carcinoma								3	week		
7210	8019					Studied dose	mg/m2	180		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7636536/	Homo sapiens						56	starting			4 cycles maximum; 21-day cycle			12	renal cell carcinoma	10 mg; oral; 4/d			dexamethasone				3	day		
7211	8022		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29592840/	Homo sapiens													383	HIV-1				NRTIs				96	week		
7212	8022		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	Homo sapiens													383	HIV-1				NRTIs				48	week		3
7213	8022		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210806s000lbl.pdf	Homo sapiens													383	HIV-1				NRTIs				48	week		5
7214	8023		adult				mg	150		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00619866	Homo sapiens													69	Endometriosis								12	week		
7215	8023		adult				mg	150		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01620528	Homo sapiens													249	Endometriosis								6	month		
7216	8023		adult				mg	150		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01931670	Homo sapiens													226	Endometriosis								6	month		
7217	8023		adult				mg	200		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01620528	Homo sapiens													248	Endometriosis								6	month		
7218	8023		adult				mg	200		steady			day	2	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01931670	Homo sapiens													229	Endometriosis								6	month		
7219	8023		adult				mg	250		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00619866	Homo sapiens													72	Endometriosis								12	week		
7220	8023		adult (premenopausal women)			Recommended	mg	150		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf	Homo sapiens													475	endometriosis								6	month		p. 143
7221	8023		adult (premenopausal women)			Recommended	mg	200		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210450Orig1s000MultiD.pdf	Homo sapiens													477	endometriosis								6	month		p. 143
7222	8023					Highest studied dose	mg	400		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/19033369/	Homo sapiens													5												
7223	8024		ADULT			Highest recorded dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29959787/	Homo sapiens												64	10	constipation					20			14	day		p.2401
7224	8024		ADULT			Highest studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28840422/	Homo sapiens						43.9						73	41	constipation					20			2	week		p.529
7225	8025		adult			Highest studied dose	mg	650		multiple			day	1	unhealthy	oral	unknown		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572791/	Homo sapiens													5	myeloid leukemia											
7226	8025		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf	Homo sapiens													214	myeloid leukemia								4.3	month		5
7227	8025		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf	Homo sapiens													214	myeloid leukemia								4.3	month		6
7228	8025		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf#page=22	Homo sapiens													214	myeloid leukemia								1	month		45
7229	8025		adult			Recommended	mg	100		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf#page=22	Homo sapiens													214	myeloid leukemia								2	month		45
7230	8026					Highest studied dose	mg	700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							2						51			28	day		
7231	8026					MTD	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							25						51			28	day		
7232	8026					MTD	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens												79	15						26			12	week		
7233	8026					RP2D	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							5						51			28	day		
7234	8026					RP2D	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						61							9						61			12	week		
7235	8026						mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							9						51			28	day		
7236	8026						mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							4						51			28	day		
7237	8026						mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							3						51			28	day		
7238	8026						mg	550		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28611198	Homo sapiens						51							4						51			28	day		
7239	8027					Highest studied dose	mg/kg	3		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													42									1	day		
7240	8027					MTD	mg/kg	1.5		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													42									1	day		
7241	8027					MTD|Highest studied dose	mg/kg	1		multiple			day	2	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													24									10	day		
7242	8027					Recommended	mg/kg	1		multiple			day	2	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													24									10	day		
7243	8027					Recommended	mg/kg	1		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													42									1	day		
7244	8027						mg/kg	0.25		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211109Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30150464/	Homo sapiens													42									1	day		
7245	8027						mg/kg	1.5		single			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211109lbl.pdf	Homo sapiens							min						42									1	day		
7246	8030		ADULT			Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24271137	Homo sapiens						43.1							70									10	day		p.287
7247	8030		ADULT			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24961753	Homo sapiens						36.8						60	25						21			14	day		p.1582
7248	8031		ADULT			Highest studied dose	mg/m2	460		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169385/	Homo sapiens										120 to 550 mg/m2, infusion over 120 hr over Days 1-5 of a 21-day cycle		73	11	leukemia					23			5	cycle		
7249	8031		ADULT			Highest studied dose	mg/m2	480		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30279233/	Homo sapiens						86				a 21-day cycle			2	multiple myeloma	40 mg oral			dexamethasone	53			4	month		
7250	8031		ADULT			Highest studied dose	mg/m2	550		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169385/	Homo sapiens										120 to 550 mg/m2, 30-60 min/day infusion on Days 1-5 of a 21-day cycle		76	38	leukemia					24			5	cycle		
7251	8031		ADULT			MTD	mg/m2	330		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169385/	Homo sapiens										120 to 550 mg/m2, infusion over 120 hr over Days 1-5 of a 21-day cycle		73	11	leukemia					23			5	cycle		
7252	8031		ADULT			MTD	mg/m2	340		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30279233/	Homo sapiens						86				a 21-day cycle			24	multiple myeloma	40 mg oral			dexamethasone	53			4	month		
7253	8031		ADULT			MTD	mg/m2	460		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169385/	Homo sapiens										120 to 550 mg/m2, 30-60 min/day infusion on Days 1-5 of a 21-day cycle		76	38	leukemia					24			5	cycle		
7254	8040					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23404627	Homo sapiens												82	7						34			28	day		
7255	8040						mg	260		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209299Orig1s000MultidisciplineR.pdf	Homo sapiens						53.5	median			range: 40-390 mg		88	102						20			86	day		p. 166
7256	8041		adults			Studied dose	mg	1050		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26423650/	Homo sapiens							mean			400 mg twice daily, 800 mg twice daily, 600 mg once daily, or 1200 mg once daily			200	HIV-1 infection				raltegravir and tenofovir disoproxil fumarate				24	week		
7257	8041		adults			Studied dose	mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26423650/	Homo sapiens													50	HIV-1 infection				raltegravir and tenofovir disoproxil fumarate				24	week		
7258	8041		adults			Studied dose	mg	400		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26423650/	Homo sapiens													50	HIV-1 infection				raltegravir and tenofovir disoproxil fumarate				24	week		
7259	8041		adults			Studied dose	mg	800		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26423650/	Homo sapiens													49	HIV-1 infection				raltegravir and tenofovir disoproxil fumarate				24	week		
7260	8041					Highest studied dose	mg	2400		steady			day	2	healthy	oral			https://www.fda.gov/media/140641/download	Homo sapiens										MTD was not determined. 60 subjects randomized to 4 arms			15									7	day		
7261	8041					Recommended	mg	600		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25870057/	Homo sapiens								100 mg; oral; 1/day				49	36		300 mg; oral; 1/day			atazanavir	18			27	day	ritonavir	
7262	8041					Recommended	mg	600		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25870057/	Homo sapiens												49	18		100 mg; oral; 1/day			ritonavir	18			27	day		
7263	8041					Recommended	mg	600		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25870057/	Homo sapiens												49	36						18			27	day		
7264	8041					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf	Homo sapiens												43	271	HIV-1 infection				optimized background therapy	17			96	week		
7265	8043					Highest studied dose	mg/m2	259		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23530663/	Homo sapiens						61				once weekly for 3 weeks, followed by a 1-week rest			6	solid tumours								28	day		
7266	8043					MTD	mg/m2	216		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23530663/	Homo sapiens						62				once weekly for 3 weeks, followed by a 1-week rest			6	solid tumours								28	day		
7267	8043					Studied dose	mg/m2	100		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25248753/	Homo sapiens						57				on days 1, 8, and 15 of each 28-day cycle			7	hepatocellular carcinoma								28	day		
7268	8043					Studied dose	mg/m2	150		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23530663/	Homo sapiens						62				once weekly for 3 weeks, followed by a 1-week rest			7	solid tumours								28	day		
7269	8045					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf |https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens						62							252	relapsed AML | refractory FLT3 mutation-positive AML					62			28	day		
7270	8045					Recommended	mg	120		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf	Homo sapiens													292	relapsed AML | refractory AML								3	month		
7271	8045						mg	300		single					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211349Orig1s000MultidisciplineR.pdf |https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens						62							252	relapsed AML | refractory FLT3 mutation-positive AML					62						
7272	8045						mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens						62							252	relapsed AML | refractory FLT3 mutation-positive AML					62			28	day		
7273	8045						mg	450		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32304015	Homo sapiens						62							252	relapsed AML | refractory FLT3 mutation-positive AML					62						
7274	8048		ADULT			Highest studied dose	mg	900		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17882161/	Homo sapiens						31.5						45	6						19						p.841
7275	8048		ADULT			Studied dose	mg	450		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17882161/	Homo sapiens						31.5						45	6						19			10	day		p.841
7276	8050		adult				mg	480		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02137772	Homo sapiens										Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.			373	Cytomegalovirus Infection								14	week		
7277	8050					Highest studied dose	mg	960		single			day	1	healthy	intravenous	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/28675594/	Homo sapiens													6									1	day		209939Orig1s000,209940Orig1s000MedR.pdf - p.104
7278	8050					Recommended	mg	480		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000MedR.pdf	Homo sapiens						53				480 mg per day (or 240 mg per day in patients taking cyclosporine)			373	CMV infection				cyclosporine				16	week		209939Orig1s000,209940Orig1s000MedR.pdf - p.87
7279	8050					Recommended	mg	480		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/29211658/	Homo sapiens						53				480 mg per day (or 240 mg per day in patients taking cyclosporine)			373	CMV infection								16	week		209939Orig1s000,209940Orig1s000MedR.pdf - p.87
7280	8052		adult				mg	100		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00865904	Homo sapiens													17	Cystic Fibrosis								28	day		
7281	8052		adult				mg	200		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00865904	Homo sapiens													19	Cystic Fibrosis								28	day		
7282	8052		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00865904	Homo sapiens													18	Cystic Fibrosis								28	day		
7283	8052		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00865904	Homo sapiens													18	Cystic Fibrosis								28	day		
7284	8052						mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21825083	Homo sapiens						25							19						25			28	day		
7285	8053					Highest studied dose	mg/m2	6.9		steady			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	Homo sapiens																						60	min		p. 57
7286	8053					MTD	mg/m2	4		steady			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	Homo sapiens													31	advanced solid tumors								60	min		p. 57
7287	8053					Recommended	mg/m2	3.2		steady			3 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf	Homo sapiens						60						83	105	small cell lung cancer					40			60	min		
7288	8053					Studied dose	mg/m2	5		steady			3 weeks	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf	Homo sapiens													31	advanced solid tumors								60	min		p. 57
7289	8054		adult			Highest studied dose	mg/kg	2		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000MedR.pdf	Homo sapiens													9									1	day		205598Orig1s000MedR.pdf - p.124
7290	8054		adult			Recommended	mg/kg	0.5		single			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/205598Orig1s000MedR.pdf	Homo sapiens													52	adult growth hormone deficiency								1	day		205598Orig1s000MedR.pdf - p.124, p.52
7291	8058		adult			Recommended	mg	0.2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208854Orig1s000MedR.pdf	Homo sapiens													1163									12	week		p. 189
7292	8058		adult				mg	0.1		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01443403	Homo sapiens													61	Opioid-Induced Constipation								28	day		
7293	8058		adult				mg	0.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01443403	Homo sapiens													60	Opioid-Induced Constipation								28	day		
7294	8058		adult				mg	0.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01965158	Homo sapiens													271	Opioid-induced Constipation								12	week		
7295	8058		adult				mg	0.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01965652	Homo sapiens													621	Opioid-induced Constipation								52	week		
7296	8058		adult				mg	0.2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01993940	Homo sapiens													271	Opioid-induced Constipation								12	week		
7297	8058		adult				mg	0.4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01443403	Homo sapiens													61	Opioid-Induced Constipation								28	day		
7298	8058					Highest studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28960888	Homo sapiens						21.8							6						21.8						
7299	8058					Highest studied dose	mg	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28960888	Homo sapiens						28.3							9						28.3			10	day		
7300	8059		adult			Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2542	Homo sapiens														solid tumors								28	day		
7301	8059					MTD	mg	720		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32236642/	Homo sapiens						61.5							7	solid tumors								28	day		
7302	8059					Studied dose	mg	480		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29397354/	Homo sapiens						64				median time of treatment			138	colorectal cancer								7	week		
7303	8060		ADULT			Highest studied dose	mg	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25285531	Homo sapiens						80				administered by continuous infusion over 24 hours for 3 days (24 h x 3 d)			5	acute myeloid leukemia								3	day		p.6
7304	8060		ADULT			MTD	mg	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25285531	Homo sapiens										infused for 3 hours on 3 consecutive days (3 h × 3 d) in 2-week cycles		90	10	acute myeloid leukemia					72			3	day		p.4, 6
7305	8060		ADULT			MTD	mg/m2	1.25		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens						63.5				weekly 1-hour infusion			1	cancer								14	week		p.5,13
7306	8060		ADULT			MTD	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens						59				weekly 3-hour infusions			6	cancer								8	week		p.5
7307	8060		ADULT			Studied dose	mg	30		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25285531	Homo sapiens						83				infused for 3 hours on 3 consecutive days (3 h × 3 d) in 2-week cycles			3	acute myeloid leukemia								3	day		p.4, 6
7308	8060		ADULT			Studied dose	mg/m2	28		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens						59				weekly 3-hour infusions			6	cancer								32	week		p.5,15
7309	8060		ADULT			Studied dose	mg/m2	7		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20538761	Homo sapiens						63.5				weekly 1-hour infusion			3	cancer								12	week		p.5,15
7310	8061		young			Highest studied dose	mg	600		single			day	1	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000OtherR.pdf	Homo sapiens													2									1	day		
7311	8061		young			MTD	mg	400		single			day	1	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000OtherR.pdf	Homo sapiens																						1	day		
7312	8061					Highest studied dose	mg	600		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29180524/	Homo sapiens						35.6							24									5	day		
7313	8061					MTD|Highest studied dose	mg	600		steady			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000OtherR.pdf	Homo sapiens						35.6							24									5	day		
7314	8061					Studied dose	mg	100		steady			day	1	healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/28696233/	Homo sapiens						38							42									13	week		
7315	8061					Studied dose	mg	300		steady			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209816Orig1s000,209817Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/29180524/	Homo sapiens						35.6							26									5	day		
7316	8064					Highest studied dose	mg	15		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20198713/	Homo sapiens						59.4				2- to 6-week titration phase and 2 to 4 days of down titration				Parkinson's disease								3	week		
7317	8064					Studied dose	mg	11.23		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19407454/	Homo sapiens						65.2	mean			mean maximum tolerated study dose; gradual dose escalation with intermediate steps			26	Parkinson's disease								7	week		
7318	8064					Studied dose	mg	24		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20198713/	Homo sapiens						59.4	median			2- to 6-week titration phase and 2 to 4 days of down titration			67	Parkinson's disease								3	week		
7319	8064					Studied dose	mg	8.66		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19407454/	Homo sapiens						64.3	mean			mean maximum tolerated study dose; gradual dose escalation without intermediate steps			24	Parkinson's disease								7	week		
7320	8065					Highest studied dose	mg	900		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26710243	Homo sapiens						32.9							6						32.9						
7321	8069		adult			Highest studied dose	mg/kg	20		single			day	1	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/30650259/	Homo sapiens													57									1	day		
7322	8069					MTD	mg/kg	15		multiple			day	1	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000ClinPharmR.pdf | https://pubmed.ncbi.nlm.nih.gov/32319833/ | https://pubmed.ncbi.nlm.nih.gov/26419762/	Homo sapiens										IV infusion over 10 minutes		65	15						18			1	day		
7323	8069					Recommended	mg/kg	15		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/29378708/	Homo sapiens						39.5							74	Complicated Urinary Tract Infections								5	day		
7324	8069					Recommended	mg/kg	15		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/29378708/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000MedR.pdf	Homo sapiens						39.5							74	Complicated Urinary Tract Infections								5	day		
7325	8069					Recommended	mg/kg	15		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210303Orig1s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/30786187/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000MedR.pdf	Homo sapiens						59.4				at least 4 days			303	Complicated Urinary Tract Infections								4	day		
7326	8069					Recommended	mg/kg	15		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210303Orig1s000MedR.pdf	Homo sapiens						59.4				at least 4 days			303	Complicated Urinary Tract Infections								4	day		
7327	8071		ADULT			RP2D	mg/m2	30		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21138873	Homo sapiens						56.5				Plinabulin was administered via intravenous (IV) infusion over 15 or 30 minutes depending on infusate volume on days 1, 8, and 15 of 4-week cycles.			18	cancer								3	week		p.5895
7328	8072		ADULT			Highest studied dose	mg	100		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000OtherR.pdf | https://clinicaltrials.gov/ct2/show/NCT02029482	Homo sapiens													12	multiple sclerosis								3	day		25 | AC-058-109
7329	8072		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf	Homo sapiens						35						55	114	relapsing-remitting multiple sclerosis					19			24	week		78 | 131 | 148 | AC-058B201
7330	8072		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000OtherR.pdf#page=29	Homo sapiens						36						55	565	multiple sclerosis					18			108	week		49 | 123 | 141 | 147 | AC-058B301
7331	8072		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000OtherR.pdf#page=30	Homo sapiens						36						55	1148	multiple sclerosis					18			528	week		49 | 78 | 132 | AC-058B201/AC-058B301 extensions
7332	8072		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf	Homo sapiens						38						55	108	relapsing-remitting multiple sclerosis					18			24	week		78 | 131 | 148 | AC-058B201
7333	8072		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000OtherR.pdf#page=30	Homo sapiens						38						55	139	relapsing-remitting multiple sclerosis					18			240	week		78 | 132 | AC-058B201 extension
7334	8072		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf	Homo sapiens						38						55	119	relapsing-remitting multiple sclerosis					18			24	week		78 | 131 |148 | AC-058B201
7335	8072		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213498Orig1s000OtherR.pdf#page=30	Homo sapiens						38						55	151	relapsing-remitting multiple sclerosis					18			240	week		78 | 132 | AC-058B201 extension
7336	8073		ADULT			Highest studied dose	mg	300		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25854859	Homo sapiens						37.5							8	obesity											p.1037
7337	8073		ADULT			Studied dose	mg	115		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27274009	Homo sapiens						31				60 minute infusion			9												p.9
7338	8074					Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31358590	Homo sapiens													8												
7339	8074						mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31570404	Homo sapiens						27						56	15						18			14	day		
7340	8075					Highest studied dose	mg	112.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30563778/	Homo sapiens						47.5							82	Huntington's disease								26	week		
7341	8075					Highest studied dose	mg	90		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32995944/	Homo sapiens						43.3							3	Huntington's disease								1	day		
7342	8078					MTD	mg	500		multiple			day	4	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens								500 mg; IV; 4 per day					24		500 mg; IV; 4 per day			imipenem				14	day	cilastatin	
7343	8078					MTD	mg	625		multiple			day	4	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens						27		500 mg; IV; 4 per day					6		500 mg; IV; 4 per day			imipenem				7	day	cilastatin	
7344	8078					MTD|Highest studied dose	mg	1150		single			day	1	healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212819Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/29914955/	Homo sapiens						28.5							6									1	day		
7345	8078					Recommended	mg	250		multiple			day	4	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29311084/	Homo sapiens								500 mg; IV; 4 per day		5 consecutive doses of relebactam at 250 mg in combination with imipenem-cilastatin at 500 mg given every 6 h,		42	17		500 mg; IV; 4 per day			imipenem	24			30	hour	cilastatin	
7346	8078					Recommended	mg	250		multiple			day	4	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf	Homo sapiens						56.4		500 mg; IV; 4 per day		The mean duration of IV therapy in patients treated with imipenem/cilastatin plus relebactam 250 mg was approximately 7 days			216	Complicated Urinary Tract Infection or Complicated Intra-Abdominal Infection	500 mg; IV; 4 per day			imipenem				7	day	cilastatin	
7347	8078						mg	125		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27503659/	Homo sapiens						49.7		500 mg; IV; 4 per day		The minimum duration of i.v. study therapy was 96 h, or 4 full days (16 doses for q6h dosing or 12 doses for q8h dosing [renal adjustment]). The total duration of i.v. study therapy generally did not exceed 7 days. If, in the investigator’s judgment, additional treatment was needed, i.v. study therapy was allowed to continue up to 14 days.			87	Complicated Intra-Abdominal Infection	500 mg; IV; 4 per day			imipenem				7	day	cilastatin	
7348	8078						mg	125		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28575389/	Homo sapiens						58		500 mg; IV; 4 per day					99	complicated urinary tract infections	500 mg; IV; 4 per day			imipenem				14	day	cilastatin	
7349	8078						mg	125		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28575389/	Homo sapiens						60		500 mg; IV; 4 per day					99	complicated urinary tract infections	500 mg; IV; 4 per day			imipenem				14	day	cilastatin	
7350	8078						mg	250		multiple			day	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28575389/	Homo sapiens						58		500 mg; IV; 4 per day					99	complicated urinary tract infections	500 mg; IV; 4 per day			imipenem				14	day	cilastatin	
7351	8079		adult				mg	3.75		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02532647	Homo sapiens							min			Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.			31	Colonoscopy											
7352	8079		adult				mg	7.5		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02290873	Homo sapiens							min			Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.			296	Colonoscopy											
7353	8079		adult				mg	7.5		single					unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02296892	Homo sapiens							min			Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.			303	Bronchoscopy											
7354	8079		adults			Recommended	mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29723512/	Homo sapiens							median			initial (5mg each) and followed (2.5 mg each) boluses until adequate sedation was achieved			296	colonoscopy	50 to 75 ug intravenous; 25 ug every 5 to 10 minutes were allowed until analgesia was adequate			fentanyl				1	day		
7355	8079		adults			Recommended	mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf	Homo sapiens							median			initial (2.5 - 5mg each) and followed (1.25 - 2.5 mg each) boluses until adequate sedation was achieved			31	Bronchoscopy	50 ug intravenous; 25 ug every 5 to 10 minutes were allowed until analgesia was adequate			fentanyl				1	day		
7356	8079		adults			Recommended	mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/29723512/	Homo sapiens							median			initial (5mg each) and followed (2.5 mg each) boluses until adequate sedation was achieved			296	colonoscopy	50 to 75 ug intravenous; 25 ug every 5 to 10 minutes were allowed until analgesia was adequate			fentanyl				1	day		
7357	8079		adults			Recommended	mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/30292760/	Homo sapiens							median			initial (5mg each) and followed (2.5 mg each) boluses until adequate sedation was achieved			303	Bronchoscopy	50 to 75 ug intravenous; 25 ug every 5 to 10 minutes were allowed until analgesia was adequate			fentanyl				1	day		
7358	8079					Highest studied dose	mg	33.16		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens										max dose administered to a patient			1												
7359	8079					Studied dose	mg	19.058		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens							mid range			pooled safety group			165												
7360	8079					Studied dose	mg	20		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens																									
7361	8079					Studied dose	mg	28.43		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens							mid range			pooled safety group			6												
7362	8079					Studied dose	mg	9.686		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens							mid range			pooled safety group			459												
7363	8079					Studied dose	mg/kg	0.2		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000MedR.pdf	Homo sapiens													25	upper endoscopy											
7364	8080		adult			Recommended	mg	600		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf	Homo sapiens													334	postmenopausal				letrozole				13	month		
7365	8080					MTD	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31285369 |https://pubmed.ncbi.nlm.nih.gov/29059492	Homo sapiens						49						66	12	grade IV glioma					31			5	day		
7366	8080					MTD	mg/m2	470		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28432176	Homo sapiens						7							12	Malignant Rhabdoid Tumors | Neuroblastoma					7			3	week		
7367	8080						mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29059492/	Homo sapiens						57							4	Breast cancer|Esophagus cancer| Peritoneum cancer					57			3	week		
7368	8080						mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29059492/	Homo sapiens						57							13	Breast cancer|Esophagus cancer| Peritoneum cancer					57			3	week		
7369	8080						mg/m2	280		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28432176	Homo sapiens						2							5	Malignant Rhabdoid Tumors | Neuroblastoma					2			3	week		
7370	8081		ADULT			Highest studied dose	mg	4200		steady			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24947095	Homo sapiens										4-hour infusion twice-a-week for 3 weeks of a 4-week cycle		65.8	1	gastric carcinoma					25.7						p.44
7371	8081		ADULT			Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23789936	Homo sapiens										twice daily for 14 d of a 21-d cycle		82	6	myelodysplastic syndrome					53			14	day		p.6, 7, 15
7372	8081		ADULT			Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens										twice daily continuously in 21-day cycles, median of 2 cycles		71	6	cancer					47			21	day		p.17
7373	8081		ADULT			MTD	mg	3200		steady			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24947095	Homo sapiens										4-hour infusion twice-a-week for 3 weeks of a 4-week cycle		65.8	4	cancer					25.7			3	week		p.41, 44
7374	8081		ADULT			MTD	mg	560		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23789936	Homo sapiens										twice daily for 14 d of a 21-d cycle		89	24	myelodysplastic syndrome					56			14	day		p.6, 7, 15
7375	8081		ADULT			MTD	mg	560		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24493827	Homo sapiens										twice daily continuously in 21-day cycles, median of 2 cycles		79	33	cancer					20			21	day		p.17
7376	8084		ADULT			Overdose	mg/kg	5		single					healthy	oral	M+F		https://www.medicines.org.uk/emc/product/12835/smpc#UNDESIRABLE_EFFECTS	Homo sapiens																									
7377	8084		ADULT			Recommended	mg	200		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26846333/	Homo sapiens						56.9	max					80	67	kidney disease					20			19	week		p.918
7378	8086		child|adult				mg/kg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02320149	Homo sapiens													481	Acne Vulgaris								12	week		
7379	8086		child|adult				mg/kg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02322866	Homo sapiens													513	Acne Vulgaris								12	week		
7380	8086					Recommended	mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens										150 mg for patients who weigh 85-136 kg; dose per mass: 1.76-1.1 mg/kg				acne vulgaris					9			12	week		
7381	8086					Recommended	mg/kg	1.5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209521s000lbl.pdf	Homo sapiens							mean			60 mg for patients who weigh 33-54 kg| 100 mg for patients who weigh 55-84 kg| 150 mg for patients who weigh 85-136 kg. dose per mass 1.1-1.8 mg/kg			1064	acne vulgaris					9			12	week		
7382	8086					Recommended	mg/kg	1.5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens							mean			60 mg for patients who weigh 33-54 kg| 100 mg for patients who weigh 55-84 kg| 150 mg for patients who weigh 85-136 kg. dose per mass 1.1-1.8 mg/kg			1064	acne vulgaris					9			12	week		p. 17
7383	8086						mg/kg	1.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209521Orig1s000MultidisciplineR.pdf	Homo sapiens						19.7	mean			Pooled (All Doses)		45	1300	acne vulgaris					19.7			152	day		p.93
7384	8087		adult			Highest studied dose	ug/kg	20		single			day	1	healthy	subcutaneous	M		https://distribute.m-anage.com/check.pic?path=events%5C176%5Cabstract%5C25575%5C343995_826.pdf	Homo sapiens													6									1	day		
7385	8087		adult			MTD	ug/kg	15		single			day	1	healthy	subcutaneous	M		https://distribute.m-anage.com/check.pic?path=events%5C176%5Cabstract%5C25575%5C343995_826.pdf	Homo sapiens													6									1	day		
7386	8087		adult			Recommended	mg	8		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000MedR.pdf	Homo sapiens							mean			3, 7, 14 mg doses pooled; 26, 52, 78 weeks			4379	Type 2 diabetes								52	week		213051Orig1s000MedR.pdf -p.153, p.175
7387	8087					Highest studied dose	mg	1.5		multiple			week	1	healthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/29799100/	Homo sapiens						37.7							83									4	week		
7388	8087					Highest studied dose	mg	1.6		multiple			week	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/26358288/	Homo sapiens						56.4							47	Type 2 diabetes								10	week		
7389	8087					Highest studied dose	mg	20		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30565096/	Homo sapiens						34.8							10		600 mg; single			sodium N-(8-[2-hydroxybenzoyl]amino) caprylate				1	day		
7390	8087					Highest studied dose	mg	40		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30565096/	Homo sapiens						40.8							32		300 mg; 10 weeks			sodium N-(8-[2-hydroxybenzoyl]amino) caprylate				10	week		
7391	8087					Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30565096/	Homo sapiens						55.3							11	Type 2 diabetes	300 mg; 10 weeks			sodium N-(8-[2-hydroxybenzoyl]amino) caprylate				10	week		
7392	8087					Recommended	mg	1		multiple			week	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/31539622/	Homo sapiens						59.5							289	Type 2 diabetes								30	week		
7393	8087														unknown				https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf	Homo sapiens																									
7394	8089		adult			Highest studied dose	mg	20		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf	Homo sapiens																						38	day		p. 38
7395	8089		adult			Highest studied dose	mg	75		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf	Homo sapiens																									p. 38
7396	8089		adult				mg	10		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf	Homo sapiens													50												p. 109
7397	8089		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01665144	Homo sapiens										Participants started on Day 1 and were uptitrated from 0.25 mg to 2 mg of BAF312 orally over a period of 6 days. After Day 7, participants continued on the treatment epoch for 3 months. During the Core Part of the study, participants participated in a maximum of 3 epochs. Following the Core Part, eligible patients enter the Extension Part during which all receive open-label BAF312.			1099	Multiple Sclerosis								3	month		
7398	8089					Recommended	mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf	Homo sapiens						49							1148	secondary progressive multiple sclerosis					49			3	month		
7399	8089					Recommended	mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf	Homo sapiens						49							1148	secondary progressive multiple sclerosis					49			3	month		p. 109
7400	8089					Recommended	mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000MedR.pdf	Homo sapiens						49							1148	secondary progressive multiple sclerosis					49			3	month		p. 109
7401	8089						mg	1		single					healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/31926605	Homo sapiens										4 consecutive 6-hour infusions of 0.25 mg at a rate of 8.5 mL/h; 24-hour infusion		50	17						18			24	hour		
7402	8096		adult			Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/19417029/	Homo sapiens													7	tumor	22.5 mg/m2			inorelbine				2	cycle		
7403	8096		adult			MTD	mg	150		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/19417029/	Homo sapiens													14	tumor	20 mg/m2			inorelbine				2	cycle		
7404	8097					Highest studied dose	mg	2400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21431416/	Homo sapiens										day 1 of each 28-day		83	3	refractory solid tumors					18			1	cycle		
7405	8097					Highest studied dose	mg	2500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228983/	Homo sapiens										day 1 of each 28-day		74	26	advanced solid tumors					41			1	cycle		
7406	8097					Highest studied dose	mg	2500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228983/	Homo sapiens										day 1 of each 28-day		74	26	advanced solid tumors					41			3	cycle		
7407	8097					MTD	mg	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23228983/	Homo sapiens										day 1 of each 28-day		74	26	advanced solid tumors					41			1	cycle		
7408	8097					MTD	mg	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23370664/	Homo sapiens										day 1 of each 28-day, 1,200–6,400 ug h/mL			6	advanced solid tumors					20			1	cycle		
7409	8097					MTD	mg	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, 1,200–6,400 ug h/mL		89	168	metastatic melanoma					22			2	cycle		
7410	8097					MTD	mg	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, 1200-6400 ug h/mL		89	124	metastatic melanoma					22			2	cycle		
7411	8097					MTD	mg	2000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, 1200-6400 ug h/mL		89	161	metastatic melanoma					22			1	cycle		
7412	8097					MTD	mg	2400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, <1200 ug h/mL		89	161	metastatic melanoma					22			1	cycle		
7413	8097					MTD	mg	2400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, 6400-10,000 ug h/mL		89	124	metastatic melanoma					22			2	cycle		
7414	8097					MTD	mg	2400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, 6400-10,000 ug h/mL		89	161	metastatic melanoma					22			1	cycle		
7415	8097					MTD	mg	2500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, >10,000 ug h/mL		89	124	metastatic melanoma					22			2	cycle		
7416	8097					MTD	mg	2500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24676877/	Homo sapiens										day 1 of each 28-day, >10,000 ug h/mL		89	161	metastatic melanoma					22			1	cycle		
7417	8097					Recommended	mg	1800		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21431416/	Homo sapiens										day 1 of each 28-day		83	10	refractory solid tumors					18			2	cycle		
7418	8101		adult			Highest studied dose	mg	500		steady			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/25636046	Homo sapiens													14	carcinoid syndrome								2	week		
7419	8101		adult			Highest studied dose	mg	500		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000MedR.pdf	Homo sapiens													70	carcinoid syndrome								12	week		
7420	8101		adult			Recommended	mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000MedR.pdf	Homo sapiens													140	carcinoid syndrome								12	week		
7421	8101		adult			Recommended	mg	250		steady			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000MedR.pdf	Homo sapiens													70	carcinoid syndrome								12	week		
7422	8102					Recommended	mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	Homo sapiens										The recommended dose is one tablet (tezacaftor 100 mg/ivacaftor 150 mg) taken in the morning and one tablet (ivacaftor 150 mg) taken in the evening, approximately 12 hours apart			334	cystic fibrosis	150 mg, 2 times per day			ivacaftor	12			12	week		
7423	8102					Recommended	mg	150		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf	Homo sapiens										The recommended dose is one tablet (tezacaftor 100 mg/ivacaftor 150 mg) taken in the morning and one tablet (ivacaftor 150 mg) taken in the evening, approximately 12 hours apart			334	cystic fibrosis				ivacaftor	12			12	week		
7424	8102					Studied dose	mg	300		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210491Orig1s000ClinPharmR.pdf	Homo sapiens													8									7	day		
7425	8103		ADULT			Highest studied dose	mg	750		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24872402	Homo sapiens						67.3							33	peripheral artery disease											p.303
7426	8103		ADULT			Studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23952636	Homo sapiens						59							16	amyotrophic lateral sclerosis								3	week		p.577
7427	8103		ADULT			Studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29402141	Homo sapiens						57.6	max						744	amyotrophic lateral sclerosis								48	week		p.6
7428	8103		ADULT			Studied dose	mg	375		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23952636	Homo sapiens						56							18	amyotrophic lateral sclerosis								3	week		p.577
7429	8104					Highest studied dose	mg	240		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25008546/	Homo sapiens						63.3							84	Parkinson's disease								12	week		
7430	8104					Studied dose	mg	240		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25008546/	Homo sapiens						63.3	max			60 to 240 mg			336	Parkinson's disease								12	week		
7431	8106					Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12114372/	Homo sapiens						66.5							8	Chronic obstructive pulmonary disease								14	day		
7432	8107					Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26400458/	Homo sapiens						35.9							201	Crohn's disease								12	week		
7433	8109		ADULT			Highest studied dose	mg/m2	90		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens						65							6	acute leukemia								4	cycle		1808-14
7434	8109		ADULT			MTD	mg/m2	15		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20233886/	Homo sapiens						61							6	cancer								6	cycle		2167-75
7435	8109		ADULT			MTD	mg/m2	40		multiple			4 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens						65							11	acute leukemia								4	cycle		1808-14
7436	8109		ADULT			MTD	mg/m2	48		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20233886/	Homo sapiens						59							11	cancer								6	cycle		2167-75
7437	8109		ADULT			MTD	mg/m2	72		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21760592/	Homo sapiens						65							12	acute leukemia								4	cycle		1808-14
7438	8109		ADULT			Studied dose	mg/m2	18		multiple			4 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20233886/	Homo sapiens						61							4	cancer								6	cycle		2167-75
7439	8109		ADULT			Studied dose	mg/m2	60		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20233886/	Homo sapiens						59							8	cancer								6	cycle		2167-75
7440	8116		ADULT			Highest studied dose	mg/m2	0.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796369	Homo sapiens						52				On day 1 of week 1, all patients received an i.v. dose of 9-ACCD over 15 min, and then  from  day  2  forward,  patients  received  9-ACCD  p.o.  One course of treatment consisted  of  p.o.  administration  of  9-ACCD  5  days/week  for four consecutive weeks, followed by a rest period of 2 weeks.			3	cancer								5	day		p.2068
7441	8116		ADULT			Highest studied dose	ug/m2	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815982	Homo sapiens						53				72-h continuous i.v. infusion (60 ug/m2/hour); patients typically received multiple courses of 9-AC, with a median of 3 (range 1-11)			3	cancer								3	day		p.272
7442	8116		ADULT			MTD	mg/m2	0.63		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12796369	Homo sapiens						52				On day 1 of week 1, all patients received an i.v. dose of 9-ACCD over 15 min, and then  from  day  2  forward,  patients  received  9-ACCD  p.o.  One course of treatment consisted  of  p.o.  administration  of  9-ACCD  5  days/week  for four consecutive weeks, followed by a rest period of 2 weeks.			5	cancer								5	day		
7443	8116		ADULT			MTD	mg/m2	1.3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10561232	Homo sapiens						55				9-aminocamptothecin (9-AC) in a colloidal dispersion (CD) formulation was administered as a 30-minute intravenous (IV) infusion over 5 consecutive days every 3 weeks.			6	cancer								5	day		p.1909
7444	8116		ADULT			MTD	ug/m2	45		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815982	Homo sapiens						53				72-h continuous i.v. infusion (45 ug/m2/hour); patients typically received multiple courses of 9-AC, with a median of 3 (range 1-11)			13	cancer								3	day		p.272
7445	8116		ADULT			RP2D	mg/m2	1.1		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10561232	Homo sapiens						55				9-aminocamptothecin (9-AC) in a colloidal dispersion (CD) formulation was administered as a 30-minute intravenous (IV) infusion over 5 consecutive days every 3 weeks.			9	cancer								5	day		p.1909
7446	8120		ADULT			Studied dose	%	6		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32576219	Homo sapiens							unknown						82	epidermolysis bullosa								90	day		
7447	8124		adult			Highest studied dose	mg/m2	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9053505/	Homo sapiens													3	advanced malignancy								28	day		
7448	8124		adult			MTD	mg/m2	75		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9053505/	Homo sapiens													20	advanced malignancy								28	day		
7449	8124					Highest studied dose	mg/m2	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11801543/	Homo sapiens												81	8	solid tumor or lymphoma					23			28	day		
7450	8124					Highest studied dose	mg/m2	250		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11801543/	Homo sapiens												81	6	solid tumor or lymphoma					23			28	day		
7451	8124					Highest studied dose	mg/m2	300		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11801543/	Homo sapiens												81	8	solid tumor or lymphoma					23			28	day		
7452	8124					MTD	mg/m2	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11801543/	Homo sapiens												81	6	solid tumor or lymphoma					23			28	day		
7453	8125					Highest studied dose	mg	2000		single					unhealthy	intravenous			https://www.ema.europa.eu/en/documents/assessment-report/zinforo-epar-public-assessment-report_en.pdf	Homo sapiens													236	Bacterial skin and soft tissue infections											p.95
7454	8125					Highest studied dose	mg	600		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30597021	Homo sapiens										2 h IV infusion of 600 mg q8h			506	Complicated bacterial skin and soft tissue infections								8.2	day		p.1089
7455	8125					Recommended	mg	600		multiple			day	2	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf	Homo sapiens													1300	Acute bacterial skin and skin structure infections|Community-acquired bacterial pneumonia											p.1
7456	8125					Recommended	mg	600		multiple			day	2	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf	Homo sapiens														Acute bacterial skin and skin structure infections|Community-acquired bacterial pneumonia											p.1
7457	8127		ADOLESCENT|ADULT			Studied dose	%	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32348828/	Homo sapiens						17.5							317	acne vulgaris								12	month		p.481
7458	8127		ADULT			Studied dose	%	1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32320027/	Homo sapiens						18				1%, applied approximately 1 g to the whole face twice daily for 12 weeks.			353	acne								12	week		
7459	8135					Highest studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27299749/	Homo sapiens						56	starting						3	solid tumors								4	week		
7460	8135					MTD	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27299749/	Homo sapiens						56	starting						16	solid tumors								4	week		
7461	8135					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27299749/	Homo sapiens						56	starting						3	solid tumors								4	week		
7462	8135					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28103904/	Homo sapiens						50				and 1 week of rest			47	colorectal cancer								3	week		
7463	8135					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28103904/	Homo sapiens						55.5				and 1 week of rest			42	colorectal cancer								3	week		
7464	8135					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32901330/	Homo sapiens										and 1 week of rest		75	278	colorectal cancer					18			3	week		
7465	8135					Studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27299749/	Homo sapiens						56	starting			and 1 week of rest			6	solid tumors								3	week		
7466	8139		adult				ug	175		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													37	Chronic Obstructive Pulmonary Disease								7	day		
7467	8139		adult				ug	175		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02040792	Homo sapiens													71	Chronic Obstructive Pulmonary Disease								28	day		
7468	8139		adult				ug	175		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02459080	Homo sapiens													198	Chronic Obstructive Pulmonary Disease								12	week		
7469	8139		adult				ug	22		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													41	Chronic Obstructive Pulmonary Disease								7	day		
7470	8139		adult				ug	22		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													42	Chronic Obstructive Pulmonary Disease								7	day		
7471	8139		adult				ug	350		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													41	Chronic Obstructive Pulmonary Disease								7	day		
7472	8139		adult				ug	350		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02040792	Homo sapiens													74	Chronic Obstructive Pulmonary Disease								28	day		
7473	8139		adult				ug	44		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													39	Chronic Obstructive Pulmonary Disease								7	day		
7474	8139		adult				ug	44		multiple			day	2	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02109172	Homo sapiens													64	Chronic Obstructive Pulmonary Disease								7	day		
7475	8139		adult				ug	44		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02040792	Homo sapiens													68	Chronic Obstructive Pulmonary Disease								28	day		
7476	8139		adult				ug	700		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													37	Chronic Obstructive Pulmonary Disease								7	day		
7477	8139		adult				ug	88		multiple			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT01704404	Homo sapiens													40	Chronic Obstructive Pulmonary Disease								7	day		
7478	8139		adult				ug	88		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02040792	Homo sapiens													71	Chronic Obstructive Pulmonary Disease								28	day		
7479	8139		adult				ug	88		steady			day	1	unhealthy	respiratory	M+F		https://clinicaltrials.gov/ct2/show/NCT02459080	Homo sapiens													212	Chronic Obstructive Pulmonary Disease								12	week		
7480	8139					Recommended	ug	175		steady			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf	Homo sapiens						64						88	418	chronic obstructive pulmonary disease					41			12	week		
7481	8139						ug	175		steady			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000MedR.pdf	Homo sapiens													427	COPD								12	week		p. 72
7482	8139						ug	175		steady			day	1	unhealthy	respiratory			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210598Orig1s000MedR.pdf	Homo sapiens													427	COPD								12	week		
7483	8141					Highest studied dose	mg	400		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10229732/	Homo sapiens						78				plus 800 mg loading dose			7	acute stroke								3	day		
7484	8141					Highest studied dose	mg	400		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11173790/	Homo sapiens						71.7				plus 800 mg loading dose			38	acute stroke								3	day		
7485	8141					Highest studied dose	mg	800		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10657406/	Homo sapiens						65							12	acute stroke								1	day		
7486	8141					Studied dose	mg	100		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10229732/	Homo sapiens						78				plus 800 mg loading dose			6	acute stroke								3	day		
7487	8141					Studied dose	mg	100		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10229732/	Homo sapiens						74							6	acute stroke								1	day		
7488	8142					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19099009	Homo sapiens						61.7							109	Osteoarthritis of the Knee								6	week		
7489	8142					Highest studied dose	mg	70		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19692798	Homo sapiens						22.2							50	Pain											p.581
7490	8147		adult			Highest studied dose	%	0.02		multiple			day	2	unhealthy	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	Homo sapiens														open-angle glaucoma or ocular hypertension								4	week		2
7491	8147		adult			Recommended	%	0.02		multiple			day	1	unhealthy	ophthalmic	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208254lbl.pdf	Homo sapiens														open-angle glaucoma or ocular hypertension								4	week		6.1
7492	8150		ADULT			Highest studied dose	mg	20		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16248851	Homo sapiens						66.8							6												p.487
7493	8150		ADULT			MTD	mg	10		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16248851	Homo sapiens						69.2							12												p.487
7494	8155		ADULT			Highest studied dose	g	100		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27208415/	Homo sapiens						64							15									12	week		1167-83
7495	8155		ADULT			Studied dose	g	68.5		multiple			day	6	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/12414409/|https://pubmed.ncbi.nlm.nih.gov/15295655/	Homo sapiens												78	10	dry eye disease					51			6	month		2024-9|321-7
7496	8165					Highest studied dose	mg	275		steady			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27217383	Homo sapiens												66	3	advanced cancer					44			28	day		
7497	8165					Highest studied dose	mg	600		single					healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208716Orig1s000MultidisciplineR.pdf	Homo sapiens													100												p. 70
7498	8165					Recommended|MTD	mg	200		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208855s000lbl.pdf	Homo sapiens													132	HR-positive, HER2-negative metastatic breast cancer								4.5	month		
7499	8165					Recommended|MTD	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27217383	Homo sapiens												68	7	advanced cancer					51			28	day		
7500	8165					Recommended|MTD	mg	200		steady			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/27312735	Homo sapiens													6	advanced cancer								28	day		
7501	8166					Highest studied dose	mg	450		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000MultidisciplineR.pdf	Homo sapiens														advanced solid malignancies											p. 68
7502	8166					MTD	mg	400		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000MultidisciplineR.pdf	Homo sapiens													33	advanced solid malignancies								2.3	month		p. 76, 87
7503	8166					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212526Orig1s000MultidisciplineR.pdf	Homo sapiens						63						92	284		500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase			fulvestrant	25			18	month		p. 138
7504	8166					Studied dose	mg	350		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30588709	Homo sapiens						54.5						72	8						31			28	day		
7505	8166					Studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30588709	Homo sapiens						48						72	7						24			28	day		
7506	8167					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32219359	Homo sapiens							unknown						1212	type 2 diabetes								12	week		
7507	8168		adult				mg	10		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19761718	Homo sapiens										10 mg avosentan in 20 ml solution for infusion for 20 minutes															
7508	8168		adult				mg	60		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15966464	Homo sapiens																						7	day		
7509	8168					Highest studied dose	mg	200		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14681342	Homo sapiens						31							6												
7510	8170		adult				mg	10		multiple			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).			8									7	day		
7511	8170		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00902486	Homo sapiens													31	Rheumatoid Arthritis								6	month		
7512	8170		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02708095	Homo sapiens													105	Systemic Lupus Erythematosus								24	week		
7513	8170		adult				mg	2		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02708095	Homo sapiens													96	Systemic Lupus Erythematosus								24	week		
7514	8170		adult				mg	4		multiple			day	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02758613	Homo sapiens										4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).			9									7	day		
7515	8170		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00902486	Homo sapiens													31	Rheumatoid Arthritis								6	month		
7516	8170		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02708095	Homo sapiens													104	Systemic Lupus Erythematosus								24	week		
7517	8170		adult				mg	7		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00902486	Homo sapiens													32	Rheumatoid Arthritis								6	month		
7518	8170					Highest studied dose	mg	20		multiple			day	1	healthy	oral	M+F		https://ec.europa.eu/health/documents/community-register/2018/20180629141659/anx_141659_en.pdf | https://pubmed.ncbi.nlm.nih.gov/24965573	Homo sapiens						30.6							8						30.6			10	day		p. 10
7519	8170					Highest studied dose	mg	40		single					healthy	oral			https://ec.europa.eu/health/documents/community-register/2018/20180629141659/anx_141659_en.pdf	Homo sapiens																									p. 10
7520	8170					Recommended	mg	2		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924Orig1s000lbl.pdf	Homo sapiens																									
7521	8170					Recommended	mg	2		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000MedR.pdf	Homo sapiens													479									16	week		p. 171
7522	8170						mg	4		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000MedR.pdf	Homo sapiens													997									16	week		p. 171
7523	8172					Highest studied dose	mg	80		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28152546/	Homo sapiens						58							4	biliary cancer| KRAS-mutant colorectal cancer					58			21	day		
7524	8172					MTD	mg	60		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28152546/	Homo sapiens						58							41	biliary cancer| KRAS-mutant colorectal cancer					58			21	day		
7525	8172					MTD	mg	60		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210498Orig1s000MultidisciplineR.pdf |https://pubmed.ncbi.nlm.nih.gov/28152546	Homo sapiens						58							41	biliary cancer| KRAS-mutant colorectal cancer					58			21	day		p. 58
7526	8172					Recommended	mg	45		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf	Homo sapiens													192	BRAF V600 mutation-positive unresectable or metastatic melanoma	450 mg once daily			encorafenib				11.8	month		
7527	8172					RP2D	mg	45		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28152546/	Homo sapiens						58							44	biliary cancer| KRAS-mutant colorectal cancer					58			21	day		
7528	8173		ADULT			Highest studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21131369	Homo sapiens						61						85	4	cancer					29						p.1415
7529	8173		ADULT			MTD	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21131369	Homo sapiens						61						85	20	cancer					29						p.1415
7530	8173		ADULT			MTD	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23980084	Homo sapiens						61						87	575	hepatocellular carcinoma					19						p.3520-3522
7531	8173		ADULT			MTD	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31522033	Homo sapiens						57							595	cancer								12	week		p.137
7532	8174					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22162589/	Homo sapiens						55							4	solid tumors								28	day		
7533	8174					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22162589/	Homo sapiens						53							17	solid tumors								28	day		
7534	8174					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24652201/	Homo sapiens						56							55	solid tumors								28	day		
7535	8174					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22162589/	Homo sapiens						53							6	solid tumors								28	day		
7536	8176					Highest studied dose	ug	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31152783/	Homo sapiens						63.9	max			dose-range 200-1000 ug			37	pain								26	week		
7537	8176					Highest studied dose	ug	800		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30531478/ | https://onlinelibrary.wiley.com/doi/epdf/10.1111/papr.12451	Homo sapiens												55	46						18			1	day		
7538	8178					Recommended	%	2		steady			day	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207695Orig1s000MedR.pdf	Homo sapiens												21	1021						2			2	year		p. 120
7539	8180		ADULT			Highest studied dose	mg	200		single					healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/34118115/	Homo sapiens						29							16									13	week		p.4
7540	8180		ADULT			Studied dose	%	0.05		multiple			day	1	healthy	vaginal	F		https://pubmed.ncbi.nlm.nih.gov/26565716/	Homo sapiens												45	15						18			7	day		p.6
7541	8181		ADULT			Highest studied dose	mg/m2	58		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28859059	Homo sapiens						53				2-h infusions administered once every 3 weeks		71	4	cancer					29						p.1260
7542	8181		ADULT			MTD	mg/m2	50		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25395429	Homo sapiens						66				Dinaciclib was administered on day 1 of a 21-day cycle; a median of 2 cycles (range, 1-12) of treatment		81	15	multiple myeloma					49			2	cycle		
7543	8181		ADULT			RP2D	mg/m2	50		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28859059	Homo sapiens						53				2-h infusions administered once every 3 weeks		71	15	cancer					29						p.1260
7544	8181		ADULT			RP2D	mg/m2	50		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28859059	Homo sapiens						59.5				8-h infusions administered once every 3 weeks		79	2	cancer					36						p.1261
7545	8182		ADULT			MTD	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18381947	Homo sapiens						56				during cycle 1, 7-day on/7-day off treatment followed by 14 days of continuous daily dosing			7	cancer								14	day		p.2078
7546	8182		ADULT			MTD	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27100354	Homo sapiens						53				500 mg/d 5 days on/2 days off; 28 day cycle			6	glioblastoma								5	day		p.6
7547	8182		ADULT			RP2D	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27100354	Homo sapiens						53				300 mg/d 5 days on/2 days off; 28 day cycle			6	cancer								5	day		p.6
7548	8182		ADULT			Studied dose	mg	175		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18381947	Homo sapiens						56				during cycle 1, 7-day on/7-day off treatment followed by 14 days of continuous daily dosing			3	cancer								14	day		p.2078
7549	8182		ADULT			Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27100354	Homo sapiens						53				400 mg/d 5 days on/2 days off; 28 day cycle			4	cancer								5	day		
7550	8183					Highest studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29191916	Homo sapiens						66.5						86	2						25			16	week		
7551	8183					MTD	mg	75		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29191916	Homo sapiens						66.5						86	6						25			16	week		
7552	8183					MTD	mg	75		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30033575	Homo sapiens						70							15						70			12	week		
7553	8183					Recommended	mg	25		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Homo sapiens						69						90	158	CLL or SLL					39			28	day		
7554	8183					Recommended	mg	25		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf	Homo sapiens						67						90	442	Hematologic Malignancies					30			28	day		p. 137
7555	8183					Recommended	mg	25		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Homo sapiens																									
7556	8183						mg	15		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29191916	Homo sapiens						66.5						86	7						25			16	week		
7557	8185					Highest studied dose	mg	1		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29912798/	Homo sapiens						44.7							41	Withdrawal-Associated Cognitive Deficits								12	week		
7558	8185					Highest studied dose	mg	180		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25438724/	Homo sapiens						26							6									1	day		
7559	8186					RP2D	mg/m2	4		multiple			month	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33438318/	Homo sapiens												20	15	solid tumors					6			1	month		
7560	8186					Studied dose	mg	10		multiple			month	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22508830/	Homo sapiens												60	65	non-small-cell lung cancer	150 mg/day			erlotinib	27			4	month		
7561	8186					Studied dose	mg	5		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23650416/	Homo sapiens												85	64	breast cancer	25 mg/week			exemestane	37			4.3	month		
7562	8187		adult			Recommended	mg	15		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000MedR.pdf	Homo sapiens													1693									4	month		p.84
7563	8187		adult			Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000MedR.pdf	Homo sapiens							starting						1716									4	month		p.84
7564	8187					Highest studied dose	mg	100		steady			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/32337660	Homo sapiens																						14	day		
7565	8187					Highest studied dose	mg	300		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/32337660	Homo sapiens																									
7566	8187					Recommended	mg	15		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000MedR.pdf	Homo sapiens													1693						65			4	month		p. 97
7567	8187					Recommended	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000MedR.pdf	Homo sapiens							starting						1716						65			4	month		p. 97
7568	8189					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17011409	Homo sapiens						44.2	unknown					90	365	sinusitis					18			10	day		
7569	8192		ADULT			Highest studied dose	mg/kg	2		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12481191	Homo sapiens										Multiple doses of 2 mg i.v. were used. The dosing was initiated within 48 h of the onset of stroke symptoms.				stroke											p.359
7570	8192		ADULT			Studied dose	mg	10		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/15502007	Homo sapiens										5-ml i.v. infusion lasting 5 min		42	8						25						p.86
7571	8193		ADULT			Highest studied dose	mg/m2	90		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12067983	Homo sapiens						55						77	3	cancer					31						p.3411, 3412
7572	8193		ADULT			MTD	mg/m2	65		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens						47.5				infused intravenously over 30 min		60	6	cancer					28						p.863, 864
7573	8193		ADULT			Studied dose	mg/m2	85		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21276042	Homo sapiens						47.5				infused intravenously over 30 min		60	2	cancer					28						p.863, 864
7574	8194		adult			Highest studied dose	mg	2600		single			day	1	unhealthy	oral	M		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.e16075	Homo sapiens										Escalating doses of powder in capsule			24	prostate cancer								1	day		
7575	8194		adult			Highest studied dose	mg	3400		single			day	1	unhealthy	oral	M		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.e16075	Homo sapiens										Escalating doses of tablet			24	prostate cancer								1	day		
7576	8194					Highest studied dose	mg	2550		multiple			day	1	unhealthy	oral	M		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.4_suppl.71 | https://pubmed.ncbi.nlm.nih.gov/26527750/	Homo sapiens						70				spray dry dispersion			14	prostate cancer								12	week		
7577	8194					Highest studied dose	mg	3400		multiple			day	1	unhealthy	oral	M		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.4_suppl.71 | https://pubmed.ncbi.nlm.nih.gov/26527750/	Homo sapiens						70				median duration			8	prostate cancer								8	month		
7578	8196		ADULT			Studied dose	mg	30		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25297016	Homo sapiens						74							145	Alzheimer disease											p.1096
7579	8198		adult				mg	100		multiple			week	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03012334	Homo sapiens													86									5	week		
7580	8198		adult				mg	100		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00883051	Homo sapiens													82	Migraine											
7581	8198		adult				mg	200		multiple			week	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03012334	Homo sapiens													89									5	week		
7582	8198		adult				mg	200		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03182920	Homo sapiens													17												
7583	8198		adult				mg	200		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03459612	Homo sapiens													68												
7584	8198		adult				mg	200		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00883051	Homo sapiens													71	Migraine											
7585	8198		adult				mg	400		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03465436	Homo sapiens													55												
7586	8198		adult				mg	400		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00883051	Homo sapiens													70	Migraine											
7587	8198		adult				mg	50		multiple			week	1	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03012334	Homo sapiens													87									5	week		
7588	8198		adult				mg	50		single					unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00883051	Homo sapiens													82	Migraine											
7589	8198		adults			Highest studied dose	mg	120		single			day	5	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf	Homo sapiens										One of the three subjects took a cumulative of 600 mg in 24 hours on five separate occasions.			1	migraine								1	day		
7590	8198		adults			Highest studied dose	mg	400		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf	Homo sapiens													70	migraine											
7591	8198		adults			Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf	Homo sapiens													991	migraine								3	month		
7592	8198		adults			Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211280Orig1s000MedR.pdf	Homo sapiens													1039	migraine								3	month		
7593	8198		elderly				mg	200		single					healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03182920	Homo sapiens													18												
7594	8198					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf	Homo sapiens												81	1265	migraine					18			3	month		
7595	8198					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf	Homo sapiens												81	1258	migraine					18			3	month		
7596	8198					Recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf	Homo sapiens												81	654	migraine					18			3	month		
7597	8199		ADULT			Highest studied dose	mg	400		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15089890	Homo sapiens						41.6	unknown						30									4	week		
7598	8200		ADULT			MTD	mg/kg	0.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19720910	Homo sapiens						56							3	cancer											p.4721
7599	8200		ADULT			RP2D	mg/kg	0.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19720910	Homo sapiens						56							12	cancer											p.4721
7600	8200		ADULT			RP2D	mg/kg	0.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21597387	Homo sapiens						62							74	Non-small cell lung cancer								16	week		p.1424
7601	8200		ADULT			RP2D	mg/kg	0.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22382879	Homo sapiens						53							6	cancer								147	day		p.1479
7602	8200		ADULT			RP2D	mg/kg	0.25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22833179	Homo sapiens						62.5				Linifanib at a fasting dose of 0.25 mg/kg was admin-\nistered at bedtime: daily to patients with Child-Pugh class\nA hepatic function (n=38) and every other day to patients with\nChild-Pugh class B hepatic function (n=6).			44	hepatocellular carcinoma								100.5	day		p.384
7603	8201					Highest studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29206629/	Homo sapiens						66.4							90	Chronic obstructive pulmonary disease								52	week		
7604	8201					Highest studied dose	mg	20		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25612153/	Homo sapiens													50									5	day		
7605	8201					Highest studied dose	mg	20		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27136906/	Homo sapiens						26.6							14									1	day		
7606	8202					Highest studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27634203/	Homo sapiens						60							7	myelofibrosis								28	day		
7607	8202					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23459451/	Homo sapiens						62.8				9 x 28-day cycles			6	myelofibrosis								36	week		
7608	8202					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23459451/	Homo sapiens						65.6				9 x 28-day cycles			27	myelofibrosis								36	week		
7609	8202					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23459451/	Homo sapiens						64				9 x 28-day cycles			21	myelofibrosis								36	week		
7610	8202					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28622623/	Homo sapiens						56.6	mean			median duration			39	polycythemia vera | essential thrombocythemia								143.5	day		
7611	8203		ADULT			Highest studied dose	mg	175		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17557949	Homo sapiens						58				intermittent dosing schedule (administration for\ndays 1 to 21 followed by 7 treatment-free days)		90	6	cancer					25			21	day		p.2371
7612	8203		ADULT			MTD	mg	125		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23321064	Homo sapiens						64.5						82	22	cancer					50						p.5
7613	8203		ADULT			MTD	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17557949	Homo sapiens						58				once-daily dosing for 28 days		90	28	cancer					25			28	day		p.2371
7614	8204		adult				mg	240		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT00878709	Homo sapiens													1408	Breast Cancer								12	month		
7615	8204					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19318484	Homo sapiens						49.5						63	6	Non–small cell lung cancer | breast cancer					42			21	day		
7616	8204					MTD	mg	320		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19318484	Homo sapiens						57						80	39	cancers					34			21	day		
7617	8204					Recommended	mg	240		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf	Homo sapiens						52							1408	HER2-positive early-stage breast cancer					52			11.6	month		
7618	8204					Recommended	mg	240		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208051s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000MultidisciplineR.pdf	Homo sapiens						52							1408	HER2-positive early-stage breast cancer					52			11.6	month		
7619	8204					Recommended	mg	240		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208051Orig1s000MultidisciplineR.pdf	Homo sapiens						52							1408	HER2-positive early-stage breast cancer					52			11.6	month		p. 117
7620	8204						mg	180		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19318484	Homo sapiens						56.5						90	6	Breast cancer					46			14	day		
7621	8205		adult				mg	300		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT01847274	Homo sapiens													367	Ovarian Cancer								28	day		
7622	8205		adult				mg	300		steady			day	1	unhealthy	oral	F		https://clinicaltrials.gov/ct2/show/NCT02655016	Homo sapiens										Participants received niraparib 300 mg (3×100 mg capsules) (fixed dose) QD orally beginning on Day 1 of every cycle (each cycle of 28-days) in a double-blind fashion until a modified starting dose regimen was implemented in protocol amendment. After the protocol amendment, participants received niraparib based upon the participant's Baseline body weight or Baseline platelet count (individualized dose): 300 mg (3×100 mg capsules for participants with a Baseline body weight >=77 kg and Baseline platelet count >=150,000 per μL) or 200 mg (2×100 mg capsules for participants with a Baseline body weight <77 kg or Baseline platelet count <150,000 per μL).			484	Ovarian Cancer								28	day		
7623	8205					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23810788/	Homo sapiens						59							6	advanced solid tumours					59			21	day		
7624	8205					Recommended|MTD	mg	300		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208447lbl.pdf	Homo sapiens													367	platinum-sensitive recurrent ovarian cancer | fallopian tube cancer|primary peritoneal cancer								250	day		
7625	8205						mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23810788/	Homo sapiens						59							6	advanced solid tumours					59			21	day		
7626	8205						mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23810788/	Homo sapiens						59							7	advanced solid tumours					59			21	day		
7627	8206		ADULT			Studied dose	mg	50		multiple			week	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33200257	Homo sapiens						69	unknown						146	osteoporosis								24	month		
7628	8206					Highest recorded dose	mg	300		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31175709	Homo sapiens							starting			day 1: 300 mg of odanacatib (6 × 50-mg tablets); days 2 through 4/21 days: once-daily dosing of 25 mg of odanacatib		45	56						18			4	day		
7629	8206					Studied dose	mg	50		multiple			week	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/26879200	Homo sapiens							unknown						28	low bone mineral density								8	year		
7630	8207					Highest studied dose	mg	200		single			day	1	healthy	oral	M		https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf	Homo sapiens													37									1	day		
7631	8207					Highest studied dose	mg	30		steady			day	2	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/32730798/	Homo sapiens							median			max highest daily dose			5	Cushing's disease								12	week		
7632	8207					Recommended	mg	30		steady			day	2	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf	Homo sapiens													5									12	week		
7633	8207					Recommended	mg	5		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32730798/	Homo sapiens							median			2 mg twice daily with dose adjustments every 2 weeks (range 1-30 mg twice a day). Median dose 5 mg bid		69	36	Cushing's disease					20			48	week		
7634	8207					Recommended	mg	7		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000MedR.pdf	Homo sapiens							typical			2 mg twice daily with dose adjustments every 2 weeks (range 1–30 mg twice a day)		70	137	Cushing's disease					19			48	week		
7635	8207					Recommended	mg	7		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212801Orig1s000MedR.pdf	Homo sapiens							typical			upper limit of typical dose range reported. Recommended dose starts at 2 mg and is titrated up to a maximum of 30 mg twice daily at no greater than 2-week intervals.		70	137	Cushing's disease					19			48	week		
7636	8207					Studied dose	mg	150		single					healthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf	Homo sapiens													86												
7637	8207					Studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/isturisa-epar-public-assessment-report_en.pdf	Homo sapiens							median			median highest daily dose for study C2201			19	Cushing's disease								12	week		
7638	8208					Recommended	mg	0.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31492651/	Homo sapiens												55	467	multiple sclerosis					18			24	month		9
7639	8208					Recommended	mg	0.84		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	Homo sapiens						35.4							882	multiple sclerosis								24	month		8
7640	8208					Recommended	mg	0.92		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf	Homo sapiens						35.4							882	multiple sclerosis								24	month		6
7641	8208					Recommended	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31492651/	Homo sapiens												55	448	multiple sclerosis					18			24	month		9
7642	8209					Highest studied dose	mg	200		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27162173/	Homo sapiens												60	8						18			14	day		
7643	8209					Highest studied dose	mg	300		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27162173/	Homo sapiens												55	6						18			1	day		
7644	8209					Studied dose	mg	100		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27162173/	Homo sapiens												60	9						18			14	day		
7645	8209					Studied dose	mg	100		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27162173/	Homo sapiens												60	9						18			14	day		
7646	8209					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25704750/	Homo sapiens						48.1							17	psoriasis								6	week		
7647	8209					Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25704750/	Homo sapiens						48.1							19	psoriasis								6	week		
7648	8210					MTD	mg	1000		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/30825104	Homo sapiens						63				patients received 1000 mg/d (400 mg in the morning and 600 mg in the evening)			8						63			2	week		p. 65, 95
7649	8210					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf	Homo sapiens						44				400 mg in the morning and 600 mg in the evening for 2 weeks followed by 400 mg twice daily.		79	61	symptomatic tenosynovial giant cell tumor					18			6	month		
7650	8210					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf	Homo sapiens						44				400 mg in the morning and 600 mg in the evening for 2 weeks followed by 400 mg twice daily.		79	61	symptomatic tenosynovial giant cell tumor					18			6	month		p. 149
7651	8210					Recommended	mg	400		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf	Homo sapiens																									
7652	8210					Studied dose	mg	5000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32330242	Homo sapiens						60.6						82	4						24			15	day		
7653	8212					Highest studied dose	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens						57.8				intermittent schedule of 14 days followed by a 14-day rest for each 28-day cycle			6	acute myeloid leukemia								14	day		
7654	8212					MTD	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens						52.4							17	acute myeloid leukemia								28	day		
7655	8212					MTD	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30081867/	Homo sapiens						49.5							8	solid tumors								28	day		
7656	8212						mg	135		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30081867/	Homo sapiens						56							5	solid tumors								28	day		
7657	8212						mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens						52	mean						25	acute myeloid leukemia								28	day		
7658	8212						mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens						52							8	acute myeloid leukemia								28	day		
7659	8212						mg	316.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens							mean						16	acute myeloid leukemia								28	day		
7660	8212						mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31175001/	Homo sapiens						55				30 mg lead-in			241	acute myeloid leukaemia								28	day		
7661	8212						mg	73.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24002496/	Homo sapiens						64	mean						35	acute myeloid leukemia								28	day		
7662	8213					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26313450/	Homo sapiens						57.3				Mean exposure durations			268	diabetic sensorimotor polyneuropathy								22	month		
7663	8216		ADULT			Highest studied dose	mg	60		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20027105	Homo sapiens						33.1				2-hour intravenous infusion of 60 mg rolofylline			48												p.14
7664	8216		ADULT			Studied dose	mg	30		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22339573	Homo sapiens						70.2				Intravenous rolofylline 30 mg was infused over 4 hours daily for up to 3 days.			1356	heart disease								3	day		p.243
7665	8217					Highest studied dose	mg	840		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28264872	Homo sapiens						51							3						51			3.2	month		
7666	8217					Recommended	mg	600		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf	Homo sapiens						62						86	377	ovarian cancer					31			5.5	month		
7667	8217					Recommended	mg	600		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000MultiDisciplineR.pdf	Homo sapiens						62						86	378	ovarian cancer					31			5.5	month		p. 11-77
7668	8217					Recommended	mg	600		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209115Orig1s000MultiDisciplineR.pdf	Homo sapiens						62						86	378	ovarian cancer					31			5.5	month		p. 11-81
7669	8217					Recommended	mg	600		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32128485	Homo sapiens						86							1						86			9	month		
7670	8217						mg/m2	18		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/27002934	Homo sapiens						52				92 mg daily that is bioequivalent to an 18 mg/m2 i.v. dose			33						52			21	day		
7671	8218					Highest studied dose	mg	300		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18390968	Homo sapiens						58							8	Advanced Cancers					58			28	day		
7672	8218					Recommended	mg/m2	25		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf	Homo sapiens						10.2						17.4	50						3.5			7.2	month		
7673	8218					Recommended	mg/m2	25		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf	Homo sapiens						10.2						17.4	50						3.5			7.2	month		p. 237
7674	8218						mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20179232	Homo sapiens						57.9						76	8						30			2	month		
7675	8218						mg	75		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20179232	Homo sapiens						57.9						76	7						30			2	month		
7676	8219		adult			Highest studied dose	mg	2000		single			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/25690134/ | https://clinicaltrials.gov/ct2/show/NCT01913002	Homo sapiens																						1	day		
7677	8219		adult			Highest studied dose	mg	800		multiple			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/25690134/ | https://clinicaltrials.gov/ct2/show/NCT01916850	Homo sapiens																						10	day		
7678	8219					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25216510/	Homo sapiens						56.1							60	type 2 diabetes								12	week		
7679	8219					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25216510/	Homo sapiens						55.6							60	type 2 diabetes								12	week		
7680	8219					Studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25216510/	Homo sapiens						56.1							59	type 2 diabetes								12	week		
7681	8221		unknown			MTD	mg	1.1		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Homo sapiens													6	breast cancer								5	day		66
7682	8221		unknown			Recommended	mg	1		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	Homo sapiens													286	breast cancer								6.1	month		6
7683	8221		unknown			Recommended	mg	1		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Homo sapiens													286	breast cancer								6.1	month		127
7684	8221		unknown			Recommended	mg	1		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211651Orig1s000MultidisciplineR.pdf	Homo sapiens													286	breast cancer								6.1	month		128
7685	8221		unknown			Recommended	mg	1		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf	Homo sapiens													286	breast cancer								6.1	month		5
7686	8221					Recommended	mg	1		steady			day	1	unhealthy	oral	F		https://clincancerres.aacrjournals.org/content/clincanres/25/9/2717.full.pdf	Homo sapiens												75	84	breast cancer					31			4.9	month		
7687	8222					Highest studied dose	mg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens						55.5							11	solid tumors								28	day		
7688	8222					Studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28331003/	Homo sapiens						55.5							10	solid tumors								28	day		
7689	8222					Studied dose	mg	2		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29500843/	Homo sapiens						66							3	breast cancer	500 mg; IM; 2/week			fulvestrant				28	day		
7690	8222					Studied dose	mg	4		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29500843/	Homo sapiens						67							3	breast cancer	500 mg; IM; 2/week			fulvestrant				28	day		
7691	8222					Studied dose	mg	4		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33186740/	Homo sapiens						60							416	breast cancer	500 mg; IM; 2/week			fulvestrant				28	day		
7692	8222					Studied dose	mg	6		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29500843/	Homo sapiens						47							3	breast cancer								28	day		
7693	8223		ADULT			Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15978101	Homo sapiens						54.2							6	peripheral artery disease								12	week		p.1442
7694	8224					Highest studied dose	mg	350		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22722787/	Homo sapiens						66.2	total daily dose			350 mg for 5 days every 14 days.		86	41	NSCLC					45			5	day		
7695	8224					Highest studied dose	mg	350		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30030583/	Homo sapiens						57.7	total daily dose			corresponds to 259.18 mg of XL647 freebase		79	5	advanced solid malignancies					31			3	cycle		
7696	8224					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30030583/	Homo sapiens						57.7	total daily dose			corresponds to 222.15 mg of XL647 freebase		79	6	advanced solid malignancies					31			3	cycle		
7697	8224					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22722787/	Homo sapiens						65.7				daily-dosing cohort		80	14	NSCLC					42			28	day		
7698	8224					Studied dose	mg/kg	7		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/30030583/	Homo sapiens						57.7	unknown					79	2	advanced solid malignancies					31			3	cycle		
7699	8226		ADULT			Highest studied dose	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21976547/	Homo sapiens						56				A cycle was defined as 28 days on treatment followed by 14 days of\nmedication		73	7	cancer					28			28	day		p.7159
7700	8226		ADULT			MTD	mg	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21976547/	Homo sapiens						56				A cycle was defined as 28 days on treatment followed by 14 days of\nmedication		73	16	cancer					28			28	day		p.7159
7701	8229		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29733524	Homo sapiens													3	cancer											p.2365
7702	8229		ADULT			MTD	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29733524	Homo sapiens													9	cancer											p.2365
7703	8229		ADULT			RP2D	mg	400		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/28665051	Homo sapiens						59				twice daily on days 1-28 of 28-day cycles			12	cancer								165	day		p.1836
7704	8229		ADULT			Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29733524	Homo sapiens													5	cancer											p.2365
7705	8231		ADULT			Highest studied dose	mg	450		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22119200	Homo sapiens						58							2	cance											p.182
7706	8231		ADULT			MTD	mg	300		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26627079	Homo sapiens						64				Intravenous infusion over 2 h on day 1 every 21 days; patients received a median of two (range 1–26) cycles of volasertib treatment			6	cancer								2	cycle		p.4
7707	8231		ADULT			MTD	mg	400		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22119200	Homo sapiens						58							10	cancer											p.182
7708	8231		ADULT			RP2D	mg	300		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22119200	Homo sapiens						58							29	cancer											p.182
7709	8231		ADULT			Studied dose	mg	350		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26627079	Homo sapiens						64				Intravenous infusion over 2 h on day 1 every 21 days; patients received a median of two (range 1–26) cycles of volasertib treatment			6	cancer								2	cycle		p.4
7710	8233		adult				mg	600		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00588731	Homo sapiens							total daily dose			Related publication: [PMID:29619533]:  This study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day)			21	Schizophrenia								6	week		
7711	8233		adult				mg/kg/day	50		multiple			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/26724101	Homo sapiens													5									12	week		
7712	8233		child				mg/kg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02091206	Homo sapiens													9	Dravet syndrome								3	week		
7713	8233		child				mg/kg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02091375	Homo sapiens													61	Dravet syndrome								12	week		
7714	8233		child				mg/kg	2.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02091206	Homo sapiens													10	Dravet syndrome								3	week		
7715	8233		child				mg/kg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02091206	Homo sapiens													8	Dravet syndrome								3	week		
7716	8233					Recommended	mg/kg/day	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf	Homo sapiens						14				Patients who are tolerating EPIDIOLEX at 5 mg/kg twice daily and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day), in weekly increments of 2.5 mg/kg twice daily (5 mg/kg/day), as tolerated.		48	75	seizures associated with Lennox-Gastaut syndrome or Dravet syndrome					2			12	week		
7717	8233					Recommended	mg/kg/day	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf	Homo sapiens						14				Patients who are tolerating EPIDIOLEX at 5 mg/kg twice daily and require further reduction of seizures may benefit from a dosage increase up to a maximum recommended maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day), in weekly increments of 2.5 mg/kg twice daily (5 mg/kg/day), as tolerated.		48	238	seizures associated with Lennox-Gastaut syndrome or Dravet syndrome					2			12	week		
7718	8237		adult			Studied dose	ug	30		steady			day	2	unhealthy	subcutaneous	unknown		https://pubmed.ncbi.nlm.nih.gov/21655148/	Homo sapiens													45	cancer pain								4	day		
7719	8237					Highest studied dose	ug	45		single					healthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/32784930/	Homo sapiens												53	46						24						
7720	8237					Studied dose	ug	30		steady			day	2	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/28555092/	Homo sapiens						55.5							77	cancer pain								4	day		
7721	8241		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21934307/	Homo sapiens												79	408	digestive system disorder					20			48	week		p.265, 266
7722	8241		ADULT			Recommended	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29315999/	Homo sapiens						42.6							207	digestive system disorder								1	year		p.4
7723	8242		ADULT			Recommended	%	0.025		multiple			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/17451383/	Homo sapiens						45.6							51	androgenetic alopecia								6	month		p.393
7724	8243		ADULT			Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25819061/	Homo sapiens						57.7							30	type 2 diabetes								24	week		449-62
7725	8243		ADULT			Highest studied dose	mg	400		single					healthy	oral	M		https://professional.diabetes.org/files/Posters/2007/p0482-P.pdf	Homo sapiens						24.1							6									1	day		p0482-P
7726	8243		ADULT			Studied dose	mg	200		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23972359/	Homo sapiens						60	total daily dose						1	type 2 diabetes								2	month		e106
7727	8245		ADULT			Highest studied dose	mg/kg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens												30	6						18			1	day		430-44
7728	8245		ADULT			Highest studied dose	mg/kg	50		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17389552/	Homo sapiens												30	12						18			14	day		430-44
7729	8247		ADULT			Studied dose	mg	200		multiple			day	3	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/28746179/	Homo sapiens						63.89							146	stroke								21	day		p.3
7730	8248		adult			Highest studied dose	mg	200		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/21837752	Homo sapiens																									
7731	8248					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21837752	Homo sapiens						44						49	4	HCV infection					34			14	day		
7732	8250		ADULT			Higher than recommended	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22670901/	Homo sapiens						33				in combination with a background drug regimen developed according to World Health Organization guidelines		63	160	pulmonary tuberculosis					18			8	week		p.2157;  Supplementary Appendix p.4
7733	8253		ADULT			Accidental dose	mg	100		single					unknown	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/2628587/	Homo sapiens						31				about 100 mg (the whole blood concentration was 1526 ng/ml)			1									1	day		385-8
7734	8253		ADULT			Highest recorded dose	mg	40		multiple			hour	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6017168/	Homo sapiens							max			different regiments during treatment			1	pain disorder								19	day		568-9
7735	8253		ADULT			Highest studied dose	mg	20		single					unhealthy	rectal	F		https://pubmed.ncbi.nlm.nih.gov/13539148/	Homo sapiens													27	pain disorder								1	day		379-84
7736	8254		ADULT			Highest studied dose	mg/m2	40		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/943554/	Homo sapiens						57				five daily iv treatments repeated every 6 weeks		75	16	cancer					15			5	day		
7737	8254		ADULT			Studied dose	mg/m2	16		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/943554/	Homo sapiens						57				five daily iv treatments repeated every 6 weeks		75	12	cancer					15			5	day		
7738	8254		ADULT			Studied dose	mg/m2	20		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/943554/	Homo sapiens						57				five daily iv treatments repeated every 6 weeks		75	15	cancer					15			5	day		
7739	8254		ADULT			Studied dose	mg/m2	30		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/943554/	Homo sapiens						57				five daily iv treatments repeated every 6 weeks		75	13	cancer					15			5	day		
7740	8257		adult			Recommended	mg	56		steady			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf	Homo sapiens							starting			Day 1 starting dose: 56 mg. Subsequent doses: 56 mg or 84 mg. Administer twice per week				major depressive disorder	oral			antidepressant				4	week		
7741	8257		adult			Recommended	mg	56		steady			week	2	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf	Homo sapiens							starting			Day 1 starting dose: 56 mg. Subsequent doses: 56 mg or 84 mg. Administer twice per week				major depressive disorder				antidepressant				4	week		
7742	8257		adult				mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31783823	Homo sapiens							starting			During the first 3 days, dosages are gradually increased from 10 mg at administration day 1 to 30 mg at administration day 3. During the last 3 days, dosages are gradually decreased from 30 mg at administration day 40 to 10 mg at administration day 42				treatment resistant depression								42	day		
7743	8257						mg	28		single					unhealthy|healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000ClinPharmR.pdf	Homo sapiens										combined data including healthy subjects from Phase 1, subjects with treatment-resistant depression (TRD) enrolled in Phase 2 and Phase 3 studies			18	treatment-resistant depression											p. 43
7744	8257						mg	84		single					unhealthy|healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000ClinPharmR.pdf	Homo sapiens										combined data including healthy subjects from Phase 1, subjects with treatment-resistant depression (TRD) enrolled in Phase 2 and Phase 3 studies			14	treatment-resistant depression											p. 43
7745	8257						mg/kg	40		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26707087	Homo sapiens						41.8				two doses: on day 1 and day 4		63	11	treatment resistant depression					11			35	day		
7746	8257						mg/kg	40		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26707087	Homo sapiens						41.8						63	11	treatment resistant depression					11			35	day		
7747	8258		ADULT			Highest studied dose	mg	60		multiple			day	3	unhealthy	oral	M+F		https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	Homo sapiens						41.1	max|total daily dose						186	anxiety disorder								6	week		259
7748	8259		ADULT			Highest studied dose	mg	480		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens						32.1						54	6						19						p.338
7749	8259		ADULT			Studied dose	mg	360		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21910510/	Homo sapiens						43							5									7	day		p.338
7750	8262		ADULT			Highest studied dose	mg	20		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26998954/	Homo sapiens						24.9							15									1	day		1133-1141
7751	8262		ADULT			Highest studied dose	mg	40		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25041486/	Homo sapiens						36.8							35									5	day		548-61
7752	8264		adult			Recommended	mg	200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													490												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.136
7753	8264		adult			Recommended	mg	200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													490												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.137
7754	8264		adult			Recommended	mg	200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													490												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.138
7755	8264		adult			Recommended	mg	200		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													490												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.139
7756	8264		adult			Studied dose	mg	40		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													6												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.134
7757	8264		adult			Studied dose	mg	40		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													6												nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.135
7758	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.140
7759	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.141
7760	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.142
7761	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.143
7762	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.144
7763	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.145
7764	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.146
7765	8264		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens													39									11	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.147
7766	8264					Highest studied dose	mg	533.3		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/25624327/	Homo sapiens						48.4	mean			800/400/400 mg day 1, 400/400 mg day 2, and 400 mg once daily from day 3 to the end of treatment			12	acute myeloid leukemia								1	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.31
7767	8264					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens						51.1				Loading dose - 200 mg administered q8h IV for 2 days; Maintenance dose - 200 mg once per day IV or oral			257	Invasive aspergillosis								180	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.131
7768	8264					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207500Orig1207501Orig1s000MedR.pdf	Homo sapiens						51.1				Loading dose - 200 mg administered q8h IV for 2 days; Maintenance dose - 200 mg once per day IV or oral			257	Invasive aspergillosis								180	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.149
7769	8264					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25561337/	Homo sapiens						39.1				400 mg on day 1 and then 100 mg once daily			41	uncomplicated esophageal candidiasis								21	day		
7770	8264					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25624327/	Homo sapiens						48.4	mean			800/400/400 mg day 1, 400/400 mg day 2, and 400 mg once daily from day 3 to the end of treatment			12	acute myeloid leukemia								28	day		nda/2015/207500Orig1207501Orig1s000MedR.pdf - p.31
7771	8266		ADULT			Studied dose	mg	20		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20142523/	Homo sapiens						53.7							46	Huntington disease								90	day		p.6
7772	8271		ADULT			Highest studied dose	mg	10		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens												29.6	8						28.1			7	day		345-61
7773	8271		ADULT			Highest studied dose	mg	25		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24535625/	Homo sapiens												28	8						23			1	day		345-61
7774	8274		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18638004/	Homo sapiens						53.6				100 mg for 12 weeks on an """"""""""""""""as needed"""""""""""""""" basis.			74	erectile dysfunction								12	week		p.2677
7775	8276		adult			Recommended	mg	1200		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000MedR.pdf	Homo sapiens							median						976	acute bacterial skin								8	day		111
7776	8276		adult			Recommended	mg	1200		multiple			day	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206334Orig1s000MedR.pdf	Homo sapiens							median						976	acute bacterial skin								8	day		112
7777	8276					Recommended	mg	1200		single					unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206334s000lbl.pdf	Homo sapiens												89	976	acute bacterial skin					18						5
7778	8278		ADULT			Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24705186/	Homo sapiens						43						75	77	chronic myeloid leukemia					22			378	day		1191-6
7779	8278		ADULT			Studied dose	mg	800		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28891531/	Homo sapiens							total daily dose			max duration		59	3	chronic myeloid leukemia					25			1	year		704-707
7780	8279		ADULT			Highest studied dose	mg	300		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14681344/	Homo sapiens						25.5						36	6						20			7	day		p.78, 79
7781	8279		ADULT			Recommended	mg	200		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22858177/	Homo sapiens						31.9							30									7	day		p.2005, 2006
7782	8280		ADULT			Highest studied dose	%	0.8		multiple			day	2	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/23787820/	Homo sapiens												35	8						20			7	day		1288-95
7783	8280		ADULT			Highest studied dose	%	0.8		single					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/23787820/	Homo sapiens												35	8						20			1	day		1288-95
7784	8280		ADULT			Recommended	%	0.4		multiple			day	2	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/33866572/	Homo sapiens						60							1	glaucoma								5	month		379-380
7785	8283		adult				mg/kg	16		single					healthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02028065	Homo sapiens													148												
7786	8283		adult				mg/kg	4		single					healthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT02028065	Homo sapiens													151												
7787	8283					Highest studied dose	mg/kg	96		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20825252	Homo sapiens												65	12						18						
7788	8283					Recommended	mg/kg	16		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf	Homo sapiens													496												p. 66
7789	8283					Recommended	mg/kg	4		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf	Homo sapiens													1505												p. 66
7790	8283						mg/kg	32		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf	Homo sapiens													165												p. 66
7791	8283						mg/kg	8		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022225Orig1s000MedR.pdf	Homo sapiens													156												p. 66
7792	8285		ADULT			Recommended	mg	40		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26212570/	Homo sapiens						39.2						63	20						19			5	day		p.8
7793	8287		ADULT			Highest studied dose	mg	640		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28427104/	Homo sapiens						24.8							6												p.7
7794	8287		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24678906/	Homo sapiens						57							58	type 2 diabetes mellitus								24	week		p.6
7795	8287		ADULT			Studied dose	mg	80		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28427104/	Homo sapiens						27.4							6									7	day		p.7
7796	8291		ADULT			Studied dose	mg/kg	3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21029824/	Homo sapiens						62				Vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated.			138	atrial fibrillation											p.1282
7797	8291		ADULT			Studied dose	mg/kg	3		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27233239/	Homo sapiens						63.7				Participants received either a 10-min\nintravenous infusion of vernakalant (3 mg/kg). They were\nthen observed for 15 min; if patients were in AF or\natrial flutter at the end of the observation period, a\nsecond 10-min infusion of vernakalant (2 mg/kg) was administered.			129	atrial fibrillation											p.5
7798	8292		ADULT			Highest studied dose	mg	40		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25707624/	Homo sapiens						27							9									7	day		p.641
7799	8292		ADULT			Highest studied dose	mg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27928738/	Homo sapiens						27.3							16												p.4
7800	8292		ADULT			Recommended	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31409606/	Homo sapiens						54.1							244	esophagitis								8	week		p.228
7801	8295		ADULT			Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://assets.website-files.com/5bd270b2e599946e65c2ff05/5bd3e30af2904427b3a4e03b_LAM-Therapeutics_ASH_2017.pdf	Homo sapiens						69				The duration of therapy ranged from <1 to ≥12 cycles			5	B-cell lymphoma											
7802	8295		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22170479	Homo sapiens													9	rheumatoid arthritis								4	week		p.1752
7803	8295		ADULT			Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22170479	Homo sapiens													5	rheumatoid arthritis								8	week		p.1752
7804	8298		adult				mg	3		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00896363	Homo sapiens														Depressive Disorder								6	week		
7805	8317					Highest studied dose	mg	15		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20930279/	Homo sapiens						71.2							255	Alzheimer’s disease					71.2			12	week		
7806	8317					Highest studied dose	mg	20		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16248851/	Homo sapiens						66.8							6						66.8						
7807	8317					MTD	mg	10		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16248851/	Homo sapiens						69.2							12						69.2						
7808	8317					Studied dose	mg	15		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28440045/	Homo sapiens						44.8							78	obesity	10 mg twice daily			lorcaserin	44.8			12	week		
7809	8335					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21254914/	Homo sapiens						46.7							7	thyroid proliferative disease								14	day		
7810	8335					Highest studied dose	mg	300		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18843002/	Homo sapiens						30.9							8									1	day		
7811	8335					Recommended	mg	125		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/26298826/	Homo sapiens						36							1						36			4	week		
7812	8343		adult			MTD	mg/m2	134		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25567350/	Homo sapiens													6	solid tumors	350 mg/m(2)/day			THU				3	week		
7813	8345					Highest studied dose	mg/m2	112		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25605849	Homo sapiens						58	unknown					80	8	Advanced Solid Tumors					38						
7814	8345					Highest studied dose	mg/m2	150		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25605849/	Homo sapiens						58	unknown			was administered intravenously (IV) using an infusion pump over at least 30 minutes		80	3	Advanced Solid Tumors					38						
7815	8350					Highest studied dose	mg	700		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26711747	Homo sapiens						50.3							9	chronic HCV infection								3	day		
7816	8351					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens												55	8						18			10	day		
7817	8351					Highest studied dose	mg	600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28464496	Homo sapiens												55	6						18						
7818	8361					Highest studied dose	mg/m2	165		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							3	neuroblastoma and other solid tumors					11			21	day		
7819	8361					Highest studied dose	mg/m2	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							2	neuroblastoma and other solid tumors					11			7	day		
7820	8361					Recommended	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16166440/	Homo sapiens							median					77	9	refractory hematologic malignancies					20			3	week		
7821	8361					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16166440/	Homo sapiens							median					77	4	refractory hematologic malignancies					20			4	week		
7822	8361					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18520803/	Homo sapiens						65							35	non-small cell lung carcinoma					65			21	day		
7823	8361					Recommended	mg/m2	130		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							4	neuroblastoma and other solid tumors					11			21	day		
7824	8361					Recommended	mg/m2	165		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							6	neuroblastoma and other solid tumors					11			7	day		
7825	8361					Recommended	mg/m2	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							29	neuroblastoma and other solid tumors					11			7	day		
7826	8361					Studied dose	mg/m2	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							6	neuroblastoma and other solid tumors					11			21	day		
7827	8361					Studied dose	mg/m2	130		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20044751/	Homo sapiens						11							5	neuroblastoma and other solid tumors					11			7	day		
7828	8372					Highest studied dose	mg	500		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25656305/	Homo sapiens						44							23												
7829	8372					Highest studied dose	mg	500		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25656305/	Homo sapiens						44							23	type 2 diabetes								28	day		
7830	8373					Highest studied dose	mg	225		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25735992/	Homo sapiens						42.5							6									7	day		
7831	8373					Highest studied dose	mg	500		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25735992/	Homo sapiens						29				12 h postchallenge			8		0.005 mg/kg; IV; 1/d			S(+) ketamine				1	day		
7832	8373					Highest studied dose	mg	500		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25735992/	Homo sapiens						29				3 h postchallenge			20		0.005 mg/kg; IV; 1/d			S(+) ketamine				1	day		
7833	8373					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26804646/	Homo sapiens						44	max						62	major depressive disorder								28	day		
7834	8375					Highest studied dose	mg	400		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26431470/	Homo sapiens						28.6							6									10	day		
7835	8375					Highest studied dose	mg	400		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens						28.1							6									1	day		
7836	8375					Highest studied dose	mg	400		single			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26357940/	Homo sapiens						28.3							6									1	day		
7837	8375					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26711777/	Homo sapiens						40.6							103	Acute Bacterial Skin and Skin Structure Infections								14	day		
7838	8390		adult			Highest studied dose	mg	40		multiple			day	1	healthy	oral	M		https://professional.diabetes.org/abstract/t0903131-selective-modulator-ppar-gamma-activity-increases-adiponectin-levels-healthy	Homo sapiens													8									14	day		
7839	8395		adult			Studied dose	mg	0.4		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30231665/	Homo sapiens																									
7840	8395					Highest studied dose	mg	0.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33115374/	Homo sapiens												64	5	systemic lupus erythematosus					28			24	week		
7841	8421		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26989892	Homo sapiens						52.5							51	gout								12	week		p.2030
7842	8422		adult			Studied dose	mg	600		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29786857/	Homo sapiens													15	non-childbearing potential	10 mg			pravastatin				1	cycle		
7843	8423		adult			Higher than recommended	mg	150		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/30624546/	Homo sapiens													7	solid tumours								28	day		
7844	8423		adult			Highest studied dose	mg	200		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/30624546/	Homo sapiens													6	solid tumours								28	day		
7845	8423		adult			Highest studied dose	mg	200		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_211710Orig1s000MultidisciplineR.pdf	Homo sapiens													6	solid tumor								12	month		91
7846	8423		adult			Recommended	mg	100		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/30624546/	Homo sapiens													6	solid tumours								28	day		
7847	8423					Recommended	mg	100		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	Homo sapiens												82	176	solid tumor					28			12	month		6.1
7848	8423					Recommended	mg	100		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	Homo sapiens												82	176	solid tumor					28			12	month		Table 2
7849	8423					Recommended	mg	100		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf	Homo sapiens												82	176	solid tumor					28			12	month		Table 3
7850	8424					Highest studied dose	mg	1600		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22759078/	Homo sapiens						35.6				rising dose			6									1	day		
7851	8424					Highest studied dose	mg	800		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22759078/	Homo sapiens						40.1				rising dose			6									3	day		
7852	8424					Studied dose	mg	800		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22759078/	Homo sapiens						35.6				rising dose			6									1	day		
7853	8430					Highest studied dose	mg	250		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18971325	Homo sapiens													4												p.35
7854	8439					Highest studied dose	mg	1.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27304433/	Homo sapiens												69	111	Major Depression					23			6	week		
7855	8440		adult			Highest studied dose	mg	250		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28236228/	Homo sapiens													6									1	day		
7856	8440					Highest studied dose	mg	240		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33833333/	Homo sapiens						42.6							12									14	day		
7857	8453		adults			Recommended	mg	180		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29910030/	Homo sapiens													181	hypercholesterolemia	10 mg/day; oral; 4 weeks			ezetimibe				12	week		
7858	8453		adults			Recommended	mg	180		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30922146/	Homo sapiens													234	hypercholesterolemia								24	week		
7859	8453		adults			Recommended	mg	180		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf	Homo sapiens													2009	atherosclerotic cardiovascular disease & heterozygous familial hypercholesterolemia				Statin				52	week	Other Lipid Lowering Therapies	
7860	8453					Highest studied dose	mg	220		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000IntegratedR.pdf	Homo sapiens																						14	day		
7861	8453					Highest studied dose	mg	240		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000IntegratedR.pdf	Homo sapiens													36	hypercholesterolemia											
7862	8453					Highest studied dose	mg	250		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211616Orig1s000IntegratedR.pdf	Homo sapiens													9												
7863	8453					Recommended	mg	180		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf	Homo sapiens						65.4							2009	atherosclerotic cardiovascular disease & heterozygous familial hypercholesterolemia				Statin	65.4			52	week	Other Lipid Lowering Therapies	
7864	8459					Highest studied dose	mg	800		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24097863	Homo sapiens						61							4	Cancer								3	week		p.448
7865	8459					MTD	mg	700		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24097863	Homo sapiens						61				The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 weeks out of each 4-week course.			17	Cancer								3	week		p.448
7866	8479					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral			https://www.firstwordpharma.com/node/1096205?tsid=17	Homo sapiens														advanced non-small cell lung cancer											
7867	8479					Recommended	mg	180		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf	Homo sapiens						54				90 mg orally once daily for seven days followed by (if tolerated) 180 mg orally once daily		82	109	locally advanced or metastatic ALK-positive non-small cell lung cancer					18			7.5	month		
7868	8479						mg	240		multiple			day	1	unhealthy	oral			https://www.firstwordpharma.com/node/1096205?tsid=17	Homo sapiens														advanced non-small cell lung cancer											
7869	8490		ADULT			Higher than recommended	mg	50		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24144896/	Homo sapiens						31.3							7												p.200
7870	8490		ADULT			Higher than recommended	mg	800		multiple			3 months	1	healthy	intramuscular	M		https://pubmed.ncbi.nlm.nih.gov/28546090/	Homo sapiens						31						61	106						20			9	month		p.5
7871	8490		ADULT			Recommended	mg	30		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30230694/	Homo sapiens						39.7							21												p.445
7872	8490		ADULT				mg	600		multiple			2 months	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/28750935/	Homo sapiens												64	115	HIV infection	900 mg			rilpivirine	20			96	week		p.8
7873	8490					Recommended	mg	30		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24144896/	Homo sapiens						39.6							11	HIV infection								10	day		p.200
7874	8493		ADULT			Highest studied dose	mg	20		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22370739	Homo sapiens						58.7							10	coronary artery disease											p.589
7875	8506		adult			Highest studied dose	mg	0.15		multiple			day	1	unhealthy	oral			https://n.neurology.org/content/82/10_Supplement/P3.161.short | https://clinicaltrials.gov/ct2/show/NCT01081782 | https://pubmed.ncbi.nlm.nih.gov/26239599/	Homo sapiens														Multiple Sclerosis								26	week		
7876	8506					Studied dose	mg	0.01		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25855155/	Homo sapiens						35							24									14	day		
7877	8508					Highest studied dose	mg	2100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens						27							12												p.436
7878	8508					Studied dose	mg	600		multiple			day	3	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8739022	Homo sapiens						69.2							12									5	day		p.436
7879	8512					Highest studied dose	ug	1000		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/18779378/	Homo sapiens						32.3	total daily dose			250 ug/h during 4 hours			5									1	day		
7880	8512					MTD	ug	800		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/18779378/	Homo sapiens						32.3	total daily dose			200 ug/h during 4 hours			6									1	day		
7881	8512					Studied dose	ug/h	100		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22713287/	Homo sapiens						64.6				infusion up to 48 hrs			2	heart failure								1	day		
7882	8512					Studied dose	ug/h	100		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22713287/	Homo sapiens						68.3				infusion up to 48 hrs			15	heart failure								1	day		
7883	8512					Studied dose	ug/h	150		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22713287/	Homo sapiens						64.6				infusion up to 48 hrs			3	heart failure								1	day		
7884	8512					Studied dose	ug/h	150		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22713287/	Homo sapiens						68.3				infusion up to 48 hrs			14	heart failure								1	day		
7885	8512					Studied dose	ug/h	400		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/19451356/	Homo sapiens						65.5	max						15	heart failure								1	day		
7886	8512					Studied dose	ug/h	50		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22713287/	Homo sapiens						68.3				infusion up to 48 hrs			14	heart failure								1	day		
7887	8513					Highest studied dose	mg	150		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25114127/	Homo sapiens						25.4							8									3	day		
7888	8513					Highest studied dose	mg	300		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25114127/	Homo sapiens						25.2							5									1	day		
7889	8514					Highest studied dose	mg	300		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/27853809/	Homo sapiens						31							8									1	day		
7890	8528					Highest studied dose	mg/m2	1000		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28495639/	Homo sapiens												68	2	metastatic pancreatic adenocarcinoma				FOLFIRINOX	55			11	cycle		
7891	8528					Highest studied dose	mg/m2	3780		multiple			month	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25165100/	Homo sapiens												81	6	advanced hematologic malignancies					19			1	month		
7892	8528					MTD	mg/m2	2940		multiple			month	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25165100/	Homo sapiens												81	6	advanced hematologic malignancies					19			1	month		
7893	8528					MTD	mg/m2	2940		multiple			week	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29437791/	Homo sapiens							max	6 mg/m2				79	67	relapsed or refractory acute myeloid leukemia	3 g/m2			cytarabine	21			2	week	mitoxantrone	
7894	8528					MTD	mg/m2	500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28495639/	Homo sapiens												68	18	metastatic pancreatic adenocarcinoma				FOLFIRINOX	55			11	cycle		
7895	8531		ADULT			Highest studied dose	mg	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25270629	Homo sapiens						66.9							19	stroke								28	day		
7896	8536					Highest studied dose	mg	64		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28750582/	Homo sapiens						40.6							83	Schizophrenia								12	week		
7897	8542					Highest studied dose	mg	30		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31619187/	Homo sapiens						65.9							22	anemia								29	day		
7898	8542					Highest studied dose	mg	500		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28419747/	Homo sapiens						28							54									1	day		
7899	8542					Studied dose	mg	5.7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33964183/	Homo sapiens						64.4	median			median duration			56	anemia								365	day		
7900	8543		ADULT			Highest studied dose	mg/m2	588		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19584162	Homo sapiens						61.5				i.v. darinaparsin daily for 5 days every 4 weeks; 8 cycles			4	cancer								5	day		p.4772
7901	8543		ADULT			MTD	mg/m2	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19584162	Homo sapiens						61.5				i.v. darinaparsin daily for 5 days every 4 weeks; 6 cycles			3	cancer								5	day		p.4772
7902	8543		ADULT			Studied dose	mg/m2	420		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19584162	Homo sapiens						61.5				i.v. darinaparsin daily for 5 days every 4 weeks; 16 cycles			8	cancer								5	day		p.4772
7903	8543		ADULT			Studied dose	mg/m2	500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19584162	Homo sapiens						61.5				i.v. darinaparsin daily for 5 days every 4 weeks; 11 cycles			4	cancer								5	day		p.4772
7904	8553					Highest studied dose	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26334219/	Homo sapiens						57				Fasting state			3	solid tumors								21	day		
7905	8553					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26334219/	Homo sapiens						57				Fasting state			6	solid tumors								21	day		
7906	8553					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26334219/	Homo sapiens						57				Fasting state			6	solid tumors								21	day		
7907	8553					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31739184/	Homo sapiens						62				mean duration			55	non-small cell lung cancer								89	day		
7908	8553					Studied dose	mg	425		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26334219/	Homo sapiens						57				Fasting state			6	solid tumors								21	day		
7909	8553					Studied dose	mg	425		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26334219/	Homo sapiens						57				Fed state			6	solid tumors								21	day		
7910	8556		adult			Highest studied dose	mg/m2	2.4		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28140719/	Homo sapiens										4th week - rest			44	multiple myeloma								28	day		
7911	8556		adult			MTD	mg/m2	2.1		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28140719/	Homo sapiens										4th week - rest			47	multiple myeloma								28	day		
7912	8556		adult			Studied dose	mg/m2	1.8		multiple			3 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23058787/	Homo sapiens													5	Solid tumours								21	day		
7913	8556					MTD	mg/m2	1.5		multiple			3 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23058787/	Homo sapiens						63							5	Solid tumours								21	day		
7914	8556					MTD	mg/m2	1.5		multiple			3 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23058787/	Homo sapiens						63							7	multiple myeloma								21	day		
7915	8563					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22101764/	Homo sapiens						57.1	total daily dose			300 mg d−1 (as 150 mg orally every 12 h)			44	amyotrophic lateral sclerosis								12	week		
7916	8564		ADULT			Highest studied dose	mg	600		multiple			day	2	healthy	oral	M+F		https://www.researchgate.net/publication/228774168_The_potential_of_dextofisopam_for_treatment_of_irritable_bowel_syndrome_and_inflammatory_bowel_disease	Homo sapiens													6									7	day		p.2
7917	8564		ADULT			Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17973974	Homo sapiens						44							66	irritable bowel syndrome								12	week		p.203
7918	8573					Highest studied dose	mg	455		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10100703/	Homo sapiens										every 21 days		75	6	advanced solid tumors					28			2	cycle		
7919	8573					Highest studied dose	ug/m2	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10778954/	Homo sapiens										every 3 week		72	9	advanced solid tumors					27			2	cycle		
7920	8573					MTD	mg	400		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10100703/	Homo sapiens										every 21 days		75	6	advanced solid tumors					28			2	cycle		
7921	8573					Recommended	mg	325		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10100703/	Homo sapiens										every 21 days		75	9	advanced solid tumors					28			2	cycle		
7922	8589		adult			MTD	ug/m2	1800		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/4075312/	Homo sapiens														infections								1	month		
7923	8589		adult			RP2D	ug/m2	1500		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/4075312/	Homo sapiens														infections								1	month		
7924	8589		adult			Studied dose	ug/m2	1000		multiple			month	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/4075312/	Homo sapiens														infections								1	month		
7925	8589					MTD	ug/m2	2128		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2737217/	Homo sapiens												79	11	advanced cancer					32			4	month		
7926	8589					RP2D	ug/m2	1600		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2737217/	Homo sapiens												79	11	advanced cancer					32			4	month		
7927	8589					Studied dose	mg/m2	1.2		multiple			month	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2084072/	Homo sapiens												90	34	advanced soft tissue sarcomas					26			4	month		
7928	8589					Studied dose	mg/m2	1.2		multiple			week	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/1783527/	Homo sapiens												69	21	breast cancer					27			4	week		
7929	8594		ADULT			Highest studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26874076	Homo sapiens						52.4							89	non-alcoholic steatohepatitis								52	week		p.1155
7930	8598		ADULT			Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22647518	Homo sapiens						61	max			80 or 120 -mg IV bolus of elinogrel was given immediately before PCI, followed by twice-daily oral elinogrel administration of 100 or 150 mg for 60 days. The initial oral dose was administered concurrently with the IV bolus.			408	coronary artery disease								60	day		p.339, 340
7931	8607					Recommended|MTD	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf	Homo sapiens						55				The doses ranged from 100 mg/m2 to 1600 mg/m2 once daily in adults and 250 mg/m2 to 750 mg/m2 once daily in pediatric patients		86	355						4			6	month		
7932	8607					Recommended|MTD	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf	Homo sapiens						55				The doses ranged from 100 mg/m2 to 1600 mg/m2 once daily in adults and 250 mg/m2 to 750 mg/m2 once daily in pediatric patients		86	355						4			6	month		p. 149
7933	8607					Recommended|MTD	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf	Homo sapiens						55				The doses ranged from 100 mg/m2 to 1600 mg/m2 once daily in adults and 250 mg/m2 to 750 mg/m2 once daily in pediatric patients		86	355						4			6	month		p. 149
7934	8607					Recommended|MTD	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf	Homo sapiens						55				The doses ranged from 100 mg/m2 to 1600 mg/m2 once daily in adults and 250 mg/m2 to 750 mg/m2 once daily in pediatric patients		86	355						4			6	month		p. 150
7935	8607					Recommended|MTD	mg	600		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf	Homo sapiens						55				The doses ranged from 100 mg/m2 to 1600 mg/m2 once daily in adults and 250 mg/m2 to 750 mg/m2 once daily in pediatric patients		86	355						4			6	month		p. 151
7936	8607						mg	800		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28183697	Homo sapiens						55							65						55			28	day		
7937	8607						mg/m2	550		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/30425456 | https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10536	Homo sapiens												21	6						2			4	week		
7938	8607						mg/m2	750		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/30425456 | https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10536	Homo sapiens												21	3						2			4	week		
7939	8613		adult			Highest studied dose	mg	160		steady			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21341397/	Homo sapiens													40									14	day		
7940	8613		adult			Highest studied dose	mg	320		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21341397/	Homo sapiens													61												
7941	8613					Recommended	mg	100		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30889096/	Homo sapiens												60	24	perimenopausal					46			12	week		
7942	8615		ADULT			Highest studied dose	mg	863		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217639Orig1s000MultidisciplineR.pdf#page=103 | https://pubmed.ncbi.nlm.nih.gov/32661909/	Homo sapiens						62				1000 mg as Elacestrant dihydrochloride		75	9						50			7	day		EudraCT number: 2014-001699-67
7943	8615		ADULT			Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s000correctedlbl.pdf#page=4 | https://pubmed.ncbi.nlm.nih.gov/35584336/	Homo sapiens						63						89	237	breast carcinoma					24			4	month		NCT03778931 (EMERALD)
7944	8616		adult			Highest studied dose	mg	12		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/26324363/	Homo sapiens										cycle of 7 days-on/7 days-off			13	solid tumors								4	cycle		
7945	8616		adult			Highest studied dose	mg	12		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf	Homo sapiens													7	urothelial carcinoma											84
7946	8616		adult			Recommended	mg	8		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Homo sapiens													87	urothelial carcinoma								5.3	month		6.1
7947	8616		adult			Recommended	mg	8		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Homo sapiens													87	urothelial carcinoma								5.3	month		Table 3
7948	8616		adult			Recommended	mg	8		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf	Homo sapiens													87	urothelial carcinoma								5.3	month		Table 4
7949	8616					Highest studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28965185/	Homo sapiens						62.7				cycle of 7 days-on/7 days-off			7	Cancer					62.7			4	cycle		
7950	8616					RP2D	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28965185/	Homo sapiens						65.7				cycle of 7 days-on/7 days-off			3	Cancer					65.7			4	cycle		
7951	8617		ADULT			Highest studied dose	mg	100		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18464021	Homo sapiens						59.9							6												p.34
7952	8617		ADULT			Minumum effective dose	mg	15		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32379217	Homo sapiens						55.2							49	reproductive system disease								12	week		p.855
7953	8617		ADULT			Studied dose	mg	60		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/33242131	Homo sapiens													3	breast cancer								12	week		p.1837
7954	8637					Highest studied dose	mg/m2	3.6		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						63							1	myeloid leukemia								1	week		
7955	8637					Highest studied dose	mg/m2	5.6		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						69							2	myeloid leukemia								1	day		
7956	8637					MTD	mg/m2	1.25		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						62							9	solid tumors								4	week		
7957	8637					MTD	mg/m2	1.5		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						60				median duration			6	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				14	week		
7958	8637					MTD	mg/m2	1.5		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						63				median duration			32	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				10	week		
7959	8637					MTD	mg/m2	1.5		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						65				median duration			32	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				10	week		
7960	8637					MTD	mg/m2	1.5		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						63							6	myeloid leukemia								1	week		
7961	8637					MTD	mg/m2	2.5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						60							7	solid tumors								6	week		
7962	8637					MTD	mg/m2	4.5		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						69							4	myeloid leukemia								1	day		
7963	8637					Studied dose	mg/m2	1.2		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						63							6	myeloid leukemia								1	week		
7964	8637					Studied dose	mg/m2	1.25		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						60				median duration			6	multiple myeloma								14	week		
7965	8637					Studied dose	mg/m2	1.5		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						65		40 mg; oral; 1/week		median duration			55	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				12	week	dexamethasone	
7966	8637					Studied dose	mg/m2	1.6		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						67.5							3	solid tumors								4	week		
7967	8637					Studied dose	mg/m2	1.75		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						60				median duration			6	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				14	week		
7968	8637					Studied dose	mg/m2	1.8		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22139909/	Homo sapiens						63							2	myeloid leukemia								1	week		
7969	8637					Studied dose	mg/m2	2		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						60				median duration			6	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				14	week		
7970	8637					Studied dose	mg/m2	2.25		multiple			2 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28817190/	Homo sapiens						60				median duration			2	multiple myeloma	subcutaneous; 1/d; 5-7 days			filgrastim				14	week		
7971	8637					Studied dose	mg/m2	3.3		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25684345/	Homo sapiens						59							3	solid tumors								6	week		
7972	8638		ADULT			MTD	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23419064	Homo sapiens						39.5	max			Male subjects received a dose of 1200 mg bid\nand female subjects a dose of 900 mg bid; 30 females\nand 16 males		61	46	multiple sclerosis					21			24	week		p.1038
7973	8663					Highest studied dose	mg	1000		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28373199/	Homo sapiens						45.8							24	Bacterial Skin Infections								2	day		
7974	8663					Highest studied dose	mg	1000		multiple			day	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28373199/	Homo sapiens						45.8							25	Bacterial Skin Infections								2	day		
7975	8663					Highest studied dose	mg	1800		single			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28223381/	Homo sapiens						31							53									1	day		
7976	8663					Highest studied dose	mg	2000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28373199/	Homo sapiens						45.8				mean exposure			24	Bacterial Skin Infections								7.5	day		
7977	8663					Highest studied dose	mg	3000		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29617982/	Homo sapiens						32.4							53	Urogenital Gonorrhea								1	day		
7978	8675					Studied dose	mg	300		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23256625	Homo sapiens													27		10 mg, single			rosuvastatin, p.o							
7979	8685		ADULT			Highest studied dose	mg	800		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21540741	Homo sapiens						24.9						38	27	pain disorder					18						p.672, 673
7980	8697					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30922248	Homo sapiens						43							6	Hepatocellular carcinoma								28	day		p.3
7981	8707					Highest studied dose	mg	1200		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17164373	Homo sapiens												58	4						23						p.2478
7982	8707					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15193659	Homo sapiens						43.2							33	Respiratory papillomatosis											p.251
7983	8707					Studied dose	mg	400		multiple			day	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17164373	Homo sapiens												58	14						23			4	week		p.2478
7984	8708					Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27008709/	Homo sapiens						60							6	solid tumors								28	day		
7985	8708					Studied dose	mg	1200		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30241153/	Homo sapiens						61				3 cycles			1	breast cancer	60 mg/m2; IV; 1/3 weeks			Docetaxel	61			2	week		
7986	8708					Studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25327557/	Homo sapiens						53							2	solid tumors	60 mg/m2; IV; 1/3 weeks			Docetaxel				3	week		
7987	8708					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25327557/	Homo sapiens						53							7	solid tumors	60 mg/m2; IV; 1/3 weeks			Docetaxel				3	week		
7988	8712		ADULT			Studied dose	ug/kg/min	1		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31975496	Homo sapiens						52.3	unknown						40	acute heart failure								24	hour		
7989	8716					Highest studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22464973	Homo sapiens						39.4							98	Schizophrenia								12	week		p.729
7990	8723					Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28389592	Homo sapiens													7	psoriasis								12	week		p.3811
7991	8732					Highest studied dose	mg	1.2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33313070/	Homo sapiens						37	max						17	Ulcerative Colitis								8	week		
7992	8734		ADULT			Highest studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens						60				21 days on and 7 days off		79	3	cancer					31			21	day		p.969
7993	8734		ADULT			MTD	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens						60				40 mg PO BID for 21 days on and 7 days off was determined to be the MTD on an interrupted dose schedule. 40 mg PO BID continuously was also well tolerated.		79	3	cancer					31						p.969, 970
7994	8734		ADULT			Recommended	%	1		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/33567191/	Homo sapiens						69.5				Ointment was applied by the patient to the\nentire 25-cm2  area, once daily for 5 consecutive\ndays.			175	actinic keratosis								5	day		p.517
7995	8734		ADULT			Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens						60				21 days on and 7 days off		79	4	cancer					31			21	day		p.969
7996	8734		ADULT			Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23361621/	Homo sapiens						60				21 days on and 7 days off		79	6	cancer					31			21	day		p.969
7997	8746		adults			Highest studied dose	mg	200		multiple			day	2	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000MultidisciplineR.pdf	Homo sapiens																						6	day		
7998	8746		adults			Highest studied dose	mg	400		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000MultidisciplineR.pdf	Homo sapiens																									
7999	8746		adults			Highest studied dose	mg	600		multiple			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000MultidisciplineR.pdf	Homo sapiens																						10	day		
8000	8746		adults			Highest studied dose	mg	750		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000MultidisciplineR.pdf	Homo sapiens																									
8001	8746		adults			Recommended	mg	600		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens													368	community-acquired bacterial pneumonia (CABP)								5	day		
8002	8746		adults			Recommended	mg|mg	150 | 600		multiple|multiple			day|day	2 | 2	unhealthy	intravenous|oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf	Homo sapiens							complex			150 mg every 12 hours by intravenous infusion over 60 minutes with the option to switch to tablets 600 mg every 12 hours to complete the treatment course.			273	community-acquired bacterial pneumonia (CABP)								5-7 | 5	day|day		
8003	8746		adults			Recommended	mg|mg	150 | 600		multiple|multiple			day|day	2 | 2	unhealthy	intravenous|oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211672Orig1s000,%20211673Orig1s000MultidisciplineR.pdf	Homo sapiens							complex			subjects were initially treated with IV lefamulin 150 mg q12h. After 3 days of IV therapy, subjects could be switched to oral lefamulin 600 mg q12h.			273	community-acquired bacterial pneumonia (CABP)								3 | 4	day|day		
8004	8747					Highest studied dose	mg	200		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/32468649/	Homo sapiens													6												
8005	8747					Highest studied dose	mg	75		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf | https://pubmed.ncbi.nlm.nih.gov/32468649	Homo sapiens													6									14	day		p. 91
8006	8747					Recommended	mg	10		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	Homo sapiens						55						88	323	insomnia					18			6	month		
8007	8747					Recommended	mg	5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	Homo sapiens						55						88	323	insomnia					18			6	month		
8008	8748		ADULT			Highest studied dose	mg	2400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22371898	Homo sapiens						39.1							48												p.2410
8009	8748		ADULT			Studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25350959	Homo sapiens						41							32	HIV infection	100 mg bid for 96 weeks			darunavir				96	week	ritonavir	p.213
8010	8748		ADULT			Studied dose	mg	500		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19779321	Homo sapiens												55	6	HIV infection					18			8	day		p.2120
8011	8748		ADULT			Studied dose	mg	750		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19779321	Homo sapiens												55	6	HIV infection					18			8	day		p.2120
8012	8752		ADULT			MTD	mg/m2	164		multiple			2 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22451157	Homo sapiens						63				median 2 doses per patient, range 1–7		77	6	cancer					48			1	month		p.130
8013	8752		ADULT			MTD	mg/m2	358		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20733579	Homo sapiens						57				continuous intravenous infusion over 24 h every 3 weeks		75	3	cancer					21						p.600
8014	8754		ADULT			Studied dose	mg/kg	3		multiple			6 hours	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10673700	Homo sapiens						37						59	19	Hematologic malignancy					21			28	day		p.286
8015	8757		adult			Highest studied dose	mg	1500		multiple			day	1	unhealthy	oral			https://www.journal-of-hepatology.eu/article/S0168-8278(10)60033-5/pdf	Homo sapiens													8	hepatitis C								3	day		
8016	8757		adult			Highest studied dose	mg	750		multiple			day	2	unhealthy	oral			https://www.journal-of-hepatology.eu/article/S0168-8278(10)60033-5/pdf	Homo sapiens													8	hepatitis C								3	day		
8017	8757					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24901821/	Homo sapiens						52							29	hepatitis C								12	week		
8018	8759		adult			Highest studied dose	mg	25		multiple			day	1	healthy	oral			https://academic.oup.com/DocumentLibrary/SLEEP/2012abstractsupplement.pdf	Homo sapiens													6									7	day		
8019	8759		adult			Highest studied dose	mg	40		single					healthy	oral			https://academic.oup.com/DocumentLibrary/SLEEP/2012abstractsupplement.pdf	Homo sapiens													6												
8020	8763					Highest studied dose	mg/m2	70		multiple			week	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/25085789/	Homo sapiens						55.2							16	breast cancer								8	week		
8021	8763					Highest studied dose	mg/m2	70		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23757357/	Homo sapiens						57							28	Solid Tumors								28	day		
8022	8763					Studied dose	mg/m2	22		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23757357/	Homo sapiens						57							12	Solid Tumors								28	day		
8023	8763					Studied dose	mg/m2	40		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23757357/	Homo sapiens						57							16	Solid Tumors								28	day		
8024	8763					Studied dose	mg/m2	50		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25809731/	Homo sapiens						68				median duration			5	multiple myeloma	1.3 mg/m2;IV; 3 weeks			bortezomib				3	week		
8025	8763					Studied dose	mg/m2	54		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23757357/	Homo sapiens						57							19	Solid Tumors								28	day		
8026	8765		adult			Highest studied dose	mg	1000		multiple			day	4	healthy	oral			https://www.gastrojournal.org/article/S0016-5085(09)60208-0/abstract	Homo sapiens																						14	day		
8027	8776		CHILD			Highest studied dose	ug/kg/day	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf	Homo sapiens						4.5						15	31	Alagille syndrome					1			22	week		80 | 82 | 94 | Study LUM001-304
8028	8776		CHILD			Highest studied dose	ug/kg/day	400		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214662Orig1s000IntegratedR.pdf	Homo sapiens						5						15	23	Alagille syndrome					1			26	week		80 | 94 | Study LUM001-304 Long Term Exposure
8029	8779		adult			Highest studied dose	mg	1000		single					healthy	oral			https://www.researchgate.net/publication/296146052_MBX-2982_a_NovelOral_GPR119_Agonist_for_the_Treatment_of_Type_2_Diabetes_Results_of_Single_and_Multiple_Dose_Studies	Homo sapiens													8												
8030	8779		adult			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M		https://www.researchgate.net/publication/296146052_MBX-2982_a_NovelOral_GPR119_Agonist_for_the_Treatment_of_Type_2_Diabetes_Results_of_Single_and_Multiple_Dose_Studies	Homo sapiens														Impaired fasting glycemia								4	day		
8031	8782		ADULT			MTD|Highest studied dose	mg	55		multiple			week	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf	Homo sapiens													23	multiple myeloma								21	day		60 | 101 | O-12-M1
8032	8782		ADULT			Studied dose	mg	40		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf#page=87	Homo sapiens							total daily dose						157	multiple myeloma	40mg PO QW			Dexamethasone	18						87 | OP-106
8033	8783					Highest studied dose	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32537847/	Homo sapiens						60							3	cancers								28	day		
8034	8783					Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30833489/	Homo sapiens						59							10	cholangiocarcinoma	25 mg/m2; IV			cisplatin				28	day		
8035	8783					Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30833489/	Homo sapiens						60							10	cancers								28	day		
8036	8783					Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30833489/	Homo sapiens						63							10	Head and neck squamous cell carcinoma	250 mg/m2;IV;1/week			cetuximab				28	day		
8037	8783					Studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30833489/	Homo sapiens						60							8	cancers								28	day		
8038	8783					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32537847/	Homo sapiens						59							23	Colorectal Cancer	8 mg/kg; IV; 1/2 weeks			Ramucirumab				28	day		
8039	8783					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32537847/	Homo sapiens						59							7	Colorectal Cancer	8 mg/kg; IV; 1/2 weeks			Ramucirumab				28	day		
8040	8784		adult			Highest studied dose	mg	1000		multiple			day	2	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/24602156	Homo sapiens													10									5	day		
8041	8793					Studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19135348	Homo sapiens						31.15							79	Asthma								14	day		p.344
8042	8794					Studied dose	mg	7		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19491335/	Homo sapiens												76	22	Parkinson Disease					45						
8043	8794					Studied dose	mg	7		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29059133/	Homo sapiens												78	22	Parkinson Disease	1 mg/kg as a 2-hour intravenous infusion			levodopa	46						
8044	8796					Studied dose	mg	50		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23732550	Homo sapiens						75							81	Sarcopenia								6	month		p.538
8045	8799		ADULT			Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://professional.diabetes.org/abstract/efficacy-and-tolerability-mk-0893-glucagon-receptor-antagonist-gra-patients-type-2-diabetes	Homo sapiens						55								type 2 diabetes mellitus								12	week		
8046	8805					MTD	mg	320		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21225315/	Homo sapiens												77	5	advanced or metastatic solid malignancies					44			8	week		
8047	8805					Recommended	mg	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21800081/	Homo sapiens												81	20	unresectable or metastatic pancreatic cancer					44			14	day		
8048	8810					Highest studied dose	mg/m2	3.5		multiple			week	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/27810904/	Homo sapiens						62				administered on days 1, 8, and 15			3	squamous cell carcinoma of the head and neck	250 mg/m2; IV: 1/week			Cetuximab				28	day		
8049	8810					Highest studied dose	mg/m2	3.9		multiple			week	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/24807889/	Homo sapiens						65				administered on days 1, 8, and 15			8	solid tumors | lymphoma								28	day		
8050	8810					MTD	mg/m2	3		multiple			week	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/27810904/	Homo sapiens						62				administered on days 1, 8, and 15			6	squamous cell carcinoma of the head and neck	250 mg/m2; IV: 1/week			Cetuximab				28	day		
8051	8828		adult			Highest studied dose	mg	45		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19212877/	Homo sapiens													2												
8052	8828		adult			MTD	mg	35		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19212877/	Homo sapiens													10												
8053	8829					Highest studied dose	mg	120		multiple			day	1	healthy	oral	M		https://www.natap.org/2009/EASL/EASL_46.htm	Homo sapiens						32.5							6									2	week		
8054	8829					Highest studied dose	mg	120		single			day	1	healthy	oral	M		https://www.natap.org/2009/EASL/EASL_46.htm	Homo sapiens						40.5							6									1	day		
8055	8829					Studied dose	mg	40		multiple			day	1	healthy	oral	M		https://www.natap.org/2009/EASL/EASL_46.htm	Homo sapiens						33.5							6									2	week		
8056	8832		ADULT			Recommended|Highest studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19234797/	Homo sapiens							total daily dose						31	cognitive disorder								56	day		311-21
8057	8841					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23025511/	Homo sapiens						29.7							35	Grass allergy								8	day		
8058	8841					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21762224/	Homo sapiens						43.4							65	asthma								28	day		
8059	8845		ADULT			Recommended	mg	27		multiple					unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210730s001lbl.pdf	Homo sapiens							max|total daily dose			Initiate treatment with a 1.5 mg dose. The cumulative total daily dose should not exceed 27 mg.				pain disorder											p.1, 3
8060	8845		ADULT			Studied dose	mg	7		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/24122908/	Homo sapiens						30.6						49	6						19						p.354
8061	8846					Highest studied dose	mg	200		multiple			day	1	healthy	oral			https://www.journal-of-hepatology.eu/article/S0168-8278(11)61206-3/abstract | https://pubmed.ncbi.nlm.nih.gov/28229375	Homo sapiens													6									10	day		
8062	8846					Highest studied dose	mg	350		single					healthy	oral			https://www.journal-of-hepatology.eu/article/S0168-8278(11)61206-3/abstract | https://pubmed.ncbi.nlm.nih.gov/28229375	Homo sapiens													6												
8063	8847					Highest studied dose	mg/kg	1		multiple			week	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21856480	Homo sapiens							unknown					50	2						18			6	hour		
8064	8847					MTD	mg/kg	0.5		multiple			week	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21856480	Homo sapiens							unknown					50	16						18			6	hour		
8065	8847					Studied dose	mg/kg	0.75		multiple			week	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21856480	Homo sapiens							unknown					50	2						18			6	hour		
8066	8849					Highest studied dose	mg/m2	310		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25336693/ | https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3028	Homo sapiens						59				dosing days 1, 8, and 15 of a 28-day cycle			5	solid tumors								28	day		
8067	8849					MTD	mg/m2	120		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25336693/	Homo sapiens						54				dosing days 1, 4, 8, 11, 15, and 18 of a 28-day cycle			13	solid tumors								28	day		
8068	8849					MTD	mg/m2	260		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25336693/	Homo sapiens						59				dosing days 1, 8, and 15 of a 28-day cycle			13	solid tumors								28	day		
8069	8849					RP2D	mg/m2	160		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26082332/	Homo sapiens						55				days 1, 2, 8, 9, 15, and 16			19	solid tumors								28	day		
8070	8849					Studied dose	mg/m2	210		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26082332/	Homo sapiens						55				days 1, 2, 8, 9, 15, and 16			5	solid tumors								28	day		
8071	8854					Highest studied dose	mg	16		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24525661	Homo sapiens						38.8	max						73	Schizophrenia								12	week		p.194
8072	8854					Highest studied dose	mg	30		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23116363	Homo sapiens						24							4												p.1457
8073	8858					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24418642/	Homo sapiens						70				7 treatment cycles (median)			5	prostate cancer								28	day		
8074	8858					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24418642/	Homo sapiens						70				9 treatment cycles (median)			26	prostate cancer	5 mg; oral; 2/day			prednisone				28	day		
8075	8858					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24965748/	Homo sapiens						71							39	prostate cancer								6	month		
8076	8858					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25537627/	Homo sapiens						71				median duration			3	prostate cancer	5 mg; oral; 2/day			prednisolone				499	day		
8077	8858					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25537627/	Homo sapiens						71				median duration			3	prostate cancer								60	day		
8078	8859					Highest studied dose|Studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32034016	Homo sapiens						69	unknown					83	16	cancer					43			4	week		
8079	8870					Highest studied dose	mg/kg	1.5		multiple			day	2	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/30844808	Homo sapiens						61	max						8	Pancreatic cancer	1 g/m2; 1/week; 3 weeks out of every 4 weeks			gemcitabine, i.v				19	week		
8080	8880		ADULT			MTD	mg	45		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31482223/	Homo sapiens						65						73	6	cancer					39			21	day		p.4,5
8081	8880		ADULT			Studied dose	mg	45		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/31482223/	Homo sapiens						63						72	1	hepatocellular carcinoma					38			21	day		p.4,5
8082	8880		ADULT			Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31482223/	Homo sapiens						65						73	3	cancer					39			21	day		p.4,5
8083	8880					Studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31482223/	Homo sapiens						63						72	3	hepatocellular carcinoma					38			21	day		p.4,5
8084	8891					Highest studied dose	mg/m2	130		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						62				median number of cycles			2	solid tumors								3	cycle		
8085	8891					MTD	mg/m2	105		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						62				median number of cycles			4	solid tumors								3	cycle		
8086	8891					MTD	mg/m2	40		multiple			2 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						56				median number of cycles			3	solid tumors								3	cycle		
8087	8891					RP2D	mg/m2	105		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29643063/	Homo sapiens						60				the median duration of disease control			101	Squamous Cell Carcinoma								4	month		
8088	8891					Studied dose	mg/m2	120		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						62				median number of cycles			3	solid tumors								3	cycle		
8089	8891					Studied dose	mg/m2	30		multiple			2 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						56				median number of cycles			6	solid tumors								3	cycle		
8090	8891					Studied dose	mg/m2	50		multiple			2 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27044938/	Homo sapiens						56				median number of cycles			6	solid tumors								3	cycle		
8091	8898					Highest studied dose	mg	1200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22578529	Homo sapiens						25.8							10												p.6
8092	8899					Highest studied dose	mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16336295	Homo sapiens						53							14	constipation								2	week		
8093	8906					Highest studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56							2	solid tumors								3	week		
8094	8906					Highest studied dose	mg	12		multiple			week	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56				4 on/3 of			7	solid tumors								3	week		
8095	8906					Highest studied dose	mg	19		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56				Monday and Thursday schedule			3	solid tumors								3	week		
8096	8906					MTD	mg	10		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26758913/	Homo sapiens						62.7		20 mg; oral; 4/5 weeks		Monday, Wednesday, Friday schedule			6	multiple myeloma	1.3 mg/m2; subcutaneous; 4/3 weeks			bortezomib				231	day	dexamethasone	
8097	8906					MTD	mg	10		multiple			week	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56				4 on/3 of			6	solid tumors								3	week		
8098	8906					MTD	mg	12		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56				Monday, Wednesday, Friday schedule			26	solid tumors								3	week		
8099	8906					MTD	mg	15		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56							6	solid tumors								3	week		
8100	8906					MTD	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56							8	solid tumors								3	week		
8101	8906					Studied dose	mg	12		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26758913/	Homo sapiens						66.2		20 mg; oral; 4/5 weeks		Monday, Wednesday, Friday schedule			6	multiple myeloma	1.3 mg/m2; subcutaneous; 4/3 weeks			bortezomib				231	day	dexamethasone	
8102	8906					Studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23741066/	Homo sapiens						56							6	solid tumors								3	week		
8103	8912		ADULT			Studied dose	mg	30		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30705758	Homo sapiens						24.3							10												p.4
8104	8914					Highest studied dose	mg/kg	30		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24251380/ | https://pubmed.ncbi.nlm.nih.gov/25782764/	Homo sapiens						47.3							21	major depressive disorder								1	day		
8105	8925		adults			Overdose	mg	2250		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000MedR.pdf	Homo sapiens										The spouse of CT patiens was estd. to have taken 30 tabts of rimegepant 75 mg without known sequelae			1												
8106	8925		adults			Recommended	mg	75		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31291516/	Homo sapiens													543	migraine											
8107	8925		adults			Recommended	mg	75		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31311674/	Homo sapiens													682	migraine											
8108	8925					Highest studied dose	mg	600		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212728Orig1s000MedR.pdf	Homo sapiens													84	migraine											
8109	8925					Recommended	mg	75		single			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf	Homo sapiens												75	682	migraine					18						
8110	8927					Studied dose	mg	0.05		multiple			day		unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21235787	Homo sapiens							unknown					59	84	hypertension					30			5	week		
8111	8927					Studied dose	mg	0.15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21235787	Homo sapiens							unknown					59	84	hypertension					30			5	week		
8112	8927					Studied dose	mg	0.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21235787	Homo sapiens							unknown						81	hypertension								5	week		
8113	8930		ADULT			Highest studied dose	mg/m2	83		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26296952	Homo sapiens						63				For some patients in the highest dose cohort (83  mg/m²), the total dose and delivery of RRx-001 was split into a twice-weekly regimen.		75	6	cancer					36						p.5
8114	8930		ADULT			RP2D	mg/m2	16.7		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26296952	Homo sapiens						63						75	3	cancer					36						p.5
8115	8935		ADULT			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf	Homo sapiens						40						50	226	schizophrenia				Olanzapine	18			24	week		199 | Study A302
8116	8935		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf	Homo sapiens						40						65	134	schizophrenia	10mg QD or 20mg QD			Olanzapine	18			4	week		198 | Study A305
8117	8935		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf	Homo sapiens												55	274	schizophrenia	10mg QD or 20mg QD			Olanzapine	18			24	week		198 | Study A303
8118	8935		ADULT			Studied dose	mg	30		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30476361/	Homo sapiens							total daily dose			10 or 30 mg QD		55	47						15			4	day		
8119	8935					Recommended	mg	10		multiple					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000OtherR.pdf#page=139	Homo sapiens														schizophrenia	10, 15, or 20 mg			Olanzapine				52	week		199 | Study A304
8120	8935					Recommended	mg	10		multiple					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000MultidisciplineR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213378Orig1Orig2s000OtherR.pdf#page=139	Homo sapiens														schizophrenia	10, 15, or 20 mg			Olanzapine							199 | Study A306
8121	8937					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens												76	4	Advanced Solid Malignancies or EGFRm NSCLC	80 mg			osimertinib	44			28	day		
8122	8937					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32469384/	Homo sapiens												78	33	MET-Driven Papillary Renal Cell Carcinoma					23			4	week		
8123	8937					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens							max					76	17	Advanced Solid Malignancies or EGFRm NSCLC					55			28	day		
8124	8937					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens												76	10	Advanced Solid Malignancies or EGFRm NSCLC					55			28	day		
8125	8937					Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens												76	9	Advanced Solid Malignancies or EGFRm NSCLC					55			28	day		
8126	8937					MTD	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens												72	7	Advanced Solid Malignancies or EGFRm NSCLC					59			28	day		
8127	8937					MTD	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33939068/	Homo sapiens												75	6	Advanced Solid Malignancies or EGFRm NSCLC	80 mg			osimertinib	58			28	day		
8128	8943					Highest studied dose	mg	100		multiple			week	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/32589977	Homo sapiens										the 100 mg dose was discontinued			92												
8129	8943						mg	60		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32589977	Homo sapiens						67				on days 1 and 3 weekly			127						67			9	week		
8130	8943						mg/m2	50		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31822399	Homo sapiens						63				50 mg/m2 (~80 mg) BIW in 28-day cycles (8 doses per cycle)		80	73						31			28	day		
8131	8946		ADOLESCENT			MTD	mg/m2	16		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11297238	Homo sapiens						55.1				SEMAPIMOD was  administered once daily in conjunction with high-dose IL-2 in two 5-day courses separated by a 9-day rest period, days 1–5 and 15–19. IL-2 was administered at the standard recommended dose and schedule, 600,000 IU/kg/dose every 8 h for up to 14 doses/course.			7	melanoma				Interleukin-2				5	day		p.489
8132	8946		ADULT			Highest studied dose	mg	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20551461	Homo sapiens						37							51	Crohn's disease								3	day		p,763
8133	8946		ADULT			Studied dose	mg/m2	32		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11297238	Homo sapiens						55.9							6	melanoma								5	day		p.489
8134	8952		CHILD|ADOLESCENT|ADULT			Highest studied dose	mg	3		multiple			day	1	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213793Orig1s000MedR.pdf#page=147	Homo sapiens							max			Dose titration up to 12 weeks (3 or 2.5 mg max) with the initial dose of 0.5 mg		37	27	obesity, proprotein convertase 1/3 deficiency, polygenic desease					11			52	week		RM-493-012, RM-493-015
8135	8956		ADULT			Highest studied dose	mg	25		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18635696	Homo sapiens						25						38	20						19						p.628
8136	8964					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M		https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&amp;parentIdentifier=116439&amp;attachmentIdentifier=36be8834-03c8-4fd8-af93-c2ffda8362e5&amp;fileName=gsk-116439-clinical-study-report-redact.pdf&amp;versionIdentifier=	Homo sapiens						39				with food			8									13	day		
8137	8964					Highest studied dose	mg	800		single			day	1	healthy	oral	F		https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217381&amp;parentIdentifier=116439&amp;attachmentIdentifier=36be8834-03c8-4fd8-af93-c2ffda8362e5&amp;fileName=gsk-116439-clinical-study-report-redact.pdf&amp;versionIdentifier=	Homo sapiens						58.1				with and without food			7									1	day		
8138	8964					Studied dose	mg	200		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25724932/ | https://pubmed.ncbi.nlm.nih.gov/27055521/	Homo sapiens						37.3							10	systemic lupus erythematosus								12	week		
8139	8975		ADULT			Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24732289/	Homo sapiens						34.1							25	pulmonary tuberculosis											p.6
8140	8982		ADULT			Highest studied dose	mg/kg	12		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11032702	Homo sapiens												40	6						25						p.195
8141	8985					Studied dose	mg	1		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17714122/	Homo sapiens												76	19	psoriasis					25			8	week		
8142	8986					Highest studied dose	mg/m2	525		multiple			month	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20618337/	Homo sapiens										given on days 1, 4, 8, and 11 of each 3-week cycle		75	3	relapsed multiple myeloma					47			8	cycle		
8143	8994		adult			Highest studied dose	mg	240		multiple			day	2	healthy	oral	M+F		https://www.natap.org/2007/AASLD/AASLD_39.htm	Homo sapiens														Hepatitis C								8	day		
8144	8994					Highest studied dose	mg	480		single			day	1	healthy	oral	M+F		https://www.natap.org/2007/AASLD/AASLD_39.htm | https://pubmed.ncbi.nlm.nih.gov/27004425/	Homo sapiens						47							6	Hepatitis C								1	day		
8145	8995					Highest studied dose	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19002179/	Homo sapiens						60				median duration; 14 days on/7 days off (noncontinuous dosing)			6	solid tumors								58.5	day		
8146	8995					Highest studied dose	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19002179/	Homo sapiens						60				median duration; continuous dosing			6	solid tumors								83	day		
8147	8995					Highest studied dose	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19636022/	Homo sapiens						55				4 cycles			6	solid tumors								21	day		
8148	8995					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19636022/	Homo sapiens						55				4 cycles			6	solid tumors								21	day		
8149	8995					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19002179/	Homo sapiens						60				median duration; 14 days on/7 days off (noncontinuous dosing)			8	solid tumors								58.5	day		
8150	8996		adult			Highest studied dose	mg	4200		multiple			week	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/22323663/	Homo sapiens										and one week of rest				solid tumors								3	week		
8151	8996					MTD	mg	1700		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22323663/	Homo sapiens						46				each month			3	glioma								5	day		
8152	8996					Studied dose	mg	1567		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25523151/	Homo sapiens						67	mean			and 1 week of rest; doses: 1000, 1500 and 2200 mg			15	acute myeloid leukemia | myelodysplastic syndrome								2	week		
8153	8996					Studied dose	mg	2200		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22323663/	Homo sapiens						46				PEG-free formulation; each month			3	glioma								5	day		
8154	8996					Studied dose	mg	2200		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22323663/	Homo sapiens						46				PEG formulation; each month			6	glioma								5	day		
8155	8996					Studied dose	mg	3300		multiple			4 weeks	5	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2007.25.18_suppl.3584	Homo sapiens						61				5 days every 28 days			3	cancer								28	day		
8156	8999					Highest studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18950853/	Homo sapiens													49	obesity								24	week		
8157	9010					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://www.natap.org/2013/EASL/EASL_41.htm	Homo sapiens						51							8	Hepatitis C	150 mg; oral; 1/d			simeprevir				10	day		
8158	9010					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral			https://www.natap.org/2011/AASLD/AASLD_04.htm	Homo sapiens												63	6	Hepatitis C					35			6	day		
8159	9010					Highest studied dose	mg	1250		multiple			day	2	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/24144360/ | https://www.natap.org/2011/AASLD/AASLD_04.htm	Homo sapiens												55	9						19			5.5	day		
8160	9010					Highest studied dose	mg	1500		single			day	1	healthy	oral			https://www.natap.org/2011/AASLD/AASLD_04.htm	Homo sapiens												55	9						19			1	day		
8161	9015					Highest studied dose	mg	240		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23453583/	Homo sapiens										240 mg once daily for 2 monthfollowed by 120 mg for 4 months		86	35	relapsed/refractory acute myeloid leukaemia					65			2	month		
8162	9015					MTD	mg	180		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20733120/	Homo sapiens							max			60 mg to 180 mg		84	57	acute myeloid leukemia and myelodysplasia					34			28	day		
8163	9015					RP2D	mg	120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32175106/	Homo sapiens										days 1-21 of each 21-day cycle		73	16	advanced pancreatic adenocarcinoma	1000 mg/m2			capecitabine	42			1	cycle		
8164	9015					Studied dose	mg	120		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23453583/	Homo sapiens												86	35	relapsed/refractory acute myeloid leukaemia					65			6	month		
8165	9021					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22105720/	Homo sapiens						60				5 consecutive doses on days 1-3, days 8-10, and days 15-17			2	solid tumors								28	day		
8166	9021					Highest studied dose	mg/m2	200		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17640728/	Homo sapiens						67				Triapine over 24h followed by 5 days of fludarabine; 21 days cycle			9	myeloid malignancies	30 mg/m2; IV: 1/day			fludarabine				1	cycle		
8167	9021					MTD	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22105720/	Homo sapiens						60				5 consecutive doses on days 1-3, days 8-10, and days 15-17			8	solid tumors								28	day		
8168	9021					MTD	mg/m2	160		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12921943/	Homo sapiens						60				continuous intravenous infusion over 96 h			11	leukemia								3	week		
8169	9021					Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22105720/	Homo sapiens						60				5 consecutive doses on days 1-3, days 8-10, and days 15-17			6	solid tumors								28	day		
8170	9023					Highest studied dose	g/kg/day	1.25		multiple			day	4	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000OtherR.pdf	Homo sapiens																									
8171	9023					Highest studied dose	g/kg/day	1.5		single			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000OtherR.pdf	Homo sapiens																						1	day		
8172	9023					MTD	% caloric input	35		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30126760/	Homo sapiens							median					18	12	refractory epilepsy					3			12	week		
8173	9023					Recommended	% caloric input	30		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28189603/	Homo sapiens							mean			target dose: 25-35% of total daily caloric intake		58.78	29	long-chain fatty acid oxidation disorders					0.87			24	week		
8174	9023					Recommended	% caloric input	30.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30126760/	Homo sapiens							median			maximum of 35% caloric input or a maximum of 100 mL/day to be distributed over three to five meals per day		18	12	refractory epilepsy					3			12	week		
8175	9023						% caloric input	20		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28871440/	Homo sapiens												64	16	long-chain fatty acid oxidation disorders					7			4	month		
8176	9023						g/kg	1.3		multiple					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213687s000lbl.pdf	Homo sapiens							total daily dose			0.7 g/kg/day to 6.0 g/kg/day for pediatric patients and 0.5 g/kg/day to 1.3 g/kg/day for adult patients			79	long-chain fatty acid oxidation disorders								23	month		
8177	9027					Highest studied dose	mg	400		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/31899602/	Homo sapiens													6									10	day		
8178	9027					Highest studied dose	mg	400		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31628854/	Homo sapiens						29.2							76									1	day		
8179	9027					Recommended	mg	100		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31913519/	Homo sapiens													409	migraine								52	week		
8180	9027					Recommended	mg	100		multiple					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	Homo sapiens												75	485	migraine					18						
8181	9027					Recommended	mg	50		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31742631/	Homo sapiens												75	488	migraine					18			30	day		
8182	9027					Recommended	mg	50		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31742631/	Homo sapiens												75	488	migraine					18			52	week		
8183	9027					Recommended	mg	50		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31913519/	Homo sapiens													404	migraine								52	week		
8184	9027					Recommended	mg	50		multiple					unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf	Homo sapiens												75	954	migraine					18						
8185	9027					Recommended	mg	50		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31742631/	Homo sapiens										Within 48 Hours After Initial or Optional Second Dose		75	488	migraine					18			2	day		
8186	9027						mg	25		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31742631/	Homo sapiens												71	478	migraine					18			30	day		
8187	9027						mg	25		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31742631/	Homo sapiens										Within 48 Hours After Initial or Optional Second Dose		71	478	migraine					18			2	day		
8188	9032		adult			Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://pubs.rsc.org/en/content/articlelanding/2016/md/c6md00240d/unauth#!divAbstract	Homo sapiens																						1	day		
8189	9032					Studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27650732/	Homo sapiens						66.6	max						138	anemia								20	week		
8190	9037		ADULT			Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://www.researchgate.net/publication/274997361_Abstract_B54_A_phase_1_study_to_assess_the_safety_tolerability_and_pharmacokinetics_of_the_ErbB-family_inhibitor_ARRY-334543_in_patients_with_advanced_solid_tumors	Homo sapiens													4	cancer											
8191	9037		ADULT			MTD	mg	300		multiple			day	2	unhealthy	oral	M+F		https://www.annalsofoncology.org/article/S0923-7534(19)58694-X/pdf	Homo sapiens						62				Varlitinib was combined with mFOLFIRI chemotherapy. Varlitinib was combined with mFOLFIRI up to 9 cycles followed by Varlitinib monotherapy.			6	cancer			irinotecan	5-fluorouracil						leucovorin	
8192	9039					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26183611	Homo sapiens						49							31	genotype 1–4 hepatitis C virus					49			3	day		
8193	9040		ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26547357/	Homo sapiens						69	max						91	heart disease								12	week		E8, E10
8194	9040		ADULT			Recommended	mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf	Homo sapiens							max							heart disease											p.1
8195	9041		ADULT			Highest studied dose	mg/m2	4.5		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens						56				MPC-6827 was administered intravenously over 1 to\n2 hours once weekly for 3 consecutive weeks in a 28-day cycle		76	7	cancer					26			3	week		p.3413
8196	9041		ADULT			MTD	mg/m2	3.3		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens						56				MPC-6827 was administered intravenously over 1 to\n2 hours once weekly for 3 consecutive weeks in a 28-day cycle		76	13	cance					26			3	week		p.3413
8197	9041		ADULT			MTD	mg/m2	3.3		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24740196	Homo sapiens						53				Drug was administered once weekly for three consecutive weeks as an\nintravenous infusion over 2-h, followed by a 1-week\nrecovery period. A median of 2.0 cycles were administered in Group 1\n(range 0—15).		77	31	glioblastoma					23			3	week		p.338
8198	9041		ADULT			Studied dose	mg/m2	3.9		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21159616	Homo sapiens						56				MPC-6827 was administered intravenously over 1 to\n2 hours once weekly for 3 consecutive weeks in a 28-day cycle			6	cancer								3	week		p.3413
8199	9043		adult			Overdose	mg	10		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29104121/	Homo sapiens										plus tenofovir disoproxil fumarate or Entecavir or other oral antiviral drug			1	chronic hepatitis B								1	day		
8200	9043		adult			Overdose	mg	10		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29104121/	Homo sapiens													1	chronic hepatitis B								1	day		
8201	9043		adult			Overdose	mg	20		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29104121/	Homo sapiens													1	chronic hepatitis B								1	day		
8202	9043					Highest studied dose	mg	12		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23416308/	Homo sapiens						25				fasted			6									1	day		
8203	9043					Studied dose	mg	2		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29851204/	Homo sapiens						44							56	chronic hepatitis B	300 mg; oral; 1/day			tenofovir disoproxil fumarate				12	week		
8204	9043					Studied dose	mg	4		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29104121/	Homo sapiens						52				plus tenofovir disoproxil fumarate or Entecavir or other oral antiviral drug			14	chronic hepatitis B								12	week		
8205	9043					Studied dose	mg	4		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29851204/	Homo sapiens						44							55	chronic hepatitis B	300 mg; oral; 1/day			tenofovir disoproxil fumarate				12	week		
8206	9044					Studied dose	mg	35		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23078909/	Homo sapiens												71	34	inflammatory bowel disease					22			12	week		
8207	9044					Studied dose	mg	35		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31621054/	Homo sapiens												81	122	Active Rheumatoid Arthritis					21			13	week		
8208	9058					Highest studied dose	mg/m2	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25030840	Homo sapiens							max			12 patients received seven doses of 40 mg/m² per day and 2 patients received a reduced dose of 10 mg/m² per day.			14	Leber congenital amaurosis								7	day		p.1516
8209	9060					Highest studied dose	mg	150		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens						28							6						28						
8210	9060					Highest studied dose	mg	60		multiple			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25814318	Homo sapiens						26							10						26			5	day		
8211	9152		ADULT			Highest studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27768695	Homo sapiens						40.3						43	6						34						p.9
8212	9152		ADULT			Studied dose	mg	50		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27768695	Homo sapiens						37.5						45	6						21			7	day		p.9
8213	9162					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2508	Homo sapiens						59							1	solid tumors								28	day		
8214	9162					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2508 | https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.1	Homo sapiens						59							6	solid tumors								28	day		
8215	9162					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2508 | https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.1	Homo sapiens						59							8	solid tumors								28	day		
8216	9162					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2508 | https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.1	Homo sapiens						59							9	solid tumors								28	day		
8217	9162					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.2508 | https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.1	Homo sapiens						59							15	solid tumors								28	day		
8218	9162					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30366938/	Homo sapiens						62							58	Solid Tumors								28	day		
8219	9171					Recommended	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf	Homo sapiens										median duration - 9 days		93	300	Complicated Urinary Tract Infections					18			9	day		
8220	9171					Recommended	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf	Homo sapiens													148	Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia								5	day		
8221	9171						g	1		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27874971/	Homo sapiens						60.1							8	Gram-Negative Bacterial Infections								1	day		
8222	9177		adult			Recommended	mg	15		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf	Homo sapiens														serious infection								24	week		
8223	9177		adult			Recommended	mg	15		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211675Orig1s000MedR.pdf	Homo sapiens													1035	rheumatoid arthritis								12	week		p. 165
8224	9177					Highest studied dose	mg	30		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31786154	Homo sapiens						39.9						75	42	Moderate-to-Severe Atopic Dermatitis					18			16	week		
8225	9178					Highest studied dose	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29103081/	Homo sapiens												55	8	stable schizophrenia					18			7	day		
8226	9178					Highest studied dose	mg	1000		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27572830/	Homo sapiens						32.5							11						32.5						
8227	9178					Highest studied dose	mg	20		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29103081/	Homo sapiens												55	8						20			7	day		
8228	9195		adult			Recommended	mg	100		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/210259Orig1s000MultidisciplineR.pdf	Homo sapiens													610	hematological malignancies								15.2	month		p. 132
8229	9195					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26641137	Homo sapiens						62								Relapsed Chronic Lymphocytic Leukemia					62			14.3	month		
8230	9196						mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29434192	Homo sapiens						69						73	29	relapsed/refractory lymphoid malignancies					59			21	day		
8231	9215		ADULT			Highest studied dose	mg/m2	450		multiple			3 weeks	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/25312684	Homo sapiens						42.5							2	cancer								1	cycle		p.574
8232	9215		ADULT			MTD	mg/m2	350		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25312684	Homo sapiens						56.2							18	cancer								8	cycle		p.574
8233	9226		adult			Highest studied dose	mg	500		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3615	Homo sapiens														colorectal cancer								28	day		
8234	9234		ADULT			Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23178951	Homo sapiens						60							3	cancer								2	cycle		p.466
8235	9240					Highest studied dose	g	1.14		multiple			day	12	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1622852/	Homo sapiens						56	max						26	cancer								4	day		
8236	9241					Highest studied dose	mg	80		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18559649/	Homo sapiens												44	32						21						
8237	9241					Highest studied dose	mg	80		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18559649/	Homo sapiens						33.3							24									3	day		
8238	9252					Highest studied dose	mg	1000		multiple			day	3	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/25813217	Homo sapiens													6									5	day		
8239	9252					Highest studied dose	mg	2000		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/25813217	Homo sapiens													6									30	min		
8240	9252						mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25813217	Homo sapiens						28.9							8						28.9						
8241	9255		ADULT			Highest studied dose	mg	4500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18553458/	Homo sapiens						46.9						57	9	hepatitis C					31			14	day		p.403
8242	9255		ADULT			Studied dose	mg	1500		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22166557/	Homo sapiens						45.7							71	hepatitis C	1,000/1,200 mg/day; oral			peginterferon alfa-2a				24	week		p.7
8243	9261					Highest studied dose	mg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31217479/	Homo sapiens										28-day treatment cycle		77	31	advanced solid tumours and lymphomas					21			1	cycle		
8244	9267		ADULT			Studied dose	mg	13.34		steady			day	1	healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/29025138/	Homo sapiens						37.6							44		650 mg			acetaminophen				7	day		
8245	9275		adult			Recommended	mg	50		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf	Homo sapiens													314	HIV-1								48	week		7
8246	9275		adult			Recommended	mg	50		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf	Homo sapiens													314	HIV-1								48	week		8
8247	9275		adult				mg	100		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02275065	Homo sapiens													4	HIV-1 Infection								10	day		
8248	9275		adult				mg	5		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02275065	Homo sapiens													4	HIV-1 Infection								10	day		
8249	9275		adult				mg	50		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02275065	Homo sapiens													4	HIV-1 Infection								10	day		
8250	9280		ADULT			Recommended	g	7.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27896908/	Homo sapiens						62.9	max|total daily dose			Bixalomer was started at 1500 mg/day and adjusted up to 7500 mg/day depending on serum phosphorus concentrations.			80	hyperphosphatemia											p.6
8251	9280		ADULT			Recommended	g	7.5		multiple			day	1	unhealthy	oral	M+F		https://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=32581	Homo sapiens							max|total daily dose							hyperphosphatemia											
8252	9280		ADULT			Recommended	g	7.5		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/24720402/	Homo sapiens						62	max|total daily dose			Administration of bixalomer was started at 1.5 g/day and adjusted to a maximum of 7.5 g/day depending on the serum phosphate level.			54	hyperphosphatemia											p.8
8253	9286		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00175825	Homo sapiens													52	Epilepsy								7	week		
8254	9286		adult				mg	10		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00490035	Homo sapiens													99	Epilepsy								12	week		
8255	9286		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00160667	Homo sapiens													51	Post-herpetic Neuralgia								4	week		
8256	9286		adult				mg	2.5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00175825	Homo sapiens													50	Epilepsy								7	week		
8257	9286		adult				mg	200		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00160667	Homo sapiens													51	Post-herpetic Neuralgia								4	week		
8258	9286		adult				mg	25		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00175825	Homo sapiens													52	Epilepsy								7	week		
8259	9286		adult				mg	25		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00490035	Homo sapiens													99	Epilepsy								12	week		
8260	9286		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00490035	Homo sapiens													100	Epilepsy								12	week		
8261	9286		child|adult				mg	75		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00504881	Homo sapiens							max			A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day			359	Epilepsy								16	week		
8262	9286					Highest studied dose	mg	800		steady			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836Orig1s000_205837Orig1s000_205838Orig1s000MedR.pdf	Homo sapiens						64.1				pool other			7						64.1						p. 28
8263	9286					Highest studied dose	mg/kg	2		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31250322	Homo sapiens										patients aged<8 years received approximately 1.0, 2.0, and 4.0 mg/kg/day in two divided daily doses at weeks 1, 2, and 3, respectively.				generalized epilepsy								1	week		
8264	9286					Highest studied dose|MID	mg	1400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17223857	Homo sapiens												55	6						18						
8265	9286					MTD	mg	1000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17223857	Homo sapiens												55	6						18						
8266	9286					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27265725	Homo sapiens						37.2	max			pooled data			2186						37.2			8	year		
8267	9293		adult			Recommended	%	0.05		multiple			day	4	unhealthy	ophthalmic	unknown		https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	Homo sapiens													148	allergic conjunctivitis								2	week		11
8268	9293					Recommended	%	0.05		multiple			day	4	unhealthy	ophthalmic	M+F		https://db.cbg-meb.nl/veegactie/csp/Levocabastine_okt2014.pdf	Homo sapiens												17	24	paralimbic keratitis of immuno-allergic type					5			2	week		12
8269	9293					Recommended	mg/mL	0.2		multiple			day	2	unhealthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/10088031/	Homo sapiens						38.8							137	seasonal allergic rhinitis								4	week		
8270	9293					Recommended	mg/mL	0.5		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	Homo sapiens													177	allergic conjunctivitis	20 mg/ml			sodium cromoglycate nasal spray				4	week		
8271	9293					Recommended	mg/mL	0.5		multiple			day	2	unhealthy	ophthalmic	M+F		https://www.researchgate.net/publication/5375238_Levocabastine_eye_drops_are_effective_and_well_tolerated_for_the_treatment_of_allergic_conjunctivitis_in_children	Homo sapiens													56	allergic conjunctivitis	20 mg/ml			sodium cromoglycate nasal spray	12			4	week		
8272	9314		ADULT			Highest recorded dose	mg	87.5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14680722/	Homo sapiens						45	max						1									20	year		423-5
8273	9314		ADULT			Recommended	mg	30		multiple			week	2	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8164019/	Homo sapiens						43				dosage reduction to 30 mg NPE every 3-4 days			1									12	month		167-9
8274	9314		ADULT			Recommended	mg	49		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9775158/	Homo sapiens						43							1									6	week		287-8
8275	9314		ADULT			Studied dose	mg	53.3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28873376/	Homo sapiens						49.3							60	obesity								24	week		407-419
8276	9318					Highest studied dose	mg	750		single			day	1	healthy	oral	M		http://az9194.vo.msecnd.net/pdfs/110404/11.08.pdf | https://pubmed.ncbi.nlm.nih.gov/32087001/	Homo sapiens													7									1	day		
8277	9318					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf	Homo sapiens						39				the median length of treatment - 18 weeks			108	partial-onset seizures								18	week		
8278	9318					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32409485/	Homo sapiens												65	113	partial-onset seizures					18			12	week		
8279	9318					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf	Homo sapiens						39				the median length of treatment - 18 weeks			109	partial-onset seizures								18	week		
8280	9318					Recommended	mg	200		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf	Homo sapiens						39				the median length of treatment - 18 weeks			223	partial-onset seizures								18	week		
8281	9318					Recommended	mg	350		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf	Homo sapiens						39	mean			the median length of treatment - 18 weeks			442	partial-onset seizures								18	week		
8282	9318					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf	Homo sapiens						39				the median length of treatment - 18 weeks			111	partial-onset seizures								18	week		
8283	9319					Highest studied dose	mg	100		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30592080/	Homo sapiens						67.8							2	B-cell malignancies								28	day		
8284	9319					Studied dose	mg	45		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30592080/	Homo sapiens						67.8							5	B-cell malignancies								28	day		
8285	9319					Studied dose	mg	45		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30592080/ | https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.7557	Homo sapiens						67.8							5	B-cell malignancies								28	day		
8286	9323		ADULT			Highest studied dose	mg/m2	31.5		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20697774	Homo sapiens						58				intravenously on days 1, 8 and 15 of a 28-day cycle		73	7	cancer					34			3	week		p.268
8287	9332		ADULT			Higher than recommended	mg	20		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2527543/	Homo sapiens						49						66	12	hypertension					20			1	day		303S-307S
8288	9332		ADULT			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11061364/	Homo sapiens													34	hypertension								6	month		674-83
8289	9356		ADULT			Studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23126252	Homo sapiens						60.3	unknown						7938	acute coronary syndrome								4	week		
8290	9356					Highest studied dose	mg	3900		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21366361	Homo sapiens							unknown					65	8						18			7	day		
8291	9356					Highest studied dose	mg	4500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21366361	Homo sapiens							unknown					65	11						18						
8292	9359		ADULT			Highest studied dose	mg	36		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26794682	Homo sapiens													39												p.32
8293	9359		ADULT			Studied dose	mg	5.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32926604	Homo sapiens						38.7	mean						155	eating disorder								12	week		e5, sup. table 2
8294	9359		CHILD			Studied dose	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30694697	Homo sapiens						9.1							115	attention deficit hyperactivity disorder								6	week		p.6
8295	9384		adult			Highest studied dose	mg	16		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24408516/	Homo sapiens													8									1	day		
8296	9384					Studied dose	mg	4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25602163/	Homo sapiens						41.6	max			3 cohorts: 0.5, 2, 4 mg			480	major depressive disorder				selective serotonin/norepinephrine reuptake inhibitors				8	week	selective serotonin reuptake inhibitors	
8297	9384					Studied dose	mg	4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25602163/	Homo sapiens						45.5	max			3 cohorts: 0.1, 1, 4 mg			522	major depressive disorder				selective serotonin/norepinephrine reuptake inhibitors				8	week	selective serotonin reuptake inhibitors	
8298	9395		ADULT			Highest studied dose	ug/kg	15		single					healthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000OtherR.pdf	Homo sapiens						28						55	39						19						30 | CR845-CLIN1006
8299	9395		ADULT			Recommended	ug/kg	0.5		multiple			week	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	Homo sapiens						60						85	235	chronic kidney disease					24			12	week		99 | CR845-CLIN3103DB
8300	9395		ADULT			Recommended|Studied dose	ug/kg	0.5		multiple			week	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214916Orig1s000MultidisciplineR.pdf	Homo sapiens						57						88	189	chronic kidney disease					24			12	week		90 | 99 | CR845-CLIN3102DB
8301	9419					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29703432	Homo sapiens						34.6							5	HCV GT3 infection					34.6			5	day		
8302	9424					Highest studied dose	mg/kg	1		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9322459/	Homo sapiens						47		50 ug; IV; 1/day					26		2 mg; IV: 1/day			midazolam				1	day	fentanyl	
8303	9433		ADULT			Recommended	g	2		multiple			day	3	unhealthy	oral	M+F		https://avexima.com/medicines/nobazit/	Homo sapiens							max|total daily dose			Nobazit® is taken orally after the meal without chewing; 0.5 g 3 times daily. Maximal single dose is 1 g, and daily dose is 2 g.				influenza								7	day		
8304	9433		ADULT			Recommended	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33558285/	Homo sapiens												60	60	influenza					18			7	day		p.6
8305	9439		adult			Studied dose	%	1		single					healthy	ophthalmic	unknown		https://pubmed.ncbi.nlm.nih.gov/1200898/	Homo sapiens													20	model of allergic conjunctivitis											
8306	9442						ug	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24731671	Homo sapiens						55							22	familial hypercholesterolaemia					55			12	week		
8307	9442						ug	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24731671	Homo sapiens						54							24	familial hypercholesterolaemia					54			12	week		
8308	9460		ADULT			Recommended	mg	2		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=36	Homo sapiens						58				Japanese		73	30	secondary hyperparathyroidism					26			21	day		7580-005
8309	9460		ADULT			Recommended	mg	4		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=30	Homo sapiens						64				Japanese		74	24	secondary hyperparathyroidism					40			14	day		7580-003
8310	9460		ADULT			Studied dose	mg	12		multiple			day	1	healthy	oral	M		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=28	Homo sapiens										Japanese Healthy Adult Males		40	6						20			8	day		7580-002
8311	9460		ADULT			Studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=41	Homo sapiens						62				Japanese SHPT patients under hemodialysis, up to 12mg/day		84	137	secondary hyperparathyroidism					28			52	week		7580-011
8312	9460		ADULT			Studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=43	Homo sapiens						63				Japanese SHPT patients under peritoneal dialysis, up to 12mg/day		78	39	secondary hyperparathyroidism					30			52	week		7580-012
8313	9460		ADULT			Studied dose	mg	8		multiple			day	1	unhealthy	oral	M+F		https://www.pmda.go.jp/drugs/2018/P20180413003/230124000_23000AMX00465_A100_1.pdf#page=38	Homo sapiens						63				Japanese, up to 8mg/day		86	317	secondary hyperparathyroidism					29			30	week		7580-010
8314	9463		ADULT			Highest studied dose	mg/kg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25651188	Homo sapiens												53	6						19						p.701
8315	9463		ADULT			Studied dose	mg/kg	200		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25651188	Homo sapiens												47	6						20			10	day		p.701
8316	9463		CHILD			Studied dose	mg	2500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30650257	Homo sapiens						8.45							4	Duchenne muscular dystrophy								14	day		p.7
8317	9466		ADULT			Studied dose	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32405421/	Homo sapiens							min			from 400 mg up to 1200 mg per day, split into twice or three times daily doses			132	COVID-19								7	day		
8318	9466		ADULT			Studied dose	mg	3000		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32405421/	Homo sapiens							max			from 1200 mg up to 6000 mg per day, split into twice or three times daily doses			189	COVID-19								7	day		
8319	9466		ADULT			Studied dose	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32346491/	Homo sapiens						43				Day 1: 1600 mg twice daily; Days 2-14: 600 mg twice daily			35	COVID-19								14	day		
8320	9467		ADULT			MTD	mg/m2/hour	2		multiple			hour	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/1379523	Homo sapiens						53				intravenously over 72 h every 28 days		73	5	cancer					36			3	day		p.323
8321	9467		ADULT			MTD	mg/m2/hour	425		multiple			hour	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10492074	Homo sapiens						46				continuous infusion over 3 days every 3 to 4 weeks		90	3	leukemia					17			3	day		p.514
8322	9480					Highest studied dose	mg	1000		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22803688/	Homo sapiens						54							6									1	day		
8323	9480					Highest studied dose	mg	450		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22803688/	Homo sapiens						60							6									11	day		
8324	9480					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23331559/	Homo sapiens						29.8							20	asthma								5	day		
8325	9482		ADULT			Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21488067	Homo sapiens						54.9							10	hepatitis C								3	day		p.56
8326	9499					Highest studied dose	mg	600		single			day	1	healthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205718s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/25105088/	Homo sapiens						32.8							49		1.5 mg; single dose			palonosetron				1	day		
8327	9499					Recommended	mg	300		multiple			5 weeks	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000MedR.pdf | https://www.ema.europa.eu/en/documents/assessment-report/akynzeo-epar-public-assessment-report_en.pdf	Homo sapiens						55				5 weeks in cycle 1 and at least 4 weeks in each cycle of the Multiple-Cycle Extension			1033	cancer	0.5 mg; prior to the start of chemotherapy cycle			palonosetron				5	week		nda/2014/205718Orig1s000MedR.pdf - p.138 | assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.121
8328	9499					Recommended	mg	300		multiple			5 weeks	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/akynzeo-epar-public-assessment-report_en.pdf	Homo sapiens						55				5 weeks in cycle 1 and at least 4 weeks in each cycle of the Multiple-Cycle Extension			1033	cancer	0.5 mg; prior to the start of chemotherapy cycle			palonosetron				5	week		assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
8329	9499					Recommended	mg	300		multiple			5 weeks	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/akynzeo-epar-public-assessment-report_en.pdf	Homo sapiens						55				5 weeks in cycle 1 and at least 4 weeks in each cycle of the Multiple-Cycle Extension			1033	cancer	0.5 mg; prior to the start of chemotherapy cycle			palonosetron				5	week		assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
8330	9524		adult			Highest studied dose|MTD	mg	1600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24666106 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208261Orig1s000OtherR.pdf	Homo sapiens													24												
8331	9524		adult			Studied dose	mg	1000		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24666106	Homo sapiens													40									10	day		
8332	9524						mg	800		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24666106| https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.24666	Homo sapiens												65	84	HCV genotype 1 infection | HCV genotype 3 infection					18			7	day		
8333	9537		adult			Highest studied dose	mg	150		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32851809/	Homo sapiens													5												
8334	9537		adult			Highest studied dose	mg	20		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32851809/	Homo sapiens													9									14	day		
8335	9537		adult			Studied dose	mg	100		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32851809/	Homo sapiens													6												
8336	9537		adult			Studied dose	mg	50		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32851809/	Homo sapiens													6												
8337	9541		ADULT			Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33302031	Homo sapiens						67.5				microprecipitate bulk powder			12	acute myeloid leukemia											p.3, 4
8338	9550					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404582	Homo sapiens						59	unknown					82	5	cancer					44			21	day		
8339	9550					Highest studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17146730/	Homo sapiens						55	unknown					63	8	cancer					46			14	day		
8340	9550					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404582	Homo sapiens						59	unknown					82	3	cancer					44			21	day		
8341	9550					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404582	Homo sapiens						59	unknown					82	3	cancer					44			21	day		
8342	9550					Studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404582	Homo sapiens						59	unknown					82	3	cancer					44			21	day		
8343	9556		ADULT			MTD	mg/kg	8.6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26285766	Homo sapiens						55				Iniparib was administered intravenously (IV) on two consecutive days weekly (weeks 1-4 with mTMZ)			9	malignant glioma	Patients in the monthly dose TMZ (mTMZ)  group were prescribed TMZ 150 mg/m2 in cycle 1 and 200 mg/m2 in cycles 2-6 on days 1-5 of each of six 4-week cycles.			temozolomide				2	day		p.6
8344	9556		ADULT			Studied dose	mg/kg	9.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26285766	Homo sapiens						57				Iniparib was administered intravenously (IV) on two consecutive days weekly (weeks 1-4 with mTMZ)			4	malignant glioma	Patients in the monthly dose TMZ (mTMZ)  group were prescribed TMZ 150 mg/m2 in cycle 1 and 200 mg/m2 in cycles 2-6 on days 1-5 of each of six 4-week cycles.			temozolomide				2	day		p.5
8345	9595		adult			Highest studied dose	mg/m2	3.95		multiple			week	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000ClinPharmR.pdf	Homo sapiens								40mg, PO, 1-21 day, Days 1, 8, 15, 22		in 28-day cycles			4	cancer	25mg, PO, 1-21 day			lenalidomide				3	week	dexamethasone	C16005
8346	9595		adult			Recommended	mg/m2	2.97		multiple			week	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000ClinPharmR.pdf	Homo sapiens								40mg, PO, 1-21 day, Days 1, 8, 15, 22		in 28-day cycles			31	cancer	25mg, PO, 1-21 day			lenalidomide				3	week	dexamethasone	C16005
8347	9595		adult				mg	4		multiple			4 weeks	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02181413	Homo sapiens							max			Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.			394	Multiple Myeloma								24	month		
8348	9595					Highest studied dose	mg/m2	3.95		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24904120	Homo sapiens						64				equivalent to 8.9 mg		76	4	relapsed/refractory multiple myeloma					40			28	day		
8349	9595					MTD	mg	4		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28550039	Homo sapiens						66				4 mg on Days 1, 8, and 15 of a 28-day cycle			6	relapsed/refractory AL amyloidosis					66			28	day		
8350	9595					MTD	mg/m2	2.97		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24904120	Homo sapiens						64				equivalent to 5.5 mg. Administered on days 1, 8, and 15 of a 28-day cycle for up to 12 cycles		76		relapsed/refractory multiple myeloma					40			28	day		
8351	9595					Recommended	mg	4		multiple			week	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf	Homo sapiens						66		40 mg on Days 1, 8, 15, and 22 of a 28-day cycle		4 mg or placebo on Days 1, 8, and 15 of a 28-day cycle		91	360	relapsed and/or refractory multiple myeloma	25 mg on Days 1 throughn21			lenalidomide	38			28	day	dexamethasone	
8352	9595					Recommended	mg	4		multiple			week	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000MedR.pdf	Homo sapiens								40 mg on Days 1, 8, 15, and 22 of a 28-day cycle		4 mg or placebo on Days 1, 8, and 15 of a 28-day cycle			360		25 mg on Days 1 throughn21			lenalidomide				28	day	dexamethasone	p. 55
8353	9595					Recommended	mg	4		multiple			week	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000MedR.pdf	Homo sapiens								40 mg on Days 1, 8, 15, and 22 of a 28-day cycle		4 mg or placebo on Days 1, 8, and 15 of a 28-day cycle			360		25 mg on Days 1 throughn21			lenalidomide				28	day	dexamethasone	p. 56
8354	9595						mg	5.5		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28550039	Homo sapiens						66				5.5 mg on Days 1, 8, and 15 of a 28-day cycle			5	relapsed/refractory AL amyloidosis					66			28	day		
8355	9601		ADULT			Recommended	%	0.024		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/26875002/	Homo sapiens						64.7							284	glaucoma								3	month		965-73
8356	9601		ADULT			Recommended	%	0.024		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/26875002/	Homo sapiens													130	glaucoma								52	week		1612-27
8357	9610					Highest studied dose	mg	1600		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27826183/	Homo sapiens						42							10												
8358	9618		adult			Highest studied dose	mg/kg	40		multiple			week	3	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020182s015lbl.pdf	Homo sapiens													34	End Stage Renal Disease								24	week		
8359	9627		ADULT			Highest studied dose	mg	20		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12648882/	Homo sapiens												65	50	osteoporosis					45			12	month		
8360	9627		ADULT			Studied dose	mg	1.25		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12237621/	Homo sapiens							max			0.5 mg or 1.25 mg daily			2924	osteoporosis					65			10	month		
8361	9627		ADULT			Studied dose	mg	1.25		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12648882/	Homo sapiens												65	51	osteoporosis					45			12	month		
8362	9627		ADULT			Studied dose	mg	10		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12648882/	Homo sapiens							median			1.25 to 20 mg		65	234	osteoporosis					45			12	month		
8363	9627		ADULT			Studied dose	mg	10		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12648882/	Homo sapiens												65	50	osteoporosis					45			12	month		
8364	9627		ADULT			Studied dose	mg	5		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/12648882/	Homo sapiens												65	50	osteoporosis					45			12	month		
8365	9633		adult				%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/NCT01636206	Homo sapiens													220	Dry Eye								1	year		
8366	9633		adult				%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/NCT01743729	Homo sapiens													359	Dry Eye								84	day		
8367	9633		adult				%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://clinicaltrials.gov/ct2/show/NCT02284516	Homo sapiens													357	Dry Eye								84	day		
8368	9633					Recommended	%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/27055211	Homo sapiens						58.8				5% (50 mg/mL)		89	220	dry eye disease					21			1	year		
8369	9633					Recommended	%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000MedR.pdf	Homo sapiens						58.6				Single eye: 1 drop BID for 84 days		84	355	dry eye disease					14			84	day		p. 55
8370	9633					Recommended	%	5		steady			day	2	unhealthy	ophthalmic	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000MedR.pdf	Homo sapiens						58.6				Single eye: 1 drop BID for 84 days. 5% (50 mg/mL)		84	355	dry eye disease					14			84	day		p. 55
8371	9647		adult				mg	3		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02389621	Homo sapiens													107	Thrombocytopenia								7	day		
8372	9647					Recommended	mg	3		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210923s000lbl.pdf	Homo sapiens													171	thrombocytopeni								7	day		
8373	9647					Recommended	mg	3		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210923Orig1s000MultidisciplineR.pdf	Homo sapiens													171	thrombocytopeni								7	day		
8374	9654		ADULT			Highest studied dose	mg/m2	0.9		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						63.5				Marizomib was administered on days 1, 8, and 15 every 4 weeks by intravenous injection over 10 minutes; the median number of cycles completed (range) was 2 (0–15).		80	2	cancer					23			3	week		p.4563
8375	9654		ADULT			MTD	mg/m2	0.5		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						62.5				Marizomib was administered on days 1, 4, 8, and 11 every 3 weeks by intravenous infusion over120 minutes		79	10	cancer					38			3	week		p.4563
8376	9654		ADULT			MTD	mg/m2	0.7		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						63.5				Marizomib was administered on days 1, 8, and 15 every 4 weeks by intravenous injection over 10 minutes; the median number of cycles completed (range) was 2 (0–15)		80	12	cancer					23			3	week		p.4563
8377	9654		ADULT			RP2D	mg/m2	0.7		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27009059	Homo sapiens						61				once weekly on days 1, 8, and 15 of 4-week cycles; infused over 10 minutes		82	13	multiple myeloma					45			3	week		
8378	9654		ADULT			Studied dose	mg/m2	0.5		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						62.5				Marizomib was administered on days 1, 4, 8, and 11 every 3 weeks by intravenous infusion over 10 minutes		79	9	cancer					38			3	week		p.4563
8379	9654		ADULT			Studied dose	mg/m2	0.6		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						62.5				Marizomib was administered on days 1, 4, 8, and 11 every 3 weeks by intravenous infusion over 120 minutes		79	4	cancer					38			3	week		
8380	9654		ADULT			Studied dose	mg/m2	0.8		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27117181	Homo sapiens						63.5				Marizomib was administered on days 1, 8, and 15 every 4 weeks by intravenous injection over 10 minutes; the median number of cycles completed (range) was 2 (0–15).		80	3	cancer					23			3	week		p.4563
8381	9657		ADULT			Highest studied dose	mg	400		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28337838	Homo sapiens						45						62	11	gastroesophageal reflux disease					23						
8382	9657		ADULT			Highest studied dose	mg	50		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27823869	Homo sapiens						34.7							12												p.2593
8383	9657		ADULT			Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25689146	Homo sapiens						56.6	max			days 1-4, 25 mg twice-daily [BID]; days 5-8, 50 mg BID; days 9-12, 100 mg BID; days 13-28,  150 mg BID [maintenance  period]; days 29-32, 50 mg BID			21	Huntington's disease								32	day		p.3
8384	9660		ADULT			Highest studied dose	g	2		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30328291/	Homo sapiens													16									3	week		
8385	9660		ADULT			Studied dose	mg	500		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28213178/	Homo sapiens												49	5						31			6	day		
8386	9665						mL	2		multiple			2 days	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/5958596	Homo sapiens													11	cirrhosis								10	day		
8387	9666					Studied dose	%	0.1		single			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/18132526/	Homo sapiens						40				patch test o.2% Mercresin			1	leg ulcer	0.1%; topical; single			amyltricresol secondary	40			1	day		
8388	9688		ADULT			MTD	mg/m2	1800		multiple			month	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3517245	Homo sapiens						52						69	5	cancer					23						p.756
8389	9688		ADULT			Studied dose	mg/m2	180		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/2685182	Homo sapiens						47				DBD was administered\norally at a dose  of 180 mg/m2  per day  (rounded to the  nearest\n50 mg) for 10 consecutive days,  repeated every 4  weeks.		79	60	squamous cell carcinoma of the Cervix Uteri					29			10	day		p.1893
8390	9691		ADULT			Highest studied dose	mg/kg	25		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32960289/	Homo sapiens												74	2	cancer					50			28	day		ACTRN12614000612617
8391	9691		ADULT			Studied dose	mg/kg	5		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32960289/	Homo sapiens												74	6	cancer					50			28	day		ACTRN12614000612617
8392	9735		ADULT			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30656180	Homo sapiens						25.9							10	Friedreich ataxia								12	week		p.19
8393	9736					Highest studied dose	mg/m2	25		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27566973/	Homo sapiens						51.2				30-min IV infusion once every 3 week			6	advanced solid tumors	75 mg/m2			cisplatin				1	cycle		
8394	9736					Highest studied dose	mg/m2	50		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24477603/	Homo sapiens										30-min IV infusion once every 3 week		69	6	advanced solid tumors					29			3	cycle		
8395	9736					Studied dose	mg/m2	15.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24477603/	Homo sapiens										30-min IV infusion once every 3 week		63	3	advanced solid tumors					57			3	cycle		
8396	9737		ADULT			Highest studied dose	mg	15		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17709710	Homo sapiens													105	amyotrophic lateral sclerosis								24	week		p.781
8397	9737		ADULT			Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17110281	Homo sapiens						62.3							73	Parkinson's disease								18	week		p.1017
8398	9738					Highest studied dose	mg	2.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26603258/	Homo sapiens						56.7							3	solid tumors								28	day		
8399	9738					Highest studied dose	mg	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26603258/	Homo sapiens						56.7							9	solid tumors								28	day		
8400	9738					MTD	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							7	solid tumors	1.5 mg; oral; 1/d			Trametinib				28	day		
8401	9738					MTD	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							6	solid tumors	1 mg; oral; 1/d			Trametinib				28	day		
8402	9738					MTD	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26603258/	Homo sapiens						56.7							57	solid tumors								28	day		
8403	9738					Studied dose	mg	0.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							5	solid tumors	2 mg; oral; 1/d			Trametinib				28	day		
8404	9738					Studied dose	mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							6	solid tumors	1.5 mg; oral; 1/d			Trametinib				28	day		
8405	9738					Studied dose	mg	0.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						68				4 days on, 10 days 0ff			7	solid tumors	1.5 mg; oral; 1/d			Trametinib				28	day		
8406	9738					Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							6	solid tumors	1 mg; oral; 1/d			Trametinib				28	day		
8407	9738					Studied dose	mg	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26603258/	Homo sapiens						56.7							14	solid tumors								28	day		
8408	9738					Studied dose	mg	1.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27450049/	Homo sapiens						58							8	solid tumors	1 mg; oral; 1/d			Trametinib				28	day		
8409	9742		adult				mg	10		multiple			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02071810	Homo sapiens													6									8	day		
8410	9742		adult				mg	1200		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01520727	Homo sapiens													6												
8411	9742		adult				mg	20		multiple			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02071810	Homo sapiens													6									8	day		
8412	9742		adult				mg	200		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01520727	Homo sapiens													6												
8413	9742		adult				mg	30		multiple			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02071810	Homo sapiens													7									8	day		
8414	9742		adult				mg	400		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01520727	Homo sapiens													6												
8415	9742		adult				mg	5		multiple			day	1	healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT02071810	Homo sapiens													6									8	day		
8416	9742		adult				mg	50		single					healthy	oral	M		https://clinicaltrials.gov/ct2/show/NCT01520727	Homo sapiens													6												
8417	9742		adults			Recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf	Homo sapiens													115	Parkinson's disease				levodopa				14	week		
8418	9742		adults			Recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf	Homo sapiens													265	Parkinson's disease				levodopa				14	week		
8419	9742		adults			Recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens										14-15 weeks			265	Parkinson's disease				levodopa				15	week		
8420	9742		adults			Studied dose	mg	25		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens										14-15 weeks			244	Parkinson's disease								15	week		
8421	9742		adults			Studied dose	mg	5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000MedR.pdf	Homo sapiens										14-15 weeks			122	Parkinson's disease								15	week		
8422	9742					Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000OtherR.pdf / https://pubmed.ncbi.nlm.nih.gov/23248072/	Homo sapiens												45	6						18			1	day		
8423	9742					Recommended	mg	50		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens						67.7							495	Parkinson's disease					67.7			9	month		
8424	9742					Recommended	mg	50		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000OtherR.pdf	Homo sapiens													356	Parkinson's disease								15	week		
8425	9742					Recommended	mg	50		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000SumR.pdf	Homo sapiens										14-15 weeks			265	Parkinson's disease				levodopa				15	week		
8426	9742					Studied dose	mg	25		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000OtherR.pdf	Homo sapiens														Parkinson's disease								15	week		
8427	9742					Studied dose	mg	5		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212489Orig1s000OtherR.pdf	Homo sapiens														Parkinson's disease								15	week		
8428	9747		ADULT			Studied dose	mg/kg	0.14		multiple			hour	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23995608	Homo sapiens						62				0.080-mg/kg bolus and 0.140-mg/kg per hour Infusion		94	5106	myocardial infarction					25						p.1150
8429	9753		adult			Highest studied dose	mg	50		single			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/25209519/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208945Orig1s000MedR.pdf	Homo sapiens										5 g of ozenoxacin 1% ointment applied to 5% BSA			8									1	day		208945Orig1s000MedR.pdf - p.112
8430	9753					Recommended	%	1		multiple			day	2	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208945Orig1s000MedR.pdf	Homo sapiens													206	impetigo								5	day		208945Orig1s000MedR.pdf - p.49 | 208945Orig1s000MedR.pdf - p.102
8431	9756					Studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26882015/	Homo sapiens													136	Sleeping sickness					12			10	day		
8432	9756					Studied dose	mg/kg	4		steady			day	1	unhealthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/26882015/	Homo sapiens													137	Sleeping sickness					12			7	day		
8433	9760					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19180516	Homo sapiens						50.2	unknown						48	rheumatoid arthritis	orally once a week, commencing at 7.5 mg (three 2.5-mg tablets) on day 1			methotrexate				16	week		
8434	9779		ADULT			Highest studied dose	mg/m2	278		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27056178	Homo sapiens						62.9				Patients received pevonedistat as 1 h intravenous infusions on Days 1, 4, 8, and 11 of 21-day cycles.		79	2	melanoma					34						p.442
8435	9779		ADULT			MTD	mg/m2	209		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27056178	Homo sapiens										Patients received pevonedistat as 1 h intravenous infusions on Days 1, 4, 8, and 11 of 21-day cycles.			11	melanoma											p.442
8436	9779		ADULT			MTD	mg/m2	59		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens						59.1				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 every 21-days; median of 2 (range 1–19) cycles.		84	13	acute myeloid leukaemia					29						p.537
8437	9779		ADULT			MTD	mg/m2	83		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens						62.7				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 every 21-days, median of 2 (range 1–13) cycles.		83	22	acute myeloid leukaemia					19						p.537
8438	9779		ADULT			Studied dose	mg/m2	147		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens						62.7				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 4, 8 and 11 every 21-days, median of 2 (range 1–13) cycles.		83	3	acute myeloid leukaemia					19						p.537
8439	9779		ADULT			Studied dose	mg/m2	157		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27056178	Homo sapiens						57.8				Patients received pevonedistat as 1 h intravenous infusions on Days 1, 8, and 15 of 21-day cycles; the median number of treatment cycles of pevonedistat administered was 2 (range 1–11)		76	11	melanoma					33						p.442
8440	9779		ADULT			Studied dose	mg/m2	78		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25733005	Homo sapiens						59.1				Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 every 21-days; median of 2 (range 1–19) cycles.		84	4	acute myeloid leukaemia					29						p.536, 537
8441	9780					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25480830/	Homo sapiens						72							16	myelodysplastic syndrome								28	day		
8442	9780					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25480830/	Homo sapiens						72							7	myelodysplastic syndrome								28	day		
8443	9787					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25840972	Homo sapiens							unknown					83	25	Refractory Lymphoma, chronic lymphocytic leukemia					28			28	day		
8444	9787					Studied dose	mg	600		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/27169794	Homo sapiens						58	unknown					83	12	lymphoma					45			28	day		
8445	9794		adult				mg	20		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00690274	Homo sapiens							max|total daily dose			up to 20mg per day			15	Schizophrenia|Schizoaffective Disorder								12	week		
8446	9794		adults			Highest studied dose	mg	240		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000SumR.pdf	Homo sapiens																									
8447	9794		adults			Highest studied dose	mg	50		multiple			day	1	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000SumR.pdf	Homo sapiens																									
8448	9794		adults			Highest studied dose	mg	53.4		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000SumR.pdf	Homo sapiens							max						6	excessive daytime sleepiness (EDS)								8	week		
8449	9794		adults			Recommended	mg	17.8		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211150Orig1s000SumR.pdf	Homo sapiens							max			pitolisant 4.45 mg to 17.8 mg			166	excessive daytime sleepiness (EDS)								8	week		P09-15
8450	9794		adults			Recommended	mg	35.6		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf	Homo sapiens							typical			data on all pivotal trials joined; 35.6 is a highest dose tested on a significan fraction of patients			152	excessive daytime sleepiness (EDS)								8	week		
8451	9821					Recommended	%	1		multiple			week	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/12476017	Homo sapiens										at least twice a week			160	Severe dandruff |Seborrheic dermatitis								4	week		p.436, 438
8452	9835						mg	5		multiple					unhealthy	subcutaneous	F		https://pubmed.ncbi.nlm.nih.gov/13069264	Homo sapiens						54				two doses of 5 mg. each given 15 hours apart			1						54			2	day		
8453	9849					Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27927766/	Homo sapiens						56.5							3	myeloid leukemia								28	day		
8454	9849					MTD	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27927766/	Homo sapiens						56.5				in tablets			34	myeloid leukemia								28	day		
8455	9849					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27927766/	Homo sapiens						56.5				in tablets			4	myeloid leukemia								28	day		
8456	9858		ADULT				mg/kg	1		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/11504275	Homo sapiens						36				continuous  2-hour  intravenous  infusion			4												p.873
8457	9886					Recommended	mg	0.15		multiple			day	1	healthy	vaginal	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209627s000lbl.pdf	Homo sapiens												40	2308		0.013 mg/day			ethinyl estradiol	18			13	cycle		13
8458	9887		adult			Highest studied dose	mg	90		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/28160012/	Homo sapiens													9	immune and inflammatory diseases								14	day		
8459	9887		adult			Studied dose	mg	30		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/28650526/	Homo sapiens													10												
8460	9887					Studied dose	mg	45		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32949140/	Homo sapiens						52.2							13	primary Sjo¨ gren’s syndrome								12	week		
8461	9888					Highest studied dose	ug	1800		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25277144/	Homo sapiens										The dose was up-titrated starting from 400 ug b.i.d., in increments of 200-ug steps every third day, up to a maximum tolerated dose			8									3	day		
8462	9888					MTD	ug	1600		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25277144/	Homo sapiens										The dose was up-titrated starting from 400 ug b.i.d., in increments of 200-ug steps every third day, up to a maximum tolerated dose			9									3	day		
8463	9888					Studied dose	ug	1000		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25277144/	Homo sapiens										The dose was up-titrated starting from 400 ug b.i.d., in increments of 200-ug steps every third day, up to a maximum tolerated dose			9									3	day		
8464	9888					Studied dose	ug	3200		single			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/2015/207947s000lbl.pdf	Homo sapiens													1	pulmonary arterial hypertension								1	day		nda/2015/207947Orig1s000MedR.pdf - p.131
8465	9888					Studied dose	ug	400		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25277144/	Homo sapiens										The dose was up-titrated starting from 400 ug b.i.d., in increments of 200-ug steps every third day, up to a maximum tolerated dose			12									3	day		
8466	9888					Studied dose	ug	600		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25277144/	Homo sapiens										The dose was up-titrated starting from 400 ug b.i.d., in increments of 200-ug steps every third day, up to a maximum tolerated dose			11									3	day		
8467	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					18			26	week		nda/2015/207947Orig1s000MedR.pdf - p.98
8468	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					19			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8469	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					20			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8470	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					21			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8471	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					22			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8472	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					23			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8473	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					24			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8474	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					25			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8475	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					26			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8476	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					27			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8477	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					28			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8478	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					29			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8479	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					30			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8480	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					31			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8481	9888					Studied dose	ug	900		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf	Homo sapiens							mean			dose in the range of 200–1600 ug b.i.d.		75	575	pulmonary arterial hypertension					32			26	week		nda/2015/207947Orig1s000MedR.pdf - p.102
8482	9889		ADULT			Highest studied dose	mg/kg	2		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7709405	Homo sapiens						61						74	6	stroke					50						
8483	9890						mg	100		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32333325	Homo sapiens													14									14	day		
8484	9890						mg	18		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32147362	Homo sapiens						59							322	bridging fibrosis					59			48	week		
8485	9890						mg	18		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32147362	Homo sapiens						59							354	compensated cirrhosis					59			48	week		
8486	9890						mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32147362	Homo sapiens						59							321	bridging fibrosis					59			48	week		
8487	9892		ADULT			Highest studied dose	mg/m2/day	10.6		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19470738	Homo sapiens						59				continuous i.v. infusion for 168 hours in 21-day cycles		81	5	cancer					26			7	day		p.3874
8488	9892		ADULT			MTD	mg/m2/day	4.8		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18824702	Homo sapiens						61				168-hour continuous intravenous infusion		78	25	cancer					29			7	day		p.5200
8489	9892		ADULT			MTD	mg/m2/day	8		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19470738	Homo sapiens						59				continuous i.v. infusion for 168 hours in 21-day cycles		81	6	cancer					26			7	day		p.3874
8490	9892		ADULT			Studied dose	mg/m2/day	6		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18824702	Homo sapiens						61				168-hour continuous intravenous infusion		78	2	cancer					29			7	day		p.5200
8491	9895					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831953/	Homo sapiens						57							3	solid tumor								3	week		
8492	9895					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831953/	Homo sapiens						57							3	solid tumor								3	week		
8493	9895					MTD	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831953/	Homo sapiens						57							8	solid tumor								3	week		
8494	9895					MTD	mg	350		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831953/	Homo sapiens						57							8	solid tumor								3	week		
8495	9895					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21831953/	Homo sapiens						57							16	solid tumor								3	week		
8496	9933		adult			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral			https://www.ejcancer.com/article/S0959-8049(12)72391-2/pdf	Homo sapiens													7	solid tumors								28	day		
8497	9933		adult			MTD	mg	400		multiple			day	1	unhealthy	oral			https://www.ejcancer.com/article/S0959-8049(12)72391-2/pdf	Homo sapiens													6	solid tumors								28	day		
8498	9933		adult			Studied dose	mg	100		multiple			day	1	unhealthy	oral			https://www.ejcancer.com/article/S0959-8049(12)72391-2/pdf	Homo sapiens													6	solid tumors								28	day		
8499	9933					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29483143/	Homo sapiens						62.5							7	solid tumors								28	day		
8500	9933					MTD	mg	400		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29453627/	Homo sapiens													13	solid tumors								28	day		
8501	9933					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29483143/	Homo sapiens						62.5							6	solid tumors								28	day		
8502	9940		adult			Highest studied dose	mg	200		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25482583/	Homo sapiens													6									1	day		
8503	9940					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27590145/	Homo sapiens						69.7							8	idiopathic pulmonary fibrosis								60	week		
8504	9940					Highest studied dose	mg	200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27590145/	Homo sapiens						31							15									6	day		
8505	9941					Highest studied dose	mg	25		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18508950/	Homo sapiens												45	12						19			14	day		
8506	9941					Highest studied dose	mg	600		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18258750/	Homo sapiens						25.8							7									1	day		
8507	9941					Studied dose	mg	5		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18508950/	Homo sapiens												45	9						19			14	day		
8508	9941					Studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20157323/	Homo sapiens						49.1							1256	obesity								1	year		
8509	9944		adult				mg	400		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00907803	Homo sapiens													45	Orthopoxviral Disease								14	day		
8510	9944		adult				mg	600		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00907803	Homo sapiens													46	Orthopoxviral Disease								14	day		
8511	9944		adult				mg	600		multiple			day	2	healthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02474589	Homo sapiens													359									14	day		
8512	9944					Highest studied dose	mg	2000		single					healthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2346641/	Homo sapiens												33	7						30						table 2
8513	9944					Recommended	mg	1000		single					healthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2346641/	Homo sapiens												33	8						30						table 2
8514	9944					Recommended	mg	500		single					healthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2346641/	Homo sapiens												33	8						30						table 2
8515	9944					Recommended	mg	600		steady			day	2	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf	Homo sapiens												79	359						18			14	day		4
8516	9944					Recommended	mg	600		steady			day	2	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf	Homo sapiens												79	359						18			14	day		5
8517	9944					Recommended	mg	600		steady			day	2	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/208627Orig1s000SumR.pdf	Homo sapiens												79	359						18			14	day		14
8518	9951					Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20173082/	Homo sapiens						31							6									1	day		
8519	9951					Highest studied dose	mg	400		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20173082/	Homo sapiens						29							6									5	day		
8520	9951					Studied dose	mg	140		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25107879/	Homo sapiens						41.4							263	migraine								12	week		
8521	9951					Studied dose	mg	140		multiple			month	7	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25926620/	Homo sapiens						36.5				seven consecutive days each month			2659	migraine								6	month		
8522	9951					Studied dose	mg	280		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25107879/	Homo sapiens						40.8							265	migraine								12	week		
8523	9951					Studied dose	mg	600		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20173082/	Homo sapiens						31							6									1	day		
8524	9954					Highest studied dose	mg	1000		single			day	1	healthy	oral	M+F		http://regist2.virology-education.com/2011/12HIV_PK/docs/08_Nettles.pdf	Homo sapiens						30				immediate release			6									1	day		
8525	9954					Highest studied dose	mg	1200		multiple			day	2	healthy	oral	M		http://regist2.virology-education.com/2011/12HIV_PK/docs/08_Nettles.pdf	Homo sapiens						36				extended release			6		100 mg;oral;2/d			ritonavir				10	day		
8526	9954					Highest studied dose	mg	2400		multiple			day	2	healthy	oral	M+F		https://www.natap.org/2014/Pharm/Pharm_26.htm	Homo sapiens						31.8				BMS-663068 prodrug			15									7	day		
8527	9956		ADULT			Highest studied dose	mg	1400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214096Orig1s000MultidisciplineR.pdf | https://clinicaltrials.gov/ct2/show/NCT01014936?term=NCT+01014936&draw=2&rank=1 | https://pubmed.ncbi.nlm.nih.gov/31822497/	Homo sapiens						57.8				as Tepotinib hydrochloride hydrate		80.5	7	cancer					23.2			21	day		87 | 90 | 118 | 253 / NCT01014936
8528	9956		ADULT			Recommended	mg	450		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf#page=5 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214096Orig1s000MultidisciplineR.pdf#page=171	Homo sapiens						72.6				450mg as base			255	lung non-small cell carcinoma					41			31	week		Study MS200095-0022 (VISION)
8529	9988					Overdose	mL	500		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19003597	Homo sapiens						47							1		500 mL, single			benzodiazepines	47						
8530	9990		adolescents; adults			Highest studied dose	%	0.02		multiple			week	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/31713811/	Homo sapiens										200 ug/g cream				Lamellar Ichthyosis								12	week		
8531	9990					Highest studied dose	g	12		multiple			week	2	healthy	topical			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf	Homo sapiens										100 ug/g gel												12	week		
8532	9990					Recommended	g	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf	Homo sapiens										50 ug/g cream; 0.005%			1220	acne vulgaris					9			12	week		
8533	9990					Recommended	g	2		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211527Orig1s000MultidisclipineR.pdf	Homo sapiens										50 ug/g cream; 0.005%			1220	acne vulgaris					9			12	week		
8534	9990					Studied dose	%	0.01		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32017149	Homo sapiens						15				100 ug/g cream; 0.01%		17		acne vulgaris					12			29	day		
8535	9990					Studied dose	%	0.01		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32017149	Homo sapiens						20				100 ug/g cream; 0.01%		34	18	acne vulgaris					18			29	day		
8536	9990					Studied dose	%	0.01		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/32017149	Homo sapiens						20				100 ug/g cream; 0.01%		34		acne vulgaris					18			29	day		
8537	9991					Studied dose	mg	300		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14431862	Homo sapiens												61	19	hypertension					19			4	month		
8538	9997					Highest studied dose	mg	800		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053023	Homo sapiens						58							4						58						
8539	9997					MTD	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053022	Homo sapiens						58							27						58						
8540	9997					Recommended	mg	300		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf	Homo sapiens						54		1000 mg/m2 orally twice daily on Days 1 through 14 of every 21-day cycle				82	404		loading dose of 8 mg/kg on Day 1 of Cycle 1 if needed and then a maintenance dose of 6 mg/kg on Day 1 of every 21-day cycle			trastuzumab	22			5.8	month	capecitabine	
8541	10003					Highest studied dose	mg	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29247021/	Homo sapiens						62							7	solid tumors								21	day		
8542	10003					MTD	mg	600		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/32729890/	Homo sapiens						64							1	lung adenocarcinoma					64			10	day		
8543	10003					MTD	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29247021/	Homo sapiens						62							115	solid tumors								21	day		
8544	10003					MTD	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29247021/	Homo sapiens						62							7	solid tumors								21	day		
8545	10003					Studied dose	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29247021/	Homo sapiens						62							4	solid tumors								21	day		
8546	10005		ADULT			Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/34801738/	Homo sapiens						46.08							60	COVID19								14	day		p.64
8547	10007					Studied dose	g	0.5		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/18911201	Homo sapiens						2				The daily dose varied from 0.75 to 1.5 Gm. per day for the child.			1						2			9	day		
8548	10007					Studied dose	g	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18911201	Homo sapiens										The daily dose varied from 0.5 to 6.0 Gm. per day for the adults. The total doses, which varied from 26.5 to 221 Gm., were given over periods ranging from nine to fifty-four days		76	8						51			9	day		
8549	10007						%	10		multiple					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/13366677	Homo sapiens						21							1	burns	0.005			acetic acid	21			4	day	penicillin	
8550	10007						g	10		multiple					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/18911201	Homo sapiens							total			10 cc. of a 20 per cent solution morning and evening, and gave up to 10 Gm. by this route															
8551	10009		adult			Recommended	g	2		multiple			day	3	healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000ClinPharmR.pdf	Homo sapiens													26		2 g; 3 per day for 2 days			Meropenem				2	day		2017/209776Orig1s000ClinPharmR.pdf - p.132
8552	10009		adult			Recommended	g	2		multiple			day	3	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000MedR.pdf	Homo sapiens										up to 14 days			295		2 g; 3 per day up to 14 days			Meropenem				14	day		209776Orig1s000MedR.pdf - p.192
8553	10009					Highest studied dose|Recommended	g	2		multiple			day	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209776Orig1s000ClinPharmR.pdf	Homo sapiens										Meropenem 2 g and vaborbactam 2 g administered every 8 hours by intravenous (IV) infusion over 3 hours is the highest dose regimen evaluated					2 g; 3 per day for 5 days			Meropenem				5	day		209776Orig1s000ClinPharmR.pdf - p.147
8554	10010		ADULT			Highest studied dose	mg/m2	4900		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12698178	Homo sapiens						58				20-min  intravenous  infusion			1	cancer											p.1162
8555	10010		ADULT			MTD	mg/m2	3700		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12799625	Homo sapiens						55				DMXAA was administered every 3 weeks as a 20-min i.v. infusion.			7	cancer											p.1847
8556	10010		ADULT			MTD	mg/m2	3700		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12698178	Homo sapiens						58				20-min  intravenous  infusion			3	cancer											p.1162
8557	10010					Highest studied dose	mg/m2	4900		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12799625	Homo sapiens						55				DMXAA was administered every 3 weeks as a 20-min i.v. infusion.			3	cancer											p.1847
8558	10029		adult			Highest studied dose	mg	850		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3011	Homo sapiens										and 1 week of rest				solid tumors								14	day		
8559	10029		adult			MTD	mg	600		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3011	Homo sapiens										and 1 week of rest				solid tumors								14	day		
8560	10029					Studied dose	mg	350		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3013	Homo sapiens						63				and 1 week of rest			24	solid tumors								14	day		
8561	10029					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3013	Homo sapiens						63				and 1 week of rest			6	solid tumors								14	day		
8562	10030					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26957110	Homo sapiens						43							15	C virus genotype 1–4 infection					43			3	day		
8563	10031		ADULT			Highest studied dose	mg	120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24583798	Homo sapiens						60						80	7	cancer					23						p.2447
8564	10031		ADULT			MTD	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens						62						78	6	cancer					29						p.4
8565	10031		ADULT			MTD	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24583798	Homo sapiens						60						80	25	cancer					23						p.2447
8566	10031		ADULT			MTD	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens						56						78	15	cancer					35						p.4
8567	10031		ADULT			MTD	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24583798	Homo sapiens						60						80	19	cancer					23						p.2448
8568	10031		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24583798	Homo sapiens						60						80	7	cancer					23						p.2447
8569	10031		ADULT			Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens						62						78	6	cancer					29						p.4
8570	10031		ADULT			Studied dose	mg	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28417284	Homo sapiens						56						78	6	cancer					35						p.4
8571	10052					Highest studied dose	mg	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25153538	Homo sapiens						56							6	locally advanced, or metastatic NSCLC					56			14	month		
8572	10052					Highest studied dose	mg	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25153538/	Homo sapiens						56							6	locally advanced, or metastatic NSCLC					56			14	month		
8573	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						53							253	ALK-positive non-small cell lung cancer					53			9.3	month		
8574	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							134	ALK-positive NSCLC					56			17.9	month		
8575	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							143	ALK-positive NSCLC					56			17.9	month		
8576	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							146	ALK-positive NSCLC					56			17.9	month		
8577	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							147	ALK-positive NSCLC					56			17.9	month		
8578	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							152	ALK-positive NSCLC					56			17.9	month		
8579	10052					Recommended	mg	600		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf	Homo sapiens						56							253	ALK-positive non-small cell lung cancer					56			9.3	month		
8580	10053		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01810380	Homo sapiens							max			Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.			150	Schizophrenia								6	week		
8581	10053		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03257865	Homo sapiens							max|total daily dose			Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.			162	Bipolar I Disorder								3	week		
8582	10053		adult				mg	4		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT03259555	Homo sapiens							max|total daily dose			Brexpiprazole was administered orally with flexible dosing from 2 to 4 mg/day; titrated to a maximum of 4 mg/day for 3 weeks.			158	Bipolar I Disorder								3	week		
8583	10053					Highest studied dose	mg	5		steady			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						48							1	Schizophrenia					48			42	day		p. 118
8584	10053					Recommended	mg	4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30319261	Homo sapiens												65	477	Schizophrenia					18			6	week		
8585	10053						mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						39.7	max			pivotal trials			341	Schizophrenia					39.7			6	week		p. 132
8586	10053						mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						43.9	max			pivotal trials			182	Schizophrenia					43.9			6	week		p. 132
8587	10053						mg	2		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						43.9	max			pivotal trials			949	Schizophrenia					43.9			6	week		p. 132
8588	10053						mg	4		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						38.8	max			pivotal trials			822	Schizophrenia					38.8			6	week		p. 132
8589	10053						mg	4		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205422Orig1Orig2s000MedR.pdf	Homo sapiens						39.5	min			pivotal trials			93	Schizophrenia					39.5			6	week		p. 132
8590	10055		adult			Overdose	mg	562.5		single			day	1	unknown	oral			https://pubmed.ncbi.nlm.nih.gov/321205/	Homo sapiens								200 mg; oral; 1/day					1		3187.5 mg; oral; 1/day			trans-doxepin				1	day	diazepam	
8591	10055					Recommended	mg	0.45		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036Orig1s000MedR.pdf	Homo sapiens										mean duration			313	insomnia	2.55 mg; oral; 1/day			trans-doxepin				2	month		
8592	10055					Recommended	mg	0.9		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036Orig1s000MedR.pdf	Homo sapiens													730	insomnia	5.1 mg; oral; 1/day			trans-doxepin				1	month		
8593	10056					Highest studied dose	mg	125		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27424159	Homo sapiens						60				once daily with oral cobimetinib on Days 1–14 of a 28-day cycle (14/14)				metastatic or unresectable solid tumors					60			14	day		
8594	10056					Highest studied dose	mg	80		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27424159	Homo sapiens						60				once daily with oral cobimetinib on Days 1–21 of a 28-day cycle (21/7)			27	metastatic or unresectable solid tumors					60			21	day		
8595	10056					MTD	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27424159	Homo sapiens						60				once daily with oral cobimetinib on Days 1–14 of a 28-day cycle (14/14)			29	metastatic or unresectable solid tumors					60			14	day		
8596	10056					MTD	mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27424159 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206192Orig1s000MedR.pdf	Homo sapiens						60				once daily with oral cobimetinib on Days 1–21 of a 28-day cycle (21/7)			27	metastatic or unresectable solid tumors					60			21	day		
8597	10056					Recommended	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf	Homo sapiens						55						88	185	BRAF V600 mutation-positive, unresectable or metastatic melanoma	960 mg twice daily on Days 1 -28			vemurafenib	23			21	day		
8598	10056					Recommended	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf	Homo sapiens						55						88	213	BRAF V600 mutation-positive, unresectable or metastatic melanoma	960 mg twice daily on Days 1 -28			vemurafenib	23			21	day		
8599	10056					Recommended	mg	60		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf	Homo sapiens						55						88	247	BRAF V600 mutation-positive, unresectable or metastatic melanoma	960 mg twice daily on Days 1 -28			vemurafenib	23			21	day		
8600	10056						mg	40		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27424159	Homo sapiens						60				once daily with oral cobimetinib on Days 1–21 of a 28-day cycle (21/7)			27	metastatic or unresectable solid tumors					60			21	day		
8601	10057					Highest studied dose	mg	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27291448	Homo sapiens						14.6							8	type 2 diabetes mellitus					14.6						
8602	10057					Highest studied dose	mg	20		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21226818	Homo sapiens						62						70	12	type 2 diabetes mellitus					20			14	day		
8603	10057					Highest studied dose	mg	50		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21226818	Homo sapiens						24							8						24						
8604	10057					Recommended	mg	10		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30653152	Homo sapiens						23							1	type 2 diabetes mellitus					23			2	year		
8605	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02096705	Homo sapiens													139	Type 2 Diabetes								24	week		
8606	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02113241	Homo sapiens													12	Metabolic Syndrome								90	day		
8607	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02371187	Homo sapiens													18	Type 2 Diabetes								70	day		
8608	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02613897	Homo sapiens													22	Type 2 Diabetes								16	week		
8609	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02700334	Homo sapiens													12	Type 2 Diabetes								12	week		
8610	10057						mg	10		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT03006471	Homo sapiens													15	PreDiabetes								12	week		
8611	10057						mg	2.5		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00736879	Homo sapiens													74	Type 2 Diabetes								24	week		
8612	10058		adult				mg	15		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01203072	Homo sapiens													106	Venous Thromboembolism								2	week		
8613	10058		adult				mg	30		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01203072	Homo sapiens													103	Venous Thromboembolism								2	week		
8614	10058		adult				mg	5		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01203072	Homo sapiens													103	Venous Thromboembolism								2	week		
8615	10058		adult				mg	60		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01203072	Homo sapiens													106	Venous Thromboembolism								2	week		
8616	10058					Highest studied dose	mg	120		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens												55	9						18			10	day		
8617	10058					Highest studied dose	mg	150		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens												55	9						18						
8618	10058					Highest studied dose	mg	60		steady			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20081065	Homo sapiens												55	10						18			10	day		
8619	10058					Overdose	mg	750		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/32944263	Homo sapiens						57							1						57						
8620	10058					Recommended	mg	60		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Homo sapiens													5417									2.5	year		
8621	10058					Recommended	mg	60		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf	Homo sapiens																						2.5	year		
8622	10059		ADULT			Highest studied dose	ug	0.75		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30117129/	Homo sapiens													24												
8623	10059		ADULT			Studied dose	ug	0.75		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24101867/	Homo sapiens												92	528	osteoporosis					46			6	month		
8624	10060					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26496621/	Homo sapiens						47.3							44	secondary hypogonadism								16	week		
8625	10061		adult			Highest studied dose	mg	40		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	Homo sapiens																									
8626	10061					Highest studied dose	mg	32		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22516948	Homo sapiens						54							7	advanced solid tumours					54			28	day		
8627	10061					MTD	mg	25		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22516948	Homo sapiens						54							24	advanced solid tumours					54			28	day		
8628	10061					Recommended	mg	24		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf	Homo sapiens						64							261						64			16.1	month		
8629	10061					Recommended	mg	24		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000MedR.pdf	Homo sapiens						64							261						64			16.1	month		p. 108
8630	10061						mg	12.5		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22516948	Homo sapiens						54							21	advanced solid tumours					54			28	day		
8631	10061						mg	16		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22516948	Homo sapiens						54							30	advanced solid tumours					54			28	day		
8632	10061						mg	6.4		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22516948	Homo sapiens						54							21	advanced solid tumours					54			28	day		
8633	10065		ADULT			Highest studied dose	mg	100		multiple			week	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27225334/|https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	Homo sapiens												45	6						19			3	week		1528-1537|A284
8634	10065		ADULT			Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27225334/|https://watermark.silverchair.com/db13-859-1394.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAucwggLjBgkqhkiG9w0BBwagggLUMIIC0AIBADCCAskGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMpRKCKnm2m7NlCSluAgEQgIICmtryKcW28A77bCuwwqofqasx6X4wHcBYyJSSr8Do5NnWHRLnvht71slBiwROtTsoB7qDBscPrQvx07NBWC2tokZ14WogWAEq19BYXtZ7aXDVG6tr_0b5uLfc-thBwMGHVC1NYvOJZLQc4GE2m5Es4iCcJ-_MnJtuBwH7qiZYCZI6YlVBYvXBHTOe-ecNcGmo-GierZQo4lkxW1p14RnvpYaRMKMQ3AfUiyhCq_DEeRAH8Y7mfU0mB9C6x2am1cyiXoPixIV_m43h1QqsNHMDeYAqxnYW4bdn1nebwsQX99o8OmypbZkJ4WfrArFknYkua_0Bm43tRWbya2qeAhto7xU0S6BJsMqfPPmUca1qE-9kVSvpMUA_Cg37hqGn1CNB9Eoc6aZwYSbtp9D8QDnx-eJsTkJjiDyo6FCfASuvvcTC_YLVEBxsJTROS3bJFz2ohIot18TkZ8p0VhtQAHU-N2FdEMNckMS8GCvbgU0A2DdS72tWG3cVzdDulJxSYrEu-HoIq_kGyRzv9Wtv_edsoJiUUndpquI9s2hTt9W3Hbpzav8q7udmQq7ubVUGq_l75gEUZAk4oWPZChgWqi7PtAH63CQslmuC9iQsNiiDcfaznjYxR7iO3mStdA-I_iRKwTuvr4YTuvdGa5GJLMb8PKOCyDPHHHbToKr67MTBQe6_3X1rAGMmZqN_h7xswiqO8dRbzluw2cB5E3FBZBLj6f5pvwLw-I_7K5WCBAshIPnZr-llIbDu5g9cSfyKjVA6exPVqMs9Wdkx80Z4rbob8vJdLuvZa_Haa0D9556YxUUaH562aMu9EXj3VTgYZnRzW_vkd64d8HDM5FeZyQnRAY9osYOyTYd7v3MIpxsnN-TijL_VWAwi6WlCeA	Homo sapiens												45	6						19			1	day		1528-1537|A284
8635	10066					Highest studied dose	mg	240		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29074213	Homo sapiens						71							1	EGFR L858R–mutant metastatic lung adenocarcinoma					71			2	week		
8636	10066					Highest studied dose	mg	240		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000ClinPharmR.pdf	Homo sapiens													13	NSCLC											53
8637	10066					Recommended	mg	80		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf	Homo sapiens						63							411	EGFR T790M mutation-positive non-small cell lung cancer					63			6	month		
8638	10067		adult			Overdose	mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000MedR.pdf	Homo sapiens													1									13	day		p. 112
8639	10067		adult			Overdose	mg	250		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000MedR.pdf	Homo sapiens													1									21	day		p. 112
8640	10067					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22090362/	Homo sapiens						54							3						54			21	day		
8641	10067					MTD|RP2D	mg	125		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22090362/	Homo sapiens						54							22						54			21	day		
8642	10067					Recommended	mg	125		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207103s000lbl.pdf	Homo sapiens						63						89	83		2.5 mg/day			letrozole	38			21	day		
8643	10067						mg	150		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22090362/	Homo sapiens						54							3						54			21	day		
8644	10067						mg	75		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22090362/	Homo sapiens						54							7						54			21	day		
8645	10068		adult				mg	45		steady			2 weeks	3	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01034163	Homo sapiens										Participants received 45 mg orally 3 times a week (TIW), every other week (QOW)			26	Hodgkin's Lymphoma								23	month		
8646	10068					Highest studied dose	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21964801	Homo sapiens						63				weekly (days 1, 8) as a 30 min infusion. Each 21-day period was defined as one course			8	advanced solid tumors					63			21	day		
8647	10068					Highest studied dose|RP2D	mg/m2	34		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32338562	Homo sapiens										orally every other day, 3 days a week, every week. For each schedule, one cycle was considered 28 days.		21	11	relapsed and refractory hematologic malignancies					1			28	day		
8648	10068					Recommended|MTD	mg	20		multiple			week	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000CrossR.pdf	Homo sapiens						60				once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles		79	386		1.3 mg/m2			bortezomib	28			8	cycle	dexamethasone	p. 36, 45
8649	10068					Recommended|MTD	mg	20		multiple			week	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205353s000lbl.pdf	Homo sapiens										once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles												8	cycle		
8650	10068						mg/m2	15		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29987369	Homo sapiens							starting			weekly (days 1, 8) as a 30 min infusion starting at a dose of 15 mg/m2. Each 21-day period was defined as one course		17	9	refractory solid tumors					3			21	day		
8651	10069					Highest studied dose	mg	300		single					healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf	Homo sapiens						23							1						23						p. 30
8652	10069					Studied dose	mg	720		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30256537	Homo sapiens						26							6						26						
8653	10069						mg	20		single					healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf	Homo sapiens													1												p. 30
8654	10069						mg	200		single					healthy	intravenous	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208399Orig1s000MedR.pdf	Homo sapiens													1												p. 30
8655	10069						mg	200		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21385988	Homo sapiens						47.4							104						47.4						
8656	10070					Highest studied dose	mg	3000		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/26898300 |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000ClinPharmR.pdf	Homo sapiens													10									102	day		18
8657	10070					MTD	mg	800		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													150									18	month		104
8658	10070					MTD	mg	800		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													150									18	month		105
8659	10070					MTD	mg	800		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													150									18	month		106
8660	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf	Homo sapiens													79	locally advanced BCC								18	month		
8661	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		104
8662	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		106
8663	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266Orig1s000lbl.pdf|https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		106
8664	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		104
8665	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		106
8666	10070					Recommended	mg	200		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205266Orig1s000MedR.pdf	Homo sapiens													79	locally advanced BCC								18	month		107
8667	10071					Highest studied dose	mg	480		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000MedR.pdf	Homo sapiens												54	9						24			1	day		
8668	10071					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000MedR.pdf	Homo sapiens						75							176	transthyretin mediated amyloidosis								30	month		
8669	10071					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf	Homo sapiens						75							176	transthyretin mediated amyloidosis								30	month		
8670	10071						mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22843282/	Homo sapiens						39.8							65	transthyretin familial amyloid polyneuropathy								18	month		
8671	10071						mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24101373/	Homo sapiens						63.1							21	non-Val30Met transthyretin amyloidosis								12	month		
8672	10071						mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000MedR.pdf	Homo sapiens						75							88	transthyretin mediated amyloidosis								30	month		
8673	10071						mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf	Homo sapiens						75				average of 538 days (ranging from 15 to 994 days)			127	transthyretin mediated amyloidosis								538	day		
8674	10071						mg	50		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211996Orig1s000,%20212161Orig1s000MedR.pdf	Homo sapiens						75	mean						264	transthyretin mediated amyloidosis								30	month		
8675	10073		ADULT			Highest studied dose	mg	180		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24214189/	Homo sapiens												59	6						47			1	day		446-52
8676	10073		ADULT			Highest studied dose	mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30219951/	Homo sapiens						50.7	max|total daily dose						13	hyperuricemia								16	week		1135-43
8677	10075		ADULT			Highest studied dose	mg	400		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21609207/	Homo sapiens						35.8							25									5	day		p.1459
8678	10075		ADULT			Recommended	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17373638/	Homo sapiens						53.6							155	type 2 diabetes								24	week		p.222
8679	10078					Highest studied dose	mg	100		multiple			day	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/17002607	Homo sapiens						31				In this study, a treatment course consisted of 5 consecutive days of once-daily subcutaneous injections of HE2000, followed by a 37-day observation period. Subjects received up to three 5-day treatment courses over a 19-week period			9	Human immunodeficiency virus 1 infection								5	day		p.1085
8680	10079		ADULT			Highest studied dose	mg/kg	12		multiple			day	6	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/31625480	Homo sapiens										every 4 h (6 administrations in total)		55	6						18			1	day		p.155
8681	10079		ADULT			MTD	mg/kg	6		multiple			day	6	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/31625480	Homo sapiens										every 4 h (6 administrations in total)		55	6						18			1	day		p.155
8682	10081		ADULT			Highest studied dose	mg/m2	53		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11304786	Homo sapiens						58				72-hour continuous intravenous infusion			9	cancer								3	day		p.2329
8683	10081		ADULT			Highest studied dose	mg/m2	90		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17429623	Homo sapiens													4	cancer								2	cycle		p.6
8684	10081		ADULT			MTD	mg/m2	70		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17429623	Homo sapiens													6	cancer	60 mg/m(2) IV irinotecan on days 1 and 8 in a 21-day cycle			irinotecan				2	cycle		p.6
8685	10081		ADULT			RP2D	mg/m2	42.5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11304786	Homo sapiens						58				72-hour continuous intravenous infusion			11	cancer								3	day		p.2322
8686	10083		adult			MTD	mg/m2	105		multiple			week	4	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/23790467/	Homo sapiens										4 days on/3 days off			3	solid tumors								3	week		
8687	10083		adult			MTD	mg/m2	75		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/23790467/	Homo sapiens										14 days on/7 days off			7	solid tumors								3	week		
8688	10083					MTD	mg/m2	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26482040/	Homo sapiens						66				5 days/week			5	Lymphoma								3	week		
8689	10083					MTD	mg/m2	45		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26482040/	Homo sapiens						66				7 days/week every other week			3	Lymphoma								3	week		
8690	10083					MTD	mg/m2	45		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26482040/	Homo sapiens						67				7 days/week every other week			30	Lymphoma								3	week		
8691	10083					MTD	mg/m2	60		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25600050/	Homo sapiens						54.3				14 days on/7 days off			3	B-cell lymphoma | chronic lymphocytic leukaemia								2	week		
8692	10083					Studied dose	mg/m2	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25600050/	Homo sapiens						48.7				14 days on/7 days off			6	B-cell lymphoma | chronic lymphocytic leukaemia								2	week		
8693	10083					Studied dose	mg/m2	45		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26482040/	Homo sapiens						66				5 days/week			7	Lymphoma								3	week		
8694	10083					Studied dose	mg/m2	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25600050/	Homo sapiens						60.8				three 4-day treatment periods			5	B-cell lymphoma | chronic lymphocytic leukaemia								3	week		
8695	10083					Studied dose	mg/m2	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25600050/	Homo sapiens						66				two five-day treatment periods			3	B-cell lymphoma | chronic lymphocytic leukaemia								3	week		
8696	10083					Studied dose	mg/m2	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26482040/	Homo sapiens						66				7 days/week every other week			9	Lymphoma								3	week		
8697	10087					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25075128/	Homo sapiens						63							6	multiple myeloma								21	day		
8698	10087					MTD	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25075128/	Homo sapiens						63				median duration			55	multiple myeloma								103.5	day		
8699	10087					MTD	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27804235/	Homo sapiens						39				median duration			17	Langerhans cell histiocytosis								7	month		
8700	10088					Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26084989/	Homo sapiens										7 days in 21-day cycle		74	6	cancer					21			2.5	cycle		
8701	10088					Highest studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24879333/	Homo sapiens										7 days in 21-day cycle		81	3	advanced, non-hematologic malignancies					34			2	cycle		
8702	10088					RP2D	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26084989/	Homo sapiens										7 days in 21-day cycle		74	30	cancer					37			1	cycle		
8703	10088					RP2D	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24879333/	Homo sapiens										7 days in 21-day cycle		81	12	advanced, non-hematologic malignancies					34			2	cycle		
8704	10088					Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27502708/	Homo sapiens										7 days in 21-day cycle		84	72	advanced/metastatic sarcoma					20			4	cycle		
8705	10088					Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30707661/	Homo sapiens										7 days in 21-day cycle		82	137	Relapsed or Refractory Peripheral T-Cell Lymphoma					19			4	cycle		
8706	10093					Highest studied dose	mg/m2	162		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24355079	Homo sapiens						61				a continuous 72h infusion every 21 days			3	Leukemia								3	day		p.7
8707	10093					MTD	mg/m2	108		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24355079	Homo sapiens						61				a continuous 72h infusion every 21 days			6	Leukemia								3	day		p.6
8708	10093					MTD	mg/m2	9		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens						63.1				continuous central venous infusion over 3 days			18	Cancer								3	day		p.1309
8709	10093					Studied dose	mg/m2	12		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22015452	Homo sapiens						63.1				continuous central venous infusion over 3 days			6	Cancer								3	day		p.1309
8710	10094					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23827726	Homo sapiens						64.1							61	COPD								4	week		p.1725
8711	10096					Studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28615371	Homo sapiens						66				21 day cycle			15	Cancer								21	day		p.5
8712	10099					Highest studied dose	mg	480		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20310049/	Homo sapiens						57						77	5	chronic myeloid leukemia					18			24	month		
8713	10099					RP2D	mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20310049/	Homo sapiens						57	unknown					77	17	CML - chronic Myelogenous Leukemia					18			24	month		
8714	10100		ADULT			Highest studied dose	mg	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22661287	Homo sapiens						56	total			two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle  (110 mg/day, days 1, 2, 15 and 16).			5	cancer								2	day		p.375
8715	10100		ADULT			MTD	mg	1200		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21976672	Homo sapiens						68	total			continuous 7-day infusion every 21 days			6	acute myeloid leukemia								7	day		
8716	10100		ADULT			MTD	mg	150		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22661287	Homo sapiens						63	total			48-h continuous infusion every 14 days of a 28-day cycle.			20	cancer								2	day		p.375
8717	10100		ADULT			MTD	mg	220		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22661287	Homo sapiens						56	total			two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle  (110 mg/day, days 1, 2, 15 and 16).			6	cancer								2	day		p.375
8718	10100		ADULT			Studied dose	mg	1600		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21976672	Homo sapiens						68	total			continuous 7-day infusion every 21 days			6	acute myeloid leukemia								7	day		
8719	10100		ADULT			Studied dose	mg	225		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22661287	Homo sapiens						63	total			48-h continuous infusion every 14 days of a 28-day cycle.			4	cancer								2	day		p.375
8720	10101		ADULT			MTD	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens						60				Bardoxolone methyl was administered orally once daily for 21 days of a 28-day cycle for up to 12 cycles.			25	cancer								21	day		p.7
8721	10101					Highest studied dose	mg	1300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens						60				Bardoxolone methyl was administered orally once daily for 21 days of a 28-day cycle for up to 12 cycles.			6	cancer								21	day		p.7
8722	10103					Highest studied dose	mg	200		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17596104/	Homo sapiens												54	6						19			10	day		
8723	10103					Highest studied dose	mg	250		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17576843/	Homo sapiens												55	6						18						
8724	10104					Highest studied dose	mg	325		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22658814	Homo sapiens						62				1-hour infusion, up to 6 cycles			3	Non-small-cell lung cancer	500 mg/m2			pemetrexed, i.v				6	cycle		p.21
8725	10104					MTD	mg	200		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18955456	Homo sapiens						61				1-hour infusion			25	Cancer											p.5513
8726	10104					MTD	mg	200		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18955456	Homo sapiens						61							25	Cancer											p.5513
8727	10104					MTD	mg	300		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22658814	Homo sapiens						62				1-hour infusion, up to 6 cycles			11	Non-small-cell lung cancer	500 mg/m2			pemetrexed, i.v				6	cycle		p.21
8728	10104					Studied dose	mg	250		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18955456	Homo sapiens						61				1-hour infusion			6	Cancer											p.5513
8729	10105					Highest studied dose	mg/m2	63		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26333381/	Homo sapiens						58.5				4-week dosing cycle			3	solid tumors								21	day		
8730	10105					MTD	mg/m2	47		multiple			week	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/26566079/	Homo sapiens						59				4-week dosing cycle			11	ovarian cancer								21	day		
8731	10105					MTD	mg/m2	47		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26333381/	Homo sapiens						58.5				4-week dosing cycle			6	solid tumors								21	day		
8732	10109		adult			Highest studied dose	mg	250		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/23490650/	Homo sapiens													4	advanced or metastatic solid tumours								9	week		
8733	10109		adult			Highest studied dose	mg	300		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/23490650/	Homo sapiens													6	advanced or metastatic solid tumours								9	week		
8734	10109		adult			MTD	mg	200		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/23490650/	Homo sapiens													62	advanced or metastatic solid tumours								9	week		
8735	10109					Highest studied dose	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22878519/	Homo sapiens												65	3	advanced or metastatic solid tumors					33			29	day		
8736	10109					Highest studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22878519/	Homo sapiens												65	6	advanced or metastatic solid tumors					33			29	day		
8737	10109					Studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22031621/	Homo sapiens						37							85												
8738	10113		adult			Highest studied dose	mg	125		multiple			day	1	healthy	oral	M		https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2982.2010.01548.x	Homo sapiens													6									14	day		
8739	10113		adult			Highest studied dose	mg	150		single			day	1	healthy	oral	M+F		https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2982.2009.01343_2.x	Homo sapiens													40									1	day		
8740	10113					Highest studied dose	mg	125		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26924243/	Homo sapiens						50				highest for the unhealthy human			6	type 1 diabetes mellitus								1	day		
8741	10113					Highest studied dose	mg	150		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28782145/	Homo sapiens						33.1							4									1	day		
8742	10115					Highest studied dose	mg	600		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31778267	Homo sapiens						56							8						56			3	month		
8743	10115					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf	Homo sapiens						71						90	334	Non-Small Cell Lung Cancer					49			6	month		
8744	10115					Recommended	mg	400		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213591Orig1s000MultidisciplineR.pdf	Homo sapiens						71						90	334	Non-Small Cell Lung Cancer					49			6	month		p. 135
8745	10115					Studied dose	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31778267	Homo sapiens						56							5						56			3	month		
8746	10115					Studied dose	mg	250		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31778267	Homo sapiens						56							4						56			3	month		
8747	10115					Studied dose	mg	450		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31778267	Homo sapiens						56							9						56			3	month		
8748	10118		ADULT			Highest studied dose	mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23299770	Homo sapiens													6	hepatocellular carcinoma											p.1
8749	10119		adult			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23968157/	Homo sapiens													24	mild cognitive impairment								12	week		
8750	10119					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22922591/ | https://pubmed.ncbi.nlm.nih.gov/28393633/	Homo sapiens						32.8							12									14	day		
8751	10122		ADULT			Highest studied dose	mg	250		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens						58.9							5	Non-small cell lung cancer	AUC = 6			paclitaxel						carboplatin	p.85
8752	10122		ADULT			MTD	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17031646	Homo sapiens						58.9							8	Non-small cell lung cancer	AUC = 6			paclitaxel						carboplatin	p.85
8753	10123					Highest studied dose	mg	340		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				Without-Food			5	solid tumors								28	day		
8754	10123					MTD	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				Film-Coated Treatment Cohort			5	solid tumors								28	day		
8755	10123					MTD	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				Without-Food			6	solid tumors								28	day		
8756	10123					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				With-Food			12	solid tumors								28	day		
8757	10123					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20959830/	Homo sapiens						55				median duration			25	solid tumors	75 mg/m2; IV; 1/3 weeks			Docetaxe				1.48	month		
8758	10123					Studied dose	mg	140		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				Film-Coated Treatment Cohort			3	solid tumors								28	day		
8759	10123					Studied dose	mg	280		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				Without-Food			7	solid tumors								28	day		
8760	10123					Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19738123/	Homo sapiens						58.6				With-Food			8	solid tumors								28	day		
8761	10123					Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20959830/	Homo sapiens						55				median duration			7	solid tumors	75 mg/m2; IV; 1/3 weeks			Docetaxe				3.45	month		
8762	10123					Studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20959830/	Homo sapiens						59		5 mg; oral; 2/day		median duration			9	solid tumors	75 mg/m2; IV; 1/3 weeks			Docetaxe				5.3	month	Axitinib	
8763	10125		adult			Highest studied dose|MTD	mg	1600		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3066	Homo sapiens													7	solid tumors											
8764	10125		adult			Studied dose	mg	1400		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3066	Homo sapiens													8	solid tumors											
8765	10125					MTD	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25707361/	Homo sapiens						62							12	solid tumors											
8766	10125					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26851029/	Homo sapiens						60				median duration			20	pancreatic neuroendocrine tumours								16.6	week		
8767	10125					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25707361/	Homo sapiens						62				median duration			2	solid tumors								8	week		
8768	10125					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26851029/	Homo sapiens						60				median duration			11	pancreatic neuroendocrine tumours								16.6	week		
8769	10125					Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25707361/	Homo sapiens						62				median duration			7	solid tumors								8	week		
8770	10125					Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25707361/	Homo sapiens						62				median duration; lead-in QD dosing			3	solid tumors								8	week		
8771	10127		ADULT			Highest studied dose	mg/m2	1000		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19825950	Homo sapiens						59.4				24-hour infusion every 14 days with G-CSF		81	7	cancer	Treatment with G-CSF (5μg/kg/daily) was started 24 h after the end of danusertib infusion\nand continued for 10 days (from Day 3 to Day 12) ending 48 h before the next infusion.			Filgrastim	35			3	cycle		p.5, 6, 16
8772	10127		ADULT			MTD	mg/m2	330		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19770380	Homo sapiens						54				Danusertib was administered intravenously on days 1, 8, and 15 every 28 days in 6-hour infusion schedule		75	8	cancer					22			3	week		p.5096, 5097
8773	10127		ADULT			MTD	mg/m2	500		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19825950	Homo sapiens						56.8				24-hour infusion every 14 days without G-CSF		80	12	cancer					27			3	cycle		p.5, 6, 16
8774	10127		ADULT			MTD	mg/m2	750		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19825950	Homo sapiens						59.4				24-hour infusion every 14 days with G-CSF		81	6	cancer	Treatment with G-CSF (5μg/kg/daily) was started 24 h after the end of danusertib infusion\nand continued for 10 days (from Day 3 to Day 12) ending 48 h before the next infusion.			Filgrastim	35			3	cycle		p.5, 6, 16
8775	10127		ADULT			Studied dose	mg/m2	330		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19770380	Homo sapiens						61				Danusertib was administered intravenously on days 1, 8, and 15 every 28 days in 3-hour infusion schedule		74	7	cancer					46			3	week		p.5096
8776	10127		ADULT			Studied dose	mg/m2	400		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19770380	Homo sapiens						54				Danusertib was administered intravenously on days 1, 8, and 15 every 28 days in 6-hour infusion schedule		75	4	cancer					22			3	week		p.5096
8777	10127		ADULT			Studied dose	mg/m2	580		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19825950	Homo sapiens						56.8				24-hour infusion every 14 days without G-CSF		80	6	cancer					27			2	cycle		p.5, 6, 16
8778	10127		ADULT			Studied dose	mg/m2	650		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19825950	Homo sapiens						56.8				24-hour infusion every 14 days without G-CSF		80	7	cancer					27			2	cycle		p.5, 6, 16
8779	10129					Highest studied dose	mg/m2	500		multiple			3 days	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21863237/	Homo sapiens						66				median duration;			1	solid tumors								42	day		
8780	10129					MTD	mg/m2	226		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17404093/	Homo sapiens						63				mean duration; 3-h infusion			4	solid tumors								58	day		
8781	10129					MTD	mg/m2	400		multiple			3 days	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21863237/	Homo sapiens						66				median duration;			6	solid tumors								42	day		
8782	10129					Studied dose	mg/m2	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17404093/	Homo sapiens						63				mean duration; 3-h infusion			3	solid tumors								35	day		
8783	10131		ADULT			Highest studied dose	mg	15		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21641345	Homo sapiens						75.9				1 hour intravenous infusions every 12 hours for 3 days			9	heart disease								3	day		p.1016
8784	10131		ADULT			Highest studied dose	mg	15		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19919976	Homo sapiens						56.9				1-hour infusion			22	heart disease											p.527
8785	10135					Highest studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27214664	Homo sapiens							unknown					75	76	Parkinson disease					30			4	week		
8786	10137		ADULT			Studied dose	mg/kg	100		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12118029/	Homo sapiens						58				Patients received daily RSR13 100 mg/kg intravenously infused for 30 minutes immediately before cranial RT (60 Gy in 30 fractions).			50	glioblastoma multiforme											p.3151
8787	10140		ADULT			Highest studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31887369	Homo sapiens							unknown						106	non-alcoholic steatohepatitis								72	week		
8788	10142		ADULT			Highest studied dose	mg	1200		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27785737	Homo sapiens						32							8									7	day		p.199
8789	10142		ADULT			Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25696919	Homo sapiens						73						89	186	chronic lymphocytic leukemia					51			36	week		
8790	10144		adult			Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M		https://academic.oup.com/schizophreniabulletin/article-abstract/46/Supplement_1/S43/5839265	Homo sapiens													24	schizophrenia								8	week		
8791	10144					Highest studied dose	mg	500		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27136911/ | https://www.clinicaltrials.gov/ProvidedDocs/56/NCT01874756/Prot_SAP_000.pdf	Homo sapiens						44.3							39									1	day		
8792	10147					Highest studied dose	mg	3000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19398716	Homo sapiens										Patients received ezatiostat tablets in divided doses on days 1 to 7 of a 21-day cycle for a maximum of 8 cycles.			12	myelodysplastic syndrome								7	day		p.6537
8793	10148		ADULT			Highest studied dose	mg	450		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31797578	Homo sapiens						38							47									7	day		p.6
8794	10149		adult			Highest studied dose	mg	120		single			day	1	healthy	oral	M		https://link.springer.com/article/10.1111/j.1479-8425.2011.00518.x	Homo sapiens													16									1	day		
8795	10149					Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26979830/ | https://www.nature.com/npp/articles?type=abstract&year=2011	Homo sapiens						48.3							81	insomnia								4	week		
8796	10149					Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25106663/	Homo sapiens						42.5							120	migraine								3	month		
8797	10149					Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26979830/ | https://www.nature.com/npp/articles?type=abstract&year=2011	Homo sapiens						45.4							80	insomnia								4	week		
8798	10149					Studied dose	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26979830/ | https://www.nature.com/npp/articles?type=abstract&year=2011	Homo sapiens						47.3							79	insomnia								4	week		
8799	10149					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26979830/ | https://www.nature.com/npp/articles?type=abstract&year=2011	Homo sapiens						46.4							78	insomnia								4	week		
8800	10153		ADULT			Highest studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23054208	Homo sapiens						52.8							3	cancer								28	day		p.745
8801	10153		ADULT			MTD	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23054208	Homo sapiens						52.8							25	cancer								28	day		p.745
8802	10155					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28934680/	Homo sapiens						66.3				the median number of cycles completed was 6			5	myelofibrosis | polycythemia vera | essential thrombocythemia								28	day		
8803	10155					MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28934680/	Homo sapiens						66.3				the median number of cycles completed was 6			34	myelofibrosis | polycythemia vera | essential thrombocythemia								28	day		
8804	10155					MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30025280/	Homo sapiens						65.5				median duration			138	myeloproliferative neoplasms								497	day		
8805	10156		ADULT			Highest studied dose	mg	800		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21451120	Homo sapiens													8												
8806	10156		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20151971	Homo sapiens						59.3							64	hypertonic bladder								12	week		p.671
8807	10157		adult			MTD	mg	100		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32047238/	Homo sapiens							median			4-week cycle			35	polycythemia vera								6	cycle		
8808	10157		adult			MTD	mg	100		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32047238/	Homo sapiens										4-week cycle			35	polycythemia vera								6	cycle		
8809	10157					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19633847/	Homo sapiens												75	6	multiple myeloma					45			1	cycle		
8810	10157					MTD	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19633847/	Homo sapiens							min					75	6	multiple myeloma					45			2	cycle		
8811	10157					MTD	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19633847/	Homo sapiens												75	19	multiple myeloma					45			6	week		
8812	10158					Highest studied dose	mg	640		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25388167	Homo sapiens						61							8	Advanced Solid Tumors					61			28	day		
8813	10158					MTD	mg	320		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25388167	Homo sapiens						61							7	Advanced Solid Tumors					61			28	day		
8814	10158					MTD	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26688487	Homo sapiens						69							9	myeloid malignancies					69			28	day		
8815	10158						mg	100		multiple			day	1	pregnant	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf	Homo sapiens																									
8816	10158						mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26688487	Homo sapiens						69							5	myeloid malignancies					69			28	day		
8817	10158						mg	80		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26688487	Homo sapiens						69							8	myeloid malignancies					69			28	day		
8818	10164		ADULT			Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22814748/	Homo sapiens						49							59	metabolic disease								12	week		
8819	10166		ADULT			Highest studied dose	mg	4		multiple			day	1	unhealthy	transdermal	F		https://pubmed.ncbi.nlm.nih.gov/17351746/	Homo sapiens						35.8						48	45	pain disorder					19						p.393, 394
8820	10167		ADULT			Highest studied dose	mg/kg	4		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/19116277	Homo sapiens																									p.264
8821	10170		adult			Studied dose	mg	125		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/34358484/	Homo sapiens										21 days of 28-day treatment cycle			108	advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements								1	cycle		
8822	10173					Highest studied dose	mg	80		single			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23797179/	Homo sapiens						64.4							6	breast cancer								1	day		
8823	10173					Highest studied dose|MTD	mg	80		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23797179/	Homo sapiens						64.4							6	breast cancer								28	day		
8824	10173					Studied dose	mg	40		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23797179/	Homo sapiens						65.2							13	breast cancer								28	day		
8825	10173					Studied dose	mg	40		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27870712/	Homo sapiens						68.1							36	Endometrial Cancer								2	year		
8826	10176					Highest studied dose	mg/m2	1120		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11751480	Homo sapiens						55				continuous i.v. infusion for 7 days every 3 weeks; 6 courses			4	Cancer								7	day		p.3898
8827	10176					MTD	mg/m2	280		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15328183	Homo sapiens						59				L-778,123 was given by continuous intravenous infusion with concomitant radiotherapy to 59.4 Gy in standard fractions. 280 mg/m2/day over weeks 1, 2, 4, and 5.			8	Pancreatic cancer											p.5452
8828	10176					Studied dose	mg/m2	560		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15328183	Homo sapiens						59				L-778,123 was given by continuous intravenous infusion with concomitant radiotherapy to 59.4 Gy in standard fractions. 560 mg/m2/day over weeks 1, 2, 4, 5, and 7.			4	Pancreatic cancer											p.5451
8829	10177		ADULT			Highest studied dose	mg	3000		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25113756	Homo sapiens						53				CL-161 was administered orally, once weekly in 21-day cycles		60	2	cancer					46			2	cycle		p.3, 4
8830	10177		ADULT			RP2D	mg	1800		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25113756	Homo sapiens						57						77	24	cancer					27			2	cycle		p.3, 4
8831	10177		ADULT			Studied dose	mg	2100		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25113756	Homo sapiens						41				CL-161 was administered orally, once weekly in 21-day cycles		48	2	cancer					34			2	cycle		p.3, 4
8832	10179		adult			Studied dose	mg	150		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/26972330/	Homo sapiens													5	cancer											
8833	10179					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31792037/	Homo sapiens												62	20	Gastrointestinal Stromal Tumors					18			7.7	month		
8834	10179					Studied dose	mg	150		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27694157/	Homo sapiens												79	28	small-cell lung cancer					37			4.2	month		
8835	10180					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29074098	Homo sapiens						51							3						51			7	day		
8836	10180					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf	Homo sapiens						53						85	295	non-small cell lung cancer (NSCLC)					19			12.5	month		
8837	10180					Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000MultidisciplineR.pdf	Homo sapiens						53						85	295	non-small cell lung cancer (NSCLC)					19			12.5	month		p. 164
8838	10181					MTD	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25193991/	Homo sapiens						56.5							7	solid tumors								28	day		
8839	10181					Studied dose	mg	10		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30684019/	Homo sapiens						64							3	breast cancer	500 mg; IM: monthly			fulvestrant				28	day		
8840	10181					Studied dose	mg	15		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31619444/	Homo sapiens						32	starting			median duration			16	breast cancer								57	day		
8841	10183					Highest studied dose	mg	24		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens						56.5							3	solid tumors								56	day		
8842	10183					MTD	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28589492/	Homo sapiens						56.5							6	solid tumors								56	day		
8843	10185		ADULT			MTD	ug/kg	250		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15014352	Homo sapiens						64							3	pancreatic cancer								30	min		p.206
8844	10185		ADULT			Studied dose	ug/kg	50		multiple			day	2	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/15014352	Homo sapiens						59							6	pancreatic cancer											p.206
8845	10188					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						62.8				median duration (2-week cycle, i.e. 7 days on/7 days off)			1	solid tumors								7.1	week		
8846	10188					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						56.8				median duration in 4-week cycles, i.e. 4 days on/3 days off x 3wks			5	solid tumors								8	week		
8847	10188					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						62.8				median duration (2-week cycle, i.e. 7 days on/7 days off)			6	solid tumors								7.1	week		
8848	10188					Studied dose	mg	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						56.8				median duration in 4-week cycles, i.e. 4 days on/3 days off x 3wks			6	solid tumors								8	week		
8849	10188					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						56.8				median duration in 4-week cycles, i.e. 4 days on/3 days off x 3wks			4	solid tumors								8	week		
8850	10188					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22160853/	Homo sapiens						62.8				median duration (2-week cycle, i.e. 7 days on/7 days off)			6	solid tumors								7.1	week		
8851	10188					Studied dose	mg/m2	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28424962/	Homo sapiens						61				7 days on/7 days off			10	solid tumors	1000 mg/m2; IV; 1/w			gemcitabine				4	week		
8852	10191		ADULT			MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33863809	Homo sapiens							starting			once daily on days 1-5 and 8-12 of each 21-day cycle			6	solid tumor								21	day		
8853	10191		ADULT			Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33863809	Homo sapiens							starting			once daily on days 1-5 and 8-12 in 21-day cycles.			3	solid tumour								21	day		
8854	10191					MTD	mg	225		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25964244	Homo sapiens						52	unknown			for 2.5 days per week for 2 consecutive weeks		78	19	solid tumors					22			2	week		
8855	10191					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25964244	Homo sapiens							unknown			for 2.5 days per week for 2 consecutive weeks			3	solid tumors								2	week		
8856	10192		ADULT			Highest studied dose	mg	300		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens						59						75	3	cancer					32						p.5, 25
8857	10192		ADULT			MTD	mg	200		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens						59						75	17	cancer					32						p.5, 25
8858	10192		ADULT			MTD	mg	60		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens						56				MK-2206 was administered on alternate days in 28-day cycles		84	20	cancer					25						p.4690
8859	10192		ADULT			MTD	mg	60		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25239610	Homo sapiens						63				MK-2206 tablets were administered at 60mg QOD in 28-day cycles		75	38	cancer					39						sup. table1
8860	10192		ADULT			Studied dose	mg	90		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22025163	Homo sapiens						56				MK-2206 was administered on alternate days in 28-day cycles		84	7	cancer					25						p.4690
8861	10193		ADULT			Highest studied dose	mg	110		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22033282	Homo sapiens						28				mocetinostat was administered orally three times per week, in 28-day cycles			23	Hodgkin's lymphoma											p.6
8862	10193		ADULT			Highest studied dose	mg	110		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29238851	Homo sapiens						57							4	cancer	1000 mg/m2, day 1 of three consecutive weeks, 4-week cycles			gemcitabine							p.5
8863	10193		ADULT			MTD	mg	90		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29238851	Homo sapiens						57							4	cancer	1000 mg/m2, day 1 of three consecutive weeks, 4-week cycles			gemcitabine							p.5
8864	10194					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30559105/	Homo sapiens						59	starting			mean duration; adapted dose - 200 mg			29	Chronic kidney disease								95	day		
8865	10194					Highest studied dose	mg	50		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29575006/	Homo sapiens						32.3							9									1	day		
8866	10196					Highest studied dose	mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20006921/	Homo sapiens						62.5							12	pancreatic cancer	1000 mg/m2; IV; 1/week			gemcitabine				12	week		
8867	10196					Highest studied dose	mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28634650/	Homo sapiens						67				median overall survival			42	pancreatic cancer	1000 mg/m2; IV; 1/week			gemcitabine				7.2	month		
8868	10198					RP2D	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33236943	Homo sapiens						62	starting			150 mg orally daily on lead-in days 1 through 7, and proceeded to 250 mg daily on cycle 1, day 1 if the pre-dose platelet count was 50,000/mm3 and was stable or increasing.		86	15	Follicular lymphoma					44			7	day		
8869	10204					Highest studied dose	mg	2000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19625629	Homo sapiens							unknown						6												
8870	10204					Highest studied dose	mg	500		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30384375	Homo sapiens							unknown					48	6						22			6.5	day		
8871	10206					Highest studied dose	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16710023/	Homo sapiens						57				intermittent-dose schedule (14 days of a 28-day cycle)			7	solid tumors								14	day		
8872	10206					MTD	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18765554/	Homo sapiens						56				86 cycles			20	colorectal cancer	1000 mg/m2;oral:2/d			capecitabine				21	day		
8873	10206					MTD	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16710023/	Homo sapiens						57				intermittent-dose schedule (14 days of a 28-day cycle)			13	solid tumors								14	day		
8874	10206					MTD	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16710023/	Homo sapiens						60							13	solid tumors								28	day		
8875	10206					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16710023/	Homo sapiens						60							5	solid tumors								28	day		
8876	10206					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16710023/	Homo sapiens						57				intermittent-dose schedule (14 days of a 28-day cycle)			7	solid tumors								14	day		
8877	10206					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18765554/	Homo sapiens						56				131 cycles			6	colorectal cancer	750 mg/m2;oral:2/d			capecitabine				21	day		
8878	10206					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18765554/	Homo sapiens						56				42 cycles			7	colorectal cancer	750 mg/m2;oral:2/d			capecitabine				21	day		
8879	10206					Studied dose	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18765554/	Homo sapiens						56				6 cycles			4	colorectal cancer	1000 mg/m2;oral:2/d			capecitabine				21	day		
8880	10208					Highest studied dose	mg	40		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22044402	Homo sapiens												48	9						21						p.712
8881	10208					Highest studied dose	mg	8		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22044402	Homo sapiens												48	8						21			14	day		p.712
8882	10209					Studied dose	mg	30		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28122201	Homo sapiens						51	unknown						1												
8883	10210					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23539534/	Homo sapiens						65							48	Chronic obstructive pulmonary disease								6	week		
8884	10210					Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19720877/	Homo sapiens												55	6						18			1	day		
8885	10210					Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26265232/	Homo sapiens						34							17									1	day		
8886	10212					Highest studied dose	mg	930		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens						64						80	4	non-small cell lung carcinoma					27			1	week		
8887	10212					RP2D	mg	390		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens						64	unknown					80	5	non-small cell lung carcinoma					27			3	week		
8888	10212					Studied dose	mg	520		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26161618/	Homo sapiens						64						80	7	non-small cell lung carcinoma					27			1	week		
8889	10213					Highest studied dose	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/	Homo sapiens						59				every 28 days			3	solid tumors								21	day		
8890	10213					MTD	mg	330		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/ | https://pubmed.ncbi.nlm.nih.gov/27565810/	Homo sapiens						59				every 28 days			7	solid tumors								21	day		
8891	10213					MTD	mg	330		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/ | https://pubmed.ncbi.nlm.nih.gov/27565810/	Homo sapiens						59							10	solid tumors								28	day		
8892	10213					MTD	mg	340		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/ | https://pubmed.ncbi.nlm.nih.gov/27565810/	Homo sapiens						65							6	non-squamous non-small cell lung cancer								28	day		
8893	10213					Studied dose	mg	260		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27155741/	Homo sapiens						58							42	breast cancer	500 mg; IM; 1/2 or 4 weeks			fulvestrant				28	day		
8894	10213					Studied dose	mg	260		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/ | https://pubmed.ncbi.nlm.nih.gov/27565810/	Homo sapiens						66		200 mg/m2;IV; 1/3 weeks		22 days cycle			3	non-squamous non-small cell lung cancer	IV; 1/3 weeks		bevacizumab	carboplatin			15 mg/kg; IV; 1/3 weeks	15	day	paclitaxel	
8895	10213					Studied dose	mg	340		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/27155741/	Homo sapiens						60				28 day cycles			89	breast cancer	500 mg; IM; 1/2 or 4 weeks			fulvestrant				2	week		
8896	10213					Studied dose	mg	340		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25370471/ | https://pubmed.ncbi.nlm.nih.gov/27565810/	Homo sapiens						63		200 mg/m2;IV; 1/3 weeks		22 days cycle			4	non-squamous non-small cell lung cancer	IV; 1/3 weeks		bevacizumab	carboplatin			15 mg/kg; IV; 1/3 weeks	15	day	paclitaxel	
8897	10214		ADULT			Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21748252	Homo sapiens						38.6							37	attention deficit hyperactivity disorder								4	week		p.720
8898	10215					Highest studied dose	mg	24		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens												77	3	Advanced Solid Tumors					32			21	day		
8899	10215					Highest studied dose	mg	32		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens										14-day on, and 7-day off (intermittent schedule)		77	7	Advanced Solid Tumors					32			1	cycle		
8900	10215					MTD	mg	18		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens												77	6	Advanced Solid Tumors					32			21	day		
8901	10215					MTD	mg	24		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens										14-day on, and 7-day off (intermittent schedule)		77	18	Advanced Solid Tumors					32			1	cycle		
8902	10215					Studied dose	mg	12		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens							median			14-day on, and 7-day off (intermittent schedule)		77	55	Advanced Solid Tumors					32			1	cycle		
8903	10215					Studied dose	mg	12		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens							median					77	20	Advanced Solid Tumors					32			21	day		
8904	10215					Studied dose	mg	12		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens										14-day on, and 7-day off (intermittent schedule)		77	6	Advanced Solid Tumors					32			1	cycle		
8905	10215					Studied dose	mg	16		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28859471/	Homo sapiens										14-day on, and 7-day off (intermittent schedule)		77	6	Advanced Solid Tumors					32			1	cycle		
8906	10216		ADULT			MTD	mg	120		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28841236	Homo sapiens						70				Pracinostat was administered orally thrice weekly for 3 weeks on a 28-day cycle			6	Hematological tumors								3	week		p.5
8907	10216		ADULT			MTD	mg	80		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21385886	Homo sapiens						57				orally thrice weekly for 3 weeks in a 4-week cycle; median treatment duration of 2 cycles (range, 1–12 cycles)			6	cancer								3	week		p.2518
8908	10217		ADULT				mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20556817	Homo sapiens						54							74	rheumatoid arthritis								12	week		p.1590
8909	10218					Highest studied dose	mg	275		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24942404/	Homo sapiens						59		75 mg/m2;IV; 1/3 weeks		275 mg is about 150 mg/m2; 1-7 cycles			14	solid tumors	500 mg/m2; IV; 1/2 weeks			pemetrexed				21	day	cisplatin	
8910	10218					Highest studied dose	mg/m2	195		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22492020/	Homo sapiens						60				1-7 cycles			3	solid tumors	500 mg/m2; IV; 1/3 weeks			pemetrexed				21	day		
8911	10218					Highest studied dose	mg/m2	200		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27598338/	Homo sapiens						59				Mean number of completed cycles - 2.9			11	solid tumors	1000 mg/m2; IV; 1/week			gemcitabine				28	day		
8912	10218					Highest studied dose	mg/m2	250		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27598338/	Homo sapiens						59				Mean number of completed cycles - 2.9			6	solid tumors	1000 mg/m2; IV; 1/week			gemcitabine				28	day		
8913	10218					MTD	mg/m2	150		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22492020/	Homo sapiens						60				1-7 cycles			6	solid tumors	500 mg/m2; IV; 1/3 weeks			pemetrexed				21	day		
8914	10218					Studied dose	mg/m2	105		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22492020/	Homo sapiens						60				1-7 cycles			13	solid tumors	500 mg/m2; IV; 1/3 weeks			pemetrexed				21	day		
8915	10218					Studied dose	mg/m2	150		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27350064/	Homo sapiens						62				until disease progression			55	non-small cell lung cancer	500 mg/m2; IV; 1/3 weeks			pemetrexed				21	day		
8916	10221		adult			Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens													5	solid tumors								28	day		
8917	10221		adult			Studied dose	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens							mean			2-3 mg dose			6	solid tumors								28	day		
8918	10221		adult			Studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens													6	solid tumors								28	day		
8919	10221					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens						64.7							10	solid tumors								28	day		
8920	10221					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens						64.7							11	solid tumors								28	day		
8921	10221					MTD	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23434733/	Homo sapiens						57.8							10	solid tumors								28	day		
8922	10223		ADULT			Highest studied dose|Studied dose	mg	360		multiple			day	1	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf	Homo sapiens							starting			360 mg on first day followed by 120 mg once daily			622	prostate cancer								48	week		4/HERO
8923	10226					Highest studied dose	mg	160		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27646843/	Homo sapiens						63		40 mg; oral; 1/week		and 1 week of rest			6	multiple myeloma	25 mg; oral; 1/d			Lenalidomide				3	week	dexamethasone	
8924	10226					Highest studied dose	mg	360		multiple			3 weeks	10	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053023/	Homo sapiens						70	total daily dose						3	multiple myeloma								3	week		
8925	10226					Studied dose	mg	320		multiple			3 weeks	15	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27646843/	Homo sapiens						63	total daily dose	40 mg; oral; 1/week		and 1 week of rest; on days 1–5, 8–12, and 15–19			6	multiple myeloma	25 mg; oral; 1/d			Lenalidomide				3	week	dexamethasone	
8926	10229					Studied dose	mg	135		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22529266/	Homo sapiens							max			with 3 to 135 mg, 7 consecutive days every 3 weeks		81	47	Refractory Metastatic or Locally Advanced Solid Tumors					26			3	cycle		
8927	10229					Studied dose	mg	20		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25769658/	Homo sapiens										3 days on/4 days off each week		81	44	recurrent platinum-resistant epithelial ovarian cancer					26			3	cycle		
8928	10229					Studied dose	mg	270		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22529266/	Homo sapiens							max			with 3 to 270 mg, 3 consecutive days per week for 2 weeks every 3 weeks		81	58	Refractory Metastatic or Locally Advanced Solid Tumors					26			3	cycle		
8929	10231					Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29992354/	Homo sapiens										to 21 of a 28-day		80	3	relapsed/refractory solid tumors					43			2	cycle		
8930	10231					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22547163/	Homo sapiens										to 21 of a 28-day		80	9	pancreatic cancer					40			4	cycle		
8931	10231					Highest studied dose	mg	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25795639/	Homo sapiens										to 21 of a 28-day		85	2	refractory hematologic malignancies					35			2	cycle		
8932	10231					RP2D	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29992354/	Homo sapiens										to 21 of a 28-day		80	6	relapsed/refractory solid tumors					43			2	cycle		
8933	10232					Highest studied dose	mg	12		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26800393/	Homo sapiens						61				3 days on/4 days off			7	cancers								28	day		
8934	10232					Highest studied dose	mg	13		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						62				5 days on/2 days off			3	cancers								28	day		
8935	10232					Highest studied dose	mg	20		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						54				3 days on/4 days off			4	cancers								28	day		
8936	10232					Highest studied dose	mg	7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26800393/	Homo sapiens						61							8	cancers								28	day		
8937	10232					Highest studied dose	mg	7		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						61							8	cancers								28	day		
8938	10232					MTD	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26800393/	Homo sapiens						61							7	cancers								28	day		
8939	10232					MTD	mg	40		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						57							15	cancers								28	day		
8940	10232					MTD	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						61							13	cancers								28	day		
8941	10232					MTD	mg	7		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						62				5 days on/2 days off			6	cancers								28	day		
8942	10232					MTD	mg	9		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26800393/	Homo sapiens						61				3 days on/4 days off			6	cancers								28	day		
8943	10232					MTD	mg	9		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						54				3 days on/4 days off			8	cancers								28	day		
8944	10232					Studied dose	mg	10		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						62				5 days on/2 days off			13	cancers								28	day		
8945	10232					Studied dose	mg	12		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						54				3 days on/4 days off			6	cancers								28	day		
8946	10232					Studied dose	mg	16		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						54				3 days on/4 days off			12	cancers								28	day		
8947	10232					Studied dose	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32913286/	Homo sapiens						61							7	cancers								28	day		
8948	10232					Studied dose	mg	6		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26800393/	Homo sapiens						61							6	cancers								28	day		
8949	10233					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23589215/	Homo sapiens						57							3	solid tumors								21	day		
8950	10233					MTD	mg	240		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23589215/	Homo sapiens						57							6	solid tumors								21	day		
8951	10233					Studied dose	mg	160		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23589215/	Homo sapiens						57							6	solid tumors								21	day		
8952	10233					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23589215/	Homo sapiens						57							5	solid tumors								21	day		
8953	10233					Studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23589215/	Homo sapiens						57				4-week dosing cycle			8	solid tumors								21	day		
8954	10234		ADULT			Highest studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20805299	Homo sapiens						54							7	cancer								21	day		p.4879
8955	10234		ADULT			MTD	mg	175		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20805299	Homo sapiens						54							5	cancer								21	day		4879
8956	10234		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20805299	Homo sapiens						54							7	cancer								21	day		p.4879
8957	10235					Highest studied dose	mg	12		multiple			day	1	healthy	intranasal	M+F		https://pubmed.ncbi.nlm.nih.gov/23909699	Homo sapiens						40.1							10									14	day		p.781
8958	10235					Highest studied dose	mg	400		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17659837	Homo sapiens						39							19												p.135
8959	10238		ADULT			Highest studied dose	mg	1800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20822897	Homo sapiens						53				Schedule C: 3 d every 2 weeks			6	cancer								3	day		p.3246, 3247
8960	10238		ADULT			MTD	mg	1250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20822897	Homo sapiens						53				Schedule A: 5 d every 3 weeks			3	cancer								5	day		p.3245, 3246
8961	10238		ADULT			MTD	mg	1600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20822897	Homo sapiens						53				Schedule C: 3 d every 2 weeks			3	cancer								3	day		p.3246, 3247
8962	10238		ADULT			Studied dose	mg	1600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20822897	Homo sapiens						53				Schedule A: 5 d every 3 weeks			6	cancer								5	day		p.3245, 3246
8963	10238		ADULT			Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17179992	Homo sapiens						62				administered twice daily for 7 days every 21 days			12	cancer								7	day		p.32
8964	10239		ADULT			Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25223836	Homo sapiens						37							6												p.483
8965	10239		ADULT			Studied dose	mg	300		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25223836	Homo sapiens						28							6									7	day		p.483
8966	10242		CHILD|ADULT			Highest studied dose|Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30361325/	Homo sapiens										200, 400, 800 mg/d		75	73	focal segmental glomerulosclerosis					8			8	week		DUET ( NCT01613118)
8967	10242		UNKNOWN			Highest studied dose	mg	1600		multiple			day	1	healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf#page=13	Homo sapiens																									
8968	10243					Highest studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27151992/	Homo sapiens						66.5				median number; 28 days cycle			13	chronic lymphocytic leukemia								15	cycle		
8969	10243					RP2D	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27151992/	Homo sapiens						66.5				median number; 28 days cycle			39	chronic lymphocytic leukemia								9.5	cycle		
8970	10243					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27151992/	Homo sapiens						66.5				median number; 28 days cycle			9	chronic lymphocytic leukemia								7.5	cycle		
8971	10245		ADULT			Highest studied dose	mg	360		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23032694	Homo sapiens						73							17	myelodysplastic syndrome								16	week		
8972	10246					Highest studied dose	mg	1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19755981/	Homo sapiens						77							7	prostate cancer								28	day		
8973	10246					Highest studied dose	mg	1		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21931019/	Homo sapiens						72.3	max			dose-titration from 0.25 to 1.0 mg			134	prostate cancer								6	month		
8974	10246					MTD	mg	0.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19755981/	Homo sapiens						72							17	prostate cancer								28	day		
8975	10247		adult			Highest studied dose	mg	1600		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211723Orig1s000MultidisciplineR.pdf	Homo sapiens													64	epithelioid sarcoma								12	month		89
8976	10247		adult			Highest studied dose	mg	1600		single			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/29650362/	Homo sapiens													1	B-cell non-Hodgkin lymphoma or Solid tumour											
8977	10247		adult			Recommended	mg	800		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	Homo sapiens													62	epithelioid sarcoma								12	month		6.1
8978	10247		adult			Recommended	mg	800		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	Homo sapiens													62	epithelioid sarcoma								12	month		Table 4
8979	10247		adult			Recommended	mg	800		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf	Homo sapiens													62	epithelioid sarcoma								12	month		Table 5
8980	10247					Studied dose	mg	100		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29650362/	Homo sapiens												70	64	B-cell non-Hodgkin lymphoma or Solid tumour					38			28	day		
8981	10249					Highest studied dose	mg	150		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23110368/	Homo sapiens						28.6							18									1	day		
8982	10249					Highest studied dose	mg/kg	2		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9821993/	Homo sapiens												47	20						21			1	day		
8983	10249					MTD	mg/kg	1.3		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9821993/	Homo sapiens												47	20						21			1	day		
8984	10250		ADULT			Highest studied dose	mg/m2	235		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10473076	Homo sapiens						54							6	cancer								7.5	week		p.1991
8985	10250		ADULT			MTD	mg/m2	177		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10473076	Homo sapiens						54							12	cancer								7.5	week		p.1991
8986	10254					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62							3	solid tumors								21	day		
8987	10254					Highest studied dose	mg	150		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62							3	solid tumors								1	day		
8988	10254					MTD	mg	75		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62							15	solid tumors								21	day		
8989	10254					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62				7 days on/7 days off			5	solid tumors								28	day		
8990	10254					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62							4	solid tumors								21	day		
8991	10254					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29611022/	Homo sapiens						62							4	solid tumors								21	day		
8992	10256		adult			Highest studied dose	mg	50		multiple			day	1	healthy	oral			https://www.gastrojournal.org/article/S0016-5085(07)60009-2/pdf	Homo sapiens													9									2	week		
8993	10256		adult			Highest studied dose	mg	90		single			day	1	healthy	oral			https://www.gastrojournal.org/article/S0016-5085(07)60009-2/pdf	Homo sapiens													1									1	day		
8994	10256					Highest studied dose	mg	50		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19691492/	Homo sapiens						34.9							11									6	day		
8995	10256					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21039672/	Homo sapiens						45.8							97	chronic idiopathic constipation								4	week		
8996	10258					Highest studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25805799/	Homo sapiens						59							4	cancers								28	day		
8997	10258					MTD	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25805799/	Homo sapiens						59							41	cancers								28	day		
8998	10258					RP2D	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26364551/	Homo sapiens						58							26	renal cell carcinoma								16	month		
8999	10258					Studied dose	mg	70		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25805799/	Homo sapiens						59							5	cancers								28	day		
9000	10259		adult			Highest studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19950901/ | https://pubmed.ncbi.nlm.nih.gov/16178744/	Homo sapiens													59	Rheumatoid Arthritis								12	week		
9001	10260		ADULT			Highest studied dose	mg	22.5		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19763400	Homo sapiens						65							3	prostate cancer								28	day		p.5
9002	10260		ADULT			Studied dose	mg	15		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19763400	Homo sapiens						65				maximum well-tolerated dose			10	cancer								28	day		p.5
9003	10263		adult			MTD	mg/kg	0.16		multiple			month	10	healthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000OtherR.pdf	Homo sapiens																						3	month		
9004	10263		adult			Studied dose	mg	18		multiple			60 days	1	unhealthy	subcutaneous	M+F		https://www.ema.europa.eu/en/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf | https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-005321-40/results	Homo sapiens							mean						36	Polymorphous Light Eruption								120	day		
9005	10263					Highest studied dose	mg	20		multiple			2 months	1	unhealthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000OtherR.pdf	Homo sapiens													43	organ transplant recipients								2	year		
9006	10263					Highest studied dose	mg	40		single			day	1	healthy	subcutaneous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210797Orig1s000OtherR.pdf	Homo sapiens													6									1	day		
9007	10263					Recommended	mg	16		multiple			2 months	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/26132941/	Homo sapiens						38.3							38	erythropoietic protoporphyria								270	day		
9008	10263					Recommended	mg	16		multiple			2 months	1	unhealthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/26132941/	Homo sapiens						40.4							48	erythropoietic protoporphyria								180	day		
9009	10263					Recommended	mg	16		multiple			2 months	1	unhealthy	subcutaneous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf	Homo sapiens												74	125	erythropoietic protoporphyria					18			6	month		
9010	10263					Recommended	mg	16		multiple			2 months	1	unhealthy	subcutaneous			https://www.ema.europa.eu/en/documents/assessment-report/scenesse-epar-public-assessment-report_en.pdf	Homo sapiens													74	erythropoietic protoporphyria								270	day		
9011	10264					Highest studied dose	ug	3000		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22113345/	Homo sapiens						38.7							50	type 2 diabetes mellitus								1	day		
9012	10264					Studied dose	ug	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens						61.6							9	type 2 diabetes mellitus								6	week		
9013	10264					Studied dose	ug	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25728612/	Homo sapiens						54.7		2-8 mg;oral;1/d					96	type 2 diabetes mellitus	>1500 mg/day;oral			Metformin				26	week	sulphonylurea	
9014	10264					Studied dose	ug	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25728612/	Homo sapiens						54.7							98	type 2 diabetes mellitus								26	week		
9015	10264					Studied dose	ug	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25728612/	Homo sapiens						54.7							99	type 2 diabetes mellitus	>1500 mg/day;oral			Metformin				26	week		
9016	10264					Studied dose	ug	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens						63.2							9	type 2 diabetes mellitus								6	week		
9017	10264					Studied dose	ug	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20336066/	Homo sapiens						61.9							9	type 2 diabetes mellitus								6	week		
9018	10265					Studied dose	%	0.05		single			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/4277993/	Homo sapiens						38				patch test			1						38			1	day		
9019	10265					Studied dose	%	0.1		single			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/14162316/	Homo sapiens						61				patch test			1						61			1	day		
9020	10266					Highest studied dose	mg	1000		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22695489/	Homo sapiens						22							8									6	day		
9021	10266					Highest studied dose	mg	1000		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20376002/	Homo sapiens						22							6									1	day		
9022	10266					Studied dose	mg	200		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23737453/	Homo sapiens						29							14									10	day		
9023	10267		ADULT			Studied dose	mg	60		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22458939	Homo sapiens						61							202	COPD								12	week		p.117
9024	10268		ADULT			Highest studied dose	mg/m2	106		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21278242	Homo sapiens						58				Drug was administered over one hour, every week, continuously and one cycle was defined as 4 weeks of treatment.			4	cancer								4	week		p.5, 6
9025	10268		ADULT			MTD	mg/m2	24		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20111068	Homo sapiens						72				twice weekly, for 2 of 3 weeks			11	acute myeloid leukemia								3	week		p.702
9026	10268		ADULT			MTD	mg/m2	80		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21278242	Homo sapiens						58				Drug was administered over one hour, every week, continuously and one cycle was defined as 4 weeks of treatment.			8	cancer								4	week		p.6
9027	10268		ADULT			Studied dose	mg/m2	32		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20111068	Homo sapiens						72				twice weekly, for 2 of 3 weeks			2	acute myeloid leukemia								3	week		p.701, 702
9028	10272		ADULT			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21502571	Homo sapiens						64							186	coronary artery disease								24	month		p.1858
9029	10272		ADULT			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21502577	Homo sapiens						62.3							148	coronary artery disease								12	week		p.1848
9030	10273		ADULT			Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22381714	Homo sapiens						30.3							6												p.660
9031	10273		ADULT			Studied dose	mg	125		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22892585	Homo sapiens													40	Alzheimer disease								24	week		p.1434
9032	10274		adult			Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/21571394/	Homo sapiens										additional to 1 year study			541	osteoporosis								6	month		
9033	10274					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20025055/ | https://pubmed.ncbi.nlm.nih.gov/21571394/	Homo sapiens						64.5							135	osteoporosis								12	month		
9034	10274					Studied dose	mg	10		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20025055/ | https://pubmed.ncbi.nlm.nih.gov/21571394/	Homo sapiens						64.5							135	osteoporosis								12	month		
9035	10274					Studied dose	mg	25		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20025055/ | https://pubmed.ncbi.nlm.nih.gov/21571394/	Homo sapiens						64.5							135	osteoporosis								12	month		
9036	10276		ADULT			Highest studied dose	mg	1300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens						60				Bardoxolone methyl was administered orally once daily for 21 days of a 28-day cycle for up to 12 cycles.			9	cancer								21	day		p.7
9037	10276		ADULT			MTD	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22634319	Homo sapiens						60				Bardoxolone methyl was administered orally once daily for 21 days of a 28-day cycle for up to 12 cycles.			25	cancer								21	day		p.7
9038	10278					Highest studied dose	mg	175		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22980315/	Homo sapiens												59	56						19			10	day		
9039	10280		adult				mg	0.75		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01396447	Homo sapiens										Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.			141	Depression, Bipolar								8	week		
9040	10280		adult				mg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00694707	Homo sapiens													145	Schizophrenia								6	week		
9041	10280		adult				mg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01396447	Homo sapiens										Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.			146	Depression, Bipolar								8	week		
9042	10280		adult				mg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02670538	Homo sapiens													167	Bipolar I Disorder								6	week		
9043	10280		adult				mg	1.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02670551	Homo sapiens													157	Bipolar I Disorder								6	week		
9044	10280		adult				mg	12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01058096	Homo sapiens							max			Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.			158	Bipolar I Disorder								3	week		
9045	10280		adult				mg	12		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01058668	Homo sapiens							max			Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.			169	Bipolar I Disorder								3	week		
9046	10280		adult				mg	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00694707	Homo sapiens													146	Schizophrenia								6	week		
9047	10280		adult				mg	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01396447	Homo sapiens										Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.			146	Depression, Bipolar								8	week		
9048	10280		adult				mg	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02670538	Homo sapiens										Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.			103	Bipolar I Disorder								6	week		
9049	10280		adult				mg	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02670538	Homo sapiens										Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.			158	Bipolar I Disorder								6	week		
9050	10280		adult				mg	3		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02670551	Homo sapiens										Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.			165	Bipolar I Disorder								6	week		
9051	10280		adult				mg	4.5		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00694707	Homo sapiens													147	Schizophrenia								6	week		
9052	10280		adult				mg	6		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01058668	Homo sapiens							max			Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.			167	Bipolar I Disorder								3	week		
9053	10280		adult				mg	9		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01412060	Homo sapiens							max			Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks			101	Schizophrenia								72	week		
9054	10280		adult				mg	9		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01412060	Homo sapiens							max			Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.			765	Schizophrenia								20	week		
9055	10280		Elderly			Recommended	mg	6		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Homo sapiens													17	dementia related psychosis								10	week		
9056	10280					Highest studied dose	mg	12		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25562205	Homo sapiens							mean			Patients randomly assigned to cariprazine 6–12 mg/d received 1.5 mg on day 0, 3 mg on day 1, and 6 mg on day 2; starting on day 3, the dose could be increased in 3-mg increments to 12 mg/d by day 5		65	169	bipolar I disorder					18			3	week		
9057	10280					Recommended	mg	3		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204370lbl.pdf	Homo sapiens														bipolar mania								3	week		
9058	10280					Recommended	mg	5.7		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28478771	Homo sapiens						39.1	mean			The most frequent modal daily dose was cariprazine 6 mg/d (50.9%), followed by 9 mg/d (25.3%), 3 mg/d (22.9%), and 1.5 mg/d)			586	schizophrenia					39.1			183.2	day		
9059	10282		ADULT			Highest studied dose	mg	45		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19308410/	Homo sapiens						46						73	6	cance					26			28	day		p.1168
9060	10282		ADULT			MTD	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19308410/	Homo sapiens						46						73	3	cancer					26						p.1168
9061	10282		CHILD|ADOLESCENT			MTD	mg/m2	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21060028/	Homo sapiens						15						18	6	cancer					8						p.5176
9062	10282		CHILD|ADOLESCENT			Studied dose	mg/m2	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21060028/	Homo sapiens						15						18	2	cance					8						p.5176
9063	10282		CHILD|ADOLESCENT			Studied dose	mg/m2	17		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21060028/	Homo sapiens						15						18	4	cancer					8						p.5176
9064	10287		adult			Highest studied dose	mg	150		multiple			day	2	healthy	oral			https://ard.bmj.com/content/71/Suppl_3/203.1.abstract	Homo sapiens																						14	day		
9065	10287		adult			Highest studied dose	mg	400		single			day	1	healthy	oral			https://ard.bmj.com/content/71/Suppl_3/203.1.abstract	Homo sapiens																						1	day		
9066	10287					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25385260/	Homo sapiens						57							41	rheumatoid arthritis								12	week		
9067	10287					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27084959/	Homo sapiens						55.5							10	rheumatoid arthritis								12	week		
9068	10287					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25385260/	Homo sapiens						56.5							40	rheumatoid arthritis								12	week		
9069	10288		adult				mg	12		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02291861	Homo sapiens										SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.			73	Tardive Dyskinesia								12	week		
9070	10288		adult				mg	18		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02291861	Homo sapiens										SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.			74	Tardive Dyskinesia								12	week		
9071	10288		adult				mg	6		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02291861	Homo sapiens										SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.			74	Tardive Dyskinesia								12	week		
9072	10288					Highest studied dose	mg	36		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						71				up to 106 weeks			119	Tardive dyskinesia					71			54	week		208082Orig1s000MedR.pdf - p.36
9073	10288					Recommended	mg	12		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						32				up to 106 weeks			119	Tardive dyskinesia					32			54	week		208082Orig1s000MedR.pdf - p.33
9074	10288					Recommended	mg	12		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						49				up to 106 weeks			119	Tardive dyskinesia					49			54	week		208082Orig1s000MedR.pdf - p.22
9075	10288					Recommended	mg	12		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf	Homo sapiens												75	298	Tardive dyskinesia					18			12	week		209885Orig1s000MedR.pdf - p.116
9076	10288					Recommended	mg	15		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209885Orig1s000OtherR.pdf	Homo sapiens						5.59	mean			up to 106 weeks			202	Tardive dyskinesia								54	week		209885Orig1s000OtherR.pdf - p.28 | 209885Orig1s000SumR.pdf - p.5
9077	10288					Recommended	mg	15		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209885Orig1s000OtherR.pdf	Homo sapiens							mean			12 mg/day then titrated to a maximum total daily dose of 48 mg/day		75	58	Tardive dyskinesia					25			12	week		209885Orig1s000OtherR.pdf - p.28 | 209885Orig1s000SumR.pdf - p.5
9078	10288					Recommended	mg	18		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						49				up to 106 weeks			119	Tardive dyskinesia					49			54	week		208082Orig1s000MedR.pdf - p.35
9079	10288					Recommended	mg	18		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						53				up to 106 weeks			119	Tardive dyskinesia					53			54	week		208082Orig1s000MedR.pdf - p.32
9080	10288					Recommended	mg	18		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf	Homo sapiens												75	298	Tardive dyskinesia					18			12	week		209885Orig1s000MedR.pdf - p.116
9081	10288					Recommended	mg	6		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf	Homo sapiens												75	298	Tardive dyskinesia					18			12	week		209885Orig1s000MedR.pdf - p.116
9082	10288						mg	15		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						61				up to 106 weeks			119	Tardive dyskinesia					61			54	week		208082Orig1s000MedR.pdf - p.28
9083	10288						mg	21		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						44				up to 106 weeks			119	Tardive dyskinesia					44			54	week		208082Orig1s000MedR.pdf - p.34
9084	10288						mg	21		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						60				up to 106 weeks			119	Tardive dyskinesia					60			54	week		208082Orig1s000MedR.pdf - p.31
9085	10288						mg	21		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						62				up to 106 weeks			119	Tardive dyskinesia					62			54	week		208082Orig1s000MedR.pdf - p.30
9086	10288						mg	24		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						53				up to 106 weeks			119	Tardive dyskinesia					53			54	week		208082Orig1s000MedR.pdf - p.29
9087	10288						mg	27		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						54				up to 106 weeks			119	Tardive dyskinesia					54			54	week		208082Orig1s000MedR.pdf - p.26
9088	10288						mg	27		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						56				up to 106 weeks			119	Tardive dyskinesia					56			54	week		208082Orig1s000MedR.pdf - p.22
9089	10288						mg	27		multiple			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						60				up to 106 weeks			119	Tardive dyskinesia					60			54	week		208082Orig1s000MedR.pdf - p.27
9090	10288						mg	27		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						51				up to 106 weeks			119	Tardive dyskinesia					51			54	week		208082Orig1s000MedR.pdf - p.25
9091	10288						mg	9		multiple			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208082Orig1s000MedR.pdf	Homo sapiens						56				up to 106 weeks			119	Tardive dyskinesia					56			54	week		208082Orig1s000MedR.pdf - p.24
9092	10292					Highest studied dose	ug	150		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22626580	Homo sapiens						58						75	87	Overactive Bladder | Idiopathic Detrusor Overactivity					22			4	week		
9093	10292						ug	75		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22626580	Homo sapiens						55						75	84	Overactive Bladder | Idiopathic Detrusor Overactivity					22			4	week		
9094	10295		adult				mg	15		steady			week	3	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01785849	Homo sapiens							max			Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.			251	Hyperparathyroidism, Secondary								26	week		
9095	10295		adult				mg	15		steady			week	3	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT01788046	Homo sapiens							max			Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.			252	Hyperparathyroidism, Secondary								26	week		
9096	10295		adult				mg	5		multiple			day	3	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/NCT03283098	Homo sapiens													25	Chronic Kidney Disease								4	week		
9097	10295					Recommended	mg	5		steady			week	3	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208325Orig1s000MedR.pdf	Homo sapiens										most frequent dose per administration			503									6	month		p. 30
9098	10295					Studied dose	mg	45		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31330805/	Homo sapiens						61	total weekly dose															30	day		
9099	10296					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12008195/	Homo sapiens						61				7 cycles			5	solid tumours								28	day		
9100	10297					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22669289/	Homo sapiens						58.2							9	type 2 diabetes mellitus								14	day		
9101	10297					Highest studied dose	mg	800		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21610201/	Homo sapiens						34							8									1	day		
9102	10297					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29492878/	Homo sapiens						59.6				mean duration			3300	type 2 diabetes mellitus								224	day		
9103	10297					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29492878/	Homo sapiens						59.6				mean duration			3300	type 2 diabetes mellitus								304.5	day		
9104	10298		adult			Highest studied dose	mg	800		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens													1	myelofibrosis											20
9105	10298		adult			MTD	mg	680		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens										6 28-day cycles			31	myelofibrosis								6	cycle		68
9106	10298		adult				mg	680		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24165976/	Homo sapiens													2												
9107	10298					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens													6									6	cycle		
9108	10298					Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens						65						86	96	intermediate-2 or high-risk myelofibrosis | post-polycythemia vera myelofibrosis | post-essential thrombocythemia myelofibrosis with splenomegaly					27			6	cycle		
9109	10298					Recommended	mg	400		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens						65						86	96	myelofibrosis					27			6	cycle		123
9110	10298					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	Homo sapiens												86	96	myelofibrosis					27			12	month		6.1
9111	10298					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	Homo sapiens												86	96	myelofibrosis					27			12	month		Table 3
9112	10298					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf	Homo sapiens												86	96	myelofibrosis					27			12	month		Table 4
9113	10298					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens												75	97	intermediate-2 or high-risk myelofibrosis | post-polycythemia vera myelofibrosis | post-essential thrombocythemia myelofibrosis with splenomegaly					65			6	cycle		123
9114	10298					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens												75	97	intermediate-2 or high-risk myelofibrosis | post-polycythemia vera myelofibrosis | post-essential thrombocythemia myelofibrosis with splenomegaly					65			6	cycle		
9115	10298					Studied dose	mg	500		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf	Homo sapiens												75	97	intermediate-2 or high-risk myelofibrosis | post-polycythemia vera myelofibrosis | post-essential thrombocythemia myelofibrosis with splenomegaly					65			6	cycle		
9116	10299					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25424852/	Homo sapiens						54				and 14 days off			39	cancer | glioma								14	day		
9117	10299					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25488804/	Homo sapiens						54				cohort 1-2 daily and cohort 3-5 intermittent cycle			39	solid tumors								28	day		
9118	10299					Highest studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26526984/	Homo sapiens						59.4				and 14 days off			9	solid tumors								14	day		
9119	10300		ADULT			Highest studied dose	mg	319		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25652454	Homo sapiens						53.8				The median number of dosing days for this weekly regimen ranged from 7 days to 18 days (range, 1 to 48 days) across dose levels			4	cancer								18	week		p.6, 17
9120	10300		ADULT			MTD	mg	154		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25652454	Homo sapiens						53.8				The median number of dosing days for this weekly regimen ranged from 7 days to 18 days (range, 1 to 48 days) across dose levels			42	cancer								18	week		p.6, 17
9121	10300		ADULT			Studied dose	mg	222		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25652454	Homo sapiens						53.8				The median number of dosing days for this weekly regimen ranged from 7 days to 18 days (range, 1 to 48 days) across dose levels			7	cancer								18	week		p.6, 17
9122	10300		ADULT			Studied dose	mg	266		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25652454	Homo sapiens						53.8				The median number of dosing days for this weekly regimen ranged from 7 days to 18 days (range, 1 to 48 days) across dose levels			8	cancer								18	week		p.6, 17
9123	10303		ADULT			Highest studied dose	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25278451	Homo sapiens						63.5				Golvatinib was administered orally, once daily,\ncontinuously, in 28-day cycles		78	2	cancer					32						p.6287
9124	10303		ADULT			MTD	mg	200		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3079	Homo sapiens													3	cancer											
9125	10303		ADULT			MTD	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25278451	Homo sapiens						63.5				Golvatinib was administered orally, once daily,\ncontinuously, in 28-day cycles. Patients completed a\nmedian of 2 cycles of golvatinib (range, 1—8)		78	16	cancer					32						p.6287
9126	10303		ADULT			Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3079	Homo sapiens													2	cancer											
9127	10307					Highest studied dose	mg	5.5		multiple			month	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28550039	Homo sapiens						66				on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles			5	relapsed or refractory light-chain (AL) amyloidosis					66			12	cycle		
9128	10307					Highest studied dose	mg/m2	3.11		multiple			month	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25325301	Homo sapiens						56				on days 1, 8 and 15 of 28-day cycles			5	non-hematologic malignancies					56			2	cycle		
9129	10307					MTD	mg/m2	2.34		multiple			month	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25325301	Homo sapiens						69.5				on days 1, 8 and 15 of 28-day cycles.			10	non-hematologic malignancies					69.5			2	cycle		
9130	10307					MTD|RP2D|Recommended	mg	4		multiple			month	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28550039	Homo sapiens						66				on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles			6	relapsed or refractory light-chain (AL) amyloidosis					66			12	cycle		
9131	10307						mg/m2	1.76		multiple			month	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25325301	Homo sapiens						45				on days 1, 8 and 15 of 28-day cycles			7	non-hematologic malignancies					45			2	cycle		
9132	10312		ADULT			Highest studied dose	mg	800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9094151	Homo sapiens						59.44							32	pancreatic cancer								3	year		p.225
9133	10312		ADULT			Studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12131781	Homo sapiens						54							50	pancreatitis								4	week		e3
9134	10312		ADULT			Studied dose	mg	50		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12895218	Homo sapiens						48							7	biliary tract disease											p.335
9135	10313		ADULT			Highest studied dose	mg/kg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19541476/	Homo sapiens						53	max|total daily dose					79	40	cancer					25			56	day		p.2339
9136	10316		adult			Highest studied dose	mg	2000		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000ClinPharmR.pdf | https://www.ema.europa.eu/en/documents/assessment-report/truberzi-epar-public-assessment-report_en.pdf	Homo sapiens																						1	day		2015/206940Orig1s000ClinPharmR.pdf - p.29, 11
9137	10316		adult			MTD	mg	1000		single			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000ClinPharmR.pdf | https://www.ema.europa.eu/en/documents/assessment-report/truberzi-epar-public-assessment-report_en.pdf	Homo sapiens													8									1	day		documents/assessment-report/truberzi-epar-public-assessment-report_en.pdf - p.28
9138	10316		adult			MTD	mg	1500		single			day	1	healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000ClinPharmR.pdf	Homo sapiens													5									1	day		2015/206940Orig1s000ClinPharmR.pdf - p.29, 11
9139	10316		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01130272	Homo sapiens													165	Irritable Bowel Syndrome With Diarrhea								12	week		
9140	10316		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01553591	Homo sapiens													479	Irritable Bowel Syndrome								52	week		
9141	10316		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01553747	Homo sapiens													380	Irritable Bowel Syndrome								26	week		
9142	10316		adult				mg	100		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02959983	Homo sapiens													171	Irritable Bowel Syndrome								12	week		
9143	10316		adult				mg	200		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01130272	Homo sapiens													172	Irritable Bowel Syndrome With Diarrhea								12	week		
9144	10316		adult				mg	25		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01130272	Homo sapiens													170	Irritable Bowel Syndrome With Diarrhea								12	week		
9145	10316		adult				mg	5		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01130272	Homo sapiens													105	Irritable Bowel Syndrome With Diarrhea								12	week		
9146	10316		adult				mg	75		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01553591	Homo sapiens													428	Irritable Bowel Syndrome								52	week		
9147	10316		adult				mg	75		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01553747	Homo sapiens													379	Irritable Bowel Syndrome								26	week		
9148	10316					Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940Orig1s000lbl.pdf	Homo sapiens						45.5				52 and 26 weeks studies			1032	irritable bowel syndrome with diarrhea								26	week		
9149	10316					Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf	Homo sapiens						45.5				52 and 26 weeks studies			1032	irritable bowel syndrome with diarrhea								26	week		
9150	10316					Recommended	mg	75		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206940Orig1s000lbl.pdf	Homo sapiens						45.5				52 and 26 weeks studies			807	irritable bowel syndrome with diarrhea								26	week		
9151	10316					Recommended	mg	75		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf	Homo sapiens						45.5				52 and 26 weeks studies			807	irritable bowel syndrome with diarrhea								26	week		
9152	10316					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206940Orig1s000MedR.pdf	Homo sapiens						63.6							171	irritable bowel syndrome with diarrhea								12	week		nda/2015/206940Orig1s000MedR.pdf - p.3
9153	10317		ADULT			MTD	mg/m2	240		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15187995	Homo sapiens						62				30-min infusion once every 4 weeks			3	cancer											p.52
9154	10317		ADULT			MTD	mg/m2	68		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12237769	Homo sapiens						56							3	cancer								2	cycle		p.610
9155	10317		ADULT			RP2D	mg/m2	200		multiple			4 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15187995	Homo sapiens						62				30-min infusion once every 4 weeks			8	cancer											p.52
9156	10317		ADULT			Studied dose	mg/m2	130		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/12237769	Homo sapiens						56							4	cancer								2	course		
9157	10319		adult			Highest studied dose	mg	120		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15134605/	Homo sapiens																						10	day		
9158	10320		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01473524	Homo sapiens							max			OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.			70	Primary Biliary Cirrhosis								12	month		
9159	10320		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT01473524	Homo sapiens													73	Primary Biliary Cirrhosis								12	month		
9160	10320		adult				mg	10		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02039219	Homo sapiens													8	Alcoholic Hepatitis								6	week		
9161	10320		adult				mg	25		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00501592	Homo sapiens													20	Type 2 diabetes mellitus and nonalcoholic fatty liver disease								6	week		
9162	10320		adult				mg	50		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00501592	Homo sapiens													21	Type 2 diabetes mellitus and nonalcoholic fatty liver disease								6	week		
9163	10320					Overdose	mg	50		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf	Homo sapiens														primary biliary cholangitis											
9164	10320						mg	10		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf	Homo sapiens						56						86	73	primary biliary cholangitis					29			12	month		
9165	10321					Highest studied dose	mg	10		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15265053	Homo sapiens													6												p.652
9166	10322		ADULT			Highest studied dose	mg	330		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31142508	Homo sapiens						62				Oprozomib (150–330 mg/day) was administered once daily on days 1, 2, 8, and 9 (2/7 schedule) of a 14-day cycle. Median oprozomib treatment duration for patients with multiple myeloma was 11.4 weeks, for patients with Waldenström macroglobulinemia, these values were 34.6 weeks. Oprozomib was administered to patients in the fasted state (>/=2 hours since the previous meal and fasting for>/=2 hours after dosing) in cycle 1, and after a meal in cycle 2 and subsequent cycles.			7	multiple myeloma								34.6	week		p.4910
9167	10322		ADULT			MTD	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26924128	Homo sapiens						66				days 1-5 of 14-day cycles; a median of 3 (range: 1–16) cycles of treatment			7	cancer								5	day		p.5
9168	10322		ADULT			MTD	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31142508	Homo sapiens						63				Oprozomib (120–270 mg/day) was administered once daily on days 1 to 5 (5/14 schedule) of a 14-day cycle. Median oprozomib treatment duration for patients with multiple myeloma was 5.4 weeks, for patients with Waldenström macroglobulinemia, these values were 8.1 weeks. Oprozomib was administered to patients in the fasted state (>/=2 hours since the previous meal and fasting for>/=2 hours after dosing) in cycle 1, and after a meal in cycle 2 and subsequent cycles.			8	multiple myeloma								5	day		p.4910
9169	10322		ADULT			MTD	mg	300		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31142508	Homo sapiens						62				Oprozomib (150–330 mg/day) was administered once daily on days 1, 2, 8, and 9 (2/7 schedule) of a 14-day cycle. Median oprozomib treatment duration for patients with multiple myeloma was 11.4 weeks, for patients with Waldenström macroglobulinemia, these values were 34.6 weeks. Oprozomib was administered to patients in the fasted state (>/=2 hours since the previous meal and fasting for>/=2 hours after dosing) in cycle 1, and after a meal in cycle 2 and subsequent cycles.			7	multiple myeloma								34.6	week		p.4910
9170	10322		ADULT			MTD	mg	90		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26924128	Homo sapiens						57				days 1-5 of 14-day cycles; a median of 4 (range: 1–7) cycles of treatment			7	cancer								5	day		p.5
9171	10322		ADULT			Studied dose	mg	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26924128	Homo sapiens						66				days 1-5 of 14-day cycles; a median of 3 (range: 1–16) cycles of treatment			6	cancer								5	day		p.5
9172	10322		ADULT			Studied dose	mg	210		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26924128	Homo sapiens						57	total			120-mg/90-mg; days 1-5 of 14-day cycles; a median of 4 (range: 1–7) cycles of treatment			5	cancer								5	day		p.5
9173	10322		ADULT			Studied dose	mg	270		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31142508	Homo sapiens						63				Oprozomib (120–270 mg/day) was administered once daily on days 1 to 5 (5/14 schedule) of a 14-day cycle. Median oprozomib treatment duration for patients with multiple myeloma was 5.4 weeks, for patients with Waldenström macroglobulinemia, these values were 8.1 weeks. Oprozomib was administered to patients in the fasted state (>/=2 hours since the previous meal and fasting for>/=2 hours after dosing) in cycle 1, and after a meal in cycle 2 and subsequent cycles.			8	multiple myeloma								5	day		p.4910
9174	10323					Highest studied dose	mg/m2	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20676675/	Homo sapiens						52							3	solid tumours								28	day		
9175	10323					Highest studied dose	mg/m2	400		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16144927/	Homo sapiens						52				Treatment could be continued to a maximum period of 1 year unless progressive disease or unacceptable toxicity occurred			3	solid tumours								28	day		
9176	10323					Highest studied dose	mg/m2	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20676675/	Homo sapiens						52							6	solid tumours								28	day		
9177	10323					MTD	mg/m2	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16144927/	Homo sapiens						52				Treatment could be continued to a maximum period of 1 year unless progressive disease or unacceptable toxicity occurred			6	solid tumours								28	day		
9178	10323					Studied dose	mg/m2	100		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16406576/	Homo sapiens						55				median 28-days cycles: 2			8	solid tumours								28	day		
9179	10323					Studied dose	mg/m2	200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16144927/	Homo sapiens						52				Treatment could be continued to a maximum period of 1 year unless progressive disease or unacceptable toxicity occurred			7	solid tumours								28	day		
9180	10323					Studied dose	mg/m2	300		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/16406576/	Homo sapiens						55				median 28-days cycles: 2			7	solid tumours								28	day		
9181	10324		ADULT			Recommended	mg/m2	185		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25816934	Homo sapiens						67				days 1 to 5 of a 21-day cycle			13	mantle cell lymphoma								5	day		p.13
9182	10325					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens										28-day cycle		76	6	myelofibrosis or other myeloid malignancies					53			1	cycle		
9183	10325					MTD	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens										28-day cycle		77	7	myelofibrosis or other myeloid malignancies					49			1	cycle		
9184	10325					RP2D	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens										28-day cycle		83	6	myelofibrosis or other myeloid malignancies					52			1	cycle		
9185	10325					RP2D	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens												83	31	myelofibrosis or other myeloid malignancies					47			11.5	month		
9186	10325					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens										28-day cycle		86	6	myelofibrosis or other myeloid malignancies					66			1	cycle		
9187	10325					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27931243/	Homo sapiens										28-day cycle		77	6	myelofibrosis or other myeloid malignancies					50			1	cycle		
9188	10329		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02035553	Homo sapiens													90	Alzheimer's disease psychosis								12	week		
9189	10329					Highest studied dose	mg	150		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens						23.8						28	6						19			14	day		
9190	10329					Highest studied dose	mg	300		single					healthy	nasogastric	M		https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens						25.8						28	4						25						
9191	10329					Highest studied dose	mg	50		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens						25.8						28	4						25						
9192	10329					Recommended	mg	17		multiple			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf	Homo sapiens														dementia-related psychosis								6	week		
9193	10329					Recommended	mg	34		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf	Homo sapiens													202	hallucinations and delusions associated with Parkinson’s disease psychosis					40			6	week		
9194	10329					Recommended	mg	34		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207318Orig1s000MedR.pdf	Homo sapiens						71						85	202	hallucinations and delusions associated with Parkinson’s disease psychosis					41			6	week		109
9195	10329						mg	100		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17473118	Homo sapiens						23.8						28	6						19			14	day		
9196	10330					Highest studied dose	mg/m2	90		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29724899/	Homo sapiens							unknown			CIV infusion for 21 days of a 28-day cycle			6	acute leukemia								5.1	week		
9197	10332					Highest studied dose	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28490648	Homo sapiens						63.3	unknown						200	Parkinson disease								26	week		
9198	10336					Highest studied dose	mg	560		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			5	solid tumors								14	day		
9199	10336					MTD	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			8	solid tumors								14	day		
9200	10336					Studied dose	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			4	solid tumors								14	day		
9201	10336					Studied dose	mg	200		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31791552/	Homo sapiens						61.5		1000 mg/m2; IV; 2/3 weeks		and 14 days off; six cycles			58	ovarian cancer	600 mg; IV; 1/3 weeks			Carboplatin				14	day	Gemcitabine	
9202	10336					Studied dose	mg	200		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31791552/	Homo sapiens						63				and 14 days off			8	ovarian cancer								14	day		
9203	10336					Studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			7	solid tumors								14	day		
9204	10336					Studied dose	mg	250		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31791552/	Homo sapiens						63	mean			and 14 days off			8	ovarian cancer								14	day		
9205	10336					Studied dose	mg	420		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			18	solid tumors								14	day		
9206	10336					Studied dose	mg	90		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26581242/	Homo sapiens						61				and 14 days off			5	solid tumors								14	day		
9207	10341		ADULT			Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM494782.pdf	Homo sapiens													6	Non-small cell lung cancer											p.29, 31
9208	10341		ADULT			Highest studied dose	mg	900		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25923550/	Homo sapiens						59							19	Non-small cell lung cancer											p.1705, 1706
9209	10342		adult			Recommended	mg	49		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207620Orig1s000lbl.pdf	Homo sapiens													10495	heart failure	51 mg/2/day			valsartan				29	day		6.1
9210	10342					Recommended	mg	194		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27230850/	Homo sapiens												65	22		206 mg/1/day			valsartan	18			5	day		
9211	10342					Recommended	mg	194		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27230850/	Homo sapiens												65	6	severe renal impairment	206 mg/1/day			valsartan	18			5	day		
9212	10342					Recommended	mg	194		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27230850/	Homo sapiens												65	8	mild renal impairment	206 mg/1/day			valsartan	18			5	day		
9213	10342					Recommended	mg	194		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27230850/	Homo sapiens												65	8	moderate renal impairment	206 mg/1/day			valsartan	18			5	day		
9214	10344		ADULT			Highest studied dose	mg	280		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19360898	Homo sapiens												50	5						21						p.4
9215	10344		ADULT			Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18695053	Homo sapiens													22	Alzheimer disease								6	week		p.17, 5
9216	10344		ADULT			Studied dose	mg	140		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18695053	Homo sapiens													14	Alzheimer disease								6	week		p.17
9217	10344		ADULT			Studied dose	mg	140		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21724950	Homo sapiens													27												p.911
9218	10345					Highest studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21323872/	Homo sapiens						28.5	typical			loading dose - 20 mg twice daily for 4 days			146	sickle cell disease								52	week		
9219	10345					Highest studied dose	mg	150		single			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17064199/	Homo sapiens						30.2							6	sickle cell disease								1	day		
9220	10346		adult			MTD|Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.294	Homo sapiens								25 mg/m2; IV; on days 1 and 8 every 21 days		on days 0,1,2 and 7,8,9			5	advanced cholangiocarcinoma	1000 mg/m2; IV; on days 1 and 8 every 21 days			gemcitabine				10	day	cisplatin	
9221	10348		adult			Highest studied dose	mg	500		single			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/18688284/	Homo sapiens													6									1	day		
9222	10348					MTD	mg	800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32029634/ | https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.9030	Homo sapiens						59	total daily dose			28 day cycle (max duration of exposure up to 800 days)			11	Uveal Melanoma								28	day		
9223	10348					MTD|Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32029634/ | https://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.9030	Homo sapiens						59				28 day cycle (max duration of exposure up to 800 days)			29	Uveal Melanoma								28	day		
9224	10348					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21564523/	Homo sapiens						46.4				median duration			81	renal transplantation								75	day		
9225	10349					Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17239657	Homo sapiens							unknown					75	49	restless legs syndrome					18			3	week		
9226	10349					Studied dose	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17239657	Homo sapiens							unknown					75	59	restless legs syndrome					18			3	week		
9227	10350		ADULT			Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16902153	Homo sapiens						72.5							3	hematologic cancer								1	year		
9228	10350		ADULT			Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27663390	Homo sapiens						58							3	glioblastoma											p.571
9229	10350		ADULT			MTD	mg	525		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16902153	Homo sapiens						70.5							6	hematologic cancer								1	year		
9230	10350		ADULT			MTD	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27663390	Homo sapiens						58							6	glioblastoma											p.571
9231	10352					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18090435/	Homo sapiens						67.8							12									21	day		
9232	10352					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18450517/	Homo sapiens						75.8							70	Alzheimer's disease								12	month		
9233	10352					Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20009055/	Homo sapiens						74.6				about 40 participants (among 860) had 400 mg dose			860	Alzheimer's disease								18	month		
9234	10353					Highest studied dose	ug	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19632048/	Homo sapiens						64.7							67	diabetic peripheral neuropathic pain								6	week		
9235	10354		adult			Recommended	mg	50		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf	Homo sapiens													1203	IBS-C								52	week		
9236	10354		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02621892	Homo sapiens													307	Irritable Bowel Syndrome								12	week		
9237	10354		adult				mg	50		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02686138	Homo sapiens													293	Irritable Bowel Syndrome								26	week		
9238	10354					Highest studied dose	mg	180		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27368672/	Homo sapiens						37.5							6												
9239	10354					Highest studied dose	mg	60		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27368672/	Homo sapiens						37.5							12									7	day		
9240	10354					Highest studied dose	mg	90		steady			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27368672/	Homo sapiens						29.3							12									7	day		
9241	10354					Recommended	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31934897/	Homo sapiens						45							307	IBS-C								12	week		
9242	10355					Highest studied dose	mg	1000		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25537011/	Homo sapiens						71.9							81	Alzheimer's disease					71.9			26	week		
9243	10355					Highest studied dose	mg	1000		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32942085/	Homo sapiens												34	16	congenital and childhood-onset type 1 myotonic dystrophy					13			12	week		
9244	10358					Highest studied dose|MTD	mg/m2/day	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	Homo sapiens						59				once daily for five consecutive days per week for 1 week with cycles repeated every 3 weeks			6	solid tumors								3	week		
9245	10358					MTD	mg/m2/day	110		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/	Homo sapiens						59				once daily for 5 consecutive days per week for 2 weeks (days 1–5 and 8–12) with cycles repeated every 4 weeks			3	solid tumors								4	week		
9246	10358					MTD	mg/m2/day	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16902987/ | https://pubmed.ncbi.nlm.nih.gov/16902987/	Homo sapiens						54				for 14 days, followed by a 1-week rest, repeated every 3 weeks			6	solid tumors								3	week		
9247	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.100
9248	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.101
9249	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.102
9250	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.103
9251	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.104
9252	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.105
9253	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.106
9254	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.107
9255	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.108
9256	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.109
9257	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.110
9258	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.111
9259	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.112
9260	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.113
9261	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.114
9262	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.115
9263	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.116
9264	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.117
9265	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.118
9266	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.119
9267	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.120
9268	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.121
9269	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.122
9270	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.123
9271	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.124
9272	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.77
9273	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.78
9274	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.79
9275	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.80
9276	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.81
9277	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.82
9278	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.83
9279	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.84
9280	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.85
9281	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.86
9282	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.87
9283	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.88
9284	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.89
9285	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.90
9286	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.91
9287	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.92
9288	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.93
9289	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.94
9290	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.95
9291	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.96
9292	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.97
9293	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.98
9294	10358					Recommended	mg/m2	35		multiple			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207981Orig1s000MedR.pdf	Homo sapiens						63				5 days with 2 days rest, then 5 days again with 2 days rest, followed by 14 days off drug			533	metastatic colorectal cancer								28	day		nda/2015/207981Orig1s000MedR.pdf - p.99
9295	10358					Studied dose	mg/m2/day	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16902987/	Homo sapiens						54				for 14 days, followed by a 1-week rest, repeated every 3 weeks			3	solid tumors								3	week		
9296	10358					Studied dose	mg/m2/day	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/	Homo sapiens						59				once daily for 5 consecutive days per week for 2 weeks (days 1–5 and 8–12) with cycles repeated every 4 weeks			6	solid tumors								4	week		
9297	10358					Studied dose	mg/m2/day	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	Homo sapiens						59				once daily for five consecutive days per week for 1 week with cycles repeated every 3 weeks			9	solid tumors								3	week		
9298	10358					Studied dose	mg/m2/day	140		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	Homo sapiens						59				once daily for five consecutive days per week for 1 week with cycles repeated every 3 weeks			3	solid tumors								3	week		
9299	10358					Studied dose	mg/m2/day	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	Homo sapiens						59				once daily for five consecutive days per week for 1 week with cycles repeated every 3 weeks			3	solid tumors								3	week		
9300	10358					Studied dose	mg/m2/day	170		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/ | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207981s000lbl.pdf	Homo sapiens						59				once daily for five consecutive days per week for 1 week with cycles repeated every 3 weeks			3	solid tumors								3	week		
9301	10358					Studied dose	mg/m2/day	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16902987/	Homo sapiens						54				for 14 days, followed by a 1-week rest, repeated every 3 weeks			3	solid tumors								3	week		
9302	10358					Studied dose	mg/m2/day	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/	Homo sapiens						59				once daily for 5 consecutive days per week for 2 weeks (days 1–5 and 8–12) with cycles repeated every 4 weeks			6	solid tumors								4	week		
9303	10358					Studied dose	mg/m2/day	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18528634/	Homo sapiens						59				once daily for 5 consecutive days per week for 2 weeks (days 1–5 and 8–12) with cycles repeated every 4 weeks			3	solid tumors								4	week		
9304	10359					MTD	mg/m2/hour	144		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22772060/	Homo sapiens										and 1 week of rest; 24-h continuous intravenous (CIV) infusion			6	leukemia								3	week		
9305	10359					MTD	mg/m2/hour	40		multiple			2 weeks	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25127392/	Homo sapiens						49.5				5-day continuous infusion			26	myelogenous leukemia | lymphoblastic leukemia								2	week		
9306	10359					MTD	mg/m2/hour	40		multiple			3 weeks	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22772060/	Homo sapiens										and 1 week of rest; 5-day continuous infusion			6	leukemia								3	week		
9307	10359					MTD	mg/m2/hour	64		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20386909/	Homo sapiens						61				average duration			2	solid tumors								51	day		
9308	10359					Studied dose	mg/m2/hour	96		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20386909/	Homo sapiens						61				average duration			6	solid tumors								51	day		
9309	10362					Highest studied dose	mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28095146	Homo sapiens						66						86	52	Relapsed or Refractory Non-Hodgkin Lymphoma					25			21	day		
9310	10362					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf	Homo sapiens						66				pooled dataset		85	240	CLL					29			10.3	month		
9311	10362						mg	600		steady			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29018077	Homo sapiens													9	relapsed/refractory MM								21	day		
9312	10374		ADULT			Highest studied dose	g/kg	1		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17573745/	Homo sapiens						52							57	colorectal cancer								11	day		515-20
9313	10379		ADULT			Studied dose	mg	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29200411/	Homo sapiens													79	drug-induced hepatitis								4	week		
9314	10379		ADULT			Studied dose	mg	25		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/35567757/	Homo sapiens						45.7						60.1	81	drug-induced hepatitis					30.9			8	week		NCT02944552
9315	10380		ADULT			Highest studied dose	mg	67.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12133500/	Homo sapiens						24	total daily dose						45	hepatitis B								12	month		
9316	10393		adult				mg	20		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01069939	Homo sapiens													214	Continuous Low-dose Aspirin								72	week		
9317	10393					Recommended	mg	20		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15741423/	Homo sapiens						81							1	gastroesophageal reflux					81			5	day		
9318	10393					Recommended	mg	20		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/23548825/	Homo sapiens						31							1	gastroesophageal reflux					31			7	week		
9319	10393					Recommended	mg	40		multiple			4 days	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15741426/	Homo sapiens						64							1	gastritis					64			4	day		
9320	10400		ADULT			Highest studied dose	mg	320		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6110504/	Homo sapiens												26	8						20			8	day		434-9
9321	10406		ADULT			Studied dose	%	0.03		multiple			day	2	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/18047609/	Homo sapiens						40							27		4%			niacinamide				12	week		p.247
9322	10406		ADULT			Studied dose	%	0.1		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/17868391/	Homo sapiens												67	17	rosacea					30						p.694
9323	10409		ADULT			Highest studied dose	mg	1800		multiple			day	2	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/1678735/	Homo sapiens							total daily dose						20	withdrawal disorder								10	day		35-40
9324	10409		ADULT			Highest studied dose	mg	2000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11496744/	Homo sapiens							total daily dose						20	Alcoholic hepatitis								30	day		56-8
9325	10410					Highest studied dose	g	6		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23790912/	Homo sapiens						33.1							10									1	day		
9326	10427		ADULT			Highest studied dose	mg	40		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20176435/	Homo sapiens												45	4	endometriosis	800 mg/day			palmitoylethanolamide	27			90	day		76-9
9327	10723					Studied dose	mg/m2	100		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2990323/	Homo sapiens							max					43	2	herpesvirus infections					39						
9328	17717		ADULT			Highest studied dose	mg/kg	714		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22561291/	Homo sapiens						35.5							12									5	day		p.7
9329	18005		ADULT			Overdose	g	1.5		multiple			day	4	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24713208/	Homo sapiens						25							1	Depressive-manic psych.								2	day		
9330	18005		ADULT			Overdose	g	30		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/26107626/	Homo sapiens						43							1												p.783
9331	18005		ADULT			Recommended	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29265084/	Homo sapiens						54.1							33	chronic fatigue syndrome								6	week		p.35
9332	19004					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30347469/	Homo sapiens						68.5							6	solid tumors								21	day		
9333	20304					Highest studied dose	mg/kg	0.28		multiple					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7492104	Homo sapiens							total daily dose			0.28 mg/kg/h. A 24-h infusion of the scheduled dose during 3 days of confinement constituted the first part of the study		65	9	HIV-1 infection					18			24	hour		
9334	20536		ADULT			Highest studied dose	g	4		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18357530/	Homo sapiens						48	total daily dose						60	hepatic encephalopathy								90	day		3018-25
9335	20536		ADULT			Recommended	g	2		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14759641/	Homo sapiens						44.5	total daily dose						18	multiple sclerosis								3	month		103-8
9336	20538		adult			Highest studied dose	g	11		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207916s000lbl.pdf	Homo sapiens													29												
9337	20538						mg	1200		multiple			day	2	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00993265	Homo sapiens													20	Trichotillomania								8	week		
9338	20538						mg	3000		multiple					unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01063348	Homo sapiens							total daily dose			1200mg in the morning, 1800mg in the evening			35	Pathologic Skin Picking								6	week		
9339	20538						mg	600		multiple			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT02579772	Homo sapiens													9	Pulmonary Disease, Chronic Obstructive								4	day		
9340	20538						mg	900		multiple			day	3	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01172275	Homo sapiens													5	Obsessive-Compulsive Disorder								10	week		
9341	20538						mg/kg	6.25		multiple					unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/32821982/	Homo sapiens						17								Acute Acetaminophen Toxicity					17			3.5	hour		
9342	20558		ADULT			Highest studied dose	mg	2.7		multiple			hour	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/13309667	Homo sapiens							total daily dose						30	heart disease								24	hour		
9343	20722					Studied dose	mg/m2	2400		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19190075/	Homo sapiens							max			from 150 to 2400 mg/m2			129	solid tumours								4	week		
9344	20842		ADULT			Studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30666799/	Homo sapiens										from day 1 to 14 of a 21-day cycle		75	294	Non-small cell lung cancer					20			1	cycle		
9345	20842		ADULT			Studied dose	mg	12		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33586360/	Homo sapiens										from day 1 to 14 of a 21-day cycle		74	109	carcinoma					43			1	cycle		
9346	21072					Studied dose	mg	100		multiple			day	4	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/12372097	Homo sapiens							unknown			100 mg ⁄g vehicle		27	15						23			15	day		
9347	21084		ADULT			Studied dose	%	7		steady			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/20482238/	Homo sapiens													35	refractory melasma				laser sessions				2	month		
9348	21096					Higher than recommended	mg/kg	3		multiple					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11760927/	Homo sapiens												57	6	heroin dependency					23						
9349	21284		ADULT			Highest studied dose	mg	1100		single			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18442035	Homo sapiens							total daily dose																		
9350	21284		ADULT			Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/18442035	Homo sapiens							unknown							psoriasis								28	day		
9351	21592		adult			Recommended	%	2		single			day	1	unhealthy	intraurethral	M		https://pubmed.ncbi.nlm.nih.gov/18737364/	Homo sapiens													2									1	day		
9352	21592		adult			Studied dose	%	10		single			day	1	healthy	intraurethral	M		https://jamanetwork.com/journals/jama/article-abstract/453290	Homo sapiens													3									1	day		
9353	21616		adult			Studied dose	g/m2	3.3		multiple			week	2	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/12114414/	Homo sapiens							max						28	advanced solid malignancies								3	week		
9354	21616					Studied dose	g/m2	2.34		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/15301879/	Homo sapiens										days1—3 and repeated every 21 daysuntil disease progression		82	47	non-small cell lung cancer					43			3	cycle		
9355	21634					Recommended	mg	500		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24148088/	Homo sapiens							mean						26	upper and lower respiratory tract infection								1	day		
9356	21705		adult			Highest studied dose	mg	500		multiple			day	1	healthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/10591035/	Homo sapiens							total daily dose																		
9357	21705					Highest studied dose	mg/kg	0.5		multiple			8 hours	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/2257065/	Homo sapiens						31.5				3 doses at all with an interval of 8.4 h			8	burn shock								2	day		
9358	21705					Studied dose	mg	10		multiple			day	3	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/20862715/	Homo sapiens						49.1							30	breast cancer								4	day		
9359	21842					Studied dose	mg	3		single					unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/22296407	Homo sapiens						35	total			Six milliliters of apocynin of total dose 3 mg (0.5mg/mL dissolved in sterile 0.9% NaCl), was nebulized for 20 minutes through the mouthpiece with the use of a nose clip.			14	Bronchial asthma											p.93
9360	21851					Highest studied dose	mg/kg	135		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27421096/	Homo sapiens										21 day cycle		78	3	hematological malignancies					32			1	cycle		
9361	21851					Highest studied dose	mg/kg	90		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22965953/	Homo sapiens							median					81	3	hematologic malignancies and prostate cancer					55			4	day		
9362	21851					MTD	mg/kg	60		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22965953/	Homo sapiens							median					81	3	hematologic malignancies and prostate cancer					55			4	day		
9363	21851					Studied dose	mg/kg	105		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27421096/	Homo sapiens										21 day cycle		78	7	hematological malignancies					32			1	cycle		
9364	21851					Studied dose	mg/kg	30		steady			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22965953/	Homo sapiens							median					81	12	hematologic malignancies and prostate cancer					55			4	day		
9365	21859					Highest studied dose	mg/m2	387		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26268924	Homo sapiens						58.4				APTO-253 was administered IV on days 1 and 2, and 15 and 16 of each 28 day cycle			3	Cancer											p.1089
9366	21859					MTD	mg/m2	298		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26268924	Homo sapiens						58.4				APTO-253 was administered IV on days 1 and 2, and 15 and 16 of each 28 day cycle			5	Cancer											p.1089
9367	21868					Highest studied dose	mg	80		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33492438/	Homo sapiens												80	2	neurofibromatosis type 2-associated tumors and advanced solid malignancies					20			3	week		
9368	21868					RP2D	mg	60		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33492438/	Homo sapiens												80	17	neurofibromatosis type 2-associated tumors and advanced solid malignancies					20			3	week		
9369	21868					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32037935/	Homo sapiens							max					83	13	acute myeloid leukemia					42			2	cycle		
9370	21878					Highest studied dose	g	3		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21677059/	Homo sapiens						25							15									1	day		
9371	21913					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27685612/	Homo sapiens						65				12 g of GBS-01 is 400 mg equivalent of Arctigenin https://pubmed.ncbi.nlm.nih.gov/29856804/			9	pancreatic cancer								28	day		
9372	21984					RP2D	mg/m2	280		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3076	Homo sapiens										Drug was administered over 1-2 hours weekly.				Cancer											
9373	22065					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens						61							3	Cancer											p.5
9374	22065					MTD	mg	525		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26966027	Homo sapiens						61							16	Cancer											p.5
9375	22117					Highest studied dose	mg	240		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens							max			AT13148 was administered orally three days a week in 28-day cycles.			7	Cancer											p.4778
9376	22117					Highest studied dose	mg	240		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens										AT13148 was administered orally three days a week in 28-day cycles.			6	Cancer											p.4778
9377	22117					Highest studied dose	mg	300		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens										AT13148 was administered orally three days a week in 28-day cycles.			5	Cancer											p.4778
9378	22117					MTD	mg	180		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32616501	Homo sapiens										AT13148 was administered orally three days a week in 28-day cycles.			7	Cancer											p.4778
9379	22178		ADULT			Highest studied dose	mg	500		multiple					unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3103	Homo sapiens						60						80		cancer					27						
9380	22178		ADULT			MTD	mg	100		multiple			day	3	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3103	Homo sapiens						60						80		cancer					27			49	day		
9381	22178		ADULT			MTD	mg	400		multiple			week	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3103	Homo sapiens						60						80		cancer					27						
9382	22178		ADULT			Studied dose	mg	200		multiple			week	3	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3103	Homo sapiens						60						80		cancer					27			49	day		
9383	22179					Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22221140	Homo sapiens						32.3							16	Irritable bowel syndrome											p.6
9384	22196					Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32015461	Homo sapiens						35.6							24	Schizophrenia								5	day		p.3
9385	22196					Highest studied dose	mg	30		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28196430	Homo sapiens						32							6												p.5
9386	22255					Highest studied dose	mg	13		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22469098	Homo sapiens						22.1																			p.1240
9387	22269					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens													3	Cancer											p.1526
9388	22269					MTD	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23433846	Homo sapiens													9	Cancer											p.1526
9389	22297		ADULT			MTD	g	2		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/11192866	Homo sapiens						62	unknown						11	AIDS					31			3	month		
9390	22302					Recommended	g	23.5		multiple			day	1	unhealthy	oral			https://jamanetwork.com/journals/jama/article-abstract/282163	Homo sapiens							mean			Average dose per course of treatment: 23.5 Gm. (Largest single dose per day: 6 Gm.; Largest total quantity given any patient: 90 Gm.). Average duration of treatment: 7 days (Longest duration of treatment: 25 days).		83	84	infection					13			7	day		
9391	22334		ADULT			Highest studied dose	mg	12		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/3313099	Homo sapiens							unknown						11	Trigeminal neuralgia								7	day		
9392	22342					Highest studied dose	mg	2800		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25219601/	Homo sapiens						29.2							6									1	day		
9393	22342					Highest studied dose	mg	800		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27352310/	Homo sapiens						27.8							10									7	day		
9394	22342					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27352310/	Homo sapiens						27.8							10									7	day		
9395	22342					Studied dose	mg	1600		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25219601/	Homo sapiens						29.2	typical						70									1	day		
9396	22342					Studied dose	mg	200		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27352310/	Homo sapiens						27.8							10									7	day		
9397	22343					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27352310	Homo sapiens						27.83							10									6	day		p.4
9398	22343					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29935544	Homo sapiens						51.3							166	Coronary artery disease|Rheumatoid arthritis								12	week		p.3
9399	22347					Studied dose	%	0.5		multiple			day	2	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/29947134	Homo sapiens						48.1							21	Facial photoageing								12	week		p.292
9400	22492		adult			Highest studied dose	mg/kg	10		single			day	1	healthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/27095300/	Homo sapiens																						1	day		
9401	22492		adult			Highest studied dose	mg/kg	2.5		multiple			day	1	healthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/27095300/	Homo sapiens																						7	day		
9402	22513					Recommended	ug	320		steady			day	1	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	Homo sapiens										combined data from PAR and SAR studies		82	935	allergic rhinitis					12			2	week		page 114
9403	22513					Recommended	ug	320		steady			day	1	unhealthy	intranasal	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202813Orig1s000MedR.pdf	Homo sapiens												74	414	allergic rhinitis					12			30	week		page 114
9404	22772					Highest studied dose	mg	12		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/14933771	Homo sapiens													1	anzesthesia											
9405	22875		ADULT			Recommended|Highest studied dose	%	12		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11716099/	Homo sapiens						22.3							35	cutaneous leishmaniasis	15%			paromomycin				20	day		466-70
9406	22924		ADULT			Studied dose	mg/kg	1.2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/1344660/	Homo sapiens						46.4				The drug was taken orally 2 hours before the PUVA irradiation.		64	25	psoriasis					21			1	year		p.48
9407	23004		ADULT			Studied dose	%	72		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/30559054	Homo sapiens							unknown			Oleogel-S10 is a sterile wound gel for topical use containing 10% refined triterpene dry extract from birch bark (quantified to 72%–88% betulin) and 90% refined sunflower oil			20	burns								21	day		
9408	23016		adult			Highest studied dose	mg	200		single			day	1	healthy	oral	M		https://www.natap.org/2011/ICAAC/ICAAC_35.htm	Homo sapiens													6									1	day		
9409	23017					Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25861737	Homo sapiens						41.8							81	Asthma											p.42
9410	23295		adult			Highest studied dose	mg	10		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/10023943/	Homo sapiens							max			1.25 to 10 mg			1327	heart failure								1.3	year		
9411	23295		adult			Highest studied dose	mg	5		steady			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/11527129/	Homo sapiens							max			1 to 5 mg			37	myocardial infarction								5	day		
9412	23295		adult			Recommended	mg	20		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Homo sapiens							max			5 - 20 mg			273	hypertension								4	week		
9413	23295		adult			Recommended	mg	20		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Homo sapiens							max						273	hypertension								4	week		
9414	23295		adult			Recommended	mg	40		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Homo sapiens							max			2.5 - 40 mg			404	hypertension								12	week		
9415	23295		adult			Recommended	mg	40		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019982s014lbl.pdf	Homo sapiens							max						404	hypertension								12	week		
9416	23295					Studied dose	mg	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2897298/	Homo sapiens												52	15	liver disease					37						
9417	23428		ADULT			Highest studied dose	mg	8.4		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2515	Homo sapiens													7	cancer								4	week		
9418	23428		ADULT			MTD	mg	4		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2515	Homo sapiens													7	cancer								4	week		
9419	23428		ADULT			MTD	mg	6		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2515	Homo sapiens													6	cancer								4	week		
9420	23836					Studied dose	%	10		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/13367523	Homo sapiens							max			duration 0.5-4 months			89	fungal infection								4	month		p.154
9421	23874					MTD	mg/m2	640		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/20031390	Homo sapiens						56.5	unknown						2	advanced solid tumours								3	week		
9422	24251					Overdose	mg	500		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/3286910	Homo sapiens						33				injested 20-30 25 mg tablets			1		10 mg; single			alprazolam, p.o							p.3303
9423	24251					Overdose	mg	750		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/1758810	Homo sapiens						22							1												
9424	24251					Recommended	mg	50		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/6753911	Homo sapiens													81	Hypertension								7	week		100S
9425	24251					Recommended	mg	50		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9074572	Homo sapiens						73	max						370	Hypertension								48	week		p.750
9426	24251					Recommended	mg	50		multiple			day	3	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018343s084lbl.pdf	Homo sapiens										The initial dose of CAPOTEN (captopril tablets, USP) is 25 mg b.i.d. or t.i.d. If satisfactory reduction of blood pressure has not been achieved after one or two weeks, the dose may be increased to 50 mg b.i.d. or t.i.d.				Hypertension											p.1
9427	24421		adult			Highest studied dose	mg/m2	2700		multiple			month	3	unhealthy	intravenous			https://www.clinicaltrials.gov/ct2/show/NCT01905228?term=CBL0137	Homo sapiens										administered intravenously on Days 1, 8 and 15 of every 28 day cycle.															
9428	24461		adult			Recommended	mg	200		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2079371/	Homo sapiens													37	ENT-infections								5	day		
9429	24461		children			Recommended	mg/kg	8		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/2188437/	Homo sapiens													61	urinary tract infections											
9430	24466		adult			Highest studied dose	g	12		multiple			day	1	unhealthy	intravenous|intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/6294793| https://pubmed.ncbi.nlm.nih.gov/4055056|	Homo sapiens														serious infection								52	day		
9431	24466		adult			Recommended	g	1		single					unhealthy	parenteral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050547s071,050596s042lbl.pdf	Homo sapiens										0.5 to 2 g			1509	infections											
9432	24466						g	1		multiple			day	4	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/12773067	Homo sapiens						72							1						72			2	day		
9433	24466						g	2		multiple			day	3	unhealthy	intravenous|intramuscular	F		https://pubmed.ncbi.nlm.nih.gov/8150763	Homo sapiens						27.7						64	72						16			10	day		
9434	24466						g	3		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21817121	Homo sapiens												52	2		4 g per day			fosfomycin	32			23	day		
9435	24470		adult			Highest studied dose	g	1		multiple			day	3	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050578s061,050634s028lbl.pdf	Homo sapiens													1	pneumonia								3	day		
9436	24470		children			Highest studied dose	mg/kg	300		multiple			day	14	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/8821302/	Homo sapiens													15	cystic fibrosis								3	day		
9437	24472					Highest studied dose	g	3.5		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30698733/	Homo sapiens						59	median			median duration; 12 g per day - maximum dosage			198	CNS infection								8	day		
9438	24472					Highest studied dose	g	7		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30698733/	Homo sapiens						59	median			median duration; 12 g per day - maximum dosage			198	CNS infection								8	day		
9439	24472					Recommended	g	2		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23613806/	Homo sapiens						54							22	amyotrophic lateral sclerosis								20	week		
9440	24472					Studied dose	g	0.3		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22761158/	Homo sapiens										readministration case			1	Hyperbilirubinemia				Vitamin C				1	day	Vitamin B6	
9441	24472					Studied dose	g	2		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22761158/	Homo sapiens						4				readministration case			1	Bronchitis				Dexamethasone	4			1	day		
9442	24472					Studied dose	g	7		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30698733/	Homo sapiens						59	median			median duration; 12 g per day - maximum dosage			198	CNS infection								8	day		
9443	24472						g	2		steady			day	2	unhealthy	intravenous			https://clinicaltrials.gov/ct2/show/NCT00349622	Homo sapiens													340	Amyotrophic Lateral Sclerosis								6	year		
9444	24729					Accidental dose	mg/kg	39		single					healthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8632499	Homo sapiens						3							1												p.102
9445	24729					Accidental dose	mg/kg	88		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8632499	Homo sapiens						1				A 15-month-old, 9 kg, previously healthy male, inadvertently received 800 mg chloral hydrate elixir (88 mg/kg) IV in preparation for a diagnostic CT scan.			1												p.102
9446	24729					Overdose	g	30		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/7353427	Homo sapiens						67							1												p.232
9447	24729					Overdose	g	5		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7733528	Homo sapiens						67							1												
9448	24729					Overdose	g	8		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/16520840	Homo sapiens						0.67							1												p.235
9449	24729					Recommended	mg/kg	70		single					healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/24532346	Homo sapiens						4				A 4-year-old girl weighing 12.8 kg was prescribed chloralhydrate 900 mg (70 mg/kg) by her dentist, given orally at home prior to a dental extraction.			1	Sedation											p.220
9450	25061					MTD	mg	500		multiple			3 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15763645	Homo sapiens						56							3	Cancer											p.704
9451	25061					RP2D	mg	420		multiple			3 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15763645	Homo sapiens						56							4	Cancer											p.704
9452	25077					Highest studied dose	mg	50		single					healthy	oral	F		https://onlinelibrary.wiley.com/doi/10.1002/ddr.430210309	Homo sapiens													2												
9453	25327		adult			Recommended	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14971863/	Homo sapiens										Fixed dose is 450 mg/day			10	schizophrenia, treatment-resistant								8	week		
9454	25327		adult			Recommended	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3046553/	Homo sapiens							max			DSM-III schizophrenics who had failed to respond to at least three different neuroleptics underwent a prospective, single-blind trial of haloperidol (mean dosage, 61 +/- 14 mg/d) for six weeks. Patients whose condition remained unimproved were then randomly assigned, in a double-blind manner, to clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d) for six weeks. During the first two weeks, the dosage was titrated upward, if well tolerated, to dosage levels of either 500 mg/d of clozapine or 1000 mg/d of chlorpromazine (plus 6 mg/d of benztropine mesylate for chlorpromazine patients only). Dosing during the final four weeks was flexible, to maximum allowable dosages of 900 mg/d of clozapine and 1800 mg/d of chlorpromazine (plus up to 6 mg/d of benztropine mesylate).			126	schizophrenia, treatment-resistant								6	week		
9455	25327					Recommended	mg	289		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10831480/	Homo sapiens						41	mean			After a 2-10-day drug washout period, patients began treatment with clozapine at 25 mg/day; the dose was increased 25 mg/day (as tolerated) to a maximum level of 550 mg/day.			22	refractory psychotic mania								12	week		
9456	25327					Recommended	mg	296		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20586532/	Homo sapiens						74.2	mean			Clozapine doses ranged from 25 – 800 mg/day with a mean dose of 296 mg. Excluding four patients who were lost to follow-up after transfer to other mental health services between 1 and 7 years after starting clozapine, the mean total time on treatment was 53.4 months (range 1 – 168).		89	75	schizophrenia | schizoaffective disorder | Parkinson’ s disease with psychotic symptoms | bipolar disorder | acquired brain injury					65			53.4	month		
9457	25673					Highest studied dose	mg	1200		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28584140/	Homo sapiens						29.2							6									1	day		
9458	25673					Highest studied dose	mg	600		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31685472/	Homo sapiens						29							8									10	day		
9459	25718					Highest studied dose	mg/m2	300		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25107918	Homo sapiens						60				CUDC-101 was administered i.v over 1-hour on days 1 to 5 of a 14-day cycle.			4	Cancer											p.5036
9460	25718					MTD	mg/m2	275		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25107918	Homo sapiens						60				CUDC-101 was administered i.v over 1-hour on days 1 to 5 of a 14-day cycle.			6	Cancer											p.5035
9461	25719		ADULT			MTD	mg	1600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25646368/	Homo sapiens						54.9							3	cancer											p.1007
9462	25720					MTD	mg	150		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27049457/	Homo sapiens						63							3	refractory lymphoma or multiple myeloma								21	day		
9463	25720					MTD	mg	150		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27049457/	Homo sapiens						63							4	refractory lymphoma or multiple myeloma								21	day		
9464	25720					MTD	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27049457/	Homo sapiens						63							3	refractory lymphoma or multiple myeloma								21	day		
9465	25720					MTD	mg	60		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27049457/	Homo sapiens						63				daily for 5 days followed by a 2-day break			7	refractory lymphoma or multiple myeloma								21	day		
9466	25720					MTD	mg	60		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28860342/	Homo sapiens						60.6				median duration; daily for 5 days followed by a 2-day break			25	B-cell lymphoma								1.3	month		
9467	25720					Studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27049457/	Homo sapiens						63							7	refractory lymphoma or multiple myeloma								21	day		
9468	25845					Highest studied dose	mg/m2	250		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31092402	Homo sapiens						60				the median treatment duration was 2 cycles, i.e., 6 weeks (range, 1–18 cycles)			2	Cancer								2	cycle		p.1039
9469	25845					MTD	mg/m2	170		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31092402	Homo sapiens						60				the median treatment duration was 2 cycles, i.e., 6 weeks (range, 1–18 cycles)			3	Cancer								2	cycle		p.1039
9470	26044		ADULT			Studied dose	mg	2		single					healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/16765010	Homo sapiens												24	16						18						
9471	26104		ADULT			Highest studied dose	ug/mL	8		single					unhealthy	intravascular	M+F		https://pubmed.ncbi.nlm.nih.gov/10716458	Homo sapiens						60				Cytochalasin  B  was  administered by a microporous balloon infusion catheter to the target  lesion  immediately  after  successful  balloon  angioplasty.			13	coronary artery disease											p.587
9472	26111						mg	40		multiple			day	1	unhealthy	oral	F		https://jamanetwork.com/journals/jama/article-abstract/253067	Homo sapiens						49				a case report			1	abdominal pain											
9473	26554					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32338063	Homo sapiens						52.59							69	Type 2 diabetes								12	week		p.8
9474	26580					Highest studied dose	%	0.1		single					healthy	topical			https://www.mattilsynet.no/kosmetikk/stoffer_i_kosmetikk/risk_profile_dimethyl_mea.9957/binary/Risk%20Profile%20Dimethyl%20Mea	Homo sapiens																									p.10
9475	26580					Highest studied dose	mg	6000		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/111283	Homo sapiens														Involuntary movement disorders								14	month		p.188
9476	26583					Highest studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens						58.5							3	solid tumors								4	week		
9477	26583					Studied dose	mg	110		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens						58.5							9	solid tumors								4	week		
9478	26583					Studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens						58.5							6	solid tumors								4	week		
9479	26583					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30745300/	Homo sapiens						58.5							10	solid tumors								4	week		
9480	26730		ADULT			Accidental dose	g	10		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/20568424/	Homo sapiens						32							1									1	day		303-5
9481	26730		ADULT			Highest studied dose	mg/kg	0.01		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21035527/	Homo sapiens										acceptable daily intake (ADI) dose		55	5						23			1	day		41-5
9482	26781		adult			MTD	mg/m2	2792		multiple			5 days	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/7795272/ | https://link.springer.com/chapter/10.1007/978-1-4615-3492-1_15	Homo sapiens							max			Q4W				solid tumors								4	week		
9483	26781					Studied dose	mg/m2	1800		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8349436/	Homo sapiens						59	total						15	squamous cell head and neck cancer								5	day		
9484	26781					Studied dose	mg/m2	500		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7781137/	Homo sapiens						55.5							5	cancers								5	day		
9485	26788					Studied dose	ug	20		single					unhealthy	intrathecal	M+F		https://pubmed.ncbi.nlm.nih.gov/3831962	Homo sapiens						53.4	unknown					80	50	pain					19						
9486	26949					Highest studied dose	mg	200		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9314087	Homo sapiens																									
9487	26949					Studied dose	mg	150		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/11990913	Homo sapiens												65	20	Head injury					16						p.551
9488	27432					Recommended	%	10		multiple			day	3	unhealthy	topical			https://www.medicines.org.uk/emc/product/4815/smpc#POSOLOGY|https://www.mims.com/philippines/drug/info/diethylamine%20salicylate?mtype=generic	Homo sapiens														Musculoskeletal pain											
9489	27846		ADULT			Highest studied dose	mg	8		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7906578/	Homo sapiens						25.9							12	allergic rhinitis											
9490	27846		ADULT			Studied dose	mg	2		single					healthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/7726737/	Homo sapiens													8									6	day		
9491	27846		ADULT			Studied dose	mg	4		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7976801/	Homo sapiens													18												
9492	27947		ADULT			Studied dose	g	2.6		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12006124/	Homo sapiens						46	max			Subjects consumed four 650-mg capsules of MSM\nper day for 30 days;\ntwo capsules were consumed in the morning\nand two in the afternoon. A subset of subjects\n(n=16) that were either nonresponders or who\nexperienced mild response at the initial dose\nwas selected to continue treatment for an additional 14 days. During this time, MSM supplementation was increased to 5200 mg per day, four capsules taken in the morning and\nfour capsules taken in the evening.			50	seasonal allergic rhinitis								30	day		p.171
9493	28748					Highest studied dose	mg	150		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens												35	7						18			1	day		
9494	28748					Highest studied dose	mg	50		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15545306/	Homo sapiens												35	6						18			10	day		
9495	28748					Highest studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21925682/	Homo sapiens						48.2	typical						33	major depressive disorder								6	week		
9496	28763		adults				mg	40		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT01308619	Homo sapiens													84	Papulopustular Rosacea											
9497	28763					Recommended	mg	100		multiple			day	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9785106	Homo sapiens						24.7							223	Chlamydia trachomatis endocervical infection								7	day		p.114
9498	28763					Recommended	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22431798	Homo sapiens						23.9				Vibramycin (doxycycline hyclate capsule)			190	Urogenital Chlamydia trachomatis infection								7	day		p.86
9499	28763					Recommended	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22431798	Homo sapiens						24.1				WC2031 (doxycycline hyclate delayed-release 200-mg tablet)			188	Urogenital Chlamydia trachomatis infection								7	day		p.86
9500	28763						mg	50		steady			day	1	unhealthy	oral			https://clinicaltrials.gov/ct2/show/NCT00511875	Homo sapiens													15	Proliferative Diabetic Retinopathy								24	month		
9501	28828					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens						65				administered once daily in 28-day cycles; median - 2 cycles			6	Cancer								28	day		p.527
9502	28828					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32523090	Homo sapiens						65				administered once daily in 28-day cycles; median - 2 cycles			8	Cancer								28	day		p.527
9503	28832					Highest studied dose	mg/m2	5.7		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24258465	Homo sapiens						61.3				E7107 was administered as a 30-min intravenous infusion on Days 1 and 8 of each 21-day cycle in patients with solid tumors.			4	Cancer											p.5
9504	28832					MTD	mg/m2	4.3		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24258465	Homo sapiens						61.3				E7107 was administered as a 30-min intravenous infusion on Days 1 and 8 of each 21-day cycle in patients with solid tumors.			6	Cancer											p.5
9505	28885		adult			Recommended	%	13.9		multiple			day	2	unhealthy	topical	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21145lbl.pdf	Homo sapiens										VANIQA (eflornithine hydrochloride) Cream, 13.9%. Apply a thin layer of VANIQA to affected areas of the face and adjacent involved areas under the chin and rub in thoroughly. Do not wash treated area for at least 4 hours. Use twice daily at least 8 hours apart or as directed by a physician			1373	hirsutism											
9506	28885					Highest studied dose	g/m2	1		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/9516915/	Homo sapiens												41	6	cervical intraepithelial neoplasia					23			31	day		
9507	28913					Studied dose	mg/m2	80		multiple			day	1	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/8484977/	Homo sapiens						55	unknown			80 mg/m 2 daily for 3 consecutive days every 21 days		73	80	breast cancer					27			3	day		
9508	28981					Highest studied dose	mg	280		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33659039/	Homo sapiens												80	1	cancer					21			4	week		
9509	28981					Highest studied dose	mg	360		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33659039/	Homo sapiens												80	1	cancer					21			4	week		
9510	28981					Studied dose	mg	20		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33659039/	Homo sapiens												80	16	cancer					21			4	week		
9511	28981					Studied dose	mg	40		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33659039/	Homo sapiens												80	16	cancer					21			4	week		
9512	29027		ADULT			Highest studied dose	mg	200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25598082	Homo sapiens						33						68	3						23						p.7
9513	29027		ADULT			Studied dose	mg	50		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25598082	Homo sapiens						25						45	8						22			5	day		p.7
9514	29094		ADULT			Highest studied dose	mg	0.625		multiple			day	1	unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/3338581/	Homo sapiens						47.2						60	5						34			25	day		
9515	29736					Highest recorded dose	%	10		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/26876063/	Homo sapiens												66	3	allergic contact dermatitis					57			2	day		282-286
9516	29803					Studied dose	%	8		single			day	1	unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/20756737/	Homo sapiens						70							1	new growth in the right nostril					70			1	day		
9517	29803					Studied dose	%	8		single			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/20756737/	Homo sapiens						25							1	otitis media					25			1	day		
9518	29864		adult			Highest studied dose	mg	26.6		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23024710/	Homo sapiens													1022	chronic pain and inflammation of stomach	800 mg			ibuprofen				52	week		
9519	29864					Highest studied dose	mg	80		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32499303/	Homo sapiens												70	10	COVID-19					20			11	day		
9520	29864					Recommended	mg/kg	0.5		steady			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7846741/	Homo sapiens												15	8	gastric or duodenal ulcers					11			8	week		
9521	29864					Recommended	mg/kg	1		steady			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7846741/	Homo sapiens												15	6	gastric or duodenal ulcers					6			8	week		
9522	30199		ADULT			Highest studied dose	mg	1200		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32928796/	Homo sapiens														chronic myeloid leukemia								1	day		70-77
9523	30199		ADULT			Studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32928796/	Homo sapiens						45						75	196	chronic myeloid leukemia					18			335	day		70-77
9524	30199		ADULT			Studied dose	mg	800		single					unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32928796/	Homo sapiens							total daily dose							chronic myeloid leukemia								1	day		70-77
9525	30219					Highest studied dose	ug	6		multiple			day	1	unhealthy	intravitreal	M+F		https://pubmed.ncbi.nlm.nih.gov/15767049	Homo sapiens										6-mg implant releasing approximately 6 ug/d.			6	Subfoveal choroidal neovascularization								33	month		p.425
9526	30219					Recommended	ug	0.6		multiple			day	1	unhealthy	intravitreal			https://pubmed.ncbi.nlm.nih.gov/21813090	Homo sapiens										The sustained-release FA intravitreal implant (0.59 mg). Rec.dose (https://www.bausch.com/Portals/69/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/retisert-prescribing-information.pdf?ver=2018-04-23-125740-133). The implant was designed to release FA at an initial rate of approximately 0.6 ug/d, decreasing over the first month to a steady rate of 0.3 to 0.4 ug/d with a duration of approximately 30 months.			127	Diabetic macular edema											p.1584
9527	30219					Studied dose	ug	2		multiple			day	1	unhealthy	intravitreal			https://pubmed.ncbi.nlm.nih.gov/15921758	Homo sapiens						43.2				2.1-mg device designed to release fluocinolone acetonide at a targeted initial release rate of 2 ug/day over 1000 days. 5 eyes received a 2.1-mg device, 31 additional eyes of 28 patients were randomized to receive either a 0.59-mg or a 2.1-mg fluocinolone acetonide implant. Results of the aggregate data (0.59 mg and 2.1 mg) are presented.			5	Posterior uveitis								1000	day		p.1196
9528	30219					Studied dose	ug	2		multiple			day	1	unhealthy	intravitreal			https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf	Homo sapiens													168	Non-infectious uveitis								3	year		p.17, 18
9529	30264		ADULT				mg	700		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/34417914/	Homo sapiens						67							46	pancreatic adenocarcinoma	nab-Pac (albumin–bound paclitaxel): (intravenous (IV) 125 mg/m2 once weekly) for 3 weeks with 1 week off per a 4-week cycle			paclitaxel				102	day		p.6
9530	30356					Overdose	g	4.8		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/7906658	Homo sapiens													1												p.203
9531	30356					Overdose	g	9.6		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17952747	Homo sapiens						25							1	Depression											p.791
9532	30356					Recommended	mg	300		multiple			day		unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							max			Recommended starting dose is 50 mg at bedtime, with increases of 50 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 300 mg/day. Daily doses over 100mg should be divided			1087	Obsessive compulsive disorder|depression											p.12
9533	30356					Recommended	mg	300		multiple			day		unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf	Homo sapiens							max			Recommended starting dose is 50 mg at bedtime, with increases of 50 mg every 4 to 7 days as tolerated to maximum effect, not to exceed 300 mg/day. Daily doses over 100mg should be divided				Obsessive compulsive disorder											p.1
9534	30402					MTD	g	5.7		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7508621/	Homo sapiens						68				Fosfestrol was given in a 3.5 hr infusion in 0.9% normal saline at a starting dose of 1.5 g/d. The dose was increased daily in the same patient according to the following schedule: 1.5, 1.8, 2.4, 3.0, 3.6, 3.9, 4.5, 5.1 and 5.7 g/d. The duration of the infusion was prolonged to 7 or 10.5 hr, if a major side effect occurred.			21	prostate cancer	200 mg; 1/day			SALICYLIC ACID							
9535	30402					Recommended	mg	100		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10761752/	Homo sapiens						70				Fosfestrol was given orally at an initial dose of 100 mg 3x daily, continuously, until the advent of progressive disease or excessive toxicity.			38	prostate cancer											
9536	30402					Recommended	mg	1104		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/12496896/	Homo sapiens										Infusions comprised 1104 mg Honvan daily for 5 d prior to September 1996, 1200 mg daily for 7 d subsequent to this, representing standard hospital formulary regimes at these times in our unit. Each infusion was given over a standard 30 min, diluted to a volume of 250 ml with 0.9% saline, and preceded by an infusion of metoclopramide as an antiemetic.		87	17	prostate cancer					56			5	day		
9537	30402					Recommended	mg	120		multiple			day	3	unhealthy	oral	M		https://www.ijmpo.org/article.asp?issn=0971-5851;year=2019;volume=40;issue=1;spage=79;epage=84;aulast=Kalaiyarasi	Homo sapiens						65							47	prostate cancer											
9538	30402					RP2D	g	4		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7508621/	Homo sapiens										The suggested dose to phase II trial is 4 g/d in 3.5 hr infusion for a duration of up to 10 days.				prostate cancer								10	day		
9539	30402						mg	1104		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9607886/	Homo sapiens						74		12.5 mg; i.m; 1/day		The treatment consisted of a pre-medication with 75 mg of pethidine and 12.5 mg of prochlorperazine (Stemetil TM) or cyclizine intramuscularly, half an hour before a slow intravenous injection of 1104 mg of fosfestrol (Honvan TM) given late in the evening. The treatment was repeated for 7 days.			17	prostate cancer	75 mg; i.m; 1/day			MEPERIDINE				7	day	PROCHLORPERAZINE	
9540	30402						mg	600		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/10526944/	Homo sapiens						59				a case report			1	prostate cancer								10	year		
9541	30642		ADULT			Studied dose	mg/kg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21336736/	Homo sapiens						58							100	cognitive disorder											p.125
9542	30649					Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/12/11_supplement/b75	Homo sapiens										On the QD regimen, 45 pts enrolled in eight successive cohorts (7-160 mg); Patients were administered oral GDC-0623 as on a 21-day on/7-day off dosing schedule in the fasted state				Cancer								21	day		
9543	30649					MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/12/11_supplement/b75	Homo sapiens										On the QD regimen, 45 pts enrolled in eight successive cohorts (7-160 mg)				Cancer											
9544	30649					MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/12/11_supplement/b75	Homo sapiens										On the QD regimen, 45 pts enrolled in eight successive cohorts (7-160 mg); Patients were administered oral GDC-0623 as on a 21-day on/7-day off dosing schedule in the fasted state				Cancer								21	day		
9545	30651					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27076626	Homo sapiens						60.5				14-day on/7-day off dosing schedule (21-day cycles)			3	Cancer								14	day		p.4567
9546	30652					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens						58				21-day on/7-day off schedule			6	Solid Tumors								28	day		
9547	30652					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31848189/	Homo sapiens						58				21-day on/7-day off schedule			3	Solid Tumors								28	day		
9548	30652					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32311798/	Homo sapiens						55				21-day on/7-day off schedule			6	Solid Tumors	80 mg; oral; 1/28 days			Cobimetinib				28	day		
9549	30741					MTD	mg/m2	2060		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31372813/	Homo sapiens						60.9	unknown			30-min IV infusion on days 1–5 of each 21-day cycle.		73	6	cancer					47			5	day		
9550	30750					Highest studied dose	mg	180		multiple			day	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7897422	Homo sapiens						36						64	32	multiple sclerosis					23			7	day		
9551	30774					Studied dose	mg	280		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13292450	Homo sapiens						63							1	amebiasis					63			5	day		
9552	30786		ADULT			Studied dose	umol/kg	11		single					unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/761444/	Homo sapiens							median			10.6 to 22 umol/day		63	5	burn					16						
9553	30786		ADULT			Studied dose	umol/kg	27.5		single					healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/761444/	Homo sapiens							median			22.6 to 40.9 umol/day		69	6						20						
9554	30797		adult			Studied dose	g	5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/5950351/	Homo sapiens										1 to 5 gm daily for 6 days a week, Sunday excepted. 10 months is an average treatment duration.			68	leprosy								10	month		
9555	31147					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23263000/	Homo sapiens						43	total daily dose					61	8	hepatitis C infection					24			3	day		
9556	31147					Highest studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23262999	Homo sapiens							total daily dose					55	8						18						
9557	31161					Highest studied dose	mg	20		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens						32.4							14												p.974
9558	31161					Studied dose	mg	18		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/26620151	Homo sapiens						42.4							12									14	day		p.974
9559	31164					Highest studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens						59.7							4	Cancer											p.5986
9560	31164					RP2D	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens						59.7							12	Cancer											p.5986
9561	31164					RP2D	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28645941	Homo sapiens						59.7							6	Cancer											p.5986
9562	31167					Highest studied dose	mg	4		multiple			2 weeks	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31260835/	Homo sapiens						60.6							2	small cell lung carcinoma								2	week		
9563	31167					Studied dose	mg	2		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31260835/	Homo sapiens						60.6							7	small cell lung carcinoma								28	day		
9564	31167					Studied dose	mg	3		multiple			2 weeks	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31260835/	Homo sapiens						60.6							5	small cell lung carcinoma								2	week		
9565	31167					Studied dose	mg	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31260835/	Homo sapiens						60.6							3	small cell lung carcinoma								28	day		
9566	31674		ADULT			Highest studied dose	mg	150		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25591969/	Homo sapiens						23.7	max|total daily dose						12									8	week		935-45
9567	31674		ADULT			Highest studied dose	mg	300		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25591969/	Homo sapiens						24.3	max|total daily dose						12		250 mg			caffeine				8	week		935-45
9568	31674		ADULT			Highest studied dose	ug/kg	22.5		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23085737/	Homo sapiens						30							10									1	day		1353-8
9569	31699					Highest studied dose	mg	360		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens												50	8						20			5	day		
9570	31699					Highest studied dose	mg	900		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/22284902/	Homo sapiens							unknown					50	8						20						
9571	31702		ADULT			MTD	mg/m2	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16951237	Homo sapiens						63				continuous 21-day dosing schedule every 28 days		79	8	cancer					37			21	day		p.5185
9572	31702					Highest studied dose	mg/m2	9.9		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16951237	Homo sapiens						63				continuous 21-day dosing schedule every 28 days		79	7	cancer					37			21	day		p.5185
9573	31756					Highest studied dose	mg	60		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25625276/ | https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2561	Homo sapiens						56.5				median duration; 28-days cycle			5	solid tumours | lymphoma								8	week		
9574	31756					MTD	mg	50		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25625276/ | https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2561	Homo sapiens						56.5				median duration; 28-days cycle			22	solid tumours | lymphoma								8	week		
9575	31756					Studied dose	mg	20		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25625276/ | https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2561	Homo sapiens						56.5				median duration; 28-days cycle			6	solid tumours | lymphoma								8	week		
9576	31798		adult			Highest studied dose	mg	160		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf	Homo sapiens																						15	day		p. 141
9577	31798		adult			Recommended	mg	20		multiple			day	1	pregnant	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf	Homo sapiens																									
9578	31798		adult			Recommended	mg	20		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf	Homo sapiens																									
9579	31798		adult				mg	20		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000MedR.pdf	Homo sapiens										pooled chronic pain studies: 20-120 mg per day			296									3	week		p. 115
9580	31798					Overdose	mg	30		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20837591	Homo sapiens						5	total	250 mg, 2 times per day					1	cold				clarithromycin	5			1	day	valproic acid	
9581	31831					Highest studied dose	mg	768		multiple			day	6	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7521784	Homo sapiens							max|total daily dose			The mean daily hydromorphone hydrochloride dose was 76 -+ 133 mg (range, 6-768 mg).			48	Pain											p.1810
9582	31831					Overdose	mg	10		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/21620461	Homo sapiens													1	Pain											p.378
9583	31831					Overdose	mg	540		single					unhealthy	intrathecal	F		https://pubmed.ncbi.nlm.nih.gov/15336340	Homo sapiens						27							1	Pain											p.274
9584	31831					Recommended	mg	2		multiple			day	3	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/21620461	Homo sapiens						40							1	Pain											p.378
9585	31831					Recommended	mg	2		multiple			day	6	unhealthy	subcutaneous|intramuscular			https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019034s018lbl.pdf	Homo sapiens										The usual starting dose is 1-2 mg subcutaneously or intramuscularly every 4 to 6 hours as necessary for pain control.				Pain											p.1
9586	31831					Recommended	mg	4		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29659913	Homo sapiens						67.7	max			The initial dose of hydromorphone was 4 mg/day, when a dose increase was deemed necessary during study drug administration, the dose could be increased up to the fourth dose (16 mg/day)			88	Pain											p.545
9587	31831					Recommended	mg	4		multiple			day	6	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019891s024,019892s029lbl.pdf	Homo sapiens										Usual adult starting dose for DILAUDID Tablets is 2 mg to 4 mg, orally, every 4 to 6 hours.				Pain											p.1
9588	31834		ADULT			Studied dose	mg	150		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10938184/	Homo sapiens						37.7						67	5	myotonic disease					20			6	week		p.75
9589	31834		ADULT			Studied dose	mg	738		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28411139/	Homo sapiens						47	mean						50	Brugada syndrome								18	month		p.3, 4
9590	31836		ADULT			Accidental dose	mg	590		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/7273674/	Homo sapiens						16							1		410 mg			amobarbital				1	day		659-62
9591	31836		ADULT			Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2484920/	Homo sapiens						50				900 mg/day equal to 809 mg of DQ base		67	14	cardiovascular system disease					28			7	day		679-86
9592	31836		ADULT			Highest studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8745663/	Homo sapiens						62							44	atrial fibrillation								12	month		525-31
9593	31836		ADULT			Highest studied dose	mg	600		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2484920/	Homo sapiens						50						67	14	cardiovascular system disease					28			1	day		679-86
9594	31996		adult			Studied dose	mg	500		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6875384/	Homo sapiens													5												
9595	32045					Studied dose	mg	50		multiple			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2564208/	Homo sapiens							unknown					44	10	schizophrenia					35			3	day		
9596	32169		ADULT			Highest studied dose	mg/kg	200		multiple			week	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/28815560/	Homo sapiens												65	23	psoriasis					20			8	week		p.14
9597	32216		ADULT			Highest studied dose	mg/m2	135		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens						63				weekly regimen; days 1, 8, and 15 in 28-day cycles; number of cycles ranged from 1–4;			7	cancer								4	cycle		p.5
9598	32216		ADULT			MTD	mg/m2	60		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens						57				5 days in 28-day cycles			6	cancer								5	day		p.5
9599	32216		ADULT			MTD	mg/m2	90		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens						63				weekly regimen; days 1, 8, and 15 in 28-day cycles; number of cycles ranged from 1–4;			8	cancer								4	cycle		p.5
9600	32216		ADULT			Studied dose	mg/m2	80		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/27169793	Homo sapiens						57				5 days in 28-day cycles			3	cancer								5	day		p.5
9601	32289					Highest studied dose	%	0.2		multiple			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/30663063/ |https://pubmed.ncbi.nlm.nih.gov/23869727/	Homo sapiens													9755												
9602	32308					Overdose	mL	250		single					unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018905s025lbl.pdf	Homo sapiens							min			HEXABRIX (Ioxaglate Meglumine + Ioxaglate Sodium) is indicated for use in pediatric angiocardiography, selective coronary arteriography with or without left ventriculography, peripheral arteriography, aortography, selective visceral arteriography, cerebral angiography, intra-arterial digital subtraction angiography, intravenous digital subtraction angiography, peripheral venography (phlebography), excretory urography, contrast enhancement of computed tomographic head imaging and body imaging, arthrography and hysterosalpingography. For Intravenous digital subtraction angiography (IV DSA) the total procedural dose should not exceed 250 mL. Each milliliter contains 393 mg of ioxaglate meglumine, 196 mg of ioxaglate sodium.				Cardiovascular diseases											p.11
9603	32308					Recommended	mL	101		single					unhealthy	intraarterial	M+F		https://pubmed.ncbi.nlm.nih.gov/1552109	Homo sapiens										Total amount injected			250	Cardiovascular diseases											p.901
9604	32308					Recommended	mL	194.8		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/16949481	Homo sapiens							mean						135	Cardiovascular diseases											p.926
9605	32789		adult			Highest studied dose	mg	1000		single			day	1	healthy	oral			https://pubmed.ncbi.nlm.nih.gov/28097231/	Homo sapiens													10									1	day		
9606	32789					Highest studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30652973/	Homo sapiens						65							29	advanced cancer								56	day		
9607	32949					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25745036	Homo sapiens						59							5	Cancer								21	day		p.5
9608	33115					RP2D|Highest studied dose	mg/m2	176		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26695442	Homo sapiens						59.7				once daily on days 1–5 every 2 weeks			6						59.7			5	day		
9609	33464					Highest studied dose	mg/m2	1000		multiple			day	8	unhealthy	intravenous	F		https://pubmed.ncbi.nlm.nih.gov/21509165/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000medR.pdf	Homo sapiens						7							1	osteosarcoma					7						
9610	33464					MTD	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2003.01.238	Homo sapiens						52		50 mg/m2 IV; on days 1 and 15 every 6 weeks		median, 2.5 courses (6 weeks course)			6	advanced solid tumors	320 mg/m2 IV; 1 per week		CPT-11	fluorouracil			75 mg/m2 IV: 1 per week	15	week	oxaliplatin	
9611	33464					Studied dose	mg	100		single			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10932085/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000medR.pdf	Homo sapiens						32							1						32			1	day		020140s000medR.pdf - p.26
9612	33464					Studied dose	mg/m2	20		multiple			day	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2003.01.238	Homo sapiens						60.5		110 mg/m2 IV; 1st day every 3 weeks		days 2 to 5			3	advanced solid tumors	240 mg/m2 IV; days 2 to 5 every 3 weeks		CPT-11	fluorouracil			250 mg/m2 IV: 1st day every 3 weeks	3	week	oxaliplatin	
9613	33464					Studied dose	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2003.01.238	Homo sapiens						52		70 mg/m2 IV; on days 1 and 15 every 6 weeks		median 2 course			4	advanced solid tumors	425 mg/m2 IV; 1 per week		CPT-11	fluorouracil			100 mg/m2 IV: 1 per week	14	week	oxaliplatin	
9614	33464					Studied dose	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2003.01.238	Homo sapiens						52		70 mg/m2 IV; on days 1 and 15 every 6 weeks		median 2 course			4	advanced solid tumors	425 mg/m2 IV; 1 week		CPT-11	fluorouracil			100 mg/m2 IV: 1 per week	14	week	oxaliplatin	
9615	33464					Studied dose	mg/m2	20		multiple			week	1	unhealthy	intravenous	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2003.01.238	Homo sapiens						52		70 mg/m2 IV; on days 1 and 15 every 6 weeks		median 4 courses			3	advanced solid tumors	320 mg/m2 IV; 1 per week		CPT-11	fluorouracil			70 mg/m2 IV: 1 per week	28	week	oxaliplatin	
9616	33464					Studied dose	mg/m2	200		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/11996482/ | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/020140s000medR.pdf	Homo sapiens						80							1	colon cancer					80			2	day		020140s000medR.pdf - p.26
9617	33538		ADULT			Highest studied dose	mg	1800		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32864754/	Homo sapiens						24.5						31	6						19						p.6
9618	33538		ADULT				mg	1400		multiple			day	2	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32864754/	Homo sapiens						32.1						38	12						25			6.5	day		p.6
9619	33779					Highest studied dose	mg	7		multiple			week	1	unhealthy	intralesional	M+F		https://pubmed.ncbi.nlm.nih.gov/33542073/	Homo sapiens						60	typical			4 mg - Day 1; Day 2 and 3 - 7 mg			4	Solid Tumors								18	week		
9620	33779					Highest studied dose	mg	8		multiple			week	1	unhealthy	intralesional	M+F		https://pubmed.ncbi.nlm.nih.gov/33542073/	Homo sapiens						60	total daily dose			4 mg twice daily on Day 1,2,3			3	Solid Tumors								18	week		
9621	33779					Studied dose	mg	6		multiple			week	1	unhealthy	intralesional	M+F		https://pubmed.ncbi.nlm.nih.gov/33542073/	Homo sapiens						60	mean			4 mg - Day 1; Day 2 and 3 - 7 mg			14	Solid Tumors								18	week		
9622	33789					Recommended	mg	240		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Homo sapiens						2				4 doses at 1 day and 2 at second			310	malaria	40 mg; PO; 4D1+2D2			artemether				2	day		A2403
9623	33789					Recommended	mg	240		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Homo sapiens						3				4 doses at 1 day and 2 at second			447	malaria	40 mg; PO; 4D1+2D2			artemether				2	day		B2303
9624	33789					Recommended	mg	480		multiple			day	3	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Homo sapiens						25				4 doses at 1 day and 2 at second			115	malaria	80 mg; PO; 4D1+2D2			artemether				2	day		A028
9625	33819					Highest studied dose	mg/kg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23688534/	Homo sapiens						6.7		3 mg/kg; oral; 1/day					40	autism spectrum disorders	7 mg/kg; oral; 1/day			quercetin				26	week	rutin	
9626	33839		ADULT			Highest studied dose	mg	100		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens						60				every other day for 21 days, followed by 7 drug-free days			9	cancer								21	day		1206-16
9627	33839		ADULT			Highest studied dose	mg	90		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens						60				once daily for 7 days every other week (28-days cycle)			7	cancer								7	day		1206-16
9628	33839		ADULT			MTD	mg	30		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23616084/	Homo sapiens						63				once daily for 14 days, followed by a 7-day drug-free period			6	cancer								14	day		1645-55
9629	33839		ADULT			MTD	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21753156/	Homo sapiens						61				once daily for 14 days of a 21-day cycle		81	8	cancer					43			14	day		6071-82
9630	33839		ADULT			MTD	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens						60				once daily for 7 days every other week (28-days cycle)			9	cancer								7	day		1206-16
9631	33839		ADULT			MTD	mg	90		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26377590/	Homo sapiens						60				every other day for 21 days, followed by 7 drug-free days			5	cancer								21	day		1206-16
9632	33839		ADULT			Studied dose	mg	40		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/23616084/	Homo sapiens						55.5				once daily for 14 days, followed by a 7-day drug-free period			4	cancer								14	day		1645-55
9633	33848		ADULT			Highest studied dose	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31645440	Homo sapiens						54.5				28-day cycle; the majority of patients (84.3%) completed one or two cycles of treatment			2	cancer								2	cycle		p.462, 463
9634	33848		ADULT			RP2D	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31645440	Homo sapiens						59				28-day cycle; the majority of patients (84.3%) completed one or two cycles of treatment			16	cancer								2	cycle		p.462, 463
9635	33850		adult			Studied dose	mg	200		steady			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/33495309/	Homo sapiens													53	solid tumors	105 mg/m2 intravenously every 14 days			prexasertib				14	day		
9636	33851					Highest studied dose	mg	100		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						59				median duration			10	solid tumors								56	day		
9637	33851					MTD	mg	75		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						54				median duration			25	solid tumors								56	day		
9638	33851					MTD	mg	75		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						59				median duration			5	solid tumors								56	day		
9639	33851					RP2D	mg	50		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30953269/	Homo sapiens						60				median duration			22	adenoid cystic carcinoma								84	day		
9640	33851					Studied dose	mg	20		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						59				median duration			8	solid tumors								56	day		
9641	33851					Studied dose	mg	30		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						59				median duration			7	solid tumors								56	day		
9642	33851					Studied dose	mg	60		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						59				median duration			9	solid tumors								56	day		
9643	33851					Studied dose	mg	62.5		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30060061/	Homo sapiens						54	mean			median duration			55	solid tumors								56	day		
9644	34147		ADULT			Highest studied dose	g/m2	55.1		single					unknown	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/22036967/	Homo sapiens										applied once for 48 hours			52									2	day		S265
9645	34147		ADULT			Highest studied dose	g/m2	99.2		multiple			week	3	unknown	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/22036967/	Homo sapiens													98									3	week		S265
9646	34353					Recommended	mg	100		multiple					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/010721s063lbl.pdf	Homo sapiens							total daily dose			Recommended dosage: 25 mg to 100 mg daily, in divided dose				Vertigo											p.1
9647	34353					Recommended	mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32282831	Homo sapiens										second 25 mg dose was received 10 hours after the first administration		10	6	Achondroplasia					5			1	day		
9648	34353					Recommended	mg	25		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32282831	Homo sapiens												10	6	Achondroplasia					6						
9649	34497						mg	4		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13521594	Homo sapiens						77							1	pain | spasms					77			27	day		
9650	34502					Highest studied dose	mg	300		single					healthy	intramuscular	M+F		https://pubmed.ncbi.nlm.nih.gov/13331850	Homo sapiens												29	21						18						
9651	34523		adult			Studied dose	mg	132		single					unhealthy	intramuscular	unknown		https://pubmed.ncbi.nlm.nih.gov/14783072/	Homo sapiens													20	congestive heart failure											
9652	34661		adult			Overdose	g	2		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/26402425/	Homo sapiens							max			0.5 to 2 g			25	methamphetamine dependence											
9653	34661		adult			Studied dose	mg	40		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32986459/	Homo sapiens													19												
9654	34736		ADULT			Highest studied dose	mg/m2	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens						60				Patients received oral TRC102 daily for 4 days. Two weeks later, patients began standard-dose pemetrexed (500 mg/m2) on day 1 in combination with oral TRC102 on days 1 to 4. The pemetrexed-TRC102 combination was repeated every 3 weeks until disease progression.			6	cancer	Patients received oral TRC102 daily for 4 days. Two weeks later, patients began standard-dose pemetrexed (500 mg/m2) on day 1 in combination with oral TRC102 on days 1 to 4. The pemetrexed-TRC102 combination was repeated every 3 weeks until disease progression.			pemetrexed				4	day		p.7, 16
9655	34736		ADULT			MTD	mg/m2	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23054206	Homo sapiens						60				Patients received oral TRC102 daily for 4 days. Two weeks later, patients began standard-dose pemetrexed (500 mg/m2) on day 1 in combination with oral TRC102 on days 1 to 4. The pemetrexed-TRC102 combination was repeated every 3 weeks until disease progression.			11	cancer	Patients received oral TRC102 daily for 4 days. Two weeks later, patients began standard-dose pemetrexed (500 mg/m2) on day 1 in combination with oral TRC102 on days 1 to 4. The pemetrexed-TRC102 combination was repeated every 3 weeks until disease progression.			pemetrexed				4	day		p.7
9656	34755		adult			Studied dose	%	50		multiple			day	1	unhealthy	topical			https://www.sciencedirect.com/science/article/abs/pii/S0140673601463811	Homo sapiens													100	chronic articular rheumatism	0.5			olive oil							
9657	34755		adult			Studied dose	%	55		multiple			day	1	unhealthy	topical	F		https://jamanetwork.com/journals/jamadermatology/article-abstract/504166	Homo sapiens							mean			4 patients - 10%; others - 100%			11												
9658	35227		ADULT			Higher than recommended	mg	160		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/32617471/	Homo sapiens						52	max						1		1800 mg		chlorpheniramine	acetaminophen			20 mg	20	day	caffeine	1-4
9659	35227		ADULT			Recommended	mg	60		multiple			day	3	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20154441/	Homo sapiens						32	total daily dose						1		250 mg							3	day		335-8
9660	35337					Highest studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.mirati.com/wp-content/uploads/20160603_A-First-in-Human-Phase-1-Study-of-Receptor-Tyrosine-Kinase-RTK-Inhibitor-MGCD516-in-Patients-with-Advanced-Solid-Tumors.pdf	Homo sapiens						64	unknown					85	3	Advanced Solid Tumors					27			21	day		
9661	35337					Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://www.mirati.com/wp-content/uploads/20160603_A-First-in-Human-Phase-1-Study-of-Receptor-Tyrosine-Kinase-RTK-Inhibitor-MGCD516-in-Patients-with-Advanced-Solid-Tumors.pdf	Homo sapiens						64						85	6						27			21	day		
9662	35340		ADULT			Highest studied dose	mg	200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24075770	Homo sapiens												44	6						27.7			2	week		p.375
9663	35399					Highest studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17011500	Homo sapiens						42.9							116	Obesity								12	week		p.277
9664	35399					Highest studied dose	mg	750		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17011500	Homo sapiens													6												p.276
9665	35399					Studied dose	mg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17426325	Homo sapiens													182	Obesity								52	week		p.901
9666	35409					Studied dose	mg	30		steady			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/30289444/	Homo sapiens												45	6	HIV-uninfected	182 mg			vicriviroc	18			28	day		
9667	35411					Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21383045	Homo sapiens						40.5							63	Migraine											p.717
9668	35423					Highest studied dose	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29376210	Homo sapiens						65							3	Cancer											p.16
9669	35423					MTD	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29376210	Homo sapiens						65							18	Cancer											p.16
9670	35424		ADULT			Highest studied dose	mg	2		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2573444	Homo sapiens												28	9						20						p.570
9671	35430					Highest studied dose	mg	18		multiple			week	2	unhealthy	intravenous	M+F		https://clinicaltrials.gov/ct2/show/results/NCT02045095	Homo sapiens						56.8							8	Advanced Solid Tumors								21	day		
9672	35577					Recommended	mg	540		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14646190	Homo sapiens										provided in tea		59	16				caffeine oral 52 mg	Thiamin oral 1.1 mg	24			12	week	Arginine oral 1240 mg	p.2326
9673	35845		ADULT			Highest studied dose	mg/m2	6000		single					unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/11422263/	Homo sapiens													74	allergy											p.24
9674	36065					Studied dose	mg	5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/29642282	Homo sapiens						32.9							14	Asthma								7	day		p.326
9675	36710		ADULT			Highest studied dose	mg/kg	400		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/14005854/	Homo sapiens													13	cancer								3	day		151-2
9676	36941		ADULT			Highest studied dose	mg	1000		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/27075024/|https://pubmed.ncbi.nlm.nih.gov/14628338/	Homo sapiens							total			Day1 - 600 mg; Day 2 - 400 mg		55	30	malaria					16			2	day		789-804|131-3
9677	36941		ADULT			Highest studied dose	mg	600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/20197487/	Homo sapiens												40	10		1500 mg			artemisinin	20			1	day		1310-8
9678	36966		ADULT			Highest studied dose	%	0.5		multiple			day	5	unhealthy	topical	M+F		https://idsa.confex.com/idsa/2008/webprogram/Paper26282.html	Homo sapiens										Subjects applied 200 µL of medication 5 times daily for a maximum of 4 days.				herpes simplex								4	day		
9679	36973					Highest studied dose	mg	800		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12612897	Homo sapiens						29.5							8									7	day		p.605
9680	37453					RP2D	mg	625		multiple			3 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28331050/	Homo sapiens						63.4				21-day cycle			24	solid tumours								3.3	cycle		
9681	37453					RP2D	mg	625		multiple			3 weeks	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31118108/	Homo sapiens						64	max			median duration			20	solid tumours								60.9	week		
9682	37453					RP2D	mg	625		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31702782/	Homo sapiens						55				Progression-free survival (PFS6)			20	glioblastoma								6	month		
9683	37458					Highest studied dose	mg	40		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26643541	Homo sapiens						40.5							6	Major depressive disorder											p.1377
9684	37797					Highest studied dose	mg	900		steady			day	2	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf |https://pubmed.ncbi.nlm.nih.gov/24974051	Homo sapiens										highest pre-specifi ed dose level of 1800 mg			3	non-metastatic castration-resistant prostate cancer											
9685	37797					Recommended	mg	600		steady			day	2	unhealthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf	Homo sapiens						74							954	non-metastatic castration-resistant prostate cancer					74			14.8	month		
9686	38523					Highest studied dose	mg	240		multiple			week	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens						56.5							15	Cancer											p.891
9687	38523					MTD	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens						56.5				QD continuously			4	Cancer											p.891
9688	38523					Studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens						56.5				once daily for three consecutive days every week			5	Cancer											p.891
9689	38523					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27002938	Homo sapiens						56.5				QD continuously			3	Cancer											p.891
9690	38525					Highest studied dose	mg	1600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens						57							3	Cancer											p.6
9691	38525					Highest studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens						57							8	Cancer											p.6
9692	38525					MTD	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens						57							33	Cancer											p.6
9693	38525					MTD	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23403628	Homo sapiens						57							8	Cancer											p.6
9694	38608		ADULT			Highest studied dose	mg/kg	100		multiple			8 hours	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/9186317	Homo sapiens						29							6									32	hour		p.35
9695	38608		ADULT			Studied dose	g	0.5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9621294	Homo sapiens						60							10	renal failure - chronic								14	day		p.1097
9696	38624		ADULT			Studied dose	g	0.6		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28112799/	Homo sapiens						31.81							37	psoriasis								8	week		p.1451
9697	38624		ADULT			Studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15484298/	Homo sapiens												65	72	viral hepatitis					18			52	week		p.3272
9698	38977					Studied dose	mg	1.9		multiple			month	1	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/23689994	Homo sapiens										subconjunctival injections were performed at baseline, week 4,and week 8.		87	5	Macular degeneration					68			12	week		p.6
9699	39035		ADULT			Highest studied dose	mg	4		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15122077/	Homo sapiens						73							3	cancer								28	day		299-305
9700	39035		ADULT			Studied dose	%	0.1		single					unhealthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/18021604/	Homo sapiens						45				patch test			1	Ehlers-Danlos syndrome								1	day		225-9
9701	39081					Highest studied dose	MBq	629		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24335566	Homo sapiens							unknown					67	11	glioma, malignant					29						
9702	39300						mg	5		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8937366	Homo sapiens						63.5						85	20						36			4	week		
9703	39326					Highest studied dose	mg	170		single			day	1	healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26838074/	Homo sapiens							max					31	12						19			1	day		
9704	39326					Highest studied dose	mg	85		multiple			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/26838074/	Homo sapiens							max					31	6						19			5	day		
9705	39385					Highest studied dose	mg/m2	2800		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12695855/	Homo sapiens						55							3	advanced solid tumors								28	day		
9706	39385					MTD	mg/m2	1200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10690515/	Homo sapiens						50							7	advanced refractory malignancies								1	month		
9707	39385					MTD	mg/m2	2100		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12695855/	Homo sapiens						55							9	advanced solid tumors								28	day		
9708	39385					Studied dose	mg/m2	1200		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12794248/	Homo sapiens						66				median duration (range 1 to 3 months)			27	metastatic colorectal cancer								1.8	month		
9709	39385					Studied dose	mg/m2	2800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10955786/	Homo sapiens						56							9	refractory solid malignancies								14	day		
9710	39388						mg	14		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205003Orig1s000MedR.pdf	Homo sapiens												75	279	hypertension	10 mg QD; 6 weeks			amlodipine	65			6	week		205003Orig1s000MedR.pdf p.85
9711	39388						mg	180		single			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205003s000lbl.pdf	Homo sapiens													1	hypertension								1	day		
9712	39390		adult			Recommended	mg	4		steady			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/12076191/	Homo sapiens													320	hypertension								6	month		
9713	39411		adult			Recommended	%	1		multiple			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/31985943/	Homo sapiens										cream				pediculosis								7	day		
9714	39411		adult			Recommended	%	5		multiple			day	1	unhealthy	topical	unknown		https://pubmed.ncbi.nlm.nih.gov/31985943/	Homo sapiens										cream				scabies								7	day		
9715	39411		adult			Recommended	ug/kg	200		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/31985943/	Homo sapiens														crusted scabies								7	day		
9716	39464					Highest studied dose	mg	10		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22196768	Homo sapiens												52	20	Allergic rhinitis	60 mg; single			fexofenadine, p.o	21						p.411
9717	39468					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens						63.6				On Schedule A, patients received PF-03814735 QD on days 1–5 of a 21-day cycle;			7	Cancer								5	day		p.2259
9718	39468					MTD	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens						63.6				On Schedule B, PF-03814735 was administered QD on days 1–10 of a 21-day cycle.			13	Cancer								10	day		p.2259, 2260
9719	39468					MTD	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21852114	Homo sapiens						63.6				On Schedule A, patients received PF-03814735 QD on days 1–5 of a 21-day cycle;			15	Cancer								5	day		p.2259
9720	39469					Highest studied dose	mg	3		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/results/NCT01488877	Homo sapiens												64	6	Type 2 Diabetic Nephropathy					45			14	day		
9721	39473		ADULT			Studied dose	mg	30		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/21098644	Homo sapiens													6												p.386
9722	39476					Highest studied dose	mg	25		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30597771	Homo sapiens						36.3							15	Sickle Cell Disease								29	day		p.184
9723	39496		adult			Highest studied dose	mg	30		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21847689/ | https://link.springer.com/chapter/10.1007/164_2020_401	Homo sapiens																						1	day		
9724	39502					Highest studied dose	mg	15		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17986636	Homo sapiens							unknown					55	9						18			14	day		
9725	39509					Highest studied dose	mg/m2	66		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21368575	Homo sapiens						57.1				median of two cycles per patient (range, 1–8) and a median treatment duration of 8.14 weeks (range 0.86–34.00 weeks).			3	Cancer								8.14	week		p.965
9726	39837		adult			MTD	mg	1000		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/21188521/	Homo sapiens													2	HCC											
9727	39837					Highest studied dose	mg	200		steady			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/8066968/	Homo sapiens						39							1	overdose of brodifacoum					39			5	month		
9728	39864		ADULT			Studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8491012/	Homo sapiens						63.4							1150	peripheral vascular disease								18	month		p.1565
9729	39864		ADULT			Studied dose	mg	300		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8971437/	Homo sapiens													230	diabetes mellitus											p.783
9730	40105					Highest studied dose	mg	100		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10543315	Homo sapiens							unknown						6												
9731	40616		adult			Studied dose	mg	1000		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4847425/	Homo sapiens							mean						32	heroin and methadone dependence								66	day		
9732	40616		adult			Studied dose	mg	200		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/4936999/	Homo sapiens													48	pain								6	hour		
9733	40616		adult			Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://jamanetwork.com/journals/jama/article-abstract/351679	Homo sapiens							mean						272	heroin dependence								300	day		
9734	40616					Highest studied dose	mg	1700		multiple			day	1	unhealthy	oral	M		https://www.tandfonline.com/doi/abs/10.1080/02791072.1974.10471830	Homo sapiens						29							1	heroin dependence					29			22	day		
9735	40616					Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/805264/	Homo sapiens						28.5	starting			The initial detoxification dosage of propoxyphene napsylate was 800 mg. Dose of propoxyphene napsylate was systematically reduced to zero over a 21-day period.			32	heroin dependence								21	day		
9736	40781					Highest studied dose	mg	1.4		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13378636	Homo sapiens																									
9737	40781					Highest studied dose	ug/kg	2.5		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13785790	Homo sapiens													10	hypertension								2	min		
9738	40781					Studied dose	mg	3.6		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13460332	Homo sapiens												56	2	HYPERTENSION					40			11	month		
9739	40782					Highest studied dose	mg	17		multiple					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13378636	Homo sapiens										17 mg was administered in a period of 29 hours, beginning with an initial dose of 4 mg.			1												
9740	40782					Highest studied dose	mg	7.5		single					unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/13378636	Homo sapiens																									
9741	40782					Highest studied dose	ug/kg	4.3		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13785790	Homo sapiens													13	hypertension								2	min		
9742	40814					Highest studied dose	mg	1.148		multiple			day	3	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9342768	Homo sapiens										Two tabletes of LI 160 t.i.d. were administered for 2 weeks		35	50						21			2	week		
9743	40814					Highest studied dose	mg	6.88		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/9342768	Homo sapiens										single oral doses of 12 tablets containing L1160. Pseudohypericin content of one tablet LI160 was 574 ug.		35	13						21						
9744	40862					Highest studied dose	mg/m2	470		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/28808818/	Homo sapiens						59				median duration; administered intravenously over 1 h on days 1 and 8 of 21-day cycles			1	solid tumors								42	day		
9745	40991						%	10		multiple			day	1	unhealthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/3835960	Homo sapiens						77							1	Psoriasis					77			40	year		
9746	40991						g	10		single					unknown	topical			https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/pyrogallol_508.pdf	Homo sapiens										(a dose of 143 mg/kg [1.13 mmol/kg] based on a 70-kg body weight)			1												
9747	41037		ADULT			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32212527	Homo sapiens														pulmonary tuberculosis								2	week		p.2
9748	41113		adult				g	9.75		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/14640479	Homo sapiens													1												
9749	41113					Overdose	g	1.8		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/28778932	Homo sapiens						46							1						46						
9750	41113					Overdose	mg	16250		single					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/8340583	Homo sapiens						49				fifty 325 mg tablets of quinine sulfate			1						49						
9751	41113						g	12.6		multiple					unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/17967270	Homo sapiens						32	total						1						32			3	week		
9752	41113						g	5		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2566088	Homo sapiens						17							1						17						
9753	41427					Highest studied dose	mg	10.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens						53							4	Cancer											p.4798
9754	41427					MTD	mg	10.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens						53							4	Cancer											p.4798
9755	41427					MTD	mg	8.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22767668	Homo sapiens						53							9	Cancer											p.4798
9756	41427					MTD	mg	8.5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24947927	Homo sapiens												86	95	Cancer					20						p.4254
9757	41431		ADULT			Highest studied dose	mg/m2	1920		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens						60						85	3	leukemia					19			10	day		p.7
9758	41431		ADULT			MTD	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26459177	Homo sapiens						60						85	30	leukemia					19			10	day		p.7
9759	41461		ADULT			Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33122694/	Homo sapiens						73.42							12	Alzheimer disease								48	week		p.2
9760	41537		ADULT			Highest studied dose	mg	0.66		multiple			day	3	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20633465/	Homo sapiens						34.8	total daily dose						20	obesity	6.75 mg			evodiamine				8	week		128-38
9761	41695					Highest studied dose	mg	1800		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens						60							6	Cancer											p.147
9762	41695					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens						61							21	Liposarcoma											p.147
9763	41695					MTD	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens						61							7	Cancer											p.147
9764	41695					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28324749	Homo sapiens						61							7	Cancer											p.147
9765	41699					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21508860/	Homo sapiens								1 mg; oral; 1/day				62	26	obsessive compulsive disorder	60 mg; oral; 1/day			Fluoxetine	19			10	week	Risperidone	
9766	42037					MTD	mg/m2	100		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens						61				every-other-day (QOD) 3 weeks on/1 week off			5	Cancer								3	week		p.2900
9767	42037					MTD	mg/m2	67		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens						61				once-daily (QD) 3 weeks on/1 week off			1	Cancer								3	week		p.2900
9768	42037					Studied dose	mg/m2	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens						61							3	Cancer								28	day		p.2900
9769	42037					Studied dose	mg/m2	89		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25262379	Homo sapiens						61				once-daily (QD) 3 weeks on/1 week off			3	Cancer								3	week		p.2900
9770	42362		adult			Recommended	g	3		single					unknown	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/6985742/	Homo sapiens													48	used for diagnosis											
9771	42362					Overdose	g	75		single					unknown	oral	M		https://pubmed.ncbi.nlm.nih.gov/418662/	Homo sapiens						42							1	used for diagnosis					42						
9772	42436						%	30		multiple			2 weeks	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/27904577/	Homo sapiens						23.05				salicylic acid 30% was applied on the patient's face with a cotton applicator			43	Acne vulgaris								8	week		
9773	42775					Highest studied dose	g	3		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22616762	Homo sapiens													4									7	week		p.189
9774	42775					Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26595549	Homo sapiens						43.7							15	Ulcerative Colitis								8	week		p.609
9775	42915					Studied dose	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/14693305	Homo sapiens						52						75	168	essential hypertension					20			2	year		
9776	43003						g	1.3		multiple			hour	1	unhealthy	oral	M+F		https://jamanetwork.com/journals/jama/article-abstract/435863	Homo sapiens										Strontium salicylate was given in 20 grain doses combined with an equal amount of sodium bicarbonate, hourly, until symptoms of intoxication appeared. The extremes of the toxic dose are 80 and 500 grains. The mean dose is 180.		48	29	inflammatory condition (rheumatic fever, tonsillitis, and endocarditis mainly)	1.3 g; 1/hour			sodium bicarbonate	12			25	hour		
9777	43124					Recommended	g	1		multiple			day	6	unhealthy	oral			https://jamanetwork.com/journals/jama/article-abstract/307661	Homo sapiens										The oral dosage of sulfathiazole in the treatment of older children and adults with pneumonia consisted of an initial dose of from 2 to 4 Gm. and then 1 Gm. every four hours until the temperature remained normal for forty-eight hours. The dose then was gradually reduced and therapy was discontinued on the fifth to the seventh day.			100	infection								6	day		
9778	43229					Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22240796	Homo sapiens						63							2	Cancer											p.668
9779	43229					MTD	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22240796	Homo sapiens						62.5							4	Cancer											p.668
9780	43285					Highest studied dose	mg	50		single					healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/33214209	Homo sapiens						32.8							4												p.8
9781	43285					Studied dose	mg	10		multiple			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/33214209	Homo sapiens						79.2							5	Idiopathic pulmonary fibrosis								14	day		p.8
9782	43356		ADULT			Studied dose	mg/mL	70		multiple			day	1	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/15475427	Homo sapiens						54.3				One hundred milliliters of Tempol  (70  mg/mL) in 70%  EtOH was applied uniformly to the patient’s scalp 15 minutes before each fraction of radiation.		83	12	alopecia					32						p.6414
9783	43589					Highest studied dose	mg	1000		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18427285	Homo sapiens						30							6						30			7	day		
9784	43651		ADULT			Studied dose	mg	30		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27363313	Homo sapiens						42.7							11									6	day		p.7, 8
9785	43664		ADULT			Studied dose	%	2		multiple			day	1	healthy	topical	F		https://pubmed.ncbi.nlm.nih.gov/33683782	Homo sapiens													59	skin								12	week		
9786	43705		ADULT			Studied dose	%	2		multiple			day	2	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/21725874/	Homo sapiens						31.2							22	dermatophytosis								4	week		p.502, 503
9787	43746		adult			Highest studied dose	mg/m2	650		multiple			week	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/14977826/	Homo sapiens										2 hour infusional schedule			3	Advanced Solid Tumors								4	week		
9788	43746					Highest studied dose	mg/m2	800		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/8729947/	Homo sapiens										24 hour infusional schedule		68	3	refractory solid tumors					38			4	week		
9789	43770		ADULT			Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30580081/	Homo sapiens							max						46	anxiety disorder								8	week		31-37
9790	43814					Recommended	mg	120		steady			day	3	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/13005124/	Homo sapiens						16							1	epilepsy					16			9	month		
9791	43999					Highest studied dose	g/m2	75		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/7471098/	Homo sapiens						26	total					68	11	cancer					11			5	day		
9792	44033					Higher than recommended	mg	1200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8427515/	Homo sapiens												87	6	Paget's disease of bone					57			5	day		
9793	44033					Higher than recommended	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9307742/	Homo sapiens						68							28	Paget's disease of bone					68			24	week		
9794	44033					Higher than recommended	mg	800		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8911885/	Homo sapiens												45	10						18			12	day		
9795	44033					Recommended	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9307742/	Homo sapiens						72							29	Paget's disease of bone					72			24	week		
9796	44293					Studied dose	%	1		single			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/1838318/	Homo sapiens						30				patch test			1						30			1	day		
9797	44293					Studied dose	%	90		multiple					healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/8673514/	Homo sapiens						31				many hours during a weekend			1						31			2	day		
9798	44293					Studied dose	oz	1		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/5951961/	Homo sapiens						47							1						47			1	day		
9799	44293					Studied dose	ppm	1380		single			day	1	healthy	respiratory	M		https://www.tandfonline.com/doi/abs/10.1080/00028896109343404	Homo sapiens							mean					60	7						30			15	min		
9800	44293					Studied dose	ppm	17718		multiple					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/2669664/	Homo sapiens						27	max			Industrial hygiene samples for 1,1,1-TCE obtained over an 11-year period were reviewed. They ranged from 35 ppm (one tenth of the permissible exposure level of 350 ppm) to 17 718 ppm (50-fold the permissible exposure level).			1						27			4	year		
9801	44293					Studied dose	ppm	735		multiple					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/7329041/	Homo sapiens						16							1						16			6	week		
9802	44476					Studied dose	mg	500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19324944	Homo sapiens						39.9							15												p.1023
9803	44576		ADULT			Highest studied dose	mg/m2	7		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/2208579	Homo sapiens										Trimethylcolchicinic acid (TMCA) given orally once daily for 5 days every 3rd week		67	2	cancer					64			5	day		p.360, 361
9804	44576		ADULT			RP2D	mg/m2	5		multiple			day	1	unhealthy	oral	M		https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1525-1411.1999.14010.x	Homo sapiens						72				TMCA, 5 mg/m2/day, was given orally for 4 days with cycles repeated every 3 weeks (median 2 cycles; range 1–8 cycles)		86	12	prostate cancer					61			4	day		p.198,199
9805	44576		ADULT			RP2D	mg/m2	5		multiple			day	1	unhealthy	oral	M		https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1525-1411.1999.14010.x	Homo sapiens						72				TMCA, 5 mg/m2/day, was given orally for 5 days		86	6	prostate cancer					61			5	day		p.198,199
9806	44576		ADULT			RP2D	mg/m2	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2208579	Homo sapiens										Trimethylcolchicinic acid (TMCA) given orally once daily for 5 days every 3rd week		74	11	cancer					37			5	day		p.360, 361
9807	44687		adult			Highest studied dose	mg/m2	0.8		multiple			week	5	unhealthy	intravenous			https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps472 | https://cancerres.aacrjournals.org/content/75/15_Supplement/CT207.short	Homo sapiens										4 week cycle; as Minnelide prodrug			3	gastrointestinal malignancies								21	day		
9808	44687					Studied dose	mg	45		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16150204/	Homo sapiens						31.6	mean						103	psoriasis vulgaris								60	day		
9809	44687					Studied dose	mg/kg	1		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24455682/	Homo sapiens						8.26				6 to 9 months duration			42	Henoch-Schönlein purpura nephritis	2 mg/kg; oral; 1/day			prednisone				6	month		
9810	44687					Studied dose	ug	470		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/22847205/	Homo sapiens						69							1	rheumatoid arthritis	oral; 1/day			tripdiolide	69			10	year		
9811	44904		ADULT			Highest studied dose	mg/m2	234		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23053399	Homo sapiens						67				Intravenous (IV) infusion over 1 h weekly for 3 weeks followed by 1 week of no treatment. The median number of cycles administered per patients was 2 (range = 1–5)		81	3	cancer					23			3	week		p.5
9812	44964		ADULT			Highest studied dose	mg	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2969799/	Homo sapiens						54.7							9	essential hypertension								8	week		p.94
9813	44964		ADULT			Studied dose	mg	120		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3519043/	Homo sapiens						45.5						53	8	hypertension					33						p.694,695
9814	44964		ADULT			Studied dose	mg	90		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/3519043/	Homo sapiens						45.5						53	9	hypertension					33						p.694,695
9815	44991					Highest studied dose	mg/m2	130		single					unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/23134084	Homo sapiens						19	total daily dose					23	3	solid tumors					19						
9816	44991					MTD	mg/m2	94		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23134084	Homo sapiens						21	unknown					29	11	solid tumors					20						
9817	44991					Studied dose	mg/m2	74		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23134084	Homo sapiens						23	unknown					24	6	solid tumor					20						
9818	45009					Highest studied dose	g	4.5		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12197992/	Homo sapiens						26							10									9	day		
9819	45177					Studied dose	%	2		single			day	1	healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/13929916/	Homo sapiens												55	6						25			5	min		
9820	45177					Studied dose	ppm	683		multiple					unhealthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/27544804/	Homo sapiens						78	total yearly dose						1						78			6	year		
9821	45180					Recommended	mL	3		single					unhealthy	respiratory			https://pubmed.ncbi.nlm.nih.gov/20782931/	Homo sapiens										Anaesthesia was produced by means of a Goldman inhaler, using 3 c.cm. of vinesthene for each case.		9	2210	dental extractions					3						
9822	45218		ADULT			Studied dose	mg	360		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/14664747/	Homo sapiens						45.77				The powder contains the flavonoids vitexin and isovitexin\n(9:1 approximate ratio). Vitexina capsules (350 mg) contain 100 mg\nVitexina powder each. Patients in the Vitexina group received 4 capsules\n(400 mg active compounds) daily during 6 weeks of radiation therapy.			36	breast cancer								6	week		p.40
9823	45220					Highest studied dose	mg	135		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/30460505	Homo sapiens						63				VLX600 was administered intravenously on days 1, 8, and 15 of each 28-day treatment cycle.			1	Cancer								1.8	cycle		p.4
9824	45237					Highest studied dose	mg	600		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24470465	Homo sapiens						27							6									10	day		p.4
9825	45275					Highest studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://www.nature.com/articles/s41416-021-01389-8	Homo sapiens														Cancer											
9826	45290					Highest studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29563138/	Homo sapiens						56							10	non-small cell lung cancer								28	day		
9827	45290					Studied dose	mg	142		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29563138/	Homo sapiens						56	mean						97	non-small cell lung cancer								28	day		
9828	45290					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29563138/	Homo sapiens						56							8	non-small cell lung cancer								28	day		
9829	45290					Studied dose	mg	225		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31628085/	Homo sapiens						52				median duration			160	non-small-cell lung cancer								294	day		
9830	45300		adult			Studied dose	mg	24		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/33028396/	Homo sapiens																						8	week		
9831	45324					Highest studied dose	mg	2750		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18425419/	Homo sapiens						53	unknown			over 30 to 60 min on days 1, 3, and 5 of a 21-day cycle		85	14	acute leukemia					20			21	day		
9832	45324					MTD	mg/m2	260		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17103044/	Homo sapiens						55.6				5 or 20 min IV infusion on days 1-5 every 21 days		80	6	solid tumours					16			5	day		
9833	45324					RP2D	mg	1750		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18425419/	Homo sapiens						53	total daily dose					85	12	acute leukemia					20			21	day		
9834	45324					Studied dose	mg	2200		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18425419/	Homo sapiens						53				over 30 to 60 min on days 1, 3, and 5 of a 21-day cycle		85	14	acute leukemia					20			21	day		
9835	45324					Studied dose	mg/m2	346		multiple			day	1	unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/17103044/	Homo sapiens						55.6	unknown			5 or 20 min IV infusion on days 1-5 every 21 days		80	2	solid tumours					16			5	day		
9836	45325					Highest studied dose	mg	3200		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens						60							5	Cancer											p.5
9837	45325					MTD	mg	2500		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/18650079	Homo sapiens						60							12	Cancer											p.5
9838	45328					MTD	mg/kg	6.5		multiple			week	1	unhealthy	intravenous	M+F		DOI:10.1200/jco.2010.28.15_suppl.3105	Homo sapiens						60.1				Patients receive XL228 as a weekly 1-hour IV infusion.			43	Cancer											
9839	45330		adult			MTD	mg	135		multiple			week	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/29674508/	Homo sapiens														solid tumors								8	week		
9840	45330					Highest studied dose	mg	135		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29674508/ | https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9544	Homo sapiens						60							6	Melanoma	960 mg; oral; 2/d			Vemurafenib				8	week		
9841	45330					Highest studied dose	mg	90		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29674508/ | https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9544	Homo sapiens						60							9	Melanoma	960 mg; oral; 2/d			Vemurafenib				8	week		
9842	45330					MTD	mg	60		multiple			week	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9553	Homo sapiens						62		40 mg; oral; 1/d					12	Melanoma	720 mg; oral; 2/d			Vemurafenib				4	week	cobimetinib	
9843	45330					Studied dose	mg	60		multiple			week	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9553	Homo sapiens						62		60 mg; oral; 1/d						Melanoma	960 mg; oral; 2/d			Vemurafenib				4	week	cobimetinib	
9844	45330					Studied dose	mg	75		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29674508/	Homo sapiens						60	mean						21	Melanoma	960 mg; oral; 2/d			Vemurafenib				8	week		
9845	45330					Studied dose	mg	90		multiple			week	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.830	Homo sapiens						66.5							3	gastrointestinal adenocarcinomas	200 mg; IV; 1/3 weeks			pembrolizumab				3	week		
9846	45349					Highest studied dose	mg	1		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8739023	Homo sapiens							unknown					39	9						20			3	day		
9847	45398		ADULT			Highest studied dose	mg	20		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28079755/	Homo sapiens												79	5	telangiectasia					38			24	month		2238-2247
9848	45742					Highest studied dose	mg	40		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22966986	Homo sapiens													9												p.1034
9849	45742					Highest studied dose	mg	8		multiple			day	2	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22966986	Homo sapiens													9									7	day		p.1034
9850	45837		ADULT			Highest studied dose	mg	22		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27650277	Homo sapiens						58				Patients received oral TAK-733 once daily on days 1–21 of 28-day treatment			7	cancer								21	day		p.50
9851	45837					MTD	mg	16		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27650277	Homo sapiens						58				Patients received oral TAK-733 once daily on days 1–21 of 28-day treatment cycles.			7	cancer								21	day		p.50
9852	45889					Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25920479	Homo sapiens						69							5	Prostate cancer											p.679
9853	45889					Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25920479	Homo sapiens						69							5	Prostate cancer											p.679, p.682
9854	45910		ADULT			Highest studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						59							3	cancer								2	week		99-108
9855	45910		ADULT			Highest studied dose	mg	180		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						53.5							3	cancer								3	week		99-108
9856	45910		ADULT			MTD	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						59							6	cancer								2	week		99-108
9857	45910		ADULT			MTD	mg	150		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						53.5							6	cancer								3	week		99-108
9858	45910		ADULT			Studied dose	mg	130		multiple			week	5	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						53.5							6	cancer								3	week		99-108
9859	45910		ADULT			Studied dose	mg	26		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						59							6	cancer								2	week		99-108
9860	45910		ADULT			Studied dose	mg	33		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26650227/	Homo sapiens						59							6	cancer								2	week		99-108
9861	45918					Highest studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27129013	Homo sapiens												55							18						p.399
9862	45929					Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24691844	Homo sapiens													6												p.982
9863	45939					Highest studied dose	mg	300		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/25039273	Homo sapiens						43.5							6												p.1337
9864	45956		ADULT			Highest studied dose	mg/m2	295		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens						54.5				21-day cycles		72	5	cancer					34			21	day		p.533, 534, 536
9865	45956		ADULT			MTD	mg/m2	107.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens						55.5				21-day cycles		74	3	cancer					34			21	day		p.533, 536
9866	45956		ADULT			MTD	mg/m2	210.7		multiple			2 days	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens						54.5				21-day cycles		72	3	cancer					34			21	day		p.533, 536
9867	45956		ADULT			Studied dose	mg/m2	150.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30679388	Homo sapiens						55.5				21-day cycles		74	3	cancer					34			21	day		p.533, 536
9868	45957		ADULT			Highest studied dose	mg	480		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31359240	Homo sapiens						64				seven days every 3 weeks			6	cancer								7	day		p.834
9869	45957		ADULT			Studied dose	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31359240	Homo sapiens						64				Seven days every 3 weeks; Based on the protocol-specified definition using DLTs incidence, the MTD for AMG 232 for 7 days Q3W was not reached. However, when the DLTs and delayed cytopenias were considered, the highest safe and tolerable dose of AMG 232 was 240 mg			68	cancer								7	day		p.834, 835
9870	45957		ADULT			Studied dose	mg	360		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31359240	Homo sapiens						64				seven days every 3 weeks			4	cancer								7	day		p.834
9871	45967					Highest studied dose	mg	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26177599/	Homo sapiens										28-day cycles		80	7	advanced solid tumors or multiple myeloma					25			2	cycle		
9872	45967					MTD	mg	45		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26177599/	Homo sapiens										28-day cycles		80	9	advanced solid tumors or multiple myeloma					25			2	cycle		
9873	45967					MTD	mg	45		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31527867/	Homo sapiens										28-day cycles			24	solid tumors								2	cycle		
9874	45967					Studied dose	mg	26		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31527867/	Homo sapiens							mean			28-day cycles			47	solid tumors								13.5	cycle		
9875	45967					Studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26177599/	Homo sapiens										28-day cycles		80	9	advanced solid tumors or multiple myeloma					25			2	cycle		
9876	45972					Highest studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens						54				mean exposure			3	Hematologic Malignancies								88	day		
9877	45972					Highest studied dose	mg	800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31761713/	Homo sapiens						54				mean exposure			3	Hematologic Malignancies								70	day		
9878	45972					MTD	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32824175/	Homo sapiens						67.1				fasted cohort			39	T-Cell Lymphoma								224	day		
9879	45972					Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32824175/	Homo sapiens						67.1				fed cohort			5	T-Cell Lymphoma								28	day		
9880	45976					Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens						54							6	Cancer											p. 10469
9881	45976					MTD	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens						62							6	Cancer											p. 10469
9882	45976					MTD	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens						54							7	Cancer											p. 10469
9883	45976					Studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31853198	Homo sapiens						62							6	Cancer											p. 10469
9884	45981					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://ashpublications.org/blood/article/128/22/625/95414/Expanded-Phase-1-Study-of-ABL001-a-Potent	Homo sapiens						55				median duration			5	chronic myeloid leukemia								34	week		
9885	45981					Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31826340/	Homo sapiens						54							16	Chronic Myeloid Leukemia								12	month		
9886	45981					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://ashpublications.org/blood/article/128/22/625/95414/Expanded-Phase-1-Study-of-ABL001-a-Potent	Homo sapiens						55				median duration			9	chronic myeloid leukemia								34	week		
9887	45981					Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31826340/	Homo sapiens						54							13	Chronic Myeloid Leukemia								12	month		
9888	45981					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://ashpublications.org/blood/article/128/22/625/95414/Expanded-Phase-1-Study-of-ABL001-a-Potent	Homo sapiens						55				median duration			5	chronic myeloid leukemia								34	week		
9889	45981					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31826340/	Homo sapiens						57							12	Chronic Myeloid Leukemia								12	month		
9890	45981					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://ashpublications.org/blood/article/128/22/625/95414/Expanded-Phase-1-Study-of-ABL001-a-Potent	Homo sapiens						55				median duration			30	chronic myeloid leukemia								34	week		
9891	45981					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31826340/	Homo sapiens						54							35	Chronic Myeloid Leukemia								12	month		
9892	45981					Studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://ashpublications.org/blood/article/128/22/625/95414/Expanded-Phase-1-Study-of-ABL001-a-Potent	Homo sapiens						55				median duration			14	chronic myeloid leukemia								34	week		
9893	45981					Studied dose	mg	80		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31826340/	Homo sapiens						54							12	Chronic Myeloid Leukemia								12	month		
9894	45997		ADULT			Highest studied dose	mg	180		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31797489	Homo sapiens						65							3	cancer											p.574
9895	46009		ADULT			Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/results/NCT02349633	Homo sapiens						61	unknown					74	4	Non-small cell lung cancer					46			21	day		
9896	46019					Highest studied dose	mg	50		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22362161/	Homo sapiens						48							2	solid tumors								4	week		
9897	46019					MTD	mg	32.5		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22362161/	Homo sapiens						48							7	solid tumors								4	week		
9898	46019					Recommended	mg	30		multiple			week	2	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/31036468/	Homo sapiens						55							244	breast cancer	25 mg orally: daily			exemestane				4	week		
9899	46019					Studied dose	mg	20		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33097085/	Homo sapiens						67		750 mg/m2 IV; day 1		plus vincristine 1.4 mg/m2 IV on day 1 and prednisone 60 mg/m2 orally on days 1–5			49	diffuse large B-cell lymphoma	375 mg/m2 IV; day 0		doxorubicin	rituximab			50 mg/m2 IV; day 1	2	week	cyclophosphamide	
9900	46019					Studied dose	mg	50		multiple			week	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22362161/	Homo sapiens						48							4	solid tumors								4	week		
9901	46021					Recommended	mg	32		multiple			day		unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/638709/	Homo sapiens										Cyproheptadine doses of between 16 and 32 mg daily for periods up to nine months.			20	endocrine disorders								9	month		
9902	46021					Recommended	mg	6		multiple			day		unhealthy	digestive tract route	M+F		https://pubmed.ncbi.nlm.nih.gov/23419589/	Homo sapiens						9.8	median			Median dose of cyproheptadine was 6mg per day, equivalent to 0.19mg/kg/day with a range of 0.04-0.62 mg/kg/d. Median duration of therapy was 20 weeks with a range of 2-222 weeks. Only 1 patient was treated for 2 weeks (stopped due to side effects) and the rest for > 4 weeks.			80	refractory upper gastrointestinal symptoms								20	week		
9903	46021					Recommended	mg/kg	0.227		multiple			day	3	unhealthy	digestive tract route	M+F		https://pubmed.ncbi.nlm.nih.gov/27194450/	Homo sapiens							median			The daily starting dose ranged widely with a median of 0.227 mg/kg/day (range 0.069–0.825 mg/kg/day). The medication was usually prescribed TID but was sometimes started QD and titrated up to TID.			39	feeding intolerance or vomiting											
9904	46021						mg	22.5		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/2699315/	Homo sapiens						4				A four year old child with a history of alleged accidental ingestion of half a bottle of cyproheptadine (Peritol drops) containing approximately 22.5 mg of the drug, which is ten times the therapeutic dose.			1												
9905	46110					Highest studied dose	mg	3000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16357512/	Homo sapiens						57.5							3	solid tumors								28	day		
9906	46110					MTD	mg	1000		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19228747/	Homo sapiens						64.4				NanoCrystal Dispersion formulation			3	solid tumors								28	day		
9907	46110					Studied dose	mg	1000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19228747/	Homo sapiens						64.3				NanoCrystal Dispersion formulation			10	solid tumors								28	day		
9908	46110					Studied dose	mg	1500		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19228747/	Homo sapiens						64.4				NanoCrystal Dispersion formulation			3	solid tumors								28	day		
9909	46110					Studied dose	mg	500		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19228747/	Homo sapiens						64.4				NanoCrystal Dispersion formulation			7	solid tumors								28	day		
9910	46174		adult			Highest studied dose	mg	1600		single			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/19442208/ | https://www.fiercebiotech.com/biotech/press-release-neuromed-pharmaceuticals-says-to-end-development-of-pain-drug	Homo sapiens														pain								1	day		
9911	46180					Highest studied dose	mg	700		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053021	Homo sapiens							unknown					78	4	Advanced Solid Malignancies					38			28	day		
9912	46180					Studied dose	mg	100		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32564277	Homo sapiens							unknown						6	advanced solid tumors	200 mg intravenously (IV) Q3W			pembrolizumab				7	day		
9913	46180					Studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053021	Homo sapiens							unknown					78	6	Advanced Solid Malignancies					38			28	day		
9914	46180					Studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28053021	Homo sapiens							unknown					78	11	Advanced Solid Malignancies					38			28	day		
9915	46260					Highest studied dose	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28420720	Homo sapiens						60							2	Cancer								28	day		p.20
9916	46260					Highest studied dose	mg	750		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28420720	Homo sapiens						60							4	Cancer								28	day		p.20
9917	46260					MTD	mg	500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28420720	Homo sapiens						60							6	Cancer								28	day		p.5
9918	46291		ADULT			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22392572	Homo sapiens						48						68	6	glioblastoma					29						p.8
9919	46291		ADULT			MTD	mg	450		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23014528	Homo sapiens						57						78	6	cancer					20			95	day		p.6367
9920	46291		ADULT			Studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23014528	Homo sapiens						57						78	6	cancer					20			54	day		p.6367
9921	46291		ADULT			Studied dose	mg	550		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23014528	Homo sapiens						57						78	6	cancer					20			54	day		p.6367
9922	46300					Highest studied dose	mg/h	1300		multiple			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/7660927/	Homo sapiens						29	max			once or twice per day			1	Lesch-Nyhan syndrome	400 mg; oral; 1/d			allopurinol	29			12	day		
9923	46300					Highest studied dose	mg/kg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/7660927/	Homo sapiens						16	max			30 mg/kg/day for four days followed by 100 mg/kg/day for four days			1	Lesch-Nyhan syndrome	400 mg; oral; 1/d			allopurinol	16			8	day		
9924	46300					Highest studied dose	mg/kg/h	45		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/18709353/	Homo sapiens						64							10	type 2 diabetes								1	day		
9925	46310					Highest studied dose	mg	400		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17452489	Homo sapiens							unknown						6									1	week		
9926	46311					Highest studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26155941	Homo sapiens						60.5				Patients received AMG 208 orally on days 1 and days 4-28 once daily.			8	Cancer											p.18696
9927	46312					Highest studied dose	mg	10		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18337008	Homo sapiens							unknown					34	6						18			7	day		
9928	46312					Highest studied dose	mg	25		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18337008	Homo sapiens							unknown					34	7						18						
9929	46315					Highest studied dose	mg	100		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/28370201	Homo sapiens						71				4 days on/10 days off			1	Acute myeloid leukemia											p.15
9930	46315					MTD	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29980894	Homo sapiens						57				4 days on/10 days off			7	Cancer											p.7
9931	46315					MTD	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29980894	Homo sapiens						57				4 days on/10 days off			11	Cancer	300 or 480 μg; dosage based on weight; q.d			G-CSF, s.c							p.7
9932	46331		ADULT			Highest studied dose	mg	3200		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2608	Homo sapiens													3	cancer								28	day		
9933	46331		ADULT			RP2D	mg	800		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2608	Homo sapiens													7	cancer								28	day		
9934	46331		ADULT			Studied dose	mg	1600		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2608	Homo sapiens													7	cancer								28	day		
9935	46342		ADULT			Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25716544	Homo sapiens						52				Oral treatment had to be taken daily on days 1–5, initially every 14 days,  later every 21 days			6	cancer								5	day		p.854
9936	46343		ADULT			MTD	mg/m2	32.4		multiple			3 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25393368	Homo sapiens						61				1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks.		77	5	cancer					40			1	cycle		p.2264
9937	46343		ADULT			RP2D	mg/m2	27		multiple			3 weeks	4	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25393368	Homo sapiens						61				1-h intravenous infusion on days 1, 4, 8 and 11 every 3 weeks.		77	15	cancer					40			2	cycle		p.2264
9938	46353		ADULT			Studied dose	mg	15		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23410232	Homo sapiens												64	6						45			14	day		p.453
9939	46359					Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29765150	Homo sapiens						65							9	Acute myeloid leukaemia											p.1430
9940	46359					Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29765150	Homo sapiens						65							6	Cancer											p.1430
9941	46361					Highest studied dose	mg	45		single			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23847256/	Homo sapiens						54							3	solid tumours | lymphoma								1	day		
9942	46361					Highest studied dose	mg	70		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25530567/	Homo sapiens						56				median duration			1	myelofibrosis					56			112	day		
9943	46361					Highest studied dose	mg	70		single			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23847256/	Homo sapiens						54							6	solid tumours | lymphoma								1	day		
9944	46361					Studied dose	mg	2.5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25530567/	Homo sapiens						58				median duration			6	myelofibrosis								98	day		
9945	46361					Studied dose	mg	20		single			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23847256/	Homo sapiens						54							6	solid tumours | lymphoma								1	day		
9946	46361					Studied dose	mg	30		single			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23847256/	Homo sapiens						54							7	solid tumours | lymphoma								1	day		
9947	46361					Studied dose	mg	35		single			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23847256/	Homo sapiens						54							5	solid tumours | lymphoma								1	day		
9948	46361					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25530567/	Homo sapiens						69				median duration			6	myelofibrosis								154	day		
9949	46367					MTD	mg	60		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17115157	Homo sapiens						35.4	unknown					47	4						20						
9950	46367					Studied dose	mg	160		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17115157	Homo sapiens						35.4	unknown					47	8						20						
9951	46369					Highest studied dose	mg	455.8		single			day	1	healthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/22906130/	Homo sapiens						26							6									1	day		
9952	46374					Highest studied dose	mg	40		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24448638/	Homo sapiens						59.5				median duration			8	solid tumours | lymphoma								43	day		
9953	46374					Highest studied dose	mg	40		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24448638/	Homo sapiens						59.5				median duration; combination treatment on days 1 and 8 of a 21-day cycle			8	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				43	day		
9954	46374					MTD	mg	21		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23892959/	Homo sapiens						55				median duration; combination treatment on days 1 and 8 of a 22-day cycle			6	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				26	day		
9955	46374					MTD	mg	30		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24448638/	Homo sapiens						59.5				median duration; combination treatment on days 1 and 8 of a 21-day cycle			7	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				43	day		
9956	46374					Studied dose	mg	30		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23892959/	Homo sapiens						55				median duration; combination treatment on days 1 and 8 of a 22-day cycle			8	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				45	day		
9957	46374					Studied dose	mg	30		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23892959/	Homo sapiens						55				median duration; on days 1 and 8 of a 14-day cycle			8	solid tumours | lymphoma								45	day		
9958	46374					Studied dose	mg	32		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24448638/	Homo sapiens						59.5				median duration			6	solid tumours | lymphoma								43	day		
9959	46374					Studied dose	mg	32		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24448638/	Homo sapiens						59.5				median duration; combination treatment on days 1 and 8 of a 21-day cycle			6	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				43	day		
9960	46374					Studied dose	mg	9		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/23892959/	Homo sapiens						69				median duration; combination treatment on days 1 and 8 of a 22-day cycle			3	solid tumours | lymphoma	1000 mg/m2; IV; 1/week			gemcitabine				65	day		
9961	46375					Highest studied dose	mg	120		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22935583/	Homo sapiens						57				median duration			10	solid tumours | lymphoma								62	day		
9962	46375					MTD	mg	90		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22843211/	Homo sapiens						52				median duration			7	solid tumours | lymphoma								30	day		
9963	46375					MTD	mg	90		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22935583/	Homo sapiens						57				median duration			11	solid tumours | lymphoma								62	day		
9964	46375					Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22935583/	Homo sapiens						57				median duration			6	solid tumours | lymphoma								62	day		
9965	46397		ADULT			Highest studied dose	mg	250		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17638699	Homo sapiens						40.7								HIV infection											p.3577
9966	46397		ADULT			Studied dose	mg	200		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/17596104	Homo sapiens						40							6									10	day		p.594
9967	46400					MTD	mg	125		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22357447	Homo sapiens						60							11	Cancer								28	day		p.2402
9968	46404		ADULT			Highest studied dose	mg	400		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/27406873	Homo sapiens													6												p.203
9969	46404		ADULT			Studied dose	mg	110		steady			day	1	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/27406873	Homo sapiens													6									15	day		p.204
9970	46415		ADULT			RP2D	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://cancerres.aacrjournals.org/content/80/16_Supplement/CT171	Homo sapiens						57.5				4d on/10d off; median duration of exposure (DOE) was 8 weeks				cancer								4	day		
9971	46419					Highest studied dose	mg	660		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21576284/	Homo sapiens						56							6	solid tumors								28	day		
9972	46419					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21576284/	Homo sapiens						56							24	solid tumors								28	day		
9973	46422		ADULT			MTD	mg	200		multiple			day	2	unhealthy	oral	M+F		https://www.researchgate.net/publication/336490176_BMS-911543_A_Selective_JAK2_Inhibitor_A_Multicenter_Phase_12a_Study_In_Myelofibrosis	Homo sapiens														cancer											
9974	46447					Highest studied dose	mg	1200		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19740402	Homo sapiens						37	max			The first dose of BX471 on day 1 was 600 mg, and the 8 h between this and the second administration (also 600 mg) were used for the analyses of the putative therapeutic dose. The third BX471 dose on day 1 and the first on day 2 were 900 mg; the remaining two doses on day 2 and the morning dose on day 3 were 1200 mg.			74									2	day		p.440
9975	46482					Highest studied dose	mg	72		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231405/ | https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3022 | https://www.annalsofoncology.org/article/S0923-7534(19)66450-1/fulltext	Homo sapiens						58.5				Median duration			3	solid tumors								52	day		
9976	46482					Highest studied dose	mg	96		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231405/ | https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3022 | https://www.annalsofoncology.org/article/S0923-7534(19)66450-1/fulltext	Homo sapiens						58.5				Median duration			4	solid tumors								52	day		
9977	46482					MTD	mg	48		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231405/ | https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3022 | https://www.annalsofoncology.org/article/S0923-7534(19)66450-1/fulltext	Homo sapiens						58.5				Median duration			7	solid tumors								52	day		
9978	46482					Studied dose	mg	56		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231405/ | https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.3022 | https://www.annalsofoncology.org/article/S0923-7534(19)66450-1/fulltext	Homo sapiens						58.5				Median duration			5	solid tumors								52	day		
9979	46495					Highest studied dose	mg	1600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16009947/	Homo sapiens						61				21 days repeated every 28 days; 39 courses			13	cancer								21	day		
9980	46495					Highest studied dose	mg	800		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16009947/	Homo sapiens						61				21 days repeated every 28 days; 18 courses			8	cancer								21	day		
9981	46495					MTD	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15483017/	Homo sapiens						58				with food; 21 days repeated every 28 days; 2 - courses median duration			67	cancer								21	day		
9982	46495					MTD	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16009947/	Homo sapiens						61				with food; 21 days repeated every 28 days; 26 courses			15	cancer								21	day		
9983	46495					Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16009947/	Homo sapiens						61				21 days repeated every 28 days; 29 courses			9	cancer								21	day		
9984	46521		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens						51				administered daily in 21-day cycles			5	cancer								21	day		p.1241
9985	46521		ADULT			Highest studied dose	mg	400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17805538	Homo sapiens						51.2							5	cancer								21	day		p.108
9986	46521		ADULT			RP2D	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17317835	Homo sapiens						51				administered daily in 21-day cycles			15	cancer								21	day		p.1241
9987	46532					Recommended	mg	750		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12223253/	Homo sapiens							median					46	8	schizophrenia					23			4	week		
9988	46532					Recommended	mg	900		steady			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17069542/	Homo sapiens												50	49	fragile X syndrome					18			3	week		
9989	46607		ADULT			Highest studied dose	mg	1600		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/12760312/	Homo sapiens						27.5						45	8						18			1	day		93
9990	46607		ADULT			Highest studied dose	mg	800		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/12960117/	Homo sapiens						39.5							8									4	week		3315
9991	46609					Highest studied dose	mg/m2	120		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22072399	Homo sapiens						58	total daily dose			intravenous infusion over 90 minutes on days 1, 8, and 15 of a 28-day cycle		77	2	solid tumors					39			28	day		
9992	46609					Studied dose	mg/m2	100		multiple			3 weeks	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22072399	Homo sapiens						48	total daily dose					69	10	solid tumours					25			28	day		
9993	46609					Studied dose	mg/m2	100		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22072399	Homo sapiens						58	total daily dose			intravenous infusion over 90 minutes on days 1, 8, and 15 of a 28-day cycle		77	10	tumor cancer					39			29	day		
9994	46629					Highest studied dose	mg	340		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31300967	Homo sapiens						62							4	cancer											
9995	46641					Studied dose	mg/kg	20		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21115615	Homo sapiens												82	12	End-stage renal disease					27						
9996	46663					Highest studied dose	mg/kg	1.48		multiple			2 weeks	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/22413863	Homo sapiens										1.48 mg/kg as a 0.5 hr intravenousm infusion every 14 days												0.5	hour		
9997	46682					Highest studied dose	g	4.8		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26079223/	Homo sapiens						22.5							12									6	week		
9998	46682					Studied dose	g	2.4		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23351309/	Homo sapiens						23.7							9									8	week		
9999	46682					Studied dose	g	3		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27560540/ | https://pubmed.ncbi.nlm.nih.gov/26840330/	Homo sapiens						24.3							5									4	week		
10000	46682					Studied dose	mg/kg	48		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27497517/	Homo sapiens						24.8				36 mg/kg body weight (BW) of GAA for the first 4 wk of the intervention; afterward GAA dosage was titrated ≤60 mg/kg (4.5 g) BW of GAA daily.			5									8	week		
10001	46689					Highest studied dose	ug/kg	10		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17416906	Homo sapiens													21	dental pain								15	min		
10002	46692		ADULT			Highest studied dose	mg/m2	102.2		multiple			day	1	unhealthy	intravenous	unknown		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2525	Homo sapiens							unknown			1 hour i.v. infusion on days 1 – 5, every 21 days			9	cancer								5	day		
10003	46692		ADULT			MTD	mg/m2	85		multiple			day	1	unhealthy	intravenous	unknown		https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.2525	Homo sapiens							unknown			1 hour i.v. infusion on days 1 – 5, every 21 days			23	cancer								5	day		
10004	46695					Highest studied dose	mg	100		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens						62				28-day cycle			7	solid tumours								3	week		
10005	46695					Highest studied dose	mg	300		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens						62				28-day cycle			7	solid tumours								3	week		
10006	46695					MTD	mg	225		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens						62				28-day cycle			8	solid tumours								3	week		
10007	46695					MTD	mg	75		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens						62				28-day cycle			6	solid tumours								3	week		
10008	46695					Studied dose	mg	62.5		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/21459796/	Homo sapiens						62	mean			28-day cycle			17	solid tumours								3	week		
10009	46698		adult			Highest studied dose	mg	115		multiple			week	1	unhealthy	intravenous			https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-68.short	Homo sapiens										patients remaining on study from four to at least 30 weeks			3	solid tumors | lymphoma								4	week		
10010	46698		adult			Studied dose	mg	50		multiple			week	1	unhealthy	intravenous			https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-68.short	Homo sapiens										patients remaining on study from four to at least 30 weeks			3	solid tumors | lymphoma								4	week		
10011	46698		adult			Studied dose	mg	75		multiple			week	1	unhealthy	intravenous			https://cancerres.aacrjournals.org/content/68/9_Supplement/LB-68.short	Homo sapiens										patients remaining on study from four to at least 30 weeks			3	solid tumors | lymphoma								4	week		
10012	46757					Highest studied dose	mg	1075		single			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/24488324/	Homo sapiens													8									1	day		
10013	46757					MTD	mg	500		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27789778/	Homo sapiens						57							6	Advanced Non-Small Cell Lung Cancer								28	day		
10014	46757					Recommended	mg	125		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21144613/	Homo sapiens						58							6	non-small-cell lung cancer								28	day		
10015	46757					Recommended	mg	125		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23948351/	Homo sapiens						57				until disease progression or unacceptable toxicity			200	non-small-cell lung cancer											
10016	46757					Recommended	mg	125		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28734822/	Homo sapiens						57				until unacceptable adverse events or intracranial disease progression occurred			85	non-small-cell lung cancer											
10017	46757					Recommended	mg	125		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28945850/	Homo sapiens						56				median duration			147	lung adenocarcinoma								10	month		
10018	46757					Studied dose	mg	100		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21144613/	Homo sapiens						58							13	non-small-cell lung cancer								28	day		
10019	46757					Studied dose	mg	625		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27789778/	Homo sapiens						57							6	Advanced Non-Small Cell Lung Cancer								28	day		
10020	46818		adult			Highest studied dose	mg	250		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19029442/	Homo sapiens													5	leukemia								14	day		
10021	46818		adult			Studied dose	mg	50		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19029442/	Homo sapiens													9	leukemia								14	day		
10022	46820		ADULT			Highest studied dose	%	0.5		multiple			day	1	healthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/29421218	Homo sapiens												65	20						18			30	day		p.13
10023	46824		ADULT			Studied dose	mg	90		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/7786960/	Homo sapiens							total			three 10-mg capsules qid			40	panic disorder								6	week		
10024	46829		ADULT			Highest studied dose	mg	6		multiple			day	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19770002	Homo sapiens							total daily dose						7									10	day		
10025	46829		ADULT			Highest studied dose	mg	6		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19770002	Homo sapiens							total daily dose						8												
10026	46839					MTD	ug/kg	11		multiple					unhealthy	topical			https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf	Homo sapiens										ocular route															
10027	46839					Overdose	ug/kg	10		single					healthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf	Homo sapiens							max			5.5 to 10 mcg/kg															
10028	46839					Recommended	%	0.005		multiple			day	1	unhealthy	topical	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf	Homo sapiens						63.1				0.04 ug/kg			289	open-angle glaucoma | ocular hypertension								12	week		
10029	46860					Highest studied dose	mg/kg	10		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15737556	Homo sapiens						56	total daily dose			10 mg/kg/day x 14 days, every 21 days. Total daily dose was divided into 4 doses.			6	Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix								14	day		p.527
10030	46860					MTD	mg/kg	7.5		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15737556	Homo sapiens						56	total daily dose			7.5 mg/kg/day x 21 days, every 28 days. Total daily dose was divided into 4 doses.			7	Squamous cell carcinoma of the head and neck |Squamous cell carcinoma of the cervix								21	day		p.527
10031	46860					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/8481075	Homo sapiens						50	max			Seventy-seven percent of patients had titrations of lovastatin to 80 mg/d. The drug was administered either as a single dose with the evening meal or as divided doses with the morning and evening meals			745	Hypercholesterolemia								5.2	year		p.1082, 1083
10032	46864					Highest studied dose	mg	120		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26403509	Homo sapiens						59							4	Cancer											p.5
10033	46864					MTD	mg	40		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/26403509	Homo sapiens						59		AUC 6 mg/mL•min; 30-min IV infusion					7	Cancer	500 mg/m2			pemetrexed, i.v						carboplatin, i.v	p.5
10034	46865					Highest studied dose	mg	300		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens						61.5							2	Cancer											p.871
10035	46865					MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens						61.5							3	Cancer											p.871
10036	46865					MTD	mg	75		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24440085	Homo sapiens						61.5							3	Cancer											p.871
10037	46866					Highest studied dose	mg	90		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22090477	Homo sapiens													30												
10038	46869					Highest studied dose	mg/m2	1100		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22921184	Homo sapiens						62	unknown			on day 1 and 4, repeated weekly on a 28-day cycle		84	8	cancer					25			28	day		
10039	46869					Studied dose	mg/m2	180		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22921184	Homo sapiens						62	unknown			on day 1 and 4, repeated weekly on a 28-day cycle		84	6	cancer					25			28	day		
10040	46913					Highest studied dose	mg	3600		multiple			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens													6									7	day		p.380
10041	46913					Highest studied dose	mg	4000		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21291763	Homo sapiens													6												p.380
10042	46916					Highest studied dose	mg	180		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2008.26.15_suppl.14657	Homo sapiens						54							3	Cancer								28	day		
10043	46918					Highest studied dose	mg	3600		multiple			3 weeks	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26620496/	Homo sapiens						63.5	total daily dose			median duration was 5 cycles (by 21 days)			3	solid tumors								105	day		
10044	46918					MTD	mg	300		multiple			3 weeks	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26620496/	Homo sapiens						61	total daily dose			median duration was 5 cycles (by 21 days)			6	solid tumors	60 mg/m2;IV;1/21 day			docetaxel				105	day		
10045	46918					Studied dose	mg	200		multiple			3 weeks	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26620496/	Homo sapiens						61	total daily dose			median duration was 2 cycles (by 21 days)			6	solid tumors	60 mg/m2;IV;1/21 day			docetaxel				42	day		
10046	46918					Studied dose	mg	450		multiple			3 weeks	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26620496/	Homo sapiens						61	total daily dose			median duration was 2 cycles (by 21 days)			5	solid tumors	60 mg/m2;IV;1/21 day			docetaxel				42	day		
10047	46923					Highest studied dose	mg	80		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20607239	Homo sapiens						60	total daily dose						3	Cancer				methylphenidate or modafinil				7	day		p.14
10048	46923					Highest studied dose	mg	80		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20724522	Homo sapiens						60	total daily dose			28-day cycle			6	Cancer								14	day		p.2847
10049	46923					MTD	mg	60		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20607239	Homo sapiens						60	total daily dose						3	Cancer				methylphenidate or modafinil				14	day		p.14
10050	46923					MTD	mg	70		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20724522	Homo sapiens						60	total daily dose			28-day cycle			6	Cancer								14	day		p.2847
10051	46923					Studied dose	mg	70		multiple			day	4	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20607239	Homo sapiens						60	total daily dose						2	Cancer				methylphenidate or modafinil				14	day		p.14
10052	47044					MTD	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens													4	Advanced Cancers								3	week		
10053	47044					Studied dose	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			continuous with breaks (5 d on/2 d off treatment)		86	13	Advanced Cancers					29			5	day		
10054	47044					Studied dose	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			intermittent (3 wk on treatment/1 wk off)		86	7	Advanced Cancers					29			28	day		
10055	47044					Studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			continuous [daily (QD)]		86	6	Advanced Cancers					29			28	day		
10056	47044					Studied dose	mg	15		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20332327/	Homo sapiens						62	unknown			intermittently (3 weeks on/1 week off)		81	13	NSCLC					47			3	week		
10057	47044					Studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			continuous [daily (QD)]		86	6	Advanced Cancers					29			28	day		
10058	47044					Studied dose	mg	20		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			intermittent (3 wk on treatment/1 wk off)		86	5	Advanced Cancers					29			3	week		
10059	47044					Studied dose	mg	30		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20215549/	Homo sapiens						57	unknown			intermittent (3 wk on treatment/1 wk off)		86	6	Advanced Cancers					29			3	week		
10060	47055		adult			Highest studied dose	mg	21		single					healthy	oral			https://pubmed.ncbi.nlm.nih.gov/23558010	Homo sapiens													6												
10061	47056					Highest studied dose	mg	11		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24395457	Homo sapiens						59.6							5	Cancer											p.4
10062	47056					MTD	mg	8		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24395457	Homo sapiens						59.6							12	Cancer											p.4
10063	47061		ADULT			Studied dose	mg	40		single					healthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pubmed/17446264	Homo sapiens						35							8												p.1191
10064	47080		ADULT			Highest studied dose	mg	24		multiple			day	2	healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/22725836/	Homo sapiens												52	8		4 g			curcuminoid	24			2	day		450-62
10065	47127		ADULT			Recommended	mg	10		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/2093414/	Homo sapiens						77.6							99	cognitive disorder	30 mg b.i.d			almitrine				6	month		S103
10066	47131		ADULT			Highest studied dose	g	5		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20935227/	Homo sapiens						25.4						32.8	10						19.2			29	day		9003-11
10067	47131		ADULT			Highest studied dose	g	5		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25845763/	Homo sapiens						39.2	total daily dose						14	Friedreich ataxia								12	week		1344-53
10068	47131		ADULT			Highest studied dose	g	5		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17548692/	Homo sapiens						32.5						61	10						19			1	day		1246-52
10069	47131		ADULT			Studied dose	g	1		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/25115686/	Homo sapiens						58							34	obesity								12	week		223
10070	47135					Highest studied dose	mg	160		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens						64				days 1 to 5 within 1 hour, with cycles repeated once every 28 days			4	solid tumors								5	day		
10071	47135					MTD	mg	120		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens						64				days 1 to 5 within 1 hour, with cycles repeated once every 28 days			6	solid tumors								5	day		
10072	47135					Studied dose	mg	10		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens						64				days 1 to 5 within 1 hour, with cycles repeated once every 28 days			3	solid tumors								5	day		
10073	47135					Studied dose	mg	80		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25024258/	Homo sapiens						64				days 1 to 5 within 1 hour, with cycles repeated once every 28 days			6	solid tumors								5	day		
10074	47140		ADULT			Studied dose	%	1		multiple			day	4	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/383851	Homo sapiens							unknown			The Ro 20-1724 formulation consisted of the same cream with Ro 20-1724 added to a 1% final concentration			17	psoriasis								4	week		
10075	47161					Highest studied dose	ug/kg	21		single					healthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/23135605	Homo sapiens												35	8						21						p.1
10076	47180					Highest studied dose	mg	2000		multiple			day	2	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27121673/	Homo sapiens						30							8									10	day		
10077	47180					Highest studied dose	mg	2000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21917766/	Homo sapiens						72.2							91	Alzheimer disease								48	week		
10078	47185		adult			Highest studied dose	mg	60		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/22547164/	Homo sapiens										cycle: 14 days on/7 days off			2	solid tumors								2	week		
10079	47185		adult			MTD	mg	20		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/22547164/	Homo sapiens													4	solid tumors								28	day		
10080	47185		adult			Studied dose	mg	40		multiple			day	2	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/22547164/	Homo sapiens													4	solid tumors								28	day		
10081	47191					Highest studied dose	mg/m2	16		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17938863/	Homo sapiens												78	4	metastatic refractory solid tumors	1 time/cycle			SNS-032	42			2	cycle		
10082	47191					MTD	mg/m2	75		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20479412/	Homo sapiens										6-hour infusion weekly for 3 weeks of each 4-week		82	19	chronic lymphocytic leukemia					45			1	cycle		
10083	47191					Studied dose	mg/m2	13		multiple			week	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/17938863/	Homo sapiens												78	6	metastatic refractory solid tumors	1 time/cycle			SNS-032	42			2	cycle		
10084	47191					Studied dose	mg/m2	50		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20479412/	Homo sapiens							median			6-hour infusion weekly for 3 weeks of each 4-week		82	18	multiple myeloma					45			1	cycle		
10085	47191					Studied dose	mg/m2	50		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20479412/	Homo sapiens							median			6-hour infusion weekly for 3 weeks of each 4-week		82	19	chronic lymphocytic leukemia					45			1	cycle		
10086	47198		ADULT			Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25630641	Homo sapiens														tuberculosis								14	day		p.3
10087	47207		ADULT			Highest studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens						54.5				4 weeks followed by 1 week off treatment (schedule 4/1); 7 cycles (median)			6	cancer								8	cycle		p.197
10088	47207		ADULT			MTD	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens						54.5				continuous daily dosing			6	cancer								4	cycle		p.197
10089	47207		ADULT			MTD	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens						54.5				4 weeks followed by 1 week off treatment (schedule 4/1); 7 cycles (median)			6	cancer								4	week		p.197
10090	47207		ADULT			Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20605934	Homo sapiens						54.5				continuous daily dosing			33	cancer								4	cycle		p.197
10091	47244					Studied dose	mg	150		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/6224405/	Homo sapiens												77	42	after myelography					18						
10092	47244					Studied dose	mg/mL	1.25		steady			day	1	unhealthy	respiratory	M+F		https://pubmed.ncbi.nlm.nih.gov/8872633/	Homo sapiens												26	13	asthma					18			2	day		
10093	47287		ADULT			RP2D	mg/m2	240		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32568634	Homo sapiens						63.4				twice weekly in 21-day cycles			6	cancer											p.3197
10094	47287		ADULT			Studied dose	mg/m2	480		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32568634	Homo sapiens						63.4				twice weekly in 21-day cycles			7	cancer											p.3197
10095	47321					Highest studied dose	mg	300		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens						71						74	5	refractory peripheral T/natural killer-cell malignancies					58			28	day		
10096	47321					Studied dose	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens						56						70	5	refractory peripheral T/natural killer-cell malignancies					30			100	day		
10097	47321					Studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22448814/	Homo sapiens						60						77	3	refractory peripheral T/natural killer-cell malignancies					51			157	day		
10098	47330					Highest studied dose	mg/kg/h	0.25		multiple			2 weeks	10	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815994/	Homo sapiens						58				5 days/week for 2 weeks followed by a 1-week rest			2	cancer								2	week		
10099	47330					MTD	mg/kg/h	0.045		multiple			3 weeks	5	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10430069/	Homo sapiens						56				4-week cycle			9	cancer								3	week		
10100	47330					MTD	mg/kg/h	0.15		multiple			3 weeks	3	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/10430069/	Homo sapiens						56				4-week cycle			4	cancer								3	week		
10101	47330					MTD	mg/kg/h	0.2		multiple			2 weeks	10	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9815994/	Homo sapiens						58				5 days/week for 2 weeks followed by a 1-week rest			3	cancer								2	week		
10102	47341		adult			Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/15013947/ | https://www.unica.it/UserFiles/File/Direzioni/DirRic/XVI%20Set%20Ric-%20Poster%20ricercatori/Area06/Settimana%20Scientifica%20HCV_La_Colla.pdf | https://pubmed.ncbi.nlm.nih.gov/16787301/	Homo sapiens										15 days with a 2-week follow-up period			10	chronic hepatitis C								15	day		
10103	47344		adult			Highest studied dose	mg/m2	340		multiple			day	1	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3108	Homo sapiens										1 week on/1 week off schedule			3	cancers								28	day		
10104	47344		adult			Studied dose	mg/m2	300		multiple			day	2	unhealthy	oral			https://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3106	Homo sapiens													4	solid tumors								21	day		
10105	47344		adult			Studied dose	mg/m2	313		multiple			day	1	unhealthy	oral			https://www.sciencedirect.com/science/article/pii/S0923753420330313	Homo sapiens							max							Solid Tumors								21	day		
10106	47344					MTD	mg	1050		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2589	Homo sapiens						57							3	solid tumors								21	day		
10107	47344					MTD	mg/m2	128		multiple			day	1	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/10/11_Supplement/A95.short	Homo sapiens						60				1 week on/1 week off schedule				solid tumors								28	day		
10108	47344					MTD	mg/m2	72		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3032	Homo sapiens						69								solid tumors	75 mg/m2; IV			Docetaxel				21	day		
10109	47344					Studied dose	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2589	Homo sapiens						57							6	solid tumors								21	day		
10110	47344					Studied dose	mg/m2	144		multiple			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3083	Homo sapiens						57							9	solid tumors	150 mg; oral; 1/d			erlotinib				21	day		
10111	47344					Studied dose	mg/m2	170		multiple			day	1	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/10/11_Supplement/A95.short	Homo sapiens						60				1 week on/1 week off schedule			6	solid tumors								28	day		
10112	47344					Studied dose	mg/m2	96		multiple			day	2	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.e13604	Homo sapiens						64								solid tumors	75 mg/m2; IV			Docetaxel				21	day		
10113	47344					Studied dose	mg/m2	96		single			day	1	unhealthy	oral	M+F		https://ascopubs.org/doi/abs/10.1200/jco.2011.29.15_suppl.3083	Homo sapiens						57							8	solid tumors								1	day		
10114	47345		adult			Highest studied dose	mg	1200		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf	Homo sapiens													4	acute myeloid leukemia											52
10115	47345		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf	Homo sapiens													179	acute myeloid leukemia								3.9	month		6.1
10116	47345		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf	Homo sapiens													179	acute myeloid leukemia								3.9	month		Table 2
10117	47345		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf	Homo sapiens													179	acute myeloid leukemia								3.9	month		Table 3
10118	47345		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf	Homo sapiens													179	acute myeloid leukemia								3.9	month		122
10119	47345		adult			Recommended	mg	500		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf	Homo sapiens													179	acute myeloid leukemia								3.9	month		Table 3
10120	47346		ADULT			Highest studied dose	mg	3		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22031847	Homo sapiens						64.5							24									12	week		p.155
10121	47346		ADULT			Highest studied dose	mg	3		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23499390	Homo sapiens						66						82	54	cancer					39			113	day		p.7
10122	47355		ADULT			Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/30012563	Homo sapiens						81							1	prostate cancer								23	day		p.5227
10123	47355		ADULT			RP2D	mg	450		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29744674	Homo sapiens						61						77	7	breast cancer					42			136	day		p.5
10124	47355		ADULT			Studied dose	mg	600		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29744674	Homo sapiens						76						91	6	breast cancer					52			30	day		p.5
10125	47355		ADULT			Studied dose	mg	750		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/29744674	Homo sapiens						65						86	6	breast cancer					46			35.5	day		p.5
10126	47370					Highest studied dose	mg/m2	14		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22123335	Homo sapiens						50				1-h infusion on days 1 and 15 every 28 days; the median number of treatment cycleswas 3 (range, 1–20)			7	Breast cancer								2	week		p.338
10127	47370					MTD	mg/m2	12		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22123335	Homo sapiens						50				1-h infusion on days 1 and 15 every 28 days; the median number of treatment cycleswas 3 (range, 1–20)			6	Breast cancer								2	week		p.338
10128	47370					MTD	mg/m2	7		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20069338	Homo sapiens										1-h infusion weekly for three consecutive weeks of a 28 day schedule; the median number of cycles per patient was 2(range 1–18 cycles)			13	Cancer								3	week		p.469
10129	47370					Studied dose	mg/m2	8		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20069338	Homo sapiens										1-h infusion weekly for three consecutive weeks of a 28 day schedule; the median number of cycles per patient was 2(range 1–18 cycles)			3	Cancer								3	week		p.469
10130	47382					Highest studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24374145/	Homo sapiens						63				median duration; 3 weeks on/ 1 week off			3	myelofibrosis								91	day		
10131	47382					Studied dose	mg	25		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24374145/	Homo sapiens						63				median duration; continuously daily - 28 days cycle			8	myelofibrosis								91	day		
10132	47382					Studied dose	mg	25		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24374145/	Homo sapiens						63				median duration;			8	myelofibrosis								91	day		
10133	47382					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24374145/	Homo sapiens						63				median duration; continuously daily - 28 days cycle			5	myelofibrosis								91	day		
10134	47383		ADULT			Highest studied dose	mg	800		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/27328054/|https://pubmed.ncbi.nlm.nih.gov/24622716/|http://ndi.fda.moph.go.th/uploads/drug_detail_corporation/doc/word/805/1330e56852e1efc924102c4c3eaad4a4-a1.pdf	Homo sapiens													65									1	day		e0157509|125-32
10135	47387		ADULT			Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/9296310/	Homo sapiens						57.4	max						367	hypertension								12	week		229-34
10136	47398		ADULT			Recommended	mg	60		multiple			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19878447/	Homo sapiens						41	max			on demand			356	premature ejaculation								12	week		p.265
10137	47408					Highest studied dose	mg	60		multiple			day	2	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/10/11_Supplement/A177	Homo sapiens						62				median duration				solid tumors								3	cycle		
10138	47415					MTD	mg	360		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21976535/	Homo sapiens										14 days on/7 days off		86	18	metastatic solid tumors					16			3	cycle		
10139	47415					Studied dose	mg	120		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32716114/	Homo sapiens												86	133	MET-high hepatocellular carcinoma					36			13	week		
10140	47417					Highest studied dose	mg	70		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26787751/	Homo sapiens						58							8	solid tumors								21	day		
10141	47417					MTD	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26787751/	Homo sapiens						58							6	solid tumors								21	day		
10142	47417					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26787751/	Homo sapiens						58							4	solid tumors								21	day		
10143	47417					Studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26787751/	Homo sapiens						58.5							14	solid tumors								28	day		
10144	47418					Highest studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27872130/	Homo sapiens						57				28-day cycle (21 consecutive days followed by 7 days off)			7	Solid Tumors								21	day		
10145	47418					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27872130/	Homo sapiens						57				28-day cycle (21 consecutive days followed by 7 days off)			29	Solid Tumors								21	day		
10146	47418					MTD	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31227862/	Homo sapiens						66				28-day cycle (21 consecutive days followed by 7 days off)			8	Solid Tumors								21	day		
10147	47418					Studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32205017/	Homo sapiens						58				median duration. 28-day cycle (21 consecutive days followed by 7 days off)			6	Solid Tumors	20 mg/kg; IV; 1/week			paclitaxel				11	week		
10148	47423		ADULT			Highest studied dose	mg	5		multiple			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/32318621/	Homo sapiens							total daily dose							Alzheimer disease								5	week		
10149	47423		ADULT			Highest studied dose	mg	60		multiple			day	1	healthy	oral	M		https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	Homo sapiens							unknown						22	Alzheimer disease								7	day		
10150	47423		ADULT			MTD	mg	55		multiple			day	1	healthy	oral	M		https://www.anavex.com/anavex-announces-positive-phase-1-data-for-anavex-2-73-lead-candidate-for-the-treatment-of-alzheimers/	Homo sapiens													22									7	day		
10151	47447		ADULT			Highest studied dose	mg	50		steady			day	1	healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21223356	Homo sapiens						24.8						38	19						18			11	day		p.912
10152	47447		ADULT			Studied dose	mg	35		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/20043816	Homo sapiens						69.6							121	Alzheimer disease								24	week		p.382
10153	47448					Overdose	mg	320		multiple			day	1	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200796s000lbl.pdf	Homo sapiens																						7	day		p.6
10154	47448					Recommended	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25619410	Homo sapiens							max						179	Hypertension								26	week		p.187
10155	47448					Recommended	mg	80		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200796s000lbl.pdf	Homo sapiens							max						2146	Hypertension											p.4
10156	47453					Highest studied dose	mg	2400		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						60.9							8	B-cell chronic lymphocytic leukemia								8	week		
10157	47453					MTD	mg	1200		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						60.6							8	B-cell chronic lymphocytic leukemia								8	week		
10158	47453					Studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						58.5							6	B-cell chronic lymphocytic leukemia								8	week		
10159	47453					Studied dose	mg	1800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						63.1							8	B-cell chronic lymphocytic leukemia								8	week		
10160	47453					Studied dose	mg	600		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						64.7							7	B-cell chronic lymphocytic leukemia								8	week		
10161	47453					Studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/18094935/	Homo sapiens						65.8							6	B-cell chronic lymphocytic leukemia								8	week		
10162	47480					Highest studied dose	mg	400		single					healthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/24989138	Homo sapiens						29							9						29						
10163	47480					Highest studied dose	mg	400		steady			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27317442	Homo sapiens						31							8						31			21	day		
10164	47480					Recommended	mg	200		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205435Orig1s000MedR.pdf	Homo sapiens						42				Adults and adolescents with ABSSSI, IV with optional oral switch 200 mg tedizolid phosphate for 6 days		86	662						17			6	day		p. 117
10165	47480					Studied dose	mg	1200		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27342387	Homo sapiens										six tedizolid phosphate tablets		45	6						18						
10166	47492		ADULT			Highest studied dose	mg	1000		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/23472197	Homo sapiens						47.2						53.9	14	multiple sclerosis					41.3			28	day		p.7, 8
10167	47493		ADULT			Highest studied dose	mg	330		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231399	Homo sapiens						61						80	2	cancer					23						p.62
10168	47493		ADULT			MTD	mg	220		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/25231399	Homo sapiens						61						80	6	cancer					23						p.62
10169	47493		ADULT			Studied dose	mg	150		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28350521	Homo sapiens						34						69	17	desmoid tumor					19						p.1565
10170	47498					Highest studied dose	mg	400		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22607269/	Homo sapiens												45	8						18			8	day		
10171	47498					Highest studied dose	mg	800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/22607269/	Homo sapiens							unknown					35	31						18						
10172	47534					MTD	mg	45		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf	Homo sapiens													227	non-small cell lung cancer								15	month		
10173	47534					MTD	mg	45		multiple			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	Homo sapiens													227	non-small cell lung cancer								15	month		
10174	47534						mg	60		steady			day	1	unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211288Orig1s000MultidisciplineR.pdf	Homo sapiens														advanced solid tumors								14	day		
10175	47535					Highest studied dose	mg/m2	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens						60				median duration			7	solid tumors								84	day		
10176	47535					MTD	mg/m2	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens						60				median duration			8	solid tumors								84	day		
10177	47535					Studied dose	mg/m2	60		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/21131552/	Homo sapiens						60				median duration			7	solid tumors								56	day		
10178	47540		adult			Highest studied dose	mg	40		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17117592/	Homo sapiens														angina								5	day		
10179	47540		adult			Highest studied dose	mg	80		single			day	1	healthy	oral	M+F		https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1016/j.clpt.2003.11.197 | https://pubmed.ncbi.nlm.nih.gov/17117592/	Homo sapiens													5									1	day		
10180	47540					Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404957/	Homo sapiens						54							104	rheumatoid arthritis								12	week		
10181	47540					Studied dose	mg	10		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404957/	Homo sapiens						54							40	rheumatoid arthritis								12	week		
10182	47540					Studied dose	mg	5		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19404957/	Homo sapiens						52							103	rheumatoid arthritis								12	week		
10183	47560					Highest studied dose	mg	1500		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8126129	Homo sapiens						29							6						29						
10184	47561		ADULT			Highest studied dose	mg	900		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/15885050/	Homo sapiens						63.3	total daily dose						9	ischemia								9	week		453-61
10185	47561		ADULT			Overdose	mg	15000		single					unknown	oral	F		https://pubmed.ncbi.nlm.nih.gov/25772423/	Homo sapiens						25							1									1	day		470-6
10186	47561		ADULT			Studied dose	mg	25		single					unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/21905508/	Homo sapiens						57							1	pain disorder								1	day		411-2
10187	47561		CHILD			Accidental dose	mg	2700		single					healthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/25772423/	Homo sapiens						2				225 mg/kg			1									1	day		470-6
10188	47594					Highest studied dose	mg	20		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/15107205	Homo sapiens										70 days of 2 mg daily E2V, followed by 14 days of 2 mg daily E2V plus 20mg daily MPA, and the cycle is completed with a seven-day hormone free period. Women were treated for a maximum of 21 three-month cycles.		66	132	Postmenopause	2 mg; q.d			E2V, p.o	45			14	day		p.12
10189	47594					Recommended	mg	10		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	Homo sapiens							max			PROVERA tablets may be given in dosages of 5 or 10 mg daily for 12 to 14 consecutive days per month, in postmenopausal women receiving daily 0.625 mg conjugated estrogens, either beginning on the 1st day of the cycle or the 16th day of the cycle		79	8506	Postmenopause	0.625 mg; q.d			conjugated estrogens, p.o	50			13	day		p.1, p.5
10190	47594					Recommended	mg	10		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/20733445/	Homo sapiens													83	Idiopathic heavy menstrual bleeding								10	day		p.628
10191	47594					Recommended	mg	10		multiple			day	1	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	Homo sapiens							max			5 or 10 mg daily for 5 to 10 days				Secondary Amenorrhea|Abnormal Uterine Bleeding Due to Hormonal Imbalance								10	day		p.1
10192	47594					Recommended	mg	150		multiple			month	3	healthy	intramuscular	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf	Homo sapiens										The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle.				Prevention of pregnancy											p.1
10193	47594					Recommended	mg	150		multiple			month	3	healthy	intramuscular	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020246s035lbl.pdf	Homo sapiens												51	3900	Prevention of pregnancy					15			13	month		p.7
10194	47594					Studied dose	mg	2.5		multiple			day	1	healthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/16875644	Homo sapiens												79	284	Postmenopause	0.625 mg; q.d			conjugated estrogens, p.o	45			3	year		p.1325
10195	47594					Studied dose	mg	2.5		multiple			day	1	healthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011839s071lbl.pdf	Homo sapiens														Postmenopause	0.625 mg; q.d			conjugated estrogens, p.o				5.6	year		p.1, p.5
10196	47595		ADULT			Recommended	%	1		multiple			day	4	unhealthy	ophthalmic	M+F		https://pubmed.ncbi.nlm.nih.gov/17762913/	Homo sapiens						65						87	36	eye disease					25			15	day		p.284
10197	47647					Highest studied dose	mg/m2	250		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens						63				4 weeks cycle (3 weeks on/ 1 week off)			8	solid tumors								3	week		
10198	47647					MTD	mg/m2	190		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens						63				4 weeks cycle (3 weeks on/ 1 week off)			7	solid tumors								3	week		
10199	47647					Studied dose	mg/m2	140		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens						63				4 weeks cycle (3 weeks on/ 1 week off)			8	solid tumors								3	week		
10200	47647					Studied dose	mg/m2	80		multiple			week	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/22020315/	Homo sapiens						63				4 weeks cycle (3 weeks on/ 1 week off)			7	solid tumors								3	week		
10201	47662		ADULT			Highest studied dose	mg	3000		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens						58.2				GSK2816126 was given 3-weeks-on/1-week-off in 28-day cycles.			7	cancer								3	week		p.8, 9
10202	47662		ADULT			MTD	mg	2400		multiple			week	2	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/31471312/	Homo sapiens						58.2				GSK2816126 was given 3-weeks-on/1-week-off in 28-day cycles.			12	cancer								3	week		p.8, 9
10203	47666					Highest studied dose	mg	320		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens						51.1							6	Type 2 Diabetes Mellitus								7	day		
10204	47666					Studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens						51.1							8	Type 2 Diabetes Mellitus								7	day		
10205	47666					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens						51.1	mean						9	Type 2 Diabetes Mellitus								28	day		
10206	47666					Studied dose	mg	240		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens						51.1							6	Type 2 Diabetes Mellitus								7	day		
10207	47666					Studied dose	mg	65		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33125674/	Homo sapiens						51.1	mean						9	Type 2 Diabetes Mellitus								28	day		
10208	47676		ADULT			Highest studied dose	mg	1500		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens						56						75	6	cancer					28			21	day		p.4
10209	47676		ADULT			MTD	mg	1000		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens						56						75	21	cancer					28			21	day		p.4
10210	47676		ADULT			Studied dose	mg	1200		multiple			day	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/24612546/	Homo sapiens						56						75	3	cancer					28			21	day		p.4
10211	47698		ADULT			Highest studied dose	mg/m2	10		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25665464/	Homo sapiens						67							7	lymphoma	300 ug/day on days 5 to 9			G-CSF				1	cycle		2585-91
10212	47698		ADULT			MTD	mg/m2	4		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens						61							27	cancer								2	cycle		447-54
10213	47698		ADULT			MTD	mg/m2	6		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25665464/	Homo sapiens						67							10	lymphoma								1	cycle		2585-91
10214	47698		ADULT			MTD	mg/m2	9		multiple			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25665464/	Homo sapiens						67							7	lymphoma	300 ug/day on days 5 to 9			G-CSF				1	cycle		2585-91
10215	47698		ADULT			Studied dose	mg/m2	5		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens						61							6	cancer								2	cycle		447-54
10216	47698		ADULT			Studied dose	mg/m2	6		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens						61							3	cancer								2	cycle		447-54
10217	47698		ADULT			Studied dose	mg/m2	8		multiple			3 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/20461380/	Homo sapiens						61							6	cancer								2	cycle		447-54
10218	48273					Studied dose	mg	3		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/14999362	Homo sapiens							total daily dose			Nebulizer			12												
10219	48290		ADULT			Studied dose	mg	100		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/8148229/	Homo sapiens						26						35							20						p.98
10220	48399		ADULT			Highest studied dose	mg	200		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11675061	Homo sapiens						44.8							26	migraine											p.1233
10221	48475		ADULT			Studied dose	mg	500		single					healthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24290410/	Homo sapiens												65	11						18						
10222	48475		ADULT			Studied dose	mg	500		single					unhealthy	intravenous	unknown		https://pubmed.ncbi.nlm.nih.gov/24290410/	Homo sapiens												65	11	renal impairment					18						
10223	48530		ADULT			Highest studied dose	mg	800		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29921320/	Homo sapiens						69						70	6	cancer					38			21	day		p.5
10224	48567		ADULT			MTD	ug/m2	220		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33052756	Homo sapiens							unknown			Iadademstat was administered orally after a minimum of 2 hours of fasting using a precharged syringe in a 28-day cycle (5 days on/2 days off *4 weeks).			5	Leukemia, Myelocytic, acute								5	day		
10225	48567					Recommended	ug/m2	140		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33052756	Homo sapiens						63	unknown					78	14	Leukemia, Myelocytic, acute					30			26	day		
10226	48569					Highest studied dose	mg	45		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30132786	Homo sapiens						47	unknown			The start dose of 15 mg × 2 was given daily during the first 28 days, with a possibility to increase the dose up to 30 mg × 2 during the following 28 days and up to 45 mg × 2 during the last 28 days.		70.4	28	multiple sclerosis					25.3			4	week		
10227	48571		ADULT			Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5				14 of 21 days			3	Hematologic malignancy								14	day		p.5
10228	48571		ADULT			Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5				5 of 7 days			4	Hematologic malignancy								5	day		p.5
10229	48571		ADULT			Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5				7 of 21 days			5	Hematologic malignancy								7	day		p.5
10230	48571		ADULT			Studied dose	mg	120		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5							6	Hematologic malignancy								21	day		p.5
10231	48571		ADULT			Studied dose	mg	160		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063977	Homo sapiens						70				once a day for 14 days consecutive, followed by a 1-week rest  \nwithout OTX015 (21-day cycles)		75	5	acute leukemia					60			14	day		p.4
10232	48571		ADULT			Studied dose	mg	40		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5							6	Hematologic malignancy								21	day		p.5
10233	48571		ADULT			Studied dose	mg	80		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27063978	Homo sapiens						66.5							7	Hematologic malignancy								21	day		p.5
10234	48582		ADULT			Highest studied dose	mg	40		multiple			week	3	unhealthy	oral	M+F		https://www.karyopharm.com/wp-content/uploads/2019/02/KPT-9274-Poster-ESMO-2017-FINAL-1.pdf	Homo sapiens						61						74	7	cancer					28						
10235	48646					Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens						55	unknown			once daily for 2 weeks every 4 weeks		79	5	Advanced Solid Malignancies					28			2	week		
10236	48646					MTD	mg	750		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens							unknown			once daily for 2 weeks every 4 weeks			13	Advanced Solid Malignancies								2	week		
10237	48646					Studied dose	mg	100		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens						52						67	8	Advanced Solid Malignancies					40			28	day		
10238	48646					Studied dose	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/16203782/	Homo sapiens						52						67	7	Advanced Solid Malignancies					40			28	day		
10239	48652		ADULT			RP2D	mg	900		multiple			day	2	unhealthy	oral	M+F		https://mct.aacrjournals.org/content/17/1_Supplement/B176	Homo sapiens													6	cancer				cobicistat							
10240	48752		ADULT			Highest studied dose	mg	50		multiple			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/19643947/	Homo sapiens						33.3							18									4	day		p.567
10241	48752		ADULT			Studied dose	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/27640067/	Homo sapiens						26.8							19	asthma								8	day		p.36
10242	48791		ADULT			Highest studied dose	mg/kg	24		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens						19						21	6	thalassemia					18			28	day		p.1358
10243	48791		ADULT			Studied dose	mg/kg	9		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28940308/	Homo sapiens						31						46	6	thalassemia minor					19			28	day		p.1359
10244	49024		ADULT			Highest studied dose	mg	80		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/19144772/	Homo sapiens						28.6						45	6						18						p.830
10245	49025					Highest studied dose	mg	400		single					healthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/29178434	Homo sapiens						26							19												p.304
10246	49026		ADULT			Highest studied dose	mg	1200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31447004/	Homo sapiens										cycle was 21 days		85	6	Non-small cell lung cancer					32			1	cycle		
10247	49026		ADULT			MTD	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31447004/	Homo sapiens							median			75 to 1200 mg, cycle was 21 days		85	272	Non-small cell lung cancer					32			1	cycle		
10248	49026		ADULT			Studied dose	mg	800		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33434335/	Homo sapiens										21-day cycles		85	162	Non-small cell lung cancer					36			1	cycle		
10249	49027					Recommended	mg	30		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/11854821/	Homo sapiens						55.4							45	hypertension								8	week		
10250	49030					Highest studied dose	mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29972716/	Homo sapiens						66				median duration			4	non-small-cell lung cancer								170	day		
10251	49030					MTD	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29972716/	Homo sapiens						67				median duration			10	non-small-cell lung cancer								170	day		
10252	49030					RP2D	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28954786/	Homo sapiens						64							63	non-small-cell lung cancer								21	day		
10253	49030					Studied dose	mg	300		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/29972716/	Homo sapiens						63				median duration			76	non-small-cell lung cancer								196	day		
10254	49030					Studied dose	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28954786/	Homo sapiens						65							13	non-small-cell lung cancer								21	day		
10255	49033					Highest studied dose	mg	80		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31835495/	Homo sapiens												70	4	advanced solid tumors					38			21	day		
10256	49033					MTD	mg	80		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31835495/	Homo sapiens												75	13	advanced solid tumors					48			21	day		
10257	49033					RP2D	mg	60		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31835495/	Homo sapiens												74	15	advanced solid tumors					40			21	day		
10258	49034		adult			Highest studied dose	mg	600		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32615108/	Homo sapiens													3	Gastrointestinal Stromal Tumor								28	day		
10259	49034		adult			MTD	mg	400		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000MultidisciplineR.pdf	Homo sapiens													221	Gastrointestinal Stromal Tumor											76, 164, 166
10260	49034					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	Homo sapiens												90	204	Gastrointestinal Stromal Tumor					29			12	month		5
10261	49034					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	Homo sapiens												90	204	Gastrointestinal Stromal Tumor					29			12	month		6
10262	49034					Recommended	mg	300		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf	Homo sapiens												90	204	Gastrointestinal Stromal Tumor					29			12	month		7
10263	49036					Highest studied dose	mg	500		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32436060/	Homo sapiens						58.1				Median duration			8	malignant glioma								8.1	week		
10264	49038					Highest studied dose	mg	425		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28972963/	Homo sapiens						65	max			median duration			19	solid tumours								56	day		
10265	49038					Highest studied dose	mg	425		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28972963/	Homo sapiens						65				median duration			7	solid tumours								56	day		
10266	49038					MTD	mg	400		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28972963/	Homo sapiens						65				median duration			12	solid tumours								56	day		
10267	49038					Studied dose	mg	250		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28972963/	Homo sapiens						65				median duration			7	solid tumours								56	day		
10268	49040					Highest studied dose	mg	1200		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28490463/	Homo sapiens						59							3	Solid Tumors								21	day		
10269	49040					MTD	mg	150		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28490463/	Homo sapiens						58.5							6	Solid Tumors								21	day		
10270	49040					MTD	mg	900		multiple			week	3	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28490463/	Homo sapiens						57.5							23	Solid Tumors								21	day		
10271	49040					Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28490463/	Homo sapiens						58.5							8	Solid Tumors								21	day		
10272	49040					Studied dose	mg	900		multiple			2 weeks	4	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30168905/	Homo sapiens												44	34						22			28	day		
10273	49041					Highest studied dose	mg	200		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31577341/	Homo sapiens						38.7							55	Atopic Dermatitis								12	week		
10274	49041					Highest studied dose	mg	200		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28949012/	Homo sapiens						52.1							14	moderate-to-severe psoriasis								4	week		
10275	49041					Highest studied dose	mg	400		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/28949012/	Homo sapiens						42.8							16	moderate-to-severe psoriasis								4	week		
10276	49291					Recommended	mg	40		steady			day	1	unhealthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878201/pdf/40264_2017_Article_623.pdf	Homo sapiens												85	110	schizophrenia or schizoaffective disorder, or mood disorder					18			42	week		
10277	49291					Recommended	mg	40		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf	Homo sapiens												84	262	tardive dyskinesia					26			6	week		Table 1
10278	49291					Recommended	mg	80		steady			day	1	unhealthy	oral	M+F		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5878201/pdf/40264_2017_Article_623.pdf	Homo sapiens												85	112	schizophrenia or schizoaffective disorder, or mood disorder					18			42	week		
10279	49291					Recommended	mg	80		steady			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209241lbl.pdf	Homo sapiens												84		tardive dyskinesia					26				week		8.1
10280	49345					Highest studied dose	mg/kg	10		steady			2 weeks	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/25977344	Homo sapiens						66							10						66			1	year		
10281	49345					Recommended	mg/kg	2		steady			3 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						59						88	89	melanoma					18			6.2	month		
10282	49345					Recommended	mg/kg	2		steady			3 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000MedR.pdf	Homo sapiens						59						88	89	melanoma					18			6.2	month		p. 99
10283	49345					Recommended	mg/kg	2		steady			3 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000MedR.pdf	Homo sapiens						59						88	89	melanoma					18			6.2	month		p. 99
10284	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			1.1	month		
10285	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			1.7	month		
10286	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			11.6	month		
10287	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			2.6	month		
10288	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			2.8	month		
10289	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			4.9	month		
10290	49345						mg/kg	2 |10		steady			3 weeks|2 weeks	1	unhealthy	intravenous	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf	Homo sapiens						61	complex			2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks		94	411	melanoma					18			6.2	month		
10291	49365		adult			Highest studied dose	mg	190		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210296s000lbl.pdf	Homo sapiens													769	multiple sclerosis											6.1
10292	49365					Highest studied dose	mg	190		multiple			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/32629403/	Homo sapiens						37							105	multiple sclerosis								4	week		
10293	49416						mg	20		multiple			day	2	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18747313	Homo sapiens							max					9	5	hyperactivity	1-2 g			chlorothiazide	6			4	week		
10294	49416						mg/kg	0.15		single					unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/9397427 |https://pubmed.ncbi.nlm.nih.gov/6593753/	Homo sapiens						36						58	64	depression					20						
10295	49587					Highest studied dose	mg/kg	8		steady			week	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/10604742	Homo sapiens													6									3	week		
10296	49587						mg/kg	1		steady			week	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/10604742	Homo sapiens							starting						6									3	week		
10297	49587						mg/kg	4		steady			week	1	unhealthy	intravenous			https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/trasgen092598lb.pdf |https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761091s000lbl.pdf	Homo sapiens						50	starting			HERCEPTIN as a single agent in 352 patients at doses of 10–500 mg administered weekly. Most of the patients received 4 mg/kg initial dose of trastuzumab followed by 2 mg/kg weekly.			352						50			6	week		
10298	50369						%	35		single					unhealthy	intraarterial			https://pubmed.ncbi.nlm.nih.gov/13584747/	Homo sapiens													123	arteriography											
10299	50369						g	10		single					unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/13057637/	Homo sapiens										The author has investigated the effects of the preparation designated """"""""""""""""Diodone cum Diphenhydramino 'Lundbeck' """""""""""""""". This contains the diethanolamine salt of 3: 5-diiodo-pyridone-N-acetic acid, with the addition of diphenhydramine 1 mg per ml. The usual amount for urography in adults is twenty ml of a fifty per cent solution and consequently the patient receives 20 mg of diphenhydramine.			416	urography	20 mg			diphenhydramine							
10300	50379		adult				mg	300		multiple			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT02806895	Homo sapiens										150 mg/day for first 3 days and 300 mg/day for next 4 days			34	Obstructive Sleep Apnea								7	day		
10301	50379					Highest studied dose	mg	1200		single			day	1	healthy	oral	M		https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf | https://pubmed.ncbi.nlm.nih.gov/30269642/	Homo sapiens						29.3							42									1	day		
10302	50379					Recommended	mg	112.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	161	narcolepsy					18			12	week		
10303	50379					Recommended	mg	150		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	218	narcolepsy | obstructive sleep apnea					18			12	week		
10304	50379					Recommended	mg	37.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	58	obstructive sleep apnea					18			12	week		
10305	50379					Recommended	mg	75		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	120	narcolepsy | obstructive sleep apnea					18			12	week		
10306	50379					Recommended	mg	87.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	235	obstructive sleep apnea					18			12	week		
10307	50379					Recommended	mg	87.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf	Homo sapiens							mean					75	396	narcolepsy | obstructive sleep apnea					18			12	week		
10308	50379					Studied dose	mg	150		multiple			day	1	unhealthy	oral	M+F		https://www.ema.europa.eu/en/documents/assessment-report/sunosi-epar-public-assessment-report_en.pdf	Homo sapiens							mean						417	narcolepsy | obstructive sleep apnea								52	week		
10309	50379					Studied dose	mg	300		single			day	1	healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30598342/	Homo sapiens										Subjects were randomized to receive either a 300-mg dose of solriamfetol in the fasted condition followed by a 300- mg dose of solriamfetol in the fed condition, or the reverse schedule, with the 2 administrations separated by a washout period of at least 7 days		54	32						19			1	day		
10310	50435					Overdose	mg	23.5		steady			day	1	unhealthy	oral	M		https://pubmed.ncbi.nlm.nih.gov/18936971/	Homo sapiens						3	mean						2	upper respiratory tract infection					3				day		
10311	50435					Recommended	mg	60		single					unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31378383/	Homo sapiens								1 g					60	acute musculoskeletal pain	400 mg			ibuprofen						paracetamol	
10312	50594					Highest studied dose	mg	2800		single					healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000Multidiscipline.pdf	Homo sapiens										max tested dose in healthy volunteers			30												
10313	50594					Recommended	mg	1000		steady					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000Multidiscipline.pdf	Homo sapiens										max recommended dose for pts with severe hepatic impairment				sickle cell disease|severe hepatic impairment											
10314	50594					Recommended	mg	1500		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf	Homo sapiens												59	88	sickle cell disease					12			24	week		
10315	50594					Recommended	mg	1500		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213137Orig1s000Multidiscipline.pdf	Homo sapiens												59	88	sickle cell disease					12			24	week		
10316	50879		ADULT			Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf#page=8	Homo sapiens						66	total daily dose					88	221	marginal zone B-cell lymphoma, follicular lymphoma,					29			6	month		pooled safety population (TGR-1202-101, TGR-1202-202, UTX-TGR-205, and UTX-TGR-501)
10317	50879		ADULT			Recommended	mg	800		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf#page=122	Homo sapiens						67	total daily dose					88	69	marginal zone B-cell lymphoma					34			120	day		122 | 124 | UTX-TGR-205
10318	51481		adult			Overdose	mg	50		steady			day	2	healthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000MedR.pdf | https://pubmed.ncbi.nlm.nih.gov/27285466	Homo sapiens													8									4.5	day		p.87
10319	51481		adult				mg	20		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00456092	Homo sapiens													69	Psoriatic Arthritis								12	week		
10320	51481		adult				mg	30		steady			day	2	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00944658	Homo sapiens										10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks			19	Ankylosing Spondylitis								12	week		
10321	51481		adult				mg	40		steady			day	1	unhealthy	oral	M+F		https://clinicaltrials.gov/ct2/show/NCT00456092	Homo sapiens													67	Psoriatic Arthritis								12	week		
10322	51481					Recommended	mg	30		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000MedR.pdf	Homo sapiens													501									52	week		p. 61
10323	51481						mg	20		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205437Orig1s000MedR.pdf	Homo sapiens													501									52	week		p. 61
10324	51529		adult			Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32804590/	Homo sapiens													7	Gastrointestinal Stromal Tumor								6.2	month		
10325	51529		adult			Highest studied dose	mg	200		multiple			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213973Orig1s000MultidisciplineR.pdf	Homo sapiens														advanced malignancies											79
10326	51529		adult			Recommended	mg	150		multiple			day	1	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32804590/	Homo sapiens													12	Gastrointestinal Stromal Tumor								6.2	month		
10327	51529		adult			Recommended	mg	150		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf	Homo sapiens													85	Gastrointestinal Stromal Tumor								12	month		5
10328	51529		adult			Recommended	mg	150		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf	Homo sapiens													85	Gastrointestinal Stromal Tumor								12	month		6
10329	51529		adult			Studied dose	mg	100		multiple			day	2	unhealthy	oral	unknown		https://pubmed.ncbi.nlm.nih.gov/32804590/	Homo sapiens													12	Gastrointestinal Stromal Tumor								6.2	month		
10330	51767		adult			Recommended	mg	500		steady			day	3	unhealthy	intravenous	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s037lbl.pdf	Homo sapiens													2904	skin and skin structure infections											6.1
10331	51767					Highest studied dose	g	2		steady			day	3	unhealthy	intrathecal	unknown		https://pubmed.ncbi.nlm.nih.gov/24882451/	Homo sapiens						60.6							5	Infection								22.6	day		
10332	51767					Highest studied dose	g	2		steady			day	3	unhealthy	intravenous	M		https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301467/	Homo sapiens						63							1	frontal lobe abscess	2 g every 8 hours			vancomycin	63						
10333	51848		adult			MTD	mg	80		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf	Homo sapiens													1	Hypertension											14
10334	51848		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf	Homo sapiens							max			2.5 to 40 mg			1349	Hypertension								24	week		14
10335	51848		adult			Recommended	mg	40		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019777s054lbl.pdf	Homo sapiens							max			2.5 to 40 mg			407	Heart Failure								12	week		15
10336	51905		adult			Recommended	mg	125		steady			day	2	unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf	Homo sapiens														pregnant								4	week		
10337	51905		adult			Recommended	mg	125		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf	Homo sapiens													658	pulmonary arterial hypertension								4	week		
10338	51905		adult			Recommended	mg	125		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf	Homo sapiens													95	pulmonary arterial hypertension								4	week		
10339	51905		adult			Recommended	mg	250		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf	Homo sapiens													70	pulmonary arterial hypertension								4	week		
10340	51905		children			Recommended	mg	125		steady			day	2	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf	Homo sapiens													100	pulmonary arterial hypertension								4	week		
10341	51905					MTD	mg	4000		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/17901934/	Homo sapiens												58	10	subarachnoid hemorrhage-induced cerebral vasospasm					32			14	day		
10342	51905					Recommended	mg	125		steady			day	2	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30378090/	Homo sapiens													10	steroid-resistant pulmonary sarcoidosis								11	month		
10343	51945					Recommended	drop	1		multiple			day	4	unhealthy	topical	M+F		https://pubmed.ncbi.nlm.nih.gov/9124242	Homo sapiens						3.4				0.5% ophthalmic suspension			109	Giant papillary conjunctivitis								6	week		p.461
10344	52444					Recommended	mg	100		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/040735s004,040770s003lbl.pdf	Homo sapiens										For Edema: The usual adult dosage is 25 mg to 100 mg daily as a single or divided dose.				Edema											
10345	52444					Recommended	mg	50		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/10423601	Homo sapiens						55.5	max						89	Hypertension								8	week		p.128
10346	52444					Recommended	mg	50		multiple			day	1	unhealthy	oral			https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a24c641e-85f0-4aac-8703-2e596d673448&type=display	Homo sapiens							total daily dose			The adult initial dose of hydrochlorothiazide capsules is one capsule (12.5 mg) given once daily. Total daily doses greater than 50 mg are not recommended.				Hypertension											
10347	52704					MTD	mg	750		multiple			day	3	unhealthy	oral			https://www.medsafe.govt.nz/Profs/Datasheet/a/APOHEALTHFamciclovirOncetab.pdf|https://www.ema.europa.eu/en/documents/referral/famvir-article-30-referral-assessment-report_en.pdf	Homo sapiens										Genital herpes patients receiving up to 750mg three times daily for 5 days tolerated the product well.				Herpes zoster								5	day		p.4|p.16/18
10348	52704					Recommended	mg	1500		single					unhealthy	oral			https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf	Homo sapiens														Herpes labialis											p.1
10349	53096					Highest studied dose	mg	900		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13080166	Homo sapiens												78	1	cardiac failure				2-amino-2-methyl-1-propanol	44			14	day		
10350	53096						mg	25		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/19681920	Homo sapiens						26							1					2-amino-2-methyl-1-propanol	26						
10351	53096						mg	600		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/13080166	Homo sapiens												78	18	cardiac failure				2-amino-2-methyl-1-propanol	44			14	day		
10352	53802					Highest studied dose	mg	50		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/1457272	Homo sapiens						54						65	10	essential hypertension					39			4	week		
10353	53802						mg	50		multiple			day	1	unhealthy	oral	F		https://pubmed.ncbi.nlm.nih.gov/10225674	Homo sapiens						65							1	type 2 diabetes					65			4	month		
10354	53992		adult				mg	100		multiple			week	1	unhealthy	intramuscular			https://pubmed.ncbi.nlm.nih.gov/318825	Homo sapiens													5	Anemias								6	month		
10355	58468					Studied dose	mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/33757798/	Homo sapiens						34	max			60 mg 4 weeks and 30 mg 20 weeks			47	alopecia areata					34			24	week		
10356	58489		ADULT			Highest studied dose	mg	120		single					healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/20145259/	Homo sapiens						22						25	8						20						p.1326, 1327
10357	58489		ADULT			Studied dose	mg	40		multiple			day	2	healthy	respiratory	M		https://pubmed.ncbi.nlm.nih.gov/20145259/	Homo sapiens						24						35	6						20						p.1326, 1327
10358	58492		adult			Highest studied dose	mg	100		multiple			day	1	unhealthy	oral			https://pubmed.ncbi.nlm.nih.gov/6930216	Homo sapiens													1	Guillain-Barré syndrome								1	week		
10359	58596					Highest studied dose	mg	120		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26444072/	Homo sapiens						41.1							83	Schizophrenia								4	week		
10360	58596					Recommended	mg	42		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31913424/	Homo sapiens						42.4							150	Schizophrenia								4	week		
10361	58596					Recommended	mg	42		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf	Homo sapiens										4- to 6-week		60	406	Schizophrenia					19			5	week		
10362	58596					Studied dose	mg	28		multiple			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/31913424/	Homo sapiens						43.5							150	Schizophrenia								4	week		
10363	58596					Studied dose	mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26444072/	Homo sapiens						38.3							84	Schizophrenia								4	week		
10364	58596					Studied dose	mg	60		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30449883/	Homo sapiens												57	10	Schizophrenia					26			2	week		
10365	58596					Studied dose	mg	90		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/26444072/	Homo sapiens						39.7	mean						167	Schizophrenia								4	week		
10366	59512					Highest studied dose	mg	20		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213736Orig1s000MultidisciplineR.pdf	Homo sapiens													7	metastatic cholangiocarcinoma								5.9	month		
10367	59512					Recommended	mg	13.5		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf	Homo sapiens										The median duration of treatment was 181 days (range: 7 to 730 days). Drug was dosed in 21-day cycles: day 1-14 - 13.5 mg qd; days 15-21 - off therapy		78	146	metastatic cholangiocarcinoma					26			181	day		
10368	59513		adults			Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/30926081/	Homo sapiens										cohorts: 40, 60 and 100 mg; Treatment cycles lasted 28 days, with 5 days of drug administration			44	myelodysplastic syndromes	20. 30, 40 mg; oral; 1/day			decitabine				28	day		
10369	59513		adults			Recommended	mg	100		steady			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212576s000lbl.pdf	Homo sapiens										once daily on Days 1 through 5 of each 28-day cycle			107	myelodysplastic syndromes	35 mg; oral; 1/day			decitabine				28	day		
10370	59514		adult			Highest studied dose	mg	720		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf	Homo sapiens																									118
10371	59514					Highest studied dose	mg	240		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213246Orig1s000MultidisciplineR.pdf	Homo sapiens												92	6	cancer					15			28	day		118
10372	59514					Recommended	mg	160		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Homo sapiens												92	684	cancer					15			12	month		Table 6
10373	59514					Recommended	mg	160		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Homo sapiens												92	702	cancer					15			12	month		6.1
10374	59514					Recommended	mg	160		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Homo sapiens												92	702	cancer					15			12	month		Table 5
10375	59514					Recommended	mg	160		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf	Homo sapiens												92	702	cancer					15			12	month		Table 6
10376	59515					Recommended	mg	160		steady			day	2	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf	Homo sapiens						60.5						75	118						34			30	month		
10377	59516					Recommended	mg	40		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210854Orig1s000MedR.pdf	Homo sapiens													100	acute uncomplicated influenza					12						
10378	59516					Recommended	mg|mg	40 | 80		single					unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf	Homo sapiens							complex			40 kg to less than 80 kg | At least 80 kg			710	acute uncomplicated influenza					12						
10379	59524					Recommended	%	0.75		single			day	1	unhealthy	intravenous	M		https://pubmed.ncbi.nlm.nih.gov/19977217/	Homo sapiens						43							1	double frontal sinusitis					43			1	day		
10380	59524					Recommended	%	0.75		single			day	1	unhealthy	intravenous	M+F		https://pubmed.ncbi.nlm.nih.gov/19976305/	Homo sapiens													75									1	day		
10381	59524					Recommended	%	0.75		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/20766269/	Homo sapiens						19							1	iinguinal hernia					19			1	day		
10382	59524					Recommended	%	0.75		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/20766269/	Homo sapiens						20							1	recurrent appendicitis					20			1	day		
10383	59524					Recommended	%	0.75		single			day	1	unhealthy	intravenous			https://pubmed.ncbi.nlm.nih.gov/20766269/	Homo sapiens						30							1	gastric ulcer					30			1	day		
10384	59528					Studied dose	%	0.25		single			day	1	healthy	topical	M		https://pubmed.ncbi.nlm.nih.gov/14007052/	Homo sapiens										patch test - 0.25%; the exact TCSA concentration in the soap is unknown			2									1	day		
10385	59536		ADULT			MTD	mg	1600		single					healthy	oral	M		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf	Homo sapiens													16									1	times		p82, 121/SCY-078-001
10386	59536		ADULT			Studied dose	mg	750		single					unhealthy	oral	F		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214900Orig1s000MultidisciplineR.pdf	Homo sapiens													32	Vulvovaginal Candidiasis								1	times		p221/SCY-078-204
10387	59553		ADULT			Highest studied dose	mg	1800		single					healthy	oral	M+F		https://pubmed.ncbi.nlm.nih.gov/34871187/ | https://journals.lww.com/co-hivandaids/Fulltext/2022/01000/Lenacapavir__a_first_in_class_HIV_1_capsid.4.aspx | https://www.croiconference.org/wp-content/uploads/sites/2/posters/2020/1430_5_Begley_00470.pdf	Homo sapiens						37						43	7						21			1	day		
10388	59553		ADULT			Highest studied dose	mg	927		single					healthy	subcutaneous	M+F		https://pubmed.ncbi.nlm.nih.gov/34871187/ | https://journals.lww.com/co-hivandaids/Fulltext/2022/01000/Lenacapavir__a_first_in_class_HIV_1_capsid.4.aspx | https://programme.aids2020.org/Abstract/Abstract/8533	Homo sapiens						42				927 mg (2x1.5 mL)		44	10						25			1	day		
10389	59553		ADULT			Studied dose	mg	600		multiple			day	1	unhealthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf#page=6 | https://pubmed.ncbi.nlm.nih.gov/35544387/	Homo sapiens						55				Oral dose of 600 mg on Days 1 and 2 and 300 mg on Day 8; starting on day 15, 927 mg as 2x1.5 mL SC (abdomen) once every 6 months		71	24	human					24			438	day		CAPELLA
10390	59554		ADULT			Highest studied dose	mg	900		single					healthy	oral	unknown		https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216059Orig1s000MultidisciplineR.pdf#page=68	Homo sapiens																						1	day		
10391	59554		ADULT			Studied dose	mg	200		multiple			day	1	unhealthy	oral	M+F		https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf	Homo sapiens						71						88	128	Mantle cell lymphoma					46			6	month		NCT03740529
